Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

TECHNICAL FIELD

This application pertains to compounds that stabilize phenylalanine hydroxylase (PAH) mutations, pharmaceutical compositions comprising those compounds, and methods of using those compounds for treating phenylketonuria.

BACKGROUND

Phenylketonuria (PKU) is an autosomal recessive disorder affecting approximately 1:10,000 people worldwide (approx. 1:15,000-1:20,000 in the U.S.). The number of patients varies globally depending on region. PKU arises in patients who have mutations in the gene encoding the phenylalanine hydroxylase (PAH) enzyme responsible for converting phenylalanine to tyrosine. PAH is a tetrameric enzyme expressed in the liver requiring BH4 cofactor for activity. Reduction or loss of PAH activity results in toxic accumulation of phenylalanine (Phe) in the blood and brain. High levels of Phe damage brain white matter and interfere with neurotransmitter production. If untreated, high levels of Phe can result in mental retardation and decreased IQ in children and neurocognitive and psychiatric issues in adults, such as executive function deficits (for example, difficulty with attention, memory, flexible thinking, and organization/time management), psychological issues (for example, depression, anxiety, and mood swings), psychiatric and/or behavioral issues (for example, attention deficit hyperactivity disorder, self-harm, schizophrenia, agoraphobia, and agitation) and neurological abnormalities (for example, spasticity, tremor, gait disturbances, and seizures).

PKU phenotypes can vary from mild hyperphenylalaninemia (HPA) to more severe phenotypes that result in untreated blood Phe concentrations exceeding 1200 PM. American medical guidelines currently recommend maintaining blood Phe concentration in the range of 120 to 360 μM in both adults and children under the age of 12 years. European medical guidelines currently recommend maintaining blood Phe concentration below 360 μM in children under the age of 12 years and in pregnant women and below 600 μM in non-pregnant patients older than 12 years.

A standard of care for treating PKU is a Phe-restricted diet that severely limits the intake of natural protein. Such diets are very strict diets and challenging to adhere to. Two medications are currently approved for treating PKU, each having its own challenges. Kuvan (sapropterin dihydrochloride) is a synthetic BH4 cofactor approved in 2007 for use in infants to adults. Kuvan is not effective for all PKU patients, and the current guidelines suggest response testing in patients unless the patient is known to have two null mutations. Pegvaliase is an enzyme substitution therapy approved in 2018 for adults with a blood Phe concentration greater than 600 μM, despite prior management with available treatment options. Pegvaliase typically involves injection of a purified PEGylated form of phenylalanine ammonia lyase that reduces Phe by converting it to ammonia and trans-cinnamic acid instead of tyrosine. One of the main complications with enzyme substitution therapy is the attainment and maintenance of therapeutically effective amounts of protein in vivo due to rapid degradation or inactivation of the infused protein. A current approach to overcome this problem is to perform numerous costly high dose injections.

Pharmaceutical agents that enable patients to increase their intake of natural protein are desired.

SUMMARY

In some aspects, the disclosure provides compounds of Formula I:

embedded image

- or a pharmaceutically acceptable salt thereof, wherein:
  - m is 1 or 2;
  - R¹is

embedded image

- - x is 0 to 5;
  - each R^aindependently is halo, C_1-6alkyl, C_3-6cycloalkyl, C_1-6haloalkyl, C_1-6alkoxy or C_1-6haloalkoxy;
  - R²is C_1-4alkyl, optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
  - R³is H or C_1-6alkyl;
  - R⁴is H or C_1-6alkyl;
  - or R³and R⁴, together with the atom to which they are attached, form a C_3-6cycloalkyl;
  - R⁵is H or D;
  - R^5Ais H or D; and
  - L is a bond, carbonyl, optionally substituted C_1-6alkylene, optionally substituted C_1-6alkylenecarbonyl, optionally substituted C_2-6alkenylenecarbonyl, optionally substituted C_1-6haloalkylenecarbonyl, or optionally substituted —C(O)NR^b(C_1-6alkylene)-, wherein the carbon atom of the carbonyl group is connected to N in Formula I; and
  - R^bis H or C_1-6alkyl.

In other aspects, the disclosure provides compounds of Formula I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H, I-I, I-J, I-K, I-L, or I-M, or a pharmaceutically acceptable salt thereof:

embedded image

Stereoisomers and mixtures of stereoisomers of the compounds of Formula I, I-A, I-B, I-C, I-D, I-E, I-F, I-G, I-H, I-I, I-J, I-K, I-L, and I-M, and the pharmaceutical salts thereof, are also described.

In further aspects, the disclosure provides pharmaceutical compositions comprising one or more compound described herein or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

In yet other aspects, the disclosure provides methods for stabilizing a mutant PAH protein, comprising contacting the protein with one or more compound as described herein or a pharmaceutically acceptable salt thereof. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

In still further aspects, the disclosure provides methods for reducing phenylalanine levels in a subject suffering from phenylketonuria comprising administering a therapeutically effective amount of one or more compound as described herein or a pharmaceutically acceptable salt thereof.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
Definitions

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.

As used in structures herein, “ custom character ” indicates the point of attachment of the particular depicted structure or substituent group to the appropriate atom(s) in the remainder of the molecule.

The articles “a” and “an” as used herein and in the appended claims are used herein to refer to one or to more than one (e.g., to at least one) of the grammatical object of the article unless the context clearly indicates otherwise. By way of example, “an element” means one element or more than one element.

“Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in a country other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.

“Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic and may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, fumarate, tartrate, mesylate, acetate, maleate, oxalate and the like.

A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.

The term “alkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“C_1-12”), for example 1 to 6 carbons atoms (“C_1-6”), in the group. Examples of alkyl groups include methyl (C₁), ethyl (C₂), propyl (C₃) (e.g., n-propyl, isopropyl), butyl (C₄) (e.g., n-butyl, tert-butyl, sec-butyl, iso-butyl), pentyl (C₅) (e.g., n-pentyl, 3-pentyl, amyl, neopentyl, 3-methyl-2-butanyl, tertiary amyl), hexyl (C₆) (e.g., n-hexyl), heptyl (C₇) (e.g., n-heptyl), octyl (C₈) (e.g., n-octyl), and the like. In some embodiments, the alkyl group is a C_1-6alkyl; in other embodiments, it is a C_1-4alkyl; and in other embodiments, it is a C_1-3alkyl.

The term “alkylene,” when used alone or as part of a substituent group, refers to an alkyl diradical, i.e., a straight- or branched-chain hydrocarbon group that is attached to two other groups. For example, one embodiment of a C₂alkylene is the diradical —CH₂CH₂—. In some embodiments, the alkylene group is C_1-6alkylene; in other embodiments, it is C_1-4alkylene.

When a range of carbon atoms is used herein, for example, C_1-6, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C_1-3” includes C_1-3, C_1-2, C_2-3, C₁, C₂, and C₃.

The term “cycloalkyl” when used alone or as part of a substituent group refers to cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms (“C_3-10”), for example from 3 to 7 carbon atoms (“C_3-7”). Examples of cycloalkyl groups include cyclopropyl (C₃), cyclobutyl (C₄), cyclopentyl (C₅), cyclohexyl (C₆), cycloheptyl (C₇), and the like. In some embodiments, the cycloalkyl group is a C_3-4cycloalkyl; in other embodiments, it is a C_3-6cycloalkyl; and in other embodiments, it is C_3-8cycloalkyl. The cycloalkyl may be unsubstituted or substituted. In some embodiments, the cycloalkyl is substituted with two substituents. In further embodiments, the cycloalkyl is substituted with one substituent. In yet other embodiments, the cycloalkyl is substituted with three substituents. In still further embodiments, the cycloalkyl is unsubstituted.

The term “aryl” when used alone or as part of a substituent group also refers to a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted. The term “aryl” also includes a mono- or bicyclic-aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein two adjacent carbon atoms in the ring are optionally substituted such that said two adjacent carbon atoms and their respective substituents form a cycloalkyl or heterocyclyl ring. Examples of aryl groups include phenyl, indenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, and the like. The aryl may be unsubstituted or substituted. In other embodiments, the optionally substituted phenyl has four substituents. In further embodiments, the optionally substituted phenyl has three substituents. In yet other embodiments, the optionally substituted phenyl has two substituents. In still further embodiments, the optionally substituted phenyl has one substituent. In other embodiments, the optionally substituted phenyl is unsubstituted.

As used herein, the term “alkenyl” refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C_2-12”) in the group, wherein the group includes at least one carbon-carbon double bond. Examples of alkenyl groups include vinyl (—CH═CH₂; C₂alkenyl), allyl (—CH₂—CH═CH₂; C₃alkenyl), propenyl (—CH═CHCH₃; C₃alkenyl), isopropenyl (—C(CH₃)═CH₂; C₃alkenyl), butenyl (—CH═CHCH₂CH₃; C₄alkenyl), sec-butenyl (—C(CH₃)═CHCH₃; C₄alkenyl), iso-butenyl (—CH═C(CH₃)₂; C₄alkenyl), 2-butenyl (—CH₂CH═CHCH₃; C₄alkyl), pentenyl (—CH═CHCH₂CH₂CH₃; C₅alkenyl), and the like. In some embodiments, the alkenyl group is a C_2-6alkenyl group; in other embodiments, it is C_2-4alkenyl.

As used herein, the term “alkynyl” refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C_2-12”) in the group, and wherein the group includes at least one carbon-carbon triple bond. Examples of alkynyl groups include ethynyl (—C≡CH; C₂alkynyl), propargyl (—CH₂—C≡CH; C₃alkynyl), propynyl (—C≡CCH₃; C₃alkynyl), butynyl (—C≡CCH₂CH₃; C₄alkynyl), pentynyl (—C≡CCH₂CH₂CH₃; C₅alkynyl), and the like. In some embodiments, the alkynyl group is a C_2-6alkynyl group; in other embodiments, it is C_2-4alkynyl.

The term “carbonyl” as used by itself or as part of another group refers to C(O) or C(═O).

The term “alkylcarbonyl” as used by itself or as part of another group refers to an alkyl group as defined above wherein at least one carbon is bonded to an oxo group. For example, one embodiment of an C₃alkylcarbonyl is —CH₂C(O)CH₃. In some embodiments, the alkylcarbonyl group is a C_1-6alkylcarbonyl group.

The term “alkenylenecarbonyl” as used by itself or as part of another group refers to an —C(O)-(alkenylene) group, where alkenylene refers to an alkylene diradical, i.e., a straight- or branched-chain hydrocarbon group containing at least one carbon-carbon double bond that is attached to two other groups. For example, one embodiment of a —C(O)—C₂alkenylene is —C(O)—CH═CH—. In some embodiments, the alkenylene group of the alkenylenecarbonyl is a C_2-6alkenylene group; in other embodiments, the alkenylene group is C_2-4alkenylene.

The term “halo” or “halogen,” as used by itself or as part of another group refers to a fluorine, chlorine, bromine, or iodine atom.

As used herein, the term “haloalkyl” refers to an alkyl group wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms which may be the same or different. In some embodiments, the alkyl is substituted by at least one halogen. In other embodiments, the alkyl is substituted by one, two, or three F and/or Cl. Examples of haloalkyl groups include fluoromethyl (CH₂F), 1-fluoroethyl (CH(CH₃)F), 2-fluoroethyl, difluoromethyl (CHF₂), trifluoromethyl (CF₃), pentafluoroethyl, 1,1-difluoroethyl (C(CH₃)F₂), 2,2-difluoroethyl (CH₂CHF₂), 2,2,2-trifluoroethyl (CH₂CF₃), 2-fluoropropan-2-yl (C(CH₃)₂F), 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, trichloromethyl and the like. In some embodiments, the haloalkyl group is a C_1-6haloalkyl; in other embodiments, it is a C_1-4haloalkyl; and in other embodiments, it is a C_1-3haloalkyl.

The term “haloalkylenecarbonyl” as used by itself or as part of another group refers to a —C(O)-(haloalkylene) group, where the haloalkylene refers to a haloalkyl diradical. For example, one embodiment of a —C(O)—C₁haloalkylene is —C(O)—CF₂—. In some embodiments, the haloalkylene group is a C_1-6haloalkylene; in other embodiments, it is a C_1-4haloalkylene; and in other embodiments, it is a C_1-3haloalkylene.

The term “cyanoalkyl” as used by itself or as part of another group refers to an alkyl as defined herein that is substituted by one or more CN. In some embodiments, the alkyl is substituted by at least one CN. In other embodiments, the alkyl is substituted by one, two, or three CN. In further embodiments, the cyanoalkyl group is a C_1-6cyanoalkyl. In yet other embodiments, the cyanoalkyl is a C_1-4cyanoalkyl. Examples of cyanoalkyl groups include CH₂CN, CH₂CH₂CN, CH(CN)CH₃, CH₂CH₂CH₂CN, C(CH₃)₂CN, CH₂CH(CN)CH₃, CH(CN)CH₂CH₃, and the like.

The term “hydroxyalkyl” as used by itself or as part of another group refers to an alkyl group as defined herein wherein one or more of the hydrogen atoms has been replaced with one or more hydroxyl (i.e., —OH). In some embodiments, the hydroxyalkyl contains one OH. In other embodiments, the hydroxyalkyl contains two OH. In further embodiments, the hydroxyalkyl contains three OH. Examples of hydroxyalkyl groups include hydroxymethyl, hydroxyethyl (e.g., 1-hydroxyethyl, 2-hydroxyethyl), 1,2-dihydroxyethyl, hydroxypropyl (e.g., 2-hydroxypropyl, 3-hydroxypropyl), hydroxybutyl (e.g., 3-hydroxybutyl, 4-hydroxybutyl), 2-hydroxy-1-methylpropyl, 1,3-dihydroxyprop-2-yl, and the like. In some embodiments, the hydroxyalkyl group is C_1-6hydoxyalkyl; in other embodiments, it is C_1-4hydroxyalkyl; and in other embodiments, it is C_1-3hydroxyalkyl.

The term “cycloalkylsulfonyl” as used by itself or as part of another group refers to a cycloalkyl as defined herein that is bound to a sulfonyl, i.e., —SO₂—, and the sulfonyl group forms the point of attachment to the remainder of the molecule. In some embodiments, the cycloalkylsulfonyl is a C_3-8cycloalkylsulfonyl; in other embodiments, it is a C_3-6cycloalkylsulfonyl. Examples of cycloalkylsulfonyl groups include —SO₂-cyclopropyl, —SO₂— cyclobutyl, —SO₂-cyclopentyl, and the like.

The term “alkylsulfonyl” as used by itself or as part of another group refers to an alkyl as defined herein that is bound to a sulfonyl, i.e., —SO₂—, and the sulfonyl group forms the point of attachment to the remainder of the molecule. In some embodiments, the alkylsulfonyl is C_1-6alkylsulfonyl; in other embodiments, it is a C_1-4alkylsulfonyl. Examples of alkylsulfonyl groups include —SO₂CH₃, —SO₂CH₂CH₃, and the like.

The term “alkylsulfonyl(alkylene)” as used by itself or as part of another group refers to an alkylene group as defined herein that is bound to the sulfonyl of an alkylsulfonyl group as defined herein. Examples of alkylsulfonyl(alkylene) groups include —C(CH₃)₂SO₂CH₃, —CH₂SO₂CH₃, —CH(CH₃)SO₂CH₃, and the like.

The term “alkoxy” as used by itself or as part of another group refers to an oxygen radical attached to an alkyl group by a single bond. Examples of alkoxyl groups include methoxy (OCH₃), ethoxy (OCH₂CH₃), propoxy (e.g., —OⁿPr, —OⁱPr), or butoxy (e.g., —OⁿBu, —OⁱBu, —O^sBu, —O^tBu), and the like. In other embodiments, the alkoxy group is a C_1-6alkoxy. In further embodiments, the alkoxy group is a C_1-4alkoxy.

The term “alkoxy(alkylene)” as used by itself or as part of another group refers to an alkylene group as defined herein that is bound to an alkoxy group as defined herein. Examples of alkoxy(alkylene) groups include —CH₂OCH₃, —CH₂CH₂OCH₃, and the like.

The term “haloalkoxy” as used by itself or as part of another group refers an oxygen radical attached to a haloalkyl group by a single bond, wherein haloalkyl is defined above. Examples of haloalkoxy groups include fluoromethoxy (OCH₂F), 2-fluoroethoxy, difluoromethoxy (OCHF₂), trifluoromethoxy (OCF₃), pentafluoroethoxy, 1,1-difluoroethoxy (OC(CH₃)F₂), 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy (OCH₂CF₃), 3,3,3-trifluoropropoxy, 4,4,4-trifluorobutoxy, trichloromethoxy groups, and the like. In some embodiments, the haloalkoxy group is a C_1-6haloalkoxy; in other embodiments, it is C_1-4haloalkoxy; and in other embodiments, it is C_1-3haloalkoxy.

The term “haloalkoxy(alkylene)” as used by itself or as part of another group refers to an alkylene group as defined herein that is bound to an haloalkoxy group as defined herein. Examples of haloalkoxy(alkylene) groups include —CH₂OCF₃, and the like.

The term “heteroaryl” when used alone or as part of a substituent group refers to a mono- or bicyclic-aromatic ring structure including carbon atoms as well as up to four heteroatoms that are each independently nitrogen, oxygen, or sulfur. Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms. In some embodiments, heteroaryl rings are characterized by the number of ring atoms in the heteroaryl group. For example, a 6-membered heteroaryl group refers to a heteroaryl group having 6 ring atoms in the group. Similarly, a 5-membered heteroaryl group refers to a heteroaryl group having 5 ring atoms in the group. The heteroaryl moiety can be unsubstituted, or one or more of the carbon atoms or nitrogen atoms in the ring can be substituted. Examples of heteroaryl groups include thienyl, benzo[b]thienyl, furanyl, benzofuryl, pyranyl, thiophenyl, isobenzofuranyl, benzoxazinyl, chromenyl, xanthenyl, 2H pyrrolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl, isoquinolyl, quinolyl, quinoxalyl, phthalazinyl, naphthyridinyl, cinnolinyl, triazolyl, tetrazolyl, thiadiazolyl, oxadiazolyl, quinazolinyl, pteridinyl, pyrimidinyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, furazanyl, pyrazolo[1,5-a]pyridinyl, benzoisothiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzoisoxazolyl, isothiazolyl, tetrahydropyrazolo[1,5-a]pyridinyl and the like. In some embodiments, the heteroaryl is thienyl (e.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furanyl, 3-furanyl, 4-furanyl), pyrrolyl (e.g., pyrrol-2-yl, pyrrol-3-yl), imidazolyl (e.g., imidazol-2-yl, imidazol-4-yl), pyrazolyl (e.g., pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl), pyridyl (e.g., pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl, pyrimidin-4-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl, thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl, isothiazol-4-yl, and isothiazol-5-yl), oxazolyl (e.g., oxazol-2-yl, oxazol-4-yl, and oxazol-5-yl), isoxazolyl (e.g., isoxazol-3-yl, isoxazol-4-yl, and isoxazol-5-yl), pyrazinyl (e.g., pyrazin-2-yl, pyrazin-3-yl, pyrazin-5-yl, pyrazin-6-yl), triazolyl (e.g., 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl), thiadiazolyl (e.g., 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thidiazolyl, 1,3,4-thiadiazolyl), oxadiazolyl (e.g., 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl), indazolyl (e.g., indazol-3-yl), pyrazolo[1,5-a]pyridinyl (e.g., pyrazolo[1,5-a]pyridin-3-yl), imidazol[1,5-a]pyridinyl (e.g., imidazol[1,5-a]pyridin-1-yl), pyrrolo[1,2]pyridazinyl (e.g., pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl), benzo[d]thiazolyl (e.g., benzo[d]thiazol-3-yl, benzo[d]thiazol-2-yl), benzo[d]imidazolyl (e.g., benzo[d]imidazol-2-yl), benzo[d]oxazolyl (e.g., benzo[d]oxazol-2-yl), benzo[d]isoxazolyl (e.g., benzo[d]isoxazol-3-yl), benzo[d]isothiazolyl (e.g., benzo[d]isothiazol-3-yl), benzo[c]isoxazolyl (e.g., benzo[c]isoxazol-3-yl), quinolinyl (e.g., quinolin-3-yl), and pyridazinyl (e.g., pyridazin-3-yl, pyridazin-4-yl). The term “heteroaryl” also includes N-oxides. The heteroaryl may be unsubstituted or substituted. In some embodiments, the heteroaryl is substituted with two substituents. In further embodiments, the heteroaryl is substituted with one substituent. In yet other embodiments, the heteroaryl is substituted with three substituents. In still further embodiments, the heteroaryl is unsubstituted. Substitution may occur on any available carbon or heteroatom (e.g., nitrogen), or both, as permitted by substituent valency.

In some embodiments, the heteroaryl is a 5- or 6-membered heteroaryl. In some embodiments, the heteroaryl is a 5-membered heteroaryl, i.e., the heteroaryl is a monocyclic aromatic ring system having 5 ring atoms wherein at least one carbon atom of the ring is replaced with a heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of 5-membered heteroaryl groups include thienyl, furyl, pyrrolyl, oxazolyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, and isoxazolyl and the like. In other embodiments, the heteroaryl is a 6-membered heteroaryl, e.g., the heteroaryl is a monocyclic aromatic ring system having 6 ring atoms wherein at least one carbon atom of the ring is replaced with a nitrogen atom. Examples of 6-membered heteroaryl groups include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl and the like.

The term “heterocyclyl” as used by itself or as part of another group refers to non-aromatic, saturated or partially unsaturated, e.g., containing one or two double bonds, cyclic groups containing one, two, or three rings having from three to fourteen ring members, i.e., a 3-14-membered heterocyclyl, wherein at least one carbon atom of one of the rings is replaced with a heteroatom. Each heteroatom is independently selected from oxygen, sulfur, including sulfoxide and sulfone, and/or nitrogen atoms, which can be oxidized or quaternized. The term “heterocyclyl” also includes groups wherein a ring —CH₂— is replaced with a —C(O)—. The term “heterocyclyl” also includes groups having fused optionally substituted aryl groups, e.g., indolinyl or chroman-4-yl and groups having fused optionally substituted cycloalkyl groups, e.g., 6-azaspiro[2.5]octanyl. In some embodiments, the heterocyclyl group is a C_4-6heterocyclyl, i.e., a 4-, 5- or 6-membered cyclic group, containing one ring and one or two oxygen and/or nitrogen atoms. In other embodiments, the heterocyclyl is a C_4-6heterocyclyl containing one ring and one nitrogen atom. The heterocyclyl can be optionally linked to the rest of the molecule through any available carbon or heteroatom that results in a stable structure. Examples of heterocyclyl groups include azetidinyl, dioxanyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, pyrrolidinyl, indolinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, azepanyl, aziridinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, thianyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, tetrahydropyranyl, and the like. In some embodiments, the heterocyclyl group includes azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 6-azaspiro[2.5]octanyl. The heterocyclyl may be unsubstituted or substituted. In some embodiments, the heterocyclyl is substituted with two substituents. In further embodiments, the heterocyclyl is substituted with one substituent. In yet other embodiments, the heterocyclyl is substituted with three substituents. In still further embodiments, the heterocyclyl is unsubstituted.

The term “(heterocyclyl)alkylene” as used by itself or part of another group refers to an alkylene group as defined herein that is bound to a heterocyclyl group as defined herein.

The term “optionally substituted,” as used herein to describe a chemical moiety defined herein, means that the moiety may, but is not required to be, substituted with one or more suitable functional groups or other substituents as provided herein. For example, a substituent may be optionally substituted with one or more of: halo, cyano, —NO₂, —N₃, —OH, —SH, C_1-6alkyl, C_3-8cycloalkyl, C_3-8cycloalkenyl, C_2-6alkenyl, C_2-6alkynyl, C_1-6haloalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6alkylcarbonyl, C_1-6cyanoalkyl, C_1-6hydroxyalkyl, C_1-6alkylenethio, (CR^vR^x)_pNR^yR^z(wherein R^vand R^xare, independently, H or C_1-6alkyl; R^yand R^z, are independently, H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), or C(O)OC_1-6alkyl, and p is 0, 1, 2, or 3), —C(O)NH₂, —C(O)NHC_1-6alkyl, —C(O)N(C_1-6alkyl)₂, —C(O)NHC_3-6cycloalkyl, —C(O)N(C_3-6cycloalkyl)₂, —COOH, —C_1-6alkyleneCOOH, —C_3-6cycloalkylCOOH, —C_1-6alkyleneCONH₂, C_3-6cycloalkylCONH₂, —C_1-6alkyleneCONHC_1-6alkyl, —C_1-6alkyleneCON(C_1-6alkyl)₂, —C(O)OC_1-6alkyl, —NHCO(C_1-6alkyl), —N(C_1-6alkyl)C(O)(C_1-6alkyl), —S(O)C_1-6alkyl, —S(O)C_3-6cycloalkyl, C_1-6alkylsulfonyl, C_3-8cycloalkylsulfonyl, C_1-6alkylsulfonyl(alkylene), oxo (═O), 3-7-membered heterocyclyl, heterocyclyl(alkylene), aryl, aryl(alkylene), or heteroaryl groups. In some embodiments, the C_1-6alkyl group in any of the substituent groups in this paragraph is a C_1-4alkyl; in other embodiments it is C_1-3alkyl. In some embodiments, the C_1-6alkylene group in any of the substituent groups in this paragraph is a C_1-4alkylene. In some embodiments, the C_1-6haloalkyl substituent is a C_1-4haloalkyl; in other embodiments, it is C_1-3haloalkyl. In some embodiments, the C_3-6cycloalkyl substituent is a C₃₄cycloalkyl substituent. In some embodiments, the C_1-6alkoxy substituent is a C_1-3alkoxy; in other embodiments, it is C_1-4alkoxy. In some embodiments, the C_1-6haloalkoxy substituent is a C_1-3haloalkoxy; in other embodiments, it is C_1-4haloalkoxy.

In some embodiments, a substituent may be optionally substituted with one or more of: C_1-6alkyl, optionally substituted C_2-6alkenyl, halo, CN, C_1-6cyanoalkyl, C_1-6haloalkyl, OH, optionally substituted C_3-8cycloalkyl, optionally substituted C_3-8cycloalkenyl, optionally substituted aryl, optionally substituted aryl(alkylene), optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), C_1-6hydroxyalkyl, C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene), C_1-6alkylcarbonyl, C_3-8cycloalkylsulfonyl, C_1-6alkylsulfonyl(alkylene), (CR^vR^x)_pNR^yR^z(wherein R^vand R^xare, independently, H or C_1-6alkyl; R^yand R^z, are independently, H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), or C(O)OC_1-6alkyl, and p is 0, 1, 2, or 3), and C(O)NR^y2R^z2(wherein R^y2and R^z2, are independently, H, C_1-6alkyl, or C_3-6cycloalkyl).

The term “nitrogen protecting group” refers to a moiety that is attached to a nitrogen atom to prevent reaction at that nitrogen atom. Nitrogen protecting groups will be known by those skilled in the art and include those described in Wuts, P. G., Greene's Protective Groups in Organic Synthesis. Wiley; 5th edition (Oct. 27, 2014), which is incorporated by reference herein.

Recitation of ranges of values herein are intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended to better illustrate the disclosure and is not a limitation on the scope of the disclosure unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.

The term “about” when used in combination with a numeric value or range of values means the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art.

Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including supercritical fluid chromatography (SFC), chiral high-pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds (McGraw-Hill, N Y, 1962); and Wilen, S. H. Tables of Resolving Agents and Optical Resolutions p. 268 (E. L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

Exemplary compounds of the disclosure including a chiral center may be depicted herein as having particular stereochemistries, but for which absolute stereochemistry has not been obtained. Absolute configurations can be obtained using methods known in the art.

As used herein, the term “stereoisomers” refers to compounds which have identical chemical constitution and connectivity but differ with regard to the arrangement of the atoms or groups in space, e.g., enantiomers or diastereomers.

When the stereochemical configuration at a chiral center in a compound having one or more chiral centers is depicted by its chemical name (e.g., where the configuration is indicated in the chemical name by “R” or “S”) or structure (e.g., the configuration is indicated by dashed or wedge bonds), the enrichment of the indicated configuration relative to the opposite configuration is greater than 50%, 60%, 70%, 80%, 90%, 99% or 99.9%. “Enrichment of the indicated configuration relative to the opposite configuration” is a mole percent and is determined by dividing the number of compounds with the indicated stereochemical configuration at the chiral center(s) by the total number of all of the compounds with the same or opposite stereochemical configuration in a mixture.

When a disclosed compound is named or depicted by structure without indicating stereochemistry, it is understood that the name or the structure encompasses one of the possible stereoisomers or geometric isomers free of the others, or a mixture of the encompassed stereoisomers or geometric isomers.

It will be understood that certain compounds disclosed herein may exist in tautomeric forms. Such forms are included as part of the present disclosure. Thus, when a compound herein is represented by a structural formula or designated by a chemical name herein, all tautomeric forms which may exist for the compound are encompassed by the structural formula.

When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that they include both E and Z geometric isomers.

In some embodiments, the compounds described herein are isotopically enriched compound, e.g., an isotopologue. The term “isotopically enriched” refers to an atom having an isotopic composition other than the naturally abundant isotopic composition of that atom. “Isotopically enriched” may also refer to a compound containing at least one atom having an isotopic composition other than the natural isotopic composition of that atom. In an isotopologue, “isotopic enrichment” refers to the percentage of incorporation of an amount of a specific isotope of a given atom in a molecule in the place of that atom's natural isotopic composition. For example, deuterium enrichment of 1% at a given position means that 1% of the molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. In one embodiment, one or more hydrogen atoms on a described compound may be replaced by deuterium.

Thus, as used herein, and unless otherwise indicated, the term “isotopic enrichment factor” refers to the ratio between the isotopic composition and the natural isotopic composition of a specified isotope.

With regard to the compounds provided herein, when a particular atom's position is designated as having deuterium or “D” or “²H”, it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015%. A position designated as having deuterium typically has a minimum isotopic enrichment factor of, in particular embodiments, at least 1000 (15% deuterium incorporation), at least 2000 (30% deuterium incorporation), at least 3000 (45% deuterium incorporation), at least 3500 (520.5% deuterium incorporation), at least 4000 (60% deuterium incorporation), at least 5500 (820.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation) at each designated deuterium atom. The isotopic enrichment and isotopic enrichment factor of the compounds provided herein can be determined using conventional analytical methods known to one of ordinary skill in the art, including mass spectrometry and nuclear magnetic resonance spectroscopy.

The term “patient” or “subject” is used throughout the specification to describe an animal, preferably a human or a domesticated animal, to whom treatment, including prophylactic treatment, with the compounds or compositions according to the present disclosure is provided. For treatment of those conditions or disease states which are specific for a specific animal such as a human patient, the term patient refers to that specific animal, including a domesticated animal such as a dog or cat or a farm animal such as a horse, cow, sheep, etc. In general, in the present disclosure, the term patient refers to a human patient unless otherwise stated or implied from the context of the use of the term.

The terms “therapeutically effective amount” or “effective amount” means an amount or dose of a compound of the disclosure (or a pharmaceutically acceptable salt thereof) sufficient to generally bring about the desired therapeutic benefit in subjects in need of such treatment for the designated disease or disorder. Further, a therapeutically effective amount with respect to a compound of the disclosure means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or prevention of a disease.

“Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (e.g., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder.

The terms “prevent,” “preventing,” and “prevention” refer to the prevention of the onset, recurrence, or spread of the disease in a subject resulting from the administration of a prophylactic or therapeutic agent.

Compounds

The present disclosure provides compounds of Formula I or pharmaceutically acceptable salts thereof:

embedded image

In Formula I, m is 1 or 2. In some embodiments, m is 1. In other embodiments, m is 2.

In formula I, R¹is

embedded image

In the structures for R¹, x is 0 to 5. In some embodiments, x is 0. In other embodiments, x is 1. In further embodiments, x is 2. In yet other embodiments, x is 3. In still further embodiments, x is 4. In other embodiments, x is 5.

In further embodiments, R¹is

embedded image

and x is 0 or 1, such as

embedded image

In other embodiments, R¹is

embedded image

In yet other embodiments, R¹is

embedded image

In still other embodiments, R¹is

embedded image

In yet other embodiment, R¹is

embedded image

In still further embodiments, R¹is

embedded image

In other embodiments, R¹is

embedded image

In some embodiments, the compound is a single enantiomer and the R¹moiety is in an alpha (α) configuration. In some embodiments, the compound is a single enantiomer and the R¹moiety is in an beta (β) configuration.

In the structures for R¹, each R^ais independently halo, C_1-6alkyl, C_3-6cycloalkyl, C_1-6haloalkyl, C_1-6alkoxy or C_1-6haloalkoxy. In some embodiments, R^ais halo such as F, Cl, Br, or I. In other embodiments, R^ais F, Br, or Cl. In still other embodiments, R^ais F. In further embodiments, R^ais Br. In yet other embodiments, R^ais Cl. In still further embodiments, R^ais I. In other embodiments, R^ais C_1-6alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R^ais methyl, ethyl, or isopropyl. In yet other embodiments, R^ais methyl. In further embodiments, R^ais C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In still further embodiments, R^ais cyclopropyl. In yet other embodiments, R^ais C_1-6haloalkyl such as CF₃, CHF₂, CH₂F, CH₂CF₃, C(CH₃)₂F, or C(CH₃)F₂. In still other embodiments, R^ais CF₃or CHF₂. In further embodiments, R^ais C_1-6alkoxy such as methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy. In yet other embodiments, R^ais methoxy or ethoxy. In other embodiments, R^ais C_1-6haloalkoxy such as OCF₃or OCH₂CF₃. In still other embodiments, one R^ais halo and the second R^ais C_1-6alkoxy or C_1-6alkyl.

In Formula I, R²is C_1-4alkyl, optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R²is optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In further embodiments, R²is unsubstituted C_3-8cycloalkyl, unsubstituted heterocyclyl, unsubstituted aryl, or unsubstituted heteroaryl. In other embodiments, R²is substituted C_3-8cycloalkyl, substituted heterocyclyl, substituted aryl, or substituted heteroaryl. In some embodiments, R²is C_1-4alkyl such as methyl, ethyl, propyl, butyl, or tert-butyl. In other embodiments, R²is optionally substituted C_3-8cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl. In further embodiments, R²is optionally substituted heterocyclyl such as azetidinyl. In still other embodiments, R²is optionally substituted aryl such as phenyl. In yet further embodiments, R²is optionally substituted heteroaryl such as pyridinyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, indazolyl, pyrazolo[1,5-a]pyridinyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2-b]pyridazinyl, benzo[d]thiazolyl, benzo[d]isothiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, or benzo[d]isothiazolyl.

In Formula I, R³is H or C_1-6alkyl. In some embodiments, R³is H. In other embodiments, R³is C_1-6alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R³is methyl. In yet other embodiments, R³is ethyl. In still further embodiments, R³is propyl. In other embodiments, R³is butyl. In further embodiments, R³is pentyl. In yet other embodiments, R³is hexyl.

In Formula I, R⁴is H or C_1-6alkyl. In some embodiments, R⁴is H. In other embodiments, R⁴is C_1-6alkyl such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R⁴is methyl. In yet other embodiments, R⁴is ethyl. In still further embodiments, R⁴is propyl. In other embodiments, R⁴is butyl. In further embodiments, R⁴is pentyl. In yet other embodiments, R⁴is hexyl.

Alternatively, R³and R⁴, together with the atom to which they are attached, form a C_3-6cycloalkyl. In some embodiments, R³and R⁴together form a cyclopropyl. In other embodiments, R³and R⁴together form a cyclobutyl. In further embodiments, R³and R⁴together form a cyclopentyl. In yet other embodiments, R³and R⁴together form a cyclohexyl.

In some embodiments, both R³and R⁴are H. In other embodiments, R³is methyl and R⁴is H. In still other embodiments, both R³and R⁴are methyl.

In Formula I, R⁵is H or D. In some embodiments, R⁵is H. In further embodiments, R⁵is D.

In Formula I, R^5Ais H or D. In some embodiments, R^5Ais H. In further embodiments, R^5Ais D.

In Formula I, L is a bond, carbonyl, optionally substituted C_1-6alkylene, optionally substituted C_1-6alkylenecarbonyl, optionally substituted C_2-6alkenylenecarbonyl, optionally substituted C_1-6haloalkylenecarbonyl, or optionally substituted —C(O)NR^b(C_1-6alkylene)-, wherein the carbon atom of the carbonyl group is connected to N in Formula I. In some embodiments, L is a bond. In other embodiments, L is carbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In further embodiments, L is optionally substituted C_1-6alkylene such as methylene, ethylene, propylene, butylene, pentylene, or hexylene. In other embodiments, L is C₁alkylene. In still other embodiments, L is C₂alkylene. In further embodiments, L is C₃alkylene. In yet other embodiments, L is C₄alkylene. In still further embodiments, L is C₅alkylene. In other embodiments, L is C₆alkylene. In yet other embodiments, L is optionally substituted C_1-6alkylenecarbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In further embodiments, L is —C₁alkylene-C(O)—. In other embodiments, L is —C₂alkylene-C(O)—. In further embodiments, L is —C₃alkylene-C(O)—. In yet other embodiments, L is —C₄alkylene-C(O)—. In still further embodiments, L is —C₅alkylene-C(O)—. In other embodiments, L is —C₆alkylene-C(O)—. In still further embodiments, L is optionally substituted C_2-6alkenylenecarbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In other embodiments, L is —C₂alkenylene-C(O)—. In further embodiments, L is —C₃alkenylene-C(O)—. In yet other embodiments, L is —C₄alkenylene-C(O)—. In still further embodiments, L is —C₅alkenylene-C(O)—. In other embodiments, L is —C₆alkenylene-C(O)—. In other embodiments, L is optionally substituted C_1-6haloalkylenecarbonyl (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In yet other embodiments, L is —C₁haloalkylene-C(O)—. In other embodiments, L is —C₂haloalkylene-C(O)—. In further embodiments, L is —C₃haloalkylene-C(O)—. In yet other embodiments, L is —C₄haloalkylene-C(O)—. In still further embodiments, L is —C₅haloalkylene-C(O)—. In other embodiments, L is —C₆haloalkylene-C(O)—. In further embodiments, L is —C(O)NR^b(C_1-6alkylene)- (wherein the carbon atom of the carbonyl group is connected to N in Formula I). In yet other embodiments, L is —C(O)NR^bC₁alkylene-. In other embodiments, L is —C(O)NR^bC₂alkylene-. In further embodiments, L is —C(O)NR^bC₃alkylene-. In yet other embodiments, L is —C(O)NR^bC₄alkylene-. In still further embodiments, L is —C(O)NR^bC₅alkylene-. In other embodiments, L is —C(O)NR^bC₆alkylene-.

In the structures for L, R^bis H or C_1-6alkyl. In some embodiments, R^bis H. In other embodiments, R^bis C_1-6alkyl, such as methyl, ethyl, propyl, butyl, pentyl, or hexyl. In further embodiments, R^bis methyl. In yet other embodiments, R^bis ethyl. In still further embodiments, R^bis propyl. In other embodiments, R^bis butyl. In further embodiments, R^bis pentyl. In yet other embodiments, R^bis hexyl.

In some embodiments, L is a bond, —C(O)—, —C(O)CH₂—, —C(O)CH₂CH₂—, —C(O)CH₂CH₂CH₂—, —C(O)CF₂—, —C(O)CHF—, —C(O)C(CH₃)₂—, —C(O)CH═CH—,

embedded image

—C(O)NHCH₂—, —CH₂—, or —CH₂CH₂—. In yet other embodiments, L is a bond, —C(O)—, —C(O)CH₂—, or —C(O)CF₂.

In some embodiments, R²is cyclopentyl, cyclobutyl, cyclopropyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[d]isothiazolyl, furanyl, or pyrazinyl, each of which is optionally substituted.

In further embodiments, R²is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[c]isoxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl or quinolinyl, each of which is optionally substituted.

In other embodiments, R²is cyclopentyl, cyclobutyl, cyclopropyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[d]isothiazolyl, furanyl, or pyrazinyl, each of which is unsubstituted.

In yet other embodiments, R²is cyclopentyl, cyclobutyl, cyclopropyl, cyclohexyl, azetidinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazolo[1,5-a]pyridinyl, indazolyl, thiadiazolyl, imidazol[1,5-a]pyridinyl, pyrrolo[1,2]pyridazinyl, thiophenyl, isoxazolyl, isothiazolyl, benzo[d]thiazolyl, benzo[d]imidazolyl, benzo[d]oxazolyl, benzo[d]isoxazolyl, benzo[c]isoxazolyl, benzo[d]isothiazolyl, furanyl, pyrazinyl or quinolinyl, each of which is unsubstituted.

In further embodiments, R²is optionally substituted cyclopentyl. In further embodiments, R²is optionally substituted cyclobutyl. In still other embodiments, R²is optionally substituted cyclopropyl. In yet other embodiments, R²is optionally substituted cyclohexyl. In yet further embodiments, R²is optionally substituted azetidinyl. In other embodiments, R²is optionally substituted phenyl. In further embodiments, R²is optionally substituted pyrazolyl. In still other embodiments, R²is optionally substituted oxazolyl. In yet further embodiments, R²is optionally substituted thiazolyl. In other embodiments, R²is optionally substituted triazolyl. In further embodiments, R²is optionally substituted oxadiazolyl. In still other embodiments, R²is optionally substituted pyridinyl. In yet further embodiments, R²is optionally substituted pyrimidinyl. In other embodiments, R²is optionally substituted pyrazolo[1,5-a]pyridinyl. In further embodiments, R²is optionally substituted indazolyl. In yet other embodiments, R²is optionally substituted thiadiazolyl. In other embodiments, R²is optionally substituted imidazol[1,5-a]pyridinyl. In further embodiments, R²is optionally substituted pyrrolo[1,2]pyridazinyl. In still other embodiments, R²is optionally substituted thiophenyl. In yet further embodiments, R²is optionally substituted isoxazolyl. In further embodiments, R²is optionally substituted isothiazolyl. In other embodiments, R²is optionally substituted benzo[d]thiazolyl. In further embodiments, R²is optionally substituted benzo[d]imidazolyl. In still other embodiments, R²is optionally substituted benzo[d]oxazolyl. In yet further embodiments, R²is benzo[d]isoxazolyl. In yet other embodiments, R²is optionally substituted benzo[c]isoxazolyl. In still further embodiments, R²is optionally substituted benzo[d]isothiazolyl. In other embodiments, R²is optionally substituted furanyl. In yet other embodiments, R²is optionally substituted pyrazinyl. In still further embodiments, R²is optionally substituted quinolinyl.

In other embodiments, R²is azetidin-1-yl, azetidin-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, pyrazolo[1,5-a]pyridin-3-yl, indazol-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,3,4-thiadiazol-2-yl, pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, imidazol[1,5-a]pyridin-1-yl, pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl, thiophen-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, benzo[d]thiazol-2-yl, benzo[d]thiazol-3-yl, benzo[d]imidazol-2-yl, benzo[d]oxazol-2-yl, benzo[d]isoxazol-3-yl, benzo[d]isothiazol-3-yl, furan-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, or pyrazin-2-yl, each of which is optionally substituted.

In yet other embodiments, R²is azetidin-1-yl, azetidin-3-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,4-triazol-1-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3-triazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, pyrazolo[1,5-a]pyridin-3-yl, indazol-3-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, 1,3,4-thiadiazol-2-yl, pyridin-1-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, imidazol[1,5-a]pyridin-1-yl, pyrrolo[1,2]pyridazin-5-yl, pyrrolo[1,2]pyridazin-6-yl, thiophen-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, benzo[d]thiazol-2-yl, benzo[d]thiazol-3-yl, benzo[d]imidazol-2-yl, benzo[d]oxazol-2-yl, benzo[d]isoxazol-3-yl, benzo[d]isothiazol-3-yl, furan-3-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, pyrazin-2-yl, benzo[c]isoxazole-3-yl, or quinolin-3-yl, each of which is optionally substituted.

In further embodiments, R²is C_3-8cycloalkyl, heterocyclyl, aryl, or heteroaryl, each of which is substituted with one or more of C_1-6alkyl, optionally substituted C_2-6alkenyl, halo, CN, C_1-6cyanoalkyl, C_1-6haloalkyl, OH, optionally substituted C_3-8cycloalkyl, optionally substituted C_3-8cycloalkyl(alkylene), optionally substituted C_3-8cycloalkenyl, optionally substituted aryl, optionally substituted aryl(alkylene), optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), C_1-6hydroxyalkyl, C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene), C_1-6alkylcarbonyl, C_3-8cycloalkylsulfonyl, C_1-6alkylsulfonyl, C_1-6alkylsulfonyl(alkylene), (CR^vR^x)_pNR^yR^z(wherein R^vand R^xare, independently, H or C_1-6alkyl; R^yand R^z, are independently, H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), or C(O)OC_1-6alkyl and p is 0, 1, 2, or 3), or C(O)NR^y2R^z2(wherein R^y2and R^z2, are independently, H, C_1-6alkyl, or C_3-6cycloalkyl). In other embodiments, R²is optionally substituted with C_1-6alkyl, such as methyl, ethyl, propyl, isopropyl, or tert-butyl. In yet further embodiments, R²is optionally substituted with C_2-6alkenyl such as CH═CH₂, CH═CHC(CH₃)₂OH, or CH═CH-cyclopropyl. In further embodiments, R²is optionally substituted with halo such as Br, Cl, or F. In yet other embodiments, R²is optionally substituted with CN. In still further embodiments, R²is optionally substituted with C_1-6cyanoalkyl such as C(CH₃)₂CN. In other embodiments, R²is optionally substituted with C_1-6haloalkyl, such as CF₃, CHF₂, CH₂F, CH(CH₃)F, CH₂CF₃, C(CH₃)₂F, C(CH₃)F₂, or CH₂CHF₂. In further embodiments, R²is optionally substituted with OH. In still other embodiments, R²is optionally substituted with optionally substituted C_3-8cycloalkyl, such as optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, or optionally substituted cyclohexyl. In further embodiments, R²is optionally substituted with optionally substituted C_3-8cycloalkyl(alkylene) such as optionally substituted cyclopropyl(alkylene) or optionally substituted cyclobutyl(alkylene). In other embodiments, R²is optionally substituted with optionally substituted C_3-8cycloalkenyl, such as optionally substituted cyclohexenyl. In yet further embodiments, R²is optionally substituted with optionally substituted aryl such as optionally substituted phenyl. In further embodiments, R²optionally substituted with optionally substituted aryl(alkylene) such as optionally substituted benzyl. In other embodiments, R²is optionally substituted with optionally substituted heteroaryl, such optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazinyl. In yet other embodiments, R²is optionally substituted with optionally substituted heteroaryl, such optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, or optionally substituted pyridazinyl. In further embodiments, R²is optionally substituted with optionally substituted heterocyclyl such as optionally substituted azetidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, or optionally substituted 6-azaspiro[2.5]octan-6-yl. In yet further embodiments, R²is optionally substituted with optionally substituted morpholinyl(alkylene), optionally substituted piperidinyl(alkylene), optionally substituted piperazinyl(alkylene), or optionally substituted azetidinyl(alkylene). In still other embodiments, R²is optionally substituted with C_1-6hydroxyalkyl such as C(CH₃)₂OH, CH(CH₃)OH, C(CH₃)₂CH₂OH, CH₂C(CH₃)₂OH, or CH(CH₂CH₃)OH. In yet further embodiments, R²is optionally substituted with C_1-6haloalkoxy such as OCF₃, OCH₂CF₃, or OCH₂CH₂CF₃. In still further embodiments, R²is optionally substituted with C_1-6haloalkoxy(alkylene) such as CH₂OCF₃. In other embodiments, R²is optionally substituted with C_1-6alkoxy, such as methoxy or ethoxy. In yet other embodiments, R²is optionally substituted with C_1-6alkoxy(alkylene), such as C(CH₃)₂OCH₃, CH₂OCH₃, or (CH₂)₂OCH₃. In further embodiments, R²is optionally substituted with C_1-6deuteratedalkoxy(alkylene) such as CH₂OCD₃. In further embodiments, R²is optionally substituted with C_1-6alkylcarbonyl, such as C(═O)CH₃or CH₂C(═O)CH₃. In yet other embodiments, R²is optionally substituted with C_3-8cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In other embodiments, R²is optionally substituted with C_1-6alkylsulfonyl such as methylsulfonyl, ethylsulfonyl, or propylsulfonyl. In yet other embodiments, R²is optionally substituted with C_1-6alkylsulfonyl(alkylene), such as C(CH₃)₂SO₂CH₃. In still further embodiments, R²is optionally substituted with (CR^vR^x)_pNR^yR^z, wherein RV, R^x, R^y, R^z, and p are defined above, such as NH₂, NHcyclopropyl, NHCH₃, N(CH₃)₂, CH₂N(CH₃)₂, (CH₂)₂N(CH₃)₂, CH₂N(CH₃)(CH₂CH₃), C(CH₃)₂NH(CH₃), C(CH₃)₂N(CH₃)₂, CH₂N(CH₃)cyclobutyl, or CH₂N(CH₃)(C(O)Otert-butyl). In some embodiments, p is 0. In other embodiments, p is 1. In further embodiments, p is 2. In still other embodiments, p is 3. In some embodiments, R^vand R^xare, independently, hydrogen or methyl. In other embodiments, R^yand R^zare, independently, hydrogen, methyl, ethyl, cyclopropyl, cyclobutyl, C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)Otert-butyl. In other embodiments, R²is C(O)NR^y2R^z2, wherein R^y2and R^z2are defined above, such as C(O)N(CH₃)₂or C(O)NHcyclopropyl. In yet other embodiments, R^y2and R^z2are, independently, hydrogen, methyl, or cyclopropyl. In further embodiments, R²is substituted with one or more of methyl, ethyl, propyl, isopropyl, tert-butyl, CH═CH₂, CH═CHC(CH₃)₂OH, CH═CH-cyclopropyl, Br, Cl, F, CN, C(CH₃)₂CN, CF₃, CHF₂, CH₂F, CH(CH₃)F, CH₂CF₃, C(CH₃)₂F, C(CH₃)F₂, CH₂CHF₂, OH, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, optionally substituted cyclohexyl, optionally substituted cyclohexenyl, optionally substituted cyclopropyl(alkylene), optionally substituted cyclobutyl(alkylene), optionally substituted phenyl, optionally substituted benzyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyrazinyl, optionally substituted azetidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, optionally substituted pyrrolidinyl, optionally substituted morpholinyl, optionally substituted 6-azaspiro[2.5]octan-6-yl, optionally substituted morpholinyl(alkylene), optionally substituted piperidinyl(alkylene), optionally substituted piperazinyl(alkylene), or optionally substituted azetidinyl(alkylene), C(CH₃)₂OH, CH(CH₃)OH, C(CH₃)₂CH₂OH, CH₂C(CH₃)₂OH, CH(CH₂CH₃)OH, OCH₂CH₂CF₃, OCF₃, OCH₂CF₃, CH₂OCF₃, methoxy, ethoxy, C(CH₃)₂OCH₃, CH₂OCH₃, (CH₂)₂OCH₃, CH₂OCD₃, C(═O)CH₃, CH₂C(═O)CH₃, cyclopropylsulfonyl, cyclobutylsulfonyl, cyclopentylsulfonyl, C(CH₃)₂SO₂CH₃, NH₂, NHcyclopropyl, NHCH₃, N(CH₃)₂, CH₂N(CH₃)₂, (CH₂)₂N(CH₃)₂, CH₂N(CH₃)(CH₂CH₃), C(CH₃)₂NH(CH₃), C(CH₃)₂N(CH₃)₂, CH₂N(CH₃)cyclobutyl, CH₂N(CH₃)(C(O)Otert-butyl), C(O)N(CH₃)₂, or C(O)NHcyclopropyl.

In yet further embodiments, R²is

embedded image

In other embodiments R²is

embedded image

In yet other embodiments, R²is

embedded image

In some embodiments, R²is heterocyclyl, optionally substituted with one or more of halo, C_1-6haloalkyl, or optionally substituted heteroaryl. In still other embodiments, R²is

embedded image

In yet other embodiments, R²is heterocyclyl, substituted with one or more of halo, C_1-6haloalkyl, or optionally substituted heteroaryl. In further embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

In some embodiments, R²is C_3-8cycloalkyl, optionally substituted with one or more of halo, C_1-6alkyl, C_1-6haloalkyl, or OH. In other embodiments, R²is C_3-8cycloalkyl, optionally substituted with one or more of halo or OH. In yet other embodiments, R²is unsubstituted cyclopropyl, unsubstituted cyclobutyl, unsubstituted cyclopentyl, unsubstituted cyclohexyl,

embedded image

In further embodiments, R²is C_3-8cycloalkyl, substituted with one or more of halo, C_1-6alkyl, C_1-6haloalkyl, or OH. In still further embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In some embodiments, R²is aryl, optionally substituted with one or more of halo or C_1-6alkoxy. In other embodiments, R²is unsubstituted phenyl,

embedded image

In yet other embodiments, R²is aryl, substituted with one or more of halo or C_1-6alkoxy. In further embodiments, R²is

embedded image

In some embodiments, R²is optionally substituted pyridinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazinyl. In other embodiments, the pyridinyl, pyrimidinyl, or pyrazinyl group is substituted with one or more of halo, C_1-6haloalkyl, cyano, or NR^yR^z, wherein R^yand R^zare independently H or C_1-6alkyl.

In still further embodiments, R²is heteroaryl, substituted with one or more of C_1-6alkyl, C_1-6cyanoalkyl, C_1-6haloalkyl, or C_1-6hydroxyalkyl. In other embodiments, R²is heteroaryl substituted with one or more of C_1-6alkyl. In yet other embodiments, R²is heteroaryl substituted with one or more of C_1-6cyanoalkyl. In further embodiments, R²is heteroaryl substituted with one or more of C_1-6haloalkyl. In still further embodiments, R²is heteroaryl substituted with one or more of C_1-6fluoroalkyl. In yet other embodiments, R²is heteroaryl substituted with one or more of C_1-6hydroxyalkyl. In other embodiments, R²is heteroaryl, substituted with one or more of methyl, ethyl, isopropyl, tert-butyl, C(CH₃)₂CN, CH(CH₃)OH, C(CH₃)₂OH, C(CH₃)₂CH₂OH, CH(CH₂CH₃)OH, CH₂C(CH₃)₂OH, CH₂F, CHF₂, CF₃, CH₂CF₃, CH₂CHF₂, CH(CH₃)F, C(CH₃)F₂, or C(CH₃)₂F. In yet other embodiments, R²is heteroaryl, substituted with one or more of methyl, isopropyl, tert-butyl, C(CH₃)₂CN, CH(CH₃)OH, C(CH₃)₂OH, CHF₂, CF₃, CH₂CF₃, CH(CH₃)F, or C(CH₃)₂F. In other embodiments, R²is heteroaryl, substituted with methyl. In yet other embodiments, R²is heteroaryl, substituted with isopropyl. In other embodiments, R²is heteroaryl, substituted with tert-butyl. In yet other embodiments, R²is heteroaryl, substituted with C(CH₃)₂CN. In still further embodiments, R²is heteroaryl, substituted with CH(CH₃)OH. In other embodiments, R²is heteroaryl, substituted with C(CH₃)₂OH. In further embodiments, R²is heteroaryl, substituted with CHF₂. In still other embodiments, R²is heteroaryl, substituted with CF₃. In further embodiments, R²is heteroaryl, substituted with CH₂CF₃. In still other embodiments, R²is heteroaryl, substituted with CH(CH₃)F. In other embodiments, R²is heteroaryl, substituted with C(CH₃)₂F.

In other embodiments, R²is heteroaryl, substituted with C_3-8cycloalkyl, wherein the C_3-8cycloalkyl itself is optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl or C_1-6alkoxy. In yet other embodiments, R²is heteroaryl, substituted with an unsubstituted C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In further embodiments, R²is heteroaryl, substituted with cyclopropyl or cyclobutyl. In yet other embodiments, R²is heteroaryl, substituted with C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the C_3-8cycloalkyl itself is substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl or C_1-6alkoxy. In some embodiments, the substituted C_3-8cycloalkyl is substituted with OH. In still further embodiments, the substituted C_3-8cycloalkyl is substituted with one or more of halo, such as F, Cl, or Br. In other embodiments, the substituted C_3-8cycloalkyl is substituted with C_1-6alkyl, such as methyl, ethyl, or propyl. In further embodiments, the substituted C_3-8cycloalkyl is substituted with C_1-6haloalkyl, such as CF₃, CH₂CF₃, or CHF₂. In still other embodiments, the substituted C_3-8cycloalkyl is substituted with C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In further embodiments, the substituted C_3-8cycloalkyl is cyclopropyl or cyclobutyl, each of which is substituted with one or more of F, OH, or methyl. In other embodiments, R²is heteroaryl, substituted with

embedded image

In still other embodiments, R²is heteroaryl, substituted with

embedded image

In other embodiments, R²is heteroaryl, substituted with aryl, wherein the aryl itself is optionally substituted with one or more of halo, C_1-6haloalkyl, C_1-6alkyl, or C_3-8cycloalkyl. In yet other embodiments, R²is heteroaryl, substituted with an unsubstituted phenyl. In further embodiments, R²is heteroaryl, substituted with aryl, such as phenyl, wherein the aryl itself is substituted with one or more of halo, C_1-6haloalkyl, C_1-6alkyl, or C_3-8cycloalkyl. In some embodiments, the substituted aryl is substituted with one or more of halo, such as F, Cl, or Br. In yet other embodiments, the substituted aryl is substituted with C_1-6haloalkyl, such as CF₃, CH₂CF₃, or CHF₂. In still further embodiments, the substituted aryl is substituted with C_1-6alkyl, such as methyl, ethyl, or propyl. In other embodiments, the substituted aryl is substituted with C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, or cyclopentyl. In yet other embodiments, the substituted aryl is phenyl that is substituted with one or more of F, methyl, or CF₃. In further embodiments, R²is heteroaryl, substituted with

embedded image

In still further embodiments, R²is heteroaryl, substituted with

embedded image

In still further embodiments, R²is heteroaryl, substituted with an optionally substituted heteroaryl. In some embodiments, the optionally substituted heteroaryl is optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, or optionally substituted pyrimidinyl. In yet other embodiments, the optional substitution on the heteroaryl is one or more of halo, C_1-6haloalkyl, C_1-6alkyl, C_1-6alkoxy, C_1-6haloalkoxy, C_3-8cycloalkyl or C_3-8cycloalkylsulfonyl. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of halo, such as F, Cl, or Br. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6haloalkyl, such as CF₃, CH₂CF₃, CH₂CHF₂, or CHF₂. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6alkyl, such as methyl, ethyl, propyl, or isopropyl. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6haloalkoxy, such as OCF₃. In yet other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the optionally substituted heteroaryl is substituted with one or more of C_3-8cycloalkylsulfonyl, such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more of F, CF₃, CH₂CHF₂, CHF₂, methyl, methoxy, cyclobutyl, or cyclopropylsulfonyl.

In yet other embodiments, R²is heteroaryl, substituted with pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, imidazol-4-yl, or imidazol-5-yl, each of which can be optionally substituted. In further embodiments, R²is substituted with pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, imidazol-4-yl, imidazol-5-yl, pyridazin-3-yl, pyridazin-4-yl, each of which is optionally substituted. In still further embodiments, R²is substituted with optionally substituted pyrazol-1-yl. In other embodiments, R²is substituted with optionally substituted pyrazol-3-yl. In further embodiments, R²is substituted with optionally substituted pyrazol-4-yl. In yet further embodiments, R²is substituted with optionally substituted pyridin-2-yl. In other embodiments, R²is substituted with optionally substituted pyridin-3-yl. In further embodiments, R²is substituted with optionally substituted pyridin-4-yl. In further embodiments, R²is substituted with optionally substituted imidazol-4-yl. In yet other embodiments, R²is substituted with optionally substituted imidazol-5-yl. In further embodiments, R²is substituted with optionally substituted pyrimidin-2-yl. In other embodiments, R²is substituted with optionally substituted pyrimidin-4-yl. In still further embodiments, R²is substituted with optionally substituted pyrimidin-5-yl. In yet other embodiments, R²is substituted with optionally substituted pyrazin-2-yl. In other embodiments, R²is substituted with optionally substituted pyridazin-3-yl. In further embodiments, R²is substituted with optionally substituted pyridazin-4-yl.

In some embodiments, R²is heteroaryl, substituted with

embedded image

In still further embodiments, R²is heteroaryl, substituted with

embedded image

In some embodiments, R²is heteroaryl, substituted with

embedded image

In other embodiments R²is heteroaryl, substituted with

embedded image

In still other embodiments, R²is heteroaryl, substituted with

embedded image

In other embodiments, R²is heteroaryl, substituted with heterocyclyl or heterocyclyl(alkylene), wherein the heterocyclyl and heterocyclyl(alkylene) groups themselves are each optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C(O)O(C_1-6alkyl), or C_3-8cycloalkyl. In yet other embodiments, R²is heteroaryl, substituted with an unsubstituted heterocyclyl group such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, or 6-azaspiro[2.5]octan-6-yl, or unsubstituted heterocyclyl(alkylene) group, such as azetidinyl(alkylene), pyrrolidinyl(alkylene), piperidinyl(alkylene), piperazinyl(alkylene), or morpholinyl(alkylene). In further embodiments, R²is heteroaryl, substituted with heterocyclyl, such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, or heterocyclyl(alkylene), such as azetidinyl(alkylene), pyrrolidinyl(alkylene), piperidinyl(alkylene), piperazinyl(alkylene), or morpholinyl(alkylene), wherein the heterocyclyl and heterocyclyl(alkylene) groups themselves are each substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C(O)O(C_1-6alkyl), or C_3-8cycloalkyl. In further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of halo, such as F, Cl, or Br. In yet further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of OH. In yet other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6haloalkyl, such as CF₃, CH₂CF₃, or CHF₂. In still further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6alkyl, such as methyl, ethyl, or propyl. In yet further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6hydroxyalkyl such as C(CH₃)₂OH, or CH(CH₃)OH. In other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In yet other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C(O)O(C_1-6alkyl), such as C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)Otert-butyl. In further embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of C_3-8cycloalkyl, such as cyclopropyl, cyclobutyl, or cyclopentyl. In yet other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more of F, OH, or methyl. In yet other embodiments where R²is heteroaryl the R²is substituted with

embedded image

In still further embodiments where R²is heteroaryl the R²is substituted with

embedded image

In further embodiments, R²is

embedded image

In yet further embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

In yet further embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

In still other embodiments, R²is

embedded image

In yet further embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In these structures for R², R⁶and R⁷are each independently, H, CN, C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene), halo, (CR^vR^x)_pNR^yR^z, C(O)NR^y2R^z2, C_1-6alkylcarbonyl, optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted C_2-6alkenyl, optionally substituted C_3-8cycloalkenyl, optionally substituted (C_3-8cycloalkyl)alkylene, optionally substituted (aryl)alkylene, optionally substituted (heterocyclyl)alkylene, or C_1-6alkylsulfonyl; R⁸is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), C_1-6alkylcarbonyl, C_1-6hydroxyalkyl, (CR^vR^x)_pNR^yR^z, optionally substituted C_3-8cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted (C_3-8cycloalkyl)alkylene; R^vand R^xare, independently, H or C_1-6alkyl; R^yand R^zare, independently, H, C_1-6alkyl, C_1-6alkoxy(alkylene), or C_3-6cycloalkyl; R^y2and R^z2are, independently, H, C_1-6alkyl, or C_3-6cycloalkyl; and p is 0, 1, 2, or 3. In some embodiments, R⁶, R⁷, and R⁸are H.

In other embodiments, R⁶is C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, or C_1-6hydroxyalkyl. In further embodiments, R⁶is C_1-6alkyl such as methyl, ethyl, isopropyl or tert-butyl. In still further embodiments, R⁶is C_1-6haloalkyl such as CF₃, CHF₂, CH₂F, CH₂CF₃, CH(CH₃)F, C(CH₃)F₂, or C(CH₃)₂F. In further embodiments, R⁶is C_1-6cyanoalkyl such as C(CH₃)₂CN. In other embodiments, R⁶is C_1-6hydroxyalkyl such as C(CH₃)₂OH, CH(CH₃)OH, CH(CH₂CH₃)OH, CH₂C(CH₃)₂OH, or C(CH₃)₂CH₂OH. In further embodiments, R⁶is methyl, isopropyl, tert-butyl, CF₃, CHF₂, C(CH₃)F₂, C(CH₃)₂F, C(CH₃)₂OH, or CH(CH₃)OH.

In other embodiments, R⁶is C_3-6cycloalkyl optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, or C_1-6alkoxy. In further embodiments, R⁶is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, or C_1-6alkoxy. In still further embodiments, R⁶is unsubstituted cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In other embodiments, R⁶is C_3-6cycloalkyl substituted with one or more halo such as F, Cl, or Br. In yet other embodiments, R⁶is C_3-6cycloalkyl substituted with one or more OH. In still further embodiments, R⁶is C_3-6cycloalkyl substituted with one or more C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂. In further embodiments, R⁶is C_3-6cycloalkyl substituted with one or more C_1-6alkyl such as methyl, ethyl, or propyl. In still further embodiments, R⁶is C_3-6cycloalkyl substituted with C_1-6alkoxy, such as one or more methoxy, ethoxy, or propoxy. In other embodiments, R⁶is cyclopropyl, cyclobutyl, or cyclohexyl, each of which is optionally substituted with one or more of F, OH, or methyl. In other embodiments, R⁶is

embedded image

In other embodiments, R⁶is

embedded image

In further embodiments, R⁶is aryl optionally substituted with one or more of halo, C_1-6haloalkyl, C_1-6alkyl or C_3-6cycloalkyl. In other embodiments, R⁶is phenyl optionally substituted with one or more of halo, C_1-6haloalkyl, C_1-6alkyl or C_3-6cycloalkyl. In still other embodiments, R⁶is aryl optionally substituted with one or more of halo such as F, Cl, or Br. In yet other embodiments, R⁶is aryl optionally substituted with one or more of C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂. In other embodiments, R⁶is aryl optionally substituted with one or more of C_1-6alkyl such as methyl, ethyl, or propyl. In yet other embodiments, R⁶is aryl optionally substituted with one or more of C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, R⁶is aryl (e.g., phenyl) optionally substituted with F, methyl, or CF₃. In other embodiments, R⁶is

embedded image

In yet other embodiments, R⁶is

embedded image

In yet other embodiments, R⁶is heteroaryl, optionally substituted with one or more of halo, C_1-6haloalkyl, C_1-6alkyl, C_1-6alkoxy, C_1-6haloalkoxy, C_3-6cycloalkyl, or C_3-6cycloalkylsulfonyl. In still other embodiments, R⁶is pyridinyl, pyrazolyl, pyrazinyl, imidazolyl, or pyrimidinyl, each of which is optionally substituted. In still other embodiments, R⁶is pyridinyl, pyrazolyl, pyrazinyl, pyridazinyl, imidazolyl, or pyrimidinyl, each of which is optionally substituted. In further embodiments, R⁶is optionally substituted pyrazinyl such as pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, or pyrazin-5-yl. In other embodiments, R⁶is optionally substituted pyrazolyl such as pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, or pyrazol-5-yl. In still further embodiments, R⁶is optionally substituted pyridinyl such as pyridin-2-yl, pyridin-3-yl, or pyridin-4-yl. In other embodiments, R⁶is optionally substituted pyridazinyl such as pyridazin-3-yl or pyridazin-4-yl. In yet other embodiments, R⁶is optionally substituted imidazolyl such as imidazol-4-yl or imidazol-5-yl. In further embodiments, R⁶is optionally substituted pyrimidinyl such as pyridimin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl. In other embodiments, R⁶is pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-4-yl, imidazol-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, or pyrimidin-5-yl, each of which is optionally substituted. In yet other embodiments, R⁶is pyrazin-2-yl, pyrazin-3-yl, pyrazin-4-yl, pyrazin-5-yl, pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, imidazol-4-yl, imidazol-5-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl or pyridazin-4-yl, each of which is optionally substituted. In further embodiments, R⁶is unsubstituted pyridin-2-yl, unsubstituted pyridin-3-yl, unsubstituted pyridin-4-yl, unsubstituted pyrimidin-2-yl, unsubstituted pyrimidin-4-yl, unsubstituted pyrimidin-5-yl, or unsubstituted pyrazin-2-yl. In further embodiments, R⁶is unsubstituted pyridin-2-yl, unsubstituted pyridin-3-yl, unsubstituted pyridin-4-yl, unsubstituted pyrimidin-2-yl, unsubstituted pyrimidin-4-yl, unsubstituted pyrimidin-5-yl, unsubstituted pyrazin-2-yl, or pyridazin-3-yl. In other embodiments, R⁶is optionally substituted with one or more halo such as F, Cl, or Br. In yet other embodiments, R⁶is optionally substituted with one or more C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂. In other embodiments, R⁶is optionally substituted with one or more C_1-6alkyl such as methyl, ethyl, propyl, or isopropyl. In still other embodiments, R⁶is optionally substituted with one or more C_1-6alkoxy such as methoxy, ethoxy, or propoxy. In yet further embodiments, R⁶is optionally substituted with one or more C_1-6haloalkoxy such as OCF₃. In further embodiments, R⁶is optionally substituted with one or more C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl. In yet further embodiments, R⁶is optionally substituted with one or more C_3-6cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In yet other embodiments, R⁶is heteroaryl optionally substituted with one or more of F, CF₃, CH₂CF₃, CHF₂, methyl, methoxy, OCF₃, cyclobutyl, or cyclopropylsulfonyl.

In other embodiments, R⁶is a five-membered heteroaryl, optionally substituted with one or more of CF₃, CH₂CF₃, CHF₂, methyl, cyclobutyl, or cyclopropylsulfonyl. In further embodiments, R⁶is

embedded image

In still further embodiments, R⁶is

embedded image

In other embodiments, R⁶is

embedded image

In still further embodiments, R⁶is

embedded image

In yet further embodiments, R⁶is

embedded image

In further embodiments, R⁶is

embedded image

In yet further embodiments, R⁶is

embedded image

In other embodiments, R⁶is a six-membered heteroaryl, optionally substituted with one or more of F, CF₃, methoxy, OCF₃, or methyl. In still other embodiments, R⁶is

embedded image

In still further embodiments, R⁶is

embedded image

In yet other embodiments R⁶is

embedded image

In yet other embodiments, R⁶is heterocyclyl or heterocyclyl(alkylene), each optionally substituted with one or more of halo, OH, C_1-6haloalkyl, C_1-6alkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C(O)O(C_1-6alkyl), or C_3-6cycloalkyl. In further embodiments, R⁶is optionally substituted azetidinyl, optionally substituted pyrrolidinyl, optionally substituted piperidinyl, optionally substituted piperazinyl, or optionally substituted morpholinyl. In other embodiments, R⁶is optionally substituted azetidinyl. In yet other embodiments, R⁶is optionally substituted pyrrolidinyl. In further embodiments, R⁶is optionally substituted piperidinyl. In yet other embodiments, R⁶is optionally substituted piperazinyl. In still further embodiments, R⁶is optionally substituted morpholinyl. In other embodiments, R⁶is optionally substituted morpholinyl(alkylene), optionally substituted piperidinyl(alkylene), optionally substituted piperazinyl(alkylene), or optionally substituted azetidinyl(alkylene). In further embodiments, R⁶is unsubstituted azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl. In other embodiments, R⁶is unsubstituted morpholinyl(alkylene), piperidinyl(alkylene), piperazinyl(alkylene), or azetidinyl(alkylene). In yet other embodiments, R⁶is unsubstituted morpholinyl or morpholinyl(alkylene). In other embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more halo such as F, Cl, or Br. In yet other embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more OH. In further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂. In still further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6alkyl such as methyl, ethyl, or propyl. In further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6hydroxyalkyl such as C(CH₃)₂OH. In yet further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_1-6alkoxy, such as methoxy, ethoxy, or propoxy. In other embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C(O)O(C_1-6alkyl), such as C(O)Omethyl, C(O)Oethyl, C(O)Opropyl, or C(O)Otert-butyl. In still further embodiments, the heterocyclyl and heterocyclyl(alkylene) groups are optionally substituted with one or more C_3-6cycloalkyl such as one or more cyclopropyl, cyclobutyl, or cyclopentyl. In yet other embodiments, R⁶is heterocyclyl and heterocyclyl(alkylene), each optionally substituted with one or more of F, OH, C(CH₃)₂(OH), methyl, C(O)O(tert-butyl), or cyclopropyl.

In further embodiments, R⁶is

embedded image

In yet other embodiments, R⁶is

embedded image

In further embodiments, R⁶is

embedded image

In still further embodiments, R⁶is

embedded image

In yet other embodiments, R⁶is

embedded image

In other embodiments, R⁶is

embedded image

In yet further embodiments, R⁶is

embedded image

In further embodiments, R⁶is H, CN, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_1-6deuteratedalkoxy(alkylene), halo, (CR^vR^x)_pNR^yR^z, C(O)NR^y2R^z2, C_1-6alkylcarbonyl, optionally substituted C_2-6alkenyl, optionally substituted C_3-6cycloalkenyl, optionally substituted (C_3-6cycloalkyl)alkylene, optionally substituted (aryl)alkylene, or C_1-6alkylsulfonyl. In other embodiments, R⁶is H. In further embodiments, R⁶is CN. In still other embodiments, R⁶is C_1-6alkoxy such as methoxy. In yet other embodiments, R⁶is C_1-6alkoxy(alkylene) such as CH₂OCH₃, C(CH₃)₂OCH₃, or (CH₂)₂OCH₃. In still other embodiments, R⁶is C_1-6haloalkoxy such as OCF₃, OCHF₂, OCH₂F, or O(CH₂)₂CF₃. In other embodiments, R⁶is C_1-6haloalkoxy(alkylene) such as CH₂OCF₃. In yet other embodiments, R⁶is C_1-6deuteratedalkoxy(alkylene) such as CH₂OCD₃. In further embodiments, R⁶is halo such as F, Br, or Cl. In yet further embodiments, R⁶is (CR^vR^x)_pNR^yR^zsuch as NH₂, N(CH₃)₂, NHCH₂CF₃, NHCH₂CH₂OCH₃, NH(cyclopropyl), CH₂N(CH₃)₂, (CH₂)₂N(CH₃)₂, C(CH₃)₂NHCH₃, C(CH₃)₂N(CH₃)₂, CH₂NH(cyclopropyl), or CH₂CH₂NH(cyclopropyl). In other embodiments, R⁶is C(O)NR^y2R^z2such as C(O)N(CH₃)₂or C(O)NH(cyclopropyl). In yet other embodiments, R⁶is C_1-6alkylcarbonyl such as C(O)CH₃. In further embodiments, R⁶is optionally substituted C_2-6alkenyl such as CH═CH₂, CH═CH-cyclopropyl, or CH═CHC(CH₃)₂OH. In yet other embodiments, R⁶is optionally substituted C_3-6cycloalkenyl such as

embedded image

In still other embodiments, R⁶is optionally substituted (C_3-6cycloalkyl)alkylene such as CH₂-cyclopropyl, CH₂CH₂-cyclopropyl or C(CH₃)OH-cyclopropyl. In further embodiments, R⁶is optionally substituted (aryl)alkylene such as benzyl. In other embodiments, C_1-6alkylsulfonyl(alkylene) such as C(CH₃)₂SO₂CH₃. In yet other embodiments, R⁶is H, CH₂OCH₃, Cl, NH(cyclopropyl), or C(O)N(CH₃)₂.

In some embodiments, R⁷is H, CN, C_1-6alkyl, C_1-6haloalkyl, halo, C_3-8cycloalkyl, aryl, or heteroaryl. In yet other embodiments, R⁷is H. In still further embodiments, R⁷is CN. In other embodiments, R⁷is C_1-6alkyl, such as methyl, ethyl, or propyl. In further embodiments, R⁷is methyl. In yet other embodiments, R⁷is C_1-6haloalkyl, such as CHF₂, CH₂F, C(CH₃)F₂, CH₂CHF₂, or CF₃. In still further embodiments, R⁷is CHF₂or CF₃. In further embodiments, R⁷is halo, such as F, Br, or Cl. In yet other embodiments, R⁷is Br or Cl. In still further embodiments, R⁷is C_3-6cycloalkyl, such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, R⁷is cyclopropyl. In further embodiments, R⁷is aryl. In yet other embodiments, R⁷is phenyl. In still further embodiments, R⁷is heteroaryl. In other embodiments, R⁷is pyridinyl. In further embodiments, R⁷is H, CN, methyl, CF₃, CH₂F, CHF₂, CF₂(CH₃), CH₂CHF₂, Br, Cl, cyclopropyl, phenyl, or pyridinyl. In yet other embodiments, R⁷is H, CN, methyl, CHF₂, CF₃, Br, Cl, cyclopropyl, phenyl, or pyridinyl.

In some embodiments of R², R⁸is H. In other embodiments, R⁸is C_1-6alkyl such as methyl, ethyl, isopropyl, or tert-butyl. In further embodiments, R⁸is C_1-6haloalkyl such as CF₃, CHF₂, CH₂F, CH₂CF₃, CH₂CHF₂, C(CH₃)₂F, or C(CH₃)F₂. In still further embodiments, R⁸is C_1-6alkoxy(alkylene) such as CH₂CH₂OCH₃. In other embodiments, R⁸is C_1-6alkylcarbonyl such as CH₂C(═O)CH₃. In still other embodiments, R⁸is C_1-6hydroxyalkyl such as CH₂C(CH₃)₂OH. In further embodiments, R⁸is (CR^vR^x)_pNR^yR^zsuch as (CH₂)₂N(CH₃)₂. In yet other embodiments, R⁸is optionally substituted C_3-8cycloalkyl such as optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, or optionally substituted cyclohexyl. In other embodiments, R⁸is optionally substituted aryl such as optionally substituted phenyl. In further embodiments, R⁸is optionally substituted heteroaryl, such as optionally substituted pyridinyl. In still further embodiments, R⁸is optionally substituted heteroaryl such as optionally substituted pyridinyl. In yet other embodiments, R⁸is optionally substituted (C_3-8cycloalkyl)alkylene such as

embedded image

In still further embodiments, R⁸is H, methyl, isopropyl, CHF₂, CH₂CF₃, CF₃, cyclopropyl, or

embedded image

In some embodiments, one or both of R^vand R^xare H. In other embodiments, one or both of R^vand R^xare C_1-6alkyl such as methyl, ethyl, propyl, or butyl. In yet other embodiments, one or both of R^vand R^xare methyl. In some embodiments, one or both of R^yand R^zare H. In other embodiments, one or both of R^yand R^zare C_1-6alkyl such as methyl, ethyl, propyl, or butyl. In yet other embodiments, one or both of R^yand R^zare C_1-6alkoxy(alkylene) such as CH₂OCH₃. In further embodiments, one or both of R^yand R^zare C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, one or both of R^y2and R^z2are H. In other embodiments, one or both of R^y2and R^z2are C_1-6alkyl such as methyl, ethyl, propyl, or butyl. In further embodiments, one or both of R^y2and R^z2are C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In further embodiments, p is 0. In other embodiments, p is 1. In still further embodiments, p is 2. In yet other embodiments, p is 3.

In some embodiments, R²is

embedded image

wherein: R⁶is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), optionally substituted C_3-6cycloalkyl, or optionally substituted heteroaryl; and R⁷is H, CN, C_1-6alkyl, C_1-6haloalkyl, halo, C_3-6cycloalkyl, aryl, or heteroaryl. In further embodiments, R⁶is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6cyanoalkyl, C_1-6hydroxyalkyl, optionally substituted C_3-6cycloalkyl, or optionally substituted heteroaryl; and R⁷is H, CN, C_1-6alkyl, C_1-6haloalkyl, halo, or C_3-6cycloalkyl. In other embodiments, R⁶is H. In further embodiments, R⁶is C_1-6alkyl. In still further embodiments, R⁶is methyl, isopropyl, or tert-butyl. In yet other embodiments, R⁶is C_1-6haloalkyl. In still further embodiments, R⁶is CF₂H, C(CH₃)₂F, CH(CH₃)F, or CF₃. In other embodiments, R⁶is C_1-6cyanoalkyl. In further embodiments, R⁶is C(CH₃)₂CN. In yet other embodiments, R⁶is C_1-6hydroxyalkyl. In still further embodiments, R⁶is C(CH₃)₂OH, CH₂C(CH₃)₂OH, CH(CH₂CH₃)OH, C(CH₃)₂(CH₂OH), or CH(CH₃)OH. In other embodiments, R⁶is C_1-6alkoxy. In still other embodiments, R⁶is methoxy or ethoxy. In yet other embodiments, R⁶is C_1-6alkoxy(alkylene). In further embodiments, R⁶is CH₂OCH₃or (CH₂)₂OCH₃. In other embodiments, R⁶is optionally substituted C_3-6cycloalkyl. In yet other embodiments, the optionally substituted C_3-6cycloalkyl is substituted with one or more OH. In further embodiments, R⁶is

embedded image

In yet other embodiments, R⁶is

embedded image

In other embodiments, R⁶is optionally substituted heteroaryl. In yet other embodiments, R⁶is optionally substituted pyridinyl, optionally substituted pyrazolyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted imidazolyl. In still other embodiments, the optionally substituted heteroaryl is substituted with one or more C_1-6alkyl such as methyl, ethyl, or isopropyl. In further embodiments, R⁶is

embedded image

In still further embodiments, R⁶is

embedded image

In other embodiments, R⁶is H, methyl, tert-butyl, C(CH₃)₂F, C(CH₃)₂CN, C(CH₃)₂OH, CH(CH₃)OH, CH₂OCH₃, cyclopropyl,

embedded image

In further embodiments, R⁶is H, tert-butyl, C(CH₃)₂F, C(CH₃)₂CN, C(CH₃)₂OH, CH(CH₃)OH,

embedded image

In yet other embodiments, R⁷is H. In still further embodiments, R⁷is CN. In other embodiments, R⁷is C_1-6alkyl. In further embodiments, R⁷is methyl. In yet other embodiments, R⁷is C_1-6haloalkyl. In still further embodiments, R⁷is CF₂H, CHF₂, CH₂F, C(CH₃)F₂, or CF₃. In other embodiments, R⁷is CHF₂or CF₃. In further embodiments, R⁷is halo. In yet other embodiments, R⁷is Br or Cl. In still further embodiments, R⁷is C_3-6cycloalkyl. In other embodiments, R⁷is cyclopropyl. In further embodiments, R⁷is aryl. In yet other embodiments, R⁷is phenyl. In still further embodiments, R⁷is heteroaryl. In other embodiments, R⁷is pyridinyl. In yet other embodiments, R⁷is H, CN, methyl, CHF₂, CF₃, Br, Cl, cyclopropyl, phenyl, or pyridinyl. In still other embodiments, R⁷is H, CN, methyl, CHF₂, CF₃, Br, Cl, or cyclopropyl.

In other embodiments, R²is

embedded image

wherein: R⁶is H, CN, C_1-6alkyl, C_1-6haloalkyl, C_1-6hydroxyalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), optionally substituted C_3-6cycloalkyl, optionally substituted heteroaryl; and R⁷is H, C_1-6alkyl, C_1-6haloalkyl, halo, or C_3-6cycloalkyl. In yet other embodiments, R⁶is H, C_1-6alkyl, C_1-6haloalkyl, or C_1-6hydroxyalkyl; and R⁷is H. In further embodiments, R⁶is H. In other embodiments, R⁶is CN. In further embodiments, R⁶is C_1-6alkyl. In still further embodiments, R⁶is methyl, isopropyl, or tert-butyl. In yet other embodiments, R⁶is C_1-6haloalkyl. In still further embodiments, R⁶is CHF₂, C(CH₃)₂F, C(CH₃)F₂, or CF₃. In yet other embodiments, R⁶is C_1-6hydroxyalkyl. In still further embodiments, R⁶is C(CH₃)₂OH. In other embodiments, R⁶is C_1-6alkoxy. In still further embodiments, R⁶is methoxy or ethoxy. In yet other embodiments, R⁶is C_1-6alkoxy(alkylene). In further embodiments, R⁶is CH₂OCH₃. In other embodiments, R⁶is optionally substituted C_3-6cycloalkyl. In yet further embodiments, R⁶is

embedded image

In other embodiments, R⁶is optionally substituted heteroaryl. In yet other embodiments, R⁶is optionally substituted pyridinyl or optionally substituted pyrazolyl. In further embodiments, R⁶is

embedded image

In other embodiments, R⁶is H, tert-butyl, C(CH₃)₂F, C(CH₃)F₂, C(CH₃)₂OH, CH₂OCH₃,

embedded image

In further embodiments, R⁶is H or C(CH₃)₂F. In yet other embodiments, R⁷is H. In other embodiments, R⁷is C_1-6alkyl. In further embodiments, R⁷is methyl. In yet other embodiments, R⁷is C_1-6haloalkyl. In still further embodiments, R⁷is CF₂H or CF₃. In further embodiments, R⁷is halo. In yet other embodiments, R⁷is Br or Cl. In still further embodiments, R⁷is C_3-6cycloalkyl. In other embodiments, R⁷is cyclopropyl. In still further embodiments, R⁷is H, methyl, CF₂H, CF₃, Br, Cl, or cyclopropyl.

In further embodiments, R²is

embedded image

wherein R⁶and R⁷are independently H, C_1-6alkyl, C_1-6haloalkyl, halo, optionally substituted C_3-6cycloalkyl, or optionally substituted aryl. In other embodiments, R⁶and R⁷are each H. In further embodiments, one of R⁶or R⁷is C_1-6alkyl such as methyl. In yet other embodiments, one of R⁶or R⁷is C_1-6haloalkyl such as CF₃. In still other embodiments, one of R⁶or R⁷is halo such as Br or Cl. In yet further embodiments, one of R⁶or R⁷is optionally substituted C_3-6cycloalkyl such as unsubstituted cyclopropyl. In other embodiments, one of R⁶or R⁷is optionally substituted aryl such as unsubstituted phenyl. In yet other embodiments, R⁶is methyl, CF₃, Cl, cyclopropyl, or phenyl and R⁷is H. In still other embodiments, R⁷is methyl, CF₃, Cl, cyclopropyl, or phenyl and R⁶is H.

In yet further embodiments, R²is

embedded image

wherein R⁶is H, C_1-6alkyl, halo, or optionally substituted aryl. In other embodiments, R⁶is H. In further embodiments, R⁶is C_1-6alkyl, such as methyl, ethyl, isopropyl, or tert-butyl. In other embodiments, R⁶is methyl or ethyl. In other embodiments, R⁶is halo, such as F, Br, or Cl. In further embodiments, R⁶is Br. In other embodiments, R⁶is optionally substituted aryl. In further embodiments, R⁶is phenyl. In yet other embodiments, R⁶is H, methyl, ethyl, Br, or phenyl. In still other embodiments, R⁶is H, methyl, or phenyl.

In yet other embodiments, R²is

embedded image

wherein R⁶is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6hydroxyalkyl, C(O)NR^y2R^z2, (CR^vR^x)_pNR^yR^z, optionally substituted C_3-6cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl; R^vand R^xare, independently, H or C_1-6alkyl; R^yand R^zare, independently, H, C_1-6alkyl, C_1-6alkoxy(alkylene), or C_3-6cycloalkyl; R^y2and R^z2are, independently, H, C_1-6alkyl, or C_3-8cycloalkyl; and p is 0, 1, 2, or 3. In further embodiments, R⁶is H, C_1-6alkyl, C_1-6haloalkyl, C_1-6hydroxyalkyl, optionally substituted C_3-6cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, or optionally substituted heteroaryl. In some embodiments, R⁶is H. In further embodiments, R⁶is C_1-6alkyl. In other embodiments, R⁶is methyl, ethyl, isopropyl, or tert-butyl. In further embodiments, R⁶is methyl, isopropyl, or tert-butyl. In other embodiments, R⁶is C_1-6haloalkyl. In further embodiments, R⁶is CHF₂, CF₃, or C(CH₃)₂F. In still further embodiments, R⁶is CF₃, CHF₂, C(CH₃)F₂, or C(CH₃)₂F. In yet other embodiments, R⁶is C_1-6hydroxyalkyl. In still further embodiments, R⁶is C(CH₃)₂OH or CH(CH₃)OH. In still other embodiments, R⁶is C(O)NR^y2R^z2. In yet further embodiments, R⁶is C(O)N(CH₃)₂or C(O)NH(cyclopropyl). In other embodiments, R⁶is (CR^vR^x)_pNR^yR^z. In further embodiments, R⁶is NH₂, N(CH₃)₂, NHCH₂CF₃, NHCH₂CH₂OCH₃, NH(cyclopropyl), CH₂N(CH₃)₂, CH₂NH(cyclopropyl), or CH₂CH₂NH(cyclopropyl). In yet other embodiments, R⁶is optionally substituted C_3-6cycloalkyl. In still other embodiments, the optionally substituted C_3-6cycloalkyl is substituted with one or more of halo such as F or C_1-6alkyl such as methyl. In still further embodiments, R⁶is

embedded image

In other embodiments, R⁶is optionally substituted aryl. In yet other embodiments, the optionally substituted aryl is substituted with one or more of halo such as F, C_1-6alkyl such as methyl, or C_1-6haloalkyl such as CF₃. In further embodiments, R⁶is

embedded image

In still other embodiments, R⁶is optionally substituted heterocyclyl. In further embodiments, the optionally substituted heterocyclyl is substituted with one or more of halo such as F or C_1-6alkyl such as methyl. In yet further embodiments, R⁶is

embedded image

In yet other embodiments, R⁶is

embedded image

In other embodiments, R⁶is optionally substituted heteroaryl such as optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted pyridinyl, or optionally substituted pyrazinyl. In further embodiments, the optionally substituted heteroaryl is substituted with one or more of C_1-6alkyl such as methyl, ethyl, or isopropyl, C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂, halo such as F, C_1-6alkoxy such as methoxy, ethoxy, or propoxy, C_3-6cycloalkyl such as cyclopropyl or cyclobutyl; or C_3-6cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In yet other embodiments, R⁶is

embedded image

In still other embodiments, R⁶is

embedded image

In further embodiments, R⁶is methyl, isopropyl, tert-butyl, CHF₂, C(CH₃)₂F, C(CH₃)₂OH, CH(CH₃)OH, C(O)N(CH₃)₂, NH(cyclopropyl),

embedded image

phenyl,

embedded image

In still further embodiments, R⁶is methyl, isopropyl, tert-butyl, CF₃, CHF₂, C(CH₃)F₂, C(CH₃)₂F, C(CH₃)₂OH,

embedded image

In still further embodiments, R²is

embedded image

wherein R⁶and R⁷are independently H, halo, C_1-6alkyl, or C_1-6haloalkyl; and R⁸is H, C_1-6alkyl, C_1-6haloalkyl, C_3-6cycloalkyl, optionally substituted aryl, or heteroaryl. In yet other embodiments, R⁶and R⁷are independently H, halo, C_1-6alkyl, C_1-6haloalkyl, or NR^yR^zwherein R^yand R^zare, independently, H or C_1-6alkyl; R⁸is H, C_1-6alkyl, C_1-6alkyl, C_3-6cycloalkyl, or heteroaryl. In other embodiments, one or both of R⁶and R⁷are H. In still other embodiments, one of R⁶or R⁷is halo. In further embodiments, one of R⁶or R⁷is Cl or Br. In still further embodiments, one of R⁶or R⁷is Cl. In yet other embodiments, one of R⁶or R⁷is C_1-6alkyl. In still further embodiments, one of R⁶or R⁷is methyl. In other embodiments, one of R⁶or R⁷is C_1-6haloalkyl. In further embodiments, one of R⁶or R⁷is CHF₂, CH₂CF₃, CF₂H, or CF₃. In other embodiments, one of R⁶or R⁷is CHF₂. In further embodiments, one of R⁶or R⁷is NR^yR^zwherein R^yand R^zare, independently, H or C_1-6alkyl, such as NH₂In yet other embodiments, one of R⁶or R⁷is Cl, Br, methyl, CHF₂, or CF₃. In further embodiments, one of R⁶or R⁷is Cl, methyl, CHF₂, or NH₂. In other embodiments, one of R⁶or R⁷is methyl, Cl, CHF₂, or CF₃. In some embodiments, R⁸is H. In other embodiments, R⁸is C_1-6alkyl. In further embodiments, R⁸is methyl, ethyl, isopropyl, or tert-butyl. In yet other embodiments, R⁸is methyl or isopropyl. In still other embodiments, R⁸is C_1-6haloalkyl. In yet further embodiments, R⁸is CHF₂, CH₂CF₃, CF₂H, CH₂CHF₂, or CF₃. In yet further embodiments, R⁸is CHF₂, CH₂CF₃, or CF₃. In other embodiments, R⁸is C_3-6cycloalkyl. In further embodiments, R⁸is cyclopropyl. In yet other embodiments, R⁸is optionally substituted aryl. In still further embodiments, R⁸is phenyl or fluorophenyl. In other embodiments, R⁸is heteroaryl. In further embodiments, R⁸is pyridinyl. In still other embodiments, R⁸is H, methyl, isopropyl, tert-butyl, CHF₂, CH₂CF₃, CH₂CHF₂, CH₂C(═O)CH₃, CH₂C(CH₃)₂OH, (CH₂)₂N(CH₃)₂, cyclopropyl, fluorophenyl, pyridinyl, CH₂-cyclopropyl or CH₂-cyclobutyl. In yet other embodiments, R⁸is methyl, isopropyl, CHF₂, CH₂CF₃, CF₃, cyclopropyl, and pyridinyl.

In further embodiments, R²is

embedded image

wherein R⁶is H, C_1-6alkyl, halo, C_1-6haloalkyl, or C_3-6cycloalkyl; and R⁸is H, C_1-6alkyl, or C_1-6haloalkyl. In still further embodiments, R⁶is H, C_1-6alkyl, halo, C_1-6haloalkyl, or C_3-6cycloalkyl; and R⁸is H or C_1-6alkyl. In other embodiments, R⁶is H. In still other embodiments, R⁶is C_1-6alkyl, such as methyl. In yet other embodiments, R⁶is halo such as Cl or Br. In further embodiments, R⁶is Cl. In other embodiments, R⁶is C_1-6haloalkyl such as CHF₂or CF₃. In yet other embodiments, R⁶is C_3-6cycloalkyl such as cyclopropyl. In still further embodiments, R⁶is H, methyl, Cl, CHF₂, CF₃, or cyclopropyl. In some embodiments, R⁸is H. In other embodiments, R⁸is C_1-6alkyl such as methyl, ethyl, or isopropyl. In yet other embodiments, R⁸is C_1-6haloalkyl, such as CF₃or CHF₂. In other embodiments, R⁸is methyl.

In yet other embodiments, R²is

embedded image

In these structures, W is S or NR¹⁵; W¹is S, O, or NR¹⁵; R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are each independently, H, C_1-6alkyl, C_1-6haloalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), C_1-6hydroxyalkyl, C_1-6haloalkoxy, C_1-6haloalkoxy(alkylene), C_2-6alkenyl, CN, halo, (CR^vR^x)_pNR^yR^z, C(O)NR^y2R^z2, optionally substituted C_3-8cycloalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted aryl, or optionally substituted heteroaryl; R^vand R^xare, independently, H or C_1-6alkyl; R^yand R^zare, independently, H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6hydroxyalkyl, C_1-6haloalkyl, C_1-6alkoxy(alkylene), or C(O)OC_1-6alkyl; R^y2and R^z2, are independently, H, C_1-6alkyl, or C_3-6cycloalkyl; p is 0, 1, 2, or 3; and R¹⁵is H or C_1-6alkyl.

In some embodiments, W is S. In other embodiments, W is NR¹⁵. In some embodiments, W¹is S. In other embodiments, W¹is O. In further embodiments, W¹is NR¹⁵. In some embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are H. In further embodiments, R¹⁰, R¹¹, R¹², and R¹³are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³and R¹⁴is C_1-6haloalkyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkoxy. In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkoxy(alkylene). In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6hydroxyalkyl. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6haloalkoxy. In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6haloalkoxy(alkylene). In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_2-6alkenyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is CN. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is halo. In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is (CR^vR^x)_pNR^yR^z. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C(O)NR^y2R^z2. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted C_3-8cycloalkyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted heterocyclyl. In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted heterocyclyl(alkylene). In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted aryl. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted heteroaryl. In some embodiments, one or both of R^vand R^xare H. In other embodiments, one or both of R^vand R^xis C_1-6alkyl. In some embodiments, one or both of R^yand R^zis H. In other embodiments, one or both of R^yand R^zis C_1-6alkyl. In further embodiments, one or both of R^yand R^zis C_3-6cycloalkyl. In yet other embodiments, one or both of R^yand R^zis C_1-6hydroxyalkyl. In still further embodiments, one or both of R^yand R^zis C_1-6haloalkyl. In further embodiments, one or both of R^yand R^zis C(O)OC_1-6alkyl. In some embodiments, one or both of R^y2and R^z2is H. In other embodiments, one or both of R^y2and R^z2is C_1-6alkyl. In further embodiments, one or both of R^y2and R^z2is C_3-6cycloalkyl. In some embodiments, p is 0. In other embodiments, p is 1. In further embodiments, p is 2. In yet other embodiments, p is 3. In some embodiments, R¹⁵is H. In other embodiments, R¹⁵is C_1-6alkyl.

In still further embodiments, R²is

embedded image

wherein R¹⁰, R¹¹, R¹²R¹³, and R¹⁴are each independently H, C_1-6alkyl, C_1-6haloalkyl, C_3-6cycloalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), halo, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted heteroaryl, or (CR^vR^x)_pNR^yR^z. In other embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are each independently H, C_1-6alkyl, C_3-6cycloalkyl, C_1-6alkoxy, C_1-6alkoxy(alkylene), optionally substituted heterocyclyl, optionally substituted heterocyclyl(alkylene), optionally substituted heteroaryl, or (CR^vR^x)_pNR^yR^z. In some embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkyl such as methyl or ethyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkyl such as methyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6haloalkyl such as CF₃, or C(CH₃)₂F. In yet further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and/or R¹⁴is C_3-6cycloalkyl such as cyclopropyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkoxy such as methoxy. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkoxy(alkylene) such as CH₂OCH₃or (CH₂)₂OCH₃. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is halo such as F, Br, or Cl. In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted aryl such as unsubstituted phenyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³and R¹⁴is optionally substituted heterocyclyl such as

embedded image

In still other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted heterocyclyl such as

embedded image

In other embodiments, the optionally substituted heterocyclyl is

embedded image

In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted heterocyclyl(alkylene). In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is

embedded image

In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is

embedded image

In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is optionally substituted heteroaryl such as optionally substituted pyridinyl, optionally substituted pyrazinyl, optionally substituted pyrimidinyl, or optionally substituted pyrazolyl. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is

embedded image

In still further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is (CR^vR^x)_pNR^yR^zsuch as NH₂, NH(CH₃), N(CH₃)₂, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is (CR^vR^x)_pNR^yR^zsuch as N(CH₃)₂, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In further embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are each independently H, methyl, C(CH₃)₂F, cyclopropyl, methoxy, CH₂OCH₃, (CH₂)₂OCH₃, Br, F, Cl, phenyl,

embedded image

N(CH₃)₂, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In yet other embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are each independently H, methyl, cyclopropyl, methoxy, CH₂OCH₃,

embedded image

N(CH₃)₂, CH₂N(CH₃)₂, or CH₂CH₂N(CH₃)₂. In other embodiments, R¹⁰, R¹³, and R¹⁴are each hydrogen. In further embodiments, R¹⁰, R¹³, and R¹⁴are each hydrogen; and R¹¹is halo.

In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is substituted heterocyclyl or substituted heterocyclyl(alkylene), substituted with one or more of halo such as F, Cl, or Br; C_1-6haloalkyl such as CF₃, CH₂CF₃, or CIF₂; C_1-6alkyl such as methyl, ethyl, or propyl; OH; C_1-6hydroxyalkyl such as C(CH₃)₂OH; C_1-6alkoxy such as methoxy, ethoxy, or propoxy; or C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl. In other embodiments, the substituted heterocyclyl or substituted heterocyclyl(alkylene) is substituted with one or more methyl, OH, or F.

In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is substituted heteroaryl, substituted with one or more of halo such as F, Cl, or Br; C_1-6haloalkyl such as CF₃, CH₂CF₃, or CHF₂; C_1-6alkyl such as methyl, ethyl, propyl, or isopropyl; C_1-6alkoxy such as methoxy, ethoxy, or propoxy; C_1-6haloalkoxy such as OCF₃; C_3-6cycloalkyl such as cyclopropyl, cyclobutyl, or cyclopentyl; or C_3-6cycloalkylsulfonyl such as cyclopropylsulfonyl, cyclobutylsulfonyl, or cyclopentylsulfonyl. In yet other embodiments, the substituted heteroaryl is substituted with one or more of F, CF₃, CHF₂, or methyl. In further embodiments, the optionally substituted heteroaryl is pyrazolyl, substituted with one methyl.

In other embodiments, R²is

embedded image

wherein R¹⁰, R¹¹, R¹², and R¹³are each independently H, C_1-6alkyl, or halo and R¹⁵is H or C_1-6alkyl. In further embodiments, R¹⁰, R¹¹, R¹², and R¹³are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³is C_1-6alkyl. In further embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³is halo. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³is Br. In some embodiments, R¹⁵is H. In other embodiments, R¹⁵is C_1-6alkyl. In further embodiments, R¹⁵is methyl. In yet other embodiments, R¹⁵is H or methyl.

In further embodiments, R²is

embedded image

wherein R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are each independently H, halo, or C_1-6alkyl. In some embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In some embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is halo. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkyl.

In yet other embodiments, R²is

embedded image

wherein R¹⁰, R¹¹, R¹², R¹³and R¹⁴are each independently H, halo, or C_1-6alkyl. In some embodiments, R¹⁰, R¹¹, R¹², R¹³, and R¹⁴are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is halo. In further embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is Br. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², R¹³, and R¹⁴is C_1-6alkyl.

In still further embodiments, R²is

embedded image

wherein R¹⁰, R¹¹, R¹², and R¹³are each independently, H, C_1-6alkyl, or halo. In some embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

In some embodiments, R¹⁰, R¹¹, R¹², and R¹³are H. In other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³is halo. In further embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³is F. In yet other embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³is C_1-6alkyl. In still further embodiments, at least one of R¹⁰, R¹¹, R¹², and R¹³is methyl. In yet other embodiments, R¹⁰, R¹¹, R¹², and R¹³are each independently H, methyl, or F.

In other embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is H. In yet other embodiments, R²is

embedded image

In still other embodiments R²is

embedded image

In further embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is CH₃. In other embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is cyclopropyl. In further embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is CHF₂. In other embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is CF₃. In still other embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is CN. In still further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is Br or Cl. In further embodiments, R²is

embedded image

In still further embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is phenyl or pyridinyl. In other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

wherein R⁶is defined herein and R⁷is H. In yet other embodiments, R²is

embedded image

In still other embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

wherein R⁶-R⁸are defined herein. In still other embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

wherein R⁶-R⁸are defined herein. In still further embodiments, R²is

embedded image

In yet other embodiments R²is

embedded image

In other embodiments, R²is

embedded image

wherein R⁶is optionally substituted heterocyclyl. In yet other embodiments, R²is

embedded image

In still other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

wherein R⁶is optionally substituted heteroaryl. In still further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

wherein R⁶is optionally substituted aryl. In still other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

wherein R⁶is C_1-6alkyl, C_1-6haloalkyl, or C_1-6hydroxyalkyl. In still further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

wherein R⁶is optionally substituted C_3-8cycloalkyl. In yet other embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

wherein R⁶is C(O)NR^y2R^z2or (CR^vR^x)_pNR^yR^zand R^y2, R^z2, p, R^v, R^x, R^y, and R^zare defined herein. In other embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

wherein R⁶is H, C_1-6alkyl, or optionally substituted aryl. In still other embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

wherein R⁶is C_1-6hydroxyalkyl. In yet further embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

wherein R⁸is C_1-6alkyl and R⁶is defined herein. In still other embodiments, R²is

embedded image

In further embodiments, R²is

embedded image

wherein R¹⁰-R¹⁴are defined herein. In still further embodiments, R²is

embedded image

In yet other embodiments, R²is

embedded image

In other embodiments, R²is

embedded image

wherein R¹³is H and R¹⁰, R¹¹, R¹², R¹⁴, and R¹⁵are defined herein. In yet other embodiments, R²is

embedded image

In some embodiments, the compound of Formula I is of Formula I-A or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, L, and m are defined herein. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In other embodiments, the compound of Formula I is of Formula I-B or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In further embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In further embodiments, the compound of Formula I is of Formula I-C or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In still other embodiments, the compound of Formula I is of Formula I-D or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In some embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In still further embodiments, the compound of Formula I is of Formula I-E or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In other embodiments, the compound of Formula I is of Formula I-F or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In yet other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In further embodiments, the compound of Formula I is of Formula I-G or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In still further embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In yet other embodiments, the compound of Formula I is of Formula I-H or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In still further embodiments, the compound of Formula I is of Formula I-I or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In other embodiments, the compound of Formula I is of Formula I-J or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In yet other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In further embodiments, the compound of Formula I is of Formula I-K or a pharmaceutically acceptable salt thereof:

embedded image

such as

embedded image

wherein R¹, R², R⁵, and m are defined herein. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In still other embodiments, the compound of Formula I is of Formula I-L or a pharmaceutically acceptable salt thereof:

embedded image

wherein R¹, R², R⁵, L, and m are defined herein. In further embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In yet further embodiments, the compound of Formula I is of Formula I-M or a pharmaceutically acceptable salt thereof:

embedded image

wherein R¹, R², R⁵, L, and m are defined herein. In other embodiments, the compound is

embedded image

or a pharmaceutically acceptable salt thereof.

In some embodiments, compounds of the disclosure are any one or more of the compounds of Table 1, and their pharmaceutically acceptable salts and/or isotopologues. Compounds having the Formula I are further disclosed in the Exemplification and are included in the present disclosure. Pharmaceutically acceptable salts thereof as well as the neutral forms are included.

The disclosure further provides R-enantiomers, S-enantiomers, or racemic mixtures of any of the compounds described herein. In some embodiments, the compound is an S-enantiomer. In other embodiments, the compound is the R-enantiomer. In further embodiments, the compound is racemic.

In another embodiment, the compounds of the disclosure may be enantiomerically enriched, e.g., the enantiomeric excess or “ee” of the compound is greater than about 5% as measured by chiral HPLC. In some embodiments, the ee is greater than about 10%. In other embodiments, the ee is greater than about 20%. In further embodiments, the ee is greater than about 30%. In yet other embodiments, the ee is greater than about 40%. In still further embodiments, the ee is greater than about 50%. In other embodiments, the ee is greater than about 60%. In further embodiments, the ee is greater than about 70%. In still other embodiments, the ee is greater than about 80%. In yet further embodiments, the ee is greater than about 85%. In other embodiments, the ee is greater than about 90%. In further embodiments, the ee is greater than about 91%. In yet other embodiments, the ee is greater than about 92%. In still further embodiments, the ee is greater than about 93%. In other embodiments, the ee is greater than about 94%. In further embodiments, the ee is greater than about 95%. In still other embodiments, the ee is greater than about 96%. In yet further embodiments, the ee is greater than about 97%. In other embodiments, the ee is greater than about 98%. In further embodiments, the ee is greater than about 99%.

The present disclosure encompasses the preparation and use of salts of compounds of the disclosure. Salts of compounds of the disclosure can be prepared during the final isolation and purification of the compounds or separately by reacting the compound with an acid or base as appropriate.

Treatment Methods

Compounds of the disclosure have several uses as described herein. In some embodiments, compounds of the disclosure are useful in methods for stabilizing mutant PAH proteins. These methods comprise contacting the protein with one or more compounds described herein or a pharmaceutically acceptable salt thereof. The compounds of the disclosure can provide for better Phe control for patients whose disease is not well-managed on diet alone and lessen the severity of a patient's phenylketonuria. Thus, patients administered a compound of the disclosure will have a better quality of life, e.g., a more normal lifestyle and/or none or fewer dietary restrictions, as compared with phenylketonuria patients who have not been administered a compound of the disclosure. In some embodiments, patients administered a compound of the disclosure may experience increases in executive function, decreases in anxiety symptoms, and/or decreases in attention deficit hyperactivity disorder symptoms.

The term “mutant PAH gene” as used herein refers to the full DNA sequence of PAH that differs in one or more ways from the canonically accepted sequence (“the basis gene”) that is published in any one of a variety of curated databases. As one example, the sequence described by GenBank Accession number NG_008690.2 describes the basis gene.

The term “mutant PAH protein” as used herein refers to a PAH protein that contains at least one mutation in the amino acid sequence relative to that encoded by the reference. The reference human PAH protein is described by Genbank Accession number NP_000268 and contains 452 amino acids. PAH protein mutations can be identified using methods known in the art. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation. In still other embodiments, the mutant PAH protein contains at least one R408W, R243Q, R408Q, V388M, or L348V mutation. In yet other embodiments, the mutant PAH protein contains at least one R408W mutation. In further embodiments, the mutant PAH protein contains at least two R408W mutations. In further embodiments, the mutant PAH protein contains at least one R261Q mutation. In yet other embodiments, the mutant PAH protein contains at least one R243Q mutation. In yet other embodiments, the mutant PAH protein contains at least one Y414C mutation. In still further embodiments, the mutant PAH protein contains at least one L48S mutation. In other embodiments, the mutant PAH protein contains at least one A403V mutation. In further embodiments, the mutant PAH protein contains at least one I65T mutation. In yet further embodiments, the mutant PAH protein contains at least one R241C mutation. In yet other embodiments, the mutant PAH protein contains at least one L348V mutation. In further embodiments, the mutant PAH protein contains at least one R408Q mutation. In other embodiments, the mutant PAH protein contains at least one V388M mutation. In other embodiments, the mutant PAH protein contains at least one F39L mutation. In still further embodiments, the mutant PAH protein contains at least one A300S mutation. In yet further embodiments, the mutant PAH protein contains at least one L48S mutation.

In other embodiments, the disclosure provides methods for stabilizing the activity of mutant phenylalanine hydroxylase (PAH) proteins as compared to wild type PAH. Such methods include contacting phenylalanine hydroxylase with one or more compounds described herein, or a pharmaceutically acceptable salt thereof. The term “stabilizing” as used herein refers to modulating the activity or quantity of a PAH enzyme so that it catalyzes hydroxylation of the aromatic side-chain of phenylalanine at a rate that is more similar to the PAH catalysis rate of a control population having wild type PAH, i.e., without a mutant PAH gene mutation, as compared to the baseline PAH catalysis rate. In some aspects, the term “stabilizing” refers to modulating the activity of a subject's PAH so that it catalyzes hydroxylation of the aromatic side-chain of phenylalanine at a flux more similar to the PAH catalytic flux of a control subject population without a mutant PAH gene mutation. In some embodiments, “stabilizing” activity of PAH includes increasing levels of the enzyme PAH as compared to baseline. By increasing the buildup of stabilized active PAH protein, a subject's toxic Phe levels can be reduced as compared to the subject's baseline levels of dietary Phe prior to administration of a compound of the disclosure or a pharmaceutical composition comprising compounds of the disclosure.

In some embodiments, the disclosure provides methods for reducing blood phenylalanine concentrations in a subject suffering from phenylketonuria to a concentration less than or equal to about 600 μM. In other embodiments, the blood Phe concentration is reduced to a concentration less than or equal to about 360 μM. In other embodiments, the disclosure provides methods for reducing blood Phe concentrations as compared to untreated baseline. In some embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by a percentage including but not limited at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90%. In other embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 10%. In further embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 20%. In yet other embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 30%. In still further embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 40%. In other embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 50%. In further embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 60%. In yet other embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 70%. In still further embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 80%. In other embodiments, a subject's blood Phe concentration as compared to untreated baseline is reduced by at least about 90%. A subject's Phe concentration can be determined by blood tests and methods for measuring such levels are known in the art. In some embodiments, the reduction in Phe concentration achieved using compounds of the disclosure is obtained in conjunction with the subject actively managing their dietary Phe intake. In other embodiments, the reduction in Phe concentration is obtained in conjunction with the subject maintaining a Phe-restricted diet.

In some embodiments, a subject is treated with compounds of the disclosure, or a pharmaceutical composition comprising compounds of the disclosure. The compound is administered in an amount sufficient for stabilizing the PAH protein, or for reducing blood phenylalanine concentration in a subject, or combinations thereof in the subject.

In further embodiments, the subject is a human patient, such as a human adult over 18 years old in need of treatment. In yet further embodiments, the human patient is a human child less than 18 years old. In still further embodiments, the human patient is a human child between 12 years and 18 years old. In yet other embodiments, the human patient is a human child less than 12 years old. In any of the embodiments, the subject has phenylketonuria (PKU), optionally classic PKU or severe PKU. In some embodiments, the subject has a blood Phe concentration greater than about 600 μM prior to administration of a compound of the disclosure or a pharmaceutical composition comprising compounds of the disclosure. In other embodiments, the subject's blood Phe concentration prior to administration is greater than about 700 μM. In further embodiments, the subject's blood Phe concentration prior to administration is greater than about 800 μM. In still further embodiments, the subject's blood Phe concentration prior to administration is greater than about 900 μM. In yet other embodiments, the subject's blood Phe concentration prior to administration is greater than about 1000 μM. In further embodiments, the subject's blood Phe concentration prior to administration is greater than about 1100 μM. In other embodiments, the subject's blood Phe concentration prior to administration is greater than about 1200 μM.

The present methods also encompass administering an additional therapeutic agent to the subject in addition to the compounds of the disclosure. In some embodiments, the additional therapeutic agent is selected from drugs known as useful in a stabilizing mutant PAH protein and/or reducing blood Phe concentrations. The additional therapeutic agent is different from the compounds of the disclosure. In some embodiments, the additional therapeutic agent is sapropterin or sepiapterin. In other embodiments, the additional therapeutic agent is a nutritional supplement. Nutritional supplements that may be used include those that contain amino acids and other nutrients. In further embodiments, the nutritional supplement contains large neutral amino acids such as leucine, tyrosine, tryptophan, methionine, histidine, isoleucine, valine, threonine. In other embodiments, the nutritional supplement contains tyrosine. In further embodiments, the nutritional supplement contains casein glycomacropeptide, i.e., a milk peptide naturally free of Phe in its pure form. In other embodiments, the additional therapeutic agent is an enzyme substrate or enzyme co-factor. In yet other embodiments, the enzyme substrate or co-factor is tetrahydrobiopterin. In other embodiments, the additional therapeutic agent is a biopterin analogue. In further embodiments, the additional therapeutic agent is a biotherapeutic, synthetic biotic, microbiota or probiotic. In yet other embodiments, the biotherapeutic, synthetic biotic, microbiota or probiotic contains a genetically modified phenylalanine ammonia lyase (PAL) gene, such as, for example, E. coli Nissle PAL. Examples of genetically modified E. coli Nissle PAL biotherapeutics include SYNB1934 and SYNB1618, and the like. In still further embodiments, the additional therapeutic agent is an inhibitor of an amino acid transporter. In some embodiments, the amino acid transporter is B⁰AT1 (also referred to as SLC6A19), and the additional therapeutic agent is a SLC6A19 inhibitor. Examples of SLC6A19 inhibitors include nimesulide, benztropine, NSC63912, NSC22789, cinromide, CB3, E62, JNT-517, and the like.

Compounds of the disclosure and the additional therapeutic agents can be administered simultaneously or sequentially to achieve the desired effect. In addition, the compounds of the disclosure and additional therapeutic agent can be administered in a single composition or two separate compositions.

The additional therapeutic agent is administered in an amount to provide its desired therapeutic effect. The effective dosage range for each additional therapeutic agent is known in the art, and the additional therapeutic agent is administered to an individual in need thereof within such established ranges.

Compounds of the disclosure and the additional therapeutic agents can be administered together as a single-unit dose or separately as multi-unit doses, wherein the compounds of the disclosure are administered before the additional therapeutic agent or vice versa. One or more doses of the compounds of the disclosure and/or one or more dose of the additional therapeutic agents can be administered.

The compounds of the disclosure may also be administered sequentially or concurrently with non-pharmacological techniques. In some embodiments, the patient uses non-pharmacological techniques to maintain lower Phe levels. In other embodiments, the non-pharmacological technique is administering a diet that is low in Phe. One skilled in the art would be able to determine what type of diet to maintain appropriate levels of Phe. In some embodiments, a phenylamine diet containing about 200 to about 500 mg/day (patients 10 years or younger) of Phe or less than about 600 mg/day (patients over 10 years of age). In other embodiments, the diet may include restricting or eliminating one or more foods that are high in Phe, such as soybeans, egg whites, shrimp, chicken breast, spirulina, watercress, fish, nuts, crayfish, lobster, tuna, turkey, legumes, and low-fat cottage cheese.

An example of a dose is in the range of from about 0.001 to about 100 mg of compound per kg of subject's body weight per day, in single or divided dosage units (e.g., BID, TID, QID). For a 70-kg human, a suitable dosage amount is from about 0.05 to about 7 g/day.

In some embodiments, the therapeutically effective amount of one or more compounds described herein is an amount that is effective in stabilizing a mutant PAH protein described herein. In other embodiments, the therapeutically effective amount of one or more compounds described herein is an amount that is effective in reducing blood phenylalanine concentrations.

Unless otherwise noted, the amounts of the compounds described herein are set forth on a free base basis. That is, the amounts indicate that amount of the compound administered, exclusive of, for example, solvent or counterions (such as in pharmaceutically acceptable salts).

Pharmaceutical Compositions

The disclosure also provides pharmaceutical compositions comprising compounds of the disclosure and a pharmaceutically acceptable carrier or excipient.

The methods of the present disclosure can be accomplished by administering compounds of the disclosure as the neat compound or as a pharmaceutical composition. Administration of a pharmaceutical composition, or neat compound of the disclosure, can be performed at any time period as determined by the attending physician. Typically, the pharmaceutical compositions contain no toxic, carcinogenic, or mutagenic compounds that would cause an adverse reaction when administered.

Pharmaceutical compositions include those wherein compounds of the disclosure are administered in an effective amount to achieve its intended purpose. The exact formulation, route of administration, and dosage is determined by an individual physician.

Compounds of the disclosure can be administered by any suitable route, e.g., by oral, buccal, inhalation, sublingual, rectal, vaginal, intracisternal or intrathecal through lumbar puncture, transurethral, nasal, percutaneous, i.e., transdermal, or parenteral (including intravenous, intramuscular, subcutaneous, intracoronary, intradermal, intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar, intrapulmonary injection and/or surgical implantation at a particular site) administration. Parenteral administration can be accomplished using a needle and syringe or using a high-pressure technique.

The above-mentioned additional therapeutically active agents, one or more of which can be used in combination with compounds of the disclosure, are prepared and administered as described in the art.

Compounds of the disclosure may be administered in admixture with pharmaceutical carriers selected with regard to the intended route of administration and standard pharmaceutical practice. Pharmaceutical compositions for use in accordance with the present disclosure are formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and/or auxiliaries that facilitate processing of compounds of the disclosure.

Administration of the compounds or pharmaceutical compositions of the disclosure can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g., transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.

The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. The desired dose can be administered in a single dose, or as multiple doses administered at appropriate intervals, e.g., as one, two, three, four or more subdoses per day. In some embodiments, the compounds disclosed herein are effective over a wide dosage range. For example, in the treatment of adult humans, dosage forms containing from about 0.01 to 2000 mg of a compound disclosed herein per day are examples of dosage forms that may be used. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g., by dividing such larger doses into several small doses for administration throughout the day.

In some embodiments, a compound of the disclosure is administered in a single dose.

Typically, such administration will be by a solid oral dosage form such as tablet or capsule. However, other routes may be used as appropriate. A single dose of a compound may also be used for treatment of an acute condition.

In some embodiments, a compound of the disclosure may be administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. In another embodiment, a compound described herein and another therapeutic agent are administered together about once per day to about 6 times per day. Administration of the compounds disclosed herein may continue as long as necessary. In some embodiments, a compound is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.

An effective amount of a compound of the disclosure may be administered in either single or multiple doses by any of the accepted modes of administration of therapeutic agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include one or more conventional pharmaceutical carriers or excipients and a compound disclosed herein as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

Exemplary parenteral administration forms include solutions or suspensions of the compound of the disclosure in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

Pharmaceutical Compositions for Oral Administration

In some embodiments, the disclosure provides a pharmaceutical composition for oral administration containing a compound of the disclosure and pharmaceutical excipients suitable for oral administration.

In some embodiments, the disclosure provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the disclosure; optionally (ii) an effective amount of a second therapeutic agent; and (iii) a pharmaceutical excipient suitable for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third therapeutic agent.

In some embodiments, the pharmaceutical composition may be a pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions containing a compound of the disclosure suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or non-aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the compound of the disclosure into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the compound of the disclosure with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

This disclosure further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf-life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms containing a compound of the disclosure can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms containing a compound of the disclosure which contain lactose can be made anhydrous if substantial contact with moisture and/or humidity during manufacturing, packaging, and/or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.

The compound of the disclosure can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.

Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl cellulose, colloidal silicon dioxide, microcrystalline cellulose, and mixtures thereof.

Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

Disintegrants may be used in the compositions of the disclosure to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, agar-agar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.

Lubricants which can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, calcium stearate, magnesium stearate, sodium stearyl fumarate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 2 weight percent of the pharmaceutical composition.

When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.

The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

Surfactants which can be used to form pharmaceutical compositions and dosage forms of the disclosure include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed.

A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (“HLB” value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.

Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical, and cosmetic emulsions.

Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acylactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP-phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/diglycerides, cholylsarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.

Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof, polyoxyethylene-polyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.

Other hydrophilic-non-ionic surfactants include, without limitation, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate/caprylate glycerides, PEG-8 caprate/caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopheryl PEG-1000 succinate, PEG-24 cholesterol, polyglyceryl-10-oleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.

Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oil-soluble vitamins/vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

In one embodiment, the composition may include a solubilizer to ensure good solubilization and/or dissolution of the compound of the disclosure and to minimize precipitation of the compound of the disclosure. This can be important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and/or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol (PEG), polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG; polyethylene glycol 660 12-hydroxystearate; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, F-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, triethylcitrate, ethyl oleate, ethyl caprylate, ethyl butyrate, triacetin, propylene glycol monoacetate, propylene glycol diacetate, F-caprolactone and isomers thereof, S-valerolactone and isomers thereof, β-butyrolactone and isomers thereof, and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.

Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG having an average molecular weight of about 100 to about 8000 g/mole, glycofurol and propylene glycol.

The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of less than about 10%, less than about 25%, less than about 50%, about 100%, or up to less than about 200% by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as less than about 5%, less than about 2%, less than about 1% or even less. Typically, the solubilizer may be present in an amount of less than about 1% to about 100%, more typically less than about 5% to less than about 25% by weight.

The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, anti-foaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

Pharmaceutical Compositions for Injection

In some embodiments, the disclosure provides a pharmaceutical composition for injection containing a compound described herein and pharmaceutical excipients suitable for injection. Components and amounts of agents in the compositions are as described herein.

The forms in which the compositions of the disclosure may be incorporated for administration by injection include aqueous or oil suspensions or emulsions. Such compositions may comprise sesame oil, corn oil, cottonseed oil, peanut oil, elixirs containing mannitol or dextrose, sterile water, and similar pharmaceutical vehicles.

Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

Sterile injectable solutions are prepared by incorporating the compound of the disclosure in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Other Pharmaceutical Compositions

Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for topical, sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 2004; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remington's Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

Synthesis of Compounds of the Disclosure

Compounds of the disclosure can be prepared by methods described in the General Schemes, procedures, and Examples set forth within, and by related methods known in the art. For example, Compounds of Formula I can be prepared by the general methods shown in General Schemes 1-11.

embedded image

Compounds of Formula I were obtained through the reactions depicted in General Scheme 1. An amine of formulas 1.1 or 1.2 and an aldehyde of formula 1.3 were first reacted under Pictet-Spengler reaction conditions to afford the core amine of formula 1.4. To the extent that an imine by-product is formed during the Pictet-Spengler reaction, the imine by-product can be converted to the core amine of formula 1.4 by reaction with sodium borohydride in an alcoholic solvent (for example, methanol or ethanol). Various L and R²groups were then installed by using either a nucleophilic substitution reaction (Method A1), a Buchwald or other similar cross-coupling reaction (Method A2), a reductive animation reaction (Method B), or amide coupling reactions (Methods C, D, E, and F). Under Method A1, a R²aryl or heteroaryl halide of formula 1.5 (wherein X is Br, Cl, or F) is coupled to the core amine of formula 1.4 using a nucleophilic substitution reaction under basic conditions, such as DIPEA, to afford compounds of formula 1.6. Under Method A2, a R²aryl or heteroaryl halide of formula 1.5 (wherein X is Br, Cl, or I) is coupled to the core amine of formula 1.4 using Buchwald coupling or cross-coupling conditions known in the art, such as using a palladium catalyst (for example, CPhos-Pd-G3, Pd(OAc)₂, Pd(dppf)Cl₂), and a base such as Cs₂CO₃to afford compounds of formula 1.6. Under Method B, a R²aryl or heteroaryl aldehyde of formula 1.7 is coupled to the core amine of formula 1.4 under reductive animation reaction conditions using a hydride such as sodium triacetoxyborohydride to afford compounds of formula 1.8. Under Method C, a R²carboxylic acid of formula 1.9 or a basic salt (i.e., Li, K, or Na) thereof is coupled to core amine of formula 1.4 using acid coupling conditions known in the art, such as using one of the following reagents—HOBt, EDCI, HATU, T3P—along with a base, such as DIPEA (Hunig's base), pyridine, or TEA, to afford compounds of formula 1.11, wherein L²is a bond, optionally substituted C_1-6alkylene, optionally substituted C_2-6alkenylene, or optionally substituted C_1-6haloalkylene. Alternatively, under Method D, a R²acid chloride of formula 1.10 is coupled to the core amine of formula 1.4 under basic conditions to afford compounds of formula 1.11, wherein L²is a bond, optionally C_1-6alkylene, optionally substituted C_2-6alkenylene, or optionally substituted C_1-6haloalkylene. Under Method E, a R²acid chloride of formula 1.12 is coupled to the core amine of formula 1.4 under basic conditions to afford compounds of formula 1.14, wherein L³is a bond or optionally substituted C_1-6alkylene. Under Method F, an R²amine of formula 1.13 is coupled to the core amine of formula 1.4 and carbonyldiimidazole under basic conditions to afford compounds of formula 1.14, wherein L³is a bond or optionally substituted C_1-6alkylene.

embedded image

Compounds of Formula I wherein R⁵is D are prepared in accordance with General Scheme 2. An amine of formula 1.1 or 1.2 and an aldehyde of formula 1.3 are reacted under Pictet-Spengler reaction conditions to afford compounds of formula 2.1 or mixtures of compounds of formula 2.1 and the imine by-product of formula 2.1a. Compounds of formula 2.1 or mixtures of compounds of formulas 2.1 and 2.1a are then reacted with sodium borodeuteride in deuterated methanol to afford deuterated core amine of formula 2.2. Deuterated core amine intermediates of formula 2.2 can then be further coupled to various L and R²groups via methods A, B, C, D, E, and F as described in General Scheme 1 to afford Compounds of Formula I, wherein R⁵is D.

embedded image

Oxazolyl R²carboxylic acid intermediates containing substitutions at the R⁶and/or R⁷positions were prepared in accordance with General Scheme 3. A carboxylic acid of formula 3.1 was reacted with oxalyl chloride and catalytic N,N-dimethylformamide to afford acid chloride of formula 3.2. Acid chloride of formula 3.2 was then reacted with an enamine of formula 3.3 to afford an enamide of formula 3.4. An enamide of formula 3.4 then underwent hypervalent iodine-mediated cyclization after reaction with [bis(trifluoroacetoxy)iodo]benzene and boron trifluoride diethyl etherate to afford oxazole of formula 3.5. Hydrolysis of the ester of the oxazole formula 3.5 with a base such as LiOH, KOH, or NaOH in THF/water afforded compounds of formula 3.6. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formula 3.6 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Oxazolyl R²carboxylic acid intermediates containing substitutions at the R⁶and/or R⁷positions were prepared in accordance with General Scheme 4. A β-keto ester of formula 4.1 was halogenated with a chlorinating agent such as SOCl₂or brominating agent such as NBS to yield compounds of formula 4.2 (wherein X¹is Br or Cl). Compounds of formula 4.2 were reacted with urea to afford amine oxazole compounds of formula 4.3. In addition, compounds of formula 4.2 were reacted with amides of formula 4.5 to afford oxazole compounds of formula 4.6. The amine in compounds of formula 4.3 was subjected to Sandmeyer reaction conditions to afford compounds of formula 4.4 (wherein X is Cl, Br, or F) and compounds of formula 4.10. Alternatively, compounds of formula 4.10 may be obtained by deprotonating a compound of formula 4.8 with a base such as LiHMDS followed by reaction in a nucleophilic substitution reaction with reagents of formula 4.9 (wherein Y is a suitable leaving group such as Br, Cl, mesylate, or tosylate) to afford compounds of formula 4.10. Hydrolysis of the ester of compounds of formulas 4.6 and 4.10 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 4.7 and 4.11. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 4.7 and 4.11 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Oxazolyl and thiazolyl R²carboxylic acid intermediates containing substitutions at the R⁶and/or R⁷positions were prepared in accordance with General Scheme 5. Under Method A, a halide of formula 5.1 was reacted with a heteroaryl or aryl of formula 5.2 in either a Suzuki coupling (where Y is a boronic acid or ester) or a Stille coupling (where Y is SnR₃) to afford compounds of formula 5.3. Under Method B, compounds of formula 5.3 were obtained by reaction of a compound of formula 5.4 with a heteroaryl or aryl halide compound of formula 5.5 in a cross-coupling reaction using a metal catalyst such as a Buchwald catalyst or Ullman catalyst. Under Method C, a halide of formula 5.1 may also be reacted with an amine of formula 5.7 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine, and a base such as TEA in a displacement reaction to afford compounds of formula 5.8. Hydrolysis of the ester of compounds of formulas 5.3 and 5.8 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 5.6 and 5.9. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 5.6 and 5.9 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Oxazolyl and thiazolyl R²carboxylic acid intermediates containing hydroxyalkyl and haloalkyl substitutions were prepared in accordance with General Scheme 6. Under Method A, a halide of formula 6.1 was reacted with tributyl(1-ethoxyvinyl)stannane in a Stille coupling, followed by hydrolysis with acid/water such as TFA to afford compounds of formula 6.3. An alkyl group (“R”) is then added to the ketone in compounds of formula 6.3 using RMgBr or RLi or through reduction of the ketone with NaBR to afford compounds of formula 6.4. Under Method B, compounds of formula 6.4 may also be obtained starting with a compound of formula 6.1 through a Grignard addition reaction with a ketone of formula 6.2 (wherein R is an alkyl) or cyclobutanone and RMgCl such as iPrMgCl. The hydroxyl substituent in compounds of formula 6.4 was converted to a fluorine substituent using a fluorinating agent such as BAST to afford compounds of formula 6.6. Hydrolysis of the ester of compounds of formulas 6.4 and 6.6 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 6.5 and 6.7. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 6.5 and 6.7 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Substituted pyrazolo[1,5-a]pyridinyl R²carboxylic acid intermediates were prepared in accordance with General Scheme 7. Under Method A, a halide of formula 7.1 (wherein X¹is Br or Cl) was reacted in a C—N cross-coupling reaction using a metal catalyst such as a Buchwald catalyst or Ullman catalyst with an amine of formula 7.2 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine to afford compounds of formula 7.3. Under Method B, a halide of formula 7.1 (wherein X¹is Br or Cl) may also be reacted with a heteroaryl or aryl compound of formula 7.5 in either a Suzuki coupling (where Y is a boronic acid or ester) or a Stille coupling (where Y is SnR₃) to afford compounds of formula 7.6. Under Method C, a halide of formula 7.1 (wherein X¹is Br or Cl) was reacted with 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane in a Suzuki coupling to afford compounds of formula 7.8. The olefin in compounds of formula 7.8 then underwent oxidative cleavage to an aldehyde to afford compounds of formula 7.9. Under Method D, the aldehyde in compounds of formula 7.9 was reduced to an alcohol with a hydride such as NaBH₄in an alcoholic solvent such as methanol or ethanol to afford formula 7.13. The alcohol in compounds of formula 7.13 was alkylated with sodium hydride and an alkyl (“R”) halide of formula 7.14 (wherein X is Cl, Br, or F) to afford compounds of formula 7.15. Under Method E, a compound of formula 7.9 was reacted with an amine of formula 7.10 under reductive animation conditions to afford compounds of formula 7.11. Hydrolysis of the ester of compounds of formulas 7.3, 7.6, 7.11, and 7.15 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 7.4, 7.7, 7.12, and 7.16. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 7.4, 7.7, 7.12, and 7.16 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Di-substituted pyrazolo[1,5-a]pyridinyl R²carboxylic acid intermediates were prepared in accordance with General Scheme 8. Starting reagent 3-bromo-4-chloropyridine was reacted with ethyl (E)-N-((mesitylsulfonyl)oxy)acetimidate to afford the N-aminopyridinium salt 8.1. A cycloaddition reaction of the N-aminopyridinium salt 8.1 with ethyl propiolate and base such as K₂CO₃afforded ethyl 6-bromo-5-chloropyrazolo[1,5-a]pyridine-3-carboxylate 8.2. Compound 8.2 was reacted in a C—N cross-coupling reaction using a metal catalyst such as a Buchwald catalyst or Ullman catalyst with an amine of formula 8.4 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine to afford compounds of formula 8.5. Hydrolysis of the ester of compounds of formulas 8.2 and 8.5 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formulas 8.3 and 8.6. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formulas 8.3 and 8.6 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Heteroaryl and aryl-substituted oxadiazolyl R²carboxylic acid intermediates were prepared in accordance with General Scheme 9. Under Method A, heteroaryl and aryl esters of formula 9.1 were reacted with hydrazine hydrate to afford hydrazines of formula 9.2. Compounds of formula 9.2 were then reacted with ethyl-2-chloro-2-oxoacetate to afford compounds of formula 9.3, which subsequently underwent intramolecular cyclization with p-toluenesulfonyl chloride and a base such as TEA to afford the 1,3,4-oxadiazole of formula 9.4. Alternatively, compounds of formula 9.4 can be made using Method B. Under Method B, ethyl 2-hydrazineyl-2-oxoacetate was reacted with 1,1′-thiocarbonyldiimidazole to form the 1,3,4-oxadiazole, which was then alkylated with methyl iodide and base such as TEA to afford ethyl 5-(methylthio)-1,3,4-oxadiazole-2-carboxylate. Ethyl 5-(methylthio)-1,3,4-oxadiazole-2-carboxylate was reacted with a heteroaryl or aryl boronic acid or ester of formula 9.5 in a desulfitative C—C cross coupling reaction (also known as Liebeskind-Srogl cross-coupling) to afford compounds of formula 9.4. Hydrolysis of the ester of compounds of formula 9.4 with a base such as LiOH, KOH, or NaOH in THF/water affords compounds of formula 9.6. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formula 9.6 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Substituted 1,3,4-oxadiazolyl R²carboxylic acid intermediates were prepared in accordance with General Scheme 10. Starting reagent ethyl 5-amino-1,3,4-oxadiazole-2-carboxylate was subjected to Sandmeyer reaction conditions to afford ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (Compound 10.1). The bromo in compound 10.1 was reacted with an amine of formula 10.2 or a heterocyclic amine such as piperidine, morpholine, piperazine, azetidine, and pyrrolidine, and a base such as TEA to afford compounds of formula 10.3. Hydrolysis of the ester of compounds of formula 10.3 with a base such as LiOH, KOH, or NaOH in THF/water afforded compounds of formula 10.4. Alternatively, the basic salt (i.e., Li, K, or Na) of the carboxylic acid of formula 10.4 may be obtained after the hydrolysis reaction by isolating the product at a basic pH. The carboxylic acid or basic salt thereof can then be used without further purification in the coupling reactions described in General Scheme 1, Method C.

embedded image

Compounds of Formula I wherein R^5Ais D are prepared in accordance with General Scheme 11. An amine of formula 2.1, prepared According to General Scheme 2, is protected with a BOC protecting group or other suitable nitrogen protecting group to afford compounds of formula 11.1. The amine in formula 11.1 is then protected with a dimethylsulfamoyl protecting group to afford a mixture of compounds of formula 11.2 and 11.3, which are separated during purification. Deuterium is then incorporated at the R^5Aposition by deprotonating compounds of formula 11.2 with butyllithium and then adding D₂O to afford compounds of formulas 11.4 and 11.5. Deprotection of the nitrogen protecting groups with acid afforded deuterated core amine intermediates of formulas 11.6. Deuterated core amine intermediates of formulas 11.6 can be further coupled to various L and R²groups via methods A, B, C, D, E, and F as described in General Scheme 1 to afford Compounds of Formula I, wherein R^5Ais D.

The present disclosure will be more fully understood by reference to the following examples. The examples provided herein are illustrative and should not, however, be construed as limiting the scope of the present disclosure.

EXAMPLES

In some embodiments, the disclosure provides specific examples of Formula I, and their pharmaceutically acceptable salts and/or isotopologues, as set forth in Table 1 below.

TABLE 1

Pyrazolo[1,5-a]pyridines

Ex. #
Structure
Name

600

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin- 3-yl)methanone

601

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5-a]pyridin- 3-yl)methanone

602

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(thiazol-5-yl)methanone

603

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(thiazol-5-yl)methanone

604

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4- oxadiazol-2-yl)methanone

605

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)-1,3,4- oxadiazol-2-yl)methanone

606

embedded image

(S)-(4-methyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

607

embedded image

(R)-(4-methyloxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

608

embedded image

(S)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)-2-(4- (trifluoromethyl)thiazol-2-yl)ethanone

609

embedded image

(R)-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)-2-(4- (trifluoromethyl)thiazol-2-yl)ethanone

610

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

611

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

612

embedded image

(S)-(2-(1,1-difluoroethyl)thiazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

613

embedded image

(R)-(2-(1,1-difluoroethyl)thiazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

614

embedded image

(S)-2-cyclopropyl-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)ethanone

615

embedded image

(R)-2-cyclopropyl-1-(4-(pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)ethanone

616

embedded image

(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

617

embedded image

(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

618

embedded image

(S)-(4-cyclopropyloxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

619

embedded image

(R)-(4-cyclopropyloxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

620

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

621

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

622

embedded image

(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

623

embedded image

(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

624

embedded image

(S)-(4-cyclopropyl-2-(2-hydroxypropan-2-yl)oxazol-5- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

625

embedded image

(R)-(4-cyclopropyl-2-(2-hydroxypropan-2-yl)oxazol-5- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

626

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

627

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

628

embedded image

(S)-(2-(2-hydroxypropan-2-yl)-4- (trifluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

629

embedded image

(R)-(2-(2-hydroxypropan-2-yl)-4- (trifluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

630

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

631

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

632

embedded image

(S)-(2-cyclopropyl-4-(difluoromethyl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

633

embedded image

(R)-(2-cyclopropyl-4-(difluoromethyl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

634

embedded image

(S)-2-(1-hydroxycyclobutyl)-1-(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)ethanone

635

embedded image

(R)-2-(1-hydroxycyclobutyl)-1-(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)ethanone

636

embedded image

(S)-2-(3-fluorocyclobutyl)-1-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)ethenone

637

embedded image

(R)-2-(3-fluorocyclobutyl)-1-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)ethanone

638

embedded image

(S)-2,2-difluoro-2-(1-hydroxycyclobutyl)-1-(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)ethanone

639

embedded image

(R)-2,2-difluoro-2-(1-hydroxycyclobutyl)-1-(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)ethanone

640

embedded image

(S)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4- carbonitrile

641

embedded image

(R)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazole-4-carbonitrile

642

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4- (trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)methanone

643

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4- (trifluoromethyl)phenyl)-1,3,4-oxadiazol-2-yl)methanone

644

embedded image

(S)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

645

embedded image

(R)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

646

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(2,2,2- trifluoroethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

647

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(2,2,2- trifluoroethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

648

embedded image

(S)-(5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

649

embedded image

(R)-(5-(3,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

650

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

651

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

652

embedded image

(S)-(5-(2,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

653

embedded image

(R)-(5-(2,4-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

654

embedded image

(S)-(5-(4-fluoro-2-methylphenyl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

655

embedded image

(R)-(5-(4-fluoro-2-methylphenyl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

656

embedded image

(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

657

embedded image

(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

658

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

659

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

660

embedded image

(S)-(1-methyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

661

embedded image

(R)-(1-methyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

662

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

663

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

664

embedded image

(R)-(3-chloro-1-methyl-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

665

embedded image

(S)-(3-chloro-1-methyl-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

666

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

667

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

668

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4- (trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2- yl)methanone

669

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(4- (trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2- yl)methanone

670

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

671

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

672

embedded image

(R)-(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

673

embedded image

(S)-(5-(5-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

674

embedded image

(S)-(3-chloro-1-(pyridin-2-yl)-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

675

embedded image

(R)-(3-chloro-1-(pyridin-2-yl)-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

676

embedded image

(S)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

677

embedded image

(R)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

678

embedded image

(S)-(5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)- 1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

679

embedded image

(R)-(5-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)- 1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

680

embedded image

(S)-(3-chloro-1-methyl-1H-pyrazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

681

embedded image

(R)-(3-chloro-1-methyl-1H-pyrazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

682

embedded image

(S)-5-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazole-4-carbonitrile

683

embedded image

(R)-5-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazole-4-carbonitrile

684

embedded image

(S)-5-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazole-4-carbonitrile

685

embedded image

(R)-5-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazole-4-carbonitrile

686

embedded image

(S)-5-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazole-4-carbonitrile

687

embedded image

(R)-5-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazole-4-carbonitrile

688

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

689

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

690

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

691

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

692

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

693

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

694

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

695

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

696

embedded image

(S)-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

697

embedded image

(R)-(4-(6-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

698

embedded image

(R)-2-(4-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazol-2-yl)-2-methylpropanenitrile

699

embedded image

(S)-2-(4-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazol-2-yl)-2-methylpropanenitrile

700

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5- yl)methanone

701

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5- yl)methanone

702

embedded image

((S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)methanone

703

embedded image

((R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)methanone

704

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5- yl)methanone

705

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5- yl)methanone

706

embedded image

((S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

707

embedded image

((R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

708

embedded image

((S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((S)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

709

embedded image

((R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((S)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

710

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

711

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

712

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

713

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

714

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

715

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

716

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(1-(trifluoromethyl)-1H- pyrazol-5-yl)methanone

717

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(1-(trifluoromethyl)-1H- pyrazol-5-yl)methanone

718

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

719

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

720

embedded image

(S)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

721

embedded image

(R)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

722

embedded image

(S)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

723

embedded image

(R)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

724

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone

725

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone

726

embedded image

((S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

727

embedded image

((R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((R)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

728

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

729

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

730

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

731

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

732

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

733

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)- 1,3,4-oxadiazol-2-yl)methanone

734

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

735

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

736

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

737

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

738

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

739

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

740

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

741

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

742

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

743

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

744

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5- yl)methanone

745

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5- yl)methanone

746

embedded image

(S)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

747

embedded image

(R)-(4-bromo-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

748

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

749

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

750

embedded image

(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((S)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

751

embedded image

(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((R)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

752

embedded image

(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)((S)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

753

embedded image

(2-((R)-1-hydroxyethyl)-4-methyloxazol-5-yl)((R)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

754

embedded image

(S)-(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

755

embedded image

(R)-(2-(2-hydroxypropan-2-yl)-4-methyloxazol-5-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

756

embedded image

(S)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

757

embedded image

(R)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

758

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

759

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

760

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

761

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

762

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

763

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

764

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

765

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

766

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

767

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

768

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

769

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

770

embedded image

(S)-(4-methyloxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

771

embedded image

(R)-(4-methyloxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

772

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

773

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

774

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4-methyloxazol-5- yl)methanone

775

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- methyloxazol-5-yl)methanone

776

embedded image

(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

777

embedded image

(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

778

embedded image

(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

779

embedded image

(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

780

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)methanone

781

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)methanone

782

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1- (difluoromethyl)-1H-pyrazol-5-yl)methanone

783

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1- (difluoromethyl)-1H-pyrazol-5-yl)methanone

784

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(3- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

785

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(3- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

786

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(3-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

787

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(3-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

788

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

789

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

790

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

791

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

792

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

793

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

794

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

795

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

796

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

797

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

798

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

799

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

800

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

801

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

802

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

803

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

804

embedded image

(S)-(2-(2-hydroxypropan-2-yl)-4- (trifluoromethyl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

805

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

806

embedded image

(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

807

embedded image

(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

808

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

809

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- imidazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

810

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

811

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

812

embedded image

(S)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

813

embedded image

(R)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

814

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

815

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

816

embedded image

(R)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

817

embedded image

(S)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

818

embedded image

(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

819

embedded image

(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

820

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

821

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

822

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

823

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

824

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

825

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

826

embedded image

(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

827

embedded image

(R)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

828

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

829

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

830

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-4-yl)- 1,3,4-oxadiazol-2-yl)methanone

831

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 4-yl)-1,3,4-oxadiazol-2-yl)methanone

832

embedded image

(S)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

833

embedded image

(R)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

834

embedded image

(S)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

835

embedded image

(R)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

836

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

837

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

838

embedded image

(S)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

839

embedded image

(R)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

840

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-1H-1,2,4- triazol-5-yl)methanone

841

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl- 1H-1,2,4-triazol-5-yl)methanone

842

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(trifluoromethyl)- 1H-pyrazol-5-yl)methanone

843

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1- (trifluoromethyl)-1H-pyrazol-5-yl)methanone

844

embedded image

(S)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

845

embedded image

(R)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

846

embedded image

(S)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

847

embedded image

(R)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

848

embedded image

(S)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

849

embedded image

(R)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

850

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 4-yl)-1,3,4-oxadiazol-2-yl)methanone

851

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 4-yl)-1,3,4-oxadiazol-2-yl)methanone

852

embedded image

(S)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

853

embedded image

(R)-(5-(1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

854

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

855

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

856

embedded image

(S)-(1-isopropyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

857

embedded image

(R)-(1-isopropyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

858

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-isopropyl-1H- pyrazol-5-yl)methanone

859

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1- isopropyl-1H-pyrazol-5-yl)methanone

860

embedded image

(S)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

861

embedded image

(R)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

862

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin- 2-yl)-1H-pyrazol-5-yl)methanone

863

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin- 2-yl)-1H-pyrazol-5-yl)methanone

864

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

865

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

866

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

867

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

868

embedded image

(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5- yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

869

embedded image

(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5- yl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

870

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

871

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

872

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- (trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2- yl)methanone

873

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- (trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2- yl)methanone

874

embedded image

(R)-(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

875

embedded image

(S)-(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

876

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

877

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-methylpyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

878

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- (trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2- yl)methanone

879

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- (trifluoromethyl)pyridin-2-yl)-1,3,4-oxadiazol-2- yl)methanone

880

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

881

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5-fluoropyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

882

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

883

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

884

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-1H- pyrazol-5-yl)methanone

885

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl- 1H-pyrazol-5-yl)methanone

886

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

887

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

888

embedded image

(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5- yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

889

embedded image

(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5- yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

890

embedded image

(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5- yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

891

embedded image

(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-5- yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

892

embedded image

(S)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

893

embedded image

(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

894

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

895

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

896

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)- 1,3,4-oxadiazol-2-yl)methanone

897

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

898

embedded image

(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin- 2-yl)-1H-pyrazol-5-yl)methanone

899

embedded image

(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin- 2-yl)-1H-pyrazol-5-yl)methanone

900

embedded image

(S)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

901

embedded image

(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

902

embedded image

(S)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4- yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

903

embedded image

(R)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4- yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

904

embedded image

(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

905

embedded image

(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

906

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

907

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

908

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

909

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

910

embedded image

(S)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

911

embedded image

(R)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

912

embedded image

(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

913

embedded image

(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

914

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

915

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

916

embedded image

(S)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

917

embedded image

(R)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

918

embedded image

(S)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

919

embedded image

(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

920

embedded image

(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4- yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H) yl)methanone

921

embedded image

(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4- yl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

922

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

923

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

924

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

925

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

926

embedded image

(S)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

927

embedded image

(R)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

928

embedded image

(S)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

929

embedded image

(R)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

930

embedded image

(R)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4- yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

931

embedded image

(S)-(4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4- yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

932

embedded image

(S)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

933

embedded image

(R)-(5-(5-methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

934

embedded image

(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

935

embedded image

(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

936

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

937

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

938

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

939

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

940

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

941

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

942

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

943

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

944

embedded image

(S)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

945

embedded image

(R)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

946

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

947

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

948

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

949

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

950

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

951

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

952

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

953

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

954

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

955

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

956

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

957

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

958

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)oxazol-5-yl)methanone

959

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)oxazol-5-yl)methanone

960

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5- yl)methanone

961

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol-5- yl)methanone

962

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)- 1,3,4-oxadiazol-2-yl)methanone

963

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

964

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

965

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

966

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

967

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

968

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

969

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

970

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

971

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

972

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

973

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

974

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

975

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)- 1,3,4-oxadiazol-2-yl)methanone

976

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

977

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

978

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

979

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

980

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

981

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

982

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

983

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

984

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

985

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

986

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

987

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

988

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

989

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

990

embedded image

(S)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

991

embedded image

(R)-(4-chloro-2-(2-hydroxypropan-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

992

embedded image

(S)-2-methyl-2-(4-methyl-5-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazol-2-yl)propanenitrile

993

embedded image

(R)-2-methyl-2-(4-methyl-5-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5- carbonyl)oxazol-2-yl)propanenitrile

994

embedded image

(S)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

995

embedded image

(R)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

996

embedded image

(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #1 (Rt = 5.586 min)

997

embedded image

(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #2 (Rt = 5.796 min)

998

embedded image

(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #1 (Rt = 4.830 min)

999

embedded image

(4-bromo-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #2 (Rt = 5.133 min)

1000

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone

1001

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone

1002

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1003

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1004

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(5- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1005

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(5- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1006

embedded image

(S)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1007

embedded image

(R)-(4-(difluoromethyl)-2-(pyridin-2-yl)oxazol-5-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1008

embedded image

(S)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4- yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1009

embedded image

(R)-(4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4- yl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1010

embedded image

(S)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1011

embedded image

(R)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1012

embedded image

(S)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1013

embedded image

(R)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1014

embedded image

(S)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1015

embedded image

(R)-(5-(4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1016

embedded image

(S)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1017

embedded image

(R)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1018

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone

1019

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1020

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1021

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1022

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1023

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1024

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1025

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1026

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1027

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1028

embedded image

(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1029

embedded image

(R)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1030

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1031

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1032

embedded image

(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1033

embedded image

(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1034

embedded image

(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1035

embedded image

(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1036

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1037

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1038

embedded image

(S)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1039

embedded image

(R)-(5-(1-cyclobutyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1040

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1041

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1042

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1043

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1044

embedded image

(S)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1045

embedded image

(R)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1046

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1047

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1048

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1049

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1050

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl- 1H-1,2,4-triazol-5-yl)methanone

1051

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl- 1H-1,2,4-triazol-5-yl)methanone

1052

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3- (trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone

1053

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3- (trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone

1054

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1055

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1056

embedded image

(S)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1057

embedded image

(R)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1058

embedded image

(S)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1059

embedded image

(R)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1060

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1061

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1062

embedded image

(S)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1063

embedded image

(R)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1064

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1- (difluoromethyl)-1H-pyrazol-5-yl)methanone

1065

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1- (difluoromethyl)-1H-pyrazol-5-yl)methanone

1066

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1067

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1068

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1069

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1070

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1071

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1072

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)methanone

1073

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)methanone

1074

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1,3- dimethyl-1H-1,2,4-triazol-5-yl)methanone

1075

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1,3- dimethyl-1H-1,2,4-triazol-5-yl)methanone

1076

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1077

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1078

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1079

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1080

embedded image

(R)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1081

embedded image

(S)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1082

embedded image

(S)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1083

embedded image

(R)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1084

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1085

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(5-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H) yl)methanone

1086

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1087

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1088

embedded image

(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1089

embedded image

(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1090

embedded image

(S)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-2-yl)- 1,3,4-oxadiazol-2-yl)methanone

1091

embedded image

(R)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1092

embedded image

(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(5- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1093

embedded image

(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(5- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1094

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclopropyl-1,3,4-oxadiazol-2-yl)methanone

1095

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclopropyl-1,3,4-oxadiazol-2-yl)methanone

1096

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1097

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1098

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1099

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1100

embedded image

(S)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1101

embedded image

(R)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1102

embedded image

(S)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1103

embedded image

(R)-(4-(6-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1104

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1105

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1106

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-methyl- 1,3,4-oxadiazol-2-yl)methanone

1107

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-methyl- 1,3,4-oxadiazol-2-yl)methanone

1108

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1109

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1110

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1111

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1112

embedded image

(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1113

embedded image

(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1114

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1115

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1116

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1117

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(6-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1118

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1119

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1120

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1121

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1122

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1123

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1124

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1125

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1126

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1127

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1128

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1129

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1130

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(5- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1131

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(5- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1132

embedded image

(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(5- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1133

embedded image

(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(5- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1134

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2 yl)methanone

1135

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1136

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclopropyl-1,3,4-oxadiazol-2-yl)methanone

1137

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclopropyl-1,3,4-oxadiazol-2-yl)methanone

1138

embedded image

(S)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1139

embedded image

(R)-(1-(difluoromethyl)-1H-pyrazol-5-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1140

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1141

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1142

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1143

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- chloropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1144

embedded image

(S)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1145

embedded image

(R)-(1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1146

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

1147

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

1148

embedded image

(S)-(4-methyloxazol-5-yl)(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1149

embedded image

(R)-(4-methyloxazol-5-yl)(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1150

embedded image

(S)-(2-(2-hydroxypropan-2-yl)-4- (trifluoromethyl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1151

embedded image

(R)-(2-(2-hydroxypropan-2-yl)-4- (trifluoromethyl)oxazol-5-yl)(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1152

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1153

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1154

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1155

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1156

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1157

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1158

embedded image

(S)-oxazol-5-yl(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1159

embedded image

(R)-oxazol-5-yl(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1160

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1161

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1162

embedded image

(S)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1163

embedded image

(R)-(3-chloro-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1164

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1165

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1166

embedded image

(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

1167

embedded image

(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

1168

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1169

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1170

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1171

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1172

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

1173

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (trifluoromethyl)oxazol-5-yl)methanone

1174

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- methyloxazol-5-yl)methanone

1175

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- methyloxazol-5-yl)methanone

1176

embedded image

(S)-(4-(trifluoromethyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1177

embedded image

(R)-(4-(trifluoromethyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1178

embedded image

(S)-(2-(2-hydroxypropan-2-yl)-4- (trifluoromethyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1179

embedded image

(R)-(2-(2-hydroxypropan-2-yl)-4- (trifluoromethyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1180

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1181

embedded image

(4-(difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1182

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1183

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1184

embedded image

(R)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

1185

embedded image

(S)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

1186

embedded image

(R)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

1187

embedded image

(S)-(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(oxazol-5- yl)methanone

1188

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1189

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1190

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1191

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1192

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5- yl)methanone

1193

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-(trifluoromethyl)oxazol-5- yl)methanone

1194

embedded image

((R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)methanone

1195

embedded image

((S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)methanone

1196

embedded image

((S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)methanone

1197

embedded image

((R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-((R)-1-hydroxyethyl)oxazol-5- yl)methanone

1198

embedded image

(S)-(4-(trifluoromethyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1199

embedded image

(R)-(4-methyloxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1200

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((S)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1201

embedded image

(4-(difluoromethyl)-2-((S)-1-hydroxyethyl)oxazol-5- yl)((R)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1202

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1203

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1204

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1205

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1206

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1207

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1208

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1209

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1210

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone

1211

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)-4-methyloxazol-5-yl)methanone

1212

embedded image

((S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((S)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

1213

embedded image

((R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-((S)-1- hydroxyethyl)-4-methyloxazol-5-yl)methanone

1214

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1215

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1216

embedded image

(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1217

embedded image

(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol- 5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1218

embedded image

(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1219

embedded image

(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol- 5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1220

embedded image

(S)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1221

embedded image

(R)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1222

embedded image

(S)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1223

embedded image

(R)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1224

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1225

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1226

embedded image

(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1227

embedded image

(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol- 5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1228

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)methanone

1229

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)methanone

1230

embedded image

(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1231

embedded image

(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol- 5-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1232

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)methanone

1233

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)methanone

1234

embedded image

(S)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1235

embedded image

(R)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1236

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5- yl)methanone

1237

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(4- (difluoromethyl)-2-(1-hydroxycyclopropyl)oxazol-5- yl)methanone

1238

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1239

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1240

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1241

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(7- ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1242

embedded image

(S)-(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1243

embedded image

(R)-(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1244

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1245

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(7-ethoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1246

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1247

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1248

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1249

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1250

embedded image

(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1251

embedded image

(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1252

embedded image

(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1253

embedded image

(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1254

embedded image

(R)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol- 5-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1255

embedded image

(S)-(4-(difluoromethyl)-2-(2-fluoropropan-2-yl)oxazol-5- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1256

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1257

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1258

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-4-yl)- 1,3,4-oxadiazol-2-yl)methanone

1259

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1260

embedded image

(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1261

embedded image

(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1262

embedded image

(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1263

embedded image

(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1264

embedded image

(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1265

embedded image

(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1266

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- fluoropropan-2-yl)-4-methyloxazol-5-yl)methanone

1267

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- fluoropropan-2-yl)-4-methyloxazol-5-yl)methanone

1268

embedded image

(S)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1269

embedded image

(R)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1270

embedded image

(S)-pyrazolo[1,5-a]pyridin-3-yl(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1271

embedded image

(R)-pyrazolo[1,5-a]pyridin-3-yl(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1272

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1273

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1274

embedded image

(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1275

embedded image

(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1276

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- fluoropropan-2-yl)-4-methyloxazol-5-yl)methanone

1277

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- fluoropropan-2-yl)-4-methyloxazol-5-yl)methanone

1278

embedded image

(S)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1279

embedded image

(R)-(2-(2-fluoropropan-2-yl)-4-methyloxazol-5-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1280

embedded image

(S)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1281

embedded image

(R)-(4-(difluoromethyl)-2-(1- hydroxycyclopropyl)oxazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1282

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- methyl-1,3,4-oxadiazol-2-yl)methanone

1283

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- methyl-1,3,4-oxadiazol-2-yl)methanone

1284

embedded image

(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1285

embedded image

(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1286

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1287

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1288

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1289

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(pyrazolo[1,5- a]pyridin-3-yl)methanone

1290

embedded image

(R)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4- oxadiazole

1291

embedded image

(S)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin-2-yl)-1,3,4- oxadiazole

1292

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1293

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1294

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1295

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1296

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone

1297

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone

1298

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1299

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1300

embedded image

(S)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1301

embedded image

(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1302

embedded image

(S)-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1303

embedded image

(R)-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1304

embedded image

(S)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1305

embedded image

(R)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1306

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1307

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1308

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1309

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1310

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1311

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1312

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1313

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrimidin-2-yl)- 1,3,4-oxadiazol-2-yl)methanone

1314

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1315

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1316

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1317

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1318

embedded image

(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1319

embedded image

(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1320

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone

1321

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone

1322

embedded image

(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1323

embedded image

(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1324

embedded image

(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1325

embedded image

(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1326

embedded image

(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1327

embedded image

(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1328

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1329

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1330

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1331

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1332

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1333

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1334

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1335

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1336

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1337

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1338

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1339

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1340

embedded image

(S)-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1341

embedded image

(R)-(5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1342

embedded image

(S)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1343

embedded image

(R)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1344

embedded image

(S)-(5-(6-methoxypyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4- (7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1345

embedded image

(R)-(5-(6-methoxypyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4- (7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1346

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4- oxadiazol-2-yl)methanone

1347

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)-1,3,4- oxadiazol-2-yl)methanone

1348

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1349

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1350

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1351

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1352

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1353

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1354

embedded image

(S)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1355

embedded image

(R)-(5-(1-methylcyclopropyl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1356

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1357

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1358

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1359

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1360

embedded image

(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1361

embedded image

(S)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1362

embedded image

(S)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1363

embedded image

(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1364

embedded image

(S)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone imidazo[4,5- c]pyridin-5(4H)-yl)methanone

1365

embedded image

(R)-(5-(2-methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1366

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1367

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1368

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone

1369

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone

1370

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1371

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1372

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1373

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1374

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1375

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1376

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1377

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1378

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone

1379

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methylcyclopropyl)-1,3,4-oxadiazol-2-yl)methanone

1380

embedded image

(R)-(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1381

embedded image

(S)-(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1382

embedded image

(S)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1383

embedded image

(R)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1384

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone

1385

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-pyrazol-5-yl)methanone

1386

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1387

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1388

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1389

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1390

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1391

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1392

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1393

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1394

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1395

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1396

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1397

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1398

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1399

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1400

embedded image

(S)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1401

embedded image

(R)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1402

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1403

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-pyrazol-5-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1404

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1405

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1406

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1407

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1408

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1409

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1410

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1411

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1412

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1413

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1414

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1415

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1416

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2- yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1417

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2- yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1418

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1419

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1420

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1421

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1422

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1423

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1424

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1425

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1426

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1427

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1428

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1429

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1430

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1431

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1432

embedded image

(R)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1433

embedded image

(S)-(5-(6-methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1434

embedded image

(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1435

embedded image

(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1436

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1437

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1438

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1439

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1440

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1441

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1442

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1443

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1444

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1445

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1446

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1447

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1448

embedded image

(S)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1449

embedded image

(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1450

embedded image

(S)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1451

embedded image

(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1452

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4- oxadiazol-2-yl)methanone

1453

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1454

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- cyclopropyl-1,3,4-oxadiazole

1455

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- cyclopropyl-1,3,4-oxadiazole

1456

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1457

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1458

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1459

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3-fluoropyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1460

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1461

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyrazin-2-yl)- 1,3,4-oxadiazol-2-yl)methanone

1462

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1463

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1464

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1465

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1466

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,3- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1467

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,3- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1468

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1469

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1470

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1471

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1472

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1473

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1474

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1475

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1476

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1477

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1478

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1479

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1480

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1481

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1482

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1483

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1484

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1485

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1486

embedded image

(S)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1487

embedded image

(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1488

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1489

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1490

embedded image

(S)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1491

embedded image

(R)-(5-isopropyl-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1492

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1493

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1494

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2-methylpyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1495

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1496

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6-methylpyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1497

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1498

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1499

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1500

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1501

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- methylpyridin-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1502

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1503

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1504

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1505

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanonepyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1506

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1507

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1508

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1509

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1510

embedded image

(S)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1511

embedded image

(R)-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1512

embedded image

(S)-(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1513

embedded image

(R)-(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1514

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1515

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1516

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclobutyl-1,3,4-oxadiazol-2-yl)methanone

1517

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclobutyl-1,3,4-oxadiazol-2-yl)methanone

1518

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1519

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1520

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1521

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1522

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin-3-yl)- 1,3,4-oxadiazol-2-yl)methanone

1523

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 3-yl)-1,3,4-oxadiazol-2-yl)methanone

1524

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1525

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1526

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-methyl-1H- pyrazol-5-yl)-1,3,4-oxadiazol-2-yl)methanone

1527

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1528

embedded image

(S)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1529

embedded image

(R)-(5-(1,4-dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol- 2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1530

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1531

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1532

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1533

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1534

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1535

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1536

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1537

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1538

embedded image

(S)-(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1539

embedded image

(R)-(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1540

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1541

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1542

embedded image

(S)-(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1543

embedded image

(R)-(5-(1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1544

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1545

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1546

embedded image

(S)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin- 3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1547

embedded image

(R)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin- 3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1548

embedded image

(S)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1549

embedded image

(R)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1550

embedded image

(S)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1551

embedded image

(R)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1552

embedded image

(S)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1553

embedded image

(R)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1554

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- isopropyl-1,3,4-oxadiazol-2-yl)methanone

1555

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-isopropyl-1,3,4- oxadiazol-2-yl)methanone

1556

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1557

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1558

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1559

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1560

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclobutyl-1,3,4-oxadiazol-2-yl)methanone

1561

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- cyclobutyl-1,3,4-oxadiazol-2-yl)methanone

1562

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1563

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1564

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol- 2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1565

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1566

embedded image

(S)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1567

embedded image

(R)-(5-(1,3-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1568

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4- dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1569

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4- dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1570

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1571

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1572

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1573

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1574

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1575

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1576

embedded image

(R)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)benzo[d]oxazole

1577

embedded image

(S)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)benzo[d]oxazole

1578

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1579

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(5- methoxypyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1580

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1581

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1582

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,3- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1583

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,3- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1584

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4- dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1585

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,4- dimethyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1586

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3,3- difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)methanone

1587

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3,3- difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)methanone

1588

embedded image

(R)-2-cyclopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1589

embedded image

(S)-2-cyclopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1590

embedded image

(R)-2-cyclopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1591

embedded image

(S)-2-cyclopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1592

embedded image

(S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1593

embedded image

(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(pyrimidin-2-yl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1594

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1595

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(6- methylpyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1596

embedded image

(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1597

embedded image

(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1598

embedded image

(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1599

embedded image

(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1600

embedded image

(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1601

embedded image

(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1602

embedded image

(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1603

embedded image

(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1604

embedded image

(S)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1605

embedded image

(R)-(5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazol-2-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1606

embedded image

(R)-2-cyclopropyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1607

embedded image

(S)-2-cyclopropyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1608

embedded image

(S)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1609

embedded image

(R)-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)methanone

1610

embedded image

(S)-2-(pyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1611

embedded image

(R)-2-(pyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1612

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1613

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1614

embedded image

(S)-(6-morpholinopyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1615

embedded image

(R)-(6-morpholinopyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1616

embedded image

(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1617

embedded image

(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1618

embedded image

(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1619

embedded image

(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1620

embedded image

(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1621

embedded image

(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1622

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1623

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1624

embedded image

(S)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1625

embedded image

(R)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1626

embedded image

(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (pyridin-2-yl)-1,3,4-oxadiazole

1627

embedded image

(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (pyridin-2-yl)-1,3,4-oxadiazole

1628

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1629

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1630

embedded image

(S)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1631

embedded image

(R)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1632

embedded image

(S)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1633

embedded image

(R)-(6-(1-methyl-1H-pyrazol-3-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1634

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- ((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3- yl)methanone

1635

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- ((dimethylamino)methyl)pyrazolo[1,5-a]pyridin-3- yl)methanone

1636

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1637

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1638

embedded image

(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1639

embedded image

(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1640

embedded image

(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1641

embedded image

(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-(pyridin- 2-yl)-1,3,4-oxadiazole

1642

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)benzo[d]oxazole

1643

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)benzo[d]oxazole

1644

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin-2- yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1645

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin- 2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1646

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1-methyl-1H- pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1647

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1- methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3- yl)methanone

1648

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin- 2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1649

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(pyridin- 2-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1650

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1651

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1652

embedded image

(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1653

embedded image

(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1654

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1655

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1656

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1657

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1658

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1659

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1,5- dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1660

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1661

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1662

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1663

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1664

embedded image

(S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1665

embedded image

(R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1666

embedded image

(S)-(6-methylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1667

embedded image

(R)-(6-methylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1668

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1669

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1670

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1671

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1672

embedded image

(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1673

embedded image

(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1674

embedded image

(S)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1675

embedded image

(R)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1676

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1677

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1678

embedded image

(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1679

embedded image

(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1680

embedded image

(S)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1681

embedded image

(R)-(5-(pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1682

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1683

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1684

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1685

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1686

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1687

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1688

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1689

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1690

embedded image

(S)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin- 3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1691

embedded image

(R)-(6-((dimethylamino)methyl)pyrazolo[1,5-a]pyridin- 3-yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1692

embedded image

(S)-5-(pyrimidin-2-yl)-4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

1693

embedded image

(R)-5-(pyrimidin-2-yl)-4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

1694

embedded image

(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1695

embedded image

(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1696

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1697

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1698

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1699

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1700

embedded image

(R)-5-(pyrazin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2-yl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1701

embedded image

(S)-5-(pyrazin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2-yl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1702

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1703

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1704

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1705

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1706

embedded image

(S)-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1707

embedded image

(R)-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (1-(trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1708

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1709

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1710

embedded image

(R)-2-(difluoromethyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1711

embedded image

(S)-2-(difluoromethyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1712

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1713

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1714

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1715

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1716

embedded image

(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1717

embedded image

(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1718

embedded image

(S)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1719

embedded image

(R)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(7- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1720

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1721

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

1722

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1723

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

1724

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1725

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1726

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1727

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1728

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1729

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1730

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1731

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

1732

embedded image

(R)-2-(difluoromethyl)-5-(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1733

embedded image

(S)-2-(difluoromethyl)-5-(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1734

embedded image

(R)-2-(difluoromethyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1735

embedded image

(S)-2-(difluoromethyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1736

embedded image

(R)-2-(difluoromethyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1737

embedded image

(S)-2-(difluoromethyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1738

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (difluoromethyl)-1,3,4-oxadiazole

1739

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (difluoromethyl)-1,3,4-oxadiazole

1740

embedded image

(R)-2-(difluoromethyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1741

embedded image

(S)-2-(difluoromethyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1742

embedded image

(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1743

embedded image

(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1744

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone

1745

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone

1746

embedded image

(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1747

embedded image

(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1748

embedded image

(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1- methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3- yl)methanone

1749

embedded image

(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1- methyl-1H-pyrazol-3-yl)pyrazolo[1,5-a]pyridin-3- yl)methanone

1750

embedded image

(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1751

embedded image

(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1752

embedded image

(S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1753

embedded image

(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1754

embedded image

(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1755

embedded image

(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1756

embedded image

(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1757

embedded image

(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2- yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1758

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1759

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1760

embedded image

(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1761

embedded image

(R)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1762

embedded image

(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1763

embedded image

(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1764

embedded image

(R)-5-(pyrimidin-2-yl)-4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

1765

embedded image

(S)-5-(pyrimidin-2-yl)-4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

1766

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1767

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1768

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone

1769

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- cyclopropylpyrazolo[1,5-a]pyridin-3-yl)methanone

1770

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone

1771

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone

1772

embedded image

(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1773

embedded image

(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1774

embedded image

(S)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1775

embedded image

(R)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1776

embedded image

(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1777

embedded image

(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1778

embedded image

(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1779

embedded image

(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1780

embedded image

(S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1781

embedded image

(R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1782

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1783

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-(trifluoromethoxy)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

1784

embedded image

(S)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1785

embedded image

(R)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1786

embedded image

(S)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1787

embedded image

(R)-(4-(7-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

1788

embedded image

(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1789

embedded image

(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1790

embedded image

(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1791

embedded image

(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1792

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone

1793

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone

1794

embedded image

(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1795

embedded image

(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

1796

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(2- methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1797

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(2- methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

1798

embedded image

(R)-2-(tert-butyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1799

embedded image

(S)-2-(tert-butyl)-5-(4-(4-methylpyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1800

embedded image

(S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1801

embedded image

(R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1802

embedded image

(S)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1803

embedded image

(R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1804

embedded image

(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1805

embedded image

(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1806

embedded image

(R)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)- 1,3,4-oxadiazole

1807

embedded image

(S)-2-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)-5-(trifluoromethyl)- 1,3,4-oxadiazole

1808

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1809

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1810

embedded image

(S)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1811

embedded image

(R)-4-(7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1812

embedded image

(S)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1813

embedded image

(R)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

1814

embedded image

(S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1815

embedded image

(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2-yl)- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1816

embedded image

(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1817

embedded image

(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1818

embedded image

(R)-5-(pyrazin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1819

embedded image

(S)-5-(pyrazin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1820

embedded image

(R)-2-(trifluoromethyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1821

embedded image

(S)-2-(trifluoromethyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1822

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1823

embedded image

((S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1824

embedded image

(R)-2-(tert-butyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1825

embedded image

(S)-2-(tert-butyl)-5-(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1826

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)pyrimidin-5- amine

1827

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)pyrimidin-5- amine

1828

embedded image

(R)-5-(6-chloropyrazin-2-yl)-4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

1829

embedded image

(S)-5-(6-chloropyrazin-2-yl)-4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

1830

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- cyclobutyl-1,3,4-oxadiazole

1831

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- cyclobutyl-1,3,4-oxadiazole

1832

embedded image

(R)-2-(tert-butyl)-5-(4-(4-chloropyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1833

embedded image

(S)-2-(tert-butyl)-5-(4-(4-chloropyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1834

embedded image

(R)-2-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)pyrimidin-5-amine

1835

embedded image

(S)-2-(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)pyrimidin-5-amine

1836

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5- amine

1837

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5- amine

1838

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1839

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1840

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1841

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1842

embedded image

(R)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1843

embedded image

(S)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

1844

embedded image

(R)-2-(2,6-difluorophenyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1845

embedded image

(S)-2-(2,6-difluorophenyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

1846

embedded image

(R)-2-(2,6-difluorophenyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1847

embedded image

(S)-2-(2,6-difluorophenyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

1848

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1849

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1850

embedded image

(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1851

embedded image

(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

1852

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)pyrimidin-5-amine

1853

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)pyrimidin-5-amine

1854

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1855

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1856

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1857

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1858

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-methyl- 1,3,4-oxadiazol-2-yl)methanone

1859

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-methyl- 1,3,4-oxadiazol-2-yl)methanone

1860

embedded image

(R)-2-(4-fluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- 1,3,4-oxadiazole

1861

embedded image

(S)-2-(4-fluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- 1,3,4-oxadiazole

1862

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (2,6-difluorophenyl)-1,3,4-oxadiazole

1863

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (2,6-difluorophenyl)-1,3,4-oxadiazole

1864

embedded image

(R)-2-(2,6-difluorophenyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

1865

embedded image

(S)-2-(2,6-difluorophenyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

1866

embedded image

(S)-(2-(tert-butyl)oxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1867

embedded image

(R)-(2-(tert-butyl)oxazol-5-yl)(4-(pyrazolo[1,5-a]pyridin- 2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

1868

embedded image

(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1869

embedded image

(R)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1870

embedded image

(S)-5-(pyridin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1871

embedded image

(R)-5-(pyridin-2-yl)-4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1872

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5- amine

1873

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)pyrimidin-5- amine

1874

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methanone

1875

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methanone

1876

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1877

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1878

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1879

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (difluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1880

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1881

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1882

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1883

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1884

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1885

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1886

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1887

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1888

embedded image

(R)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1889

embedded image

(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1890

embedded image

(R)-2-(4-fluorophenyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

1891

embedded image

(S)-2-(4-fluorophenyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

1892

embedded image

(R)-2-(4-fluorophenyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

1893

embedded image

(S)-2-(4-fluorophenyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

1894

embedded image

(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1895

embedded image

(S)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1896

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1897

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (pyridin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1898

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1899

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1900

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1901

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1902

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1903

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1904

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1905

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1906

embedded image

(S)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1907

embedded image

(R)-(5-(3-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1908

embedded image

(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- cyclopropyl-1,3,4-oxadiazol-2-yl)methanone

1909

embedded image

(R)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- cyclopropyl-1,3,4-oxadiazol-2-yl)methanone

1910

embedded image

(R)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1911

embedded image

(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1912

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (4-fluorophenyl)-1,3,4-oxadiazole

1913

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4- fluorophenyl)-1,3,4-oxadiazole

1914

embedded image

(S)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1915

embedded image

(R)-4-(pyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1916

embedded image

(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1917

embedded image

(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1918

embedded image

(S)-(2-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1919

embedded image

(R)-(2-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1920

embedded image

(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1921

embedded image

(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1922

embedded image

(S)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1923

embedded image

(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1924

embedded image

(S)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1925

embedded image

(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

1926

embedded image

(R)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1927

embedded image

(S)-(4-(4-ethylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1928

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1929

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1930

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1931

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (difluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1932

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1933

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- (1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1934

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrazin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1935

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrazin-2- yl)-1,3,4-oxadiazol-2-yl)methanone

1936

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

1937

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

1938

embedded image

(S)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1939

embedded image

(R)-(4-(4-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

1940

embedded image

(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1941

embedded image

(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1942

embedded image

(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1943

embedded image

(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

1944

embedded image

(S)-(4-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1945

embedded image

(R)-(4-cyclopropyloxazol-5-yl)(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1946

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1947

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

1948

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1949

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1950

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1951

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

1952

embedded image

(R)-2-(4-fluorophenyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

1953

embedded image

(S)-2-(4-fluorophenyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

1954

embedded image

(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(6- fluoropyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1955

embedded image

(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(6- fluoropyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1956

embedded image

(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methanone

1957

embedded image

(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methanone

1958

embedded image

(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1959

embedded image

(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1960

embedded image

(S)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1961

embedded image

(R)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1962

embedded image

(S)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1963

embedded image

(R)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1964

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2- yl)oxazol-5-yl)methanone

1965

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2- yl)oxazol-5-yl)methanone

1966

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4- thiadiazol-2-yl)methanone

1967

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2-yl)-1,3,4- thiadiazol-2-yl)methanone

1968

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-thiadiazol-2-yl)methanone

1969

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-thiadiazol-2-yl)methanone

1970

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-thiadiazol-2-yl)methanone

1971

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyridin-2- yl)-1,3,4-thiadiazol-2-yl)methanone

1972

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin- 5-yl)-1,3,4-oxadiazol-2-yl)methanone

1973

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin- 5-yl)-1,3,4-oxadiazol-2-yl)methanone

1974

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin- 5-yl)-1,3,4-oxadiazol-2-yl)methanone

1975

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin- 5-yl)-1,3,4-oxadiazol-2-yl)methanone

1976

embedded image

(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2- yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1977

embedded image

(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin-2- yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

1978

embedded image

(R)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1979

embedded image

(S)-4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

1980

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1981

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(pyrimidin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

1982

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

1983

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-3-yl)-1,3,4- oxadiazol-2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

1984

embedded image

(S)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1985

embedded image

(R)-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)methanone

1986

embedded image

(S)-(4-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1987

embedded image

(R)-(4-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

1988

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(oxazol-2 yl)methanone-

1989

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(oxazol-2- yl)methanone

1990

embedded image

(R)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methanone

1991

embedded image

(S)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H- imidazo[4,5-c]pyridin-5-yl)methanone

1992

embedded image

(R)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1993

embedded image

(S)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1994

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)methanone

1995

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-3-yl)-1,3,4-thiadiazol-2-yl)methanone

1996

embedded image

(R)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1997

embedded image

(S)-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

1998

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

1999

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2000

embedded image

(S)-benzo[d]thiazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2001

embedded image

(R)-benzo[d]thiazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2002

embedded image

(S)-benzo[d]thiazol-2-yl(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2003

embedded image

(R)-benzo[d]thiazol-2-yl(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2004

embedded image

(S)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2005

embedded image

(R)-(5-(1-methyl-1H-pyrazol-5-yl)-1,3,4-oxadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2006

embedded image

(R)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol- 2-yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2007

embedded image

(S)-(5-(1,5-dimethyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2008

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4- fluorophenyl)-1,3,4-oxadiazole

2009

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4- fluorophenyl)-1,3,4-oxadiazole

2010

embedded image

(S)-2-(4-fluorophenyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2011

embedded image

(R)-2-(4-fluorophenyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2012

embedded image

(R)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2013

embedded image

(S)-4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2014

embedded image

(S)-(4-cyclopropyloxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2015

embedded image

(R)-(4-cyclopropyloxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2016

embedded image

(S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2017

embedded image

(R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-thiadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2018

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)methanone

2019

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-thiadiazol-2-yl)methanone

2020

embedded image

(S)-benzo[d]oxazol-2-yl(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2021

embedded image

(R)-benzo[d]oxazol-2-yl(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2022

embedded image

(S)-benzo[d]thiazol-2-yl(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2023

embedded image

(R)-benzo[d]thiazol-2-yl(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2024

embedded image

(S)-cyclopropyl(4-(4-methylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2025

embedded image

(R)-cyclopropyl(4-(4-methylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2026

embedded image

((R)-2,2-difluorocyclopropyl)((R)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2027

embedded image

((R)-2,2-difluorocyclopropyl)((S)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2028

embedded image

((S)-2,2-difluorocyclopropyl)((S)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2029

embedded image

((S)-2,2-difluorocyclopropyl)((R)-4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2030

embedded image

((S)-2,2-difluorocyclopropyl)((S)-4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2031

embedded image

((S)-2,2-difluorocyclopropyl)((R)-4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2032

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2- yl)oxazol-5-yl)methanone

2033

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyridin-2- yl)oxazol-5-yl)methanone

2034

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2- (pyridin-2-yl)oxazol-5-yl)methanone

2035

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2- (pyridin-2-yl)oxazol-5-yl)methanone

2036

embedded image

(S)-(2-(pyridin-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2037

embedded image

(R)-(2-(pyridin-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2038

embedded image

(R)-(4-cyclopropyloxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2039

embedded image

(S)-(4-cyclopropyloxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2040

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(4- cyclopropyloxazol-5-yl)methanone

2041

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(4- cyclopropyloxazol-5-yl)methanone

2042

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(4- cyclopropyloxazol-5-yl)methanone

2043

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(4- cyclopropyloxazol-5-yl)methanone

2044

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2045

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2046

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2047

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-thiadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2048

embedded image

(S)-benzo[d]oxazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2049

embedded image

(R)-benzo[d]oxazol-2-yl(4-(pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2050

embedded image

(S)-benzo[d]oxazol-2-yl(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2051

embedded image

(R)-benzo[d]oxazol-2-yl(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2052

embedded image

(S)-benzo[d]oxazol-2-yl(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2053

embedded image

(R)-benzo[d]oxazol-2-yl(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2054

embedded image

(S)-benzo[d]oxazol-2-yl(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2055

embedded image

(R)-benzo[d]oxazol-2-yl(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2056

embedded image

(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2057

embedded image

(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2058

embedded image

(R)-2-cyclopropyl-5-(4-(4-cyclopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2059

embedded image

(S)-2-cyclopropyl-5-(4-(4-cyclopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2060

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

2061

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(2- fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

2062

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6- difluorophenyl)-1,3,4-oxadiazole

2063

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6- difluorophenyl)-1,3,4-oxadiazole

2064

embedded image

(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2065

embedded image

(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2066

embedded image

(S)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2067

embedded image

(R)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2068

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2- (1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)methanone

2069

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2- (1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)methanone

2070

embedded image

(S)-(4-cyclopropyloxazol-5-yl)(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2071

embedded image

(R)-(4-cyclopropyloxazol-5-yl)(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2072

embedded image

(R)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2073

embedded image

(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2074

embedded image

(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2075

embedded image

(R)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2076

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)(oxazol-2-yl)methanone

2077

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)(oxazol-2-yl)methanone

2078

embedded image

(S)-oxazol-2-yl(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2079

embedded image

(R)-oxazol-2-yl(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2080

embedded image

(S)-cyclobutyl(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2081

embedded image

(R)-cyclobutyl(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2082

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- methyl-1,3,4-oxadiazole

2083

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- methyl-1,3,4-oxadiazole

2084

embedded image

(R)-2-(difluoromethyl)-5-(4-(4-isopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2085

embedded image

(S)-2-(difluoromethyl)-5-(4-(4-isopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2086

embedded image

(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4- fluorophenyl)-1,3,4-oxadiazole

2087

embedded image

(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4- fluorophenyl)-1,3,4-oxadiazole

2088

embedded image

(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6- difluorophenyl)-1,3,4-oxadiazole

2089

embedded image

(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2,6- difluorophenyl)-1,3,4-oxadiazole

2090

embedded image

(R)-2-(2,6-difluorophenyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2091

embedded image

(S)-2-(2,6-difluorophenyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2092

embedded image

(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (2,6-difluorophenyl)-1,3,4-oxadiazole

2093

embedded image

(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (2,6-difluorophenyl)-1,3,4-oxadiazole

2094

embedded image

(R)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2095

embedded image

(S)-4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2096

embedded image

(R)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2097

embedded image

(S)-4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2098

embedded image

(S)-(2-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2099

embedded image

(R)-(2-cyclopropyloxazol-5-yl)(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2100

embedded image

(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2101

embedded image

(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2102

embedded image

(S)-(2-cyclopropyloxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2103

embedded image

(R)-(2-cyclopropyloxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2104

embedded image

(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2105

embedded image

(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2106

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(2- fluoropropan-2-yl)oxazol-5-yl)methanone

2107

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(2- fluoropropan-2-yl)oxazol-5-yl)methanone

2108

embedded image

(R)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2109

embedded image

(S)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2110

embedded image

(S)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2111

embedded image

(R)-(2-(1,5-dimethyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2112

embedded image

(S)-(4-cyclopropyloxazol-5-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2113

embedded image

(R)-(4-cyclopropyloxazol-5-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2114

embedded image

(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2115

embedded image

(R)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2116

embedded image

(S)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2117

embedded image

(R)-(4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)oxazol- 5-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5- yl)methanone

2118

embedded image

(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2119

embedded image

(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2120

embedded image

(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2121

embedded image

(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2122

embedded image

(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2123

embedded image

(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2124

embedded image

(S)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2125

embedded image

(R)-(4-cyclopropyl-2-(pyridin-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2126

embedded image

(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2127

embedded image

(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-(pyridin- 2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2128

embedded image

(R)-2-(4-fluorophenyl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2129

embedded image

(S)-2-(4-fluorophenyl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2130

embedded image

(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (4-fluorophenyl)-1,3,4-oxadiazole

2131

embedded image

(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(4- fluorophenyl)-1,3,4-oxadiazole

2132

embedded image

(R)-2-(2,6-difluorophenyl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2133

embedded image

(S)-2-(2,6-difluorophenyl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2134

embedded image

(R)-5-(6-fluoropyridin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2- yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2135

embedded image

(S)-5-(6-fluoropyridin-2-yl)-4-(pyrazolo[1,5-a]pyridin-2- yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2136

embedded image

(S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2137

embedded image

(R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2138

embedded image

(S)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2139

embedded image

(R)-4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-5- (5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2140

embedded image

(S)-(2-cyclopropyloxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2141

embedded image

(R)-(2-cyclopropyloxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2142

embedded image

(S)-(2-(tert-butyl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2143

embedded image

(R)-(2-(tert-butyl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2144

embedded image

(S)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2145

embedded image

(R)-(2-(2-fluoropropan-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2146

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2147

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2148

embedded image

(S)-4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2149

embedded image

(R)-4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2150

embedded image

(R)-2-(difluoromethyl)-5-(4-(4-methoxypyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2151

embedded image

(S)-2-(difluoromethyl)-5-(4-(4-methoxypyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2152

embedded image

(R)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (difluoromethyl)-1,3,4-oxadiazole

2153

embedded image

(S)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (difluoromethyl)-1,3,4-oxadiazole

2154

embedded image

(R)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2155

embedded image

(S)-2-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2156

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2- yl)-1,3,4-oxadiazole

2157

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2- yl)-1,3,4-oxadiazole

2158

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2- yl)-1,3,4-oxadiazole

2159

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2- yl)-1,3,4-oxadiazole

2160

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2- yl)-1,3,4-oxadiazole

2161

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrazin-2- yl)-1,3,4-oxadiazole

2162

embedded image

(S)-2-(pyrimidin-4-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2163

embedded image

(R)-2-(pyrimidin-4-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2164

embedded image

(S)-2-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2165

embedded image

(R)-2-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2166

embedded image

(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (difluoromethyl)-1,3,4-oxadiazole

2167

embedded image

(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (difluoromethyl)-1,3,4-oxadiazole

2168

embedded image

(R)-2-cyclopropyl-5-(4-(4-isopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2169

embedded image

(S)-2-cyclopropyl-5-(4-(4-isopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2170

embedded image

(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2171

embedded image

(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2172

embedded image

(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2173

embedded image

(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2174

embedded image

(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2175

embedded image

(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2176

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyrazin-2-yl)-1,3,4-oxadiazole

2177

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyrazin-2-yl)-1,3,4-oxadiazole

2178

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin- 4-yl)-1,3,4-oxadiazole

2179

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin- 4-yl)-1,3,4-oxadiazole

2180

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyrimidin-4-yl)-1,3,4-oxadiazole

2181

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyrimidin-4-yl)-1,3,4-oxadiazole

2182

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin- 4-yl)-1,3,4-oxadiazole

2183

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyrimidin- 4-yl)-1,3,4-oxadiazole

2184

embedded image

(R)-4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2185

embedded image

(S)-4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2186

embedded image

(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- methyl-1,3,4-oxadiazole

2187

embedded image

(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- methyl-1,3,4-oxadiazole

2188

embedded image

(R)-2-(1-methylcyclopropyl)-5-(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2189

embedded image

(S)-2-(1-methylcyclopropyl)-5-(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2190

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- 1,3,4-oxadiazole

2191

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- 1,3,4-oxadiazole

2192

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2193

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2194

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2195

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2196

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2197

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(4-fluoropyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2198

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridazin- 3-yl)-1,3,4-oxadiazole

2199

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridazin- 3-yl)-1,3,4-oxadiazole

2200

embedded image

(S)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2201

embedded image

(R)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2202

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2203

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(4- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2204

embedded image

(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (1,1-difluoroethyl)-1,3,4-oxadiazole

2205

embedded image

(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (1,1-difluoroethyl)-1,3,4-oxadiazole

2206

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2207

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2208

embedded image

(S)-2-(2-methylpyridin-3-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2209

embedded image

(R)-2-(2-methylpyridin-3-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2210

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2211

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (2-methylpyridin-3-yl)-1,3,4-oxadiazole

2212

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2213

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2214

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2215

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2216

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)oxazol-5-yl)methanone

2217

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)oxazol-5-yl)methanone

2218

embedded image

(S)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2219

embedded image

(R)-(5-methyl-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2220

embedded image

(R)-2-(difluoromethyl)-5-(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2221

embedded image

(S)-2-(difluoromethyl)-5-(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2222

embedded image

((R)-2,2-difluorocyclopropyl)((R)-4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2223

embedded image

((R)-2,2-difluorocyclopropyl)((S)-4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2224

embedded image

(R)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5- (pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2225

embedded image

(S)-4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)-5- (pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2226

embedded image

(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2227

embedded image

(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2228

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2229

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2230

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(4-isopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2231

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(4-isopropylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2232

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1- difluoroethyl)-1,3,4-oxadiazole

2233

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1- difluoroethyl)-1,3,4-oxadiazole

2234

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2235

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2236

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2237

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2238

embedded image

(R)-5-phenyl-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

2239

embedded image

(S)-5-phenyl-4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

2240

embedded image

(S)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2- yl)oxazol-5-yl)methanone

2241

embedded image

(R)-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2- yl)oxazol-5-yl)methanone

2242

embedded image

(S)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2- (pyrazin-2-yl)oxazol-5-yl)methanone

2243

embedded image

(R)-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2- (pyrazin-2-yl)oxazol-5-yl)methanone

2244

embedded image

(S)-(2-(pyrazin-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2245

embedded image

(R)-(2-(pyrazin-2-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2246

embedded image

(R)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2247

embedded image

(S)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5-(5- (trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro-1H- imidazo[4,5-c]pyridine

2248

embedded image

(R)-2-methyl-5-(4-(4-(trifluoromethoxy)pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2249

embedded image

(S)-2-methyl-5-(4-(4-(trifluoromethoxy)pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2250

embedded image

(R)-2-(difluoromethyl)-5-(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2251

embedded image

(S)-2-(difluoromethyl)-5-(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2252

embedded image

(R)-2-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2253

embedded image

(S)-2-(4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2254

embedded image

(S)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2255

embedded image

(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2256

embedded image

(S)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2257

embedded image

(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2258

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2259

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2260

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyridin-3-yl)-1,3,4-oxadiazole

2261

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyridin-3-yl)-1,3,4-oxadiazole

2262

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridin-3- yl)-1,3,4-oxadiazole

2263

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(pyridin-3- yl)-1,3,4-oxadiazole

2264

embedded image

(S)-2-(2-fluoropyridin-3-yl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2265

embedded image

(R)-2-(2-fluoropyridin-3-yl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2266

embedded image

(R)-2-(3-methylpyridin-2-yl)-5-(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2267

embedded image

(S)-2-(3-methylpyridin-2-yl)-5-(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2268

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2269

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2270

embedded image

(S)-5-(pyrimidin-2-yl)-4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

2271

embedded image

(R)-5-(pyrimidin-2-yl)-4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine

2272

embedded image

(S)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2273

embedded image

(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2274

embedded image

(S)-2-(2-fluoropyridin-3-yl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2275

embedded image

(R)-2-(2-fluoropyridin-3-yl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2276

embedded image

(S)-2-(3-methylpyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2277

embedded image

(R)-2-(3-methylpyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2278

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (3-methylpyridin-2-yl)-1,3,4-oxadiazole

2279

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2280

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2281

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2282

embedded image

(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2283

embedded image

(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2284

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2285

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2286

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2287

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2288

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazole

2289

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- fluoropyridin-2-yl)-1,3,4-oxadiazole

2290

embedded image

(R)-(5-(5-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2291

embedded image

(S)-(5-(5-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2292

embedded image

(S)-(5-(4-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2293

embedded image

(R)-(5-(4-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2- yl)(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2294

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(5-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

2295

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(5-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

2296

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(4-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

2297

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(4-methyl- 1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)methanone

2298

embedded image

(R)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2299

embedded image

(S)-4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2300

embedded image

(R)-2-isopropyl-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2301

embedded image

(S)-2-isopropyl-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2302

embedded image

(R)-2-isopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- 1,3,4-oxadiazole

2303

embedded image

(S)-2-isopropyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)- 1,3,4-oxadiazole

2304

embedded image

(R)-2-isopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2305

embedded image

(S)-2-isopropyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2306

embedded image

(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2307

embedded image

(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2308

embedded image

(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2309

embedded image

(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2310

embedded image

(R)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-phenyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2311

embedded image

(S)-4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-5-phenyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2312

embedded image

(R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-phenyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2313

embedded image

(S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-phenyl- 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

2314

embedded image

(S)-2-cyclopropyl-5-(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2315

embedded image

(R)-2-cyclopropyl-5-(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2316

embedded image

(S)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2317

embedded image

(R)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyrimidin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2318

embedded image

(R)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2319

embedded image

(S)-4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2320

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- isopropyl-1,3,4-oxadiazole

2321

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- isopropyl-1,3,4-oxadiazole

2322

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl- 1,3,4-oxadiazole

2323

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl- 1,3,4-oxadiazole

2324

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl- 1,3,4-oxadiazole

2325

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-isopropyl- 1,3,4-oxadiazole

2326

embedded image

(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1- difluoroethyl)-1,3,4-oxadiazole

2327

embedded image

(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1,1- difluoroethyl)-1,3,4-oxadiazole

2328

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2329

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(7-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2330

embedded image

(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2331

embedded image

(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2332

embedded image

(S)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2333

embedded image

(R)-2-(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- methylpyridin-3-yl)-1,3,4-oxadiazole

2334

embedded image

(R)-2-(2-fluoropyridin-3-yl)-5-(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2335

embedded image

(S)-2-(2-fluoropyridin-3-yl)-5-(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2336

embedded image

(S)-2-(3-methylpyridin-2-yl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2337

embedded image

(R)-2-(3-methylpyridin-2-yl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2338

embedded image

(S)-2-(3-fluoropyridin-2-yl)-5-(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2339

embedded image

(R)-2-(3-fluoropyridin-2-yl)-5-(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2340

embedded image

(R)-2-(3-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2341

embedded image

(S)-2-(3-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2342

embedded image

(S)-2-(6-methylpyridin-2-yl)-5-(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2343

embedded image

(R)-2-(6-methylpyridin-2-yl)-5-(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2344

embedded image

(R)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6- methylpyridin-2-yl)-1,3,4-oxadiazole

2345

embedded image

(S)-2-(4-(4-methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6- methylpyridin-2-yl)-1,3,4-oxadiazole

2346

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (6-methylpyridin-2-yl)-1,3,4-oxadiazole

2347

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6- methylpyridin-2-yl)-1,3,4-oxadiazole

2348

embedded image

(S)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2349

embedded image

(R)-4-(4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 5-(5-(trifluoromethyl)pyridin-2-yl)-4,5,6,7-tetrahydro- 1H-imidazo[4,5-c]pyridine

2350

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- fluoropyridin-3-yl)-1,3,4-oxadiazole

2351

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(2- fluoropyridin-3-yl)-1,3,4-oxadiazole

2352

embedded image

(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(3- methylpyridin-2-yl)-1,3,4-oxadiazole

2353

embedded image

(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (3-methylpyridin-2-yl)-1,3,4-oxadiazole

2354

embedded image

(R)-2-(3-fluoropyridin-2-yl)-5-(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2355

embedded image

(S)-2-(3-fluoropyridin-2-yl)-5-(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2356

embedded image

(R)-2-(6-methylpyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2357

embedded image

(S)-2-(6-methylpyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2358

embedded image

(R)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6- methylpyridin-2-yl)-1,3,4-oxadiazole

2359

embedded image

(S)-2-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(6- methylpyridin-2-yl)-1,3,4-oxadiazole

2360

embedded image

(R)-2-(6-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2361

embedded image

(S)-2-(6-fluoropyridin-2-yl)-5-(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)-1,3,4-oxadiazole

2362

embedded image

(R)-2-(6-fluoropyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2363

embedded image

(S)-2-(6-fluoropyridin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2364

embedded image

(R)-(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2365

embedded image

(S)-(5-(5-fluoropyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2366

embedded image

(S)-(5-(difluoromethyl)-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2367

embedded image

(R)-(5-(difluoromethyl)-1H-pyrazol-4-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2368

embedded image

(S)-(5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)-1H- pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2369

embedded image

(R)-(5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)-1H- pyrazol-4-yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2370

embedded image

(S)-(3-amino-1-(difluoromethyl)-1H-pyrazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2371

embedded image

(R)-(3-amino-1-(difluoromethyl)-1H-pyrazol-5-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2372

embedded image

(S)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2373

embedded image

(R)-(1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazol-5- yl)(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2374

embedded image

(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #2 (Rt = 7.091 min)

2375

embedded image

(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((R)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #1 (Rt = 6.819 min)

2376

embedded image

(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #1 (Rt = 5.341 min)

2377

embedded image

(4-chloro-2-(1-hydroxyethyl)oxazol-5-yl)((S)-4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone Diastereomer #2 (Rt = 6.340 min)

2378

embedded image

(S)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- hydroxypropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

2379

embedded image

(R)-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(2- hydroxypropan-2-yl)-1,3,4-oxadiazol-2-yl)methanone

2380

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2381

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2382

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)oxazol-5-yl)methanone

2383

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(2-(2- hydroxypropan-2-yl)oxazol-5-yl)methanone

2384

embedded image

(S)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

2385

embedded image

(R)-(4-(5-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(pyridin- 2-yl)-1,3,4-oxadiazol-2-yl)methanone

2386

embedded image

(S)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

2387

embedded image

(R)-(1-cyclopropyl-1H-pyrazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

2388

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin-2-yl)-1H- pyrazol-5-yl)methanone

2389

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-(pyridin- 2-yl)-1H-pyrazol-5-yl)methanone

2390

embedded image

(S)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2391

embedded image

(R)-(1,3-dimethyl-1H-pyrazol-5-yl)(4-(4- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2392

embedded image

(R)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2393

embedded image

(S)-(1,3-dimethyl-1H-1,2,4-triazol-5-yl)(4-(4- methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2394

embedded image

(R)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2395

embedded image

(S)-(5-(1-methyl-1H-imidazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(7-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2396

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)methanone

2397

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(3- (difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)methanone

2398

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3- (trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone

2399

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3- (trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone

2400

embedded image

(S)-(4-(difluoromethyl)oxazol-5-yl)(4-(5- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2401

embedded image

(R)-(4-(difluoromethyl)oxazol-5-yl)(4-(5- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2402

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2403

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(6-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2404

embedded image

(S)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2405

embedded image

(R)-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)(4-(6- fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2406

embedded image

(S)-(4-(difluoromethyl)-2-(2-hydroxypropan-2-yl)oxazol- 5-yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2407

embedded image

(R)-(4-(difluoromethyl)-2-(2-hydroxypropan-2- yl)oxazol-5-yl)(4-(5-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

2408

embedded image

(R)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2409

embedded image

(S)-(5-(tert-butyl)-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2410

embedded image

(S)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2411

embedded image

(R)-(3-(difluoromethyl)-1-methyl-1H-1,2,4-triazol-5- yl)(4-(5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2412

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3- (trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone

2413

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(1-methyl-3- (trifluoromethyl)-1H-1,2,4-triazol-5-yl)methanone

2414

embedded image

(S)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2415

embedded image

(R)-(5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2416

embedded image

(S)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2417

embedded image

(R)-(5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)(4-(6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2418

embedded image

(R)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2419

embedded image

(S)-(3-cyclopropyl-1-methyl-1H-1,2,4-triazol-5-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2420

embedded image

(S)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2421

embedded image

(R)-(5-(2-fluoropropan-2-yl)-1,3,4-oxadiazol-2-yl)(4-(6- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2422

embedded image

(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((S)-4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2423

embedded image

(2-((S)-1-hydroxyethyl)-4-methyloxazol-5-yl)((R)-4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2424

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

2425

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)(pyrazolo[1,5-a]pyridin-3-yl)methanone

2426

embedded image

(S)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

2427

embedded image

(R)-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1-(trifluoromethyl)- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

2428

embedded image

(S)-(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

2429

embedded image

(R)-(5-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

2430

embedded image

(S)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2431

embedded image

(R)-(5-cyclobutyl-1,3,4-oxadiazol-2-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2432

embedded image

(R)-2-cyclopropyl-5-(4-(4-fluoropyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2433

embedded image

(S)-2-cyclopropyl-5-(4-(4-fluoropyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2434

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro- 1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1-methyl-1H- pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone

2435

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(1- methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3- yl)methanone

2436

embedded image

(S)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2437

embedded image

(R)-(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2438

embedded image

(S)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

2439

embedded image

(R)-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5- a]pyridin-3-yl)(4-(7-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)methanone

2440

embedded image

(S)-2-(pyridin-2-yl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

2441

embedded image

(R)-2-(pyridin-2-yl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4- oxadiazole

2442

embedded image

(R)-2-methyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2443

embedded image

(S)-2-methyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2444

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

2445

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

2446

embedded image

(S)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2447

embedded image

(R)-(5-(1-(difluoromethyl)-1H-pyrazol-4-yl)-1,3,4- oxadiazol-2-yl)(4-(4-methoxypyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2448

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

2449

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5- (pyrazin-2-yl)-1,3,4-oxadiazol-2-yl)methanone

2450

embedded image

(S)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2451

embedded image

(R)-(6-methoxypyrazolo[1,5-a]pyridin-3-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2452

embedded image

(S)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2453

embedded image

(R)-(6-(pyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2454

embedded image

(S)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2455

embedded image

(R)-4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-5- (pyrimidin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5- c]pyridine

2456

embedded image

(S)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-methyl- 1,3,4-oxadiazole

2457

embedded image

(R)-2-(4-(4-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5-methyl- 1,3,4-oxadiazole

2458

embedded image

(S)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

2459

embedded image

(R)-(4-(4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(5-(1- (trifluoromethyl)-1H-pyrazol-4-yl)-1,3,4-oxadiazol-2- yl)methanone

2460

embedded image

(R)-2-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2461

embedded image

(S)-2-(difluoromethyl)-5-(4-(pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2462

embedded image

(S)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2463

embedded image

(R)-(6-cyclopropylpyrazolo[1,5-a]pyridin-3-yl)(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2464

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

2465

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methoxypyrazolo[1,5-a]pyridin-3-yl)methanone

2466

embedded image

(R)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- methyl-1,3,4-oxadiazole

2467

embedded image

(S)-2-(4-(4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- methyl-1,3,4-oxadiazole

2468

embedded image

(R)-(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2469

embedded image

(S)-(5-(pyrimidin-2-yl)-1,3,4-oxadiazol-2-yl)(4-(4- (trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2470

embedded image

(S)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

2471

embedded image

(R)-(4-(4-methoxypyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- methylpyrazolo[1,5-a]pyridin-3-yl)methanone

2472

embedded image

(S)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2473

embedded image

(R)-(6-(dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)(4- (7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2474

embedded image

(S)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone

2475

embedded image

(R)-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-6,7- dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6- (dimethylamino)pyrazolo[1,5-a]pyridin-3-yl)methanone

2476

embedded image

(S)-(6-(2-(dimethylamino)ethyl)pyrazolo[1,5-a]pyridin- 3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2477

embedded image

(R)-(6-(2-(dimethylamino)ethyl)pyrazolo[1,5-a]pyridin- 3-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)- yl)methanone

2478

embedded image

(S)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2479

embedded image

(R)-(6-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-3-yl)(4- (4-methylpyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

2480

embedded image

(R)-2-cyclobutyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2481

embedded image

(S)-2-cyclobutyl-5-(4-(4-methylpyrazolo[1,5-a]pyridin- 2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)- 1,3,4-oxadiazole

2482

embedded image

(S)-2-cyclobutyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

2483

embedded image

(R)-2-cyclobutyl-5-(4-(4-(trifluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

2484

embedded image

(R)-2-cyclobutyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

2485

embedded image

(S)-2-cyclobutyl-5-(4-(4-(difluoromethyl)pyrazolo[1,5- a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin- 5(4H)-yl)-1,3,4-oxadiazole

2486

embedded image

(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2487

embedded image

(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2488

embedded image

(S)-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

2489

embedded image

(R)-(4-(6-bromopyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5-(1-methyl- 1H-pyrazol-4-yl)-1,3,4-oxadiazol-2-yl)methanone

2490

embedded image

(R)-2-(trifluoromethyl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2491

embedded image

(S)-2-(trifluoromethyl)-5-(4-(7- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2492

embedded image

(R)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2493

embedded image

(S)-2-(4-(7-chloropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (trifluoromethyl)-1,3,4-oxadiazole

2494

embedded image

(S)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- methyl-1,3,4-oxadiazol-2-yl)methanone

2495

embedded image

(R)-(4-(4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(5- methyl-1,3,4-oxadiazol-2-yl)methanone

2496

embedded image

(S)-(2-cyclopropyloxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2497

embedded image

(R)-(2-cyclopropyloxazol-5-yl)(4-(pyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2498

embedded image

(R)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2499

embedded image

(S)-(2-(1-methyl-1H-pyrazol-3-yl)oxazol-5-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2500

embedded image

(R)-(5-methyl-1,3,4-thiadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2501

embedded image

(S)-(5-methyl-1,3,4-thiadiazol-2-yl)(4-(4- methylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)methanone

2502

embedded image

(S)-benzo[d]thiazol-2-yl(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2503

embedded image

(R)-benzo[d]thiazol-2-yl(4-(4-methylpyrazolo[1,5- a]pyridin-2-yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5- c]pyridin-5-yl)methanone

2504

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(1-methyl- 1H-pyrazol-3-yl)oxazol-5-yl)methanone

2505

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(1-methyl- 1H-pyrazol-3-yl)oxazol-5-yl)methanone

2506

embedded image

(S)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2507

embedded image

(R)-(2-(1-methyl-1H-pyrazol-4-yl)oxazol-5-yl)(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)methanone

2508

embedded image

(R)-2-cyclopropyl-5-(4-(4- (difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2509

embedded image

(S)-2-cyclopropyl-5-(4-(4- (difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2510

embedded image

(S)-2-(pyrazin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2511

embedded image

(R)-2-(pyrazin-2-yl)-5-(4-(4- (trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2512

embedded image

(S)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyridazin-3-yl)-1,3,4-oxadiazole

2513

embedded image

(R)-2-(4-(4-isopropylpyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyridazin-3-yl)-1,3,4-oxadiazole

2514

embedded image

(R)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2515

embedded image

(S)-2-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5-(1- methylcyclopropyl)-1,3,4-oxadiazole

2516

embedded image

(S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2- yl)oxazol-5-yl)methanone

2517

embedded image

(R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)(2-(pyrazin-2- yl)oxazol-5-yl)methanone

2518

embedded image

(R)-2-(3,3-difluorocyclobutyl)-5-(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2519

embedded image

(S)-2-(3,3-difluorocyclobutyl)-5-(4-(4- isopropylpyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydro- 5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4-oxadiazole

2520

embedded image

(R)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2- yl)-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyrazin-2-yl)-1,3,4-oxadiazole

2521

embedded image

(S)-2-(4-(7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)- 1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-5- (pyrazin-2-yl)-1,3,4-oxadiazole

2522

embedded image

(R)-2-(1,1-difluoroethyl)-5-(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2523

embedded image

(S)-2-(1,1-difluoroethyl)-5-(4-(7- (difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7- tetrahydro-5H-imidazo[4,5-c]pyridin-5-yl)-1,3,4- oxadiazole

2524

embedded image

(5-(2,6-difluorophenyl)-1,3,4-oxadiazol-2-yl)(4- (pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H- imidazo[4,5-c]pyridin-5(4H)-yl)methanone

In further embodiments, the compound of Formula I is one or more of the compounds in Table 1 that is the S-enantiomer, or a pharmaceutically acceptable salt thereof.

In still further embodiments, the compound of Formula I is one or more of Examples 605, 626, 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 791, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 958, 960, 962, 964, 966, 969, 971, 972, 975, 976, 979, 980, 982, 984, 988, 1381, 1438, 1461, 1506, 1531, 1548, 1589, 1607, 1613, 1628, 1652, 1657, 1728, 1737, 1757, 1807, 1809, 1823, 1843, 1849, 1850, 1943, 1953, 1986, 2218, 2221, and 2223, or a pharmaceutically acceptable salt thereof. In yet other embodiments, the compound of Formula I is one or more of Examples 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 960, 962, 969, 971, 972, 975, 976, 979, 980, 984, 988, 1438, 1461, 1506, 1548, 1628, 1652, 1657, 1728, 1737, 1757, 1809, 1849, 1850, 1953, 1986, 2218, and 2221, or a pharmaceutically acceptable salt thereof. In still other embodiments, the compound of Formula I is one or more of Examples 640, 670, 688, 708, 710, 726, 728, 733, 748, 760, 762, 764, 836, 840, 906, 922, 938, 942, 944, 946, 948, 950, 952, 954, 957, 960, 962, 969, 971, 972, 975, 976, 979, 980, 984, 988, 1438, 1461, 1506, 1548, 1628, 1652, 1657, 1728, 1986, and 2218, or a pharmaceutically acceptable salt thereof.

Abbreviations and Terms List

aq
aqueous

min
minute(s)

hrs
hours

mL
milliliter

μL
microliter

mmol
millimole(s)

μmol
micromole(s)

mol
mole(s)

M
molar

eq
equivalents

LCMS
Liquid chromatography mass spectrometry

NMR
nuclear magnetic resonance

TLC
thin layer chromatography

HPLC
high-performance liquid chromatography

SFC
supercritical fluid chromatography

sat
saturated

° C.
degrees Celsius

rt
room temperature

N₂
nitrogen gas

Hz
Hertz

δ
chemical shift

s
singlet

d
doublet

t
triplet

q
quartet

m
multiplet

br
broad

dd
doublet of doublets

ddd
doublet of doublet or doublets

td
triplet of doublets

dt
doublet of triplets

CDCl₃
chloroform-d

CD₃OD
methanol-d₄

DMSO-d₆
dimethyl sulfoxide-d₆

Solvents and reagents:

DCE
1,2-dichloroethane

DCM
dichloromethane

DMAc
dimethylacetamide

DME
dimethoxyethane

DMF
dimethylformamide

EtOH
ethyl alcohol

EtOAc
ethyl acetate

i-PrOH or IPA
isopropanol

MeOH
methyl alcohol

TAA
tert-amyl alcohol

MeCN or ACN
acetonitrile

PE
petroleum ether

TBME
tert-butyl methyl ether

H₂O
water

THF
tetrahydrofuran

HOAc
acetic acid

HCl
hydrochloric acid

H₂SO₄
sulfuric acid

FA
formic acid

TFA
trifluoroacetic acid

TsOH
p-toluenesulfonic acid

TosCl or TsCl
p-toluenesulfonyl chloride

NH₄Cl
ammonium chloride

KOH
Potassium hydroxide

LiOH
lithium hydroxide

K₂CO₃
potassium carbonate

Na₂CO₃
sodium carbonate

Cs₂CO₃
cesium carbonate

Na₂SO₄
sodium sulfate

NaHCO₃
sodium bicarbonate

Na₂S₂O₃
sodium thiosulfate

Et₃N or TEA
triethylamine

DIPEA
N,N-diisopropylethylamine

Py
pyridine

KOAc
potassium acetate

KF
potassium fluoride

CsF
cesium fluoride

NH₃
ammonia

LDA
lithium diisopropylamine

LiHMDS
lithium bis(trimethylsilyl)amide

MeMgBr
methylmagnesium bromide

iPrMgCl•LiCl
isopropylmagnesium chloride lithium chloride complex

PFIB
perfluoroisobutene

BuOK
potassium t-butoxide

CAN
cerium ammonium nitrate

DIBAL-H
diisobutylaluminium hydride

NaOMe
sodium methoxide

DMP
Dess-Martin periodinane

MnO₂
manganese(IV) oxide

IBX
2-iodoxybenzoic acid

t-BuONO
tert-butyl nitrite

PIDA
(diacetoxyiodo)benzene

NFSI
N-fluorodi(benzenesulfonyl)amine

NBS
N-bromosuccinimide

NCS
N-chlorosuccinimide

MeI
methyl iodide

LiBH₄
lithium borohydride

NaBH₄
sodium borohydride

NaBH(OAc)₃
Sodium triacetoxyborohydride

EDCI
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide

HOBt
1-hydroxybenzotriazole

HATU
1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-

oxid hexafluorophosphate

T3P
Propanephosphonic acid anhydride

CDI
carbonyldiimidazole

Thio-CDI
1,1′-Thiocarbonyldiimidazole

DPPA
diphenylphosphoryl azide

BCl₃
boron trichloride

Boc₂O
di-tert-butyl dicarbonate

DHP
Dihydropyran

Pd/C
palladium on carbon

Pd(PPh₃)₂Cl₂
bis(triphenylphosphine)palladium(II) dichloride

Pd₂(dba)₃
tris(dibenzylideneacetone)dipalladium

Pd(dppf)Cl₂
(1,1′-Bis(diphenylphosphino)ferrocene)palladium(II) dichloride

Pd(OAc)₂
palladium(II) acetate

Xantphos
4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene

t-BuXPhos-Pd-
[(2-Di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-

G3
amino-1,1′-biphenyl)]palladium(II) methanesulfonate

CPhos-Pd-G3
[(2-Dicyclohexylphosphine-2′,6′-bis(N,N-dimethylamino)-1,1′-

biphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II)

methanesulfonate

PPh₃
triphenylphosphine

DEAD
diethyl azodicarboxylate

Pin₂B₂
bis(pinacolato)diborane

CuI
copper iodide

CuBr₂
copper (II) bromide

Zn(CN)₂
zinc cyanide

H₂
hydrogen gas

SiO₂
silica

TFAA
Trifluoroacetic anhydride

K₂OSO₄•2H₂O
potassium osmate(VI) dihydrate

NaIO₄
sodium periodate

General Experimental

In the following examples, the reagents and solvents were purchased from commercial sources (such as Alfa, Acros, AstaTech, CombiBlocks, Enamine, Sigma Aldrich, TCI, PharmaBock, Bide Pharmatech Ltd., Accela ChemBio, Aladdin, Shanghai Haohong Pharmaceutical Co., Ltd, Amkchem, Beijing Ouhe Technology Co., Ltd, Haoyuan Chemexpress Co., Ltd, Hualun, Coolpharm, Scochem, Titan and WuXi LabNetwork, and used without further purification unless otherwise specified. Flash chromatography was performed on a CombiFlashRf 150 (ISCO) via column with silica gel particles of 200-300 mesh. HPLC was performed on an Agilent 1100 Liquid Chromatography (Agilent, USA) and a Shimadzu LC 20/20A (Shimadzu, Japan). Supercritical fluid chromatography was performed on a Waters Prep SFC 150 AP/80Q/200/350 system (Waters, USA). Analytical and preparative thin layer chromatography plates (TLC) were HSGF 254 (0.15-0.2 mm thickness, Shanghai Anbang Company, China). Nuclear magnetic resonance (NMR) spectra were obtained on a Brucker AV-400 NMR or Bruker AVIII 500 MHz NMR (Bruker, Switzerland). Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Mass spectra were given with electrospray ionization (ESI) from a Waters LCT TOF Mass Spectrometer (Waters, USA). LC-MS was performed on an Agilent Prime-6125B/Agilent LC1260-MS6150/Agilent LC1260-MS6125B/Agilent LC1200-MS6110 (Agilent, USA) and a Shimadzu LC20-MS2020. Microwave reactions were run on an Initiator 2.5 Microwave Synthesizer (Biotage, Sweden).

Intermediate (1-(1H-imidazol-5-yl)cyclopropyl)methanamine hydrochloride

embedded image

Step 1: Preparation of 2-(3-tritylimidazol-4-yl)acetonitrile (B2)

B2 was prepared starting with 2-(1H-imidazol-5-yl)acetonitrile (B1) in accordance with literature procedures. See, e.g., WO2008/003766 (page 19).

Step 2: Preparation of 1-(3-tritylimidazol-4-yl)cyclopropanecarbonitrile (B3)

To a solution of 2-(3-tritylimidazol-4-yl)acetonitrile (B2) (10 g, 28.6 mmol) in THE (200 mL) was added LDA (2 M, 42.9 mL, 3 eq) dropwise at −78° C. After addition was complete, the reaction mixture was stirred at −20° C. to −10° C. for 1 hr. The reaction mixture was then cooled to −78° C., and 1,2-dibromoethane (10.75 g, 57.2 mmol, 4.32 mL, 2 eq) was added dropwise at −78° C. After the addition was complete, the reaction mixture was warmed to rt slowly and stirred for another 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was quenched with sat. NH₄Cl solution (200 mL) and stirred at rt for 0.5 hr. The aqueous portion was extracted with EtOAc (100 mL×3), and the combined organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness. The residue (combined with two other reactions performed using 10 g of B2) was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, eluent of 0˜40% EtOAc/PE, gradient @ 40 mL/min) to give B3 (23.4 g, 72% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.30-7.52 (m, 10H), 7.09 (dd, 6H), 6.84 (d, 1H), 1.51-1.66 (m, 2H), 1.29-1.46 (m, 2H).

Step 3: Preparation of 1-(3-tritylimidazol-4-yl)cyclopropyl]methanamine (B4)

A mixture of 1-(3-tritylimidazol-4-yl)cyclopropanecarbonitrile (B3) (19 g, 50.6 mmol), Raney-Ni (4.60 g, 53.7 mmol, 1.06 eq), NH₃·H₂O (591 mg, 5.06 mmol, 650 μL, 30% purity, 0.1 eq) in MeOH (200 mL) was degassed and purged with H₂3 times, and then the reaction mixture was stirred at 45° C. for 16 hrs under H₂(45 psi) atmosphere. Reaction progress was tracked using TLC (DCM:MeOH=10:1). The reaction mixture was filtered, and additional Raney-Ni (4.60 g, 53.7 mmol, 1.06 eq) was added. The reaction mixture was stirred at 45° C. under H₂(45 psi) atmosphere for another 24 hrs. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated to dryness to give B4 (18 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 7.33-7.44 (m, 9H), 7.18-7.25 (m, 1H), 7.04-7.13 (m, 6H), 6.64-6.71 (m, 1H), 3.17 (br s, 2H), 2.58-2.74 (m, 2H), 0.60-0.82 (m, 4H).

Step 4: Preparation of [1-(1H-imidazol-5-yl)cyclopropyl]methanamine hydrochloride (B5)

To a solution of [1-(3-tritylimidazol-4-yl)cyclopropyl]methanamine (B4) (18 g, 47.4 mmol) in MeOH (100 mL) was added HCl/MeOH (4 M, 100 mL, 8.4 eq). The reaction mixture was stirred at 60° C. for 16 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was concentrated to dryness, and the residue was triturated with EtOAc (40 mL) and stirred for 15 min. The precipitate was collected by filtration and then dried in vacuo to give B5 (8.5 g, 2HCl salt). ¹H NMR (400 MHz, DMSO-d₆) δ 14.73 (br s, 1H), 9.04 (s, 1H), 8.27 (br s, 2H), 7.51 (s, 1H), 2.98-3.22 (m, 2H), 0.90-1.23 (m, 4H).

Intermediate 2-(1H-imidazol-5-yl)-2-methylpropan-1-amine hydrochloride

embedded image

Step 1: Preparation of (2-methyl-2-(3-tritylimidazol-4-yl)propanenitrile (B6)

To a solution of 2-(3-tritylimidazol-4-yl)acetonitrile (B2) (12 g, 34.3 mmol) in THF (400 mL) was drop-wise added LiHMDS (1 M, 96.2 mL, 2.8 eq) at −78° C. The reaction mixture was stirred at −78° C. for 15 min, and then Mel was added (14.62 g, 103 mmol, 6.41 mL, 3 eq). The reaction mixture was stirred at −78° C. for 1 hr, and then warmed to rt for 18 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was cooled to 0° C., quenched by the addition of sat. NH₄Cl solution (15 mL) and then H₂O (60 mL) was added. The aqueous portion was extracted with EtOAc (60 mL×3). The combined organic layers were washed with brine (60 mL), dried over Na₂SO₄, and concentrated to dryness. The residue (combined with the residue from another reaction performed using 2 g of B2) was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, eluent of 0˜80% EtOAc/PE, gradient @ 60 mL/min) to give B6 (14 g, 92% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, 1H), 7.32-7.39 (m, 9H), 7.08-7.16 (m, 6H), 6.81 (d, 1H), 1.69 (s, 6H).

Step 2: Preparation of (2-methyl-2-(3-tritylimidazol-4-yl)propan-1-amine (B7)

To a solution of 2-methyl-2-(3-tritylimidazol-4-yl)propanenitrile (B6) (14 g, 37.1 mmol) in MeOH (350 mL) was added Raney-Ni (2 g, 23.3 mmol, 0.63 eq) under N₂. The reaction mixture was degassed under vacuum and purged with H₂several times. The reaction mixture was stirred under H₂(50 psi) at 40° C. for 36 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was filtered through of pad of celite, and the filtrate was concentrated to dryness to afford B7 (12 g, 85% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.38 (s, 1H), 7.29-7.36 (m, 9H), 7.10-7.18 (m, 6H), 6.55 (s, 1H), 3.49 (br s, 1H), 2.74 (s, 2H), 1.20 (s, 6H); LCMS: m/z 382.2 [M+H]⁺.

Step 3: Preparation of (2-(1H-imidazol-5-yl)-2-methyl-propan-1-amine (B8)

To a solution of 2-methyl-2-(3-tritylimidazol-4-yl)propan-1-amine (B7) (14 g, 36.7 mmol) in MeOH (150 mL) was added HCl/MeOH (4 M, 150 mL, 16.4 eq), and the reaction mixture was stirred at 50° C. for 18 hrs. Reaction progress was tracked using TLC (EtOAc). The reaction mixture was concentrated to dryness, and 200 mL of EtOAc was added. The mixture was stirred at 60° C. for 1 hr. The precipitate was collected by filtration and rinsed with EtOAc, and then dried in vacuo to give B8 (7.0 g, 90% yield, 2HCl salt). ¹H NMR (400 MHz, CD₃OD) δ 8.96 (s, 1H), 7.52 (s, 1H), 3.20-3.27 (m, 2H), 1.49 (s, 6H).

Intermediate 2-(1H-imidazol-5-yl)propan-1-amine hydrochloride

embedded image

Step 1: Preparation of 2-(3-tritylimidazol-4-yl)propanenitrile (B9)

To a solution of 2-(3-tritylimidazol-4-yl)acetonitrile (B2) (15 g, 42.9 mmol) in THF (120 mL) was added LiHMDS (1 M, 51.5 mL, 1.2 eq) dropwise at −78° C. After addition, the reaction mixture was stirred for 0.5 hr, and then Mel (10.97 g, 77.3 mmol, 4.81 mL, 1.8 eq) was added dropwise at −78° C. The reaction mixture was stirred at −78° C. for 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=2:1). The reaction mixture was quenched by the addition of sat. NH₄Cl solution (120 mL) and stirred for 15 min. The aqueous portion was extracted with EtOAc (400 mL), and the organic layer washed by water (100 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue (combined with the residue from another reaction performed using 15 g of B2) was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 2:1) to give B9 (33.5 g, 75% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.38-7.45 (m, 10H), 7.06-7.13 (m, 6H), 6.82-6.92 (m, 1H), 4.12-4.23 (m, 1H), 1.48 (d, 3H).

Step 2: Preparation of 2-(3-tritylimidazol-4-yl)propan-1-amine (B10)

A mixture of 2-(3-tritylimidazol-4-yl)propanenitrile (B9) (16.5 g, 45.4 mmol), Raney-Ni (4.08 g, 47.7 mmol, 1.05 eq), NH₃·H₂O (910 mg, 7.79 mmol, 1 mL, 30% purity) in MeOH (300 mL) was degassed under vacuum and purged with H₂3 times. The reaction mixture was stirred at 45° C. for 16 hrs under H₂(45 psi) atmosphere. Reaction progress was tracked using TLC (PE:EtOAc=2:1). The reaction mixture was filtered through a pad of Celite and the filtrate was concentrated to dryness to afford B10 (33 g), which was used without further purification. ¹H NMR (400 MHz, CD₃OD) δ 7.36-7.44 (m, 10H), 7.13-7.20 (m, 6H), 6.72 (br s, 1H), 2.57-2.92 (m, 3H), 1.21 (br d, 3H).

Step 3: Preparation of 2-(1H-imidazol-5-yl)propan-1-amine (B11)

To a solution of 2-(3-tritylimidazol-4-yl)propan-1-amine (B10) (23 g, 62.6 mmol) in MeOH (100 mL) was added HCl/MeOH (4 M, 100 mL). The mixture was stirred at rt for 12 hrs. Reaction progress was tracked using TLC (EtOAc). The reaction mixture (combined with the reaction mixture from another reaction performed using 23 g of B10) was concentrated to dryness. H₂O (40 mL) was added to the residue, and the aqueous layer washed with EtOAc (50 mL). The aqueous layer was lyophilized to give B11 (21 g, 2HCl). ¹H NMR (400 MHz, CD₃OD) δ 8.96 (d, 1H), 7.56 (s, 1H), 3.43-3.51 (m, 1H), 3.17-3.32 (m, 2H), 1.29-1.53 (m, 3H).

Intermediate 2-[(2R)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione and 2-[(2S)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione

embedded image

Step 1: Preparation of 2-[2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13)

To a solution of 2-(1H-imidazol-5-yl)propan-1-amine (B111) (10 g, 50.5 mmol, 2HCl) and phthalic anhydride (7.85 g, 53.0 mmol, 1.05 eq) in i-PrOH (400 mL) was added Et₃N (15.32 g, 151 mmol, 21.1 mL, 3 eq). The reaction mixture was stirred at 100° C. for 18 hrs under N₂atmosphere. After cooling, the reaction mixture was concentrated to dryness. Water (200 mL) was then added, and the mixture was stirred at rt for 10 mins. The precipitate was collected by filtration, rinsed with water (100 mL), and dried in vacuo to afford B13 (13 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 7.71-7.89 (m, 4H), 7.49 (s, 1H), 6.79 (s, 1H), 3.70-3.76 (m, 1H), 3.60-3.65 (m, 1H), 3.15-3.23 (m, 1H), 1.16 (d, 3H).

Step 2: SFC Separation

Compound 2-[2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (13 g) was separated by SFC separation (column: DAICEL CHIRALPAK AD (250 mm*50 mm, 10 um); mobile phase: [0.1% NH₃H₂O ETOH]; B %: 40%-40%, min) to afford Enantiomer 1 (4.8 g, 37% yield, Rt=3.953 min) and Enantiomer 2 (5.2 g, 40% yield, Rt=4.652 min).

Enantiomer 1: 2-[(2R)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13A). ¹H NMR (400 MHz, CD₃OD) δ 7.73-7.89 (m, 4H), 7.56 (d, 1H), 6.82 (s, 1H), 3.84-3.93 (m, 1H), 3.70-3.82 (m, 1H), 3.36-3.39 (m, 1H), 1.31 (d, 3H); SFC: 98.4% ee.

Enantiomer 2: 2-[(2S)-2-(1H-imidazol-5-yl)propyl]isoindoline-1,3-dione (B13B). ¹H NMR (400 MHz, CD₃OD) δ 7.77-7.88 (m, 4H), 7.55 (d, 1H), 6.82 (s, 1H), 3.84-3.97 (m, 1H), 3.72-3.82 (m, 1H), 3.36-3.42 (m, 1H), 1.31 (d, 3H); SFC: 99.1% ee.

Intermediate Pyrazolo[1,5-a]pyridine-2-carbaldehyde

embedded image

Step 1: Preparation of N-methoxy-N-methyl-pyrazolo[1,5-a]pyridine-2-carboxamide (C2)

To a solution of pyrazolo[1,5-a]pyridine-2-carboxylic acid (C1) (12.5 g, 77.1 mmol) and N-methoxymethanamine (9.42 g, 96.6 mmol, 1.25 eq, HCl) in DMF (200 mL) was added EDCI (22.17 g, 116 mmol, 1.5 eq), DIPEA (29.89 g, 231 mmol, 40.3 mL, 3 eq) and HOBt (15.63 g, 116 mmol, 1.5 eq). The reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using TLC (PE:EtOAc=1:1). The reaction mixture was combined with the reaction mixture from another reaction performed using 12.5 g of C1 and concentrated to dryness. The residue was dissolved in DCM (200 mL), and the organic layer washed with sat. Na₂CO₃solution (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 1:1) to give C2 (30.5 g, 96% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.47-8.54 (m, 1H), 7.59 (d, 1H), 7.16 (ddd, 1H), 7.02 (s, 1H), 6.86 (td, 1H), 3.81 (s, 3H), 3.51 (s, 3H).

Step 2: Preparation of pyrazolo[1,5-a]pyridine-2-carbaldehyde (C3)

To a solution of N-methoxy-N-methyl-pyrazolo[1,5-a]pyridine-2-carboxamide (C2) (15 g, 73.1 mmol) in THF (150 mL) was added DIBAL-H (1 M, 146.2 mL, 2 eq) dropwise at −78° C. under N₂, and then the reaction mixture was stirred at −78° C. for 2 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was combined with the reaction mixture from another reaction performed using 15 g of C2 and was quenched by the addition of sat. NH₄Cl solution (200 mL) slowly and stirred for 15 min. 1 M HCl solution was added until a clear solution was observed. The aqueous portion was extracted with EtOAc (250 mL×3), and the combined organic layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 1:1) to give C3 (14.2 g). ¹H NMR (400 MHz, DMSO-d₆) δ 10.14 (s, 1H), 8.81 (dd, 1H), 7.84 (d, 1H), 7.34 (t, 1H), 7.10-7.15 (m, 2H).

Intermediate 3-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 3-methylpyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 3-bromopyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 3-bromopyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 4-chloropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 4-chloropyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 6-bromopyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 6-bromopyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 6-chloropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 6-chloropyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 7-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C3, starting with 7-methylpyrazolo[1,5-a]pyridine-2-carboxylic acid.

Intermediate 4-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde

embedded image

Step 1: Preparation of 3-(3-fluoro-2-pyridyl)prop-2-yn-1yl acetate (C5)

A mixture of 2-bromo-3-fluoro-pyridine (C4) (30 g, 170 mmol), prop-2-yn-1yl acetate (23.41 g, 239 mmol, 1.4 eq), Pd(PPh₃)₂Cl₂(5.98 g, 8.52 mmol, 0.05 eq), CuI (1.62 g, 8.52 mmol, 0.05 eq) and TEA (51.75 g, 511 mmol, 71.2 mL, 3 eq) in dioxane (300 mL) was degassed and purged with N₂3 times, and then the reaction mixture was stirred at 50° C. for 6 hrs under N₂atmosphere. Reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated to dryness. EtOAc (600 mL) was added to the residue, and the organic portion washed with water (300 mL) and brine (300 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, eluent of 0˜20% EtOAc/PE, gradient @120 mL/min) to give C5 (23.4 g, 71% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.43 (d, 1H), 7.46 (td, 1H), 7.32 (dt, 1H), 4.99 (s, 2H), 2.16 (s, 3H).

Step 2: Preparation of 3-(3-fluoro-2-pyridyl)prop-2-yn-1-ol (C6)

To a solution of 3-(3-fluoro-2-pyridyl)prop-2-ynyl acetate (C5) (23.4 g, 121 mmol) in THE (300 mL) and H₂O (150 mL) and was added LiOH·H₂O (5.34 g, 127 mmol, 1.05 eq) at 0° C. The reaction mixture was stirred at rt for 2 hrs. Reaction progress was checked using TLC (PE:EtOAc=1:1). EtOAc (600 mL) was added to the reaction mixture, and the organic layer washed with H₂O (400 mL) and brine (400 mL), dried over Na₂SO₄, filtered and concentrated to dryness to afford C6 (17.5 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.34-8.53 (m, 1H), 7.72-7.88 (m, 1H), 7.50 (dt, 1H), 5.54 (t, 1H), 4.38 (d, 2H).

Step 3: Preparation of 1-amino-3-fluoro-2-(3-hydroxyprop-1-yn-1-yl)pyridin-1-ium2,4,6-trimethylbenzenesulfonate (C7)

To a mixture of H₂O (35 mL, 1.94 mol, 17.3 eq) and TFA (308.0 g, 2.70 mol, 200 mL, 24.0 eq) was added ethyl (1E)-N-(2,4,6-trimethylphenyl)sulfonyloxyethanimidate (33.70 g, 118 mmol, 1.05 eq) at 0° C., and the reaction mixture was stirred at 0° C. for 2 hrs. The reaction was quenched with ice-water (40 mL). The precipitate was filtered and washed with water (20 mL×2). The precipitate was then dissolved in DCM (200 mL) and dried over Na₂SO₄and filtered. To the filtrate was added 3-(3-fluoro-2-pyridyl)prop-2-yn-1-ol (C6) (17 g, 112 mmol, 1 eq) at 0° C. The reaction mixture was warmed to rt for 16 hrs. Reaction progress was checked using TLC (PE:EtOAc=1:1). TBME (400 mL) was slowly added to the reaction mixture, and the precipitate was collected by filtration. The precipitate was rinsed with TBME (200 mL×2) to afford C7 (26 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.66-8.88 (m, 3H), 8.32 (t, 1H), 8.01 (dt, 1H), 6.75 (s, 2H), 4.58 (s, 2H), 3.17 (s, 1H), 2.49 (s, 6H), 2.17 (s, 3H).

Step 4: Preparation of (4-fluoropyrazolo[1,5-a]pyridin-2-yl) methanol (C8)

To a solution of 1-amino-3-fluoro-2-(3-hydroxyprop-1-yn-1-yl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate (C7) (26 g, 71.0 mmol) in MeOH (250 mL) was added NaOMe (5.4 M, 26.3 mL, 2 eq) at 0° C. The reaction mixture was stirred at rt for 1 hr. The reaction progress was tracked by TLC (PE:EtOAc=1:1). The reaction mixture was quenched by the addition of ice-cold H₂O (200 mL), concentrated to remove most of the MeOH, and extracted with EtOAc (200 mL×3). The combined organic layer was washed with brine (400 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give C8 (7.5 g), which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 8.27 (d, 1H), 6.62-6.88 (m, 3H), 4.94 (s, 2H).

Step 5: Preparation of 4-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde (C9)

To a solution of (4-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C8) (7.5 g, 45.1 mmol) in MeCN (150 mL) was added IBX (15.17 g, 54.2 mmol, 1.2 eq). The reaction mixture was stirred at 80° C. for 3 hrs. Reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was filtered and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0˜4% EtOAc/PE, gradient @40 mL/min) to give C9 (4 g, 54% yield). ¹H NMR (400 MHz, CDCl₃) δ 10.22 (s, 1H), 8.33-8.41 (m, 1H), 7.20 (d, 1H), 6.85-6.98 (m, 2H).

Intermediate 4-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-3-methylpyridine.

Intermediate 4-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-3-(trifluoromethyl)pyridine.

Intermediate 4-methoxypyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-3-methoxypyridine.

Intermediate 5-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-4-methylpyridine.

Intermediate 5-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-4-fluoropyridine.

Intermediate 5-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 4-(trifluoromethyl)pyridine.

Intermediate 6-methylpyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-5-methylpyridine.

Intermediate 6-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-5-fluoropyridine.

Intermediate 6-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C9, starting with 2-bromo-5-(trifluoromethyl)pyridine.

Intermediate 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde

embedded image

Step 1: Preparation of 1-amino-2-(trifluoromethyl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate (C11)

To a mixture of TFA (215.60 g, 1.89 mol, 140 mL, 27.8 eq) and H₂O (20.00 g, 1.11 mol, 20.0 mL, 16.3 eq) was added ethyl (1E)-N-(2,4,6-trimethylphenyl) sulfonyloxyethanimidate (21.34 g, 74.8 mmol, 1.1 eq) at 0° C., and the reaction mixture was stirred at 0° C. for 2 hrs. The reaction was quenched by the addition of ice-water (100 mL), and the precipitate was filtered and rinsed with water (50 mL×2). The precipitate was then dissolved in DCM (140 mL), dried over Na₂SO₄and filtered. To the filtrate was added 2-(trifluoromethyl)pyridine (C10) (10 g, 68.0 mmol, 7.87 mL) at 0° C. The reaction mixture was warmed to rt and stirred for 16 hrs. TBME (100 mL) was slowly added to the reaction mixture, and the precipitate was collected and rinsed with TBME (40 mL×3), and then dried in vacuo to give C11 (8.5 g, 35% yield), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.06 (d, 1H), 8.40-8.60 (m, 2H), 8.20-8.26 (m, 1H), 8.12 (s, 2H), 6.60 (s, 2H), 2.34 (s, 6H), 2.02 (s, 3H).

Step 2: Preparation of dimethyl 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2,3-dicarboxylate (C12)

To a mixture of 1-amino-2-(trifluoromethyl)pyridin-1-ium 2,4,6-trimethylbenzenesulfonate (C11) (8.5 g, 23.5 mmol) and K₂CO₃(6.49 g, 46.9 mmol, 2 eq) in DMF (100 mL) was added dimethyl but-2-ynedioate (6.66 g, 46.9 mmol, 2 eq) at 0° C., The reaction mixture was warmed to rt and stirred for 16 hrs. Reaction progress was tracked by TLC (PE:EtOAc=1:1). Water (200 mL) was added, and the solution was stirred for 30 mins. The resulting precipitate was collected by vacuum filtration, rinsed with water, and dried. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, eluent of 0˜40% EtOAc:PE @ 60 mL/min) to give C12 (2.85 g, 40% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (d, 1H), 7.74-7.96 (m, 2H), 3.85-3.96 (m, 6H).

Step 3: Preparation of 2-(methoxycarbonyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (C13)

To a solution of dimethyl 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2,3-dicarboxylate (C12) (2.85 g, 9.43 mmol) in THE (20 mL) was added LiOH·H₂O (1.58 g, 37.7 mmol, 4 eq) in H₂O (20 mL), and the reaction mixture was stirred at rt for 16 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was concentrated in vacuo to remove most of THF, and the aqueous phase was adjusted to pH ˜2 with 4 M HCl. The precipitate was collected by filtration and then dried in vacuo to give C13 (2.25 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.43 (d, 1H), 7.85 (d, 1H), 7.71-7.76 (m, 1H).

Step 4: Preparation of 7-(trifluoromethyl) pyrazolo[1,5-a]pyridine-2-carboxylic acid (C14)

A mixture of 2-(methoxycarbonyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (C13) (2.25 g, 8.21 mmol) in H₂SO₄(41.40 g, 422 mmol, 22.5 mL, 51.4 eq) and H₂O (11.25 g, 624 mmol, 11.3 mL, 76.1 eq) was stirred at 90° C. for 16 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was cooled to rt, and water (60 mL) was added. The precipitate was collected by filtration and then dried in vacuo to give C14 (1.7 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.14 (d, 1H), 7.71 (d, 1H), 7.41-7.49 (m, 1H), 7.32 (s, 1H).

Step 5: Preparation of N-methoxy-N-methyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxamide (C15)

To a solution of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxylic acid (C14) (8.00 g, 34.8 mmol) and N-methoxymethanamine (10.17 g, 104 mmol, 3 eq, HCl) in DMF (80 mL) was added HOBt (7.05 g, 52.1 mmol, 1.5 eq), EDCI (10.00 g, 52.1 mmol, 1.5 eq) and DIPEA (13.48 g, 104 mmol, 18.2 mL, 3 eq). The mixture was stirred at rt for 16 hrs. Reaction progress was tracked using TLC (DCM:MeOH=10:1). DCM (150 mL) was added, and the organic portion washed with sat. Na₂CO₃solution (100 mL×2) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, eluent of 0˜10% MeOH:DCM @ 60 mL/min) to give C15 (6 g, 60% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.11 (d, 1H), 7.67 (d, 1H), 7.37-7.49 (m, 1H), 7.21 (s, 1H), 3.77 (s, 3H), 2.50-2.52 (m, 3H); LCMS: m/z 274.1 [M+H]⁺.

Step 6: Preparation of 7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde (C16)

To a solution of N-methoxy-N-methyl-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carboxamide (C15) (6 g, 22.0 mmol) in THE (60 mL) was added DIBAL-H (1 M, 65.9 mL, 3 eq) dropwise at −78° C. under N₂, and then the reaction mixture was stirred at −78° C. for 2 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc=5:1). The reaction mixture was quenched by the addition of sat. NH₄Cl solution (150 mL), and then 4 M HCl solution (80 mL) was added. The aqueous portion was extracted with EtOAc (100 mL×2), and the combined organic layer was washed with water (80 mL) and brine (80 mL). The organic layer was dried over Na₂SO₄, filtered, and evaporated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0-30% EtOAc:PE @ 40 mL/min) to give C16 (3.95 g, 68% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.20 (s, 1H), 8.20 (d, 1H), 7.79 (d, 1H), 7.49 (dd, 1H), 7.40 (s, 1H).

Intermediate 7-chloropyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C16, starting with 2-chloropyridine.

Intermediate 5-(trifluoromethyl)pyrazolo[1,5-a]pyridine-2-carbaldehyde was prepared following the general procedure described above for C16, starting with 4-(trifluoromethyl)pyridine.

Intermediate 7-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde

embedded image

Step 1: Preparation of ethyl 7-fluoropyrazolo[1,5-a] pyridine-2-carboxylate (C18)

To a solution of ethyl 7-bromopyrazolo[1,5-a]pyridine-2-carboxylate (C17) (1 g, 3.72 mmol) in DMA (8 mL) was added CsF (1.69 g, 11.2 mmol, 411 μL, 3 eq), the reaction mixture was stirred at 150° C. for 1 hr under microwave. Reaction progress was tracked using LCMS. DCM (60 mL) was added to the reaction mixture, and the organic portion washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 4/1) to give C18 (450 mg, 29% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.48 (d, 1H), 7.18-7.26 (m, 2H), 6.64 (ddd, 1H), 4.52 (q, 2H), 1.48 (t, 3H); LCMS: m/z 208.8 [M+H]⁺.

Step 2: Preparation of (7-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C19)

To a solution of ethyl 7-fluoropyrazolo[1,5-a]pyridine-2-carboxylate (C18) (450 mg, 2.16 mmol) in THF (4 mL) and EtOH (2 mL) was added LiBH₄(260 mg, 11.9 mmol, 5.5 eq) at 0° C. The reaction mixture was stirred at rt for 2 hrs. Reaction progress was tracked using LCMS. The reaction mixture was quenched by the addition of sat. NH₄Cl solution (10 mL), and the aqueous portion extracted with EtOAc (30 mL). The organic layer was washed with water (20 mL) and brine (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give C19 (360 mg), which was used without further purification. LCMS: m/z 167.0 [M+H]⁺.

Step 3: Preparation of 7-fluoropyrazolo[1,5-a]pyridine-2-carbaldehyde (C20)

To a solution of (7-fluoropyrazolo[1,5-a]pyridin-2-yl)methanol (C19) (360 mg, 2.17 mmol) in MeCN (5 mL) was added IBX (971 mg, 3.47 mmol, 1.6 eq), and the reaction mixture was stirred at 80° C. for 1 hr. Reaction progress was tracked using LCMS. The reaction mixture was filtrated and concentrated to dryness to give C20 (355 mg), which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 10.26-10.46 (m, 1H), 7.52 (dd, 1H), 7.22-7.28 (m, 1H), 7.16 (d, 1H), 6.69 (ddd, 1H); LCMS: m/z 165.0 [M+H]⁺.

Intermediate 4-(difluoromethyl)oxazole-5-carboxylic acid according to General Scheme 4

embedded image

Step 1: Preparation of ethyl 2-bromo-4,4-difluoro-3-oxo-butanoate (E1)

To a solution of ethyl 4,4-difluoro-3-oxo-butanoate (20 g, 120 mmol) in DCM (240 mL) was added TsOH (4.15 g, 24.1 mmol, 0.2 eq) and NBS (22.50 g, 126 mmol, 1.05 eq) in portions at 0° C. After addition was complete, the reaction mixture was stirred at rt for 1 hr. The reaction progress was checked using TLC (PE:EtOAc=5:1). DCM was added (100 mL), and the organic portion was washed with sat. Na₂CO₃solution (100 mL) and brine (150 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to afford E1 (34 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 5.81-6.16 (m, 1H), 4.34-4.41 (m, 1H), 4.12-4.20 (m, 2H), 1.17-1.23 (m, 3H).

Step 2: Preparation of ethyl 2-amino-4-(difluoromethyl) oxazole-5-carboxylate (E2)

A mixture of E1 (37 g, 151 mmol) and urea (45.34 g, 755 mmol, 40.5 mL, 5 eq) in DMF (30 mL) was stirred at 120° C. for 12 hrs. The reaction progress was checked using LC-MS. The reaction mixture was cooled to rt and poured into 100 mL of water. The reaction mixture was stirred for 15 min at 0° C., and the precipitate was collected by filtration, rinsed with water (50 mL), dried in vacuo to give E2 (15.5 g, 63% yield for steps 1 and 2). LC-MS: m/z 207.2 (M+H)⁺; ¹H NMR (400 MHz, DMSO-d₆) δ 7.86 (s, 2H), 6.84-7.44 (m, 1H), 4.27 (q, 2H), 1.28 (t, 3H).

Step 3: Preparation of ethyl 4-(difluoromethyl)oxazole-5-carboxylate (E3)

To a solution of ethyl 2-amino-4-(difluoromethyl)oxazole-5-carboxylate (20 g, 97.0 mmol) in THF (300 mL) was added t-BuONO (30.01 g, 291 mmol, 34.6 mL, 3 eq) dropwise at 0° C., the reaction mixture was stirred at rt for 12 hrs. DCM (300 mL) was added, and the organic portion was washed with water (200 mL) and brine (200 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 10/1) to give E3 (12.7 g, 69% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.05 (s, 1H), 6.93-7.27 (m, 1H), 4.44 (q, 2H), 1.40 (t, 3H).

Step 5: Preparation of 4-(difluoromethyl)oxazole-5-carboxylic acid (E4)

To a solution of ethyl 4-(difluoromethyl)oxazole-5-carboxylate (12.7 g, 66.5 mmol) in THE (100 mL) and H₂O (20 mL) was added LiOH·H₂O (3.07 g, 73.1 mmol, 1.1 eq). The reaction mixture was stirred at rt for 1 hr and then concentrated in vacuo to remove THF. Water (80 mL) was added, and the aqueous portion extracted with TBME (50 mL). The aqueous layer was then adjusted to pH-6 by the addition of 0.5 M HCl. The aqueous layer was concentrated to dryness to give E4 (11 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.30 (s, 1H), 7.34-7.76 (m, 1H).

Intermediate ethyl 2-bromo-4-(difluoromethyl)oxazole-5-carboxylate According to General Scheme 4

embedded image

Preparation of ethyl 2-bromo-4-(difluoromethyl)oxazole-5-carboxylate (E5)

To a solution of ethyl 2-amino-4-(difluoromethyl)oxazole-5-carboxylate (E2) (25 g, 121 mmol) in MeCN (200 mL) was added CuBr₂(40.63 g, 182 mmol, 8.5 mL, 1.5 eq) at 0° C. The mixture turned dark green and further stirred for 15 min at rt. t-BuONO (18.76 g, 182 mmol, 21.6 mL, 1.5 eq) was added at 0° C. The reaction was stirred at rt for 2 hrs, and then was heated to 50° C. and stirred for 12 hrs. Reaction progress was tracked using TLC (EtOAc:PE=5:1). The reaction mixture was filtered. DCM (200 mL) was added to the filtrate, and the organic layer was washed by water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0˜20% EtOAc/PE gradient @ 100 mL/min) to afford E5 (19 g, 58% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.02 (t, 1H), 4.39 (q, 2H), 1.35 (t, 3H).

Intermediate 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylic acid According to General Scheme 6, Method A

embedded image

Step 1: Preparation of ethyl 2-acetyl-4-(difluoromethyl)oxazole-5-carboxylate (E6)

To a solution of ethyl 2-bromo-4-(difluoromethyl)oxazole-5-carboxylate (E5) (10 g, 37.0 mmol) in toluene (150 mL) was added Pd(PPh₃)₂Cl₂(2.60 g, 3.70 mmol, 0.1 eq) and tributyl(1-ethoxyvinyl)stannane (17.39 g, 48.1 mmol, 16.3 mL, 1.3 eq). The mixture was stirred at 85° C. for 12 hrs under N₂atmosphere. The reaction progress was checked using TLC (PE:EtOAc). EtOAc (100 mL) was added to the reaction mixture, and the organic portion washed with sat. KF solution (150 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was dissolved in THE (60 mL) and treated with HCl (4 M, 60 mL), and then was stirred at 40° C. for 12 hrs. The reaction progress was checked by TLC (Petroleum ether:EtOAc=10:1). EtOAc (100 mL) was added to the reaction mixture, and the organic portion washed with water (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0˜20% EtOAc/PE gradient @ 40 mL/min) to give E6 (7.1 g, 82% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.00-7.36 (m, 1H), 4.48 (q, 2H), 2.66-2.86 (m, 3H), 1.43 (t, 3H).

Step 2: Preparation of ethyl 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylate (E7)

To a solution of E6 (2.5 g, 10.7 mmol) in THE (120 mL) was added MeMgBr (3 M, 7.15 mL, 2 eq) at −78° C. The mixture was stirred at −78° C. for 1 hr. The reaction progress was checked by TLC (PE:EtOAc=2:1). The reaction mixture was quenched by addition of sat. NH₄Cl solution (50 mL) and then water (100 mL) was added. The aqueous portion was extracted with EtOAc (100 mL×3). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0˜12% EtOAc/PE gradient @ 40 mL/min) to give E7 (3.2 g, 60% yield). ¹H NMR (400 MHz, CDCl₃) δ 6.94-7.29 (m, 1H), 4.46 (q, 2H), 2.86 (s, 1H), 1.72 (s, 6H), 1.44 (t, 3H). The starting material E6 (300 mg) was also recovered.

Step 3: Preparation of 4-(difluoromethyl)-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylic acid (E8)

To a solution of E7 (3.9 g, 15.7 mmol) in THE (40 mL) and H₂O (40 mL) was added LiOH·H₂O (690 mg, 16.4 mmol, 1.05 eq). The mixture was stirred at rt for 1 hr. The reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated to remove THF. The aqueous mixture was then adjusted to pH ˜3 by the addition of 1M HCl, and then lyophilized in vacuo to give E8 (4 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 7.35-7.71 (m, 1H), 5.68 (br s, 1H), 1.50 (s, 6H).

Intermediate 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylic acid

embedded image

Step 1: Preparation of ethyl 4-(trifluoromethyl)oxazole-5-carboxylate (E10)

To a solution of ethyl 2-amino-4-(trifluoromethyl)oxazole-5-carboxylate (2.00 g, 8.92 mmol) in THF (60 mL) was added t-BuONO (1.84 g, 17.9 mmol, 2.12 mL, 2 eq). The reaction mixture was stirred at 55° C. for 24 hrs. EtOAc (120 mL) was added to the reaction mixture, and the organic portion washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 8/1) to give E10 (1.2 g, 64% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.96 (s, 1H), 4.39 (q, 2H), 1.34 (t, 3H).

Step 2: Preparation of ethyl 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylate (E11)

To a solution of ethyl 4-(trifluoromethyl)oxazole-5-carboxylate (1.2 g, 5.74 mmol) in THF (30 mL) was added LiHMDS (1 M, 8.61 mL, 1.5 eq) at −78° C., and the reaction mixture was stirred at −78° C. for 0.5 hr. Cyclobutanone (1.21 g, 17.2 mmol, 1.29 mL, 3 eq) in THF (5 mL) was added to the reaction mixture, and the mixture was stirred at −78° C. for 2 hrs under N₂atmosphere. The reaction mixture was quenched by the addition of sat. NH₄Cl solution (30 mL), and the aqueous portion extracted with EtOAc (100 mL). The organic layer washed by water (70 mL) and brine (70 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 10/1) to give E11 (600 mg, 37% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.29 (q, 2H), 2.78-2.94 (m, 1H), 2.52-2.65 (m, 2H), 2.24-2.38 (m, 2H), 1.78-1.98 (m, 3H), 1.26 (t, 3H).

Step 3: Preparation of 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylic acid (E12)

To a solution of ethyl 2-(1-hydroxycyclobutyl)-4-(trifluoromethyl)oxazole-5-carboxylate (600 mg, 2.15 mmol) in H₂O (2 mL) and THF (10 mL) was added LiOH·H₂O (99.2 mg, 2.36 mmol, 1.1 eq) at 0° C. The reaction mixture was stirred at rt for 2 hrs and concentrated in vacuo to remove THF. Water (10 mL) was added, and the aqueous portion extracted with TBME (30 mL). The aqueous layer was then adjusted to pH-6 by the addition of 0.5 M HCl and concentrated to dryness to give E12 (540 mg), which was used without further purification. ¹H NMR (400 MHz, CD₃OD) δ 2.54-2.67 (m, 2H), 2.19-2.34 (m, 2H), 1.81-1.95 (m, 1H), 1.66-1.80 (m, 1H).

Intermediate ethyl 4-bromo-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate According to General Scheme 6

embedded image

Step 1: Preparation of Ethyl 4-bromooxazole-5-carboxylate (E14)

Ethyl oxazole-5-carboxylate (E13) (500 mg, 3.54 mmol) was added in THF (2.50 mL) and DMF (2.50 mL) at approximately 10° C. The reaction mixture was cooled to −80° C. and LiHMDS (1 M, 4.61 mL, 1.30 eq) was added dropwise at approximately −80° C. The reaction mixture was stirred at approximately −80° C. for 0.5 hr. Br₂(736 mg, 4.61 mmol, 1.3 eq) was then added dropwise at approximately −80° C. The reaction mixture was stirred at approximately −80° C. for 0.5 hr. The reaction progress was checked using LC-MS. The reaction mixture was combined with 19 other reactions performed using 500 mg of E13. The combined reaction mixture was poured into sat. citric acid at approximately −10° C. The aqueous portion was extracted with EtOAc (50 mL×3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to give E14 (3.00 g, 19% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (s, 1H), 4.29-4.34 (m, 2H), 1.29 (t, 3H); LC-MS: m/z 219.9 & 221.9 (M+H)⁺.

Step 2: Preparation of Ethyl 4-bromo-2-iodooxazole-5-carboxylate (E15)

Ethyl 4-bromooxazole-5-carboxylate (E14) (3.15 g, 14.3 mmol, 1.00 eq) was added in THF (15.0 mL) at rt. LiHMDS (1 M, 17.2 mL, 1.20 eq) was added dropwise at approximately −80° C. I₂(5.45 g, 21.5 mmol, 1.50 eq) in THF (15.0 mL) was then added dropwise at approximately −80° C. The reaction mixture was stirred at approximately −80° C. for 1 hr. The reaction progress was checked using TLC (PE/EtOAc). The reaction mixture was poured into saturated citric acid (30 mL) at approximately −10° C. The aqueous phase was extracted with ethyl acetate (30 mL×3). The combined organic layer was washed with brine (30 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to afford E15 (1.10 g, 22% yield). ¹H NMR (400 MHz, DMSO-d₆) δ: 4.29-4.35 (m, 2H), 1.30 (t, 3H). LC-MS: m/z 345.8 & 347.9 (M+H)⁺.

Step 3: Preparation of Ethyl 4-bromo-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate (E16)

Ethyl 4-bromo-2-iodooxazole-5-carboxylate (E15) (1.10 g, 3.18 mmol) was added in THE (10 mL) at approximately 10° C. under N₂. The reaction mixture was degassed under vacuum and purged with N₂three times. The mixture was cooled to −80° C., and iPr-MgCl·LiCl (1.3 M, 2.45 mL, 1 eq) was added dropwise at approximately −80° C. The reaction mixture was stirred at approximately −80° C. for 0.5 hr, and then acetone (222 mg, 3.82 mmol, 1.20 eq) was added dropwise at approximately −80° C. The mixture was stirred at approximately −80° C. for 0.5 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The reaction mixture was poured into sat. citric acid solution (5 mL) at approximately −10° C. The aqueous portion was extracted with ethyl acetate (5 mL×3). The combined organic layer was washed with brine (5 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) and further purified by prep-HPLC (column: Phenomenex luna C18 80×40 mm×3 um; mobile phase: [water (0.04% HCl)-ACN]; B %: 18%-45%, 7 min) to afford E16 (140 mg, 16% yield). ¹H NMR (400 MHz, DMSO-d₆) δ: 5.93 (s, 1H), 4.30-4.37 (m, 2H), 1.50 (s, 6H), 1.32 (t, 3H). LC-MS: m/z 277.9 & 279.9 (M+H)⁺.

Intermediate ethyl 4-chloro-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate According to General Scheme 6

embedded image

Step 1: Preparation of Ethyl 4-chlorooxazole-5-carboxylate (E17)

Ethyl oxazole-5-carboxylate (E13) (10.0 g, 70.9 mmol) was added in DMF (50 mL) at approximately 10° C. The reaction mixture was cooled to −80° C., and LiHMDS (1 M, 92.1 mL, 1.3 eq) was added dropwise at approximately −80° C. The reaction mixture was stirred at approximately −80° C. for 0.5 hr, and NCS (12.3 g, 92.1 mmol, 1.3 eq) in THE (50 mL) was then added dropwise at approximately −80° C. The mixture was stirred at approximately −80° C. for 0.5 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The reaction mixture was combined for workup with seven other reactions each performed using 10 g of E13. The combined reaction mixture was poured into sat. citric acid solution (100 mL) at approximately −10°. The aqueous portion was extracted with ethyl acetate (100 mL×3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to afford E17 (18.0 g, 18% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1H), 4.44 (q, 2H), 1.42 (t, 3H); LC-MS: m/z 176.0 (M+H)⁺.

Step 2: Preparation of Ethyl 4-chloro-2-iodooxazole-5-carboxylate (E18)

Three reactions were carried out in parallel. Ethyl 4-chlorooxazole-5-carboxylate (E17) (6.00 g, 34.2 mmol) was dissolved in THE (30 mL) at rt. LiHMDS (1 M, 41.0 mL, 1.2 eq) was added dropwise at approximately −80° C., followed by the dropwise addition of I₂(13.0 g, 51.3 mmol, 1.5 eq) in THE (30 mL) at approximately −80° C. The reaction mixture was stirred at approximately −80° C. for 1 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The three parallel reactions were combined together for workup. The combined reaction mixture was poured into sat. citric acid solution (100 mL) at approximately −5° C. The aqueous portion was extracted with ethyl acetate (100 mL×3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) to afford E18 (10.0 g, 32% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 4.20-4.27 (m, 2H), 1.21 (t, 3H); LC-MS: m/z 301.9 (M+H)⁺.

Step 3: Preparation of Ethyl 4-chloro-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylate (E19)

Two reactions were carried out in parallel. Compound E18 (5.00 g, 16.6 mmol) was added in THF (50 mL) at approximately 10° C. under N₂. The suspension was degassed under vacuum and purged with N₂three times. The mixture was cooled to −80° C., and iPr-MgCl·LiCl (1.3 M, 12.8 mL, 1 eq) was added dropwise at approximately −80° C. The mixture was stirred at approximately −80° C. for 0.5 hr, and acetone (1.16 g, 19.9 mmol, 1.2 eq) was then added dropwise at approximately −80° C. The mixture was stirred at approximately −80° C. for 0.5 hr. The reaction progress was checked using TLC (PE/EtOAc=5/1). The two parallel reactions were combined together for workup. The combined reaction mixture was poured into sat. citric acid solution (50 mL) at approximately −10° The aqueous portion was extracted with ethyl acetate (50 mL×3). The combined organic layer was washed with brine (50 mL), dried with Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 0/1) and further purified by prep-HPLC (column: Phenomenex luna C18 (250×70 mm, 15 um); mobile phase: [water (0.05% HCl)-ACN]; B %: 20%-50%, 23 min) to afford E19 (1.80 g, 23% yield). ¹H NMR (400 MHz, DMSO-d₆) δ: 5.92 (s, 1H), 4.32-4.37 (m, 2H), 1.51 (s, 6H), 1.31 (t, 3H); LC-MS: m/z 234.0 (M+H)⁺.

Intermediate 4-(difluoromethyl)-2-(2-cyanopropan-2-yl)oxazole-5-carboxylic acid

embedded image

Step 1: Preparation of 2-cyano-2-methyl-propanoyl chloride (E20)

To a solution of 2-cyano-2-methyl-propanoic acid (2 g, 17.7 mmol) and DMF (129 mg, 1.77 mmol, 136 μL, 0.1 eq) in DCM (20 mL) was added oxalyl chloride (2.69 g, 21.2 mmol, 1.86 mL, 1.2 eq) dropwise at 0° C., and then the reaction mixture was stirred at rt for 1 hr. The reaction mixture was concentrated to dryness to afford E20 (2.5 g), which was used without further purification.

Step 2: Preparation of ethyl (Z)-3-[(2-cyano-2-methyl-propanoyl)amino]-4,4-difluoro-but-2-enoate (E21)

To a solution of ethyl (Z)-3-amino-4,4-difluoro-but-2-enoate (2 g, 12.1 mmol) in dioxane (20 mL) was added a solution of 2-cyano-2-methyl-propanoyl chloride (E20) (2.39 g, 18.2 mmol, 1.5 eq) in dioxane (20 mL) at rt. The reaction mixture was stirred at 110° C. for 12 hrs. The reaction progress was checked using TLC (PE/Ethyl acetate=5/1). The reaction mixture was concentrated to dryness, and the residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0˜7% EtOAc/PE gradient @ 40 mL/min) to give E21 (2.4 g, 76% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 10.90 (s, 1H), 6.95-7.27 (m, 1H), 5.81 (s, 1H), 4.12-4.29 (m, 2H), 1.51-1.69 (m, 6H), 1.20 (t, 3H); LCMS: m/z 259.1 [M+H]⁺.

Step 3: Preparation of ethyl 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazole-5-carboxylate (E22)

To a solution of ethyl (Z)-3-[(2-cyano-2-methyl-propanoyl)amino]-4,4-difluoro-but-2-enoate (E21) (2.4 g, 9.22 mmol) in DCE (20 mL) was added BF₃·Et₂O (2.62 g, 18.4 mmol, 2.28 mL, 2 eq) and PIDA (4.16 g, 12.9 mmol, 1.4 eq) at rt. The mixture was stirred at 90° C. for 18 hrs. The reaction progress was checked by TLC (PE/EtOAc). The reaction mixture was concentrated to dryness. DCM (100 mL) was added to the residue, and the organic layer washed with sat. Na₂CO₃solution (10 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, eluent of 0˜7% EtOAc/PE gradient @ 30 mL/min) to give E22 (0.25 g, 11% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.03-7.55 (m, 1H), 4.35 (q, 2H), 1.77 (s, 6H), 1.29 (t, 3H).

Step 4: Preparation of 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazole-5-carboxylic acid (E23)

To a solution of ethyl 2-(1-cyano-1-methyl-ethyl)-4-(difluoromethyl)oxazole-5-carboxylate (E22) (0.25 g, 968 μmol) in THE (3 mL) and H₂O (1 mL) was added LiOH·H₂O (48.8 mg, 1.16 mmol, 1.2 eq). The mixture was stirred at rt for 18 hrs. Reaction completeness was checked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated under reduced pressure to remove THF. The aqueous portion was adjusted with 2 M HCl to pH ˜7, and then lyophilized under vacuo to give E23 (0.22 g, 99% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.23-7.74 (m, 1H), 1.73 (s, 6H).

Intermediate 4-(difluoromethyl)-2-(pyrimidin-2-yl)oxazole-5-carboxylic acid According to General Scheme 5, Method B

embedded image

Step 1: Preparation of ethyl 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazole-5-carboxylate (E24)

To a solution of ethyl 4-(difluoromethyl)oxazole-5-carboxylate (E4) (1 g, 5.23 mmol), Pd₂(dba)₃(240 mg, 262 μmol, 0.05 eq), (5-diphenylphosphanyl-9,9-dimethyl-xanthen-4-yl)-diphenyl-phosphane (151 mg, 262 μmol, 0.05 eq) and Cs₂CO₃(3.41 g, 10.5 mmol, 2 eq) in 1,2-dimethoxyethane (3 mL) was added 2-chloropyrimidine (599 mg, 5.23 mmol) under N₂atmosphere. The reaction mixture was stirred at 90° C. for 12 hrs. DCM (50 mL) was added to the reaction mixture, and the organic portion washed by water (40 mL) and brine (40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 1/1) to give E24 (400 mg, 25% yield). ¹H NMR (400 MHz, CDCl₃) δ 9.02 (br d, 2H), 7.52 (t, 1H), 7.38 (s, 1H), 7.24 (s, 1H), 7.11 (s, 1H), 4.54 (q, 2H), 1.48 (t, 3H).

Step 2: Preparation of 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazole-5-carboxylic acid (E25)

To a solution of ethyl 4-(difluoromethyl)-2-pyrimidin-2-yl-oxazole-5-carboxylate (E24) (450 mg, 1.67 mmol) in THF (2 mL) and H₂O (2 mL) was added LiOH·H₂O (77.2 mg, 1.84 mmol, 1.1 eq). The reaction mixture was stirred at rt for 1 hr. The reaction mixture was concentrated to remove THF, and H₂O (10 mL) was added. The aqueous layer was extracted with TBME (30 mL). The aqueous layer was then adjusted to pH-6 with 0.5 M HCl and extracted with DCM/MeOH (30/3 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E25 (350 mg), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 9.06 (d, 2H), 7.75 (t, 1H), 7.20-7.57 (m, 1H).

Intermediate 2-(1-hydroxy-1-methyl-ethyl)-4-methyl-oxazole-5-carboxylic acid According to General Scheme 4 and General Scheme 6, Method A

embedded image

Step 1: Preparation of ethyl 2-amino-4-methyl-oxazole-5-carboxylate (E26)

A mixture of ethyl 2-chloro-3-oxo-butanoate (55 g, 334 mmol, 46.2 mL) and urea (100.34 g, 1.67 mol, 89.6 mL, 5 eq) in DMF (100 mL) was stirred at 120° C. for 12 hours. Reaction progress was checked using TLC (PE:EtOAc=5:1). The reaction mixture was cooled to rt, poured into H₂O (400 ml), and stirred at 0° C. for 30 min. The solid was collected by filtration, rinsed with water (30 mL), and then dried in vacuo to give E26 (22.2 g, 39% yield). ¹H NMR (400 MHz, CD₃OD) δ 4.29 (q, 2H), 2.32 (s, 3H), 1.35 (t, 3H).

Step 2: Preparation of ethyl 2-bromo-4-methyl-oxazole-5-carboxylate (E27)

To a solution of E26 (11.1 g, 65.2 mmol) in MeCN (120 mL) was added CuBr₂(21.85 g, 97.9 mmol, 4.58 mL, 1.5 eq) at 0° C. The mixture turned dark green and was further stirred for 15 min at rt. t-BuONO (10.09 g, 97.9 mmol, 11.6 mL, 1.5 eq) was added. The reaction was stirred at rt for 2 hrs and then heated at 50° C. for 4 hrs. Reaction progress was checked using TLC (Petroleum ether:EtOAc=3:1). The reaction mixture was concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, eluent of 0˜5% EtOAc/PE gradient @ 100 mL/min) to give E27 (8.5 g, 56% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.25-4.35 (m, 2H), 2.45 (s, 3H), 1.32 (t, 3H).

Step 3: Preparation of ethyl 2-acetyl-4-methyloxazole-5-carboxylate (E28)

A mixture of E27 (9.5 g, 40.6 mmol), tributyl(1-ethoxyvinyl) stannane (17.59 g, 48.7 mmol, 16.4 mL, 1.2 eq) and Pd(PPh₃)₂Cl₂(2.85 g, 4.06 mmol, 0.1 eq) in toluene (200 mL) was stirred at 90° C. for 12 hrs under N₂atmosphere. Reaction progress was checked using TLC (Petroleum ether:EtOAc=5:1). EtOAc (300 ml) was added, followed by sat. KF solution (500 ml). The resulting mixture was stirred at rt for 40 min, the mixture filtered, and the filtrate separated. The organic layer was washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was dissolved in THE (300 ml), and 4 N HCl (300 ml) was added. The mixture was stirred at rt for 12 hrs. LCMS indicated the desired mass was detected. The reaction mixture was extracted with DCM (100 mL×3). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column, eluent of 0˜10% EtOAc/PE gradient @ 35 mL/min) to give E28 (6.8 g, 85% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.35 (q, 2H), 2.62 (s, 3H), 2.48 (s, 3H), 1.34 (t, 3H); LCMS: m/z 198.1 (M+H)⁺.

Step 4: Preparation of ethyl 2-(2-hydroxypropan-2-yl)-4-methyloxazole-5-carboxylate (E29)

To a solution of E28 (2.5 g, 12.7 mmol) in THE (25 mL) was added MeMgBr (3 M, 12.7 mL, 3 eq) dropwise under N₂at −78° C. The reaction was stirred at −78° C. for 1.5 hr. Reaction progress was checked using TLC (Petroleum ether:EtOAc=5:1, by UV). The reaction was quenched by the addition of sat. NH₄Cl solution (30 mL) slowly and then the organic portion extracted with EtOAc (30 mL×3). The combined organic phase was washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, Petroleum ether/EtOAc=1/0 to 1/1) to give E29 (1.7 g, 63% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.39 (q, 2H), 2.47 (s, 3H), 1.67 (s, 6H), 1.40 (t, 3H).

Alternatively, E29 can be prepared by reacting 2-hydroxy-2-methylpropanamide with ethyl 2-chloro-3-oxo-butanoate in a neat reaction at 150° C. for 6 hrs.

Step 5: Preparation of ethyl 2-(2-hydroxypropan-2-yl)-4-methyloxazole-5-carboxylic acid (E30)

To a solution of E29 (3.4 g, 16.0 mmol) in THE (30 mL) and H₂O (15 mL) was added LiOH·H₂O (803 mg, 19.1 mmol, 1.2 eq). The reaction was stirred at rt for 1.5 hr. Reaction progress was tracked using LCMS. The reaction mixture was adjusted to pH 7 with HCl (1 M) and concentrated to dryness to afford E30 (4 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 5.67 (s, 1H), 2.30 (s, 2H), 1.44 (s, 6H); LCMS: m/z 186.1 (M+H)⁺.

Intermediate 4-cyclopropyl-2-(2-hydroxypropan-2-yl)oxazole-5-carboxylic acid According to General Scheme 4

embedded image

Step 1: Preparation of ethyl 2-bromo-3-cyclopropyl-3-oxo-propanoate (E31)

To a solution of ethyl 3-cyclopropyl-3-oxo-propanoate (8 g, 51.2 mmol) in DCM (100 mL) was added NBS (9.12 g, 51.2 mmol) and TsOH·H₂O (1.95 g, 10.2 mmol, 0.2 eq). The reaction mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=10:1). The reaction mixture was concentrated to dryness. EtOAc (120 mL) was added to the residue, and the mixture filtered. The filtrate was washed with sat. NaHCO₃solution (2×100 mL) and water (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1:0 to 10:1) to give E31 (12 g, 100% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 5.71 (s, 1H), 4.18 (q, 2H), 2.14-2.28 (m, 1H), 1.18 (t, 3H), 1.01-1.08 (m, 2H), 0.89-0.96 (m, 2H); LCMS: m/z 235.0 [M+H]⁺.

Step 2: Preparation of ethyl 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylate (E32)

To a solution of ethyl 2-bromo-3-cyclopropyl-3-oxo-propanoate (E31) (1 g, 4.25 mmol) in DMF (2 mL) was added 2-hydroxy-2-methyl-propanamide (2.19 g, 21.3 mmol, 5 eq). The mixture was stirred at 110° C. for 40 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was adjusted to pH-8 by addition of sat. aq. NaHCO₃at 0° C. H₂O (50 mL) was added, and the aqueous portion extracted with EtOAc (3×50 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1:0 to 2:1) to give E32 (0.15 g, 14% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 5.70 (s, 1H), 4.29 (q, 2H), 2.40-2.45 (m, 1H), 1.43 (s, 6H), 1.27 (t, 3H), 0.94-1.04 (m, 2H), 0.79-0.92 (m, 2H); LCMS: m/z 240.0 [M+H]⁺.

Step 3: Preparation of 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylic acid (E33)

To a solution of ethyl 4-cyclopropyl-2-(1-hydroxy-1-methyl-ethyl)oxazole-5-carboxylate (E32) (590 mg, 2.47 mmol) in THE (4 mL) and H₂O (4 mL) was added LiOH·H₂O (114 mg, 2.71 mmol, 1.1 eq). The reaction mixture was stirred at rt for 16 hrs. Reaction progress was tracked using LC-MS. The reaction mixture was concentrated to remove THF. The aqueous portion was adjusted to pH-7 by the addition of HCl (1 M) and then lyophilized to give E33 (550 mg, 90% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 2.70-2.84 (m, 1H), 1.39 (s, 6H), 0.62-0.81 (m, 4H); LCMS: m/z 212.0 [M+H]⁺.

Intermediate 4-cyanooxazole-5-carboxylic acid

embedded image

Step 1: Preparation of ethyl 4-cyanooxazole-5-carboxylate (E34)

To a solution of ethyl 4-bromooxazole-5-carboxylate (E14) (10 g, 45.5 mmol) in THE (30 mL) and H₂O (150 mL) was added Zn(CN)₂(3.74 g, 31.8 mmol, 2.02 mL, 0.7 eq) and t-BuXPhos-Pd-G3 (1.81 g, 2.27 mmol, 0.05 eq). The reaction mixture was degassed under vacuum and purged with N₂3 times, and then the mixture was stirred at 40° C. for 16 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc=5:1). EtOAc (300 mL) was added to the reaction mixture, and the organic layer washed with H₂O (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=100/1 to 10/1) to give E34 (7.5 g, 99% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.89 (s, 1H), 4.37 (q, 2H), 1.30 (t, 3H).

Step 2: Preparation of (4-cyanooxazole-5-carbonyl)oxylithium (E35)

To a solution of E34 (5 g, 30.1 mmol) in THE (40 mL) and H₂O (80 mL) was added LiOH·H₂O (1.33 g, 31.6 mmol, 1.05 eq). The mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=5:1). The reaction mixture was concentrated in vacuo to remove most of the THF and then lyophilized in vacuo to give E35 (4.5 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.47 (s, 1H).

Intermediate [5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carbonyl]oxylithium According to General Scheme 9

embedded image

Step 1: Preparation of ethyl 5-methylsulfanyl-1,3,4-oxadiazole-2-carboxylate (E36)

A mixture of ethyl 2-hydrazino-2-oxo-acetate (16 g, 121 mmol) and di(1H-imidazol-1-yl)methanethione (25.90 g, 145 mmol, 1.2 eq) in THF (300 mL) was stirred at rt for 12 hrs, and then heated to 75° C. for 4 hrs. After cooling to rt, K₂CO₃(50.21 g, 363 mmol, 3 eq) and CH₃I (85.95 g, 606 mmol, 37.7 mL, 5 eq) were added. The resulting mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was combined with another reaction performed with 8.5 g of ethyl 2-hydrazino-2-oxo-acetate and quenched by the addition of H₂O (100 mL). DCM (500 mL) was added, and the organic layer was separated and washed with brine (2×100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (Eluent of 0˜25% PE:EtOAc @ 40 mL/min) to give E36 (25 g). ¹H NMR (400 MHz, CDCl₃) δ 4.43 (q, 2H), 2.72 (s, 3H), 1.38 (t, 3H).

Step 2: Preparation of ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37)

A mixture of E36 (233 mg, 1.24 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)pyrazole (410 mg, 1.49 mmol, 1.2 eq), Na₂CO₃(394 mg, 3.71 mmol, 3 eq), thiophene-2-carbonyloxy copper (472 mg, 2.48 mmol, 2 eq) and Pd(dppf)Cl₂(181 mg, 248 μmol, 0.2 eq) in dioxane (9 mL) was degassed and purged with N₂3 times, and then the reaction mixture was stirred at 75° C. for 16 hrs under N₂. Reaction progress was tracked using TLC (PE:EtOAc=2:1). EtOAc (100 mL) was added to the reaction mixture, and the organic layer washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 2/1) to give E37 (140 mg, 39% yield). ¹H NMR (400 MHz, CD₃OD) δ 8.61 (s, 1H), 8.22 (s, 1H), 5.12 (q, 2H), 4.51 (q, 2H), 1.44 (t, 3H); LCMS: m/z 291.1 (M+H)⁺.

Step 3: Preparation of [5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carbonyl]oxylithium (E38)

To a solution of E37 (140 mg, 482 μmol) in THF (1.5 mL) was added LiOH·H₂O (22.3 mg, 531 μmol, 1.1 eq) in H₂O (3 mL). The reaction mixture was stirred at rt for 2 hrs. Reaction progress was tracked using TLC (DCM:MeOH). The reaction mixture was concentrated in vacuo to remove most of the THF and then lyophilized in vacuo to give E38 (115 mg), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.58 (s, 1H), 8.14 (s, 1H), 5.27 (q, 2H).

Alternatively, ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37) can be Prepared Accordingly to the Following Scheme

embedded image

Step A: Preparation of ethyl 1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E39)

To a solution of ethyl 1H-pyrazole-4-carboxylate (10 g, 71.4 mmol) and K₂CO₃(19.72 g, 142 mmol, 2 eq) in DMF (45 mL) was added 2,2,2-trifluoroethyl trifluoromethanesulfonate (21.53 g, 92.8 mmol, 1.3 eq) dropwise, and then the resulting mixture was stirred at 50° C. for 6 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). EtOAc (300 mL) was added to the reaction mixture, and the organic layer washed with H₂O (100 mL) and brine (2×100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0˜12% PE/EtOAc @ 60 mL/min) to give E39 (16 g). ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, 2H), 4.73 (q, 2H), 4.32 (q, 2H), 1.36 (t, 3H).

Step B: Preparation of 1-(2,2,2-trifluoroethyl)pyrazole-4-carbohydrazide (E40)

To a solution of E39 (16 g, 72.0 mmol) in THF (100 mL) was added NH₂NH₂·H2O (7.73 g, 151 mmol, 7.5 mL, 98% purity, 2.1 eq), and then the reaction mixture was stirred at 80° C. for 15 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). The reaction mixture was concentrated to dryness. The residue was triturated with TBME (50 mL) and stirred for 15 min. The precipitate was collected by filtration, and then dried in vacuo to give E40 (13 g). ¹H NMR (400 MHz, CD₃OD) δ 8.19 (s, 1H), 7.93 (s, 1H), 4.98 (q, 2H).

Step C: Preparation of ethyl N-[[1-(2,2,2-trifluoroethyl)pyrazole-4-carbonyl]amino] carbamate (E41)

To a solution of E40 (3 g, 14.4 mmol) in THE (70 mL) was added ethyl 2-chloro-2-oxo-acetate (2.36 g, 17.3 mmol, 1.9 mL, 1.2 eq) dropwise at 0° C., and then the reaction mixture was stirred at rt for 3 hrs. The precipitate was collected by filtration and rinsed with TBME (30 mL), and then dried in vacuo to give E41 (1.5 g, 37% yield). ¹H NMR (400 MHz, CDCl₃) δ 9.75 (br s, 1H), 9.06 (br s, 1H), 8.25 (s, 1H), 7.99 (s, 1H), 4.76 (q, 2H), 4.42 (q, 2H), 1.42 (t, 3H).

Step D: Preparation of ethyl 5-[1-(2,2,2-trifluoroethyl)pyrazol-4-yl]-1,3,4-oxadiazole-2-carboxylate (E37)

To a solution of E41 (1.5 g, 5.35 mmol) and Et₃N (271 mg, 2.68 mmol, 373 μL, 0.5 eq) in DCM (30 mL) was added TsCl (491 mg, 6.96 mmol, 1.3 eq) in portions at 0° C., and then the resulting mixture was stirred at rt for 18 hrs. Reaction progress was tracked using TLC (PE:EtOAc=1:1). DCM (100 mL) was added to the reaction mixture, and the organic layer washed with sat. Na₂CO₃solution (60 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0˜16% PE/EtOAc @ 40 mL/min) to give E37 (0.65 g, 42% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.16-8.29 (m, 2H), 4.80 (q, 2H), 4.53 (q, 2H), 1.47 (t, 3H).

Intermediate lithium 5-morpholino-1,3,4-oxadiazole-2-carboxylate According to General Scheme 10

embedded image

Step 1: Preparation of ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (E42)

To a solution of ethyl 5-amino-1,3,4-oxadiazole-2-carboxylate (5 g, 31.8 mmol) in MeCN (60 mL) was added CuBr₂(10.66 g, 47.7 mmol, 2.2 mL, 1.5 eq) at 0° C. The reaction mixture turned dark green and was stirred for 15 min at rt. t-BuONO (4.92 g, 47.7 mmol, 5.7 mL, 1.5 eq) was added at 0° C., and the reaction mixture was stirred at rt for 2 hrs, then heated at 50° C. for another 12 hrs. The reaction progress was checked using TLC (PE/EtOAc=1/1). The reaction mixture was filtered and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, eluent of 0˜50% EtOAc/PE gradient @ 40 mL/min) to give E42 (4.5 g, 64% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.52 (q, 2H), 1.45 (t, 3H).

Step 2: Preparation of ethyl 5-morpholino-1,3,4-oxadiazole-2-carboxylate (E43)

To a solution of ethyl 5-bromo-1,3,4-oxadiazole-2-carboxylate (E42) (1 g, 4.52 mmol) and morpholine (473 mg, 5.43 mmol, 478 μL, 1.2 eq) in THE (40 mL) was added DIPEA (1.17 g, 9.05 mmol, 1.6 mL, 2 eq) at 0° C. The mixture was stirred at rt for 1 hr. The reaction progress was checked using TLC (PE/EtOAc=1/1). EtOAc (100 mL) was added to the reaction mixture, and the organic portion washed with water (30 mL) and brine (30 mL×2), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0˜30% EtOAc/PE gradient @ 35 mL/min) to give E43 (800 mg, 78% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 4.37 (q, 2H), 3.68-3.74 (m, 4H), 3.48-3.52 (m, 4H), 1.31 (t, 3H).

Step 3: Preparation of (5-morpholino-1,3,4-oxadiazole-2-carbonyl) oxylithium (E44)

To a solution of ethyl 5-morpholino-1,3,4-oxadiazole-2-carboxylate (E43) (800 mg, 3.52 mmol) in THE (8 mL) and H₂O (12 mL) was added LiOH·H₂O (162 mg, 3.87 mmol, 1.1 eq). The reaction mixture was stirred at rt for 12 hrs. The reaction progress was checked using TLC (PE/EtOAc=1/1). The reaction mixture was concentrated to dryness to afford E44 (600 mg), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 3.62-3.74 (m, 4H), 3.36 (br d, 4H).

Intermediate [5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carbonyl]oxylithium According to General Scheme 9, Method A

embedded image

Step 1: Preparation of methyl 5-fluoropyridine-2-carboxylate (E45)

A solution of 5-fluoropyridine-2-carbonitrile (15 g, 123 mmol) in HCl/MeOH (4 M, 180 mL, 5.9 eq) was stirred at 60° C. for 12 hrs. The reaction mixture was concentrated in vacuo, and the residue was dissolved in EtOAc (150 mL), washed with sat. NaHCO₃solution (50 mL) and brine (20 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0˜25% EtOAc/PE gradient @ 60 mL/min) to give E45 (15.24 g, 80% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, 1H), 8.20 (dd, 1H), 7.53 (ddd, 1H), 4.00 (s, 3H).

Step 2: Preparation of 5-fluoropyridine-2-carbohydrazide (E46)

A mixture of methyl 5-fluoropyridine-2-carboxylate (E45) (16 g, 103 mmol), NH₂NH₂·H₂O (11.06 g, 217 mmol, 10.7 mL, 98% purity, 2.1 eq) in EtOH (70 mL) was degassed and purged with N₂for 3 times, and then the reaction mixture was stirred at rt for 3 hrs under N₂atmosphere. The reaction mixture was concentrated to dryness to give E46 (15 g, 94% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 9.89 (br s, 1H), 8.61 (d, 1H), 8.07 (dd, 1H), 7.88 (td, 1H), 4.57 (br s, 2H).

Step 3: Preparation of ethyl 2-[2-(5-fluoropyridine-2-carbonyl)hydrazino]-2-oxo-acetate (E47)

To a mixture of 5-fluoropyridine-2-carbohydrazide (E46) (13.5 g, 87.0 mmol) and TEA (17.61 g, 174 mmol, 24.2 mL, 2 eq) in DCM (500 mL) was added ethyl 2-chloro-2-oxo-acetate (15.45 g, 113 mmol, 12.7 mL, 1.3 eq) over a period of 10 min at 0° C. The reaction mixture was stirred for 2 hrs at rt. H₂O (100 mL) was added to the reaction mixture, and the aqueous portion extracted with DCM (300 mL×3). The combined organic layer was washed with brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0˜2.5% EtOAc/PE gradient @ 60 mL/min) to give E47 (16 g, 53% yield). ¹H NMR (400 MHz, CDCl₃) δ 10.03-10.15 (m, 1H), 9.65 (br d, 1H), 8.35-8.42 (m, 1H), 8.11-8.18 (m, 1H), 7.51 (td, 2H), 4.35 (q, 1H), 1.34 (t, 3H); LCMS: m/z 256.2 [M+H]⁺.

Step 4: Preparation of ethyl 5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carboxylate (E48)

To a solution of ethyl 2-[2-(5-fluoropyridine-2-carbonyl)hydrazino]-2-oxo-acetate (E47) (16 g, 62.7 mmol) in DCM (350 mL) was added TEA (8.25 g, 81.5 mmol, 11.3 mL, 1.3 eq) and TosCl (5.98 g, 31.4 mmol, 0.5 eq) in 3 portions at 0° C. The mixture was stirred at rt for 3 hrs. Sat. NaHCO₃solution (200 mL) was added, and the aqueous portion extracted with DCM (400 mL×3). The combined organic layer was washed with brine (200 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 120 g SepaFlash® Silica Flash Column, Eluent of 0˜2.5% MeOH/DCM@ 85 mL/min) to give E48 (8.2 g, 49% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, 1H), 8.39 (dd, 1H), 7.66 (ddd, 1H), 4.59 (q, 2H), 1.51 (t, 3H); LCMS: m/z 238.2 [M+H]⁺.

Step 5: Preparation of [5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carbonyl]oxylithium (E49)

To a solution of ethyl 5-(5-fluoro-2-pyridyl)-1,3,4-oxadiazole-2-carboxylate (E48) (12 g, 50.6 mmol) in THF (140 mL) and H₂O (180 mL) was added LiOH·H₂O (2.23 g, 53.1 mmol, 1.05 eq). The mixture was stirred at rt for 2 hrs. The reaction mixture was concentrated in vacuo to remove most of THF, and the aqueous portion was lyophilized in vacuo to give E49 (11.5 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.79 (d, 1H), 8.24 (dd, 1H), 7.99 (td, 1H).

Intermediate 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic acid

embedded image

Step 1: Preparation of ethyl 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E50)

To a solution of (Z)-ethyl 2-(ethoxymethylene)-4,4-difluoro-3-oxobutanoate (1 g, 4.52 mmol) in THF (8 mL) was added 2,2,2-trifluoroethylhydrazine (670 mg, 5.88 mmol, 1.3 eq) dropwise at 0° C. The reaction mixture was stirred at 0° C. for 1 hr, and then stirred at rt for 16 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to dryness, and the residue was purified by flash silica gel chromatography (Eluent: 0˜5% EtOAc/PE gradient) to give E50 (850 mg, 69% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (s, 1H), 7.38-7.75 (m, 1H), 4.95 (q, 2H), 4.37 (q, 2H), 1.40 (t, 3H); LCMS: m/z 273.1 [M+H]⁺.

Step 2: Preparation of 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylic acid (E51)

To a solution of ethyl 5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)pyrazole-4-carboxylate (E50) (910 mg, 3.34 mmol) in THF (5 mL) and H₂O (5 mL) was added LiOH·H₂O (224 mg, 5.35 mmol, 1.6 eq). The mixture was stirred at rt for 2 hrs. The reaction progress was checked using TLC (PE:EtOAc=2:1). The reaction mixture was concentrated to remove THF. The aqueous portion was adjusted to pH-6 by the addition of HCl (1 M). The resulting precipitate was collected by filtration and then dried in vacuo to give E51 (816 mg, 100% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.08 (s, 1H), 7.45-7.78 (m, 1H), 5.30 (q, 2H).

Intermediate ethyl 2-(2-pyridyl)pyrazole-3-carboxylate

embedded image

Step 1: Preparation of ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate (E52)

Ethyl 2-oxopropanoate (2 g, 17.2 mmol, 1.9 mL) and 1,1-dimethoxy-N,N-dimethyl-methanamine (2.09 g, 17.6 mmol, 2.3 mL, 1.02 eq) were stirred at rt for 12 hrs. The reaction progress was checked using TLC (PE:EtOAc=10:1). The reaction mixture was concentrated to dryness to give E52 (2.4 g), which was used without further purification.

Step 2: Preparation of ethyl 2-(2-pyridyl)pyrazole-3-carboxylate (E53)

A mixture of ethyl (E)-4-(dimethylamino)-2-oxo-but-3-enoate (E52) (2.4 g, 14.0 mmol) and 2-pyridylhydrazine (1.53 g, 14.0 mmol) in HOAc (100 mL) was stirred at 110° C. for 12 hrs. The reaction progress was checked using TLC (PE:EtOAc=10:1). The reaction mixture was adjusted to pH ˜9 by the addition of sat. Na₂CO₃solution. The aqueous portion was extracted with EtOAc (300 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=100/1 to 50/1) to give E53 (1.03 g, 34% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.48 (dt, 1H), 8.05 (td, 1H), 7.83-7.96 (m, 1H), 7.76 (d, 1H), 7.49 (ddd, 1H), 6.96-7.05 (m, 1H), 4.21 (q, 2H), 1.05-1.23 (m, 3H); LCMS: m/z 218.1 [M+H]⁺.

Ethyl 1-(2-pyridyl)pyrazole-3-carboxylate (E53a) was also obtained (190 mg, 6% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.70-8.81 (m, 1H), 8.54 (dd, 1H), 7.92-8.13 (m, 2H), 7.47 (ddd, 1H), 7.02 (d, 1H), 4.35 (q, 2H), 1.34 (t, 3H). The regiochemistry of E53 and E53a were confirmed by HSQC and HMBC NMR analysis.

Step 3: Preparation of 2-(2-pyridyl)pyrazole-3-carboxylic acid (E54)

To a solution of ethyl 2-(2-pyridyl)pyrazole-3-carboxylate (E53) (1 g, 4.60 mmol) in THE (10 mL) and H₂O (10 mL) was added LiOH·H₂O (386 mg, 9.21 mmol, 2 eq), and the reaction mixture was stirred at rt for 12 hrs. The reaction progress was checked using TLC (PE/EtOAc=1/1). The reaction mixture was concentrated under reduced pressure to remove THF. The aqueous portion was adjusted to pH-7 by the addition of 2 M HCl and lyophilized in vacuo to give (E54) (1.2 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 8.36-8.44 (m, 1H), 7.88 (td, 1H), 7.44-7.53 (m, 2H), 7.35 (ddd, 1H), 6.44 (d, 1H).

Intermediate [5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carbonyl]oxylithium

embedded image

Step 1: Preparation of tert-butyl (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylate (E55)

Tert-butyl (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylate was prepared from ethyl 2-amino-2-thioxoacetate following the procedure in Bioorg. Med. Chem., 26 (2016) 3223-3225. The reaction was heated to reflux.

Step 2: Preparation of ethyl 3-(difluoromethyl)-1H-1,2,4-triazole-5-carboxylate (E56)

Reagent 2,2-difluoroacetyl chloride was prepared by adding oxalyl dichloride (18.90 g, 149 mmol, 13.0 mL, 1.1 eq) dropwise at 0° C. to a solution of 2,2-difluoroacetic acid (13 g, 135 mmol, 8.5 mL) and DMF (989 mg, 13.5 mmol, 1.0 mL, 0.1 eq) in DCM (80 mL). The reaction mixture was stirred at rt for 1 hr, and the solution was used without further purification.

To a solution of tert-butyl (Z)-2-(1-amino-2-ethoxy-2-oxoethylidene)hydrazine-1-carboxylate (E55) (13 g, 56.2 mmol) in pyridine (90 mL) was added 2,2-difluoroacetyl chloride (15.47 g, 135 mmol, 2.4 eq). The reaction mixture was heated to 120° C. and stirred for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to dryness. DCM (200 mL) was added to the residue, and the organic portion washed with 1 M HCl (30 mL) and brine (60 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 2:1) to give E56 (8.87 g, 83% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.01-7.32 (m, 1H), 4.36 (q, 2H), 1.30 (t, 3H); LCMS: m/z 192.0 [M+H]⁺.

Step 3: Preparation of ethyl 5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carboxylate (E57)

To a solution of ethyl 3-(difluoromethyl)-1H-1,2,4-triazole-5-carboxylate (E56) (10 g, 52.3 mmol) in DMF (80 mL) was added Mel (22.28 g, 157 mmol, 9.8 mL, 3 eq) and K₂CO₃(21.69 g, 157 mmol, 3 eq). The mixture was stirred at rt for 12 hrs. Reaction progress was checked using TLC (PE:EtOAc=1:1). The reaction mixture was filtered, and the precipitate was rinsed with EtOAc (150 mL). The filtrate was washed with water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1 to 1:1) to give E57 (4.46 g, 42% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 6.99-7.34 (m, 1H), 4.39 (q, 2H), 4.11-4.22 (m, 3H), 1.35 (t, 3H).

Step 4: Preparation of [5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carbonyl]oxylithium (E58)

To a solution of ethyl 5-(difluoromethyl)-2-methyl-1,2,4-triazole-3-carboxylate (E57) (2.35 g, 11.5 mmol) in THF (40 mL) and H₂O (10 mL) was added LiOH·H₂O (505 mg, 12.0 mmol, 1.05 eq). The reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using TLC (PE:EtOAc=2:1). The reaction mixture was concentrated in vacuo to remove THF. H₂O (20 mL) was added, and the aqueous portion extracted with TBME (20 mL), and then lyophilized in vacuo to give E58 (2.15 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 6.75-7.21 (m, 1H), 4.09 (s, 3H).

Intermediate ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate

embedded image

Step 1: Preparation of N′,2-dihydroxy-2-methyl-propanamidine (E59)

To a solution of 2-hydroxy-2-methyl-propanenitrile (2.14 g, 25.2 mmol, 2.3 mL) in EtOH (20 mL) was added hydroxylamino hydrochloride (3.49 g, 50.3 mmol, 2 eq) and Na₂CO₃(5.33 g, 50.3 mmol, 2 eq), and then the reaction was stirred at 70° C. for 16 hrs. The reaction mixture was concentrated to dryness. EtOAc (200 mL) was added to the residue, and the organic portion washed twice with water (50 mL) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to afford E59 (1 g), which was used without further purification. ¹H NMR (400 MHz, DMSO-d₆) δ 10.11 (s, 1H), 8.86 (s, 1H), 5.03 (br s, 1H), 1.70 (s, 3H), 1.66 (s, 3H).

Step 2: Preparation of ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E60)

To a solution of N′,2-dihydroxy-2-methyl-propanamidine (E59) (520 mg, 4.40 mmol) and pyridine (696 mg, 8.80 mmol, 711 μL, 2 eq) in toluene (15 mL) was added ethyl 2-chloro-2-oxo-acetate (601 mg, 4.40 mmol, 493 μL) at 0° C. The reaction mixture was stirred at rt for 1 hr, and then stirred at 100° C. for 15 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 2/1) and further purified by prep-HPLC (column: Boston Uni C18 40*150*5 um; mobile phase: [water (0.225% FA)-ACN]; B %: 16%-46%, 7.7 min) to give E60 (250 mg, 28% yield). ¹H NMR (400 MHz, CDCl₃) δ 4.52 (q, 2H), 2.65 (br s, 1H), 1.67 (s, 6H), 1.45 (t, 3H); LCMS: m/z 201.1 [M+H]⁺.

Step 3: Preparation of ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E61)

To a solution of ethyl 3-(1-hydroxy-1-methyl-ethyl)-1,2,4-oxadiazole-5-carboxylate (E60) (200 mg, 999 μmol) in THE (5 mL) and H₂O (5 mL) was added LiOH·H₂O (41.9 mg, 999 μmol), and then the reaction mixture was stirred at rt for 1 hr. The solvent was removed in vacuo, and the aqueous portion was lyophilized in vacuo to give E61 (170 mg), which was used without further purification.

Intermediates E62, E63, E64, E65, E66, and E67

embedded image

Step A: Preparation of methyl 6-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E62) and methyl 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63)

To a solution of methyl 6-bromopyrazolo[1,5-a]pyridine-3-carboxylate (1 g, 3.92 mmol) in THE (10 mL) was added i-PrMgCl—LiCl (1.3 M, 6.03 mL, 2 eq) at −78° C. The reaction mixture was stirred at −78° C. for 15 min, then acetone (1.37 g, 23.5 mmol, 1.7 mL, 6 eq) was added dropwise to the reaction mixture. The reaction mixture was stirred at −78° C. for 1 hr. Reaction progress was checked using LCMS. The reaction mixture was dropwise added to 10 mL of aq. NH₄Cl solution. Water (30 mL) was added, and the aqueous portion extracted with EtOAc (25 mL×2). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 20:1) to give E62 (320 mg, 34% yield) and E63 (300 mg, 23% yield).

E62: ¹H NMR (400 MHz, CD₃OD) δ 8.40-8.54 (m, 1H), 8.14 (dd, 1H), 7.57 (dd, 1H), 7.27 (dd, 1H), 3.88-4.03 (m, 3H), 1.77-1.92 (m, 6H); LCMS: m/z 235.2 [M+H]⁺.

E63: ¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1H), 8.02 (d, 1H), 7.76 (d, 1H), 3.93 (s, 3H), 1.95 (s, 6H); LCMS: m/z 313.0 [M+H]⁺.

Step B: Preparation of 6-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E64)

To a solution of methyl 6-(1-hydroxy-1-methyl-ethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E62) (500 mg, 2.13 mmol) in MeOH (3 mL) and H₂O (1 mL) was added LiOH·H₂O (116 mg, 2.77 mmol, 1.3 eq). The reaction mixture was stirred at 40° C. for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to remove MeOH, and water (50 mL) was added. The aqueous portion was extracted with TBME (30 mL), and the aqueous layer was then adjusted to pH ˜6 by the addition of 0.5 M HCl. The resulting suspension was extracted with DCM/MeOH (100/10 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E64 (420 mg, 89% yield). LCMS: m/z 221.1 [M+H]⁺.

Step C: Preparation of 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E65)

To a solution of methyl 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63) (120 mg, 383 μmol) in MeOH (2 mL) and H₂O (1 mL) was added LiOH·H₂O (17.69 mg, 422 μmol, 1.1 eq), the mixture was stirred at 40° C. for 12 hr. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to remove MeOH, and water (10 mL) was added. The aqueous portion was extracted with TBME (30 mL) and was then adjusted to pH ˜6 by the addition of 0.5 M HCl. The resulting suspension was extracted with DCM/MeOH (30/3 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E65 (100 mg, 87% yield). ¹H NMR (400 MHz, CD₃OD) δ 8.44 (s, 1H), 8.07 (d, 1H), 7.74 (d, 1H), 1.96 (s, 6H); LCMS: m/z 301.1 [M+H]⁺.

Step D: Preparation of methyl 7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E66)

To a solution of methyl 6-bromo-7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E63) (450 mg, 1.44 mmol) in MeOH (10 mL) was added Pd/C (100 mg, 10% purity) under N₂. The resulting mixture was degassed under vacuum and purged with H₂3 times, and then the mixture was stirred at rt for 1 hr under H₂(15 psi). Reaction progress was checked using LCMS. The reaction mixture was filtered through a pad of Celite, and the filtrate was concentrated in vacuo to afford E66 (350 mg), which was used without further purification. LCMS: m/z 234.9 [M+H]⁺.

Step E: Preparation of 7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E67)

To a solution of methyl 7-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridine-3-carboxylate (E66) (350 mg, 1.49 mmol) in MeOH (5 mL) and H₂O (1 mL) was added NaOH (89.64 mg, 2.24 mmol, 1.5 eq), the mixture was stirred at 40° C. for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to remove MeOH, and water (10 mL) was added. The aqueous portion was extracted with TBME (30 mL), and then adjusted to pH ˜6 by the addition of 0.5 M HCl. The resulting suspension was extracted with DCM/MeOH (30/3 mL) 3 times. The combined DCM/MeOH organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness to afford E67 (320 mg), which was used without further purification. LCMS: m/z 220.9 [M+H]⁺.

Intermediate E72 According to General Scheme 7, Methods C and D

embedded image

Step A: Preparation of methyl 6-vinylpyrazolo[1,5-a]pyridine-3-carboxylate (E68)

A mixture of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (8.15 g, 52.9 mmol, 8.98 mL), methyl 6-bromopyrazolo[1,5-a]pyridine-3-carboxylate (9 g, 35.3 mmol), K₃PO₄(22.47 g, 106 mmol) and Pd(dppf)Cl₂(1.29 g, 1.76 mmol) in dioxane (80 mL) and H₂O (40 mL) was stirred at 80° C. for 12 hrs under N₂. Reaction progress was checked using LCMS. The reaction mixture was combined with another 1 g batch reaction, and DCM (200 mL) was added. The organic layer was washed with brine (2×80 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 4/1) to give E68 (6.4 g, 80.2% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1H), 8.30 (s, 1H), 8.03 (d, 1H), 7.52 (dd, 1H), 6.61 (dd, 1H), 5.76 (d, 1H), 5.34 (d, 1H), 3.84 (s, 3H); LCMS: m/z 203.1 [M+H]⁺.

Step B: Preparation of methyl 6-formylpyrazolo[1,5-a]pyridine-3-carboxylate (E69)

To a solution of methyl 6-vinylpyrazolo[1,5-a]pyridine-3-carboxylate (E68) (6.4 g, 31.7 mmol) in THF (80 mL) and H₂O (80 mL) was added K₂OsO₄·2H₂O (583 mg, 1.58 mmol) and NaIO₄(16.92 g, 79.1 mmol, 4.38 mL) at 0° C., and then the reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using LCMS. DCM (200 mL) was added to the reaction mixture, and the organic layer was washed with brine (2×80 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, DCM/EtOAc=1/0 to 6/1) to give E69 (5.9 g, 91.3% yield). ¹H NMR (400 MHz, CDCl₃) δ 9.94 (s, 1H), 8.90-8.98 (m, 1H), 8.48 (s, 1H), 8.18 (d, 1H), 7.80 (dd, 1H), 3.88 (s, 3H); LCMS: m/z 204.9 [M+H]⁺.

Step C: Preparation of methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E70)

To a solution of methyl 6-formylpyrazolo[1,5-a]pyridine-3-carboxylate (E69) (2.4 g, 11.8 mmol) in THE (30 mL) and MeOH (30 mL) was added NaBH₄(1.78 g, 47.0 mmol) at 0° C., and then the reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using LCMS. The reaction mixture was quenched by the addition of sat. aq. NH₄Cl (50 mL), and the aqueous portion extracted with EtOAc (100 mL). The organic layer was washed with water (50 mL) and brine (40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness to give E70 (2.3 g, 94.9% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 1H), 8.38 (s, 1H), 8.11 (d, 1H), 7.41 (dd, 1H), 4.78 (s, 2H), 3.93 (s, 3H); LCMS: m/z 207.0 [M+H]⁺.

Step D: Preparation of methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E71)

To a solution of methyl 6-(hydroxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E70) (2.2 g, 10.7 mmol) in THE (50 mL) was added NaH (512 mg, 12.8 mmol, 60% purity) at 0° C. The reaction mixture was stirred at 0° C. for 15 min, and then Mel (1.82 g, 12.8 mmol, 797 μL) was added to the reaction mixture. The reaction mixture was stirred at rt for 1 hr, and reaction progress was checked using LCMS. The reaction mixture was quenched by the addition of sat. aq. NH₄Cl (40 mL), and the aqueous portion extracted with DCM (2×60 mL). The combined organic layer was washed by water (30 mL) and brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 5/1) to give E71 (1.8 g, 76.6% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 8.41 (s, 1H), 8.16 (d, 1H), 7.42 (dd, 1H), 4.53 (s, 2H), 3.94 (s, 3H), 3.46 (s, 3H); LCMS: m/z 221.1 [M+H]⁺.

Step E: Preparation of 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E72)

To a solution of methyl 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylate (E71) (1.8 g, 8.17 mmol) in MeOH (40 mL) and H₂O (40 mL) was added NaOH (719 mg, 18.0 mmol), and the reaction mixture was stirred at 40° C. for 12 hrs. Reaction progress was checked using LCMS. The reaction mixture was concentrated to remove MeOH, and then H₂O (10 mL) was added. The pH of the aqueous mixture was adjusted to ˜6 by the addition of 0.5 M HCl, and the aqueous mixture was filtered. The precipitate was dried in vacuo to give E72 (1.6 g, 94.9% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.57 (s, 1H), 8.45-8.51 (m, 1H), 8.21 (d, 1H), 7.48 (dd, 1H), 4.55 (s, 2H), 3.48 (s, 3H); LCMS: m/z 206.7 [M+H]⁺.

Intermediate E78 According to General Scheme 9, Method A

embedded image

Step A: Preparation of 2,6-difluorobenzohydrazide (E73)

To a solution of methyl 2,6-difluorobenzoate (25 g, 145 mmol) in MeOH (250 mL) was added NH₂NH₂·H₂O (18.18 g, 363 mmol, 17.7 mL), and the reaction mixture was stirred at 60° C. for 12 hrs. Reaction progress was checked using TLC. Additional NH₂NH₂·H₂O (7.27 g, 145 mmol, 7.05 mL) was added, and the reaction mixture was stirred at 60° C. for another 3 hrs. The reaction mixture was concentrated in vacuo to give E73 (25 g), which was used without further purification. ¹H NMR (400 MHz, CDCl₃) δ 7.37 (s, 1H), 6.93 (t, 2H), 3.45-3.89 (m, 2H).

Step B: Preparation of methyl 2-[2-(2,6-difluorobenzoyl)hydrazino]-2-oxo-acetate (E74)

To a solution of 2,6-difluorobenzohydrazide (E73) (25 g, 145 mmol) in THF (250 mL) was added methyl 2-chloro-2-oxo-acetate (19.57 g, 160 mmol, 14.7 mL) at 0° C., and the reaction mixture was stirred at 0° C. for 1 hr. Reaction progress was checked using TLC. The reaction mixture was filtered. The precipitate was washed with MTBE (800 mL), and then dried in vacuo to give E74 (37 g). ¹H NMR (400 MHz, DMSO-d₆) δ 7.59 (ddd, 2H), 7.21 (t, 1H), 3.83 (s, 2H).

Step C: Preparation of methyl 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylate (E75)

To a solution of methyl 2-[2-(2,6-difluorobenzoyl)hydrazino]-2-oxo-acetate (E74) (15 g, 58.1 mmol) in DCM (250 mL) was added Et₃N (23.52 g, 232 mmol, 32.4 mL) and TosCl (14.40 g, 75.5 mmol) in portions at 0° C. The reaction mixture was allowed to warm to rt and stirred at rt for 12 hrs. Reaction progress was checked using TLC. DCM (100 mL) was added to the reaction mixture, and the organic layer was washed with sat. aq. NaHCO₃(100 mL) and water (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 1/1) to give E75 (4.3 g, 30.8% yield). ¹H NMR (400 MHz, CDCl₃) δ 7.61 (tt, 1H), 7.14 (t, 2H), 4.10 (s, 3H).

Step D: Preparation of 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylic acid (E76)

To a solution of methyl 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylate (E75) (300 mg, 1.25 mmol) in H₂O (2 mL) and THF (4 mL) was added LiOH·H₂O (52.4 mg, 1.25 mmol). The reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using LCMS. The reaction mixture was concentrated in vacuo to give E76 (300 mg), which was used without further purification. LCMS: m/z 226.8 [M+H]⁺

Step E: Preparation of 2-(2,6-difluorophenyl)-1,3,4-oxadiazole (E77)

To a solution of 5-(2,6-difluorophenyl)-1,3,4-oxadiazole-2-carboxylic acid (E76) (4 g, 17.7 mmol) in H₂O (20 mL) was added HCl (1 M, 35.4 mL), and the reaction mixture was stirred at rt for 1 hr. Reaction progress was checked using LCMS and TLC. DCM (60 mL) was added to the reaction mixture, and the organic layer washed by water (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 1/1) to give E77 (1.5 g, 46.6% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.63 (s, 1H), 7.57 (tt, 1H), 7.12 (t, 2H); LCMS: m/z 182.8 [M+H]⁺.

Step F: Preparation of 2-bromo-5-(2,6-difluorophenyl)-1,3,4-oxadiazole (E78)

To a solution of 2-(2,6-difluorophenyl)-1,3,4-oxadiazole (E77) (1.5 g, 8.24 mmol) in THE (50 mL) was added LiHMDS (1 M, 16.5 mL) dropwise at −78° C. The reaction mixture was stirred at −78° C. for 30 min, then Br₂(2.63 g, 16.5 mmol, 849 μL) was added to the reaction mixture at −78° C. dropwise. The reaction mixture was stirred at −78° C. for 2 hrs. Reaction progress was checked using TLC. Sat. aq. NH₄Cl (100 mL) was added to the reaction mixture, and the aqueous portion extracted with DCM (3×50 mL). The combined organic layer was washed with brine (40 mL), dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by column chromatography (SiO₂, PE/EtOAc=1/0 to 3/1) to give E78 (1.6 g, 54.2% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 7.79 (tt, 1H), 7.41 (t, 2H); LCMS: m/z 341.2 [M+H]⁺.

Preparation of Examples 640 and 641 According to General Scheme 1, Method C

embedded image

Step 1: Preparation of 4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

A mixture of pyrazolo[1,5-a]pyridine-2-carbaldehyde (C3) (9.2 g, 63.0 mmol), 2-(1H-imidazol-5-yl)ethanamine (15.06 g, 81.8 mmol, 1.3 eq, 2HCl salt) and K₂CO₃(17.40 g, 126 mmol, 2 eq) in EtOH (300 mL) was stirred at 80° C. for 16 hrs under N₂. Reaction progress was checked using LCMS. The reaction mixture was combined with another reaction mixture performed using 5 g of C3 and filtered, and the filtrate was concentrated to dryness. The residue was purified by column chromatography on silica gel (DCM:MeOH=20:1 to 10:1) to give 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (11.4 g). ¹H NMR (400 MHz, CD₃OD) δ 8.48 (d, 1H), 7.54-7.62 (m, 2H), 7.09-7.29 (m, 1H), 6.82-6.90 (m, 1H), 6.44 (s, 1H), 5.28 (s, 1H), 3.28 (dt, 1H), 3.04-3.12 (m, 1H), 2.73-2.80 (m, 2H); LC-MS: m/z 240.2 (M+H)⁺.

Step 2: Preparation of 5-(4-pyrazolo[1,5-a]pyridin-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile

To a solution of 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (4 g, 16.7 mmol) and (4-cyanooxazole-5-carbonyl)oxylithium (E35) (3.37 g, 23.4 mmol, 1.4 eq) in DMF (90 mL) was added HATU (7.63 g, 20.1 mmol, 1.2 eq) and pyridine (3.97 g, 50.2 mmol, 4.1 mL, 3 eq). The reaction mixture was stirred at rt for 2 hrs. Reaction progress was checked using LCMS, and the reaction mixture was stirred at rt for another 12 hrs. Reaction progress was checked using TLC (DCM:MeOH=10:1). DCM (300 mL) was added, and the organic portion was washed with sat. NaHCO₃solution (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0˜8.5% MeOH/DCM @ 35 mL/min) to give 5-(4-pyrazolo[1,5-a]pyridin-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile (2.6 g). ¹H NMR (400 MHz, CD₃OD) δ 8.51 (s, 1H), 8.46 (d, 1H), 7.69 (s, 1H), 7.57-7.65 (m, 1H), 7.17-7.23 (m, 1H), 6.83-6.91 (m, 2H), 6.59-6.72 (m, 1H), 4.40 (br d, 1H), 3.77 (br d, 1H), 3.19 (s, 1H), 2.85 (br s, 1H); LC-MS: m/z 360.2 (M+H)⁺.

Step 3: SFC Separation

5-(4-pyrazolo[1,5-a]pyridin-2-yl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile (2.6 g) was separated by SFC (column: DAICEL CHIRALPAK AD (250 mm*50 mm, 10 um); mobile phase: [Neu-ETOH]; B %: 45%-45%, min) to afford Enantiomer 1 (650 mg, Rt=1.884 min) and Enantiomer 2 (450 mg, Rt=2.124 min).

Enantiomer 1 (Example 640): (S)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile. ¹H NMR (400 MHz, CD₃OD) δ 8.52 (s, 1H), 8.46 (dd, 1H), 7.71 (s, 1H), 7.62 (br d, 1H), 7.17-7.26 (m, 1H), 6.85-6.92 (m, 1.7H), 6.48-6.69 (m, 1.3H), 4.77-4.87 (m, 0.4H), 4.40 (br d, 0.6H), 3.79 (br s, 1H), 3.10-3.19 (m, 1H), 2.79-2.91 (m, 1H); LC-MS: m/z 360.1 (M+H)⁺; SFC: 94.1% ee.

Enantiomer 2 (Example 641): (R)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-5-carbonyl)oxazole-4-carbonitrile. ¹H NMR (400 MHz, CD₃OD) δ 8.51 (s, 1H), 8.46 (dd, 1H), 7.71 (s, 1H), 7.62 (br d, 1H), 7.13-7.26 (m, 1H), 6.84-6.94 (m, 1.7H), 6.49-6.70 (m, 1.3H), 4.77-4.87 (m, 0.4H), 4.40 (br d, 0.6H), 3.71-3.91 (m, 1H), 3.08-3.19 (m, 1H), 2.79-2.89 (m, 1H); LC-MS: m/z 360.2 (M+H)⁺; SFC: 96.7% ee.

Preparation of Examples 836 and 837 According to General Scheme 1, Method C

embedded image

Step 1: Preparation of (5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone

To a solution of 4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (150 mg, 488 μmol) and 5-(1-methylpyrazol-3-yl)-1,3,4-oxadiazole-2-carboxylic acid (prepared in accordance with General Scheme 9, Method A, starting with methyl 1-methyl-1H-pyrazole-3-carboxylate) (142 mg, 732 μmol) in DMSO (3 mL) was added pyridine (116 mg, 1.46 mmol, 118 μL) and HATU (241 mg, 635 μmol) at rt. The reaction mixture was stirred at rt for 16 hrs. Reaction progress was checked using LCMS. The reaction mixture was submitted to prep-HPLC (column: Welch Xtimate C18 150*30 mm*5 um; mobile phase: [water (0.05% NH₃H₂O+10 mM NH₄HCO₃)-ACN]; B %: 27%-57%, 9 min) to give (5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone. (100 mg, 42.4% yield). LCMS: m/z 484.1 [M+H]⁺.

Step 2: SFC Separation

Compound (5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (100 mg, 207 μmol) was separated by SFC (column: Phenomenex-Cellulose-2 (250 mm*50 mm, 10 um); mobile phase: [0.1% NH₃H₂O EtOH]; B %: 50%-50%, min) to afford Enantiomer 1 (46.1 mg, 46.1% yield, Rt=5.268 min) and Enantiomer 2 (46.2 mg, 45.6% yield, Rt=10.218 min).

Enantiomer 1 (Example 836): (S)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.59-8.76 (m, 1H), 7.81 (d, 1H), 7.74 (s, 1H), 7.53-7.66 (m, 1H), 6.86-7.12 (m, 3H), 6.76-6.84 (m, 1H), 5.08 (br dd, 1H), 4.03 (s, 3H), 3.72-3.84 (m, 0.6H), 3.41 (td, 0.4H), 3.13-3.27 (m, 0.6H), 2.95-3.09 (m, 0.4H), 2.77-2.94 (m, 1H); LCMS: m/z 484.2 [M+H]⁺; SFC: 100% ee.

Enantiomer 2 (Example 837): (R)-(5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazol-2-yl)(4-(4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.42-8.69 (m, 1H), 7.60-7.79 (m, 2H), 7.41-7.57 (m, 1H), 6.80-6.97 (m, 3H), 6.60-6.75 (m, 1H), 4.96 (br dd, 1H), 3.92 (s, 3H), 3.60-3.73 (m, 0.5H), 3.24-3.37 (m, 0.5H), 3.03-3.17 (m, 0.5H), 2.84-3.00 (m, 0.5H), 2.68-2.80 (m, 1H); LCMS: m/z 484.2 [M+H]⁺; SFC: 98.7% ee.

Preparation of Examples 1628 and 1629 According to General Scheme 1, Method C

embedded image

Step 1: Preparation of (4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone

To a solution of 6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carboxylic acid (E72) (144 mg, 700 μmol) and 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (150 mg, 583 μmol) in DMF (3 mL) was added HATU (333 mg, 875 μmol) and Py (185 mg, 2.33 mmol, 188.2 μL), and the reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using LCMS. DCM (30 mL) was added to the reaction mixture, and the organic layer washed with sat. aq. Na₂CO₃solution (10 mL) and brine (10 mL), dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by prep-HPLC (column: Boston Prime C18 150*30 mm*5 um; mobile phase: [water(NH₃H₂O+NH₄HCO₃)-ACN]; B %: 25%-55%, 7 min) to give (4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone (108 mg, 41.6% yield). LCMS: m/z 446.2 [M+H]⁺.

Step 2: SFC Separation

The compound (4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone (100 mg, 224 μmol) was separated by SFC (column: Phenomenex-Cellulose-2 (250 mm*30 mm, 10 um); mobile phase: [0.10% NH₃H₂O EtOH]; B %: 55%%, isocratic elution mode) to give Enantiomer 1 (20.1 mg, 19.5% yield, Rt=1.879 min) and Enantiomer 2 (23.3 mg, 22.7% yield, Rt=4.054 min).

Enantiomer 1 (Example 1628): (S)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.32-8.78 (m, 3H), 7.97 (d, 1H), 7.68 (s, 1H), 7.45 (d, 1H), 6.54-7.10 (m, 4H), 4.62-4.75 (m, 1H), 4.55 (s, 2H), 3.40-3.60 (m, 4H), 3.02-3.17 (m, 1H), 2.79 (br dd, 1H); LCMS: m/z 446.1 [M+H]⁺; SFC: 100%.

Enantiomer 2 (Example 1629): (R)-(4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)(6-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl)methanone. ¹H NMR (400 MHz, CD₃OD) δ 8.31-8.88 (m, 3H), 7.97 (d, 1H), 7.68 (s, 1H), 7.45 (dd, 1H), 6.55-7.06 (m, 4H), 4.62-4.73 (m, 1H), 4.55 (s, 2H), 3.40-3.76 (m, 4H), 2.99-3.17 (m, 1H), 2.79 (br dd, 1H); LCMS: m/z 446.2 [M+H]⁺; SFC: 99.8%.

Preparation of Examples 1756 and 1757 According to General Scheme 1, Method A2

embedded image

Step 1: Preparation of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone

To a solution of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo [4,5-c]pyridine (7.3 g, 28.4 mmol) and Et₃N (11.49 g, 114 mmol, 15.8 mL) in DCM (150 mL) was added TFAA (15.50 g, 73.8 mmol, 10.3 mL) dropwise at 0° C. After the addition was complete, the reaction mixture was stirred at rt for 3 hrs. Reaction progress was checked using TLC. DCM (150 mL) was added to the reaction mixture, and the organic layer was washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄, filtered and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0-15% MeOH/DCM @ 60 mL/min) to give compound 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone (10 g, 94.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.55-8.68 (m, 1H), 7.60-7.76 (m, 1H), 7.15 (dd, 1H), 6.90 (td, 1H), 6.66-6.73 (m, 1H), 6.63 (s, 1H), 4.10 (br s, 1H), 3.67-3.80 (m, 1H), 2.70-2.88 (m, 2H); LCMS: m/z 354.2 [M+H]⁺.

Step 2: Preparation of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridin-5-yl]ethanone

To a solution of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-yl]ethanone (10 g, 28.3 mmol) and DHP (7.14 g, 84.9 mmol, 7.76 mL) in toluene (140 mL) was added TsOH (487 mg, 2.83 mmol), and the reaction mixture was stirred at 120° C. for 12 hrs. Reaction progress was checked using LCMS and TLC. EtOAc (150 ml) was added, and the organic layer washed with brine (40 ml×2), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0-10% MeOH/DCM gradient @ 60 mL/min) to give compound 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a] pyridin-2-yl)-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridin-5-yl]ethanone (8.9 g, 64.8% yield). ¹HNMR (400 MHz, DMSO-d₆) δ 8.54-8.66 (m, 1H), 7.73-7.90 (m, 1H), 7.11-7.20 (m, 1H), 6.67-6.93 (m, 2H), 6.12-6.61 (m, 1H), 5.14-5.37 (m, 1H), 3.92-4.16 (m, 2H), 3.60-3.84 (m, 2H), 2.80-2.97 (m, 2H), 1.87-2.06 (m, 3H), 1.49-1.70 (m, 3H); LCMS: m/z 438.3 [M+H]⁺.

Step 3: Preparation of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine

A mixture of 2,2,2-trifluoro-1-[4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridin-5-yl]ethanone (8.8 g, 20.1 mmol) and K₂CO₃(12.51 g, 90.5 mmol) in MeOH (100 mL) was degassed and purged with N₂for 3 times, and then the reaction mixture was stirred at rt for 12 hrs under N₂atmosphere. Reaction progress was checked using LCMS and TLC. DCM (150 mL) was added to the reaction mixture, and the organic layer washed with H₂O (2×40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0-10% MeOH:DCM @ 60 mL/min) to give compound 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine (5.8 g, 79.4% yield). ¹H NMR (400 MHz, DMSO-d₆) δ 8.52 (d, 1H), 7.62 (d, 1H), 7.02-7.10 (m, 1H), 6.77-6.85 (m, 1H), 6.49 (d, 1H), 5.15-5.24 (m, 1H), 5.06 (d, 1H), 3.95-4.11 (m, 2H), 3.56-3.69 (m, 1H), 2.94 (br dd, 1H), 2.57-2.70 (m, 2H), 1.89-2.06 (m, 3H), 1.46-1.70 (m, 3H); LCMS: m/z 342.2 [M+H]⁺.

Step 4: Preparation of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-pyrazin-2-yl-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridine

A mixture of 2-bromopyrazine (1.40 g, 8.79 mmol), 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-1-tetrahydropyran-2-yl-4,5,6,7-tetrahydroimidazo[4,5-c]pyridine (1.5 g, 4.39 mmol), CPhos-Pd-G3 (177.15 mg, 220 μmol), Cs₂CO₃(4.29 g, 13.2 mmol) in tert-amyl alcohol (20 mL) was degassed and purged with N₂for 3 times, and then the reaction mixture was stirred at 100° C. for 12 hrs under N₂atmosphere. Reaction progress was checked using LCMS. DCM (100 mL) was added to the reaction mixture, and the organic layer washed with water (40 mL) and brine (40 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column, Eluent of 0˜10% MeOH:DCM @ 30 mL/min) to give 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-pyrazin-2-yl-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridine (1 g, 50.3% yield). LCMS: m/z 420.2 [M+H]⁺.

Step 5: Preparation of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine

To a solution of 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-pyrazin-2-yl-1-tetrahydropyran-2-yl-6,7-dihydro-4H-imidazo[4,5-c]pyridine (1 g, 2.38 mmol) in MeOH (15 mL) was added HCl (4 M, 20.0 mL) at rt. The reaction mixture was stirred at 70° C. for 12 hrs. Reaction progress was checked using LCMS. DCM (100 mL) was added, and the organic layer washed with sat. aq. Na₂CO₃(50 mL×2) and brine (50 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column, Eluent of 0˜10% MeOH:DCM @ 30 mL/min) to give 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (500 mg, 58.3% yield). LCMS: m/z 336.2 [M+H]⁺.

Step 6: SFC Separation

The compound 4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (1.2 g, 3.58 mmol) was separated by SFC (column: DAICEL CHIRALPAK AD(250 mm*30 mm, 10 um); mobile phase: [CO₂-EtOH (0.1% NH₃H₂O)]; B %; 40%%, isocratic elution mode) to give Enantiomer 1 (370 mg, 28.8% yield, Rt=0.530 min) and Enantiomer 2 (433 mg, 33.4% yield, Rt=0.931 min).

Enantiomer 1 (Example 1756): (R)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. ¹H NMR (400 MHz, CD₃OD) δ 8.46 (s, 1H), 8.34 (d, 1H), 8.16 (s, 1H), 7.80 (d, 1H), 7.65 (s, 1H), 6.88-7.00 (m, 1H), 6.77-6.87 (m, 2H), 6.66 (s, 1H), 4.71 (br dd, 1H), 3.56-3.67 (m, 1H), 2.92-3.05 (m, 1H), 2.76 (dd, 1H); LCMS: m/z 336.1 [M+H]⁺; SFC: 100% ee.

Enantiomer 2 (Example 1757): (S)-4-(4-fluoropyrazolo[1,5-a]pyridin-2-yl)-5-(pyrazin-2-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine. ¹H NMR (400 MHz, CD₃OD) δ 8.46 (d, 1H), 8.30-8.37 (m, 1H), 8.13-8.19 (m, 1H), 7.80 (d, 1H), 7.65 (s, 1H), 6.94 (dd, 1H), 6.77-6.87 (m, 2H), 6.65 (s, 1H), 4.71 (dd, 1H), 3.61 (ddd, 1H), 2.92-3.03 (m, 1H), 2.76 (dd, 1H); LCMS: m/z 336.2 [M+H]⁺; SFC: 99.7% ee.

Preparation of Examples 1842 and 1843 According to General Scheme 1, Method A1

embedded image

Step 1: Preparation of 2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole

To a solution of 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine (200 mg, 836 μmol) in DMF (2 mL) was added DIPEA (432 mg, 3.34 mmol, 582 μL) and 2-bromo-5-(2,6-difluorophenyl)-1,3,4-oxadiazole (E78) (262 mg, 1.00 mmol), and the reaction mixture was stirred at rt for 12 hrs. Reaction progress was checked using TLC. DCM (20 mL) was added to the reaction mixture, and the organic layer was washed by water (20 mL), dried over Na₂SO₄, filtered, and concentrated to dryness. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150*30 mm*5 um; mobile phase: [water(NH₃H₂O+NH₄HCO₃)-ACN]; B %: 30%-60%, 7 min) to afford 2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole (150 mg, 40.8% yield). LCMS: m/z 420.1 [M+H]⁺.

Step 2: SFC Separation

The compound 2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)-1,3,4-oxadiazole (100 mg, 238 μmol) was separated by SFC (column: DAICEL CHIRALPAK AD(250 mm*30 mm, 10 um); mobile phase: [0.10% NH₃H₂O EtOH]; B %: 45%-45%, 45 min) to give Enantiomer 1 (46.8 mg, 46.6% yield, Rt=1.780 min) and Enantiomer 2 (47.0 mg, 46.8% yield, Rt=1.990 min).

Enantiomer 1 (Example 1842): (R)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5 (4H)-yl)-1,3,4-oxadiazole. ¹H NMR (400 MHz, CD₃OD) δ 8.45 (d, 1H), 7.49-7.76 (m, 3H), 7.09-7.30 (m, 3H), 6.86 (td, 1H), 6.60 (s, 1H), 6.41 (s, 1H), 4.35 (dd, 1H), 3.73-3.88 (i, 1H), 2.99-3.17 (m, 1H), 2.84 (dd, 1H); LCMS: m/z 420.2 [M+H])⁺; SFC: 99.30 ee.

Enantiomer 2 (Example 1843): (S)-2-(2,6-difluorophenyl)-5-(4-(pyrazolo[1,5-a]pyridin-2-yl)-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5 (4H)-yl)-1,3,4-oxadiazole. ¹H NMR (400 MHz, CD₃OD) δ 8.45 (d, 1H), 7.49-7.79 (m, 3H), 7.12-7.30 (m, 3H), 6.86 (td, 1H), 6.61 (s, 1H), 6.41 (s, 1H), 4.36 (dd, 1H), 3.68-3.90 (m, 1H), 3.00-3.17 (m, 1H), 2.85 (dd, 1H); LCMS: m/z 420.1 [M+H]⁺; SFC: 99.2% ee.

The compounds of Table 1 were characterized using proton NMR and LCMS and the enantiomeric excess determined. See Table 2.

TABLE 2

Ex.

LCMS:

#

¹H NMR (400 MHz unless otherwise noted)
m/z
% ee

600
(CD₃OD) δ 8.22-8.79 (m, 3 H), 7.98 (d, 1 H), 7.67 (s, 1 H), 7.60
384.2
100%

(d, 1 H), 7.39-7.49 (m, 1 H), 7.15-7.24 (m, 1 H), 7.02-7.13 (m, 1
[M + H]⁺

H), 6.87 (br s, 1 H), 6.56 (br s, 1 H), 4.64 (br s, 1 H), 3.38-3.77

(m, 1 H), 2.97-3.18 (m, 1 H), 2.97-3.18 (m, 1 H), 2.70-2.87 (m, 1 H)

601
(CD₃OD) δ 8.33-8.97 (m, 3 H), 7.98 (d, 1 H), 7.68 (br s, 1 H),
384.2
99.4%

7.60 (d, 1 H), 7.44 (t, 1 H), 7.21 (t, 1 H), 7.07 (t, 1 H), 6.87 (brs,
[M + H]⁺

1 H), 6.56 (br s, 1 H), 4.65 (br s, 1 H), 3.38-3.83 (m, 1 H), 3.02-

3.16 (m, 1 H), 2.70-2.85 (m, 1 H)

602
(CD₃OD) δ 9.18 (s, 1 H), 8.19-8.81 (m, 2 H), 7.69 (s, 1 H), 7.61
351.1
100%

(d, 1 H), 7.22 (br t, 1 H), 6.89 (t, 1.5 H), 6.30-6.69 (m, 1.5 H),
[M + H]⁺

4.06-4.85 (m, 1 H), 3.77 (br s, 1 H), 2.95-3.10 (m, 1 H), 2.78 (d,

1 H)

603
(CD₃OD) δ 9.18 (s, 1 H), 8.16-8.80 (m, 2 H), 7.69 (s, 1 H), 7.61
351.1
100%

(d, 1 H), 7.22 (t, 1 H), 6.80-6.95(m, 1.5 H), 6.25-6.72 (m, 1.5H),
[M + H]⁺

4.14-4.84 (m, 1 H), 3.52-3.89 (m, 1 H), 3.52-3.53 (m, 1 H), 2.95-

3.15 (m, 1 H), 2.70-2.85 m, 1 H)

604
(CD₃OD) δ 8.70-8.85 (m, 1 H), 8.38-8.53 (m, 2 H), 8.31 (dd, 1
413.0
99.5%

H), 8.09 (td, 1 H), 7.52-7.74 (m, 2.3 H), 7.17-7.32 (m, 1 H), 7.10
[M + H]⁺

(s, 0.7 H), 6.83-6.96 (m, 1 H), 6.67-6.80 (m, 1 H), 5.12 (dd, 1

H), 3.69-3.86 (m, 0.7 H), 3.41-3.49 (m, 0.3 H), 3.19-3.28 (m, 0.4

H), 3.01-3.18 (m, 0.6 H), 2.91-2.99 (m, 1 H)

605
(CD₃OD) δ 8.72-8.81 (m, 1 H), 8.34-8.51 (m, 1 H), 8.25-8.33
413.0
100%

(m, 1 H), 8.07 (td, 1 H), 7.45-7.76 (m, 3.4 H), 7.12-7.26 (m, 1
[M + H]⁺

H), 6.97 (s, 0.6 H), 6.78-6.90 (m, 1 H), 6.52-6.74 (m, 1 H), 4.99

(br dd, 1 H), 3.72-3.88 (m, 0.7 H), 3.42 (td, 0.3 H), 3.14-3.23 (m,

0.5 H), 2.92-3.07 (m, 0.5 H), 2.79-2.89 (m, 1 H)

606
(CD₃OD) δ 8.44 (d, 1 H), 8.25 (s, 1 H), 7.51-7.72 (m, 2 H), 7.10-
349.0
100%

7.24 (m, 1 H), 6.84 (t, 1.6 H), 6.61 (br s, 1.4 H), 4.30 (br s, 1 H),
[M + H]⁺

3.53-3.86 (m, 1 H), 2.93-3.11 (m, 1 H), 2.78 (br d, 1 H), 2.38 (s,

3 H)

607
(CD₃OD) δ 8.44 (d, 1 H), 8.25 (s, 1 H), 7.51-7.73 (m, 2 H), 7.10-
349.0
99.8%

7.30 (m, 1 H), 6.73-6.95 (m, 1.7 H), 6.60 (br s, 1.3 H), 4.31 (br s,
[M + H]⁺

1 H), 3.51-3.81 (m, 1 H), 2.95-3.17 (m, 1 H), 2.69-2.89 (m, 1 H),

2.38 (s, 3 H)

608
(CD₃OD) δ 8.39-8.56 (m, 1 H), 8.10-8.17 (m, 1 H), 7.67 (br d, 1
433.1
100%

H), 7.58 (d, 1 H), 7.18-7.23 (m, 1 H), 6.84-6.93 (m, 1.6 H), 6.44-
[M + H]⁺

6.62 (m, 1.4 H), 4.77-4.89 (m, 1.4 H), 4.67-4.76 (m, 0.4 H),

4.39-4.47 (m, 0.6 H), 4.30 (dd, 0.6 H), 3.62-3.74 (m, 0.6 H),

3.19 (td, 0.4 H), 2.82-3.01 (m, 1 H), 2.67-2.81 (m, 1 H)

609
(CD₃OD) δ 8.40-8.55 (m, 1 H), 8.09-8.17 (m, 1 H), 7.65-7.69
433.1
99.8%

(m, 1 H), 7.58 (d, 1 H), 7.17-7.23 (m, 1 H), 6.83-6.93 (m, 1.6H),
[M + H]⁺

6.44-6.59 (m, 1.4 H), 4.81-4.89 (m, 1.5 H), 4.68-4.77 (m, 0.4 H),

4.40-4.46 (m, 0.5 H), 4.30 (dd, 0.6 H), 3.69 (ddd, 0.6 H), 3.19

(td, 0.4 H), 2.81-3.01 (m, 1 H), 2.68-2.81 (m, 1 H)

610
(CD₃OD) δ 8.34-8.55 (m, 2 H), 7.49-7.74 (m, 2 H), 7.13-7.24
403.1
99.0%

(m, 1 H), 6.79-6.94 (m, 2 H), 6.59 (s, 0.6 H), 6.38 (s, 0.2 H),
[M + H]⁺

5.98 (br s, 0.2 H), 4.82 (br d, 0.3 H), 3.65-3.85 (m, 1.5 H), 3.39-

3.49 (m, 0.2 H), 2.70-3.02 (m, 2 H)

611
(CD₃OD) δ 8.35-8.54 (m, 2 H), 7.45-7.75 (m, 2 H), 7.12-7.28
403.1
97.5%

(m, 1 H), 6.79-6.96 (m, 2 H), 6.60 (s, 0.6 H), 6.39 (s, 0.2 H),
[M + H]⁺

5.99 (br s, 0.2 H), 4.83 (br d, 0.3 H), 3.66-3.87 (m, 1.4 H), 3.45

(td, 0.3 H), 2.70-3.04 (m, 2 H)

612
(CD₃OD) δ 8.42-8.66 (m, 1.5 H), 8.18 (br s, 0.5 H), 7.65 (s, 1
415.0
99.2%

H), 7.57 (br d, 1 H), 7.13-7.23 (m, 1 H), 6.85 (br s, 1 H), 6.28-
[M + H]⁺

6.66 (m, 2 H), 4.23 (br s, 1 H), 3.76 (br s, 1 H), 3.01 (br s, 1 H),

2.75 (br d, 1 H), 2.10 (t, 3 H)

613
(CD₃OD) δ 8.39-8.68 (m, 1.6 H), 8.18 (br s, 0.4 H), 7.65 (s, 1
415.0
99.3%

H), 7.57 (br d, 1 H), 7.12-7.23 (m, 1 H), 6.86 (br s, 1 H), 6.22-
[M + H]⁺

6.65 (m, 2 H), 4.22 (br s, 1 H), 3.76 (br s, 1 H), 3.01 (br s, 1 H),

2.75 (br d, 1 H), 2.10 (t, 3 H)

614
(CD₃OD) δ 8.40-8.52 (m, 1 H), 7.54-7.68 (m, 2 H), 7.16-7.24
322.1
99.9%

(m, 1 H), 6.81-6.95 (m, 1.6 H), 6.55 (s, 0.6 H), 6.42(s, 0.4H),
[M + H]⁺

6.26 (s, 0.4 H), 4.82-4.88 (m, 0.6 H), 4.16 (dd, 0.4 H), 3.56-3.68

(m, 0.6 H), 3.14 (td, 0.4 H), 2.41-2.99 (m, 4 H), 1.03-1.13 (m, 1

H), 0.48-0.62 (m, 2 H), 0.16-0.29 (m, 2 H)

615
(CD₃OD) δ 8.40-8.53 (m, 1 H), 7.53-7.69 (m, 2 H), 7.14-7.24
322.2
99.9%

(m, 1 H), 6.80-6.95 (m, 1.6 H), 6.55 (s, 0.6 H), 6.42 (s, 0.4 H),
[M + H]⁺

6.26 (s, 0.4 H), 4.81-4.87 (m, 0.4 H), 4.16 (dd, 1 H), 3.56-3.67

(m, 0.6 H), 3.08-3.20 (m, 0.4 H), 2.42-2.97 (m, 4 H), 1.03-1.15

(m, 1 H), 0.48-0.62 (m, 2 H), 0.17-0.29 (m, 2 H)

616
(CD₃OD) δ 8.57-8.68 (m, 1 H), 8.33-8.48 (m, 1 H), 7.91 (t, 1 H),
431.1
100%

7.70-7.78 (m, 1 H), 7.68 (s, 1 H), 7.53-7.61 (m, 1 H), 7.46 (s, 0.3
[M + H]⁺

H), 7.09-7.26 (m, 1 H), 6.95 (s, 0.7 H), 6.75-6.88 (m, 1 H), 6.53-

6.68 (m, 1 H), 4.95 (br d, 1 H), 3.72-3.86 (m, 0.8 H), 3.37-3.46

(m, 0.2 H), 2.94-3.26 (m, 1 H), 2.83 (br d, 1 H)

617
(CD₃OD) δ 8.53-8.80 (m, 1 H), 8.31-8.50 (m, 1 H), 7.85-7.98
431.1
100%

(m, 1 H), 7.70-7.77 (m, 1 H), 7.68 (s, 1 H), 7.52-7.62 (m, 1 H),
[M + H]⁺

7.46 (s, 0.3 H), 7.10-7.23 (m, 1 H), 6.95 (s, 0.7 H), 6.75-6.88 (m,

1 H), 6.56-6.69 (m, 1 H), 4.95 (br d, 1 H), 3.72-3.84 (m, 0.7 H),

3.35-3.47 (m, 0.5 H), 2.93-3.21 (m, 1 H), 2.74-2.90 (m, 1 H)

618
(CD₃OD) δ 8.41 (d, 1 H), 8.11 (s, 1 H), 7.51-7.66 (m, 2 H), 7.11-
375.0
99.8%

7.20 (m, 1 H), 6.82 (td, 2 H), 6.56 (br s, 1 H), 4.34 (br s, 1 H),
[M + H]⁺

3.51-3.86 (m, 1 H), 2.92-3.12 (m, 1 H), 2.76 (br dd, 1 H), 2.19-

2.42 (m, 1 H), 0.84-1.03 (m, 4 H)

619
(CD₃OD) δ 8.42 (d, 1 H), 8.11 (s, 1 H), 7.51-7.67 (m, 2 H), 7.11-
375.0
99.7%

7.21 (m, 1 H), 6.77-6.85 (m, 2 H), 6.56 (br s, 1 H), 4.32 (br s, 1
[M + H]⁺

H), 3.68 (br s, 1 H), 3.01 (br s, 1 H), 2.76 (br dd, 1 H), 2.32 (br s,

1 H), 0.84-1.00 (m, 4 H)

620
(CD₃OD) δ 8.42-8.48 (m, 1 H), 7.70 (s, 1 H), 7.57-7.63 (m, 1 H),
376.0
100%

7.18-7.24 (m, 1 H), 6.83-6.95 (m, 2 H), 6.53-6.64 (m, 1 H), 4.99
[M + H]⁺

(br dd, 1 H), 3.69-3.79 (m, 0.7 H), 3.35-3.44 (m, 0.3 H), 3.07-

3.20 (m, 0.7 H), 2.91-3.04 (m, 0.3 H), 2.77-2.87 (m, 1 H), 2.26-

2.39 (m, 1 H), 1.19-1.33 (m, 4H)

621
(CD₃OD) δ 8.41-8.48 (m, 1 H), 7.69 (s, 1 H), 7.57-7.64 (m, 1 H),
376.0
99.9%

7.18-7.24 (m, 1 H), 6.80-6.97 (m, 2 H), 6.53-6.65 (m, 1 H), 4.99
[M + H]⁺

(br dd, 1 H), 3.74 (ddd, 0.7 H), 3.36-3.44 (m, 0.3 H), 3.07-3.20

(m, 0.7 H), 2.90-3.03 (m, 0.3 H), 2.75-2.88 (m, 1 H), 2.26-2.39

(m, 1 H), 1.17-1.32 (m, 4H)

622
(CD₃OD) δ 8.65 (br d, 1 H), 8.43 (br d, 1 H), 7.89-8.18 (m, 2 H),
452.2
99.7%

7.65 (br s, 1 H), 7.58 (br d, 1 H), 7.48-7.54 (m, 1 H), 7.13-7.22
[M + H]⁺

(m, 1 H), 6.61-6.92 (m, 3 H), 4.49 (br s, 1 H), 3.76 (br s, 1 H),

3.18 (br s, 1 H), 2.80 (br d, 1 H), 2.40 (br s, 1 H), 0.87-1.14 (m,

4 H)

623
(CD₃OD) δ 8.65 (br d, 1 H), 8.43 (br d, 1 H), 7.85-8.16 (m, 2 H),
452.2
99.6%

7.65 (s, 1 H), 7.57 (br d, 1 H), 7.47-7.54 (m, 1 H), 7.14-7.20 (m,
[M + H]⁺

1 H), 6.58-6.93 (m, 3 H), 4.42-4.63 (m, 1 H), 3.76 (br s, 1 H),

3.18 (br s, 1 H), 2.80 (br d, 1 H), 2.40 (br s, 1 H), 0.89-1.14 (m,

4 H)

624
(CD₃OD) δ 8.42 (d, 1 H), 7.52-7.66 (m, 2 H), 7.13-7.21 (m, 1
433.2
100%

H), 6.82 (t, 2 H), 6.59 (s, 1 H), 4.35 (br s, 1 H), 3.69 (br s, 1 H),
[M + H]⁺

3.09 (br d, 1 H), 2.76 (br d, 1 H), 2.33 (br s, 1 H), 1.55 (br s, 6

H), 0.80-1.05 (m, 4 H)

625
(CD₃OD) δ 8.42 (d, 1 H), 7.52-7.66 (m, 2 H), 7.13-7.20 (m, 1
433.1
99.5%

H), 6.82 (t, 2 H), 6.59 (s, 1 H), 4.34 (br s, 1 H), 3.66 (br s, 1 H),
[M + H]⁺

2.90-3.17 (m, 1 H), 2.76 (br d, 1 H), 2.33 (br s, 1 H), 1.55 (br s,

6 H), 0.79-1.04 (m, 4 H)

626
(CD₃OD) δ 8.36-8.48 (m, 2 H), 8.10 (s, 1 H), 7.68 (s, 1 H), 7.53-
416.2
100%

7.63 (m, 1 H), 7.14-7.23 (m, 1 H), 6.94 (br s, 1 H), 6.81-6.89 (m,
[M + H]⁺

1 H), 6.52-6.65 (m, 1 H), 4.96-5.10 (m, 0.7 H), 4.68-4.79 (m, 0.4

H), 4.00 (s, 3 H), 3.71-3.81 (m, 0.7 H), 3.36-3.51 (m, 0.4H),

2.95-3.23 (m, 1 H), 2.83 (br d, 1 H)

627
(CD₃OD) δ 8.34-8.48 (m, 2 H), 8.11 (s, 1 H), 7.69 (s, 1 H), 7.53-
416.2
99.6%

7.63 (m, 1 H), 7.14-7.25 (m, 1 H), 6.96 (br s, 1 H), 6.80-6.90 (m,
[M + H]⁺

1 H), 6.54-6.65 (m, 1 H), 5.06 (br dd, 0.7 H), 4.76-4.80 (m, 0.6

H), 4.01 (s, 3 H), 3.72-3.82 (m, 0.6 H), 3.40 (td, 0.4 H), 2.93-

3.23 (m, 1 H), 2.83 (br d, 1 H)

628
(CD₃OD) δ 8.47 (br d, 1 H), 7.53-7.77 (m, 2 H), 7.15-7.27 (m, 1
461.0
100%

H), 6.83-6.95 (m, 2 H), 6.44-6.67 (m, 1 H), 3.80 (br d, 1.5 H),
[M + H]⁺

3.41-3.55 (m, 0.5 H), 2.74-3.07 (m, 2 H), 1.55-1.74 (m, 6 H)

629
(CD₃OD) δ 8.39-8.51 (m, 1 H), 7.55-7.72 (m, 2 H), 7.31-7.53
461.0
99.6%

(m, 0.5 H), 7.15-7.26 (m, 1 H), 6.80-6.95 (m, 1.5 H), 6.42-6.65
[M + H]⁺

(m, 1 H), 3.80 (br d, 1.4 H), 3.50 (br d, 0.6 H), 2.73-3.10 (m, 2

H), 1.51-1.73 (m, 6 H)

630
(DMSO-d6) δ 11.89-12.21 (m, 1 H), 8.51-8.79 (m, 2 H), 7.44-
385.1
100%

7.76 (m, 2 H), 7.07-7.41 (m, 2 H), 6.28-6.94 (m, 3 H), 4.69 (br s,
[M + H]⁺

0.4 H), 4.23 (br d, 0.6 H), 3.57-3.81 (m, 0.5 H), 3.17-3.29 (m,

0.5 H), 2.58-2.98 (m, 2 H)

631
(CD₃OD) δ 8.39-8.48 (m, 2 H), 7.68 (s, 1 H), 7.59 (br d, 1 H),
385.1
99.7%

6.99-7.30 (m, 2 H), 6.44-6.92 (m, 3 H), 4.96-5.10 (m, 0.5 H),
[M + H]⁺

4.31 (br d, 0.7 H), 3.73 (br s, 0.5 H), 3.48 (br d, 0.3 H), 2.92-

3.16 (m, 1 H), 2.80 (br d, 1 H)

632
(CD₃OD) δ 8.43 (br d, 1 H), 7.65 (s, 1 H), 7.57 (d, 1 H), 6.91-
425.0
95.8%

7.27 (m, 2 H), 6.73-6.91 (m, 1.6 H), 6.57 (br s, 1.4 H), 4.65-4.79
[M + H]⁺

(m, 0.5 H), 4.30 (br s, 0.5 H), 3.37-3.91 (m, 1 H), 2.88-3.11 (m,

1 H), 2.79 (br d, 1 H), 2.00-2.34 (m, 1 H), 0.98-1.26 (m, 4H)

633
(CD₃OD) δ 8.43 (br d, 1 H), 7.65 (s, 1 H), 7.57 (d, 1 H), 7.02-
425.0
99.1%

7.33 (m, 2 H), 6.73-7.01 (m, 2 H), 6.50-6.60 (m, 1 H), 4.69-4.80
[M + H]⁺

(m, 0.5 H), 4.31 (br s, 0.5 H), 3.67 (br s, 1 H), 2.92-3.21 (m, 1

H), 2.79 (br d, 1 H), 1.97-2.38 (m, 1 H), 1.05-1.26 (m, 4 H)

634
(CD₃OD) δ 8.28-8.41 (m, 1 H), 7.41-7.57 (m, 2 H), 7.03-7.12
352.2
100%

(m, 1 H), 6.83 (s, 0.6 H), 6.69-6.79 (m, 1 H), 6.29-6.47 (m, 1.4
[M + H]⁺

H), 4.73 (br d, 0.5 H), 4.17 (br dd, 0.5 H), 3.41-3.54 (m, 0.6 H),

2.95-3.06 (m, 1 H), 2.55-2.90 (m, 3.4 H), 1.91-2.16 (m, 4 H),

1.50-1.76 (m, 2 H)

635
(CD₃OD) δ 8.37-8.54 (m, 1 H), 7.52-7.71 (m, 2 H), 7.13-7.25
352.2
99.5%

(m, 1 H), 6.95 (s, 0.6 H), 6.79-6.90 (m, 1 H), 6.40-6.58 (m, 1.4
[M + H]⁺

H), 4.85 (br d, 0.4 H), 4.30 (dd, 0.6 H), 3.59 (ddd, 0.6 H), 3.11-

3.16 (m, 1 H), 2.67-3.03 (m, 3.4 H), 2.03-2.27 (m, 4 H), 1.62-

1.88 (m, 2 H)

636
(CD₃OD) δ 8.40-8.54 (m, 1 H), 7.62-7.69 (m, 1 H), 7.58 (d, 1
354.2
100%

H), 7.15-7.24 (m, 1 H), 6.79-6.93 (m, 2 H), 6.37-6.54 (m, 1 H),
[M + H]⁺

4.82 (br dd, 1 H), 4.16 (br dd, 1 H), 3.47-3.66 (m, 1 H), 2.87-

3.18 (m, 2 H), 2.68-2.82 (m, 3 H), 2.30-2.51 (m, 2 H), 2.19 (br d,

2 H)

637
(CD₃OD) δ 8.38-8.53 (m, 1 H), 7.61-7.69 (m, 1 H), 7.57 (d, 1
354.2
83.3%

H), 7.14-7.23 (m, 1 H), 6.77-6.92 (m, 2 H), 6.36-6.54 (m, 1 H),
[M + H]⁺

5.03-5.25 (m, 1 H), 4.15 (br dd, 1 H), 3.46-3.66 (m, 1 H), 2.85-

3.15 (m, 2 H), 2.66-2.81 (m, 3 H), 2.29-2.60 (m, 2 H), 2.07-2.25

(m, 2 H)

638
(CD₃OD) δ 8.43 (br d, 1 H), 7.48-7.68 (m, 2 H), 7.10-7.23 (m, 1
388.2
100%

H), 6.71-6.88 (m, 2 H), 6.40-6.59 (m, 1 H), 4.54-4.64 (m, 1 H),
[M + H]⁺

3.46-3.65 (m, 1 H), 2.83-3.06 (m, 1 H), 2.67-2.79 (m, 1 H), 2.55-

2.66 (m, 2 H), 2.02-2.16 (m, 2 H), 1.91-2.02 (m, 1 H), 1.77 (br d,

1 H)

639
(CD₃OD) δ 8.43 (br d, 1 H), 7.47-7.71 (m, 2 H), 7.09-7.22 (m, 1
388.1
99.6%

H), 6.71-6.93 (m, 2 H), 6.40-6.59 (m, 1 H), 4.58 (br dd, 1 H),
[M + H]⁺

3.58 (br t, 1 H), 2.80-3.04 (m, 1 H), 2.67-2.78 (m, 1 H), 2.55-

2.66 (m, 2 H), 2.08 (br d, 2 H), 1.98 (dt, 1 H), 1.70-1.84 (m, 1 H)

640
Data provided above

641
Data provided above

642
(CD₃OD) δ 8.33-8.68 (m, 3 H), 7.96 (d, 2 H), 7.73 (br s, 1 H),
480.2
100%

7.49-7.67 (m, 1.4 H), 7.17-7.31 (m, 1 H), 7.00 (br s, 0.6 H),
[M + H]⁺

6.78-6.95 (m, 1 H), 6.56-6.74 (m, 1 H), 5.10 (br dd, 0.7 H), 4.96-

4.99 (m, 0.3 H), 3.76-3.90 (m, 0.6 H), 3.40-3.53 (m, 0.4 H),

2.99-3.28 (m, 1 H), 2.88 (br d, 1 H)

643
(CD₃OD) δ 8.13-8.55 (m, 3 H), 7.83 (br d, 2 H), 7.32-7.74 (m, 2
480.2
99.2%

H), 7.00-7.18 (m, 1 H), 6.66-6.96 (m, 2 H), 6.38-6.61 (m, 1 H),
[M + H]⁺

4.97 (br dd, 1 H), 3.59-3.83 (m, 0.7 H), 3.28-3.36 (m, 0.3 H),

2.85-3.15 (m, 1 H), 2.77 (br s, 1 H)

644
(CD₃OD) δ 8.74 (br d, 1 H), 8.47 (br d, 1 H), 8.30 (br d, 1 H),
462.1
100%

7.90-8.10 (m, 1 H), 7.54-7.77 (m, 3 H), 7.05-7.42 (m, 2 H), 6.58-
[M + H]⁺

6.97 (m, 3 H), 4.52 (br d, 1 H), 3.43-3.86 (m, 1 H), 2.92-3.25 (m,

1 H), 2.78-2.91 (m, 1 H)

645
(CD₃OD) δ 8.74 (br d, 1 H), 8.47 (br d, 1 H), 8.13-8.34 (m, 1 H),
462.1
99.5%

7.89-8.10 (m, 1 H), 7.56-7.79 (m, 3 H), 7.05-7.40 (m, 2 H), 6.51-
[M + H]⁺

7.00 (m, 3 H), 4.51 (br d, 1 H), 3.45-3.87 (m, 1 H), 2.92-3.26 (m,

1 H), 2.86 (br d, 1 H)

646
(CD₃OD) δ 8.59 (s, 1 H), 8.37-8.48 (m, 1 H), 8.22 (s, 1 H), 7.54-
484.1
100%

7.72 (m, 2 H), 7.13-7.24 (m, 1 H), 6.78-6.99 (m, 2 H), 6.53-6.66
[M + H]⁺

(m, 1 H), 5.02-5.17 (m, 3 H), 3.74-3.81 (m, 0.5 H), 3.38-3.47 (m,

0.5 H), 2.77-3.23 (m, 2 H)

647
(CD₃OD) δ 8.59 (s, 1 H), 8.37-8.47 (m, 1 H), 8.22 (s, 1 H), 7.54-
484.1
98.3%

7.72 (m, 2 H), 7.14-7.24 (m, 1 H), 6.80-6.99 (m, 2 H), 6.54-6.67
[M + H]⁺

(m, 1 H), 5.02-5.16 (m, 3 H), 3.72-3.82 (m, 0.6 H), 3.38-3.45 (m,

0.4 H), 2.80-3.16 (m, 2 H)

648
(CD₃OD) δ 8.35-8.56 (m, 1 H), 8.06-8.15 (m, 1 H), 7.98-8.05
448.1
100%

(m, 1 H), 7.71 (br s, 1 H), 7.49-7.66 (m, 2.4 H), 7.15-7.28 (m, 1
[M + H]⁺

H), 6.98 (s, 0.6 H), 6.81-6.94 (m, 1 H), 6.56-6.71 (m, 1 H), 5.09

(dd, 0.7 H), 4.94-4.96 (m, 0.3 H), 3.71-3.88 (m, 0.7 H), 3.43 (td,

0.3 H), 3.13-3.26 (m, 0.7 H), 2.95-3.08 (m, 0.3 H), 2.86 (br d, 1 H)

649
(CD₃OD) δ 8.35-8.63 (m, 1 H), 8.05-8.15 (m, 1 H), 7.97-8.05
448.1
100%

(m, 1 H), 7.71 (br s, 1 H), 7.47-7.66 (m, 2.4 H), 7.08-7.32 (m, 1
[M + H]⁺

H), 6.76-7.06 (m, 1.6 H), 6.51-6.74 (m, 1 H), 5.08 (br dd, 0.7 H),

4.95-5.00 (m, 0.3 H), 3.70-3.89 (m, 0.7 H), 3.38-3.48 (m, 0.3 H),

3.11-3.28 (m, 0.7 H), 2.96-3.09 (m, 0.3 H), 2.86 (br d, 1 H)

650
(CD₃OD) δ 8.93 (br d, 1 H), 8.24-8.57 (m, 2 H), 7.46-7.89 (m, 3
452.0
100%

H), 7.21 (br s, 1 H), 6.74-7.07 (m, 2 H), 6.50-6.69 (m, 1 H), 5.05
[M + H]⁺

(br s, 1 H), 3.79 (br s, 1 H), 2.75-3.26 (m, 2 H)

651
(CD₃OD) δ 8.94 (s, 1 H), 8.31-8.50 (m, 2 H), 7.48-7.86 (m, 3 H),
452.0
99.6%

7.14-7.31 (m, 1 H), 6.78-7.03 (m, 2 H), 6.52-6.69 (m, 1 H), 5.07
[M + H]⁺

(br dd, 1 H), 3.36-3.87 (m, 1 H), 2.79-3.25 (m, 2 H)

652
(CD₃OD) δ 8.39-8.52 (m, 1 H), 8.17-8.31 (m, 1 H), 7.71 (s, 1 H),
448.2
100%

7.53-7.66 (m, 1.3 H), 7.16-7.38 (m, 3 H), 6.98 (s, 0.7 H), 6.82-
[M + H]⁺

6.93 (m, 1 H), 6.57-6.70 (m, 1 H), 5.03 (dd, 0.7 H), 4.94-4.96

(m, 0.3 H), 3.74-3.86 (m, 0.7 H), 3.43 (td, 0.3 H), 3.16-3.26 (m,

0.7 H), 2.97-3.07 (m, 0.3 H), 2.81-2.91 (m, 1 H)

653
(CD₃OD) δ 8.26-8.39 (m, 1 H), 8.11 (td, 1 H), 7.64 (br s, 1 H),
448.2
98.6%

7.41-7.54 (m, 1.3 H), 7.07-7.25 (m, 3 H), 6.87 (s, 0.7 H), 6.71-
[M + H]⁺

6.80 (m, 1 H), 6.46-6.58 (m, 1 H), 4.92 (br dd, 0.7 H), 4.82-4.85

(m, 0.3 H), 3.63-3.73 (m, 0.7 H), 3.27-3.36 (m, 0.3 H), 3.06-3.14

(m, 0.7 H), 2.85-2.97 (m, 0.3 H), 2.69-2.80 (m, 1 H)

654
(DMSO-d6) δ 11.97-12.17 (m, 1 H), 8.48-8.69 (m, 1 H), 7.88-
444.1
100%

8.08 (m, 1 H), 7.50-7.70 (m, 2 H), 7.33-7.40 (m, 1 H), 7.13-7.32
[M + H]⁺

(m, 2 H), 7.08 (s, 0.2 H), 6.95 (br s, 1.2 H), 6.48-6.61 (m, 1.6H),

4.67-4.86 (m, 1 H), 3.62-3.79 (m, 1 H), 2.71-3.11 (m, 2 H), 2.58-

2.67 (m, 3 H)

655
(DMSO-d6) δ 12.03-12.18 (m, 1 H), 8.54-8.70 (m, 1 H), 7.95-
444.1
100%

8.07 (m, 1 H), 7.57-7.71 (m, 2 H), 7.36-7.43 (m, 1 H), 7.27-7.35
[M + H]⁺

(m, 2 H), 6.80-6.90 (m, 1 H), 6.55-6.63 (m, 1 H), 4.72-4.88 (m, 1

H), 3.61-3.85 (m, 1 H), 2.89-3.18 (m, 1 H), 2.79 (br d, 1 H),

2.61-2.69 (m, 3 H)

656
(CD₃OD) δ 8.42-8.56 (m, 1 H), 7.50-7.84 (m, 4 H), 6.73-7.26
384.1
100%

(m, 4 H), 6.24-6.64 (m, 1 H), 4.81 (br s, 1 H), 4.07 (br d, 0.5 H),
[M + H]⁺

3.71 (br t, 0.5 H), 2.99 (br s, 1 H), 2.75 (br d, 1 H)

657
(CD₃OD) δ 8.41-8.57 (m, 1 H), 7.48-7.85 (m, 4 H), 6.73-7.25
384.1
99.7%

(m, 4 H), 6.23-6.66 (m, 1 H), 4.75-4.86 (m, 1 H), 4.01-4.12 (m,
[M + H]⁺

0.5 H), 3.71 (br s, 0.5 H), 2.99 (br s, 1 H), 2.75 (br d, 1 H)

658
(CD₃OD) δ 8.34-8.58 (m, 1 H), 7.46-7.90 (m, 3.3 H), 7.10-7.34
416.1
98.1%

(m, 1 H), 6.77-7.02 (m, 2.7 H), 6.47-6.73 (m, 1 H), 5.03 (br dd, 1
[M + H]⁺

H), 4.05 (s, 3 H), 3.79 (br t, 1 H), 2.71-3.21 (m, 2 H)

659
(CD₃OD) δ 8.31-8.58 (m, 1 H), 7.44-7.96 (m, 3.3 H), 7.14-7.33
416.1
90.6%

(m, 1 H), 6.80-7.10 (m, 2.7 H), 6.52-6.71 (m, 1 H), 5.03 (br dd, 1
[M + H]⁺

H), 4.05 (s, 3 H), 3.70-3.88 (m, 1 H), 2.71-3.23 (m, 2 H)

660
(CD₃OD) δ 8.42-8.61 (m, 1 H), 7.48-7.75 (m, 3 H), 7.16-7.27
348.1
100%

(m, 1 H), 6.76-7.03 (m, 2 H), 6.53-6.71 (m, 1 H), 6.35 (br s, 1
[M + H]⁺

H), 4.04-4.19 (m, 1 H), 3.93 (s, 3 H), 3.61-3.79 (m, 1 H), 2.98

(br s, 1 H), 2.66-2.87 (m, 1 H)

661
(CD₃OD) δ 8.42-8.61 (m, 1 H), 7.47-7.75 (m, 3 H), 7.16-7.28
348.1
96.8%

(m, 1 H), 6.76-7.03 (m, 2 H), 6.52-6.72 (m, 1 H), 6.34 (br s, 1
[M + H]⁺

H), 4.03-4.20 (m, 1 H), 3.93 (s, 3 H), 3.59-3.78 (m, 1 H), 2.98

(br s, 1 H), 2.76 (br d, 1 H)

662
(CD₃OD) δ 8.30-8.64 (m, 1.5 H), 7.97 (br s, 0.5 H), 7.45-7.75
398.1
100%

(m, 2 H), 7.14-7.23 (m, 1 H), 6.75-7.03 (m, 2.6 H), 6.17-6.64 (m,
[M + H]⁺

1.4 H), 4.02-4.16 (m, 1 H), 3.96 (s, 3 H), 3.34-3.80 (m, 1 H),

2.93 (br t, 1 H), 2.70 (br dd, 1 H)

663
(CD₃OD) δ 8.25-8.66 (m, 1.5 H), 7.97 (br s, 0.5 H), 7.50-7.70
398.1
99.3%

(m, 2 H), 7.12-7.27 (m, 1 H), 6.70-7.08 (m, 2.5 H), 6.08-6.69 (m,
[M + H]⁺

1.5 H), 4.01-4.19 (m, 1 H), 3.96 (s, 3 H), 3.34-3.80 (m, 1 H),

2.93 (br t, 1 H), 2.60-2.77 (m, 1 H)

664
(CD₃OD) δ 8.17-8.60 (m, 1.5 H), 7.90 (br s, 0.5 H), 7.50-7.69
382.2
100%

(m, 2 H), 7.18 (ddd, 1 H), 6.78-7.02 (m, 1.6 H), 6.12-6.68 (m,
[M + H]⁺

1.4 H), 4.81 (br s, 0.5 H), 4.05 (br d, 0.5 H), 3.88 (s, 3 H), 3.71

(br s, 0.5 H), 3.15-3.30 (m, 0.5 H), 2.90-3.01 (m, 1 H), 2.72 (br

dd, 1 H)

665
(CD₃OD) δ 8.19-8.58 (m, 1.5 H), 7.90 (br s, 0.5 H), 7.50-7.69
382.2
99.6%

(m, 2 H), 7.17 (dd, 1 H), 6.78-7.01 (m, 1.6 H), 6.14-6.66 (m, 1.4
[M + H]⁺

H), 4.69-4.83 (m, 0.6 H), 4.04 (br d, 0.4 H), 3.87 (s, 3 H), 3.69

(br s, 0.5 H), 3.24 (br s, 0.5 H), 2.88-3.00 (m, 1 H), 2.71 (br dd,

1 H)

666
(CD₃OD) δ 8.34-8.49 (m, 2 H), 7.52-7.86 (m, 3.3 H), 7.15-7.29
452.2
100%

(m, 2 H), 6.83-7.00 (m, 1.7 H), 6.57-6.70 (m, 1 H), 5.03 (dd, 1
[M + H]⁺

H), 3.72-3.86 (m, 0.7 H), 3.38-3.51 (m, 0.3 H), 2.96-3.27 (m, 1

H), 2.79-2.93 (m, 1 H)

667
(CD₃OD) δ 8.32-8.51 (m, 2 H), 7.53-7.85 (m, 3.5 H), 7.14-7.26
452.3
97.2%

(m, 2 H), 6.81-7.01 (m, 1.5 H), 6.58-6.69 (m, 1 H), 5.03 (dd, 1
[M + H]⁺

H), 3.80 (ddd, 0.7 H), 3.43 (td, 0.3 H), 2.97-3.27 (m, 1 H), 2.86

(br dd, 1 H)

668
(CD₃OD) δ 9.04 (d, 1 H), 8.55 (s, 1 H), 8.37-8.49 (m, 1 H), 7.96
481.1
100%

(d, 1 H), 7.67-7.74 (m, 1 H), 7.51-7.64 (m, 1.3 H), 7.15-7.24 (m,
[M + H]⁺

1 H), 6.98 (s, 0.7 H), 6.80-6.90 (m, 1 H), 6.58-6.69 (m, 1 H),

5.03 (dd, 1 H), 3.81 (ddd, 0.7 H), 3.39-3.50 (m, 0.4 H), 3.11-3.23

(m, 0.6 H), 2.97-3.07 (m, 0.4 H), 2.78-2.92 (m, 1 H)

669
(CD₃OD) δ 9.04 (d, 1 H), 8.55 (s, 1 H), 8.37-8.50 (m, 1 H), 7.96
481.1
98.4%

(d, 1 H), 7.70 (s, 1 H), 7.50-7.63 (m, 1.3 H), 7.14-7.25 (m, 1 H),
[M + H]⁺

6.98 (s, 0.7 H), 6.80-6.90 (m, 1 H), 6.58-6.69 (m, 1 H), 5.02 (br

dd, 1 H), 3.76-3.85 (m, 0.7 H), 3.40-3.49 (m, 0.3 H), 3.16-3.25

(m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.78-2.90 (m, 1 H)

670
(CD₃OD) δ 8.34 (d, 1 H), 7.37-7.67 (m, 2 H), 6.99-7.19 (m, 2
443.2
100%

H), 6.68-6.93 (m, 2 H), 6.51 (s, 1 H), 4.22 (br d, 1 H), 3.26-3.80
[M + H]⁺

(m, 1 H), 2.59-3.10 (m, 2 H), 1.45-1.66 (m, 6 H)

671
(CD₃OD) δ 8.33 (br d, 1 H), 7.41-7.71 (m, 2 H), 6.99-7.19 (m, 2
443.1
98.9%

H), 6.71-6.94 (m, 2 H), 6.51 (s, 1 H), 4.23 (br d, 1 H), 3.28-3.78
[M + H]⁺

(m, 1 H), 2.58-3.11 (m, 2 H), 1.42-1.67 (m, 6H)

672
(CD₃OD) δ 8.59 (s, 1 H), 8.32-8.50 (m, 1 H), 8.07-8.24 (m, 1 H),
427.1
100%

7.80-7.95 (m, 1 H), 7.67 (s, 1 H), 7.43-7.62 (m, 1.4 H), 7.10-7.24
[M + H]⁺

(m, 1 H), 6.94 (s, 0.6 H), 6.74-6.89 (m, 1 H), 6.49-6.68 (m, 1 H),

4.97 (br dd, 1 H), 3.67-3.86 (m, 0.7 H), 3.39 (td, 0.3 H), 3.17 (br

s, 0.7 H), 2.91-3.04 (m, 0.3 H), 2.82 (br d, 1 H), 2.45 (s, 3H)

673
(CD₃OD) δ 8.59 (s, 1 H), 8.30-8.48 (m, 1 H), 8.09-8.22 (m, 1 H),
427.1
98.3%

7.83-7.93 (m, 1 H), 7.67 (s, 1 H), 7.42-7.63 (m, 1.4 H), 7.09-7.25
[M + H]⁺

(m, 1 H), 6.94 (s, 0.6 H), 6.72-6.88 (m, 1 H), 6.49-6.68 (m, 1 H),

4.97 (br dd, 1 H), 3.77 (ddd, 0.7 H), 3.39 (td, 0.3 H), 3.10-3.23

(m, 0.7 H), 2.91-3.06 (m, 0.3 H), 2.82 (br dd, 1 H), 2.45 (s, 3H)

674
(CD₃OD) δ 8.82-9.33 (m, 1 H), 8.35-8.61 (m, 2 H), 7.88-8.02
445.2
100%

(m, 2 H), 7.51-7.72 (m, 2 H), 7.37 (br t, 1 H), 7.20 (dd, 1 H),
[M + H]⁺

6.58-7.05 (m, 2 H), 6.22-6.39 (m, 1 H), 4.10 (br d, 1 H), 3.76 (br

s, 1 H), 3.00 (br s, 1 H), 2.76 (br d, 1 H)

675
(CD₃OD) δ 8.81-9.31 (m, 1 H), 8.40-8.59 (m, 2 H), 7.90-8.01
445.2
99.6%

(m, 2 H), 7.52-7.70 (m, 2 H), 7.37 (br t, 1 H), 7.20 (dd, 1 H),
[M + H]⁺

6.61-7.04 (m, 2 H), 6.23-6.38 (m, 1 H), 4.10 (br d, 1 H), 3.76 (br

s, 1 H), 3.00 (br t, 1 H), 2.75 (br d, 1 H)

676
(CD₃OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.61 (br d, 1 H), 7.13-
471.0
100%

7.30 (m, 1 H), 6.87 (td, 1.3 Hz, 1.7 H), 6.48-6.73 (m, 1 H), 6.39
[M + H]⁺

(br s, 0.3 H), 4.78 (br s, 0.3 H), 4.16 (br d, 0.7 H), 3.69-3.91 (m,

0.7 H), 3.42 (br s, 0.3 H), 2.92-3.24 (m, 1 H), 2.82 (br d, 1 H),

1.53-1.70 (m, 6 H)

677
(CD₃OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.62 (br d, 1 H), 7.13-
471.0
99.7%

7.28 (m, 1 H), 6.87 (td, 1.6 H), 6.49-6.72 (m, 1 H), 6.38 (br s,
[M + H]⁺

0.4 H), 4.79 (br s, 0.3 H), 4.16 (br d, 0.7 H), 3.70-3.88 (m, 0.7

H), 3.42 (br s, 0.3 H), 3.12 (br d, 1 H), 2.82 (br d, 1 H), 1.52-

1.72 (m, 6 H)

678
(CD₃OD) δ 8.58 (s, 1 H), 8.36-8.50 (m, 1 H), 7.71 (s, 1 H), 7.49-
484.1
100%

7.65 (m, 1.3 H), 7.15-7.27 (m, 1 H), 6.80-7.02 (m, 1.7 H), 6.53-
[M + H]⁺

6.68 (m, 1 H), 4.99 (br dd, 1 H), 4.07 (s, 3 H), 3.72-3.85 (m, 0.7

H), 3.41 (td, 0.3 H), 3.13-3.26 (m, 0.7 H), 2.93-3.09 (m, 0.3 H),

2.77-2.92 (m, 1 H)

679
(CD₃OD) δ 8.58 (s, 1 H), 8.37-8.54 (m, 1 H), 7.71 (s, 1 H), 7.47-
484.1
100%

7.65 (m, 1.3 H), 7.14-7.27 (m, 1 H), 6.78-7.01 (m, 1.7 H), 6.52-
[M + H]⁺

6.71 (m, 1 H), 4.99 (br dd, 1 H), 4.07 (s, 3 H), 3.73-3.84 (m, 0.7

H), 3.37-3.45 (m, 0.3 H), 3.12-3.26 (m, 0.7 H), 2.94-3.07 (m, 0.3

H), 2.77-2.91 (m, 1 H)

680
(CD₃OD) δ 8.40-8.59 (m, 1 H), 7.50-7.71 (m, 2 H), 7.19 (ddd, 1
382.2
100%

H), 6.74-7.01 (m, 2 H), 6.45-6.69 (m, 1 H), 6.31 (br d, 1 H), 4.80
[M + H]⁺

(br s, 0.4 H), 3.98-4.14 (m, 0.6 H), 3.81-3.89 (m, 3 H), 3.61-3.78

(m, 0.7 H), 3.29 (br s, 0.3 H), 2.90-3.04 (m, 1 H), 2.75 (br d, 1 H)

681
(CD₃OD) δ 8.40-8.59 (m, 1 H), 7.51-7.72 (m, 2 H), 7.19 (ddd, 1
382.2
99.2%

H), 6.72-7.00 (m, 2 H), 6.47-6.67 (m, 1 H), 6.31 (br d, 1 H), 4.81
[M + H]⁺

(br s, 0.5 H), 4.00-4.13 (m, 0.5 H), 3.85 (s, 3 H), 3.62-3.77 (m,

0.6 H), 3.25 (br s, 0.4 H), 2.89-3.03 (m, 1 H), 2.75 (br d, 1 H)

682
(CD₃OD) δ 8.44-8.71 (m, 2 H), 7.68 (s, 1 H), 7.53 (br d, 1 H),
440.1
100%

7.26 (dd, 1 H), 6.45-6.88 (m, 2 H), 4.39 (br d, 1 H), 3.35-3.94
[M + H]⁺

(m, 1 H), 2.73-3.20 (m, 2 H)

683
(CD₃OD) δ 8.37-8.78 (m, 2 H), 7.68 (s, 1 H), 7.55 (br d, 1 H),
440.1
99.8%

7.27 (dd, 1 H), 6.37-6.93 (m, 2 H), 4.39 (br d, 1 H), 3.34-3.94
[M + H]⁺

(m, 1 H), 2.73-3.23 (m, 2 H)

684
(CD₃OD) δ 8.40-8.62 (m, 2 H), 7.52-7.72 (m, 2 H), 7.19 (dd, 1
394.0
100%

H), 6.52-6.90 (m, 2 H), 4.38 (br d, 1 H), 3.33-3.92 (m, 1 H),
[M + H]⁺

2.72-3.22 (m, 2 H)

685
(CD₃OD) δ 8.40-8.62 (m, 2 H), 7.52-7.76 (m, 2 H), 7.20 (dd, 1
394.0
99.8%

H), 6.46-6.91 (m, 2 H), 4.39 (br d, 1 H), 3.35-3.90 (m, 1 H), 3.11
[M + H]⁺

(br s, 1 H), 2.72-2.95 (m, 1 H)

686
(CD₃OD) δ 8.38-8.54 (m, 2 H), 7.62-7.79 (m, 1 H), 7.30 (d, 1
394.2
98.6%

H), 6.48-7.00 (m, 3 H), 4.40 (br d, 1 H), 3.77 (br s, 1 H), 2.77-
[M + H]⁺

3.19 (m, 2 H)

687
(CD₃OD) δ 8.39-8.56 (m, 2 H), 7.69 (s, 1 H), 7.30 (d, 1 H), 6.46-
394.2
94.5%

6.94 (m, 3 H), 4.41 (br d, 1 H), 3.78 (br d, 1 H), 2.77-3.20 (m, 2 H)
[M + H]⁺

688
(CD₃OD) δ 8.33-8.48 (m, 2 H), 7.98-8.17 (m, 1 H), 7.53-7.72
450.2
100%

(m, 1.3 H), 7.21-7.36 (m, 1 H), 6.60-7.03 (m, 2.7 H), 4.92-5.10
[M + H]⁺

(m, 1 H), 4.00 (s, 3 H), 3.76 (ddd, 0.6 H), 3.35-3.44 (m, 0.4 H),

2.92-3.22 (m, 1 H), 2.79-2.89 (m, 1 H)

689
(CD₃OD) δ 8.35-8.49 (m, 2 H), 8.04-8.16 (m, 1 H), 7.50-7.74
450.2
99.3%

(m, 1.3 H), 7.24-7.35 (m, 1 H), 6.68-6.97 (m, 2.7 H), 4.92-5.12
[M + H]⁺

(m, 1 H), 4.00 (s, 3 H), 3.71-3.83 (m, 0.7 H), 3.40 (td, 0.3 H),

2.93-3.23 (m, 1 H), 2.77-2.90 (m, 1 H)

690
(CD₃OD) δ 8.44 (br d, 1 H), 7.54-7.70 (m, 2 H), 7.10-7.28 (m, 2
429.3
99.6%

H), 6.81-7.01 (m, 2 H), 6.60 (br s, 1 H), 4.94-5.00 (m, 1 H), 4.33
[M + H]⁺

(br d, 1 H), 3.72 (br s, 1 H), 2.92-3.20 (m, 1 H), 2.80 (br d, 1 H),

1.61 (br d, 3 H)

691
(CD₃OD) δ 8.44 (br d, 1 H), 7.53-7.71 (m, 2 H), 7.10-7.29 (m, 2
429.2
99.7%

H), 6.79-7.02 (m, 2 H), 6.60 (s, 1 H), 4.94-5.01 (m, 1 H), 4.34
[M + H]⁺

(br d, 1 H), 3.73 (br s, 1 H), 2.90-3.19 (m, 1 H), 2.81 (br d, 1 H),

1.50-1.68 (m, 3 H)

692
(CD₃OD) δ 8.44 (br d, 1 H), 7.68 (s, 1 H), 7.59 (br d, 1 H), 7.27
429.2
100%

(s, 0.2 H), 7.16-7.23 (m, 1 H), 6.97-7.14 (m, 0.8 H), 6.85 (br t, 2
[M + H]⁺

H), 6.61 (s, 1 H), 4.97 (br d, 1 H), 4.35 (br d, 1 H), 3.63-3.80 (m,

0.7 H), 3.37-3.49 (m, 0.3 H), 2.91-3.20 (m, 1 H), 2.81 (br d, 1

H), 1.60 (br d, 3 H)

693
(CD₃OD) δ 8.44 (br d, 1 H), 7.68 (s, 1 H), 7.59 (br d, 1 H), 7.26
429.2
100%

(s, 0.2 H), 7.16-7.22 (m, 1 H), 6.98-7.14 (m, 0.8 H), 6.86 (br t, 2
[M + H]⁺

H), 6.61 (s, 1 H), 4.97 (br d, 1 H), 4.34 (br d, 1 H), 3.72 (br s, 0.7

H), 3.48 (br s, 0.4 H), 2.89-3.19 (m, 1 H), 2.81 (br d, 1 H), 1.61

(br d, 3 H)

694
(CD₃OD) δ 8.40-8.48 (m, 1 H), 7.65-7.70 (m, 1 H), 7.51-7.61
383.2
99.0%

(m, 1 H), 7.13-7.24 (m, 1 H), 6.80-6.94 (m, 2 H), 6.35-6.64 (m, 1
[M + H]⁺

H), 4.83 (br s, 0.3, 4.44 (dd, 0.7 H), 4.02 (s, 3 H), 3.59-3.73 (m,

0.7 H), 3.09-3.27 (m, 1 H), 2.90-3.01 (m, 0.3 H), 2.70-2.85 (m, 1 H)

695
(CD₃OD) δ 8.40-8.48 (m, 1 H), 7.65-7.71 (m, 1 H), 7.50-7.61
383.2
98.6%

(m, 1 H), 7.13-7.23 (m, 1 H), 6.79-6.93 (m, 2 H), 6.34-6.63 (m, 1
[M + H]⁺

H), 4.83 (br s, 0.3, 4.44 (dd, 0.7 H), 4.02 (s, 3 H), 3.66 (ddd, 0.7

H), 3.08-3.27 (m, 1 H), 2.90-3.00 (m, 0.3 H), 2.70-2.85 (m, 1 H)

696
(CD₃OD) δ 8.49-8.63 (m, 1 H), 8.32 (br s, 1 H), 8.08 (s, 1 H),
450.2
100%

7.53-7.70 (m, 2.3 H), 7.08-7.27 (m, 1 H), 6.91 (s, 0.7 H), 6.58-
[M + H]⁺

6.73 (m, 1 H), 5.07 (br dd, 0.5 H), 3.99 (s, 3 H), 3.66-3.85 (m, 1

H), 3.39 (td, 0.5 H), 2.73-3.24 (m, 2 H)

697
(CD₃OD) δ 8.50-8.62 (m, 1 H), 8.38 (s, 1 H), 8.03-8.15 (m, 1 H),
450.2
99.7%

7.51-7.74 (m, 2.4 H), 7.13-7.30 (m, 1 H), 6.92 (s, 0.6 H), 6.60-
[M + H]⁺

6.73 (m, 1 H), 5.07 (br dd, 0.5 H), 4.00 (s, 3 H), 3.67-3.83 (m, 1

H), 3.33-3.48 (m, 0.5 H), 2.72-3.23 (m, 2 H)

698
(CD₃OD) δ 8.35 (d, 1 H), 7.38-7.71 (m, 2 H), 6.86-7.29 (m, 2
452.2
98.3%

H), 6.38-6.81 (m, 3 H), 4.21 (br d, 1 H), 3.29-3.78 (m, 1 H),
[M + H]⁺

2.58-3.15 (m, 2 H), 1.54-1.90 (m, 6 H)

699
(CD₃OD) δ 8.47 (d, 1 H), 7.52-7.79 (m, 2 H), 6.99-7.36 (m, 2
452.2
98.4%

H), 6.45-6.93 (m, 3 H), 4.33 (br d, 1 H), 3.38-3.85 (m, 1 H),
[M + H]⁺

2.69-3.27 (m, 2 H), 1.67-2.01 (m, 6 H))

700
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 6.94-7.35 (m, 2 H), 6.51-
477.2
94.7%

6.93 (m, 3 H), 4.36 (br d, 1 H), 3.33-3.82 (m, 1 H), 2.70-3.18 (m,
[M + H]⁺

2 H), 1.54-1.73 (m, 6 H)

701
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 6.94-7.38 (m, 2 H), 6.51-
477.2
99.4%

6.93 (m, 3 H), 4.35 (br d, 1 H), 3.37-3.88 (m, 1 H), 2.73-3.23 (m,
[M + H]⁺

2 H), 1.55-1.74 (m, 6 H)

702
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.94-7.27
463.0
98.1%

(m, 1 H), 6.85 (t, 1.7 H), 6.49-6.77 (m, 1.3 H), 4.97 (br d, 1.3 H),
[M + H]⁺

4.36 (br d, 0.7 H), 3.36-3.85 (m, 1 H), 2.73-3.23 (m, 2 H), 1.49-

1.71 (m, 3 H)

703
(CD₃OD) δ 8.43 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.97-7.27
463.0
96.7%

(m, 1 H), 6.85 (t, 1.6 H), 6.54-6.78 (m, 1.4 H), 4.97 (br d, 1.3 H),
[M + H]⁺

4.37 (br d, 0.7 H), 3.37-3.81 (m, 1 H), 2.75-3.21 (m, 2 H), 1.46-

1.67 (m, 3 H)

704
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.95-7.27
475.2
98.7%

(m, 1 H), 6.85 (t, 1.6 H), 6.54-6.77 (m, 1.4 H), 4.40 (br d, 1 H),
[M + H]⁺

3.36-3.83 (m, 1 H), 2.70-3.21 (m, 2 H), 1.20-1.46 (m, 4 H)

705
(CD₃OD) δ 8.44 (d, 1 H), 7.72 (br s, 1 H), 7.30 (d, 1 H), 6.95-
475.1
99.2%

7.27 (m, 1 H), 6.85 (t, 1.6 H), 6.74 (s, 1.4 H), 4.41 (br d, 1 H),
[M + H]⁺

3.72 (br s, 1 H), 2.73-3.23 (m, 2 H), 1.23-1.44 (m, 4 H)

706
(CD₃OD) δ 8.43 (d, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 6.34-6.98
427.2
98.7%

(m, 3 H), 4.91 (br s, 1 H), 4.28-4.79 (m, 1 H), 3.37-3.83 (m, 1
[M + H]⁺

H), 2.68-3.20 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)

707
(CD₃OD) δ 8.43 (d, 1 H), 7.66 (s, 1 H), 7.28 (d, 1 H), 6.41-6.93
427.2
97.7%

(m, 3 H), 4.88-4.94 (m, 1 H), 4.36 (br s, 1 H), 3.39-3.79 (m, 1
[M + H]⁺

H), 2.68-3.21 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)

708
(CD₃OD) δ 8.43 (d, 1 H), 7.66 (s, 1 H), 7.28 (d, 1 H), 6.41-6.93
427.2
97.7%

(m, 3 H), 4.88-4.94 (m, 1 H), 4.36 (br s, 1 H), 3.39-3.79 (m, 1
[M + H]⁺

H), 2.68-3.21 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)

709
(CD₃OD) δ 8.43 (d, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 6.32-6.97
427.2
99.5%

(m, 3 H), 4.89-4.93 (m, 1 H), 4.34 (br s, 1 H), 3.37-3.83 (m, 1
[M + H]

H), 2.68-3.23 (m, 2 H), 2.37 (s, 3 H), 1.56 (br s, 3 H)

710
(CD₃OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.91-7.29 (m, 2 H), 6.49-
447.1
98.9%

6.90 (m, 3 H), 4.97 (br d, 1.3 H), 4.36 (br d, 0.7 H), 3.34-3.80
[M + H]⁺

(m, 1 H), 2.70-3.21 (m, 2 H), 1.49-1.68 (m, 3 H)

711
(CD₃OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.92-7.31 (m, 2 H), 6.51-
447.1
99.5%

6.90 (m, 3 H), 4.97 (br d, 1.4 H), 4.36 (br d, 0.6 H), 3.37-3.85
[M + H]⁺

(m, 1 H), 2.68-3.21 (m, 2 H), 1.46-1.67 (m, 3 H)

712
(CD₃OD) δ 8.33 (d, 1 H), 7.61-7.72 (m, 1 H), 6.93-7.31 (m, 2
447.1
95.9%

H), 6.52-6.90 (m, 3 H), 4.97 (br d, 1 H), 4.36 (br d, 1 H), 3.37-
[M + H]⁺

3.80 (m, 1 H), 2.72-3.21 (m, 2 H), 1.61 (br d, 3 H)

713
(CD₃OD) δ 8.33 (d, 1 H), 7.62-7.74 (m, 1 H), 6.91-7.30 (m, 2
447.1
98.8%

H), 6.48-6.90 (m, 3 H), 4.97 (br d, 1 H), 4.30-4.45 (m, 1 H),
[M + H]

3.36-3.80 (m, 1 H), 2.72-3.22 (m, 2 H), 1.48-1.69 (m, 3 H)

714
(CD₃OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.90-7.28 (m, 2 H), 6.49-
461.1
99.7%

6.89 (m, 3 H), 4.33 (br s, 1 H), 3.37-3.86 (m, 1 H), 2.74-3.20 (m,
[M + H]⁺

2 H), 1.66 (br s, 6 H)

715
(CD₃OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.90-7.30 (m, 2 H), 6.50-
461.1
99.6%

6.89 (m, 3 H), 4.34 (br d, 1 H), 3.36-3.84 (m, 1 H), 2.73-3.22 (m,
[M + H]'

2 H), 1.56-1.71 (m, 6 H)

716
(CD₃OD) δ 8.40-8.57 (m, 1 H), 7.89 (br s, 1 H), 7.51-7.75 (m, 2
402.20
100%

H), 7.17-7.30 (m, 1 H), 6.84-7.06 (m, 2 H), 6.58-6.80 (m, 1 H),
[M + H]⁺

5.92-6.41 (m, 1 H), 4.85 (br d, 0.4 H), 3.70-3.83 (m, 1.2 H),

3.36-3.45 (m, 0.4 H), 2.67-3.09 (m, 2 H)

717
(CD₃OD) δ 8.41-8.59 (m, 1 H), 7.89 (br s, 1 H), 7.49-7.79 (m, 2
402.20
100%

H), 7.14-7.30 (m, 1 H), 6.85-7.04 (m, 2 H), 6.59-6.82 (m, 1 H),
[M + H]⁺

5.96-6.42 (m, 1 H), 4.85 (br d, 0.4 H), 3.69-3.83 (m, 1.2 H),

3.36-3.46 (m, 0.4 H), 2.64-3.04 (m, 2 H)

718
(CD₃OD) δ 8.36-8.50 (m, 2 H), 8.05-8.18 (m, 1 H), 7.53-7.76
450.1
100%

(m, 1.3 H), 7.24-7.35 (m, 1 H), 6.92 (s, 0.7 H), 6.65-6.88 (m, 2
[M + H]⁺

H), 5.07 (br dd, 1 H), 3.98 (s, 3 H), 3.67-3.82 (m, 0.7 H), 3.32-

3.45 (m, 0.3 H), 2.92-3.21 (m, 1 H), 2.78-2.89 (m, 1 H)

719
(CD₃OD) δ 8.32-8.47 (m, 2 H), 8.09 (d, 1 H), 7.73-7.87 (m, 1
450.0
99.0%

H), 7.22-7.61 (m, 1.3 H), 6.95 (s, 0.7 H), 6.67-6.89 (m, 2 H),
[M + H]⁺

5.08 (br dd, 1 H), 3.98 (s, 3 H), 3.66-3.79 (m, 0.6 H), 3.33-3.42

(m, 0.4 H), 2.93-3.22 (m, 1 H), 2.84 (br d, 1 H)

720
(CD₃OD) δ 8.46 (d, 1 H), 7.70 (s, 1 H), 7.32 (d, 1 H), 6.82-7.00
461.2
100%

(m, 1.7 H), 6.76 (br s, 1 H), 6.45 (br s, 0.3 H), 4.82 (br s, 0.4 H),
[M + H]⁺

4.24 (br d, 0.6 H), 3.68-3.91 (m, 0.6 H), 3.41 (br s, 0.4 H), 2.92-

3.25 (m, 1 H), 2.70-2.91 (m, 1 H), 1.51-1.70 (m, 6 H)

721
(CD₃OD) δ 8.46 (d, 1 H), 7.70 (s, 1 H), 7.31 (d, 1 H), 6.81-6.93
461.1
100%

(m, 1.7 H), 6.76 (br s, 1 H), 6.45 (br s, 0.3 H), 4.79 (br s, 0.3 H),
[M + H]⁺

4.24 (br d, 0.7 H), 3.78 (br t, 0.7 H), 3.41 (br s, 0.3 H), 3.15 (br

s, 1 H), 2.84 (br d, 1 H), 1.52-1.72 (m, 6 H)

722
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.84 (t, 1.6
507.1
96.2%

H), 6.25-6.76 (m, 1.4 H), 4.79 (br s, 0.4 H), 4.17 (br d, 0.6 H),
[M + H]⁺

3.36-3.84 (m, 1 H), 2.75-3.23 (m, 2 H), 1.49-1.69 (m, 6 H)

723
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.84 (t, 1.6
507.2
98.3%

H), 6.31-6.76 (m, 1.4 H), 4.82 (br s, 0.4 H), 4.17 (br d, 0.6 H),
[M + H]⁺

3.36-3.83 (m, 1 H), 2.75-3.22 (m, 2 H), 1.52-1.71 (m, 6 H)

724
(CD₃OD) δ 8.43 (d, 1 H), 7.56-7.74 (m, 1 H), 7.29 (d, 1 H),
441.3
98.3%

6.42-6.93 (m, 3 H), 4.24-4.44 (m, 1 H), 3.39-3.80 (m, 1 H), 2.70-
[M + H]

3.23 (m, 2 H), 2.37 (s, 3 H), 1.62 (br s, 6 H)

725
(CD₃OD) δ 8.44 (d, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 6.43-6.95
441.3
99.8%

(m, 3 H), 4.35 (br s, 1 H), 3.38-3.80 (m, 1 H), 2.73-3.22 (m, 2
[M + H]⁺

H), 2.37 (s, 3 H), 1.62 (br s, 6 H)

726
(CD₃OD) δ 8.33 (d, 1 H), 7.66 (s, 1 H), 6.95 (dd, 1 H), 6.46-6.89
411.2
98.4%

(m, 3 H), 4.89 (br d, 1 H), 4.35 (br s, 1 H), 3.38-3.80 (m, 1 H),
[M + H]

2.70-3.20 (m, 2 H), 2.36 (s, 3 H), 1.56 (br s, 3 H)

727
(CD₃OD) δ 8.33 (d, 1 H), 7.66 (s, 1 H), 6.95 (dd, 1 H), 6.42-6.90
411.2
99.9%

(m, 3 H), 4.90 (br d, 1 H), 4.36 (br s, 1 H), 3.36-3.79 (m, 1 H),
[M + H]

2.70-3.20 (m, 2 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)

728
(CD₃OD) δ 8.25-8.46 (m, 2 H), 8.10 (s, 1 H), 7.56-7.73 (m, 1.3
434.1
99.8%

H), 6.92-7.00 (m, 1.7 H), 6.68-6.89 (m, 2 H), 5.09 (br dd, 1 H),
[M + H]⁺

4.00 (s, 3 H), 3.70-3.83 (m, 0.7 H), 3.40 (td, 0.3 H), 2.93-3.22

(m, 1 H), 2.79-2.89 (m, 1 H)

729
(CD₃OD) δ 8.26-8.42 (m, 2 H), 8.10 (s, 1 H), 7.56-7.72 (m, 1.3
434.1
97.8%

H), 6.92-7.00 (m, 1.7 H), 6.68-6.89 (m, 2 H), 5.09 (br dd, 1 H),
[M + H]⁺

4.00 (s, 3 H), 3.70-3.84 (m, 0.7 H), 3.40 (td, 0.3 H), 2.93-3.22

(m, 1 H), 2.77-2.90 (m, 1 H)

730
(CD₃OD) δ 8.24-8.40 (m, 1 H), 7.81 (d, 1 H), 7.70 (s, 1 H), 7.51
434.2
100%

(s, 0.3 H), 6.90-7.03 (m, 2.7 H), 6.71-6.88 (m, 2 H), 5.04 (br dd,
[M + H]⁺

1 H), 4.03 (s, 3 H), 3.78 (ddd, 0.6 H), 3.37-3.45 (m, 0.4 H), 2.79-

3.24 (m, 2 H)

731
(CD₃OD) δ 8.25-8.39 (m, 1 H), 7.81 (d, 1 H), 7.69 (s, 1 H), 7.51
434.3
99.8%

(br s, 0.3 H), 6.91-7.02 (m, 2.7 H), 6.72-6.88 (m, 2 H), 4.96-5.10
[M + H]⁺

(m, 1 H), 4.03 (s, 3 H), 3.73-3.83 (m, 0.6 H), 3.38-3.45 (m, 0.4

H), 2.80-3.23 (m, 2 H)

732
(CD₃OD) δ 8.78 (d, 1 H), 8.25-8.42 (m, 2 H), 8.02-8.16 (m, 1
431.3
98.9%

H), 7.43-7.77 (m, 2.3 H), 6.90-7.06 (m, 1.7 H), 6.73-6.90 (m, 2
[M + H]⁺

H), 4.93-5.08 (m, 1 H), 3.74-3.87 (m, 0.7 H), 3.43 (td, 0.3 H),

2.82-3.26 (m, 2 H)

733
(CD₃OD) δ 8.78 (d, 1 H), 8.22-8.42 (m, 2 H), 8.08 (td, 1 H),
431.2
99.8%

7.43-7.76 (m, 2.3 H), 6.91-7.03 (m, 1.7 H), 6.74-6.88 (m, 2 H),
[M + H]⁺

4.93-5.06 (m, 1 H), 3.74-3.86 (m, 0.7 H), 3.38-3.50 (m, 0.3 H),

2.81-3.25 (m, 2 H)

734
(CD₃OD) δ 8.78 (dd, 1 H), 8.36-8.49 (m, 1 H), 8.31 (dd, 1 H),
447.3
99.6%

8.08 (td, 1 H), 7.60-7.75 (m, 2 H), 7.49 (br s, 0.3 H), 7.23-7.38
[M + H]⁺

(m, 1 H), 6.97 (s, 0.7 H), 6.69-6.90 (m, 2 H), 4.95-5.08 (m, 1 H),

3.79 (ddd, 0.7 H), 3.37-3.51 (m, 0.3 H), 2.78-3.24 (m, 2 H)

735
(CD₃OD) δ 8.77 (d, 1 H), 8.35-8.50 (m, 1 H), 8.31 (d, 1 H), 8.08
447.3
100%

(td, 1 H), 7.62-7.76 (m, 2 H), 7.49 (br s, 0.3 H), 7.23-7.37 (m, 1
[M + H]⁺

H), 6.97 (br s, 0.7 H), 6.71-6.88 (m, 2 H), 4.95-5.06 (m, 1 H),

3.72-3.86 (m, 0.7 H), 3.38-3.49 (m, 0.3 H), 2.82-3.26 (m, 2 H)

736
(CD₃OD) δ 8.30 (d, 1 H), 7.69 (br s, 1 H), 7.11-7.30 (m, 1 H),
457.4
100%

6.99 (br d, 1 H), 6.86 (br s, 1 H), 6.79 (t, 1 H), 6.52-6.70(m, 1
[M + H]⁺

H), 4.69-4.83 (m, 0.4 H), 4.25-4.40 (m, 0.6 H), 3.74 (br t, 0.6 H),

3.43 (br s, 0.4 H), 2.91-3.21 (m, 1 H), 2.83 (br d, 1 H), 2.45 (s, 3

H), 1.49-1.76 (m, 6 H)

737
(CD₃OD) δ 8.30 (d, 1 H), 7.68 (br s, 1 H), 7.10-7.30 (m, 1 H),
457.4
99.5%

6.99 (br d, 1 H), 6.86 (br s, 1 H), 6.78 (t, 1 H), 6.53-6.70 (m, 1
[M + H]⁺

H), 4.80 (br s, 0.2 H), 4.24-4.40 (m, 0.6 H), 3.65-3.83 (m, 0.6

H), 3.44 (br s, 0.4 H), 2.92-3.23 (m, 1 H), 2.82 (br d, 1 H), 2.44

(s, 3 H), 1.50-1.74 (m, 6 H)

738
(CD₃OD) δ 8.30 (br d, 1 H), 7.68 (s, 1 H), 7.09-7.31 (m, 1 H),
443.3
99.6%

6.99 (br d, 1 H), 6.86 (br s, 1 H), 6.78 (t, 1 H), 6.61 (br s, 1 H),
[M + H]⁺

4.97 (q, 1 H), 4.77 (br s, 0.3 H), 4.35 (br d, 0.6 H), 3.74 (br t, 0.6

H), 3.44 (br s, 0.3 H), 2.90-3.19 (m, 1 H), 2.81 (br d, 1 H), 2.44

(s, 3 H), 1.61 (br d, 3 H)

739
(CD₃OD) δ 8.30 (br d, 1 H), 7.68 (s, 1 H), 7.09-7.31 (m, 1 H),
443.3
99.3%

6.99 (br d, 1 H), 6.86 (br s, 1 H), 6.78 (t, 1 H), 6.51-6.70 (m, 1
[M + H]⁺

H), 4.97 (q, 1 H), 4.78 (br s, 0.1 H), 4.35 (br d, 0.6 H), 3.64-3.81

(m, 0.6 H), 3.46 (br d, 0.4 H), 2.91-3.19 (m, 1 H), 2.81 (br d, 1

H), 2.44 (s, 3 H), 1.60 (br d, 3 H)

740
(CD₃OD) δ 8.77 (d, 1 H), 8.20-8.36 (m, 2 H), 8.08 (td, 1 H),
427.3
99.6%

7.60-7.75 (m, 2 H), 7.50 (s, 0.3 H), 6.92-7.04 (m, 1.7 H), 6.71-
[M + H]⁺

6.84 (m, 1 H), 6.57-6.68 (m, 1 H), 5.00 (br dd, 1 H), 3.74-3.86

(m, 0.6 H), 3.43 (td, 0.3 H), 2.96-3.26 (m, 1 H), 2.79-2.90 (m, 1

H), 2.39-2.49 (m, 3 H)

741
(CD₃OD) δ 8.77 (d, 1 H), 8.20-8.36 (m, 2 H), 8.08 (td, 1 H),
427.3
100%

7.61-7.74 (m, 2 H), 7.50 (s, 0.3 H), 6.93-7.04 (m, 1.7 H), 6.72-
[M + H]⁺

6.83 (m, 1 H), 6.57-6.68 (m, 1 H), 5.00 (br dd, 1 H), 3.73-3.87

(m, 0.6 H), 3.43 (td, 0.4 H), 2.95-3.27 (m, 1 H), 2.85 (br d, 1 H),

2.39-2.48 (m, 3 H)

742
(CD₃OD) δ 8.20-8.34 (m, 1 H), 7.81 (d, 1 H), 7.69 (s, 1 H), 7.52
430.4
100%

(s, 0.5 H), 6.91-7.03 (m, 2.5 H), 6.71-6.85 (m, 1 H), 6.52-6.66
[M + H]⁺

(m, 1 H), 5.01 (br dd, 1 H), 4.02 (s, 3 H), 3.72-3.83 (m, 0.7 H),

3.41 (td, 0.4 H), 3.12-3.24 (m, 0.8 H), 2.93-3.06 (m, 0.4 H),

2.75-2.88 (m, 1 H), 2.35-2.48 (m, 3 H)

743
(CD₃OD) δ 8.21-8.35 (m, 1 H), 7.81 (s, 1 H), 7.69 (s, 1 H), 7.52
430.4
100%

(s, 0.5 H), 6.93-7.02 (m, 2.5 H), 6.71-6.82 (m, 1 H), 6.53-6.66
[M + H]⁺

(m, 1 H), 5.01 (br dd, 0.4 H), 4.03 (s, 3 H), 3.72-3.84 (m, 0.7 H),

3.35-3.46 (m, 1 H), 3.12-3.24 (m, 0.6 H), 2.94-3.06 (m, 0.4 H),

2.83 (br d, 1 H), 2.40-2.49 (m, 3 H)

744
(CD₃OD) δ 8.25-8.43 (m, 1 H), 7.55-7.78 (m, 1 H), 6.93-7.02
479.2
98.4%

(m, 1 H), 6.79-6.92 (m, 1.7 H), 6.55-6.75 (m, 1 H), 6.05 (br s,
[M + H]

0.3 H), 4.81-4.87 (m, 0.3 H), 3.67-3.86 (m, 1.4 H), 3.45 (td, 0.3

H), 2.71-3.08 (m, 2 H), 1.54-1.71 (m, 6 H)

745
(CD₃OD) δ 8.29-8.40 (m, 1 H), 7.63-7.73 (m, 1 H), 6.92-7.02
479.2
98.9%

(m, 1 H), 6.78-6.91 (m, 1.7 H), 6.58-6.75 (m, 1 H), 6.04 (br s,
[M + H]

0.3 H), 4.81-4.87 (m, 0.2 H), 3.68-3.86 (m, 1.4 H), 3.45 (td, 0.4

H), 2.72-3.07 (m, 2 H), 1.53-1.71 (m, 6 H)

746
(CD₃OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1 H), 6.83 (td,
489.2
98.8%

1.7 H), 6.63-6.78 (m, 1 H), 6.38 (br s, 0.3 H), 4.72-4.82 (m, 0.4
[M + H]

H), 4.16 (br d, 0.6 H), 3.37-3.84 (m, 1 H), 2.75-3.22 (m, 2 H),

1.52-1.66 (m, 6 H)

747
(CD₃OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1 H), 6.83 (td,
489.1
99.7%

1.7 H), 6.64-6.78 (m, 1 H), 6.38 (br s, 0.3 H), 4.81 (br s, 0.4 H),
[M + H]

4.16 (br d, 0.6 H), 3.36-3.86 (m, 1 H), 2.75-3.20 (m, 2 H), 1.52-

1.65 (m, 6 H)

748
(CD₃OD) δ 8.39 (s, 1 H), 8.21-8.33 (m, 1 H), 8.10 (s, 1 H), 7.52-
430.3
99.4%

7.74 (m, 1 H), 6.92-7.03 (m, 2 H), 6.71-6.82 (m, 1 H), 6.53-6.65
[M + H]⁺

(m, 1 H), 5.06 (dd, 1 H), 4.00 (s, 3 H), 3.70-3.85 (m, 0.7 H), 3.40

(td, 0.3 H), 3.10-3.23 (m, 0.7 H), 2.93-3.06 (m, 0.3 H), 2.78-2.88

(m, 1 H), 2.37-2.49 (m, 3 H)

749
(CD₃OD) δ 8.38 (s, 1 H), 8.20-8.34 (m, 1 H), 8.09 (s, 1 H), 7.54-
430.3
98.6%

7.73 (m, 1 H), 6.91-7.03 (m, 2 H), 6.70-6.82 (m, 1 H), 6.52-6.65
[M + H]⁺

(m, 1 H), 5.06 (dd, 1 H), 4.00 (s, 3 H), 3.71-3.82 (m, 0.7 H), 3.40

(td, 0.3 H), 3.09-3.23 (m, 0.7 H), 2.91-3.04 (m, 0.3 H), 2.76-2.89

(m, 1 H), 2.36-2.49 (m, 3 H)

750
(CD₃OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.49-6.89
407.3
99.1%

(m, 3 H), 4.90-4.94 (m, 1 H), 4.73 (br s, 0.3 H), 4.34 (br d, 0.7
[M + H]⁺

H), 3.38-3.79 (m, 1 H), 3.09 (br s, 1 H), 2.79 (br d, 1 H), 2.44 (s,

3 H), 2.36 (s, 3 H), 1.55 (br s, 3 H)

751
(CD₃OD) δ 8.30 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.72-6.89
407.4
99.4%

(m, 1.7 H), 6.48-6.70 (m, 1.3 H), 4.89-4.93 (m, 1 H), 4.67-4.76
[M + H]⁺

(m, 0.4 H), 4.32 (br s, 0.6 H), 3.39-3.81 (m, 1 H), 3.10 (br s, 1

H), 2.79 (br d, 1 H), 2.44 (s, 3 H), 2.36 (s, 3 H), 1.56(br s, 3 H)

752
(CD₃OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.84 (br s,
407.3
100%

0.6 H), 6.77 (t, 1 H), 6.48-6.70 (m, 1.4 H), 4.91-4.94 (m, 1 H),
[M + H]⁺

4.72 (br s, 0.5 H), 4.34 (br s, 0.5 H), 3.54-3.81 (m, 1 H), 3.11 (br

s, 1 H), 2.79 (br d, 1 H), 2.44 (s, 3 H), 2.36 (s, 3 H), 1.43-1.63

(m, 3 H)

753
(CD₃OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.84 (br s,
407.4
99.8%

0.6 H), 6.77 (t, 1 H), 6.46-6.72 (m, 1.4 H), 4.90-4.94 (m, 1 H),
[M + H]⁺

4.73 (br s, 0.4 H), 4.33 (br s, 0.6 H), 3.39-3.80 (m, 1 H), 3.10 (br

s, 1 H), 2.79 (br d, 1 H), 2.44 (s, 3 H), 2.37 (s, 3 H), 1.55 (br s, 3 H)

754
(CD₃OD) δ 8.29 (d, 1 H), 7.75 (br s, 1 H), 6.98 (d, 1 H), 6.55-
421.4
100%

6.90 (m, 3 H), 4.60-4.78 (m, 0.5 H), 4.35 (br s, 0.5 H), 3.38-3.81
[M + H]⁺

(m, 1 H), 3.12 (br d, 1 H), 2.80 (br d, 1 H), 2.32-2.50 (m, 6 H),

1.61 (br s, 6 H)

755
(CD₃OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 6.97 (d, 1 H), 6.47-6.90
421.4
99.8%

(m, 3 H), 4.63-4.77 (m, 0.5 H), 4.33 (br s, 0.5 H), 3.38-3.82 (m,
[M + H]⁺

1 H), 3.11 (br s, 1 H), 2.79 (br d, 1 H), 2.33-2.48 (m, 6 H), 1.61

(br s, 6 H)

756
(CD₃OD) δ 8.34 (d, 1 H), 7.68 (s, 1 H), 6.96 (dd, 7.7 Hz, 1 H),
445.3
100%

6.65-6.89 (m, 2.7 H), 6.43 (br s, 0.3 H), 4.15-4.82 (m, 1 H),
[M + H]⁺

3.38-3.84 (m, 1 H), 2.79-3.18 (m, 2 H), 1.53-1.68 (m, 6 H)

757
(CD₃OD) δ 8.34 (d, 1 H), 7.68 (s, 1 H), 6.96 (dd, 1 H), 6.63-6.89
445.3
100%

(m, 2.7 H), 6.43 (br s, 0.3 H), 4.13-4.81 (m, 1 H), 3.37-3.82 (m,
[M + H]⁺

1 H), 2.78-3.18 (m, 2 H), 1.52-1.67 (m, 6 H)

758
(CD₃OD) δ 8.43 (s, 1 H), 8.34 (d, 1 H), 7.68 (s, 1 H), 6.91-7.31
403.3
99.7%

(m, 2 H), 6.40-6.89 (m, 3 H), 4.28-4.83 (m, 1 H), 3.37-3.82 (m, 1
[M + H]

H), 2.74-3.16 (m, 2 H)

759
(CD₃OD) δ 8.43 (s, 1 H), 8.34 (d, 1 H), 7.68 (s, 1 H), 6.92-7.31
403.2
99.3%

(m, 2 H), 6.45-6.92 (m, 3 H), 4.27-4.83 (m, 1 H), 3.37-3.78 (m, 1
[M + H]

H), 2.77-3.13 (m, 2 H)

760
(CD₃OD) δ 8.25-8.49 (m, 2 H), 7.58-8.13 (m, 2 H), 6.92-7.01
353.2
100%

(m, 1 H), 6.53-6.91 (m, 3 H), 4.48 (br s, 1 H), 3.41-3.83 (m, 1
[M + H]⁺

H), 2.74-3.15 (m, 2 H)

761
(CD₃OD) δ 8.26-8.50 (m, 2 H), 7.64-8.14 (m, 2 H), 6.92-7.01
353.3
99.3%

(m, 1 H), 6.53-6.92 (m, 3 H), 4.39-4.79 (m, 1 H), 3.37-3.84 (m, 1
[M + H]⁺

H), 2.73-3.17 (m, 2 H)

762
(CD₃OD) δ 8.35 (br d, 1 H), 7.70 (d, 1 H), 6.88-7.02 (m, 2 H),
401.2
100%

6.50-6.88 (m, 2 H), 4.48 (dd, 1 H), 4.00-4.05 (m, 3 H), 3.62-3.71
[M + H]⁺

(m, 0.6 H), 2.92-3.22 (m, 1.4 H), 2.71-2.87 (m, 1 H)

763
(CD₃OD) δ 8.35 (br d, 1 H), 7.70 (br d, 1 H), 6.88-7.01 (m, 2 H),
401.2
100%

6.50-6.87 (m, 2 H), 4.48 (dd, 1 H), 3.98-4.07 (m, 3 H), 3.60-3.72
[M + H]'

(m, 0.6 H), 2.92-3.24 (m, 1.4 H), 2.69-2.86 (m, 1 H)

764
(CD₃OD) δ 8.35 (t, 1 H), 7.70 (br d, 1 H), 6.68-7.03 (m, 4.6 H),
417.2
100%

6.53 (s, 0.4 H), 4.47 (dd, 1 H), 4.06-4.16 (m, 3 H), 3.62-3.74 (m,
[M + H]⁺

0.6 H), 2.93-3.24 (m, 1.4 H), 2.68-2.87 (m, 1 H)

765
(CD₃OD) δ 8.29-8.41 (m, 1 H), 7.70 (br s, 1 H), 6.70-7.02 (m,
417.2
100%

4.7 H), 6.53 (s, 0.3 H), 4.47 (dd, 1 H), 4.06-4.15 (m, 3 H), 3.63-
[M + H]⁺

3.75 (m, 0.6 H), 2.93-3.23 (m, 1.4 H), 2.70-2.89 (m, 1 H)

766
(CD₃OD) δ 8.39 (s, 2 H), 7.59-8.16 (m, 2 H), 7.29 (d, 1 H), 6.53-
369.2
100%

6.91 (m, 3 H), 4.45-4.85 (m, 1 H), 3.74 (br s, 1 H), 2.71-3.17 (m,
[M + H]⁺

2 H)

767
(CD₃OD) δ 8.40 (s, 2 H), 7.68-8.13 (m, 2 H), 7.30 (d, 1 H), 6.57-
369.2
99.1%

6.93 (m, 3 H), 4.42-4.84 (m, 1 H), 3.74 (br s, 1 H), 2.77-3.17 (m,
[M + H]⁺

2 H)

768
(CD₃OD) δ 8.24-8.43 (m, 2 H), 8.08 (br s, 0.4 H), 7.77 (br s, 0.6
348.9
100%

H), 7.68 (s, 1 H), 6.99 (br d, 1 H), 6.88 (br s, 1 H), 6.78 (br t, 1
[M + H]⁺

H), 6.40-6.69 (m, 1 H), 4.47 (br s, 1 H), 3.76 (br s, 1 H), 2.91-

3.17 (m, 1 H), 2.80 (br s, 1 H), 2.44 (s, 3 H)

769
(CD₃OD) δ 8.23-8.45 (m, 2 H), 8.08 (br s, 0.4 H), 7.61-7.86 (m,
349.0
99.8%

1.6 H), 6.99 (br d, 1 H), 6.88 (br s, 1 H), 6.78 (br t, 1 H), 6.41-
[M + H]⁺

6.67 (m, 1 H), 4.78 (br s, 0.5 H), 4.47 (br s, 0.5 H), 3.76 (br s,

0.6 H), 3.35 (br s, 0.4 H), 2.91-3.16 (m, 1 H), 2.77 (br d, 1 H),

2.44 (s, 3 H)

770
(CD₃OD) δ 8.19-8.35 (m, 2 H), 7.67 (s, 1 H), 6.98 (d, 1 H), 6.71-
363.1
100%

6.90 (m, 2 H), 6.61 (br s, 1 H), 4.31 (br s, 1 H), 3.71 (br s, 1 H),
[M + H]⁺

2.92-3.15 (m, 1 H), 2.78 (br d, 1 H), 2.33-2.51 (m, 6 H)

771
(CD₃OD) δ 8.17-8.38 (m, 2 H), 7.67 (s, 1 H), 6.98 (d, 1 H), 6.73-
363.0
99.5%

6.90 (m, 2 H), 6.60 (br s, 1 H), 4.29 (br s, 1 H), 3.72 (br s, 1 H),
[M + H]⁺

2.90-3.18 (m, 1 H), 2.78 (br d, 1 H), 2.32-2.49 (m, 6 H)

772
(CD₃OD) δ 8.46-8.53 (m, 1 H), 8.31-8.39 (m, 1 H), 7.66-7.75
421.0
99.6%

(m, 1 H), 6.81-7.03 (m, 3 H), 6.74 (s, 0.6 H), 6.54 (s, 0.2 H),
[M + H]⁺

6.03 (s, 0.2 H), 3.41-3.88 (m, 2 H), 2.76-3.00 (m, 2 H)

773
(CD₃OD) δ 8.44-8.49 (m, 1 H), 8.29-8.36 (m, 1 H), 7.64-7.72
421.0
99.4%

(m, 1 H), 6.79-7.01 (m, 3 H), 6.72 (s, 0.6 H), 6.52 (s, 0.2 H),
[M + H]⁺

6.01 (br s, 0.2 H), 3.37-3.88 (m, 2 H), 2.89-2.99 (m, 1 H), 2.74-

2.86 (m, 1 H)

774
(CD₃OD) δ 8.33 (d, 1 H), 8.25 (s, 1 H), 7.67 (s, 1 H), 6.95 (dd, 1
367.1
99.2%

H), 6.49-6.88 (m, 3 H), 4.21-4.83 (m, 1 H), 3.38-3.85 (m, 1 H),
[M + H]⁺

3.06 (br s, 1 H), 2.78 (br d, 1 H), 2.38 (s, 3 H)

775
(CD₃OD) δ 8.33 (d, 1 H), 8.25 (s, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1
367.0
99.7%

H), 6.49-6.88 (m, 3 H), 4.26-4.83 (m, 1 H), 3.35-3.82 (m, 1 H),
[M + H]⁺

2.96-3.14 (m, 1 H), 2.78 (br d, 1 H), 2.38 (s, 3 H)

776
(CD₃OD) δ 8.28-8.48 (m, 1 H), 7.50-7.84 (m, 3 H), 6.74-7.08
402.0
99.5%

(m, 4 H), 6.15-6.56 (m, 1 H), 4.82 (br s, 0.5 H), 4.05-4.14 (m,
[M + H]⁺

0.5 H), 3.64-3.78 (m, 0.5 H), 3.12-3.29 (m, 0.5 H), 2.70-3.06 (m,

2 H)

777
(CD₃OD) δ 8.29-8.47 (m, 1 H), 7.50-7.84 (m, 3 H), 6.25-7.11
402.0
99.3%

(m, 5 H), 4.84 (br d, 0.5 H), 4.04-4.12 (m, 0.5 H), 3.61-3.78 (m,
[M + H]⁺

0.5 H), 3.19-3.28 (m, 0.5 H), 2.92-3.06 (m, 1 H), 2.75 (br d, 1 H)

778
(CD₃OD) δ 8.78 (br d, 1 H), 8.26-8.36 (m, 1 H), 7.99-8.14 (m, 2
443.0
100%

H), 7.59-7.74 (m, 2 H), 7.50 (s, 0.3 H), 6.97 (s, 0.7 H), 6.72-6.84
[M + H]⁺

(m, 1 H), 6.63-6.71 (m, 1 H), 6.54-6.62 (m, 1 H), 5.00 (dd, 1 H),

3.86-4.06 (m, 3 H), 3.72-3.85 (m, 0.7 H), 3.43 (td, 0.3 H), 2.93-

3.29 (m, 1 H), 2.86 (br dd, 1 H)

779
(CD₃OD) δ 8.78 (br d, 1 H), 8.28-8.34 (m, 1 H), 7.99-8.16 (m, 2
443.0
100%

H), 7.61-7.78 (m, 2 H), 7.50 (s, 0.3 H), 6.97 (s, 0.7 H), 6.74-6.83
[M + H]⁺

(m, 1 H), 6.63-6.72 (m, 1 H), 6.52-6.62 (m, 1 H), 5.00 (br dd, 1

H), 3.92-4.00 (m, 3 H), 3.72-3.84 (m, 0.7 H), 3.43 (td, 0.3 H),

2.96-3.27 (m, 1 H), 2.86 (br dd, 1 H)

780
(CD₃OD) δ 8.40-8.53 (m, 1 H), 7.70 (d, 1 H), 7.24-7.33 (m, 1
433.0
100%

H), 6.67-7.00 (m, 3.7 H), 6.51 (s, 0.3 H), 4.92 (br d, 0.3 H), 4.47
[M + H]⁺

(dd, 0.7 H), 4.05-4.15 (m, 3 H), 3.68 (ddd, 0.5 H), 2.93-3.27 (m,

1.5 H), 2.72-2.88 (m, 1 H)

781
(CD₃OD) δ 8.36-8.52 (m, 1 H), 7.70 (d, 1 H), 7.24-7.36 (m, 1
432.9
99.5%

H), 6.65-7.01 (m, 3.7 H), 6.51 (s, 0.3 H), 4.92 (br d, 0.4 H), 4.47
[M + H]⁺

(dd, 0.6 H), 4.05-4.17 (m, 3 H), 3.68 (ddd, 0.6 H), 2.92-3.27 (m,

1.4 H), 2.71-2.89 (m, 1 H)

782
(CD₃OD) δ 8.40-8.58 (m, 1 H), 7.49-7.85 (m, 3 H), 7.30 (d, 1
417.9
99.6%

H), 6.71-7.11 (m, 3.2 H), 6.25-6.54 (m, 0.8 H), 4.83 (br s, 0.5
[M + H]⁺

H), 4.02-4.14 (m, 0.5 H), 3.71 (br t, 0.5 H), 3.17-3.29 (m, 0.5 H),

2.93-3.06 (m, 1 H), 2.75 (br d, 1 H)

783
(CD₃OD) δ 8.36-8.59 (m, 1 H), 7.47-7.88 (m, 3 H), 7.30 (d, 1
418.0
99.6%

H), 6.67-7.13 (m, 3.2 H), 6.18-6.57 (m, 0.8 H), 4.82 (br s, 0.5
[M + H]⁺

H), 4.09 (br dd, 0.5 H), 3.62-3.79 (m, 0.5 H), 3.15-3.28 (m, 0.5

H), 2.90-3.07 (m, 1 H), 2.76 (br d, 1 H)

784
(CD₃OD) δ 8.27-8.50 (m, 2 H), 7.51-7.76 (m, 2 H), 7.03-7.25
399.0
100%

(m, 2 H), 6.89-7.02 (m, 1 H), 6.81 (br t, 1 H), 4.26 (br s, 1 H),
[M + H]⁺

4.06 (br s, 1 H), 3.05 (br d, 1 H), 2.86 (br d, 1 H), 2.34-2.63 (m,

3 H)

785
(CD₃OD) δ 8.42 (br s, 1 H), 8.31-8.38 (m, 1 H), 7.65 (s, 1 H),
399.0
99.8%

7.53-7.62 (m, 1 H), 7.03-7.22 (m, 2 H), 6.95 (br d, 1 H), 6.82 (br
[M + H]⁺

s, 1 H), 4.26 (br s, 1 H), 4.06 (br s, 1 H), 2.99-3.12 (m, 1 H),

2.86 (dd, 1 H), 2.47 (br s, 3 H)

786
(CD₃OD) δ 8.35 (d, 1 H), 7.74 (s, 1 H), 7.59 (br d, 1 H), 7.15-
457.0
97.5%

7.20 (m, 1 H), 6.88-7.14 (m, 2 H), 6.82 (td, 1 H), 4.29 (br s, 1
[M + H]⁺

H), 4.07 (br s, 1 H), 3.13 (br d, 1 H), 2.89 (dd, 1 H), 2.47 (br s, 3

H), 1.67 (s, 6 H)

787
(CD₃OD) δ 8.35 (d, 1 H), 7.93 (br s, 1 H), 7.60 (br d, 1 H), 7.18
457.0
99.0%

(t, 1 H), 6.89-7.10 (m, 2 H), 6.84 (td, 1 H), 4.32 (br s, 1 H), 4.05
[M + H]⁺

(br s, 1 H), 3.15 (br s, 1 H), 2.80-2.97 (m, 1 H), 2.48 (br s, 3 H),

1.67 (s, 6 H)

788
(CD₃OD) δ 8.44 (d, 1 H), 8.22-8.38 (m, 2 H), 7.70 (s, 1 H), 7.51-
461.1
96.7%

7.63 (m, 1.3 H), 6.91-7.01 (m, 1.7 H), 6.74-6.88 (m, 2 H), 4.94-
[M + H]⁺

5.08 (m, 1 H), 3.99 (s, 3 H), 3.72-3.85 (m, 0.7 H), 3.42 (td, 0.3

H), 2.96-3.25 (m, 1 H), 2.78-2.91 (m, 1 H)

789
(CD₃OD) δ 8.44 (d, 1 H), 8.21-8.39 (m, 2 H), 7.70 (s, 1 H), 7.51-
461.2
90.1%

7.63 (m, 1.3 H), 6.92-7.01 (m, 1.7 H), 6.72-6.88 (m, 2 H), 4.93-
[M + H]⁺

5.08 (m, 1 H), 3.99 (s, 3 H), 3.73-3.85 (m, 0.7 H), 3.42 (td, 0.3

H), 2.97-3.24 (m, 1 H), 2.85 (br d, 1 H)

790
(CD₃OD) δ 8.64 (d, 1 H), 8.27-8.39 (m, 1 H), 7.94 (t, 1 H), 7.67-
449.1
98.8%

7.80 (m, 2 H), 7.46 (s, 0.4 H), 6.94-7.00 (m, 1.6 H), 6.71-6.89
[M + H]⁺

(m, 2 H), 4.98 (br dd, 1 H), 3.74-3.85 (m, 0.7 H), 3.38-3.50 (m,

0.3 H), 2.97-3.26 (m, 1 H), 2.85 (br d, 1 H)

791
(CD₃OD) δ 8.64 (d, 1 H), 8.26-8.38 (m, 1 H), 7.93 (td, 1 H),
449.1
98.4%

7.68-7.79 (m, 2 H), 7.46 (s, 0.4 H), 6.93-6.99 (m, 1.6 H), 6.76-
[M + H]⁺

6.89 (m, 2 H), 4.98 (dd, 1 H), 3.76-3.85 (m, 0.7 H), 3.43 (td, 0.3

H), 2.98-3.26 (m, 1 H), 2.81-2.91 (m, 1 H)

792
(CD₃OD) δ 8.43 (s, 1 H), 7.66 (s, 1 H), 7.45 (br s, 1 H), 6.96-
399.2
100%

7.30 (m, 2 H), 6.34-6.96 (m, 3 H), 4.18-4.43 (m, 1 H), 3.36-3.98
[M + H]⁺

(m, 1 H), 2.89-3.16 (m, 1 H), 2.80 (dd, 1 H), 2.65 (br s, 3 H)

793
(CD₃OD) δ 8.43 (s, 1 H), 7.67 (s, 1 H), 7.46 (br d, 1 H), 6.97-
399.1
100%

7.29 (m, 2 H), 6.38-6.94 (m, 3 H), 4.29 (br s, 1 H), 3.35-3.97 (m,
[M + H]⁺

1 H), 3.01 (br s, 1 H), 2.80 (dd, 1 H), 2.65 (br s, 3 H)

794
(CD₃OD) δ 7.66 (s, 1 H), 7.46 (br s, 1 H), 6.93-7.28 (m, 2 H),
457.2
100%

6.41-6.90 (m, 3 H), 4.74-4.87 (m, 0.7 H), 4.33 (br s, 0.3 H),
[M + H]⁺

3.36-3.93 (m, 1 H), 2.76-3.18 (m, 2 H), 2.55-2.72 (m, 3 H), 1.36-

1.81 (m, 6 H)

795
(CD₃OD) δ 7.67 (s, 1 H), 7.45 (br s, 1 H), 6.94-7.27 (m, 2 H),
457.2
99.2%

6.44-6.90 (m, 3 H), 4.75-4.86 (m, 0.5 H), 4.34 (br d, 0.5 H),
[M + H]⁺

3.35-3.93 (m, 1 H), 2.74-3.17 (m, 2 H), 2.55-2.72 (m, 3 H), 1.54-

1.72 (m, 6 H)

796
(CD₃OD) δ 8.92 (s, 1 H), 8.27-8.39 (m, 2 H), 7.46-7.85 (m, 2.3
470.1
100%

H), 6.91-7.05 (m, 1.7 H), 6.71-6.88 (m, 2 H), 4.92-5.13 (m, 1 H),
[M + H]⁺

3.37-3.84 (m, 1 H), 2.90-3.22 (m, 1 H), 2.84 (br d, 1 H)

797
(CD₃OD) δ 8.92 (s, 1 H), 8.25-8.40 (m, 2 H), 7.48-7.83 (m, 2.4
470.1
99.4%

H), 6.92-7.01 (m, 1.6 H), 6.72-6.88 (m, 2 H), 4.92-5.14 (m, 1 H),
[M + H]⁺

3.37-3.84 (m, 1 H), 2.95-3.24 (m, 1 H), 2.86 (br d, 1 H)

798
(CD₃OD) δ 8.74-8.82 (m, 1 H), 8.26-8.37 (m, 1 H), 8.09 (tt, 1
427.1
100%

H), 7.60-7.75 (m, 2 H), 7.38-7.54 (m, 1.5 H), 7.04-7.18 (m, 1 H),
[M + H]⁺

7.00 (s, 0.5 H), 6.60-6.77 (m, 1.6 H), 6.45 (s, 0.4 H), 4.92-5.04

(m, 1 H), 3.89-4.00 (m, 0.5 H), 3.35-3.43 (m, 0.5 H), 2.96-3.25

(m, 1 H), 2.82-2.92 (m, 1 H), 2.44-2.71 (m, 3 H)

799
(CD₃OD) δ 8.73-8.81 (m, 1 H), 8.27-8.35 (m, 1 H), 8.08 (tt, 1
427.2
100%

H), 7.62-7.74 (m, 2 H), 7.37-7.52 (m, 1.5 H), 7.05-7.15 (m, 1 H),
[M + H]⁺

7.00 (s, 0.5 H), 6.59-6.76 (m, 1.6 H), 6.44 (s, 0.4 H), 4.93-5.03

(m, 1 H), 3.93 (br t, 0.5 H), 3.35-3.43 (m, 0.5 H), 2.94-3.25 (m, 1

H), 2.82-2.91 (m, 1 H), 2.44-2.70 (m, 3 H)

800
(CD₃OD) δ 8.39 (d, 1 H), 8.09 (s, 1 H), 7.68 (d, 1 H), 7.38-7.52
430.2
100%

(m, 1.5 H), 7.10 (ddd, 1 H), 6.97 (s, 0.5 H), 6.41-6.76 (m, 2 H),
[M + H]⁺

4.91-5.11 (m, 1 H), 4.00 (d, 3 H), 3.85-3.95 (m, 0.6 H), 3.34-

3.40 (m, 0.4 H), 2.93-3.22 (m, 1 H), 2.84 (dt, 1 H), 2.48-2.69 (m,

3 H)

801
(CD₃OD) δ 8.39 (s, 1 H), 8.10 (s, 1 H), 7.69 (d, 1 H), 7.39-7.52
430.2
99.4%

(m, 1.5 H), 7.10 (ddd, 1 H), 6.98 (s, 0.5 H), 6.42-6.75 (m, 2 H),
[M + H]⁺

4.92-5.11 (m, 1 H), 4.00 (d, 3 H), 3.86-3.95 (m, 0.5 H), 3.33-

3.41 (m, 0.5 H), 2.94-3.21 (m, 1 H), 2.84 (dt, 1 H), 2.48-2.69 (m,

3 H)

802
(CD₃OD) δ 7.81 (dd, 1 H), 7.70 (d, 1 H), 7.36-7.52 (m, 1.5 H),
430.2
100%

7.05-7.16 (m, 1 H), 6.98 (s, 1.5 H), 6.64-6.77 (m, 1 H), 6.35-6.63
[M + H]⁺

(m, 1 H), 5.01 (br dd, 1 H), 4.03 (d, 3 H), 3.84-3.95 (m, 0.6 H),

3.33-3.39 (m, 0.4 H), 2.93-3.22 (m, 1 H), 2.78-2.90 (m, 1 H),

2.47-2.68 (m, 3 H)

803
(CD₃OD) δ 7.82 (dd, 1 H), 7.69 (d, 1 H), 7.38-7.53 (m, 1.5 H),
430.2
100%

7.04-7.18 (m, 1 H), 6.99 (d, 1.5 H), 6.64-6.76 (m, 1 H), 6.41-
[M + H]⁺

6.64 (m, 1 H), 5.01 (br dd, 1 H), 4.03 (d, 3 H), 3.84-3.96 (m, 0.6

H), 3.34-3.39 (m, 0.4 H), 2.93-3.24 (m, 1 H), 2.80-2.91 (m, 1 H),

2.45-2.72 (m, 3 H)

804
(CD₃OD) δ 8.24 (s, 1 H), 7.67 (br s, 1 H), 7.49 (br d, 1 H), 7.11-
457.1
100%

7.28 (m, 0.7 H), 7.08 (d, 1 H), 6.99 (s, 0.3 H), 6.47-6.88 (m, 2
[M + H]⁺

H), 4.31 (br d, 1 H), 3.73 (br s, 1 H), 2.91-3.20 (m, 1 H), 2.81 (br

d, 1 H), 2.32 (s, 3 H), 1.51-1.72 (m, 6H)

805
(CD₃OD) δ 8.24 (s, 1 H), 7.66 (br s, 1 H), 7.49 (br d, 1 H), 7.11-
457.2
99.2%

7.29 (m, 0.8 H), 7.08 (d, 1 H), 6.99 (s, 0.2 H), 6.46-6.89 (m, 2
[M + H]⁺

H), 4.31 (br d, 1 H), 3.73 (br s, 1 H), 2.90-3.20 (m, 1 H), 2.81 (br

d, 1 H), 2.25-2.35 (m, 3 H), 1.52-1.76 (m, 6H)

806
(CD₃OD) δ 8.24-8.37 (m, 1 H), 8.00 (s, 1 H), 7.81-7.89 (m, 1 H),
430.2
100%

7.46-7.75 (m, 1.4 H), 6.93-7.09 (m, 1.6 H), 6.73-6.86 (m, 1 H),
[M + H]⁺

6.53-6.70 (m, 1 H), 5.07 (dd, 1 H), 4.05-4.15 (m, 3 H), 3.37-3.85

(m, 1 H), 2.96-3.27 (m, 1 H), 2.79-2.93 (m, 1 H), 2.36-2.52 (m, 3 H)

807
(CD₃OD) δ 8.25-8.37 (m, 1 H), 8.00 (s, 1 H), 7.83-7.94 (m, 1 H),
430.2
93.0%

7.54-7.80 (m, 1.3 H), 6.96-7.09 (m, 1.7 H), 6.73-6.87 (m, 1 H),
[M + H]⁺

6.51-6.69 (m, 1 H), 5.07 (dd, 1 H), 4.09-4.19 (m, 3 H), 3.38-3.89

(m, 1 H), 2.95-3.26 (m, 1 H), 2.78-2.91 (m, 1 H), 2.40-2.52 (m, 3 H)

808
(CD₃OD) δ 8.31-8.45 (m, 1 H), 8.00 (s, 1 H), 7.83-7.91 (m, 1 H),
434.2
92.5%

7.50-7.80 (m, 1.4 H), 6.94-7.06 (m, 1.6 H), 6.72-6.91 (m, 2 H),
[M + H]⁺

5.10 (dd, 1 H), 4.10-4.20 (m, 3 H), 3.38-3.88 (m, 1 H), 2.96-3.29

(m, 1 H), 2.80-2.93 (m, 1 H)

809
(CD₃OD) δ 8.29-8.40 (m, 1 H), 7.99 (s, 1 H), 7.84-7.89 (m, 1 H),
434.2
100%

7.50-7.76 (m, 1.4 H), 6.94-7.04 (m, 1.6 H), 6.74-6.90 (m, 2 H),
[M + H]⁺

4.94-5.13 (m, 1 H), 4.10-4.14 (m, 3 H), 3.38-3.87 (m, 1 H), 2.97-

3.28 (m, 1 H), 2.80-2.91 (m, 1 H)

810
(CD₃OD) δ 8.69 (d, 1 H), 7.69 (s, 1 H), 7.63 (br d, 1 H), 7.10-
511.2
98.3%

7.29 (m, 1 H), 6.96-7.01 (m, 1 H), 6.54-6.90 (m, 2 H), 4.37 (br d,
[M + H]⁺

1 H), 3.74 (br s, 1 H), 2.71-3.21 (m, 2 H), 1.55-1.70 (m, 6 H)

811
(CD₃OD) δ 8.69 (d, 1 H), 7.61-7.71 (m, 2 H), 7.11-7.27 (m, 1
511.2
99.6%

H), 6.99 (t, 1 H), 6.57-6.91 (m, 2 H), 4.37 (br d, 1 H), 3.64-3.84
[M + H]⁺

(m, 1 H), 2.75-3.21 (m, 2 H), 1.53-1.69 (m, 6 H)

812
(CD₃OD) δ 8.77 (br d, 1 H), 8.15-8.39 (m, 2 H), 8.09 (br t, 1 H),
427.2
100%

7.61-7.73 (m, 2 H), 7.40-7.57 (m, 1 H), 7.02-7.14 (m, 1 H), 6.96
[M + H]⁺

(s, 1 H), 6.46-6.64 (m, 1 H), 4.98 (br dd, 1 H), 3.74-3.85 (m, 0.9

H), 3.40 (br d, 0.1 H), 2.93-3.26 (m, 1 H), 2.84 (br d, 1 H), 2.23-

2.37 (m, 3 H)

813
(CD₃OD) δ 8.77 (dd, 1 H), 8.15-8.34 (m, 2 H), 8.03-8.12 (m, 1
427.2
99.9%

H), 7.62-7.72 (m, 2 H), 7.41-7.53 (m, 1 H), 7.01-7.12 (m, 1 H),
[M + H]⁺

6.95 (s, 1 H), 6.49-6.60 (m, 1 H), 4.98 (br dd, 1 H), 3.74-3.88

(m, 0.8 H), 3.38-3.49 (m, 0.2 H), 3.13-3.26 (m, 0.7 H), 2.93-3.06

(m, 0.3 H), 2.78-2.89 (m, 1 H), 2.23-2.36 (m, 3 H)

814
(CD₃OD) δ 8.15-8.29 (m, 1 H), 7.81 (d, 1 H), 7.68 (s, 1 H), 7.41-
430.2
100%

7.54 (m, 1 H), 7.03-7.12 (m, 1 H), 6.98-7.01 (m, 1 H), 6.94 (s, 1
[M + H]⁺

H), 6.45-6.60 (m, 1 H), 5.00 (br dd, 1 H), 3.99-4.07 (m, 3 H),

3.71-3.82 (m, 0.7 H), 3.36-3.45 (m, 0.3 H), 2.93-3.23 (m, 1 H),

2.83 (br d, 1 H), 2.25-2.35 (m, 3 H)

815
(CD₃OD) δ 8.17-8.29 (m, 1 H), 7.78-7.84 (m, 1 H), 7.69 (s, 1 H),
430.2
99.9%

7.41-7.56 (m, 1 H), 7.03-7.13 (m, 1 H), 6.97-7.02 (m, 1 H), 6.94
[M + H]⁺

(s, 1 H), 6.42-6.61 (m, 1 H), 5.00 (br dd, 1 H), 4.00-4.06 (m, 3

H), 3.70-3.83 (m, 0.6 H), 3.34-3.45 (m, 0.4 H), 2.92-3.24 (m, 1

H), 2.74-2.89 (m, 1 H), 2.26-2.35 (m, 3 H)

816
(CD₃OD) δ 8.42 (d, 1 H), 8.18-8.32 (m, 2 H), 7.70 (s, 1 H), 7.49-
457.2
100%

7.62 (m, 1 H), 6.92-7.01 (m, 2 H), 6.69-6.80 (m, 1 H), 6.55-6.66
[M + H]⁺

(m, 1 H), 5.01 (br dd, 1 H), 3.97 (s, 3 H), 3.68-3.87 (m, 0.7 H),

3.37-3.49 (m, 0.3 H), 2.93-3.25 (m, 1 H), 2.77-2.89 (m, 1 H),

2.35-2.48 (m, 3 H)

817
(CD₃OD) δ 8.43 (d, 1 H), 8.14-8.34 (m, 2 H), 7.69-7.78 (m, 1
457.2
100%

H), 7.51-7.63 (m, 1 H), 6.92-7.03 (m, 2 H), 6.70-6.83 (m, 1 H),
[M + H]⁺

6.53-6.68 (m, 1 H), 5.02 (br dd, 1 H), 3.98 (s, 3 H), 3.71-3.85

(m, 0.7 H), 3.42 (td, 0.3 H), 3.12-3.26 (m, 0.7 H), 2.95-3.07 (m,

0.3 H), 2.76-2.91 (m, 1 H), 2.39-2.49 (m, 3 H)

818
(CD₃OD) δ 8.58-8.66 (m, 1 H), 8.19-8.34 (m, 1 H), 7.83-7.98
445.2
99.4%

(m, 1 H), 7.64-7.77 (m, 2 H), 7.46 (s, 0.3 H), 6.90-7.03 (m, 1.7
[M + H]⁺

H), 6.70-6.82 (m, 1 H), 6.55-6.67 (m, 1 H), 4.92-5.01 (m, 1 H),

3.70-3.86 (m, 0.7 H), 3.44 (td, 0.3 H), 2.95-3.27 (m, 1 H), 2.76-

2.91 (m, 1 H), 2.35-2.50 (m, 3 H)

819
(CD₃OD) δ 8.58-8.68 (m, 1 H), 8.20-8.34 (m, 1 H), 7.92 (t, 1 H),
445.2
99.6%

7.65-7.80 (m, 2 H), 7.46 (s, 0.3 H), 6.90-7.02 (m, 1.7 H), 6.70-
[M + H]⁺

6.84 (m, 1 H), 6.56-6.69 (m, 1 H), 4.92-5.01 (m, 1 H), 3.72-3.86

(m, 0.7 H), 3.44 (td, 0.3 H), 3.15-3.27 (m, 0.7 H), 2.95-3.07 (m,

0.3 H), 2.85 (br dd, 1 H), 2.34-2.49 (m, 3 H)

820
(CD₃OD) δ 8.92 (s, 1 H), 8.21-8.40 (m, 2 H), 7.49-7.81 (m, 2 H),
466.2
98.8%

6.92-7.03 (m, 2 H), 6.71-6.83 (m, 1 H), 6.51-6.67 (m, 1 H), 4.98-
[M + H]⁺

5.12 (m, 1 H), 3.70-3.87 (m, 0.7 H), 3.38-3.47 (m, 0.3 H), 2.94-

3.23 (m, 1 H), 2.77-2.91 (m, 1 H), 2.37-2.48 (m, 3 H)

821
(CD₃OD) δ 8.77-9.00 (m, 1 H), 8.20-8.40 (m, 2 H), 7.48-7.82
466.2
99.5%

(m, 2 H), 6.98 (br t, 2 H), 6.70-6.82 (m, 1 H), 6.54-6.68 (m, 1
[M + H]⁺

H), 5.06 (br dd, 1 H), 3.67-3.86 (m, 0.7 H), 3.41 (td, 0.3 H),

2.93-3.26 (m, 1 H), 2.85 (br d, 1 H), 2.35-2.51 (m, 3 H)

822
(CD₃OD) δ 8.20-8.37 (m, 2 H), 7.48-7.85 (m, 2 H), 7.17-7.25
466.2
100%

(m, 1 H), 6.92-7.03 (m, 2 H), 6.70-6.82 (m, 1 H), 6.53-6.66 (m, 1
[M + H]⁺

H), 5.02 (dd, 1 H), 3.73-3.86 (m, 0.7 H), 3.42 (td, 0.3 H), 2.94-

3.25 (m, 1 H), 2.77-2.89 (m, 1 H), 2.38-2.48 (m, 3 H)

823
(CD₃OD) δ 8.21-8.35 (m, 2 H), 7.82 (s, 0.3 H), 7.69 (d, 1 H),
466.2
100%

7.53 (s, 0.6 H), 7.18-7.23 (m, 1 H), 6.93-7.02 (m, 2 H), 6.71-6.81
[M + H]⁺

(m, 1 H), 6.53-6.66 (m, 1 H), 5.02 (dd, 1 H), 3.72-3.85 (m, 0.7

H), 3.42 (td, 0.3 H), 2.95-3.25 (m, 1 H), 2.76-2.89 (m, 1 H),

2.39-2.48 (m, 3 H)

824
(CD₃OD) δ 8.26-8.39 (m, 2 H), 7.50-7.84 (m, 2.4 H), 7.21 (d, 1
470.2
99.5%

H), 6.93-7.01 (m, 1.6 H), 6.70-6.88 (m, 2 H), 4.92-5.08 (m, 1 H),
[M + H]⁺

3.74-3.86 (m, 0.7 H), 3.42 (br dd, 0.3 H), 3.15-3.24 (m, 0.7 H),

2.96-3.04 (m, 0.3 H), 2.80-2.91 (m, 1 H)

825
(CD₃OD) δ 8.23-8.43 (m, 2 H), 7.47-7.88 (m, 2.4 H), 7.21 (d, 1
470.2
100%

H), 6.91-7.04 (m, 1.6 H), 6.72-6.89 (m, 2 H), 5.04 (br dd, 1 H),
[M + H]⁺

3.73-3.85 (m, 0.5 H), 3.38-3.45 (m, 0.5 H), 3.12-3.24 (m, 0.8 H),

2.97-3.05 (m, 0.2 H), 2.78-2.91 (m, 1 H)

826
(CD₃OD) δ 8.63-8.80 (m, 2 H), 8.31 (d, 1 H), 8.09 (td, 1 H),
481.2
100%

7.59-7.72 (m, 3 H), 6.72-7.10 (m, 3 H), 4.92-5.07 (m, 1 H), 3.38-
[M + H]⁺

3.85 (m, 1 H), 2.83-3.25 (m, 2 H)

827
(CD₃OD) δ 8.63-8.80 (m, 2 H), 8.31 (d, 1 H), 8.08 (td, 1 H),
481.2
98.1%

7.58-7.72 (m, 3 H), 6.75-7.07 (m, 3 H), 4.93-5.07 (m, 1 H), 3.39-
[M + H]⁺

3.83 (m, 1 H), 2.84-3.26 (m, 2 H)

828
(CD₃OD) δ 8.66-8.73 (m, 1 H), 8.39-8.43 (m, 1 H), 8.08-8.17
484.2
100%

(m, 1 H), 7.72 (s, 1 H), 7.59-7.66 (m, 1 H), 6.93-7.05 (m, 2 H),
[M + H]⁺

6.76-6.84 (m, 1 H), 4.94-5.16 (m, 1 H), 4.02 (s, 3 H), 3.41-3.81

(m, 1 H), 2.84-3.22 (m, 2 H)

829
(CD₃OD) δ 8.66-8.73 (m, 1 H), 8.39-8.43 (m, 1 H), 8.09-8.15
484.2
98.2%

(m, 1 H), 7.62-7.73 (m, 2 H), 6.94-7.05 (m, 2 H), 6.77-6.83 (m, 1
[M + H]⁺

H), 4.95-5.17 (m, 1 H), 4.02 (s, 3 H), 3.41-3.82 (m, 1 H), 2.84-

3.22 (m, 2 H)

830
(CD₃OD) δ 8.83 (d, 2 H), 8.23-8.43 (m, 1 H), 8.03-8.19 (m, 2
431.2
100%

H), 7.46-7.80 (m, 1.3 H), 6.90-7.06 (m, 1.7 H), 6.71-6.89 (m, 2
[M + H]⁺

H), 5.07 (br dd, 0.7 H), 4.92-4.97 (m, 0.3 H), 3.80 (br t, 0.7 H),

3.43 (br t, 0.3 H), 2.96-3.25 (m, 1 H), 2.89 (br s, 1 H)

831
(CD₃OD) δ 8.83 (d, 2 H), 8.26-8.42 (m, 1 H), 8.12 (d, 2 H),
431.2
99.7%

7.46-7.83 (m, 1.3 H), 6.91-7.08 (m, 1.7 H), 6.64-6.89 (m, 2 H),
[M + H]⁺

5.07 (br dd, 0.7 H), 4.92-4.97 (m, 0.3 H), 3.80 (br t, 0.7 H), 3.38-

3.50 (m, 0.3 H), 2.96-3.26 (m, 1 H), 2.87 (br s, 1 H)

832
(CD₃OD) δ 8.48 (s, 1 H), 8.25-8.39 (m, 1 H), 8.14 (s, 1 H), 7.52-
474.2

7.76 (m, 1.4 H), 6.90-7.04 (m, 1.6 H), 6.78-6.89 (m, 1 H), 6.69-
[M + H]⁺

6.78 (m, 1 H), 5.10 (br dd, 0.5 H), 4.95 (br s, 0.5 H), 3.71-3.84

(m, 0.8 H), 3.38-3.43 (m, 0.2 H), 2.94-3.23 (m, 2 H), 2.84 (br d,

1 H), 2.48-2.65 (m, 4 H), 1.88-1.98 (m, 2 H)

833
(CD₃OD) δ 8.48 (s, 1 H), 8.24-8.39 (m, 1 H), 8.14 (s, 1 H), 7.55-
474.2
99.4%

7.75 (m, 1.4 H), 6.90-7.02 (m, 1.6 H), 6.80-6.88 (m, 1 H), 6.68-
[M + H]⁺

6.78 (m, 1 H), 4.98-5.15 (m, 1 H), 3.72-3.83 (m, 0.8 H), 3.42 (br

d, 0.2 H), 2.93-3.26 (m, 2 H), 2.84 (br d, 1 H), 2.48-2.64 (m, 4

H), 1.88-1.97 (m, 2 H)

834
(CD₃OD) δ 8.98 (s, 1 H), 8.46 (s, 1 H), 8.26-8.39 (m, 1 H), 7.49-
524.2
100%

7.77 (m, 1 H), 6.90-7.03 (m, 2 H), 6.79-6.89 (m, 1 H), 6.72-6.78
[M + H]⁺

(m, 1 H), 5.08 (dd, 1 H), 3.71-3.85 (m, 1 H), 3.36-3.52 (m, 1 H),

2.92-3.26 (m, 2 H), 2.85 (br d, 1 H), 1.41-1.55 (m, 2 H), 1.25-

1.32 (m, 2 H)

835
(CD₃OD) δ 8.98 (s, 1 H), 8.46 (s, 1 H), 8.24-8.38 (m, 1 H), 7.51-
524.2
99.5%

7.78 (m, 1 H), 6.90-7.02 (m, 2 H), 6.80-6.89 (m, 1 H), 6.71-6.78
[M + H]⁺

(m, 1 H), 5.08 (br dd, 1 H), 3.65-3.92 (m, 1 H), 3.36-3.51 (m, 1

H), 2.94-3.24 (m, 2 H), 2.77-2.91 (m, 1 H), 1.42-1.53 (m, 2 H),

1.23-1.32 (m, 2 H)

836
Data provided above

837
Data provided above

838
(CD₃OD) δ 8.22-8.41 (m, 1 H), 7.94-8.07 (m, 1 H), 7.70 (s, 1 H),
363.2
100%

6.74-7.07 (m, 3 H), 6.64 (s, 0.6 H), 6.34 (s, 0.4 H), 4.94 (br d,
[M + H]⁺

0.4 H), 4.40 (dd, 0.6 H), 3.98-4.12 (m, 3 H), 3.65-3.75 (m, 0.5

H), 2.71-3.29 (m, 2.5 H), 2.37-2.51 (m, 3 H)

839
(CD₃OD) δ 8.14-8.27 (m, 1 H), 7.84-7.94 (m, 1 H), 7.59 (d, 1
363.2
98.9%

H), 6.62-6.94 (m, 3 H), 6.52 (s, 0.6 H), 6.22 (s, 0.4 H), 4.82 (br
[M + H]⁺

s, 0.4 H), 4.28 (dd, 0.6 H), 3.84-4.01 (m, 3 H), 3.53-3.63 (m, 0.5

H), 2.59-3.17 (m, 2.5 H), 2.22-2.42 (m, 3 H)

840
(CD₃OD) δ 8.31-8.39 (m, 1 H), 8.00 (s, 1 H), 7.69 (d, 1 H), 6.73-
367.2
98.5%

7.02 (m, 3.5 H), 6.49 (s, 0.5 H), 4.90-4.94 (m, 0.5 H), 4.40 (dd,
[M + H]⁺

0.5 H), 4.00-4.09 (m, 3 H), 3.61-3.72 (m, 0.5 H), 2.70-3.27 (m,

2.5 H)

841
(CD₃OD) δ 8.33-8.41 (m, 1 H), 8.02 (s, 1 H), 7.71 (d, 1 H), 6.74-
367.2
98.3%

7.02 (m, 3.5 H), 6.51 (s, 0.5 H), 4.92-4.96 (m, 0.5 H), 4.42 (dd,
[M + H]⁺

0.5 H), 4.04-4.09 (m, 3 H), 3.64-3.73 (m, 0.5 H), 2.71-3.30 (m,

2.5 H)

842
(CD₃OD) δ 8.33-8.45 (m, 1 H), 7.86-7.92 (m, 1 H), 7.70 (br d, 1
420.1
96.9%

H), 6.94-7.03 (m, 2 H), 6.69-6.93 (m, 2.3 H), 6.48 (s, 0.3 H),
[M + H]⁺

6.03 (s, 0.4 H), 4.86 (br d, 0.6 H), 3.69-3.88 (m, 1 H), 3.35-3.42

(m, 0.4 H), 2.69-3.05 (m, 2 H)

843
(CD₃OD) δ 8.31-8.47 (m, 1 H), 7.83-7.96 (m, 1 H), 7.70 (br d, 1
420.2
92.8%

H), 6.94-7.04 (m, 2 H), 6.83-6.92 (m, 1 H), 6.71-6.81 (m, 1.3 H),
[M + H]⁺

6.48 (s, 0.3 H), 6.03 (s, 0.4 H), 4.86 (br d, 0.6 H), 3.69-3.86 (m,

1 H), 3.34-3.43 (m, 0.4 H), 2.68-3.05 (m, 2 H)

844
(CD₃OD) δ 8.23-8.34 (m, 2 H), 7.52-7.72 (m, 1 H), 6.93-7.04
444.2
98.0%

(m, 2 H), 6.52-6.85 (m, 2 H), 5.06 (br dd, 1 H), 3.92 (s, 3 H),
[M + H]⁺

3.72-3.81 (m, 1 H), 2.79-3.22 (m, 2 H), 2.51-2.56 (m, 3 H), 2.40-

2.47 (m, 3 H))

845
(CD₃OD) δ 8.20-8.34 (m, 2 H), 7.53-7.71 (m, 1 H), 6.90-7.05
444.2
98.3%

(m, 2 H), 6.48-6.83 (m, 2 H), 5.06 (br dd, 1 H), 3.92 (s, 3 H),
[M + H]

3.71-3.83 (m, 1 H), 2.77-3.22 (m, 2 H), 2.51-2.57 (m, 3 H), 2.38-

2.49 (m, 3 H)

846
(CD₃OD) δ 8.24-8.38 (m, 2 H), 7.53-7.72 (m, 1 H), 6.68-7.02
448.2
98.2%

(m, 4 H), 5.09 (dd, 1 H), 3.92 (s, 3 H), 3.70-3.80 (m, 1 H), 2.73-
[M + H]⁺

3.24 (m, 2 H), 2.45-2.59 (m, 3 H)

847
(CD₃OD) δ 8.27-8.37 (m, 2 H), 7.47-7.71 (m, 1 H), 6.65-7.04
448.2
98.8%

(m, 4 H), 5.09 (br dd, 1 H), 3.92 (s, 3 H), 3.72-3.82 (m, 1 H),
[M + H]⁺

2.74-3.28 (m, 2 H), 2.47-2.64 (m, 3 H)

848
(CD₃OD) δ 8.16-8.70 (m, 1 H), 7.70 (br s, 1 H), 7.50 (s, 1 H),
392.2
99.6%

6.94-7.07 (m, 1.6 H), 6.68-6.93 (m, 2 H), 6.42-6.61 (m, 1 H),
[M + H]⁺

6.16 (br s, 0.4 H), 3.95 (br dd, 1 H), 3.59-3.83 (m, 1.6 H), 3.35-

3.45 (m, 0.4 H), 2.89-3.11 (m, 1 H), 2.68-2.89 (m, 1 H), 1.12 (br

s, 1 H), 0.63-0.99 (m, 3 H)

849
(CD₃OD) δ 8.31-8.53 (m, 1 H), 7.70 (br s, 1 H), 7.50 (s, 1 H),
392.2
99.1%

6.94-7.13 (m, 1.6 H), 6.68-6.93 (m, 2 H), 6.39-6.61 (m, 1 H),
[M + H]⁺

6.16 (br s, 0.4 H), 3.95 (br dd, 1 H), 3.56-3.82 (m, 1.6 H), 3.36-

3.45 (m, 0.4 H), 2.89-3.11 (m, 1 H), 2.70-2.87 (m, 1 H), 1.12 (br

s, 1 H), 0.64-1.01 (m, 3 H)

850
(CD₃OD) δ 8.83 (br d, 2 H), 8.19-8.36 (m, 1 H), 8.12 (d, 2 H),
427.2
100%

7.49-7.77 (m, 1 H), 6.94-7.04 (m, 2 H), 6.72-6.85 (m, 1 H), 6.52-
[M + H]⁺

6.67 (m, 1 H), 5.05 (br dd, 0.5 H), 3.72-3.89 (m, 1 H), 3.37-3.51

(m, 0.5 H), 2.95-3.26 (m, 1 H), 2.88 (br s, 1 H), 2.38-2.51 (m, 3 H)

851
(CD₃OD) δ 8.83 (br d, 2 H), 8.19-8.38 (m, 1 H), 8.12 (d, 2 H),
427.2
98.3%

7.41-7.80 (m, 1 H), 6.91-7.06 (m, 2 H), 6.71-6.84 (m, 1 H), 6.49-
[M + H]⁺

6.68 (m, 1 H), 5.05 (br dd, 0.5 H), 3.71-3.90 (m, 1 H), 3.43 (br t,

0.5 H), 2.97-3.27 (m, 1 H), 2.88 (br s, 1 H), 2.38-2.50 (m, 3 H)

852
(CD₃OD) δ 8.99 (s, 1 H), 8.46 (s, 1 H), 8.20-8.36 (m, 1 H), 7.54-
520.2
100%

7.71 (m, 1 H), 6.74-7.09 (m, 3 H), 6.52-6.68 (m, 1 H), 4.96-5.20
[M + H]⁺

(m, 1 H), 3.79 (br t, 1 H), 3.04-3.24 (m, 2 H), 2.85 (br d, 1 H),

2.42-2.46 (m, 3 H), 1.44-1.51 (m, 2 H), 1.28 (br d, 2 H)

853
(CD₃OD) δ 8.99 (s, 1 H), 8.46 (s, 1 H), 8.19-8.36 (m, 1 H), 7.57-
520.2
99.3%

7.97 (m, 1 H), 6.50-7.20 (m, 4 H), 5.03-5.15 (m, 1 H), 3.68-3.89
[M + H]⁺

(m, 1 H), 2.99-3.26 (m, 2 H), 2.88 (br d, 1 H), 2.39-2.50 (m, 3

H), 1.44-1.52 (m, 2 H), 1.28 (br d, 2 H)

854
(CD₃OD) δ 8.14-8.38 (m, 1 H), 7.48-7.73 (m, 1 H), 6.71-7.08
444.2
96.4%

(m, 4 H), 6.49-6.68 (m, 1 H), 5.00 (br dd, 1 H), 3.90 (s, 3 H),
[M + H]

3.71-3.84 (m, 1 H), 2.94-3.23 (m, 1 H), 2.83 (br d, 1 H), 2.38-

2.47 (m, 6 H)

855
(CD₃OD) δ 8.21-8.35 (m, 1 H), 7.49-7.71 (m, 1 H), 6.71-7.08
444.2
90.2%

(m, 4 H), 6.50-6.67 (m, 1 H), 5.00 (br dd, 1 H), 3.90 (s, 3 H),
[M + H]⁺

3.36-3.83 (m, 1 H), 2.95-3.24 (m, 1 H), 2.83 (br d, 1 H), 2.36-

2.48 (m, 6 H)

856
(CD₃OD) δ 8.33-8.58 (m, 1 H), 7.47-8.01 (m, 3 H), 7.19 (br t, 1
376.2
99.9%

H), 6.15-7.02 (m, 4 H), 4.69 (br d, 2 H), 3.63-4.07 (m, 1 H),
[M + H]⁺

2.66-3.18 (m, 2 H), 1.22-1.57 (m, 6 H)

857
(CD₃OD) δ 8.34-8.61 (m, 1 H), 7.44-7.78 (m, 3 H), 7.19 (br t, 1
376.2
99.9%

H), 6.12-7.04 (m, 4 H), 4.69 (br d, 2 H), 3.60-4.03 (m, 1 H),
[M + H]⁺

2.60-3.09 (m, 2 H), 1.25-1.51 (m, 6 H)

858
(CD₃OD) δ 8.23-8.53 (m, 1 H), 7.49-7.74 (m, 2 H), 6.07-7.13
394.2
99.5%

(m, 5 H), 4.55-4.82 (m, 2 H), 3.60-4.09 (m, 1 H), 2.66-3.07 (m, 2
[M + H]⁺

H), 1.25-1.53 (m, 6 H)

859
(CD₃OD) δ 8.23-8.49 (m, 1 H), 7.43-7.78 (m, 2 H), 6.15-7.04
394.2
98.6%

(m, 5 H), 4.54-4.80 (m, 2 H), 3.61-4.14 (m, 1 H), 2.68-3.10 (m, 2
[M + H]⁺

H), 1.42 (br d, 6 H)

860
(CD₃OD) δ 8.18-8.57 (m, 1 H), 7.70 (br s, 1 H), 7.50 (d, 1 H),
388.2
98.4%

6.94-7.10 (m, 1.6 H), 6.77-6.87 (m, 1 H), 6.74 (br s, 0.4 H),
[M + H]⁺

6.06-6.70 (m, 2 H), 3.92 (br dd, 1 H), 3.75 (br t, 0.6 H), 3.66 (br

d, 1 H), 3.36-3.48 (m, 0.4 H), 2.88-3.12 (m, 1 H), 2.70-2.87 (m,

1 H), 2.33-2.53 (m, 3 H), 0.78-1.16 (m, 4H)

861
(CD₃OD) δ 8.23-8.56 (m, 1 H), 7.63-7.80 (m, 1 H), 7.50 (d, 1
388.2
99.2%

H), 6.94-7.10 (m, 1.6 H), 6.78-6.86 (m, 1 H), 6.74 (br s, 0.4 H),
[M + H]⁺

6.10-6.70 (m, 2 H), 3.92 (br dd, 1 H), 3.74 (br t, 0.6 H), 3.66 (br

d, 1 H), 3.39 (br d, 0.4 H), 2.88-3.11 (m, 1 H), 2.67-2.87 (m, 1

H), 2.39-2.54 (m, 3 H), 0.77-1.16 (m, 4H)

862
(CD₃OD) δ 8.32 (dd, 1 H), 7.66-7.89 (m, 4 H), 7.46-7.57 (m, 1
425.2
88.7%

H), 7.02-7.13 (m, 1.6 H), 6.99 (s, 1 H), 6.73-6.86 (m, 1.4H),
[M + H]⁺

5.83-6.71 (m, 2 H), 3.42-3.77 (m, 2 H), 2.58-3.13 (m, 2 H), 2.36-

2.51 (m, 3 H)

863
(CD₃OD) δ 8.24-8.36 (m, 1 H), 7.65-7.91 (m, 4 H), 7.44-7.56
425.2
85.6%

(m, 1 H), 7.02-7.14 (m, 1.6 H), 6.94-7.00 (m, 1 H), 6.73-6.86 (m,
[M + H]⁺

1.4 H), 5.83-6.72 (m, 2 H), 3.41-3.79 (m, 2 H), 2.56-3.13 (m, 2

H), 2.37-2.52 (m, 3 H)

864
(CD₃OD) δ 8.30-8.49 (m, 1 H), 7.69 (s, 1 H), 6.70-7.07 (m, 5 H),
416.2
100%

6.28-6.65 (m, 1 H), 4.76-4.86 (m, 0.4 H), 4.03-4.18 (m, 0.6 H),
[M + H]⁺

3.95 (s, 3 H), 3.72 (br t, 0.6 H), 3.26 (br s, 0.4 H), 2.90-3.05 (m,

1 H), 2.76 (br d, 1 H)

865
(CD₃OD) δ 8.29-8.50 (m, 1 H), 7.69 (s, 1 H), 6.73-7.06 (m, 5 H),
416.2
100%

6.25-6.65 (m, 1 H), 4.77-4.86 (m, 0.4 H), 4.09 (br d, 0.6 H), 3.95
[M + H]⁺

(s, 3 H), 3.72 (br t, 0.6 H), 3.27 (br s, 0.4 H), 2.90-3.07 (m, 1 H),

2.76 (br d, 1 H)

866
(CD₃OD) δ 8.25-8.42 (m, 1 H), 7.68 (s, 1 H), 6.87-7.05 (m, 2 H),
412.2
98.4%

6.72-6.84 (m, 2 H), 6.62 (s, 1 H), 6.30 (br s, 1 H), 4.01-4.16 (m,
[M + H]⁺

1 H), 3.94 (s, 3 H), 3.64-3.82 (m, 1 H), 2.96 (br d, 1 H), 2.76 (br

d, 1 H), 2.36-2.48 (m, 3 H)

867
(CD₃OD) δ 8.26-8.42 (m, 1 H), 7.68 (s, 1 H), 6.86-7.06 (m, 2 H),
412.2
97.6%

6.71-6.82 (m, 2 H), 6.62 (s, 1 H), 6.31 (br s, 1 H), 4.00-4.15 (m,
[M + H]⁺

1 H), 3.94 (s, 3 H), 3.65-3.82 (m, 1 H), 2.96 (br d, 1 H), 2.76 (br

d, 1 H), 2.34-2.50 (m, 3 H)

868
(CD₃OD) δ 8.47 (br s, 1 H), 7.49-7.99 (m, 4 H), 7.03-7.38 (m, 2
465.2
99.6%

H), 6.43-6.96 (m, 3 H), 4.47 (br s, 1 H), 3.87-4.17 (m, 3 H),
[M + H]⁺

3.37-3.85 (m, 1 H), 2.74-3.23 (m, 2 H)

869
(CD₃OD) δ 8.47 (br s, 1 H), 7.47-8.01 (m, 4 H), 7.04-7.38 (m, 2
465.2
99.7%

H), 6.51-6.97 (m, 3 H), 4.44 (br s, 1 H), 3.91-4.17 (m, 3 H),
[M + H]⁺

3.37-3.84 (m, 1 H), 2.74-3.22 (m, 2 H)

870
(CD₃OD) δ 8.60 (s, 1 H), 8.14-8.34 (m, 2 H), 7.89 (br d, 1 H),
441.2
100%

7.45-7.73 (m, 1 H), 6.92-7.03 (m, 2 H), 6.70-6.83 (m, 1 H), 6.53-
[M + H]⁺

6.66 (m, 1 H), 4.99 (br dd, 1 H), 3.72-3.86 (m, 0.7 H), 3.36-3.49

(m, 0.3 H), 3.13-3.25 (m, 0.7 H), 2.95-3.06 (m, 0.3 H), 2.80-2.94

(m, 1 H), 2.38-2.50 (m, 6 H)

871
(CD₃OD) δ 8.61 (s, 1 H), 8.15-8.33 (m, 2 H), 7.90 (br d, 1 H),
441.2
99.7%

7.46-7.73 (m, 1 H), 6.93-7.04 (m, 2 H), 6.71-6.84 (m, 1 H), 6.54-
[M + H]⁺

6.69 (m, 1 H), 4.99 (br dd, 1 H), 3.72-3.87 (m, 0.7 H), 3.37-3.51

(m, 0.3 H), 3.14-3.24 (m, 0.7 H), 2.94-3.07 (m, 0.3 H), 2.84 (br

d, 1 H), 2.38-2.51 (m, 6H)

872
(CD₃OD) δ 9.11 (s, 1 H), 8.46-8.55 (m, 1 H), 8.38-8.45 (m, 1 H),
495.2
100%

8.19-8.34 (m, 1 H), 7.46-7.75 (m, 1 H), 6.91-7.04 (m, 2 H), 6.70-
[M + H]⁺

6.84 (m, 1 H), 6.55-6.67 (m, 1 H), 5.00 (br dd, 1 H), 3.75-3.85

(m, 0.7 H), 3.43 (td, 0.4 H), 2.95-3.26 (m, 1 H), 2.79-2.90 (m, 1

H), 2.36-2.50 (m, 3 H)

873
(CD₃OD) δ 9.11 (s, 1 H), 8.45-8.53 (m, 1 H), 8.36-8.44 (m, 1 H),
495.2
100%

8.20-8.33 (m, 1 H), 7.66-7.78 (m, 1 H), 7.51 (s, 0.3 H), 6.91-7.05
[M + H]⁺

(m, 1.7 H), 6.71-6.84 (m, 1 H), 6.55-6.68 (m, 1 H), 5.01 (br dd, 1

H), 3.70-3.87 (m, 0.7 H), 3.39-3.51 (m, 0.3 H), 2.95-3.26 (m, 1

H), 2.79-2.91 (m, 1 H), 2.37-2.52 (m, 3 H)

874
(CD₃OD) δ 8.69 (d, 1 H), 8.21-8.40 (m, 2 H), 7.87 (td, 1 H),
445.2
100%

7.46-7.75 (m, 1 H), 6.93-7.02 (m, 2 H), 6.71-6.82 (m, 1 H), 6.55-
[M + H]⁺

6.67 (m, 1 H), 5.00 (br dd, 1 H), 3.72-3.86 (m, 0.7 H), 3.43 (td,

0.3 H), 3.13-3.25 (m, 0.7 H), 2.95-3.07 (m, 0.3 H), 2.78-2.89 (m,

1 H), 2.39-2.47 (m, 3 H)

875
(CD₃OD) δ 8.69 (d, 1 H), 8.19-8.40 (m, 2 H), 7.87 (td, 1 H),
445.2
99.4%

7.45-7.74 (m, 1 H), 6.89-7.04 (m, 2 H), 6.71-6.83 (m, 1 H), 6.53-
[M + H]⁺

6.67 (m, 1 H), 5.00 (br dd, 1 H), 3.72-3.85 (m, 0.7 H), 3.43 (td,

0.3 H), 3.12-3.26 (m, 0.7 H), 2.94-3.07 (m, 0.3 H), 2.78-2.89 (m,

1 H), 2.38-2.46 (m, 3 H)

876
(CD₃OD) δ 8.62 (s, 1 H), 8.27-8.38 (m, 1 H), 8.15-8.23 (m, 1 H),
445.2
100%

7.90 (br d, 1 H), 7.70 (s, 1 H), 7.50 (s, 0.3 H), 7.18 (br s, 0.2 H),
[M + H]⁺

6.92-7.00 (m, 1.5 H), 6.75-6.87 (m, 2 H), 5.02 (br dd, 1 H), 3.76-

3.85 (m, 0.7 H), 3.37-3.50 (m, 0.3 H), 2.78-3.26 (m, 2 H), 2.48

(s, 3 H)

877
(CD₃OD) δ 8.62 (s, 1 H), 8.26-8.39 (m, 1 H), 8.15-8.23 (m, 1 H),
445.2
100%

7.87-7.94 (m, 1 H), 7.70 (s, 1 H), 7.50 (s, 0.3 H), 7.20 (br s, 0.2
[M + H]⁺

H), 6.93-7.00 (m, 1.5 H), 6.75-6.87 (m, 2 H), 5.02 (br dd, 1 H),

3.74-3.85 (m, 0.6 H), 3.36-3.49 (m, 0.4 H), 2.80-3.25 (m, 2 H),

2.48 (s, 3 H)

878
(CD₃OD) δ 9.11 (s, 1 H), 8.23-8.56 (m, 3 H), 7.43-7.78 (m, 1.3
499.2
100%

H), 6.90-7.07 (m, 1.7 H), 6.74-6.88 (m, 2 H), 4.94-5.06 (m, 1 H),
[M + H]⁺

3.75-3.86 (m, 0.7 H), 3.43 (td, 0.3 H), 2.81-3.27 (m, 2 H)

879
(CD₃OD) δ 9.11 (s, 1 H), 8.23-8.57 (m, 3 H), 7.46-7.78 (m, 1.3
499.2
100%

H), 6.90-7.04 (m, 1.7 H), 6.71-6.87 (m, 2 H), 4.94-5.07 (m, 1 H),
[M + H]⁺

3.75-3.87 (m, 0.6 H), 3.44 (td, 0.4 H), 2.82-3.25 (m, 2 H)

880
(CD₃OD) δ 8.70 (d, 1 H), 8.23-8.44 (m, 2 H), 7.88 (td, 1 H), 7.70
449.2
100%

(s, 1 H), 7.51 (s, 0.3 H), 6.91-7.04 (m, 1.7 H), 6.72-6.89 (m, 2
[M + H]⁺

H), 4.93-5.08 (m, 1 H), 3.79 (ddd, 0.7 H), 3.43 (td, 0.3 H), 2.81-

3.25 (m, 2 H)

881
(CD₃OD) δ 8.70 (d, 1 H), 8.24-8.43 (m, 2 H), 7.88 (td, 1 H), 7.70
449.2
100%

(s, 1 H), 7.51 (s, 0.3 H), 6.90-7.03 (m, 1.7 H), 6.73-6.88 (m, 2
[M + H]⁺

H), 4.94-5.07 (m, 1 H), 3.73-3.86 (m, 0.7 H), 3.43 (td, 0.3 H),

2.79-3.25 (m, 2 H)

882
(CD₃OD) δ 8.20-8.41 (m, 1 H), 7.44-7.77 (m, 1 H), 6.66-7.11
448.2
99.7%

(m, 5 H), 5.02 (br dd, 1 H), 3.90 (s, 3 H), 3.68-3.85 (m, 1 H),
[M + H]⁺

2.81-3.25 (m, 2 H), 2.39 (s, 3 H)

883
(CD₃OD) δ 8.20-8.43 (m, 1 H), 7.47-7.76 (m, 1 H), 6.62-7.12
448.2
99.4%

(m, 5 H), 5.02 (br dd, 1 H), 3.90 (s, 3 H), 3.71-3.84 (m, 1 H),
[M + H]⁺

2.76-3.24 (m, 2 H), 2.39 (s, 3 H)

884
(CD₃OD) δ 8.32-8.47 (m, 1 H), 7.68 (s, 1 H), 7.52 (br s, 1 H),
366.2
99.8%

6.91-7.01 (m, 1.5 H), 6.72-6.89 (m, 2 H), 6.30-6.64 (m, 1.5 H),
[M + H]⁺

4.11 (br d, 1 H), 3.47-3.97 (m, 4 H), 2.71-3.02 (m, 2 H)

885
(CD₃OD) δ 8.29-8.49 (m, 1 H), 7.69 (s, 1 H), 7.53 (br s, 1 H),
366.2
99.6%

6.91-7.02 (m, 1.5 H), 6.73-6.89 (m, 2 H), 6.31-6.63 (m, 1.5 H),
[M + H]⁺

4.10 (br s, 1 H), 3.93 (s, 4 H), 2.71-3.04 (m, 2 H)

886
(CD₃OD) δ 8.02-8.21 (m, 1 H), 7.34-7.72 (m, 1 H), 6.86-7.06
428.2
99.1%

(m, 1 H), 6.73-6.85 (m, 2 H), 6.53-6.68 (m, 2 H), 6.31 (br d, 1
[M + H]⁺

H), 4.72-4.85 (m, 1 H), 4.05 (br d, 0.5 H), 3.90-3.98 (m, 6 H),

3.70 (br t, 0.5 H), 2.97 (br s, 1 H), 2.67-2.83 (m, 1 H)

887
(CD₃OD) δ 8.04-8.20 (m, 1 H), 7.67 (s, 1 H), 6.87-7.06 (m, 1 H),
428.2
99.1%

6.71-6.84 (m, 2 H), 6.64 (br d, 1 H), 6.57 (d, 1 H), 6.31 (br d, 1
[M + H]⁺

H), 4.76-4.83 (m, 0.4 H), 4.00-4.13 (m, 0.6 H), 3.89-3.98 (m, 6

H), 3.70 (br t, 0.7 H), 3.27 (br s, 0.3 H), 2.90-3.04 (m, 1 H),

2.68-2.82 (m, 1 H)

888
(CD₃OD) δ 8.36 (br s, 1 H), 7.45-8.01 (m, 3 H), 7.03-7.36 (m, 1
483.2
99.3%

H), 6.58-7.03 (m, 4 H), 4.47 (br d, 1 H), 3.92-4.16 (m, 3 H),
[M + H]⁺

3.36-3.85 (m, 1 H), 2.74-3.22 (m, 2 H)

889
(CD₃OD) δ 8.36 (br s, 1 H), 7.49-8.01 (m, 3 H), 7.03-7.39 (m, 1
483.2
99.6%

H), 6.60-7.03 (m, 4 H), 4.46 (br s, 1 H), 3.90-4.17 (m, 3 H),
[M + H]⁺

3.37-3.86 (m, 1 H), 2.74-3.22 (m, 2 H)

890
(CD₃OD) δ 8.32 (br d, 1 H), 7.48-8.00 (m, 3 H), 6.94-7.38 (m, 2
479.3
99.5%

H), 6.48-6.93 (m, 3 H), 4.47 (br s, 1 H), 3.90-4.16 (m, 3 H),
[M + H]⁺

3.39-3.88 (m, 1 H), 2.74-3.25 (m, 2 H), 2.45 (s, 3 H)

891
(CD₃OD) δ 8.31 (br d, 1 H), 7.45-7.98 (m, 3 H), 6.96-7.38 (m, 2
479.2
99.7%

H), 6.50-6.94 (m, 3 H), 4.46 (br s, 1 H), 3.90-4.16 (m, 3 H),
[M + H]⁺

3.37-3.85 (m, 1 H), 2.74-3.21 (m, 2 H), 2.44 (s, 3 H)

892
(CD₃OD) δ 8.28-8.65 (m, 1 H), 7.43-7.78 (m, 2 H), 7.21 (dd, 1
362.2
100%

H), 6.80-7.04 (m, 1.5 H), 6.49-6.74 (m, 1 H), 6.36 (br s, 1.3 H),
[M + H]⁺

4.80-4.87 (m, 0.8 H), 4.05-4.21 (m, 0.5 H), 3.84 (s, 3 H), 3.70

(br t, 0.5 H), 2.66-3.04 (m, 2 H), 2.20-2.36 (m, 3 H)

893
(CD₃OD) δ 8.11-8.58 (m, 1 H), 7.28-7.70 (m, 2 H), 6.89-7.25
362.2
99.7%

(m, 1 H), 6.66-6.88 (m, 1.5 H), 6.30-6.63 (m, 1 H), 6.23 (br s,
[M + H]⁺

1.3 H), 4.65-4.76 (m, 1 H), 3.92-4.08 (m, 0.5 H), 3.53-3.77 (m,

3.5 H), 2.52-2.97 (m, 2 H), 2.02-2.24 (m, 3 H)

894
(CD₃OD) δ 9.31 (d, 1 H), 8.80 (dd, 1 H), 8.55 (dd, 1 H), 8.18-
427.2
100%

8.36 (m, 1 H), 7.63-7.74 (m, 2 H), 7.56 (s, 0.3 H), 6.94-7.04 (m,
[M + H]⁺

1.7 H), 6.72-6.84 (m, 1 H), 6.53-6.67 (m, 1 H), 5.07 (dd, 1 H),

3.80 (ddd, 0.6 H), 3.37-3.51 (m, 0.4 H), 2.95-3.26 (m, 1 H),

2.76-2.92 (m, 1 H), 2.38-2.48 (m, 3 H)

895
(CD₃OD) δ 9.31 (d, 1 H), 8.80 (dd, 1 H), 8.55 (dt, 1 H), 8.20-
427.2
99.3%

8.35 (m, 1 H), 7.63-7.74 (m, 2 H), 7.56 (s, 0.3 H), 6.91-7.03 (m,
[M + H]⁺

1.7 H), 6.72-6.85 (m, 1 H), 6.53-6.67 (m, 1 H), 5.07 (dd, 1 H),

3.76-3.86 (m, 0.6 H), 3.44 (td, 0.4 H), 2.95-3.26 (m, 1 H), 2.79-

2.90 (m, 1 H), 2.37-2.50 (m, 3 H)

896
(CD₃OD) δ 9.31 (d, 1 H), 8.80 (dd, 1 H), 8.49-8.62 (m, 1 H),
431.2
99.8%

8.24-8.42 (m, 1 H), 7.66-7.71 (m, 2 H), 7.57 (s, 0.3 H), 6.93-7.01
[M + H]⁺

(m, 1.7 H), 6.73-6.88 (m, 2 H), 4.96-5.15 (m, 1 H), 3.75-3.86 (m,

0.7 H), 3.38-3.52 (m, 0.3 H), 2.82-3.23 (m, 2 H)

897
(CD₃OD) δ 9.31 (d, 1 H), 8.80 (dd, 1 H), 8.55 (dd, 1 H), 8.28-
431.1
98.3%

8.39 (m, 1 H), 7.65-7.73 (m, 2 H), 7.57 (s, 0.3 H), 6.90-7.03 (m,
[M + H]⁺

1.7 H), 6.72-6.89 (m, 2 H), 5.10 (dd, 1 H), 3.72-3.87 (m, 0.7 H),

3.40-3.49 (m, 0.3 H), 2.81-3.24 (m, 2 H)

898
(CD₃OD) δ 8.05-8.17 (m, 1 H), 7.52-7.95 (m, 5 H), 7.08-7.21
441.2
100%

(m, 1 H), 6.60-7.02 (m, 4 H), 5.84-6.59 (m, 1 H), 3.94-4.06 (m, 3
[M + H]⁺

H), 3.37-3.83 (m, 2 H), 2.57-3.18 (m, 2 H)

899
(CD₃OD) δ 8.01-8.16 (m, 1 H), 7.48-7.95 (m, 5 H), 7.04-7.21
441.2
92.8%

(m, 1 H), 6.59-6.99 (m, 4 H), 5.82-6.57 (m, 1 H), 3.89-4.06 (m, 3
[M + H]⁺

H), 3.39-3.80 (m, 2 H), 2.56-3.15 (m, 2 H)

900
(CD₃OD) δ 8.13-8.49 (m, 1 H), 7.65 (s, 1 H), 6.83-7.18 (m, 2 H),
376.2
100%

6.75 (br s, 1 H), 6.44-6.63 (m, 1 H), 6.31 (br t, 1 H), 4.02-4.16
[M + H]⁺

(m, 1 H), 3.80 (s, 3 H), 3.68 (br t, 1 H), 2.65-3.05 (m, 2 H), 2.33-

2.48 (m, 3 H), 2.23 (br s, 3 H)

901
(CD₃OD) δ 8.20-8.42 (m, 1 H), 7.65 (s, 1 H), 6.87-7.07 (m, 2 H),
376.2
99.3%

6.76 (br s, 1 H), 6.37-6.62 (m, 1 H), 6.19-6.36 (m, 1 H), 3.97-
[M + H]⁺

4.18 (m, 1 H), 3.54-3.86 (m, 4 H), 2.65-3.04 (m, 2 H), 2.33-2.48

(m, 3 H), 2.23 (br s, 3 H)

902
(CD₃OD) δ 7.83-8.43 (m, 3 H), 7.68 (s, 1 H), 7.02-7.36 (m, 1 H),
483.2
99.3%

6.93-7.00 (m, 1 H), 6.61-6.90 (m, 3 H), 4.36-4.61 (m, 1 H), 3.97
[M + H]⁺

(br s, 3 H), 3.76 (br s, 0.6 H), 3.36-3.51 (m, 0.4 H), 2.72-3.23

(m, 2 H)

903
(CD₃OD) δ 7.74-8.32 (m, 3 H), 7.59 (s, 1 H), 6.93-7.25 (m, 1 H),
483.2
98.9%

6.87 (dd, 1 H), 6.51-6.79 (m, 3 H), 4.31-4.51 (m, 1 H), 3.87 (br
[M + H]⁺

s, 3 H), 3.66 (br s, 0.6 H), 3.24-3.43 (m, 0.4 H), 2.61-3.13 (m, 2

904
(CD₃OD) δ 8.62-8.74 (m, 2 H), 7.88-8.08 (m, 2 H), 7.53-7.78H)
499.2
99.0%

(m, 2 H), 6.84-7.07 (m, 3 H), 5.05 (br dd, 1 H), 3.40-3.82 (m, 1
[M + H]⁺

H), 3.00-3.28 (m, 1 H), 2.86-2.95 (m, 1 H)

905
(CD₃OD) δ 8.62-8.72 (m, 2 H), 7.46-7.96 (m, 4 H), 6.81-7.02
499.2
94.9%

(m, 3 H), 4.98 (br dd, 1 H), 3.39-3.83 (m, 1 H), 2.98-3.27 (m, 1
[M + H]⁺

H), 2.86 (br dd, 1 H)

906
(CD₃OD) δ 8.89-8.94 (m, 1 H), 8.64-8.71 (m, 1 H), 8.30-8.38
520.2
100%

(m, 1 H), 7.50-7.80 (m, 3.5 H), 6.77-7.01 (m, 2.5 H), 4.95-5.13
[M + H]⁺

(m, 1 H), 3.36-3.81 (m, 1 H), 2.95-3.23 (m, 1 H), 2.80-2.89 (m, 1 H)

907
(CD₃OD) δ 8.90-8.94 (m, 1 H), 8.64-8.71 (m, 1 H), 8.26-8.41
520.2
95.7%

(m, 1 H), 7.49-7.82 (m, 3.5 H), 6.77-7.02 (m, 2.5 H), 4.95-5.13
[M + H]⁺

(m, 1 H), 3.39-3.82 (m, 1 H), 2.95-3.22 (m, 1 H), 2.79-2.89 (m, 1 H)

908
(CD₃OD) δ 8.62-8.73 (m, 1 H), 8.33 (d, 1 H), 7.50-7.84 (m, 3
520.2
100%

H), 6.74-7.24 (m, 4 H), 4.95-5.09 (m, 1 H), 3.36-3.82 (m, 1 H),
[M + H]⁺

2.96-3.25 (m, 1 H), 2.79-2.90 (m, 1 H)

909
(CD₃OD) δ 8.62-8.73 (m, 1 H), 8.33 (d, 1 H), 7.52-7.83 (m, 3
520.2
100%

H), 6.76-7.22 (m, 4 H), 4.94-5.09 (m, 1 H), 3.36-3.83 (m, 1 H),
[M + H]⁺

2.97-3.24 (m, 1 H), 2.79-2.92 (m, 1 H)

910
(CD₃OD) δ 8.41-8.47 (m, 1 H), 8.25 (dd, 1 H), 7.56-7.73 (m, 2
457.2
100%

H), 7.41-7.52 (m, 1.5 H), 6.98-7.15 (m, 1.5 H), 6.58-6.76 (m, 1.6
[M + H]⁺

H), 6.44 (s, 0.4 H), 4.94-5.06 (m, 1 H), 3.99 (d, 3.7 H), 3.35-3.42

(m, 0.3 H), 2.82-3.24 (m, 2 H), 2.45-2.71 (m, 3 H)

911
(CD₃OD) δ 8.39-8.49 (m, 1 H), 8.25 (dd, 1 H), 7.56-7.76 (m, 2
457.2
100%

H), 7.39-7.53 (m, 1.5 H), 6.97-7.18 (m, 1.5 H), 6.59-6.76 (m, 1.6
[M + H]⁺

H), 6.44 (s, 0.4 H), 4.94-5.06 (m, 1 H), 3.99 (d, 3.6 H), 3.36-3.42

(m, 0.4 H), 2.80-3.24 (m, 2 H), 2.44-2.70 (m, 3 H)

912
(CD₃OD) δ 8.58-8.69 (m, 1 H), 7.87-7.99 (m, 1 H), 7.64-7.80
445.2
100%

(m, 2 H), 7.36-7.52 (m, 1.4 H), 6.95-7.19 (m, 1.6 H), 6.58-6.76
[M + H]⁺

(m, 1.6 H), 6.44 (s, 0.4 H), 4.93-4.99 (m, 1 H), 3.86-4.00 (m, 0.6

H), 3.34-3.42 (m, 0.4 H), 2.81-3.26 (m, 2 H), 2.44-2.70 (m, 3 H)

913
(CD₃OD) δ 8.64 (t, 1 H), 7.86-8.00 (m, 1 H), 7.60-7.80 (m, 2 H),
445.2
100%

7.35-7.53 (m, 1.5 H), 6.93-7.18 (m, 1.5 H), 6.55-6.80 (m, 1.6 H),
[M + H]⁺

6.44 (s, 0.4 H), 4.93-5.01 (m, 1 H), 3.93 (br t, 0.5 H), 3.34-3.44

(m, 0.5 H), 2.79-3.25 (m, 2 H), 2.41-2.75 (m, 3 H)

914
(CD₃OD) δ 8.92 (d, 1 H), 8.35 (s, 1 H), 7.39-7.84 (m, 3.5 H),
466.2
100%

6.94-7.19 (m, 1.5 H), 6.40-6.77 (m, 2 H), 4.92-5.10 (m, 1 H),
[M + H]⁺

3.85-3.99 (m, 0.6 H), 3.35-3.44 (m, 0.4 H), 2.81-3.23 (m, 2 H),

2.47-2.74 (m, 3 H)

915
(CD₃OD) δ 8.92 (d, 1 H), 8.35 (s, 1 H), 7.40-7.86 (m, 3.5 H),
466.2
100%

6.90-7.22 (m, 1.5 H), 6.40-6.77 (m, 2 H), 4.93-5.11 (m, 1 H),
[M + H]⁺

3.87-3.99 (m, 0.6 H), 3.34-3.44 (m, 0.4 H), 2.81-3.21 (m, 2 H),

2.46-2.72 (m, 3 H)

916
(CD₃OD) δ 8.28-8.36 (m, 1 H), 7.70 (d, 1 H), 6.74-7.08 (m, 3
377.2
99.7%

H), 6.23-6.68 (m, 1 H), 4.93 (br s, 0.4 H), 4.36 (dd, 0.6 H), 3.96
[M + H]⁺

(d, 3 H), 3.65-3.75 (m, 0.6 H), 3.26 (td, 0.4 H), 2.93-3.19 (m, 1

H), 2.72-2.88 (m, 1 H), 2.36-2.49 (m, 6 H)

917
(CD₃OD) δ 8.27-8.38 (m, 1 H), 7.70 (d, 1 H), 6.73-7.07 (m, 3
377.2
99.1%

H), 6.22-6.66 (m, 1 H), 4.93 (br s, 0.4 H), 4.36 (dd, 0.6H), 3.96
[M + H]⁺

(d, 3 H), 3.70 (ddd, 0.6 H), 3.26 (td, 0.4 H), 2.93-3.18 (m, 1 H),

2.71-2.88 (m, 1 H), 2.34-2.51 (m, 6 H)

918
(CD₃OD) δ 8.06-8.22 (m, 1 H), 7.69 (s, 1 H), 6.94 (br s, 0.6 H),
392.2
98.8%

6.75-6.86 (m, 1 H), 6.46-6.72 (m, 2 H), 6.35 (br s, 1.4 H), 4.78-
[M + H]⁺

4.87 (m, 1 H), 4.04-4.19 (m, 0.5 H), 3.97 (br s, 3 H), 3.83 (s, 3

H), 3.62-3.75 (m, 0.5 H), 2.66-3.06 (m, 2 H), 2.27 (br s, 3 H)

919
(CD₃OD) δ 7.95-8.35 (m, 1 H), 7.69 (br s, 1 H), 6.94 (br s, 0.6
392.2
98.3%

H), 6.80 (br s, 1 H), 6.47-6.73 (m, 2 H), 6.35 (br s, 1.4 H), 4.79-
[M + H]⁺

4.87 (m, 0.7 H), 4.12 (br d, 0.5 H), 3.97 (br s, 3 H), 3.83 (s, 3 H),

3.61-3.77 (m, 0.5 H), 3.24-3.32 (m, 0.3 H), 2.56-3.16 (m, 2 H),

2.27 (br s, 3 H)

920
(CD₃OD) δ 8.34 (d, 1 H), 7.56-8.05 (m, 3 H), 7.03-7.37 (m, 1
483.2
99.0%

H), 6.68-7.02 (m, 4 H), 4.46-4.59 (m, 1 H), 3.83 (br s, 4 H),
[M + H]⁺

2.79-3.25 (m, 2 H)

921
(CD₃OD) δ 8.34 (d, 1 H), 7.63-8.01 (m, 3 H), 7.04-7.45 (m, 1
483.2
96.9%

H), 6.70-7.02 (m, 4 H), 4.44-4.59 (m, 1 H), 3.65-3.90 (m, 4 H),
[M + H]⁺

2.74-3.25 (m, 2 H)

922
(CD₃OD) δ 8.08-8.25 (m, 1 H), 7.59 (s, 1 H), 7.30 (s, 0.3 H),
410.2
100%

6.80-6.93 (m, 1.7 H), 6.61-6.75 (m, 1 H), 6.35-6.59 (m, 1 H),
[M + H]⁺

4.80-4.87 (m, 1 H), 3.65 (ddd, 0.7 H), 3.29 (td, 0.3 H), 2.82-3.11

(m, 1 H), 2.72 (dd, 1 H), 2.28-2.37 (m, 3 H), 1.72-1.84 (m, 6 H)

923
(CD₃OD) δ 8.22-8.34 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.3 H),
410.2
99.6%

6.90-7.03 (m, 1.7 H), 6.72-6.82 (m, 1 H), 6.46-6.66 (m, 1 H),
[M + H]⁺

4.90-4.98 (m, 1 H), 3.68-3.80 (m, 0.7 H), 3.39 (td, 0.3 H), 2.92-

3.21 (m, 1 H), 2.83 (br dd, 1 H), 2.38-2.48 (m, 3 H), 1.81-1.95

(m, 6 H)

924
(CD₃OD) δ 8.23-8.33 (m, 1 H), 7.68 (s, 1 H), 7.45 (s, 0.3 H),
390.2
100%

6.94-7.02 (m, 1 H), 6.91 (s, 0.7 H), 6.70-6.83 (m, 1 H), 6.48-6.65
[M + H]⁺

(m, 1 H), 4.97 (dd, 1 H), 3.72 (ddd, 0.7 H), 3.33-3.41 (m, 0.3 H),

2.89-3.19 (m, 1 H), 2.74-2.86 (m, 1 H), 2.38-2.47 (m, 3 H), 2.24-

2.36 (m, 1 H), 1.14-1.32 (m, 4H)

925
(CD₃OD) δ 8.22-8.33 (m, 1 H), 7.68 (s, 1 H), 7.45 (s, 0.3 H),
390.2
99.9%

6.95-7.03 (m, 1 H), 6.91 (s, 0.7 H), 6.71-6.82 (m, 1 H), 6.47-6.64
[M + H]⁺

(m, 1 H), 4.97 (dd, 1 H), 3.72 (ddd, 0.7 H), 3.37 (td, 0.3 H),

2.89-3.19 (m, 1 H), 2.70-2.87 (m, 1 H), 2.37-2.51 (m, 3 H), 2.21-

2.36 (m, 1 H), 1.11-1.32 (m, 4H)

926
(CD₃OD) δ 8.18-8.37 (m, 1 H), 7.70 (s, 1 H), 7.45-7.50 (m, 1 H),
444.2
100%

6.70-7.10 (m, 3 H), 6.55-6.67 (m, 1 H), 5.06 (dd, 1 H), 4.19-4.27
[M + H]⁺

(m, 3 H), 3.76-3.86 (m, 0.7 H), 3.38-3.49 (m, 0.3 H), 2.77-3.28

(m, 2 H), 2.34-2.46 (m, 6 H)

927
(CD₃OD) δ 8.21-8.38 (m, 1 H), 7.70 (s, 1 H), 7.43-7.53 (m, 1 H),
444.2
100%

6.70-7.10 (m, 3 H), 6.55-6.68 (m, 1 H), 5.06 (br dd, 1 H), 4.17-
[M + H]⁺

4.28 (m, 3 H), 3.66-3.84 (m, 0.7 H), 3.38-3.49 (m, 0.3 H), 2.96-

3.27 (m, 1 H), 2.80-2.90 (m, 1 H), 2.33-2.46 (m, 6H)

928
(CD₃OD) δ 8.25-8.39 (m, 1 H), 7.70 (s, 1 H), 7.43-7.51 (m, 1 H),
448.2
100%

6.79-7.15 (m, 3 H), 6.73-6.78 (m, 1 H), 5.09 (dd, 0.6 H), 4.20-
[M + H]⁺

4.25 (m, 3 H), 3.65-3.85 (m, 1 H), 3.35-3.46 (m, 0.4 H), 2.96-

3.26 (m, 1 H), 2.79-2.88 (m, 1 H), 2.29-2.48 (m, 3 H)

929
(CD₃OD) δ 8.26-8.41 (m, 1 H), 7.70 (s, 1 H), 7.38-7.59 (m, 1 H),
448.2
100%

6.78-7.12 (m, 3 H), 6.73-6.78 (m, 1 H), 4.92-5.12 (m, 1 H), 4.18-
[M + H]⁺

4.28 (m, 3 H), 3.72-3.88 (m, 0.7 H), 3.37-3.50 (m, 0.3 H), 2.77-

3.26 (m, 2 H), 2.28-2.45 (m, 3 H)

930
(CD₃OD) δ 8.30 (br d, 1 H), 7.63-8.08 (m, 3 H), 6.36-7.44 (m, 5
479.2
99.3%

H), 4.53 (br s, 1 H), 3.82 (br s, 4 H), 2.72-3.26 (m, 2 H), 2.45 (s,
[M + H]⁺

3 H)

931
(CD₃OD) δ 8.30 (d, 1 H), 7.51-8.10 (m, 3 H), 6.46-7.40 (m, 5
479.3
97.7%

H), 4.51 (br s, 1 H), 3.82 (br s, 4 H), 2.78-3.26 (m, 2 H), 2.45 (s,
[M + H]⁺

3 H)

932
(CD₃OD) δ 8.63-8.72 (m, 1 H), 8.43 (d, 1 H), 8.25 (d, 1 H), 7.71
511.2
100%

(s, 1 H), 7.58-7.65 (m, 2 H), 6.91-7.04 (m, 2 H), 6.77-6.83 (m, 1
[M + H]⁺

H), 4.93-5.09 (m, 1 H), 3.98 (s, 3 H), 3.37-3.83 (m, 1 H), 2.96-

3.25 (m, 1 H), 2.85 (br dd, 1 H)

933
(CD₃OD) δ 8.62-8.72 (m, 1 H), 8.43 (d, 1 H), 8.24 (d, 1 H), 7.71
511.2
94.9%

(s, 1 H), 7.56-7.66 (m, 2 H), 6.89-7.05 (m, 2 H), 6.74-6.83 (m, 1
[M + H]⁺

H), 4.93-5.09 (m, 1 H), 3.98 (s, 3 H), 3.37-3.83 (m, 1 H), 2.96-

3.25 (m, 1 H), 2.79-2.91 (m, 1 H)

934
(CD₃OD) δ 8.62-8.72 (m, 1 H), 7.97 (s, 1 H), 7.76-7.87 (m, 1 H),
484.2
100%

7.59-7.71 (m, 2 H), 6.88-7.06 (m, 2 H), 6.76-6.84 (m, 1 H), 4.92-
[M + H]⁺

5.13 (m, 1 H), 4.07-4.11 (m, 3 H), 3.37-3.83 (m, 1 H), 2.96-3.23

(m, 1 H), 2.78-2.90 (m, 1 H)

935
(CD₃OD) δ 8.63-8.73 (m, 1 H), 7.97 (s, 1 H), 7.79-7.88 (m, 1 H),
484.2
92.0%

7.70 (s, 1 H), 7.59-7.66 (m, 1 H), 6.91-7.02 (m, 2 H), 6.76-6.83
[M + H]⁺

(m, 1 H), 4.93-5.13 (m, 1 H), 4.08-4.11 (m, 3 H), 3.38-3.83 (m, 1

H), 2.96-3.24 (m, 1 H), 2.79-2.89 (m, 1 H)

936
(CD₃OD) δ 8.33 (dd, 1 H), 7.83 (d, 0.2 H), 7.64-7.75 (m, 1.5 H),
466.2
100%

7.37-7.55 (m, 1.8 H), 7.21 (t, 1 H), 7.03-7.15 (m, 1 H), 6.99 (s,
[M + H]⁺

0.5 H), 6.58-6.76 (m, 1.6 H), 6.43 (s, 0.4 H), 4.92-5.06 (m, 1 H),

3.85-3.98 (m, 0.5 H), 3.33-3.41 (m, 0.5 H), 2.80-3.24 (m, 2 H),

2.44-2.72 (m, 3 H)

937
(CD₃OD) δ 8.33 (dd, 1 H), 7.83 (d, 0.3 H), 7.62-7.75 (m, 1.5 H),
466.2
99.5%

7.37-7.57 (m, 1.7 H), 7.21 (t, 1 H), 7.03-7.17 (m, 1 H), 6.99 (s,
[M + H]⁺

0.5 H), 6.57-6.79 (m, 1.6 H), 6.44 (s, 0.4 H), 4.93-5.07 (m, 1 H),

3.86-3.98 (m, 0.5 H), 3.34-3.41 (m, 0.5 H), 2.80-3.24 (m, 2 H),

2.44-2.72 (m, 3 H)

938
(CD₃OD) δ 7.68 (d, 1 H), 7.27-7.53 (m, 1.4 H), 7.04-7.16 (m, 1
410.2
100%

H), 6.96 (s, 0.6 H), 6.39-6.76 (m, 2 H), 4.90-4.97 (m, 1 H), 3.89
[M + H]⁺

(br t, 1 H), 2.79-3.20 (m, 2 H), 2.53-2.72 (m, 3 H), 1.81-1.95 (m,

6 H)

939
(CD₃OD) δ 7.68 (d, 1 H), 7.29-7.52 (m, 1.4 H), 7.06-7.17 (m, 1
410.2
99.1%

H), 6.96 (s, 0.6 H), 6.36-6.75 (m, 2 H), 4.90-4.94 (m, 1 H), 3.82-
[M + H]⁺

3.96 (m, 1 H), 2.78-3.20 (m, 2 H), 2.54-2.71 (m, 3 H), 1.80-1.95

(m, 6 H)

940
(CD₃OD) δ 7.66 (d, 1 H), 7.32-7.51 (m, 1.4 H), 7.06-7.16 (m, 1
390.2
100%

H), 6.93 (br s, 0.6 H), 6.36-6.76 (m, 2 H), 4.97 (br dd, 1 H),
[M + H]⁺

3.78-3.95 (m, 0.5 H), 3.33-3.38 (m, 0.5 H), 2.75-3.19 (m, 2 H),

2.55-2.73 (m, 3 H), 2.31 (tq, 1 H), 1.13-1.32 (m, 4H)

941
(CD₃OD) δ 7.66 (d, 1 H), 7.28-7.54 (m, 1.4 H), 7.04-7.17 (m, 1
390.2
99.9%

H), 6.94 (s, 0.6 H), 6.38-6.77 (m, 2 H), 4.97 (br dd, 1 H), 3.81-
[M + H]⁺

3.93 (m, 0.5 H), 3.34-3.40 (m, 0.5 H), 2.76-3.17 (m, 2 H), 2.56-

2.72 (m, 3 H), 2.24-2.37 (m, 1 H), 1.10-1.40 (m, 4H)

942
(CD₃OD) δ 8.62-8.72 (m, 1 H), 7.69 (s, 1 H), 7.59-7.65 (m, 1 H),
444.2
98.9%

6.84-7.04 (m, 2 H), 6.70-6.80 (m, 1 H), 4.89-5.05 (m, 1 H), 3.35-
[M + H]⁺

3.77 (m, 1 H), 2.92-3.16 (m, 1 H), 2.76-2.86 (m, 1 H), 2.24-2.36

(m, 1 H), 1.18-1.29 (m, 4 H)

943
(CD₃OD) δ 8.62-8.72 (m, 1 H), 7.57-7.73 (m, 2 H), 6.85-7.03
444.2
94.9%

(m, 2 H), 6.67-6.81 (m, 1 H), 4.89-5.05 (m, 1 H), 3.34-3.76 (m, 1
[M + H]⁺

H), 2.91-3.18 (m, 1 H), 2.76-2.86 (m, 1 H), 2.25-2.36 (m, 1 H),

1.19-1.29 (m, 4 H)

944
(CD₃OD) δ 8.64-8.72 (m, 1 H), 7.76-7.81 (m, 1 H), 7.58-7.66
418.2
100%

(m, 1 H), 6.88-7.07 (m, 2 H), 6.73-6.82 (m, 1 H), 4.90-5.04 (m, 1
[M + H]⁺

H), 3.35-3.78 (m, 1 H), 2.95-3.19 (m, 1 H), 2.79-2.87 (m, 1 H),

2.63 (s, 3 H)

945
(CD₃OD) δ 8.63-8.72 (m, 1 H), 7.77-7.86 (m, 1 H), 7.58-7.66
418.2
92.1%

(m, 1 H), 6.89-7.04 (m, 2 H), 6.73-6.83 (m, 1 H), 4.90-5.06 (m, 1
[M + H]⁺

H), 3.35-3.77 (m, 1 H), 2.94-3.19 (m, 1 H), 2.78-2.88 (m, 1 H),

2.63 (s, 3 H)

946
(CD₃OD) δ 8.26-8.38 (m, 1 H), 7.68 (s, 1 H), 7.45 (s, 0.3 H),
394.2
99.3%

6.87-7.01 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.65-6.75 (m, 1 H),
[M + H]⁺

4.99 (dd, 1 H), 3.72 (ddd, 0.7 H), 3.35-3.42 (m, 0.3 H), 2.74-3.20

(m, 2 H), 2.26-2.38 (m, 1 H), 1.18-1.30 (m, 4H)

947
(CD₃OD) δ 8.27-8.38 (m, 1 H), 7.69 (s, 1 H), 7.45 (s, 0.3 H),
394.2
98.3%

6.87-7.02 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.63-6.77 (m, 1 H),
[M + H]⁺

4.99 (dd, 1 H), 3.63-3.80 (m, 0.7 H), 3.37-3.44 (m, 0.3 H), 2.77-

3.17 (m, 2 H), 2.24-2.40 (m, 1 H), 1.20-1.32 (m, 4H)

948
(CD₃OD) δ 8.62-8.72 (m, 1 H), 7.69 (s, 1 H), 7.58-7.65 (m, 1 H),
460.2
99.3%

6.93-7.44 (m, 2 H), 6.71-6.80 (m, 1 H), 4.90-5.03 (m, 1 H), 3.35-
[M + H]⁺

3.76 (m, 1 H), 2.80-3.15 (m, 2 H), 1.45-1.49 (m, 9H)

949
(CD₃OD) δ 8.63-8.71 (m, 1 H), 7.69 (s, 1 H), 7.59-7.65 (m, 1 H),
460.2
98.2%

6.94-7.44 (m, 2 H), 6.72-6.81 (m, 1 H), 4.90-5.03 (m, 1 H), 3.35-
[M + H]⁺

3.76 (m, 1 H), 2.80-3.17 (m, 2 H), 1.45-1.49 (m, 9H)

950
(CD₃OD) δ 8.70 (d, 1 H), 7.56-7.76 (m, 2 H), 7.41 (br s, 0.4 H),
464.2
97.2%

6.92-7.03 (m, 1.6 H), 6.69-6.83 (m, 1 H), 4.98 (br dd, 1 H), 3.69-
[M + H]⁺

3.79 (m, 0.6 H), 3.35 (s, 0.4 H), 2.81-3.20 (m, 2 H), 1.75-2.02

(m, 6 H)

951
(CD₃OD) δ 8.69 (d, 1 H), 7.57-7.76 (m, 2 H), 7.41 (s, 0.4H),
464.2
94.7%

6.92-7.03 (m, 1.6 H), 6.71-6.81 (m, 1 H), 4.98 (br dd, 1 H), 3.69-
[M + H]⁺

3.79 (m, 0.6 H), 3.34-3.41 (m, 0.4 H), 2.79-3.21 (m, 2 H), 1.79-

1.98 (m, 6 H)

952
(CD₃OD) δ 8.40 (s, 1 H), 8.10 (d, 1 H), 7.79-7.91 (m, 1 H), 7.66-
484.2
100%

7.75 (m, 1 H), 7.54-7.63 (m, 0.5 H), 7.24-7.38 (m, 2 H), 6.86 (s,
[M + H]⁺

1 H), 6.66 (s, 0.5 H), 5.08-5.14 (m, 0.5 H), 4.94 (br s, 1 H), 4.02

(d, 3 H), 3.79-3.98 (m, 0.5 H), 2.99 (s, 1 H), 2.82-2.91 (m, 1 H)

953
(CD₃OD) δ 8.39 (s, 1 H), 8.09 (d, 1 H), 7.78-7.89 (m, 1 H), 7.65-
484.2
99.2%

7.74 (m, 1 H), 7.54-7.61 (m, 0.5 H), 7.32 (br d, 2 H), 6.85 (s, 1
[M + H]⁺

H), 6.65 (s, 0.5 H), 5.10 (br dd, 0.5 H), 4.93-5.01 (m, 1 H), 4.00

(d, 3 H), 3.95 (br dd, 0.5 H), 2.94-3.18 (m, 1 H), 2.85 (br d, 1 H)

954
(CD₃OD) δ 8.23-8.40 (m, 1 H), 7.96-8.04 (m, 1 H), 7.53-7.76
448.2
98.7%

(m, 1.3 H), 6.91-7.06 (m, 1.7 H), 6.65-6.89 (m, 2 H), 5.03-5.26
[M + H]⁺

(m, 1 H), 3.69-3.93 (m, 3.7 H), 3.36-3.48 (m, 0.3 H), 2.92-3.25

(m, 1 H), 2.79-2.90 (m, 1 H), 2.57-2.75 (m, 3 H)

955
(CD₃OD) δ 8.24-8.40 (m, 1 H), 7.90-8.04 (m, 1 H), 7.51-7.74
448.2
96.7%

(m, 1.4 H), 6.89-7.01 (m, 1.6 H), 6.64-6.88 (m, 2 H), 5.05-5.22
[M + H]⁺

(m, 1 H), 3.67-3.91 (m, 3.5 H), 3.35-3.48 (m, 0.5 H), 2.91-3.24

(m, 1 H), 2.74-2.90 (m, 1 H), 2.58-2.72 (m, 3 H)

956
(CD₃OD) δ 9.40-9.53 (m, 1 H), 8.82-8.91 (m, 2 H), 8.22-8.37
428.2
99.7%

(m, 1 H), 7.73 (s, 1 H), 7.52 (s, 0.3 H), 6.97-7.03 (m, 1.7H),
[M + H]⁺

6.73-6.88 (m, 1 H), 6.59-6.68 (m, 1 H), 5.02 (br dd, 0.5 H), 3.77-

3.89 (m, 0.5 H), 3.46 (td, 0.5 H), 2.97-3.28 (m, 1.5 H), 2.80-2.93

(m, 1 H), 2.43-2.49 (m, 3 H)

957
(CD₃OD) δ 9.34-9.52 (m, 1 H), 8.84 (br d, 2 H), 8.19-8.36 (m, 1
428.2
99.3%

H), 7.70 (s, 1 H), 7.50 (s, 0.3 H), 6.96-7.01 (m, 1.7 H), 6.74-6.83
[M + H]⁺

(m, 1 H), 6.59-6.66 (m, 1 H), 5.00 (br dd, 0.5 H), 3.75-3.87 (m,

0.5 H), 3.45 (td, 0.5 H), 2.95-3.27 (m, 1.5 H), 2.80-2.90 (m, 1

H), 2.42-2.46 (m, 3 H)

958
(CD₃OD) δ 8.42 (s, 1 H), 7.72 (s, 1 H), 7.60 (br d, 1 H), 7.12-
419.1
99.6%

7.31 (m, 2 H), 7.01-7.05 (m, 1 H), 6.56-6.93 (m, 2 H), 4.24-4.43
[M + H]⁺

(m, 1 H), 3.77-3.95 (m, 1 H), 2.78-3.08 (m, 2 H)

959
(CD₃OD) δ 8.44 (s, 1 H), 7.71 (s, 1 H), 7.62 (br d, 1 H), 7.15-
419.1
99.9%

7.31 (m, 2 H), 7.03-7.06 (m, 1 H), 6.51-6.95 (m, 2 H), 4.25-4.43
[M + H]⁺

(m, 1 H), 3.73-3.98 (m, 1 H), 2.80-3.11 (m, 2 H)

960
(CD₃OD) δ 7.67 (s, 1 H), 7.61 (br d, 1 H), 6.98-7.28 (m, 3 H),
477.1
100%

6.78 (br s, 2 H), 4.26-4.48 (m, 1 H), 3.75-4.00 (m, 0.5 H), 3.35-
[M + H]⁺

3.52 (m, 0.5 H), 2.77-3.16 (m, 2 H), 1.57-1.70 (m, 6 H)

961
(CD₃OD) δ 7.67 (s, 1 H), 7.60 (br d, 1 H), 6.99-7.28 (m, 3 H),
477.1
98.3%

6.62-6.90 (m, 2 H), 4.27-4.41 (m, 1 H), 3.80-3.97 (m, 0.5 H),
[M + H]⁺

3.37-3.51 (m, 0.5 H), 2.77-3.16 (m, 2 H), 1.58-1.69 (m, 6 H)

962
(CD₃OD) δ 9.38-9.55 (m, 1 H), 8.81-8.95 (m, 2 H), 8.28-8.38
432.1
100%

(m, 1 H), 7.70 (s, 1 H), 6.70-7.05 (m, 4 H), 5.03 (br dd, 0.5H),
[M + H]⁺

3.75-3.85 (m, 0.5 H), 3.43 (td, 0.5 H), 2.94-3.28 (m, 1.5 H),

2.80-2.91 (m, 1 H)

963
(CD₃OD) δ 9.45-9.52 (m, 1 H), 8.78-8.90 (m, 2 H), 8.26-8.44
432.1
99.7%

(m, 1 H), 7.71 (s, 1 H), 6.74-7.08 (m, 4 H), 5.03 (br dd, 0.5 H),
[M + H]⁺

3.72-3.88 (m, 0.5 H), 3.38-3.51 (m, 0.5 H), 2.98-3.26 (m, 1.5 H),

2.86 (br d, 1 H)

964
(CD₃OD) δ 8.35 (dd, 1 H), 7.62-7.84 (m, 2.5 H), 7.50-7.58 (m, 1
486.1
99.7%

H), 7.14-7.25 (m, 2 H), 6.98-7.07 (m, 1.5 H), 6.60-6.84 (m, 1 H),
[M + H]⁺

5.07 (br dd, 1 H), 3.89-3.97 (m, 0.5 H), 3.37-3.44 (m, 0.5 H),

2.85-3.24 (m, 2 H)

965
(CD₃OD) δ 8.30-8.38 (m, 1 H), 7.59-7.87 (m, 2.5 H), 7.49-7.58
486.1
99.5%

(m, 1 H), 7.12-7.25 (m, 2 H), 6.97-7.07 (m, 1.5 H), 6.61-6.84 (m,
[M + H]⁺

1 H), 5.07 (br dd, 1 H), 3.87-4.00 (m, 0.6 H), 3.38-3.44 (m, 0.4

H), 2.84-3.25 (m, 2 H)

966
(CDCl₃) δ 8.06-8.22 (m, 1 H), 7.53-7.63 (m, 1 H), 7.43 (s, 0.3
390.2
100%

H), 7.30-7.38 (m, 1 H), 6.95 (s, 0.7 H), 6.93 (br d, 1 H), 6.50(s,
[M + H]⁺

1 H), 5.17 (br dd, 0.7 H), 4.94 (br dd, 0.3 H), 3.76-3.85 (m, 0.7

H), 3.44-3.51 (m, 0.3 H), 3.10-3.20 (m, 0.7 H), 2.94-3.05 (m, 0.5

H), 2.81 (br d, 0.5 H), 2.73 (br d, 0.3 H), 2.22-2.29 (m, 4 H),

1.19-1.28 (m, 4 H)

967
(CDCl₃) δ 8.08-8.21 (m, 1 H), 7.57-7.62 (m, 1 H), 7.45 (s, 0.3
390.2
100%

H), 7.31-7.38 (m, 1 H), 6.96 (s, 0.7 H), 6.93 (br d, 1 H), 6.51 (s,
[M + H]⁺

1 H), 5.18 (dd, 0.7 H), 4.96 (dd, 0.3 H), 3.76-3.87 (m, 0.7 H),

3.45-3.54 (m, 0.3 H), 3.11-3.21 (m, 0.7 H), 2.93-3.06 (m, 0.5 H),

2.82 (br d, 0.5 H), 2.74 (br d, 0.3 H), 2.26-2.31 (m, 4 H), 1.21-

1.28 (m, 4 H)

968
(CD₃OD) δ 7.71 (d, 1 H), 7.56-7.65 (m, 1 H), 7.46 (s, 0.4H),
430.2
99.6%

7.14-7.23 (m, 1 H), 7.02-7.08 (m, 1 H), 6.97 (s, 0.6 H), 6.60-6.83
[M + H]⁺

(m, 1 H), 4.95-5.03 (m, 1 H), 3.83-3.96 (m, 0.6 H), 3.36-3.43 (m,

0.4 H), 2.82-3.18 (m, 2 H), 1.87-1.94 (m, 6 H)

969
(CD₃OD) δ 7.59 (d, 1 H), 7.43-7.52 (m, 1 H), 7.33 (s, 0.4 H),
430.1
99.5%

7.02-7.10 (m, 1 H), 6.92 (d, 1 H), 6.85 (s, 0.6 H), 6.50-6.69 (m, 1
[M + H]⁺

H), 4.85-4.90 (m, 1 H), 3.72-3.82 (m, 0.6 H), 3.24-3.31 (m, 0.4

H), 2.71-3.05 (m, 2 H), 1.74-1.82 (m, 6 H)

970
(CD₃OD) δ 7.99-8.14 (m, 1 H), 7.70 (s, 1 H), 6.89-7.47 (m, 1 H),
426.2
98.8%

6.77-6.83 (m, 1 H), 6.52-6.72 (m, 2 H), 4.97 (br d, 1 H), 3.89-
[M + H]⁺

4.02 (m, 3 H), 3.37-3.82 (m, 1 H), 2.75-3.23 (m, 2 H), 1.82-2.00

(m, 6 H)

971
(CD₃OD) δ 7.87-8.04 (m, 1 H), 7.59 (s, 1 H), 6.78-7.37 (m, 1 H),
426.1
98.4%

6.68 (q, 1 H), 6.38-6.58 (m, 2 H), 4.85 (br d, 1 H), 3.79-3.90 (m,
[M + H]⁺

3 H), 3.25-3.71 (m, 1 H), 2.65-3.12 (m, 2 H), 1.72-1.84 (m, 6 H)

972
(CD₃OD) δ 8.40-8.50 (m, 1 H), 7.99-8.03 (m, 1 H), 7.71 (s, 1 H),
430.2
100%

7.53-7.66 (m, 1.3 H), 7.16-7.26 (m, 1 H), 6.97 (s, 0.7 H), 6.83-
[M + H]⁺

6.92 (m, 1 H), 6.57-6.67 (m, 1 H), 4.99-5.12 (m, 1 H), 3.90 (s, 3

H), 3.73-3.84 (m, 0.7 H), 3.42 (td, 0.3 H), 2.96-3.26 (m, 1 H),

2.80-2.91 (m, 1 H), 2.66-2.72 (m, 3 H)

973
(CD₃OD) δ 8.39-8.50 (m, 1 H), 8.00-8.03 (m, 1 H), 7.71 (br s, 1
430.2
98.6%

H), 7.56-7.65 (m, 1.3 H), 7.17-7.25 (m, 1 H), 6.97 (s, 0.7 H),
[M + H]⁺

6.83-6.92 (m, 1 H), 6.57-6.68 (m, 1 H), 5.09 (br dd, 1 H), 3.91

(s, 3 H), 3.72-3.84 (m, 0.7 H), 3.42 (td, 0.3 H), 2.96-3.26 (m, 1

H), 2.86 (br d, 1 H), 2.66-2.72 (m, 3 H)

974
(CD₃OD) δ 8.79 (d, 1 H), 8.28-8.41 (m, 1 H), 8.10 (td, 1 H),
431.1
99.7%

7.63-7.79 (m, 2 H), 7.42-7.60 (m, 1.5 H), 7.18-7.34 (m, 1 H),
[M + H]⁺

7.00 (s, 0.5 H), 6.71-6.87 (m, 1 H), 6.54-6.70 (m, 1 H), 5.06 (br

dd, 1 H), 3.79-3.93 (m, 0.6 H), 3.46 (td, 0.4 H), 2.98-3.29 (m, 1

H), 2.82-2.95 (m, 1 H)

975
(CD₃OD) δ 8.79 (d, 1 H), 8.29-8.42 (m, 1 H), 8.11 (td, 1 H),
431.2
97.2%

7.64-7.77 (m, 2 H), 7.40-7.59 (m, 1.4 H), 7.17-7.34 (m, 1 H),
[M + H]⁺

7.00 (s, 0.6 H), 6.71-6.89 (m, 1 H), 6.59-6.70 (m, 1 H), 5.06 (br

dd, 1 H), 3.80-3.96 (m, 0.5 H), 3.41-3.53 (m, 0.5 H), 2.95-3.28

(m, 1 H), 2.88 (dd, 1 H)

976
(CD₃OD) δ 7.80 (dd, 1 H), 7.69 (d, 1 H), 7.49-7.62 (m, 1.5 H),
450.1
100%

7.16 (dd, 1 H), 6.95-7.03 (m, 2.5 H), 6.60-6.78 (m, 1 H), 5.05 (br
[M + H]⁺

dd, 1 H), 4.02 (d, 3 H), 3.90 (ddd, 0.6 H), 3.33-3.41 (m, 0.4 H),

2.82-3.20 (m, 2 H)

977
(CD₃OD) δ 7.80 (dd, 1 H), 7.70 (br d, 1 H), 7.50-7.63 (m, 1.5
450.1
100%

H), 7.10-7.21 (m, 1 H), 6.94-7.04 (m, 2.5 H), 6.60-6.80 (m, 1 H),
[M + H]⁺

5.05 (br dd, 1 H), 4.02 (d, 3 H), 3.84-3.95 (m, 0.6 H), 3.34-3.41

(m, 0.4 H), 2.82-3.21 (m, 2 H)

978
(CD₃OD) δ 9.28-9.45 (m, 1 H), 8.64-8.86 (m, 2 H), 7.62 (br s, 1
448.1
98.7%

H), 7.18-7.58 (m, 2 H), 6.82-7.18 (m, 2 H), 6.48-6.81 (m, 1 H),
[M + H]⁺

4.82-5.00 (m, 1 H), 3.25-3.91 (m, 1 H), 2.72-3.16 (m, 2 H)

979
(CD₃OD) δ 9.42-9.54 (m, 1 H), 8.76-8.91 (m, 2 H), 7.74 (br d, 1
448.1
96.9%

H), 7.43-7.70 (m, 2 H), 6.98-7.23 (m, 2 H), 6.62-6.86 (m, 1 H),
[M + H]⁺

4.94-5.11 (m, 1 H), 3.38-4.01 (m, 1 H), 2.84-3.28 (m, 2 H)

980
(CD₃OD) δ 8.48-8.64 (m, 1 H), 7.69 (s, 1 H), 7.39-7.50 (m, 1.2
426.2
100%

H), 7.08-7.13 (m, 0.4 H), 6.61-7.00 (m, 3.4 H), 5.00 (br dd, 1 H),
[M + H]⁺

3.64-3.77 (m, 0.5 H), 3.39 (br d, 0.5 H), 2.77-3.18 (m, 2 H),

2.27-2.35 (m, 1 H), 1.19-1.31 (m, 4H)

981
(CD₃OD) δ 8.52-8.61 (m, 1 H), 7.69 (s, 1 H), 7.38-7.49 (m, 1.2
426.2
100%

H), 7.07-7.15 (m, 0.4 H), 6.68-7.00 (m, 3.4 H), 5.00 (br dd, 1 H),
[M + H]⁺

3.66-3.78 (m, 0.5 H), 3.34-3.40 (m, 0.5 H), 2.78-3.19 (m, 2 H),

2.25-2.36 (m, 1 H), 1.20-1.30 (m, 4 H)

982
(CD₃OD) δ 8.62-8.69 (m, 1 H), 7.91-8.01 (m, 1 H), 7.68-7.80
465.1
98.6%

(m, 2 H), 7.55-7.66 (m, 1 H), 7.48 (s, 0.4 H), 7.13-7.24 (m, 1 H),
[M + H]⁺

6.97-7.08 (m, 1.6 H), 6.64-6.84 (m, 1 H), 4.98-5.10 (m, 1 H),

3.87-4.00 (m, 0.6 H), 3.38-3.48 (m, 0.4 H), 2.85-3.26 (m, 2 H)

983
(CD₃OD) δ 8.64 (d, 1 H), 7.94 (br t, 1 H), 7.68-7.79 (m, 2 H),
465.1
96.2%

7.55-7.65 (m, 1 H), 7.47 (s, 0.4 H), 7.17 (dt, 1 H), 6.95-7.07 (m,
[M + H]⁺

1.6 H), 6.61-6.84 (m, 1 H), 4.98-5.04 (m, 1 H), 3.93 (br s, 0.6

H), 3.36-3.46 (m, 0.4 H), 2.84-3.22 (m, 2 H)

984
(CD₃OD) δ 8.83-9.06 (m, 1 H), 8.37 (s, 1 H), 7.42-7.87 (m, 3.5
470.2
98.6%

H), 7.19-7.33 (m, 1 H), 6.98 (s, 0.5 H), 6.80 (d, 0.5 H), 6.59-6.73
[M + H]⁺

(m, 1.5 H), 5.12 (br dd, 1 H), 3.75-3.91 (m, 0.6 H), 3.39-3.48 (m,

0.4 H), 3.13-3.26 (m, 0.7 H), 3.02 (br t, 0.3 H), 2.87 (br d, 1 H)

985
(CD₃OD) δ 8.84-9.10 (m, 1 H), 8.37 (s, 1 H), 7.42-7.88 (m, 3.5
470.2
95.7%

H), 7.19-7.34 (m, 1 H), 6.98 (s, 0.5 H), 6.80 (d, 0.5 H), 6.57-6.74
[M + H]⁺

(m, 1.5 H), 5.12 (br dd, 1 H), 3.79-3.91 (m, 0.7 H), 3.40-3.49 (m,

0.3 H), 3.12-3.24 (m, 1 H), 2.87 (br d, 1 H)

986
(CD₃OD) δ 7.65-7.95 (m, 1 H), 7.21-7.52 (m, 2 H), 6.53-7.08
414.2
99.4%

(m, 3 H), 4.99 (br d, 1 H), 3.38-3.88 (m, 1 H), 2.79-3.25 (m, 2
[M + H]⁺

H), 1.79-2.01 (m, 6H)

987
(CD₃OD) δ 7.63-8.07 (m, 1 H), 7.20-7.53 (m, 2 H), 6.53-7.16
414.2
95.1%

(m, 3 H), 4.97-5.02 (m, 1 H), 3.36-3.86 (m, 1 H), 2.80-3.25 (m, 2
[M + H]⁺

H), 1.82-1.99 (m, 6 H)

988
(CD₃OD) δ 8.19-8.35 (m, 1 H), 7.95-8.06 (m, 1 H), 7.52-7.74
444.2
97.4%

(m, 1.4 H), 6.95-7.06 (m, 1.6 H), 6.55-6.86 (m, 2 H), 5.09 (br dd,
[M + H]⁺

1 H), 3.70-3.99 (m, 3.7 H), 3.36-3.50 (m, 0.4 H), 2.94-3.28 (m, 1

H), 2.79-2.91 (m, 1 H), 2.60-2.74 (m, 3 H), 2.34-2.54 (m, 3 H)

989
(CD₃OD) δ 8.18-8.34 (m, 1 H), 7.93-8.04 (m, 1 H), 7.48-7.76
444.2
97.7%

(m, 1.4 H), 6.95-7.06 (m, 1.6 H), 6.51-6.85 (m, 2 H), 5.07 (br dd,
[M + H]⁺

1 H), 3.66-3.93 (m, 3.7 H), 3.35-3.48 (m, 0.3 H), 2.94-3.23 (m, 1

H), 2.78-2.92 (m, 1 H), 2.58-2.71 (m, 3 H), 2.31-2.51 (m, 3 H)

990
(CD₃OD) δ 8.46 (d, 1 H), 7.50-7.75 (m, 2 H), 7.18-7.24 (m, 1
427.2
100%

H), 6.87 (td, 1.6 H), 6.33-6.72 (m, 1.4 H), 4.79 (br s, 0.4 H), 4.21
[M + H]⁺

(br d, 0.6 H), 3.79 (br t, 0.6 H), 3.37-3.52 (m, 0.4 H), 2.91-3.21

(m, 1 H), 2.83 (br d, 1 H), 1.51-1.69 (m, 6 H)

991
(CD₃OD) δ 8.46 (d, 1 H), 7.54-7.76 (m, 2 H), 7.20 (t, 1 H), 6.86
427.3
95.9%

(td, 1.6 H), 6.32-6.69 (m, 1.4 H), 4.80 (br s, 0.3 H), 4.21 (br d,
[M + H]⁺

0.7 H), 3.79 (br t, 0.7 H), 3.41 (br s, 0.3 H), 2.92-3.22 (m, 1 H),

2.83 (br d, 1 H), 1.55-1.70 (m, 6 H)

992
(CD₃OD) δ 8.45 (br d, 1 H), 7.50-7.75 (m, 2 H), 7.10-7.28 (m, 1
416.2
100%

H), 6.85 (br t, 1.5 H), 6.34-6.71 (m, 1.5 H), 4.27 (br d, 1 H),
[M + H]⁺

3.34-3.91 (m, 1 H), 2.70-3.21 (m, 2 H), 2.37 (s, 3 H), 1.57-2.02

(m, 6 H)

993
(CD₃OD) δ 8.44 (br d, 1 H), 7.49-7.75 (m, 2 H), 7.18 (dd, 1 H),
416.3
99.6%

6.36-6.92 (m, 3 H), 4.04-4.43 (m, 1 H), 3.35-3.84 (m, 1 H), 2.64-
[M + H]⁺

3.22 (m, 2 H), 2.37 (s, 3 H), 1.64-2.06 (m, 6 H)

994
(CD₃OD) δ 8.46 (dd, 1 H), 7.69 (s, 1 H), 7.61 (br d, 1 H), 7.11-
441.2
99.3%

7.30 (m, 2 H), 6.80-7.05 (m, 2 H), 6.63 (s, 1 H), 4.39 (br d, 1 H),
[M + H]⁺

3.73 (br s, 1 H), 2.74-3.27 (m, 2 H), 1.26-1.58 (m, 4 H)

995
(CD₃OD) δ 8.34 (dd, 1 H), 7.57 (s, 1 H), 7.49 (br d, 1 H), 7.00-
441.2
99.3%

7.20 (m, 2 H), 6.68-6.92 (m, 2 H), 6.51 (s, 1 H), 4.13-4.37 (m, 1
[M + H]⁺

H), 3.51-3.77 (m, 1 H), 2.65-3.12 (m, 2 H), 1.14-1.49 (m, 4H)

996
(CD₃OD) δ 8.42 (d, 1 H), 7.50-7.69 (m, 2 H), 7.17 (t, 1 H), 6.77-
459.2
94.9%

6.88 (m, 1.6 H), 6.29-6.64 (m, 1.4 H), 4.97-5.14 (m, 1 H), 4.75
[M + H]'

(br d, 0.4 H), 4.12 (br d, 0.6 H), 3.74 (br t, 0.6 H), 3.38 (br s, 0.4

H), 2.90-3.13 (m, 1 H), 2.78 (br dd, 1 H), 1.55 (br d, 3 H)

997
(CD₃OD) δ 8.46 (d, 1 H), 7.57-7.80 (m, 2 H), 7.21 (t, 1 H), 6.82-
459.1
97.0%

6.91 (m, 1.7 H), 6.38-6.67 (m, 1.3 H), 4.97-5.11 (m, 1 H), 4.74-
[M + H]⁺

4.83 (m, 0.4 H), 4.18 (br d, 0.6 H), 3.78 (br t, 0.6 H), 3.42 (br s,

0.4 H), 2.92-3.20 (m, 1 H), 2.83 (br dd, 1 H), 1.59 (br d, 3 H)

998
(CD₃OD) δ 8.42 (d, 1 H), 7.51-7.70 (m, 2 H), 7.12-7.23 (m, 1
459.2
93.1%

H), 6.79-6.89 (m, 1.6 H), 6.25-6.64 (m, 1.4 H), 4.94-5.11 (m, 1
[M + H]⁺

H), 4.77 (br s, 0.4 H), 4.12 (br d, 0.6 H), 3.69-3.82 (m, 0.6 H),

3.38 (br s, 0.4 H), 2.89-3.16 (m, 1 H), 2.78 (br dd, 1 H), 1.55 (br

d, 3 H)

999
(CD₃OD) δ 8.46 (d, 1 H), 7.54-7.74 (m, 2 H), 7.21 (br t, 1 H),
459.2
98.8%

6.87 (t, 1.7 H), 6.35-6.69 (m, 1.3 H), 4.97-5.05 (m, 1 H), 4.74-
[M + H]⁺

4.84 (m, 0.4 H), 4.16 (br d, 0.6 H), 3.74-3.93 (m, 0.6 H), 3.42 (br

s, 0.4 H), 2.93-3.19 (m, 1 H), 2.82 (br dd, 1 H), 1.59 (br d, 3 H)

1000
(CD₃OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1 H), 6.47-6.87
425.0
98.6%

(m, 3 H), 4.26-4.81 (m, 1 H), 3.35-3.78 (m, 1 H), 2.90-3.22 (m, 1
[M + H]⁺

H), 2.80 (br d, 1 H), 2.37 (s, 3 H), 1.49-1.67 (m, 6 H)

1001
(CD₃OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.96 (dd, 1 H), 6.45-6.87
425.1
99.8%

(m, 3 H), 4.27-4.84 (m, 1 H), 3.35-3.79 (m, 1 H), 2.66-3.22 (m, 2
[M + H]⁺

H), 2.37 (s, 3 H), 1.49-1.70 (m, 6 H)

1002
(CD₃OD) δ 8.69 (d, 1 H), 8.42 (s, 1 H), 7.70 (s, 1 H), 7.63 (d, 1
453.1
99.7%

H), 7.10-7.31 (m, 1 H), 6.55-7.02 (m, 3 H), 4.33 (br s, 1 H), 3.73
[M + H]⁺

(br s, 1 H), 2.73-3.14 (m, 2 H)

1003
(CD₃OD) δ 8.69 (d, 1 H), 8.42 (s, 1 H), 7.69 (s, 1 H), 7.63 (d, 1
453.1
99.2%

H), 7.11-7.29 (m, 1 H), 6.56-7.02 (m, 3 H), 4.35 (br d, 1 H), 3.73
[M + H]⁺

(br s, 1 H), 2.74-3.15 (m, 2 H)

1004
(CD₃OD) δ 8.44 (s, 1 H), 8.33 (d, 1 H), 7.72 (s, 1 H), 7.01-7.41
399.2
99.7%

(m, 2 H), 6.61-6.92 (m, 2 H), 6.40-6.57 (m, 1 H), 4.26-4.84 (m, 1
[M + H]⁺

H), 3.48-3.82 (m, 1 H), 3.08 (br s, 1 H), 2.81 (br d, 1 H), 2.38 (s,

3 H)

1005
(CD₃OD) δ 8.44 (s, 1 H), 8.33 (d, 1 H), 7.69 (s, 1 H), 7.00-7.41
399.2
98.5%

(m, 2 H), 6.61-6.92 (m, 2 H), 6.49 (br s, 1 H), 4.24-4.79 (m, 1
[M + H]⁺

H), 3.41-3.83 (m, 1 H), 2.96-3.16 (m, 1 H), 2.81 (br d, 1 H), 2.38

(s, 3 H)

1006
(CD₃OD) δ 8.74 (d, 1 H), 8.19-8.40 (m, 2 H), 8.06 (br s, 1 H),
480.2
100%

7.59-7.78 (m, 2 H), 6.73-7.40 (m, 5 H), 4.80-4.86 (m, 0.4 H),
[M + H]⁺

4.54 (br d, 0.6 H), 3.51-3.87 (m, 1 H), 2.99-3.32 (m, 1 H), 2.87

(br d, 1 H)

1007
(CD₃OD) δ 8.74 (d, 1 H), 8.16-8.50 (m, 2 H), 8.05 (br d, 1 H),
480.2
99.3%

7.54-7.78 (m, 2 H), 6.64-7.47 (m, 5 H), 4.78-4.87 (m, 0.4H),
[M + H]⁺

4.54 (br d, 0.6 H), 3.53-3.90 (m, 1 H), 2.96-3.30 (m, 1 H), 2.87

(br d, 1 H)

1008
(CD₃OD) δ 7.87-8.40 (m, 3 H), 7.77 (br s, 1 H), 7.05-7.37 (m, 1
479.2
95.3%

H), 6.94-7.04 (m, 1 H), 6.53-6.92 (m, 3 H), 4.50 (br s, 1 H), 3.98
[M + H]⁺

(br s, 3 H), 3.77 (br s, 0.6 H), 3.49 (br s, 0.4 H), 2.71-3.26 (m, 2

H), 2.45 (s, 3 H)

1009
(CD₃OD) δ 7.85-8.39 (m, 3 H), 7.71 (s, 1 H), 7.04-7.35 (m, 1 H),
479.2
92.8%

6.99 (d, 1 H), 6.48-6.92 (m, 3 H), 4.32-4.72 (m, 1 H), 3.97 (br s,
[M + H]⁺

3 H), 3.68-3.85 (m, 0.6 H), 3.46 (br d, 0.4 H), 2.73-3.23 (m, 2

H), 2.44 (s, 3 H)

1010
(CD₃OD) δ 8.23-8.33 (m, 1 H), 7.43-7.71 (m, 1.3 H), 6.90-7.01
364.2
100%

(m, 1.7 H), 6.72-6.81 (m, 1 H), 6.51-6.63 (m, 1 H), 4.90-4.97 (m,
[M + H]⁺

1 H), 3.74 (ddd, 0.7 H), 3.38 (td, 0.3 H), 3.07-3.18 (m, 0.6 H),

2.90-3.02 (m, 0.4 H), 2.81 (br dd, 1 H), 2.60-2.65 (m, 3 H), 2.39-

2.47 (m, 3 H)

1011
(CD₃OD) δ 8.23-8.35 (m, 1 H), 7.72-7.83 (m, 1 H), 7.49 (s, 0.3
364.2
100%

H), 6.92-7.01 (m, 1.7 H), 6.71-6.83 (m, 1 H), 6.49-6.65 (m, 1 H),
[M + H]⁺

4.92-4.99 (m, 1 H), 3.74 (ddd, 0.7 H), 3.38 (td, 0.3 H), 3.07-3.19

(m, 0.7 H), 2.92-3.02 (m, 0.3 H), 2.77-2.87 (m, 1 H), 2.59-2.67

(m, 3 H), 2.38-2.48 (m, 3 H)

1012
(CD₃OD) δ 8.31 (d, 1 H), 7.69 (s, 1.3 H), 6.89-7.07 (m, 1.7 H),
451.3
100%

6.74-6.86 (m, 1 H), 6.54-6.66 (m, 1 H), 5.21 (dd, 0.7 H), 4.92-
[M + H]⁺

5.04 (m, 1 H), 3.53-3.88 (m, 5 H), 3.39 (br dd, 0.3 H), 2.75-3.22

(m, 2 H), 2.40-2.49 (m, 3 H), 1.86-2.17 (m, 4 H)

1013
(CD₃OD) δ 8.22-8.38 (m, 1 H), 7.57-7.80 (m, 1.3 H), 6.74-7.11
451.3
100%

(m, 2.7 H), 6.56-6.70 (m, 1 H), 5.21 (dd, 0.7 H), 4.97 (br s, 1 H),
[M + H]⁺

3.62-3.80 (m, 5 H), 3.37-3.45 (m, 0.3 H), 2.75-3.19 (m, 2 H),

2.41-2.51 (m, 3 H), 1.89-2.15 (m, 4H)

1014
(CD₃OD) δ 8.35 (d, 1 H), 7.54-7.82 (m, 1.4 H), 6.81-7.12 (m,
455.2
100%

2.6 H), 6.75 (s, 1 H), 5.23 (dd, 0.6 H), 4.97 (br d, 1 H), 3.61-3.82
[M + H]⁺

(m, 5 H), 3.35-3.47 (m, 0.6 H), 2.74-3.22 (m, 2 H), 1.76-2.24 (m,

4 H)

1015
(CD₃OD) δ 8.23 (d, 1 H), 7.41-7.74 (m, 1.3 H), 6.68-6.91 (m,
455.2
99.0%

2.7 H), 6.63 (s, 1 H), 5.11 (br dd, 1 H), 4.85 (br s, 1 H), 3.52-
[M + H]⁺

3.68 (m, 5 H), 3.24-3.30 (m, 0.6 H), 2.61-3.09 (m, 2 H), 1.74-

2.01 (m, 4 H)

1016
(CD₃OD) δ 8.20-8.33 (m, 1 H), 7.51-7.73 (m, 2.3 H), 7.03-7.09
430.2
99.5%

(m, 1 H), 6.93-7.01 (m, 1.7 H), 6.71-6.83 (m, 1 H), 6.54-6.67 (m,
[M + H]⁺

1 H), 5.04 (dd, 1 H), 4.26-4.36 (m, 3 H), 3.79 (ddd, 0.7 H), 3.35-

3.52 (m, 0.3 H), 2.76-3.25 (m, 2 H), 2.36-2.51 (m, 3 H)

1017
(CD₃OD) δ 8.20-8.33 (m, 1 H), 7.48-7.75 (m, 2.3 H), 7.04-7.11
430.2
99.4%

(m, 1 H), 6.91-7.03 (m, 1.7 H), 6.71-6.83 (m, 1 H), 6.53-6.67 (m,
[M + H]⁺

1 H), 4.98-5.12 (m, 1 H), 4.24-4.37 (m, 3 H), 3.71-3.86 (m, 0.7

H), 3.36-3.52 (m, 0.3 H), 2.73-3.26 (m, 2 H), 2.37-2.49 (m, 3 H)

1018
(CD₃OD) δ 8.26-8.37 (m, 1 H), 7.49-7.73 (m, 2.3 H), 7.05-7.11
434.2
99.3%

(m, 1 H), 6.90-7.02 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.72-6.78 (m,
[M + H]⁺

1 H), 5.07 (dd, 1 H), 4.28-4.33 (m, 3 H), 3.78 (ddd, 0.7 H), 3.41

(td, 0.3 H), 2.75-3.26 (m, 2 H)

1019
(CD₃OD) δ 8.25-8.38 (m, 1 H), 7.51-7.73 (m, 2.3 H), 7.05-7.11
434.2
99.2%

(m, 1 H), 6.91-7.02 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.72-6.78 (m,
[M + H]⁺

1 H), 5.07 (dd, 1 H), 4.25-4.36 (m, 3 H), 3.72-3.84 (m, 0.7 H),

3.36-3.48 (m, 0.3 H), 2.77-3.25 (m, 2 H)

1020
(CD₃OD) δ 7.68 (d, 1 H), 7.35-7.54 (m, 1.4 H), 7.04-7.19 (m, 1
406.2
98.7%

H), 6.96 (s, 0.6 H), 6.67-6.75 (m, 1 H), 6.42-6.61 (m, 1 H), 4.92-
[M + H]⁺

4.99 (m, 1 H), 3.82-3.94 (m, 0.5 H), 3.34-3.40 (m, 0.5 H), 2.76-

3.20 (m, 2 H), 2.57-2.70 (m, 3 H), 1.47 (d, 9 H)

1021
(CD₃OD) δ 7.68 (d, 1 H), 7.33-7.53 (m, 1.4 H), 7.05-7.18 (m, 1
406.3
95.3%

H), 6.95 (s, 0.6 H), 6.66-6.75 (m, 1 H), 6.40-6.63 (m, 1 H), 4.92-
[M + H]⁺

4.99 (m, 1 H), 3.87 (br t, 0.5 H), 3.34-3.42 (m, 0.5 H), 2.77-3.19

(m, 2 H), 2.55-2.72 (m, 3 H), 1.47 (d, 9H)

1022
(CD₃OD) δ 8.20-8.33 (m, 1 H), 7.69 (s, 1 H), 7.41 (s, 0.3 H),
406.2
100%

6.91-7.04 (m, 1.7 H), 6.73-6.82 (m, 1 H), 6.50-6.66 (m, 1 H),
[M + H]⁺

4.95 (br dd, 1 H), 3.69-3.78 (m, 0.5 H), 3.34-3.43 (m, 0.5 H),

2.92-3.20 (m, 1 H), 2.82 (br dd, 1 H), 2.38-2.50 (m, 3 H), 1.41-

1.56 (m, 9 H)

1023
(CD₃OD) δ 8.22-8.32 (m, 1 H), 7.71-7.78 (m, 1 H), 7.42 (s, 0.3
406.2
99.6%

H), 6.90-7.03 (m, 1.7 H), 6.72-6.83 (m, 1 H), 6.49-6.66 (m, 1 H),
[M + H]⁺

4.96 (dd, 1 H), 3.67-3.80 (m, 0.6 H), 3.38 (td, 0.4 H), 2.90-3.21

(m, 1 H), 2.83 (br dd, 1 H), 2.36-2.50 (m, 3 H), 1.45-1.50 (m, 9 H)

1024
(CD₃OD) δ 8.27-8.36 (m, 1 H), 7.69 (s, 1 H), 7.41 (s, 0.4 H),
414.2
96.1%

6.91-7.00 (m, 1.6 H), 6.78-6.88 (m, 1 H), 6.66-6.77 (m, 1 H),
[M + H]⁺

4.94-4.99 (m, 1 H), 3.70-3.82 (m, 0.7 H), 3.37 (br s, 0.3 H), 2.83

(br dd, 2 H), 1.83-1.95 (m, 6 H)

1025
(CD₃OD) δ 8.26-8.40 (m, 1 H), 7.69 (s, 1 H), 7.41 (s, 0.4 H),
414.2
95.0%

6.92-7.00 (m, 1.6 H), 6.79-6.87 (m, 1 H), 6.66-6.76 (m, 1 H),
[M + H]⁺

4.93-5.00 (m, 1 H), 3.75 (br s, 1 H), 2.79-3.21 (m, 2 H), 1.79-

1.95 (m, 6 H)

1026
(CD₃OD) δ 8.25-8.38 (m, 1 H), 7.69 (s, 1 H), 7.40 (br s, 0.3 H),
410.2
100%

6.89-7.02 (m, 1.7 H), 6.78-6.88 (m, 1 H), 6.63-6.77 (m, 1 H),
[M + H]⁺

4.91-5.03 (m, 1 H), 3.66-3.80 (m, 0.7 H), 3.35-3.44 (m, 0.3 H),

2.77-3.21 (m, 2 H), 1.45-1.51 (m, 9H)

1027
(CD₃OD) δ 8.27-8.38 (m, 1 H), 7.69 (s, 1 H), 7.40 (br s, 0.3 H),
410.2
100%

6.89-7.01 (m, 1.7 H), 6.78-6.87 (m, 1 H), 6.62-6.78 (m, 1 H),
[M + H]⁺

4.90-5.01 (m, 1 H), 3.65-3.81 (m, 0.7 H), 3.35-3.42 (m, 0.3 H),

2.74-3.19 (m, 2 H), 1.44-1.52 (m, 9 H)

1028
(CD₃OD) δ 8.78 (t, 1 H), 8.31 (d, 1 H), 8.04-8.16 (m, 1 H), 7.80-
481.2
100%

7.91 (m, 1 H), 7.65-7.75 (m, 2 H), 7.54-7.61 (m, 0.5 H), 7.29 (br
[M + H]⁺

s, 2 H), 6.88 (s, 1 H), 6.68 (s, 0.5 H), 4.94-5.08 (m, 1 H), 3.90-

4.07 (m, 0.5 H), 3.34-3.37 (m, 0.5 H), 2.84-3.26 (m, 2 H)

1029
(CD₃OD) δ 8.77 (t, 1 H), 8.30 (d, 1 H), 8.04-8.13 (m, 1 H), 7.78-
481.2
99.8%

7.90 (m, 1 H), 7.63-7.74 (m, 2 H), 7.57 (s, 0.5 H), 7.22-7.36 (m,
[M + H]⁺

2 H), 6.85-7.01 (m, 1 H), 6.67 (s, 0.5 H), 4.93-5.04 (m, 1 H),

3.97 (br s, 0.5 H), 3.33-3.38 (m, 0.5 H), 2.83-3.25 (m, 2 H)

1030
(CD₃OD) δ 7.76-7.87 (m, 2 H), 7.69 (br d, 1 H), 7.58 (s, 0.5 H),
484.2
100%

7.18-7.34 (m, 2 H), 6.82-6.99 (m, 2 H), 6.66 (s, 0.5 H), 4.96-5.08
[M + H]⁺

(m, 1 H), 4.01 (d, 3.8 H), 3.36 (br d, 0.2 H), 3.17 (br s, 0.5 H),

2.96 (br dd, 0.5 H), 2.85 (br d, 1 H)

1031
(CD₃OD) δ 7.77-7.88 (m, 2 H), 7.54-7.59 (m, 1 H), 7.58 (s, 0.5
484.2
100%

H), 7.20-7.34 (m, 2 H), 6.84-6.97 (m, 2 H), 6.66 (s, 0.5 H), 4.92-
[M + H]⁺

5.07 (m, 1 H), 4.01 (d, 3.8 H), 3.32-3.37 (m, 0.2 H), 3.10-3.21

(m, 0.5 H), 2.98 (s, 0.5 H), 2.81-2.89 (m, 1 H)

1032
(CD₃OD) δ 7.97 (d, 1 H), 7.80-7.90 (m, 2 H), 7.66-7.75 (m, 1
484.2
100%

H), 7.54 (s, 0.5 H), 7.23-7.36 (m, 2 H), 6.85-6.99 (m, 1 H), 6.66
[M + H]⁺

(s, 0.5 H), 5.08 (br dd, 0.5 H), 4.93-4.97 (m, 1 H), 4.09 (s, 3 H),

3.90-4.00 (m, 0.5 H), 2.94-3.04 (m, 1 H), 2.82-2.90 (m, 1 H)

1033
(CD₃OD) δ 7.97 (d, 1 H), 7.80-7.89 (m, 2 H), 7.79 (s, 1 H), 7.55
484.2
99.5%

(s, 0.5 H), 7.22-7.36 (m, 2 H), 6.85-7.01 (m, 1 H), 6.68 (s, 0.5
[M + H]⁺

H), 5.10 (dd, 0.5 H), 4.90-4.98 (m, 1 H), 4.09 (s, 3 H), 3.90-3.99

(m, 0.5 H), 2.94-3.04 (m, 1 H), 2.83-2.91 (m, 1 H)

1034
(CD₃OD) δ 8.60-8.74 (m, 1 H), 7.88-8.00 (m, 1.5 H), 7.73-7.86
499.2
100%

(m, 2 H), 7.54-7.72 (m, 1 H), 7.24-7.39 (m, 2 H), 6.68-7.03 (m,
[M + H]⁺

1.5 H), 5.02 (br d, 1 H), 3.92-4.07 (m, 0.5 H), 3.37-3.42 (m, 0.5

H), 2.86-3.23 (m, 2 H)

1035
(CD₃OD) δ 8.65 (t, 1 H), 7.87-7.98 (m, 1.5 H), 7.71-7.84 (m, 2
499.2
100%

H), 7.52-7.69 (m, 1 H), 7.21-7.38 (m, 2 H), 6.66-7.00 (m, 1.5 H),
[M + H]⁺

4.96 (br t, 1 H), 3.89-4.05 (m, 0.5 H), 3.34-3.41 (m, 0.5 H), 2.84-

3.22 (m, 2 H)

1036
(CD₃OD) δ 8.34 (dd, 1 H), 7.50-7.91 (m, 3.5 H), 7.19-7.39 (m, 3
520.2
98.0%

H), 6.65-7.01 (m, 1.5 H), 4.97-5.09 (m, 1 H), 3.88-4.07 (m, 0.5
[M + H]⁺

H), 3.33-3.51 (m, 0.5 H), 2.85-3.22 (m, 2 H)

1037
(CD₃OD) δ 8.33 (dd, 1 H), 7.51-7.90 (m, 3.5 H), 7.19-7.38 (m, 3
520.2
98.8%

H), 6.64-7.01 (m, 1.5 H), 4.94-5.04 (m, 1 H), 3.97 (br d, 0.5 H),
[M + H]⁺

3.33-3.39 (m, 0.5 H), 2.85-3.21 (m, 2 H)

1038
(CD₃OD) δ 8.46-8.50 (m, 1 H), 8.23-8.33 (m, 1 H), 8.14 (s, 1 H),
470.2
100%

7.69 (s, 1 H), 7.57 (s, 0.3 H), 6.93-7.02 (m, 1.7 H), 6.73-6.82 (m,
[M + H]⁺

1 H), 6.53-6.66 (m, 1 H), 4.99-5.11 (m, 2 H), 3.71-3.83 (m, 0.6

H), 3.36-3.47 (m, 0.4 H), 3.11-3.23 (m, 0.7 H), 2.92-3.06 (m, 0.3

H), 2.78-2.90 (m, 1 H), 2.57-2.67 (m, 2 H), 2.47-2.57 (m, 2 H),

2.39-2.47 (m, 3 H), 1.85-2.00 (m, 2 H)

1039
(CD₃OD) δ 8.46-8.50 (m, 1 H), 8.23-8.33 (m, 1 H), 8.14 (s, 1 H),
470.2
98.5%

7.69 (s, 1 H), 7.57 (s, 0.3 H), 6.93-7.02 (m, 1.7 H), 6.73-6.82 (m,
[M + H]⁺

1 H), 6.53-6.66 (m, 1 H), 4.99-5.11 (m, 2 H), 3.71-3.83 (m, 0.6

H), 3.36-3.47 (m, 0.4 H), 3.11-3.23 (m, 0.7 H), 2.92-3.06 (m, 0.3

H), 2.78-2.90 (m, 1 H), 2.57-2.67 (m, 2 H), 2.47-2.57 (m, 2 H),

2.39-2.47 (m, 3 H), 1.85-2.00 (m, 2 H)

1040
(CD₃OD) δ 8.91 (d, 1 H), 8.35 (d, 1 H), 7.73-7.91 (m, 2 H),
520.1
100%

7.64-7.68 (m, 1 H), 7.50-7.57 (m, 0.6 H), 7.24-7.37 (m, 2 H),
[M + H]⁺

6.84-6.99 (m, 1 H), 6.66 (s, 0.4 H), 5.10 (br dd, 1 H), 3.91-4.02

(m, 1 H), 2.84-3.18 (m, 2 H)

1041
(CD₃OD) δ 8.89 (d, 1 H), 8.33 (d, 1 H), 7.69-7.89 (m, 2 H),
520.1
98.3%

7.63-7.68 (m, 1 H), 7.48-7.55 (m, 0.6 H), 7.22-7.37 (m, 2 H),
[M + H]⁺

6.83-6.98 (m, 1 H), 6.64 (s, 0.4 H), 5.09 (dd, 1 H), 3.87-4.02 (m,

1 H), 2.84-3.20 (m, 2 H)

1042
(CD₃OD) δ 8.76 (dd, 1 H), 8.24-8.35 (m, 1 H), 8.07 (tdd, 1 H),
447.1
100%

7.54-7.71 (m, 3 H), 7.48 (s, 0.4 H), 7.10-7.21 (m, 1 H), 6.94-7.04
[M + H]⁺

(m, 1.6 H), 6.60-6.81 (m, 1 H), 4.96-5.07 (m, 1 H), 3.88-3.95 (m,

0.5 H), 3.38 (td, 0.5 H), 2.82-3.23 (m, 2 H)

1043
(CD₃OD) δ 8.76 (dd, 1 H), 8.24-8.35 (m, 1 H), 8.07 (tdd, 1 H),
447.1
97.2%

7.54-7.71 (m, 3 H), 7.48 (s, 0.4 H), 7.10-7.21 (m, 1 H), 6.94-7.04
[M + H]⁺

(m, 1.6 H), 6.60-6.81 (m, 1 H), 4.96-5.07 (m, 1 H), 3.88-3.95 (m,

0.5 H), 3.38 (td, 0.5 H), 2.82-3.23 (m, 2 H)

1044
(CD₃OD) δ 8.71 (br d, 1 H), 7.94-8.05 (m, 1 H), 7.70 (d, 1 H),
417.1
100%

7.58-7.66 (m, 1 H), 6.50-7.02 (m, 3 H), 4.91-4.96 (m, 0.5 H),
[M + H]

4.42 (dd, 0.5 H), 4.03-4.08 (m, 3 H), 3.66 (ddd, 0.6 H), 3.10-3.25

(m, 1 H), 2.93-3.03 (m, 0.4 H), 2.70-2.86 (m, 1 H)

1045
(CD₃OD) δ 8.71 (br d, 1 H), 7.96-8.03 (m, 1 H), 7.67-7.72 (m, 1
417.2
99.7%

H), 7.58-7.65 (m, 1 H), 6.51-7.01 (m, 3 H), 4.91-4.96 (m, 0.4 H),
[M + H]⁺

4.42 (dd, 0.6 H), 4.03-4.07 (m, 3 H), 3.66 (ddd, 0.6 H), 3.11-3.25

(m, 1 H), 2.93-3.02 (m, 0.4 H), 2.71-2.86 (m, 1 H)

1046
(CD₃OD) δ 8.36-8.47 (m, 1 H), 7.69 (br s, 1 H), 7.40 (br s, 0.2
426.1
100%

H), 7.23-7.33 (m, 1 H), 6.92 (br s, 0.6 H), 6.80-6.88 (m, 1 H),
[M + H]⁺

6.62-6.76 (m, 1 H), 4.95-5.01 (m, 1 H), 3.62-3.86 (m, 0.7 H),

3.33-3.41 (m, 0.4 H), 2.72-3.23 (m, 2 H), 1.42-1.52 (m, 9 H)

1047
(CD₃OD) δ 8.37-8.47 (m, 1 H), 7.70 (s, 1 H), 7.41 (br s, 0.2 H),
426.1
99.8%

7.26-7.33 (m, 1 H), 6.93 (s, 0.5 H), 6.81-6.89 (m, 1 H), 6.65-6.77
[M + H]⁺

(m, 1 H), 4.95-5.01 (m, 1 H), 3.66-3.80 (m, 0.7 H), 3.37-3.42 (m,

0.2 H), 2.79-3.22 (m, 2 H), 1.42-1.54 (m, 9 H)

1048
(CD₃OD) δ 8.25-8.38 (m, 1 H), 7.67 (d, 1 H), 7.24-7.40 (m, 1
413.2
100%

H), 6.67-6.98 (m, 3 H), 6.48 (s, 0.6 H), 6.22 (s, 0.4 H), 4.42 (dd,
[M + H]⁺

0.5 H), 4.05-4.13 (m, 3 H), 3.67 (ddd, 0.5 H), 2.91-3.30 (m, 2

H), 2.70-2.86 (m, 1 H), 2.30-2.39 (m, 3 H)

1049
(CD₃OD) δ 8.30-8.37 (m, 1 H), 7.69 (d, 1 H), 7.27-7.42 (m, 1
413.2
98.0%

H), 6.69-7.00 (m, 3 H), 6.50 (s, 0.6 H), 6.24 (s, 0.4 H), 4.44 (dd,
[M + H]⁺

0.5 H), 4.07-4.14 (m, 3 H), 3.69 (ddd, 0.5 H), 2.93-3.31 (m, 2

H), 2.72-2.88 (m, 1 H), 2.33-2.41 (m, 3 H)

1050
(CD₃OD) δ 8.40-8.47 (m, 1 H), 8.00 (s, 1 H), 7.69 (d, 1 H), 7.24-
383.1
99.9%

7.31 (m, 1 H), 6.80-6.95 (m, 2 H), 6.74 (s, 0.6 H), 6.47 (s, 0.4
[M + H]⁺

H), 4.39 (m, 1 H), 4.03-4.07 (m, 3 H), 3.66 (m, 0.6 H), 3.08-3.26

(m, 1 H), 2.92-3.01 (m, 0.4 H), 2.69-2.85 (m, 1 H)

1051
(CD₃OD) δ 8.40-8.47 (m, 1 H), 7.99 (s, 1 H), 7.69 (d, 1 H), 7.24-
383.1
99.7%

7.31 (m, 1 H), 6.80-6.95 (m, 2 H), 6.73 (s, 0.6 H), 6.46 (s, 0.4
[M + H]⁺

H), 4.39 (m, 1 H), 4.03-4.06 (m, 3 H), 3.65 (m, 0.6 H), 3.08-3.26

(m, 1 H), 2.91-3.01 (m, 0.4 H), 2.69-2.85 (m, 1H)

1052
(CD₃OD) δ 8.40-8.49 (m, 1 H), 7.73 (s, 1 H), 7.23-7.34 (m, 1 H),
451.1
99.9%

6.81-6.97 (m, 2 H), 6.75 (s, 0.6 H), 6.55 (s, 0.4 H), 4.92 (br s, 0.4
[M + H]⁺

H), 4.49 (m, 0.6 H), 4.12-4.19 (m, 3 H), 3.69 (m, 0.6 H), 3.13-

3.29 (m, 1 H), 2.94-3.04 (m, 0.4 H), 2.74-2.89 (m, 1 H)

1053
(CD₃OD) δ 8.40-8.48 (m, 1 H), 7.70 (d, 1 H), 7.25-7.33 (m, 1
451.1
98.0%

H), 6.80-6.98 (m, 2 H), 6.74 (s, 0.6 H), 6.53 (s, 0.3 H), 4.92 (br
[M + H]⁺

s, 0.5 H), 4.47 (m, 0.5 H), 4.11-4.20 (m, 3 H), 3.68 (m, 0.6 H),

3.11-3.29 (m, 1 H), 2.94-3.03 (m, 0.4 H), 2.73-2.88 (m, 1 H)

1054
(CD₃OD) δ 8.44 (m, 1 H), 7.70 (d, 1 H), 7.24-7.32 (m, 1 H),
417.1
100%

6.80-6.94 (m, 2 H), 6.73 (s, 0.6 H), 6.51 (s, 0.3 H), 4.48 (m, 0.1
[M + H]⁺

H), 3.99-4.06 (m, 3 H), 3.66 (m, 0.6 H), 3.09-3.25 (m, 1 H),

2.91-3.02 (m, 0.4 H), 2.71-2.86 (m, 1 H)

1055
(CD₃OD) δ 8.44 (m, 1 H), 7.66-7.73 (m, 1 H), 7.24-7.32 (m, 1
417.1
99.3%

H), 6.81-6.95 (m, 2 H), 6.73 (s, 0.6 H), 6.51 (s, 0.4 H), 4.48 (m,
[M + H]⁺

1 H), 4.02-4.05 (m, 3 H), 3.66 (m, 0.6 H), 3.09-3.25 (m, 1 H),

2.92-3.02 (m, 0.3 H), 2.72-2.86 (m, 1 H)

1056
(CD₃OD) δ 8.22-8.38 (m, 1 H), 7.69 (d, 1 H), 6.85-7.05 (m, 2
431.2
100%

H), 6.72-6.81 (m, 1 H), 6.36-6.66 (m, 1 H), 4.45 (dd, 1 H), 4.14
[M + H]⁺

(s, 3 H), 3.69 (ddd, 0.6 H), 3.10-3.29 (m, 1 H), 2.66-3.07 (m, 1.4

H), 2.33-2.49 (m, 3 H)

1057
(CD₃OD) δ 8.30 (dd, 1 H), 7.69 (d, 1 H), 6.86-7.05 (m, 2 H),
431.2
99.5%

6.73-6.82 (m, 1 H), 6.31-6.65 (m, 1 H), 4.45 (dd, 1 H), 4.14 (s, 3
[M + H]⁺

H), 3.69 (ddd, 0.6 H), 3.09-3.26 (m, 1 H), 2.70-3.07 (m, 1.4 H),

2.37-2.46 (m, 3 H)

1058
(CD₃OD) δ 8.23-8.33 (m, 1 H), 7.68 (d, 1 H), 6.86-7.08 (m, 1.6
403.2
99.2%

H), 6.69-6.84 (m, 1.4 H), 6.30-6.67 (m, 1 H), 4.84 (br s, 0.5 H),
[M + H]⁺

4.31 (dd, 0.5 H), 3.93 (d, 3 H), 3.57-3.72 (m, 0.5 H), 2.91-3.29

(m, 1.5 H), 2.68-2.87 (m, 1 H), 2.36-2.49 (m, 3 H), 1.93-2.08 (m,

1 H), 0.86-1.02 (m, 4 H)

1059
(CD₃OD) δ 8.20-8.35 (m, 1 H), 7.69 (d, 1 H), 6.87-7.06 (m, 1.6
403.2
98.5%

H), 6.78 (q, 1.4 H), 6.29-6.66 (m, 1 H), 4.85 (br d, 0.5 H), 4.31
[M + H]⁺

(dd, 0.5 H), 3.93 (d, 3 H), 3.67 (ddd, 0.5 H), 3.05-3.29 (m, 1 H),

2.67-3.01 (m, 1.5 H), 2.36-2.48 (m, 3 H), 1.96-2.08 (m, 1 H),

0.88-1.02 (m, 4 H)

1060
(CD₃OD) δ 8.67-8.73 (m, 1 H), 7.70 (d, 1 H), 7.62 (dd, 1 H),
467.1
100%

6.55-7.05 (m, 4 H), 4.94 (br s, 0.4 H), 4.48 (dd, 0.6 H), 4.07-4.15
[M + H]⁺

(m, 3 H), 3.68 (ddd, 0.6 H), 3.13-3.27 (m, 1 H), 2.94-3.04 (m,

0.4 H), 2.73-2.87 (m, 1 H)

1061
(CD₃OD) δ 8.67-8.73 (m, 1 H), 7.70 (d, 1 H), 7.57-7.67 (m, 1
467.2
99.7%

H), 6.55-7.04 (m, 4 H), 4.94 (br s, 0.4 H), 4.48 (dd, 0.6 H), 4.08-
[M + H]⁺

4.14 (m, 3 H), 3.63-3.72 (m, 0.6 H), 3.13-3.27 (m, 1 H), 2.94-

3.04 (m, 0.4 H), 2.73-2.87 (m, 1 H)

1062
(CD₃OD) δ 8.67-8.73 (m, 1 H), 7.71 (d, 1 H), 7.57-7.68 (m, 1
485.1
99.9%

H), 6.91-7.02 (m, 2 H), 6.62-6.82 (m, 1 H), 4.94-4.97 (m, 0.4 H),
[M + H]⁺

4.50 (dd, 0.6 H), 4.11-4.20 (m, 3 H), 3.68 (ddd, 0.6 H), 3.13-3.29

(m, 1 H), 2.94-3.04 (m, 0.4 H), 2.74-2.87 (m, 1 H)

1063
(CD₃OD) δ 8.67-8.73 (m, 1 H), 7.70 (d, 1 H), 7.56-7.68 (m, 1
485.1
98.8%

H), 6.89-7.03 (m, 2 H), 6.59-6.83 (m, 1 H), 4.93 (br s, 0.4 H),
[M + H]⁺

4.49 (dd, 0.6 H), 4.10-4.20 (m, 3 H), 3.68 (ddd, 0.6 H), 3.12-3.29

(m, 1 H), 2.94-3.05 (m, 0.4 H), 2.73-2.88 (m, 1 H)

1064
(CD₃OD) δ 7.55-7.91 (m, 4 H), 6.92-7.35 (m, 3 H), 6.80 (br d, 1
418.1
98.4%

H), 6.21-6.56 (m, 1 H), 4.04 (br dd, 1 H), 3.66-3.83 (m, 1 H),
[M + H]⁺

2.70-3.04 (m, 2 H)

1065
(CD₃OD) δ 7.51-7.98 (m, 4 H), 6.91-7.38 (m, 3 H), 6.79 (br d, 1
418.1
97.4%

H), 6.27-6.56 (m, 1 H), 4.03 (br dd, 1 H), 3.74 (br s, 1 H), 2.68-
[M + H]⁺

3.06 (m, 2 H)

1066
(CD₃OD) δ 8.39 (s, 1 H), 8.10 (s, 1 H), 7.69 (d, 1 H), 7.62 (d, 1.5
450.1
99.6%

H), 7.12-7.23 (m, 1 H), 6.95-7.07 (m, 1.5 H), 6.61-6.80 (m, 1 H),
[M + H]⁺

5.10 (br dd, 1 H), 3.98-4.04 (m, 3 H), 3.82-3.96 (m, 0.6 H), 3.34-

3.44 (m, 0.4 H), 2.82-3.20 (m, 2 H)

1067
(CD₃OD) δ 8.37 (br s, 1 H), 8.08 (s, 1 H), 7.69 (br d, 1 H), 7.52-
450.1
94.0%

7.63 (m, 1.5 H), 7.10-7.21 (m, 1 H), 6.93-7.05 (m, 1.5 H), 6.60-
[M + H]⁺

6.80 (m, 1 H), 5.09 (br dd, 1 H), 3.99 (br d, 3 H), 3.84-3.94 (m,

0.6 H), 3.35-3.42 (m, 0.4 H), 2.81-3.18 (m, 2 H)

1068
(CD₃OD) δ 8.11-8.80 (m, 2 H), 7.53-7.75 (m, 2 H), 6.97-7.28
403.1
99.4%

(m, 2 H), 6.43-6.90 (m, 2 H), 4.69-4.86 (m, 0.4 H), 4.21-4.39 (m,
[M + H]⁺

0.6 H), 3.35-3.90 (m, 1 H), 2.71-3.16 (m, 2 H)

1069
(CD₃OD) δ 8.26-8.61 (m, 2 H), 7.52-7.79 (m, 2 H), 6.94-7.34
403.1
100%

(m, 2 H), 6.44-6.91 (m, 2 H), 4.04-4.56 (m, 1 H), 3.35-3.86 (m, 1
[M + H]⁺

H), 2.75-3.18 (m, 2 H)

1070
(CD₃OD) δ 8.51 (br d, 1 H), 7.51-7.77 (m, 2 H), 6.93-7.31 (m, 2
461.2
100%

H), 6.68 (s, 2 H), 4.32 (br d, 1 H), 3.73 (br s, 1 H), 2.72-3.20 (m,
[M + H]⁺

2 H), 1.57-1.68 (m, 6 H)

1071
(CD₃OD) δ 8.51 (br d, 1 H), 7.53-7.74 (m, 2 H), 6.95-7.33 (m, 2
461.2
100%

H), 6.48-6.95 (m, 2 H), 4.11-4.47 (m, 1 H), 3.37-3.90 (m, 1 H),
[M + H]⁺

2.76-3.19 (m, 2 H), 1.57-1.70 (m, 6 H)

1072
(CD₃OD) δ 8.44 (m, 1 H), 7.69 (d, 1 H), 7.29 (m, 1 H), 6.80-6.94
423.2
99.9%

(m, 2 H), 6.73 (s, 0.5 H), 6.50 (s, 0.4 H), 4.82-4.85 (m, 0.5 H),
[M + H]⁺

4.34 (m, 0.5 H), 3.94 (d, 3 H), 3.64 (m, 0.6 H), 3.22 (m, 0.4H),

3.05-3.14 (m, 0.6 H), 2.91-3.01 (m, 0.4 H), 2.69-2.85 (m, 1 H),

1.98-2.06 (m, 1 H), 0.89-1.01 (m, 4 H)

1073
(CD₃OD) δ 8.45 (m, 1 H), 7.70 (d, 1 H), 7.30 (m, 1 H), 6.82-6.94
423.1
99.8%

(m, 2 H), 6.74 (s, 0.5 H), 6.51 (s, 0.5 H), 4.86 (br s, 0.4 H), 4.34
[M + H]⁺

(m, 0.6 H), 3.95 (d, 3 H), 3.65 (m, 0.6 H), 3.22 (m, 0.4 H), 3.05-

3.15 (m, 0.6 H), 2.91-3.01 (m, 0.4 H), 2.70-2.86 (m, 1 H), 1.97-

2.07 (m, 1 H), 0.90-1.01 (m, 4 H)

1074
(CD₃OD) δ 8.45 (m, 1 H), 7.70 (m, 1 H), 7.25-7.33 (m, 1 H),
397.2
100%

6.80-6.98 (m, 2 H), 6.74 (s, 0.5 H), 6.45 (s, 0.4 H), 4.36 (m, 0.5
[M + H]⁺

H), 3.96 (m, 3 H), 3.66 (m, 0.5 H), 2.70-3.23 (m, 2 H), 2.35 (m,

3 H)

1075
(CD₃OD) δ 8.45 (m, 1 H), 7.70 (d, 1 H), 7.29 (m, 1 H), 6.81-6.96
397.2
99.4%

(m, 2 H), 6.74 (s, 0.6 H), 6.45 (s, 0.4 H), 4.36 (m, 0.5 H), 3.96
[M + H]⁺

(d, 3 H), 3.61-3.71 (m, 0.5 H), 2.70-3.25 (m, 2 H), 2.33-2.38 (m,

3 H)

1076
(CD₃OD) δ 8.21-8.39 (m, 1 H), 7.69 (d, 1 H), 6.86-7.07 (m, 2
397.1
100%

H), 6.73-6.84 (m, 1 H), 6.61 (s, 0.6 H), 6.36 (s, 0.4 H), 4.82-4.86
[M + H]⁺

(m, 0.4 H), 4.45 (dd, 0.6 H), 3.91-4.09 (m, 3 H), 3.59-3.75 (m,

0.6 H), 3.06-3.29 (m, 1 H), 2.90-3.04 (m, 0.4 H), 2.68-2.86 (m, 1

H), 2.31-2.47 (m, 3 H)

1077
(CD₃OD) δ 8.20-8.39 (m, 1 H), 7.69 (br d, 1 H), 6.88-7.02 (m, 2
397.1
100%

H), 6.78 (q, 1 H), 6.61 (s, 0.6 H), 6.36 (s, 0.4 H), 4.81-4.86 (m,
[M + H]⁺

0.4 H), 4.45 (dd, 0.6 H), 3.98-4.07 (m, 3 H), 3.67 (ddd, 0.6 H),

3.08-3.29 (m, 1 H), 2.90-3.04 (m, 0.4 H), 2.70-2.88 (m, 1 H),

2.32-2.50 (m, 3 H)

1078
(CD₃OD) δ 8.70 (d, 1 H), 7.70 (d, 1 H), 7.57-7.67 (m, 1 H),
451.1
100%

6.50-7.11 (m, 3 H), 4.97 (br s, 0.4 H), 4.49 (dd, 0.6 H), 3.97-4.13
[M + H]⁺

(m, 3 H), 3.60-3.72 (m, 0.6 H), 3.09-3.24 (m, 1 H), 2.89-3.04 (m,

0.4 H), 2.70-2.88 (m, 1 H)

1079
(CD₃OD) δ 8.70 (br d, 1 H), 7.65-7.78 (m, 1 H), 7.57-7.65 (m, 1
451.1
99.2%

H), 6.56-7.01 (m, 3 H), 4.97 (br s, 0.4 H), 4.50 (dd, 0.6 H), 4.01-
[M + H]⁺

4.06 (m, 3 H), 3.62-3.70 (m, 0.6 H), 3.09-3.25 (m, 1 H), 2.92-

3.02 (m, 0.4 H), 2.69-2.87 (m, 1 H)

1080
(CD₃OD) δ 8.70 (dd, 1 H), 7.69 (d, 1 H), 7.59-7.66 (m, 1 H),
457.2
97.0%

6.57-7.05 (m, 3 H), 4.86 (br s, 0.5 H), 4.35 (dd, 0.5 H), 3.94 (d, 3
[M + H]⁺

H), 3.59-3.69 (m, 0.6 H), 3.05-3.27 (m, 1 H), 2.90-3.02 (m, 0.4

H), 2.70-2.86 (m, 1 H), 1.97-2.07 (m, 1 H), 0.89-1.00 (m, 4 H)

1081
(CD₃OD) δ 8.70 (dd, 1 H), 7.69 (d, 1 H), 7.62 (t, 1 H), 6.57-7.02
457.2
99.5%

(m, 3 H), 4.94-5.00 (m, 0.5 H), 4.35 (dd, 0.5 H), 3.95 (d, 3 H),
[M + H]⁺

3.59-3.69 (m, 0.6 H), 3.06-3.26 (m, 1 H), 2.90-3.02 (m, 0.4 H),

2.70-2.86 (m, 1 H), 1.98-2.06 (m, 1 H), 0.89-1.00 (m, 4H)

1082
(CD₃OD) δ 8.71 (d, 1 H), 7.73 (d, 1 H), 7.58-7.66 (m, 1 H),
431.2
100%

6.46-7.06 (m, 3 H), 4.94-4.97 (m, 0.5 H), 4.39 (dd, 0.5 H), 3.91-
[M + H]⁺

4.01 (m, 3 H), 3.61-3.71 (m, 0.6 H), 3.06-3.24 (m, 1 H), 2.91-

3.02 (m, 0.4 H), 2.69-2.88 (m, 1 H), 2.31-2.40 (m, 3 H)

1083
(CD₃OD) δ 8.71 (d, 1 H), 7.70 (d, 1 H), 7.58-7.67 (m, 1 H),
431.2
99.6%

6.41-7.07 (m, 3 H), 4.93 (br s, 0.5 H), 4.38 (dd, 0.5 H), 3.88-4.04
[M + H]⁺

(m, 3 H), 3.59-3.71 (m, 0.6 H), 3.06-3.24 (m, 1 H), 2.91-3.02 (m,

0.4 H), 2.70-2.86 (m, 1 H), 2.35 (d, 3 H)

1084
(CD₃OD) δ 8.49 (dd, 1 H), 7.69 (s, 1 H), 6.99-7.32 (m, 2 H),
461.2
100%

6.53-6.92 (m, 3 H), 4.35 (br d, 1 H), 3.74 (br s, 1 H), 2.97-3.23
[M + H]⁺

(m, 1 H), 2.83 (br d, 1 H), 1.51-1.82 (m, 6 H)

1085
(CD₃OD) δ 8.49 (dd, 1 H), 7.69 (s, 1 H), 6.94-7.43 (m, 2 H),
461.2
99.5%

6.48-6.88 (m, 3 H), 4.35 (br d, 1 H), 3.62-3.84 (m, 1 H), 2.94-
[M + H]⁺

3.24 (m, 1 H), 2.83 (br d, 1 H), 1.49-1.80 (m, 6 H)

1086
(CD₃OD) δ 7.69 (d, 1 H), 7.47 (dd, 1 H), 7.13 (dt, 1 H), 6.94(s,
397.1
98.9%

1 H), 6.73 (d, 1 H), 6.62 (s, 0.6 H), 6.34 (s, 0.4 H), 4.93 (br s, 0.5
[M + H]⁺

H), 4.41 (dd, 0.5 H), 3.92-4.09 (m, 3 H), 3.72-3.86 (m, 0.5 H),

3.25-3.31 (m, 0.5 H), 3.08-3.21 (m, 0.7 H), 2.92-3.05 (m, 0.3 H),

2.73-2.90 (m, 1 H), 2.57-2.71 (m, 3 H)

1087
(CD₃OD) δ 7.69 (d, 1 H), 7.47 (dd, 1 H), 7.08-7.19 (m, 1 H),
397.2
96.9%

6.94 (s, 1 H), 6.73 (d, 1 H), 6.62 (s, 0.5 H), 6.34 (s, 0.5 H), 4.97-
[M + H]⁺

4.98 (m, 0.5 H), 4.41 (dd, 0.5 H), 3.91-4.08 (m, 3 H), 3.73-3.86

(m, 0.5 H), 3.28 (br d, 0.5 H), 3.07-3.20 (m, 0.7 H), 2.92-3.04

(m, 0.3 H), 2.73-2.89 (m, 1 H), 2.60-2.72 (m, 3 H)

1088
(CD₃OD) δ 8.44-8.74 (m, 1 H), 7.48-7.87 (m, 4 H), 7.22 (br t, 1
402.1
100%

H), 6.65-7.13 (m, 2 H), 6.19-6.53 (m, 1 H), 4.82 (br d, 0.7 H),
[M + H]⁺

3.63-4.15 (m, 1 H), 3.16-3.27 (m, 0.3 H), 2.65-3.07 (m, 2 H)

1089
(CD₃OD) δ 8.33-8.76 (m, 1 H), 7.48-7.86 (m, 4 H), 7.22 (br t, 1
402.1
99.5%

H), 6.64-7.13 (m, 2 H), 6.16-6.51 (m, 1 H), 4.73-4.85 (m, 0.7 H),
[M + H]⁺

3.63-4.13 (m, 1 H), 3.17-3.27 (m, 0.3 H), 2.66-3.07 (m, 2 H)

1090
(CD₃OD) δ 8.69-8.87 (m, 1 H), 8.43-8.59 (m, 1 H), 8.24-8.39
431.2
100%

(m, 1 H), 8.08 (td, 1 H), 7.41-7.88 (m, 3.4 H), 7.13-7.41 (m, 1
[M + H]⁺

H), 6.49-7.08 (m, 1.6 H), 4.99 (br dd, 1 H), 3.37-3.92 (m, 1 H),

2.75-3.27 (m, 2 H)

1091
(CD₃OD) δ 8.74-8.83 (m, 1 H), 8.43-8.59 (m, 1 H), 8.27-8.37
431.1
99.2%

(m, 1 H), 8.08 (td, 1 H), 7.45-7.83 (m, 3.4 H), 7.11-7.32 (m, 1
[M + H]⁺

H), 6.59-7.01 (m, 1.6 H), 5.00 (br dd, 1 H), 3.36-3.89 (m, 1 H),

2.76-3.25 (m, 2 H)

1092
(CD₃OD) δ 8.41-8.68 (m, 1 H), 7.49-7.89 (m, 3 H), 7.26-7.44
402.2
100%

(m, 1 H), 6.18-7.10 (m, 4 H), 4.82-4.86 (m, 0.4 H), 3.99-4.18 (m,
[M + H]⁺

0.6 H), 3.72 (br t, 0.6 H), 2.95-3.31 (m, 1.4 H), 2.76 (br d, 1 H)

1093
(CD₃OD) δ 8.30-8.53 (m, 1 H), 7.38-7.79 (m, 3 H), 7.10-7.29
402.1
99.9%

(m, 1 H), 6.10-7.00 (m, 4 H), 4.69-4.75 (m, 0.4 H), 3.91-4.05 (m,
[M + H]⁺

0.6 H), 3.60 (br t, 0.6 H), 2.84-3.19 (m, 1.4 H), 2.64 (br d, 1 H)

1094
(CD₃OD) δ 8.40-8.46 (m, 1 H), 7.70 (s, 1 H), 7.46 (s, 0.3 H),
410.1
100%

7.27-7.33 (m, 1 H), 6.91 (s, 0.6 H), 6.82-6.88 (m, 1 H), 6.67-6.74
[M + H]⁺

(m, 1 H), 5.00 (dd, 0.4 H), 3.68-3.75 (m, 0.6 H), 3.26-3.40 (m,

0.2 H), 3.13-2.79 (m, 1 H), 2.82 (br dd, 1 H), 2.28-2.36 (m, 1 H),

1.18-1.31 (m, 4 H)

1095
(CD₃OD) δ 8.40-8.46 (m, 1 H), 7.70 (s, 1 H), 7.46 (s, 0.3 H),
410.1
100%

7.27-7.33 (m, 1 H), 6.91 (s, 0.6 H), 6.82-6.88 (m, 1 H), 6.67-6.74
[M + H]⁺

(m, 1 H), 4.98-5.03 (m, 0.5 H), 3.68 - 3.75 (m, 1 H), 3.36-3.41

(m, 0.3 H), 2.91-3.18 (m, 1 H), 2.79-2.84 (m, 1 H), 2.28-2.36 (m,

1 H), 1.18-1.31 (m, 4H)

1096
(CD₃OD) δ 8.44 (t, 1 H), 8.26 (dd, 1 H), 7.71 (d, 1 H), 7.55-7.66
477.1
100%

(m, 2 H), 7.52 (s, 0.4 H), 7.13-7.24 (m, 1 H), 6.97-7.08 (m, 1.6
[M + H]⁺

H), 6.61-6.83 (m, 1 H), 5.06 (br dd, 1 H), 4.00 (d, 3 H), 3.87-

3.98 (m, 0.6 H), 3.36-3.45 (m, 0.4 H), 2.84-3.24 (m, 2 H)

1097
(CD₃OD) δ 8.45 (d, 1 H), 8.27 (dd, 1 H), 7.71 (d, 1 H), 7.59-7.67
477.2
100%

(m, 2 H), 7.52 (s, 0.5 H), 7.15-7.22 (m, 1 H), 6.99-7.07 (m, 1.5
[M + H]⁺

H), 6.60-6.85 (m, 1 H), 5.03-5.08 (m, 1 H), 4.00 (d, 3 H), 3.94

(br d, 1 H), 2.87-3.23 (m, 2 H)

1098
(CD₃OD) δ 7.98 (s, 1 H), 7.84 (dd, 1 H), 7.71 (d, 1 H), 7.48-7.66
450.1
98.1%

(m, 1.5 H), 7.13-7.25 (m, 1 H), 6.97-7.06 (m, 1.5 H), 6.63-6.82
[M + H]⁺

(m, 1 H), 5.10 (br dd, 1 H), 4.11 (s, 3 H), 3.87-3.99 (m, 0.6H),

3.37-3.47 (m, 0.4 H), 2.87 (br dd, 2 H)

1099
(CD₃OD) δ 7.86 (s, 1 H), 7.72 (d, 1 H), 7.59 (d, 1 H), 7.36-7.54
450.1
94.5%

(m, 1.5 H), 7.01-7.12 (m, 1 H), 6.85-6.94 (m, 1.5 H), 6.52-6.70
[M + H]⁺

(m, 1 H), 4.87-5.04 (m, 1 H), 3.99 (s, 3 H), 3.75-3.89 (m, 0.6 H),

3.24-3.30 (m, 0.4 H), 2.73-3.12 (m, 2 H)

1100
(CD₃OD) δ 8.45-8.57 (m, 1 H), 8.38 (s, 1 H), 8.09 (s, 1 H), 7.51-
434.2
99.4%

7.75 (m, 2.4 H), 7.13-7.31 (m, 1 H), 6.92 (s, 0.6 H), 6.55-6.75
[M + H]⁺

(m, 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.34-3.81 (m, 1 H),

2.76-3.22 (m, 2 H)

1101
(CD₃OD) δ 8.45-8.54 (m, 1 H), 8.38 (s, 1 H), 8.09 (s, 1 H), 7.54-
434.2
98.8%

7.70 (m, 2.4 H), 7.12-7.28 (m, 1 H), 6.92 (s, 0.6 H), 6.54-6.76
[M + H]⁺

(m, 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.34-3.82 (m, 1 H),

2.76-3.22 (m, 2 H)

1102
(CD₃OD) δ 8.34-8.60 (m, 1 H), 7.81 (d, 1 H), 7.68 (s, 2 H), 7.50
434.2
100%

(s, 0.4 H), 7.11-7.27 (m, 1 H), 6.86-7.01 (m, 1.6 H), 6.52-6.75
[M + H]⁺

(m, 1 H), 5.00 (br dd, 0.7 H), 3.92-4.10 (m, 3 H), 3.35-3.83 (m,

1.3 H), 2.77-3.22 (m, 2 H)

1103
(CD₃OD) δ 8.37-8.62 (m, 1 H), 7.81 (d, 1 H), 7.56-7.72 (m, 2
434.1
100%

H), 7.50 (s, 0.4 H), 7.12-7.28 (m, 1 H), 6.80-7.07 (m, 1.6 H),
[M + H]⁺

6.56-6.75 (m, 1 H), 5.00 (br dd, 0.7 H), 3.92-4.07 (m, 3 H), 3.34-

3.85 (m, 1.3 H), 2.80-3.22 (m, 2 H)

1104
(CD₃OD) δ 8.92 (s, 1 H), 8.42 (s, 1 H), 7.65-7.82 (m, 2 H), 7.35
453.1
99.6%

(br d, 1 H), 6.99-7.28 (m, 1 H), 6.53-6.90 (m, 2 H), 4.34 (br d, 1
[M + H]⁺

H), 3.66-3.80 (m, 0.7 H), 3.34-3.49 (m, 0.3 H), 2.93-3.16 (m, 1

H), 2.80 (br d, 1 H)

1105
(CD₃OD) δ 8.92 (s, 1 H), 8.42 (s, 1 H), 7.63-7.86 (m, 2 H), 7.35
453.1
98.6%

(d, 1 H), 6.99-7.28 (m, 1 H), 6.47-6.92 (m, 2 H), 4.34 (br d, 1 H),
[M + H]⁺

3.74 (br t, 0.7 H), 3.35-3.48 (m, 0.3 H), 2.91-3.15 (m, 1 H), 2.79

(br d, 1 H)

1106
(CD₃OD) δ 8.38-8.45 (m, 1 H), 7.69 (s, 1 H), 7.47 (s, 0.3 H),
384.1
100%

7.24-7.32 (m, 1 H), 6.67-6.93 (m, 2.7 H), 4.96 (dd, 1 H), 3.68-
[M + H]⁺

3.77 (m, 0.7 H), 3.33-3.42 (m, 0.3 H), 2.91-3.17 (m, 1 H), 2.79 -

2.84 (m, 1 H), 2.60-2.66 (m, 3 H)

1107
(CD₃OD) δ 8.40-8.46 (m, 1 H), 7.71 (s, 1 H), 7.47 (s, 0.3 H),
384.2
99.5%

7.26-7.32 (m, 1 H), 6.68-6.94 (m, 2.7 H), 4.94 - 4.99 (m, 1 H),
[M + H]⁺

3.68-3.77 (m, 0.7 H), 3.33-3.41 (m, 0.4 H), 2.91-3.19 (m, 1 H),

2.79 - 2.84 (m, 1 H), 2.60-2.66 (m, 3 H)

1108
(CD₃OD) δ 8.38-8.47 (m, 1 H), 7.70 (s, 1 H), 7.40 (s, 0.3 H),
430.1
100%

6.93 (s, 0.6 H), 6.64-6.88 (m, 2 H), 4.97 (br dd, 1 H), 3.74 (ddd,
[M + H]⁺

0.6 H), 3.36-3.42 (m, 0.3 H), 2.80-3.21 (m, 2 H), 1.83-1.95 (m, 6 H)

1109
(CD₃OD) δ 8.37-8.47 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.3 H),
430.1
99.4%

7.27-7.33 (m, 1 H), 6.93 (s, 0.6 H), 6.63-6.88 (m, 2 H), 4.92-4.99
[M + H]⁺

(m, 1 H), 3.67-3.78 (m, 0.7 H), 3.34-3.42 (m, 0.4 H), 2.80-3.16

(m, 2 H), 1.84-1.93 (m, 6 H)

1110
(CD₃OD) δ 8.17-8.29 (m, 1 H), 7.67 (s, 1 H), 7.44-7.53 (m, 1 H),
406.2
100%

7.39 (br s, 0.3 H), 7.02-7.11 (m, 1 H), 6.91 (br s, 0.7 H), 6.54 (s,
[M + H]⁺

0.7 H), 6.45 (s, 0.3 H), 4.90-5.00 (m, 1 H), 3.72 (td, 0.7 H), 3.33-

3.42 (m, 0.3 H), 3.07-3.21 (m, 0.7 H), 2.91-3.02 (m, 0.3 H), 2.81

(br d, 1 H), 2.26-2.36 (m, 3 H), 1.47 (s, 9H)

1111
(CD₃OD) δ 8.16-8.33 (m, 1 H), 7.69 (d, 1 H), 7.43-7.53 (m, 1
406.2
99.8%

H), 7.40 (s, 0.3 H), 7.04-7.13 (m, 1 H), 6.91 (s, 0.7 H), 6.43-6.59
[M + H]⁺

(m, 1 H), 4.91-4.97 (m, 1 H), 3.68-3.77 (m, 0.7 H), 3.33-3.43 (m,

0.3 H), 3.06-3.19 (m, 0.7 H), 2.90-3.02 (m, 0.3 H), 2.81 (br d, 1

H), 2.28-2.35 (m, 3 H), 1.47 (s, 9 H)

1112
(CDCl₃) δ 8.12-8.29 (m, 1 H), 7.30-7.80 (m, 4 H), 6.96 (br d, 2
398.2
98.6%

H), 6.43-6.63 (m, 1 H), 6.34 (br d, 1 H), 4.00-4.97 (m, 1 H),
[M + H]⁺

3.23-3.80 (m, 1 H), 2.86-3.12 (m, 1 H), 2.67-2.78 (m, 1 H), 2.32

(br s, 3 H)

1113
(CDCl₃) δ 8.13-8.27 (m, 1 H), 7.31-7.80 (m, 4 H), 6.90-7.03 (m,
398.2
100%

2 H), 6.39-6.67 (m, 1 H), 6.34 (br d, 1 H), 4.04-4.95 (m, 1 H),
[M + H]⁺

3.24-3.83 (m, 1 H), 2.87-3.13 (m, 1 H), 2.65-2.80 (m, 1 H), 2.32

(br s, 3 H)

1114
(CD₃OD) δ 8.40-8.59 (m, 1 H), 7.53-7.78 (m, 2 H), 7.39 (s, 0.3
414.2
100%

H), 7.13-7.30 (m, 1 H), 6.91 (s, 0.7 H), 6.47-6.78 (m, 1 H), 4.92-
[M + H]⁺

4.98 (m, 1 H), 3.36-3.81 (m, 1 H), 2.75-3.21 (m, 2 H), 1.82-1.96

(m, 6 H)

1115
(CD₃OD) δ 8.36-8.59 (m, 1 H), 7.55-7.74 (m, 2 H), 7.39 (s, 0.4
414.2
99.4%

H), 7.14-7.28 (m, 1 H), 6.91 (s, 0.6 H), 6.54-6.76 (m, 1 H), 4.92-
[M + H]⁺

4.99 (m, 1 H), 3.35-3.79 (m, 1 H), 2.75-3.21 (m, 2 H), 1.84-1.95

(m, 6 H)

1116
(CD₃OD) δ 8.92 (s, 1 H), 7.77 (br d, 1 H), 7.68 (s, 1 H), 7.35 (br
511.2
100%

d, 1 H), 6.97-7.27 (m, 1 H), 6.78-6.87 (m, 1.6 H), 6.61 (br s, 0.4
[M + H]'

H), 4.82 (br s, 0.4 H), 4.32-4.41 (m, 0.6 H), 3.74 (br t, 0.6 H),

3.36-3.49 (m, 0.4 H), 2.74-3.20 (m, 2 H), 1.55-1.69 (m, 6 H)

1117
(CD₃OD) δ 8.92 (s, 1 H), 7.77 (br d, 1 H), 7.68 (s, 1 H), 7.35 (d,
511.2
98.5%

1 H), 6.97-7.27 (m, 1 H), 6.79-6.87 (m, 1.7 H), 6.61 (br d, 0.3
[M + H]⁺

H), 4.81 (br s, 0.3 H), 4.36 (br d, 0.7 H), 3.69-3.79 (m, 0.7 H),

3.34-3.49 (m, 0.3 H), 2.77-3.18 (m, 2 H), 1.55-1.68 (m, 6 H)

1118
(CD₃OD) δ 8.31-8.48 (m, 2 H), 7.83 (s, 0.2 H), 7.49-7.72 (m, 2
486.2
100%

H), 7.19-7.33 (m, 2 H), 6.70-6.99 (m, 2.6 H), 4.99-5.08 (m, 1 H),
[M + H]⁺

3.72-3.83 (m, 0.6 H), 3.41 (td, 0.4 H), 2.94-3.25 (m, 1 H), 2.80-

2.90 (m, 1 H)

1119
(CD₃OD) δ 8.29-8.48 (m, 2 H), 7.82 (s, 0.2 H), 7.49-7.74 (m, 2
486.1
99.8%

H), 7.18-7.35 (m, 2 H), 6.69-6.99 (m, 2.8 H), 5.02 - 5.07 (m, 1
[M + H]⁺

H), 3.72-3.82 (m, 0.7 H), 3.37 - 3.44 (m, 0.3 H), 2.96-3.26 (m, 1

H), 2.83 - 2.87 (m, 1 H)

1120
(CD₃OD) δ 8.93 (s, 1 H), 8.36 (s, 1 H), 7.51-7.74 (m, 3.4 H),
486.1
100%

7.14-7.23 (m, 1 H), 6.98-7.08 (m, 1.6 H), 6.64-6.82 (m, 1 H),
[M + H]⁺

5.11 (dd, 1 H), 3.88-3.97 (m, 0.6 H), 3.37-3.44 (m, 0.4 H), 2.99-

3.24 (m, 1 H), 2.88 (dd, 1 H)

1121
(CD₃OD) δ 8.81 (s, 1 H), 8.24 (s, 1 H), 7.38-7.64 (m, 3.4 H),
486.1
100%

7.02-7.12 (m, 1 H), 6.86-6.95 (m, 1.6 H), 6.53-6.70 (m, 1 H),
[M + H]⁺

5.00 (br dd, 1 H), 3.74-3.86 (m, 0.6 H), 3.25-3.34 (m, 0.4 H),

2.86-3.13 (m, 1 H), 2.76 (dd, 1 H)

1122
(CD₃OD) δ 7.59 (d, 1 H), 7.45-7.54 (m, 1 H), 7.34 (s, 0.4H),
426.2
100%

7.04-7.12 (m, 1 H), 6.91-6.97 (m, 1 H), 6.86 (s, 0.6 H), 6.51-6.71
[M + H]⁺

(m, 1 H), 4.89 (br dd, 1 H), 3.71-3.81 (m, 0.6 H), 3.25-3.32 (m,

0.4 H), 2.71-3.10 (m, 2 H), 1.37-1.39 (m, 9 H)

1123
(CD₃OD) δ 7.70 (d, 1 H), 7.57-7.65 (m, 1 H), 7.44 (s, 0.4 H),
426.2
98.0%

7.16-7.23 (m, 1 H), 7.02-7.07 (m, 1 H), 6.97 (s, 0.6 H), 6.63-6.81
[M + H]⁺

(m, 1 H), 5.00 (dd, 1 H), 3.81-3.93 (m, 0.6 H), 3.36-3.43 (m, 0.4

H), 2.81-3.21 (m, 2 H), 1.47-1.50 (m, 9 H)

1124
(CD₃OD) δ 8.39-8.55 (m, 1 H), 7.53-7.72 (m, 2 H), 7.39 (s, 0.3
410.2
100%

H), 7.13-7.28 (m, 1 H), 6.90 (s, 0.7 H), 6.58-6.73 (m, 1 H), 4.96
[M + H]⁺

(br s, 1 H), 3.68-3.77 (m, 0.7 H), 3.34-3.41 (m, 0.3 H), 2.78-3.18

(m, 2 H), 1.47 (s, 9 H)

1125
(CD₃OD) δ 8.39-8.61 (m, 1 H), 7.52-7.75 (m, 2 H), 7.39 (s, 0.3
410.2
99.7%

H), 7.14-7.27 (m, 1 H), 6.90 (s, 0.7 H), 6.56-6.72 (m, 1 H), 4.96
[M + H]⁺

(br d, 1 H), 3.63-3.81 (m, 0.7 H), 3.36-3.41 (m, 0.3 H), 2.74-3.21

(m, 2 H), 1.47 (s, 9 H)

1126
(CD₃OD) δ 8.90-8.96 (m, 1 H), 7.68-7.80 (m, 2 H), 7.31-7.37
467.1
100%

(m, 1 H), 6.93-6.98 (m, 1 H), 6.79-6.85 (m, 1 H), 6.69-6.72 (m,
[M + H]

0.5 H), 6.62 (s, 0.5 H), 4.93 (br d, 0.4 H), 4.48 (dd, 0.6 H), 4.07-

4.13 (m, 3 H), 3.68 (ddd, 0.6 H), 3.11-3.28 (m, 1 H), 2.93-3.04

(m, 0.4 H), 2.71-2.86 (m, 1 H)

1127
(CD₃OD) δ 8.93 (br d, 1 H), 7.66-7.81 (m, 2 H), 7.31-7.38 (m, 1
467.1
100%

H), 6.92-6.98 (m, 1 H), 6.79-6.85 (m, 1 H), 6.69-6.72 (m, 0.5 H),
[M + H]⁺

6.62 (s, 0.5 H), 4.90-4.95 (m, 0.7 H), 4.48 (dd, 0.3 H), 4.08-4.12

(m, 3 H), 3.68 (ddd, 0.6 H), 3.12-3.28 (m, 1 H), 2.94-3.04 (m,

0.4 H), 2.71-2.86 (m, 1 H)

1128
(CD₃OD) δ 8.85-8.96 (m, 1 H), 7.67-7.84 (m, 3 H), 7.51 (s, 0.2
484.2
89.9%

H), 7.31-7.38 (m, 0.8 H), 6.94-7.00 (m, 2 H), 6.76-6.83 (m, 1 H),
[M + H]⁺

5.05 (br dd, 0.6 H), 4.95 (br d, 0.4 H), 4.03 (s, 3 H), 3.74-3.84

(m, 0.6 H), 3.36-3.46 (m, 0.4 H), 3.12-3.24 (m, 0.7 H), 2.94-3.06

(m, 0.3 H), 2.83 (br d, 1 H)

1129
(CD₃OD) δ 8.86-8.97 (m, 1 H), 7.68-7.83 (m, 3 H), 7.51 (br s,
484.2
94.9%

0.3 H), 7.31-7.39 (m, 0.7 H), 6.93-7.01 (m, 2 H), 6.75-6.85 (m, 1
[M + H]⁺

H), 5.05 (br dd, 0.7 H), 4.95 (br d, 0.3 H), 4.03 (s, 3 H), 3.74-

3.84 (m, 0.7 H), 3.36-3.50 (m, 0.3 H), 3.10-3.24 (m, 0.8 H),

2.93-3.06 (m, 0.2 H), 2.79-2.88 (m, 1 H)

1130
(CD₃OD) δ 8.38-8.52 (m, 1 H), 7.23-7.74 (m, 2.3 H), 6.71-6.95
394.1
99.9%

(m, 1.7 H), 6.51-6.67 (m, 1 H), 4.97-5.04 (m, 1 H), 3.73 (ddd,
[M + H]⁺

0.6 H), 3.37-3.42 (m, 0.4 H), 2.91-3.20 (m, 1 H), 2.75-2.86 (m, 1

H), 2.24-2.41 (m, 1 H), 1.17-1.33 (m, 4H)

1131
(CD₃OD) δ 8.38-8.55 (m, 1 H), 7.25-7.82 (m, 2.3 H), 6.75-7.01
394.2
99.9%

(m, 1.7 H), 6.49-6.63 (m, 1 H), 4.96-5.06 (m, 1 H), 3.73 (ddd,
[M + H]⁺

0.6 H), 3.35-3.43 (m, 0.4 H), 2.90-3.21 (m, 1 H), 2.74-2.88 (m, 1

H), 2.21-2.45 (m, 1 H), 1.20-1.38 (m, 4H)

1132
(CD₃OD) δ 8.57-8.79 (m, 1 H), 8.04 (br d, 1 H), 7.44-7.87 (m, 3
452.2
100%

H), 6.58-7.15 (m, 3.6 H), 6.31 (br s, 0.4 H), 4.82 (br s, 0.5 H),
[M + H]⁺

4.09 (br dd, 0.5 H), 3.71 (br t, 0.5 H), 3.15-3.30 (m, 0.5 H), 2.68-

3.06 (m, 2 H)

1133
(CD₃OD) δ 8.58-8.79 (m, 1 H), 8.04 (br d, 1 H), 7.46-7.88 (m, 3
452.1
99.7%

H), 6.58-7.17 (m, 3.6 H), 6.31 (br s, 0.4 H), 4.82 (br s, 0.5 H),
[M + H]⁺

4.09 (br dd, 0.5 H), 3.65-3.78 (m, 0.5 H), 3.17-3.29 (m, 0.5 H),

2.66-3.09 (m, 2 H)

1134
(CD₃OD) δ 8.90 (br s, 1 H), 8.30-8.48 (m, 2 H), 7.49-7.80 (m, 2
486.1
100%

H), 7.22-7.33 (m, 1 H), 6.66-6.98 (m, 3 H), 5.03-5.11 (m, 1 H),
[M + H]⁺

3.77 (br t, 0.7 H), 3.35-3.45 (m, 0.3 H), 3.11-3.23 (m, 1 H), 2.78-

3.03 (m, 1 H)

1135
(CD₃OD) δ 8.90 (s, 1 H), 8.31-8.46 (m, 2 H), 7.47-7.81 (m, 2 H),
486.1
98.3%

7.24-7.32 (m, 1 H), 6.69-6.99 (m, 3 H), 5.07 (br dd, 1 H), 3.71-
[M + H]⁺

3.82 (m, 0.7 H), 3.40 (td, 0.3 H), 3.12-3.23 (m, 1 H), 2.79-3.04

(m, 1 H)

1136
(CD₃OD) δ 7.82-7.92 (m, 1 H), 7.46-7.56 (m, 1 H), 7.40 (s, 0.3
410.1
99.5%

H), 7.04-7.14 (m, 1 H), 6.85-6.97 (m, 1.7 H), 6.56-6.73 (m, 1 H),
[M + H]⁺

4.95 (br dd, 1 H), 3.66-3.77 (m, 0.6 H), 3.24-3.32 (m, 0.4 H),

2.84-3.08 (m, 1 H), 2.70-2.81 (m, 1 H), 2.16-2.29 (m, 1 H), 1.15-

1.19 (m, 2 H), 1.08-1.13 (m, 2 H)

1137
(CD₃OD) δ 7.60 (d, 1 H), 7.49 (dd, 1 H), 7.34 (s, 0.3 H), 7.03-
410.1
99.7%

7.11 (m, 1 H), 6.81-6.96 (m, 1.7 H), 6.50-6.69 (m, 1 H), 4.89 (br
[M + H]⁺

d, 1 H), 3.67-3.83 (m, 0.6 H), 3.26 (br s, 0.4 H), 3.02 (br d, 1 H),

2.72 (br dd, 1 H), 2.17-2.25 (m, 1 H), 1.14-1.19 (m, 2 H), 1.07-

1.14 (m, 2 H)

1138
(CD₃OD) δ 8.87-9.07 (m, 1 H), 7.50-7.82 (m, 4 H), 7.35 (dd, 1
452.1
100%

H), 6.89-7.09 (m, 1 H), 6.80 (br d, 1 H), 6.23-6.62 (m, 1 H),
[M + H]⁺

4.78-4.84 (m, 0.5 H), 4.10 (br dd, 0.5 H), 3.72 (br t, 0.5 H), 3.21-

3.30 (m, 0.5 H), 2.93-3.06 (m, 1 H), 2.75 (br d, 1 H)

1139
(CD₃OD) δ 8.87-9.09 (m, 1 H), 7.48-7.85 (m, 4 H), 7.35 (dd, 1
452.1
100%

H), 6.90-7.09 (m, 1 H), 6.80 (br d, 1 H), 6.24-6.60 (m, 1 H),
[M + H]⁺

4.77-4.83 (m, 0.5 H), 4.10 (br dd, 0.5 H), 3.72 (br t, 0.5 H), 3.21-

3.30 (m, 0.5 H), 2.94-3.06 (m, 1 H), 2.75 (br d, 1 H)

1140
(CD₃OD) δ 7.74 (dd, 1 H), 7.51-7.65 (m, 1 H), 7.40 (s, 0.5 H),
444.2
100%

7.11-7.29 (m, 2 H), 6.67-6.94 (m, 1 H), 6.53 (s, 0.5 H), 4.89 (br
[M + H]⁺

s, 1 H), 3.61-3.95 (m, 0.5 H), 2.67-3.19 (m, 2.5 H), 2.05-2.34

(m, 1 H), 1.09-1.21 (m, 4 H)

1141
(CD₃OD) δ 7.74 (dd, 1 H), 7.51-7.64 (m, 1 H), 7.21-7.44 (m, 1.5
444.1
97.6%

H), 7.10-7.21 (m, 1 H), 6.81 (s, 0.5 H), 6.44-6.77 (m, 1 H), 4.90
[M + H]⁺

(br dd, 1 H), 3.73-3.87 (m, 0.5 H), 2.68-3.18 (m, 2.5 H), 2.13-

2.36 (m, 1 H), 1.09-1.20 (m, 4H)

1142
(CD₃OD) δ 7.72 (d, 1 H), 7.55-7.66 (m, 1 H), 7.16-7.24 (m, 1
417.1
99.4%

H), 7.02-7.11 (m, 1 H), 6.93 (s, 1 H), 6.48-6.84 (m, 1 H), 4.41
[M + H]⁺

(br dd, 0.7 H), 4.06 (d, 3 H), 3.71-3.82 (m, 0.7 H), 2.79-3.22 (m,

2.6 H)

1143
(CD₃OD) δ 7.60 (br d, 1 H), 7.43-7.53 (m, 1 H), 7.02-7.11 (m, 1
417.1
97.7%

H), 6.94 (d, 1 H), 6.81 (s, 1 H), 6.37-6.69 (m, 1 H), 4.28 (br dd,
[M + H]⁺

0.7 H), 3.94 (d, 3 H), 3.59-3.69 (m, 0.7 H), 2.62-3.12 (m, 2.6 H)

1144
(CD₃OD) δ 8.02 (d, 1 H), 7.79-7.94 (m, 1 H), 7.72 (d, 1 H), 7.38
417.2
99.3%

(d, 1 H), 7.18-7.32 (m, 1 H), 6.94-7.08 (m, 1 H), 6.88(s, 0.5H),
[M + H]⁺

6.55 (s, 0.5 H), 4.99 (br s, 0.6 H), 4.23-4.29 (m, 0.4 H), 4.03 (d,

3 H), 3.75 (td, 0.6 H), 2.69-3.30 (m, 2.4H)

1145
(CD₃OD) δ 7.90 (d, 1 H), 7.67-7.80 (m, 1 H), 7.59 (d, 1 H),
417.2
99.3%

7.23-7.30 (m, 1 H), 7.10-7.22 (m, 1 H), 6.81-6.99 (m, 1 H), 6.76
[M + H]⁺

(s, 0.5 H), 6.42 (s, 0.5 H), 4.86 (br d, 0.5 H), 4.14 (br dd, 0.5 H),

3.91 (d, 3 H), 3.58-3.67 (m, 0.5 H), 2.57-3.18 (m, 2.5 H)

1146
(CD₃OD) δ 8.39-8.64 (m, 1 H), 7.65-7.76 (m, 1 H), 7.41-7.56
417.1
99.8%

(m, 1 H), 7.08-7.19 (m, 1 H), 6.93 (s, 0.7 H), 6.73 (d, 1 H), 6.59
[M + H]⁺

(s, 0.7 H), 6.36 (s, 0.3 H), 6.09 (s, 0.3 H), 3.76-3.94 (m, 1.5 H),

3.43-3.57 (m, 0.5 H), 2.74-3.04 (m, 2 H), 2.62-2.72 (m, 3 H)

1147
(CD₃OD) δ 8.35-8.64 (m, 1 H), 7.64-7.75 (m, 1 H), 7.38-7.56
417.1
99.8%

(m, 1 H), 7.05-7.20 (m, 1 H), 6.93 (s, 0.7 H), 6.73(d, 1H), 6.59
[M + H]⁺

(s, 0.7 H), 6.36 (s, 0.3 H), 6.09 (br s, 0.3 H), 3.74-3.94 (m, 1.5

H), 3.41-3.54 (m, 0.5 H), 2.74-3.03 (m, 2 H), 2.60-2.71 (m, 3 H)

1148
(CD₃OD) δ 8.26 (s, 1 H), 7.67 (s, 1 H), 7.47 (br d, 1 H), 7.12
363.2
100%

(dd, 1 H), 6.90 (br s, 0.6 H), 6.71 (d, 1 H), 6.60 (br s, 1.4 H),
[M + H]⁺

4.64-4.73 (m, 0.5 H), 4.18-4.42 (m, 0.5 H), 3.72-4.00 (m, 0.6 H),

3.37-3.56 (m, 0.4 H), 2.90-3.12 (m, 1 H), 2.82 (br d, 1 H), 2.67

(s, 3 H), 2.38 (s, 3 H)

1149
(CD₃OD) δ 8.26 (s, 1 H), 7.67 (s, 1 H), 7.47 (br d, 1 H), 7.12
363.2
100%

(dd, 1 H), 6.89 (br s, 0.6 H), 6.71 (d, 1 H), 6.59 (br s, 1.4 H),
[M + H]⁺

4.70-4.86 (m, 0.4 H), 4.32 (br s, 0.6 H), 3.86 (br s, 0.6 H), 3.37-

3.55 (m, 0.4 H), 3.02 (br s, 1 H), 2.80 (dd, 1 H), 2.66 (s, 3 H),

2.38 (s, 3 H)

1150
(CD₃OD) δ 7.58-7.84 (m, 1 H), 7.40-7.54 (m, 1 H), 7.07-7.19
475.2
99.3%

(m, 1 H), 6.92 (s, 0.6 H), 6.73 (d, 1 H), 6.60(s, 0.6 H), 6.40(s,
[M + H]⁺

0.4 H), 6.14 (br s, 0.4 H), 3.73-3.96 (m, 1.5 H), 3.40-3.56 (m, 0.5

H), 2.92-3.07 (m, 1 H), 2.75-2.91 (m, 1 H), 2.60-2.72 (m, 3 H),

1.59-1.69 (m, 6 H)

1151
(CD₃OD) δ 7.62-7.77 (m, 1 H), 7.42-7.55 (m, 1 H), 7.08-7.21
475.2
99.2%

(m, 1 H), 6.92 (s, 0.6 H), 6.73 (d, 1 H), 6.60 (s, 0.6 H), 6.40(s,
[M + H]

0.4 H), 6.14 (s, 0.4 H), 3.77-3.95 (m, 1.4 H), 3.49 (td, 0.6 H),

2.92-3.07 (m, 1 H), 2.75-2.90 (m, 1 H), 2.64-2.73 (m, 3 H), 1.61-

1.69 (m, 6 H)

1152
(CD₃OD) δ 7.55 (s, 1 H), 7.36 (br d, 1 H), 6.95-7.17 (m, 2 H),
443.2
99.5%

6.30-6.91 (m, 3 H), 4.84-4.90 (m, 1 H), 4.53-4.67 (m, 0.5 H),
[M + H]

4.17-4.32 (m, 0.5 H), 3.66-3.86 (m, 0.5 H), 3.27-3.42 (m, 0.5 H),

2.64-3.06 (m, 2 H), 2.44-2.63 (m, 3 H), 1.32-1.65 (m, 3 H)

1153
(CD₃OD) δ 7.55 (s, 1 H), 7.36 (br d, 1 H), 6.92-7.20 (m, 2 H),
443.2
98.8%

6.33-6.88 (m, 3 H), 4.87 (q, 1 H), 4.50-4.67 (m, 0.5 H), 4.15-
[M + H]⁺

4.33 (m, 0.5 H), 3.66-3.85 (m, 0.5 H), 3.26-3.47 (m, 0.5 H),

2.64-3.09 (m, 2 H), 2.55 (br s, 3 H), 1.49 (br s, 3 H)

1154
(CD₃OD) δ 8.32 (s, 1 H), 7.48-7.81 (m, 2 H), 7.22-7.34 (m, 1 H),
453.1
99.4%

6.48-7.20 (m, 4 H), 4.20 (br s, 1 H), 3.79 (br d, 1 H), 2.91 (br s,
[M + H]⁺

1 H), 2.70 (dd, 1 H)

1155
(CD₃OD) δ 8.32 (s, 1 H), 7.54-7.85 (m, 2 H), 7.20-7.34 (m, 1 H),
453.1
97.8%

6.47-7.19 (m, 4 H), 4.21 (br s, 1 H), 3.78 (br s, 1 H), 2.92 (br d,
[M + H]⁺

1 H), 2.70 (dd, 1 H)

1156
(CD₃OD) δ 7.87 (br s, 1 H), 7.69 (s, 1 H), 7.35-7.41 (m, 1 H),
511.2
99.8%

6.68-7.32 (m, 4 H), 4.36 (br d, 1 H), 3.92 (br s, 1 H), 2.92-3.15
[M + H]⁺

(m, 1 H), 2.83 (br d, 1 H), 1.53-1.76 (m, 6 H)

1157
(CD₃OD) δ 7.87 (br s, 1 H), 7.69 (s, 1 H), 7.33-7.45 (m, 1 H),
511.2
96.9%

6.61-7.33 (m, 4 H), 4.37 (br d, 1 H), 3.91 (br s, 1 H), 2.93-3.13
[M + H]⁺

(m, 1 H), 2.83 (br d, 1 H), 1.52-1.76 (m, 6 H)

1158
(CD₃OD) δ 8.68 (br s, 1 H), 8.39 (s, 1 H), 7.74-8.09 (m, 1 H),
403.1
99.6%

7.69 (s, 1 H), 7.62 (br d, 1 H), 6.63-7.03 (m, 3 H), 4.73-4.87 (m,
[M + H]

1 H), 4.51 (br s, 0.4 H), 3.75 (br s, 0.6 H), 3.09 (br s, 1 H), 2.82

(br d, 1 H)

1159
(CD₃OD) δ 8.68 (br s, 1 H), 8.39 (s, 1 H), 7.73-8.09 (m, 1 H),
403.1
99.7%

7.69 (s, 1 H), 7.62 (br d, 1 H), 6.63-7.03 (m, 3 H), 4.73-4.87 (m,
[M + H]'

1 H), 4.51 (br s, 0.4 H), 3.74 (br s, 0.6 H), 3.09 (br s, 1 H), 2.82

(br d, 1 H)

1160
(CD₃OD) δ 7.87 (dd, 1 H), 7.59-7.77 (m, 1 H), 7.53 (br s, 0.5 H),
464.2
99.1%

7.24-7.43 (m, 2 H), 6.87 (s, 1 H), 6.67 (s, 0.5 H), 4.95-5.02 (m, 1
[M + H]

H), 3.96 (br s, 0.5 H), 2.73-3.31 (m, 2.5 H), 1.82-1.99 (m, 6 H)

1161
(CD₃OD) δ 7.74 (dd, 1 H), 7.50-7.65 (m, 1 H), 7.41 (s, 0.5 H),
464.2
98.0%

7.08-7.27 (m, 2 H), 6.67-6.89 (m, 1 H), 6.55 (s, 0.5 H), 4.84-4.89
[M + H]⁺

(m, 1 H), 3.75-3.91 (m, 0.5 H), 2.70-3.19 (m, 2.5 H), 1.72-1.86

(m, 6 H)

1162
(CD₃OD) δ 7.68-7.80 (m, 1 H), 7.60 (d, 1 H), 7.26 (br d, 1 H),
451.1
98.4%

7.13-7.20 (m, 1 H), 7.01 (s, 0.5 H), 6.72-6.88 (m, 1 H), 6.44(s,
[M + H]⁺

0.5 H), 4.84 (br s, 0.5 H), 4.24 (dd, 0.5 H), 3.89 (d, 3 H), 3.56-

3.73 (m, 0.5 H), 2.92-3.15 (m, 1 H), 2.79-2.92 (m, 0.5 H), 2.59-

2.77 (m, 1 H)

1163
(CD₃OD) δ 7.81-7.91 (m, 1 H), 7.72 (d, 1 H), 7.34-7.43 (m, 1
451.1
99.1%

H), 7.23-7.33 (m, 1 H), 7.13 (s, 0.5 H), 6.84-6.96 (m, 1 H), 6.57
[M + H]⁺

(s, 0.5 H), 4.95 (br d, 0.5 H), 4.36 (dd, 0.5 H), 4.01 (d, 3 H),

3.70-3.81 (m, 0.5 H), 3.07-3.27 (m, 1 H), 2.91-3.03 (m, 0.5 H),

2.71-2.90 (m, 1 H)

1164
(CD₃OD) δ 7.68 (s, 1 H), 7.47 (br s, 1 H), 6.97-7.28 (m, 2 H),
443.1
98.9%

6.90 (br s, 0.4 H), 6.73 (br d, 1.3 H), 6.42-6.65 (m, 1.3 H), 4.96-
[M + H]⁺

5.01 (m, 1.8 H), 4.37 (br s, 0.2 H), 3.89 (br s, 0.5 H), 3.36-3.53

(m, 0.5 H), 2.90-3.12 (m, 1 H), 2.76-2.88 (m, 1 H), 2.68 (br s, 3

H), 1.62 (br s, 3 H)

1165
(CD₃OD) δ 7.70 (s, 1 H), 7.48 (br s, 1 H), 6.95-7.30 (m, 2 H),
443.2
98.3%

6.90 (br s, 0.5 H), 6.73 (br d, 1.3 H), 6.43-6.66 (m, 1.2 H), 4.96-
[M + H]⁺

5.00 (m, 1.7 H), 4.38 (br s, 0.3 H), 3.88 (br s, 0.5 H), 3.50 (s, 0.5

H), 2.90-3.18 (m, 1 H), 2.83 (dd, 1 H), 2.68 (br s, 3 H), 1.61 (br

s, 3 H)

1166
(CD₃OD) δ 8.29 (s, 1 H), 7.98 (br s, 1.5 H), 7.66 (br s, 0.5 H),
365.2
100%

7.56 (s, 1 H), 6.58-6.85 (m, 2 H), 6.33-6.57 (m, 2 H), 4.37 (br s,
[M + H]⁺

1 H), 3.85 (s, 3 H), 3.64 (br d, 1 H), 2.96 (br s, 1 H), 2.59-2.78

(m, 1 H)

1167
(CD₃OD) δ 8.29 (s, 1 H), 7.98 (br s, 1.5 H), 7.67 (br s, 0.5 H),
365.1
99.2%

7.56 (s, 1 H), 6.57-6.82 (m, 2 H), 6.34-6.58 (m, 2 H), 4.36 (br s,
[M + H]⁺

1 H), 3.85 (s, 3 H), 3.64 (br d, 1 H), 2.79-3.07 (m, 1 H), 2.59-

2.79 (m, 1 H)

1168
(CD₃OD) δ 7.98-8.17 (m, 1 H), 7.69 (s, 1 H), 6.87-7.49 (m, 1 H),
406.2
98.8%

6.74-6.84 (m, 1 H), 6.65 (s, 1 H), 6.56-6.62 (m, 1 H), 4.98 (br
[M + H]⁺

dd, 1 H), 3.92-4.00 (m, 3 H), 3.36-3.79 (m, 1 H), 2.77-3.21 (m, 2

H), 2.28-2.38 (m, 1 H), 1.20-1.33 (m, 4H)

1169
(CD₃OD) δ 7.87-8.04 (m, 1 H), 7.57 (s, 1 H), 6.74-7.41 (m, 1 H),
406.2
94.4%

6.65-6.71 (m, 1 H), 6.40-6.59 (m, 2 H), 4.86 (br dd, 1 H), 3.79-
[M + H]⁺

3.91 (m, 3 H), 3.24-3.66 (m, 1 H), 2.59-3.05 (m, 2 H), 2.08-2.33

(m, 1 H), 1.07-1.21 (m, 4H)

1170
(CD₃OD) δ 8.17-8.28 (m, 1 H), 7.68 (s, 1 H), 7.45-7.53 (m, 1 H),
410.2
100%

7.40 (s, 0.3 H), 7.05-7.12 (m, 1 H), 6.92 (s, 0.7 H), 6.43-6.58 (m,
[M + H]⁺

1 H), 4.94 (br d, 1 H), 3.69-3.80 (m, 0.7 H), 3.34-3.43 (m, 0.3

H), 2.78-3.19 (m, 2 H), 2.28-2.35 (m, 3 H), 1.90-1.94 (m, 3 H),

1.84-1.88 (m, 3 H)

1171
(CD₃OD) δ 8.18-8.28 (m, 1 H), 7.68 (s, 1 H), 7.45-7.53 (m, 1 H),
410.2
98.5%

7.40 (br s, 0.3 H), 7.04-7.13 (m, 1 H), 6.91 (br s, 0.7 H), 6.43-
[M + H]⁺

6.57 (m, 1 H), 4.93-4.96 (m, 1 H), 3.67-3.80 (m, 0.7 H), 3.34-

3.44 (m, 0.3 H), 2.78-3.19 (m, 2 H), 2.27-2.37 (m, 3 H), 1.91 (d,

3 H), 1.86 (d, 3 H)

1172
(CD₃OD) δ 8.43-8.54 (m, 1 H), 7.56-7.69 (m, 2 H), 7.20 (br dd,
437.1
100%

1 H), 7.06 (d, 1 H), 6.05-6.94 (m, 2 H), 3.45-3.99 (m, 2 H), 2.78-
[M + H]⁺

3.00 (m, 2 H)

1173
(CD₃OD) δ 8.40-8.51 (m, 1 H), 7.54-7.68 (m, 2 H), 7.14-7.23
437.1
100%

(m, 1 H), 7.03 (d, 1 H), 6.05-6.94 (m, 2 H), 3.42-3.94 (m, 2 H),
[M + H]⁺

2.76-2.99 (m, 2 H)

1174
(CD₃OD) δ 8.26 (s, 1 H), 7.67 (s, 1 H), 7.61 (br d, 1 H), 7.18
383.1
100%

(dd, 1 H), 7.04 (dd, 1 H), 6.49-6.94 (m, 2 H), 4.25-4.44 (m, 1 H),
[M + H]⁺

3.85 (td, 1 H), 2.76-3.07 (m, 2 H), 2.39 (s, 3 H)

1175
(CD₃OD) δ 8.26 (s, 1 H), 7.68 (br s, 1 H), 7.61 (br d, 1 H), 7.18
383.1
99.7%

(t, 1 H), 7.00-7.05 (m, 1 H), 6.57-6.91 (m, 2 H), 4.35 (br s, 1 H),
[M + H]⁺

3.74-3.97 (m, 1 H), 2.78-3.07 (m, 2 H), 2.39 (s, 3 H)

1176
(CD₃OD) δ 8.35 (s, 1 H), 7.56-7.83 (m, 2 H), 7.12-7.29 (m, 2 H),
471.1
99.1%

6.70-6.84 (m, 1.4 H), 6.47 (s, 0.3 H), 6.03 (s, 0.3 H), 3.60-3.88
[M + H]⁺

(m, 1.6 H), 3.37 (td, 0.4 H), 2.61-2.91 (m, 2 H)

1177
(CD₃OD) δ 8.48 (s, 1 H), 7.75-8.01 (m, 1 H), 7.64-7.73 (m, 1 H),
471.1
98.6%

7.24-7.43 (m, 2 H), 6.80-6.95 (m, 1.4 H), 6.59 (s, 0.3 H), 6.14 (s,
[M + H]⁺

0.3 H), 3.78-4.01 (m, 1.5 H), 3.42-3.55 (m, 0.5 H), 2.75-3.02 (m,

2 H)

1178
(CD₃OD) δ 7.80-7.95 (m, 1 H), 7.61-7.77 (m, 1 H), 7.23-7.48
529.2
96.3%

(m, 2 H), 6.80-7.00 (m, 1.3 H), 6.66 (s, 0.3 H), 5.91-6.40 (m, 0.4
[M + H]⁺

H), 4.96-5.00 (m, 0.2 H), 3.75-4.10 (m, 1.4 H), 3.51 (br d, 0.4

H), 2.90-3.08 (m, 1 H), 2.82 (br t, 1 H), 1.57-1.70 (m, 6 H)

1179
(CD₃OD) δ 7.81-7.93 (m, 1 H), 7.54-7.78 (m, 1 H), 7.13-7.46
529.2
97.8%

(m, 2 H), 6.79-7.06 (m, 1.3 H), 6.66 (s, 0.4 H), 6.21 (br s, 0.3 H),
[M + H]⁺

4.93-4.98 (m, 0.2 H), 3.77-4.00 (m, 1.4 H), 3.52 (td, 0.4 H),

2.75-3.08 (m, 2 H), 1.55-1.73 (m, 6 H)

1180
(CD₃OD) δ 7.88 (br d, 1 H), 7.68 (s, 1 H), 7.34-7.40 (m, 1 H),
497.2
96.9%

7.25-7.33 (m, 1 H), 6.92-7.25 (m, 1 H), 6.68-6.91 (m, 2 H), 4.98
[M + H]⁺

(br s, 1.5 H), 4.25-4.48 (m, 0.5 H), 3.78-4.02 (m, 0.5 H), 3.35-

3.50 (m, 0.5 H), 2.90-3.22 (m, 1 H), 2.83 (br d, 1 H), 1.46-1.75

(m, 3 H)

1181
(CD₃OD) δ 7.87 (br d, 1 H), 7.68 (s, 1 H), 7.36 (d, 1 H), 7.25-
497.2
95.5%

7.33 (m, 1 H), 6.92-7.24 (m, 1 H), 6.69-6.91 (m, 2 H), 4.98 (br s,
[M + H]⁺

1.5 H), 4.26-4.47 (m, 0.5 H), 3.78-4.02 (m, 0.5 H), 3.36-3.49 (m,

0.5 H), 2.90-3.20 (m, 1 H), 2.83 (br d, 1 H), 1.44-1.76 (m, 3 H)

1182
(CD₃OD) δ 7.85-8.07 (m, 1 H), 7.46-7.65 (m, 1 H), 7.28 (s, 0.3
422.2
100%

H), 6.81 (s, 0.7 H), 6.63-6.72 (m, 1 H), 6.39-6.58 (m, 2 H), 4.85
[M + H]⁺

(br d, 1 H), 3.80-3.89 (m, 3 H), 3.24-3.69 (m, 1 H), 2.65-3.10

(m, 2 H), 1.37 (s, 9 H)

1183
(CD₃OD) δ 7.87-8.06 (m, 1 H), 7.58 (br s, 1 H), 7.28 (br s, 0.3
422.2
99.7%

H), 6.81 (br s, 0.6 H), 6.63-6.72 (m, 1 H), 6.35-6.58 (m, 2 H),
[M + H]⁺

4.81-4.93 (m, 1 H), 3.78-3.90 (m, 3 H), 3.24-3.70 (m, 1 H), 2.64-

3.09 (m, 2 H), 1.37 (s, 9 H)

1184
(CD₃OD) δ 8.23-8.42 (m, 2 H), 7.70-8.14 (m, 1 H), 7.66 (s, 1 H),
349.2
99.5%

7.34 (s, 1 H), 6.25-6.92 (m, 3 H), 4.75 (br s, 0.5 H), 4.46 (br s,
[M + H]⁺

0.5 H), 3.74 (br s, 0.5 H), 3.35 (br s, 0.5 H), 2.66-3.19 (m, 2 H),

2.36 (s, 3 H)

1185
(CD₃OD) δ 8.25-8.44 (m, 2 H), 7.71-8.13 (m, 1 H), 7.67 (s, 1 H),
349.2
98.4%

7.33 (s, 1 H), 6.28-6.93 (m, 3 H), 4.76 (br s, 0.5 H), 4.46 (br s,
[M + H]⁺

0.5 H), 3.74 (br s, 0.5 H), 3.35 (br s, 0.5 H), 2.67-3.19 (m, 2 H),

2.36 (s, 3 H)

1186
(CD₃OD) δ 8.15-8.42 (m, 2 H), 7.66 - 8.10 (m, 2 H), 7.49 (d, 1
349.1
100%

H), 7.08 (d, 1 H), 6.29-6.96 (m, 2 H), 4.69-4.85 (m, 1 H), 4.46
[M + H]⁺

(br s, 0.5 H), 3.62-3.85 (m, 0.5 H), 2.73-3.13 (m, 2 H), 2.32 (s, 3 H)

1187
(CD₃OD) δ 8.11-8.41 (m, 2 H), 7.55-8.08 (m, 2 H), 7.49 (d, 1
349.2
99.4%

H), 7.08 (d, 1 H), 6.29-6.96 (m, 2 H), 4.76 (br s, 1 H), 4.45 (br s,
[M + H]⁺

0.5 H), 3.74 (br s, 0.5 H), 2.65-3.16 (m, 2 H), 2.32 (s, 3 H)

1188
(CD₃OD) δ 7.98 (br s, 1 H), 7.71 (d, 1 H), 7.40-7.50 (m, 1.5 H),
444.2
98.4%

7.05-7.14 (m, 1 H), 6.98 (s, 0.5 H), 6.68 (br dd, 1 H), 6.61 (s, 0.6
[M + H]⁺

H), 6.46 (s, 0.4 H), 5.03-5.12 (m, 0.6 H), 3.84-3.95 (m, 4 H),

3.33-3.42 (m, 0.4 H), 3.11-3.22 (m, 0.6 H), 2.93-3.03 (m, 0.4 H),

2.80-2.88 (m, 1 H), 2.64-2.68 (m, 5 H), 2.50 (s, 1 H)

1189
(CD₃OD) δ 7.98 (d, 1 H), 7.69 (d, 1 H), 7.40-7.50 (m, 1.5H),
444.2
92.9%

7.10 (dt, 1 H), 6.98 (s, 0.5 H), 6.69 (dd, 1 H), 6.61 (s, 0.6 H),
[M + H]⁺

6.45 (s, 0.4 H), 5.08 (br dd, 0.6 H), 3.82-3.95 (m, 4 H), 3.34-3.41

(m, 0.4 H), 3.11-3.22 (m, 0.6 H), 2.93-3.04 (m, 0.4 H), 2.80-2.88

(m, 1 H), 2.64-2.68 (m, 5 H), 2.51 (s, 1 H)

1190
(CD₃OD) δ 7.99 (d, 1 H), 7.79-7.90 (m, 1 H), 7.73 (s, 0.5 H),
498.2
98.5%

7.67 (s, 0.5 H), 7.58 (s, 0.5 H), 7.21-7.37 (m, 2 H), 6.96 (s, 0.5
[M + H]⁺

H), 6.86 (s, 0.5 H), 6.66 (s, 0.5 H), 5.11 (br dd, 0.5 H), 4.93-4.99

(m, 1 H), 3.91-3.99 (m, 0.5 H), 3.89 (d, 3 H), 3.11-3.22 (m, 0.5

H), 2.93-3.04 (m, 0.5 H), 2.85 (br d, 1 H), 2.67 (s, 3 H)

1191
(CD₃OD) δ 7.99 (br d, 1 H), 7.79-7.90 (m, 1 H), 7.74 (br s, 0.5
498.2
95.2%

H), 7.61-7.70 (m, 0.5 H), 7.59 (br s, 0.5 H), 7.22-7.37 (m, 2 H),
[M + H]⁺

6.97 (br s, 0.5 H), 6.86 (s, 0.5 H), 6.66 (s, 0.5 H), 5.06-5.15 (m,

0.5 H), 4.96 (br d, 1 H), 3.92-4.00 (m, 0.5 H), 3.89 (br d, 3 H),

3.11-3.25 (m, 0.5 H), 2.92-3.05 (m, 0.5 H), 2.80-2.91 (m, 1 H),

2.67 (s, 3 H)

1192
(CD₃OD) δ 7.54-7.73 (m, 2 H), 7.20 (br t, 1 H), 7.06 (d, 1 H),
495.2
100%

6.57-6.97 (m, 1.6 H), 6.14 (br s, 0.4 H), 3.78-4.03 (m, 1.5 H),
[M + H]

3.52 (td, 0.5 H), 2.72-3.08 (m, 2 H), 1.61-1.70 (m, 6 H)

1193
(CD₃OD) δ 7.45-7.59 (m, 2 H), 7.09 (br t, 1 H), 6.94 (d, 1 H),
495.1
97.0%

6.42-6.85 (m, 1.6 H), 6.02 (br s, 0.4 H), 3.75 (br d, 1.5 H), 3.33-
[M + H]⁺

3.49 (m, 0.5 H), 2.64-2.94 (m, 2 H), 1.49-1.57 (m, 6 H)

1194
(CD₃OD) δ 7.57-7.71 (m, 2 H), 7.12-7.32 (m, 1.7 H), 6.98-7.10
463.1
100%

(m, 1.3 H), 6.54-6.95 (m, 2 H), 4.96-5.02 (m, 1 H), 4.77-4.86 (m,
[M + H]⁺

0.5 H), 4.40 (br d, 0.5 H), 3.88 (br s, 0.5 H), 3.38-3.54 (m, 0.5

H), 2.76-3.20 (m, 2 H), 1.49-1.72 (m, 3 H)

1195
(CD₃OD) δ 7.54-7.69 (m, 2 H), 7.10-7.30 (m, 1.8 H), 6.97-7.08
463.1
91.7%

(m, 1.2 H), 6.58-6.96 (m, 2 H), 4.97 (br d, 1 H), 4.77-4.85 (m,
[M + H]⁺

0.5 H), 4.38 (br d, 0.5 H), 3.86 (br s, 0.5 H), 3.45 (br d, 0.5 H),

2.74-3.18 (m, 2 H), 1.60 (br s, 3 H)

1196
(CD₃OD) δ 7.68 (s, 1 H), 7.62 (br d, 1 H), 7.14-7.31 (m, 2 H),
463.1
97.3%

7.00-7.08 (m, 1 H), 6.61-6.92 (m, 2 H), 4.99 (br d, 1 H), 4.64-
[M + H]⁺

4.68 (m, 1 H), 4.34-4.44 (m, 0.5 H), 3.81-3.93 (m, 0.5 H), 2.80-

3.14 (m, 2 H), 1.55-1.66 (m, 3 H)

1197
(CD₃OD) δ 7.68 (s, 1 H), 7.62 (br d, 1 H), 7.14-7.29 (m, 2 H),
463.1
98.7%

7.01-7.07 (m, 1 H), 6.64-6.92 (m, 2 H), 4.99 (br d, 1 H), 4.64-
[M + H]⁺

4.67 (m, 1 H), 4.40 (br dd, 0.5 H), 3.88 (br s, 0.5 H), 2.81-3.17

(m, 2 H), 1.62 (br s, 3 H)

1198
(CD₃OD) δ 8.26 (s, 1 H), 7.86 (br d, 1 H), 7.68 (s, 1 H), 7.24-
417.1
99.8%

7.41 (m, 2 H), 6.86 (br s, 2 H), 4.33 (br s, 0.9 H), 3.55-4.05 (m,
[M + H]⁺

1.1 H), 3.01 (br s, 1 H), 2.80 (dd, 1 H), 2.37 (s, 3 H)

1199
(CD₃OD) δ 8.14 (s, 1 H), 7.75 (br d, 1 H), 7.56 (s, 1 H), 7.08-
417.1
99.7%

7.31 (m, 2 H), 6.39-6.83 (m, 2 H), 4.22 (br s, 1 H), 3.51-3.90 (m,
[M + H]⁺

1 H), 2.81-3.00 (m, 1 H), 2.68 (br dd, 1 H), 2.25 (s, 3 H)

1200
(CD₃OD) δ 7.75 (br d, 1 H), 7.57 (s, 1 H), 7.14-7.28 (m, 2 H),
497.2
88.2%

6.55-7.12 (m, 3 H), 4.86 (br s, 1 H), 4.25 (br s, 1 H), 3.26-3.86
[M + H]⁺

(m, 1 H), 2.82-3.03 (m, 1 H), 2.71 (dd, 1 H), 1.41-1.56 (m, 3H)

1201
(CD₃OD) δ 7.87 (br d, 1 H), 7.68 (s, 1 H), 7.23-7.42 (m, 2 H),
497.1
98.7%

6.60-7.23 (m, 3 H), 4.98 (br s, 1 H), 4.36 (br s, 1 H), 3.41-4.06
[M + H]⁺

(m, 1 H), 2.94-3.17 (m, 1 H), 2.83 (br d, 1 H), 1.43-1.73 (m, 3 H)

1202
(CD₃OD) δ 8.44 (s, 1 H), 7.69 (s, 1 H), 7.48 (br d, 1 H), 7.00-
403.1
99.8%

7.33 (m, 2 H), 6.73-6.95 (m, 1.4 H), 6.48-6.72 (m, 1.6 H), 4.79-
[M + H]⁺

4.86 (m, 0.3 H), 4.36 (br d, 0.7 H), 3.71-3.97 (m, 0.7 H), 3.37-

3.49 (m, 0.3 H), 3.08 (br s, 1 H), 2.82 (br d, 1 H)

1203
(CD₃OD) δ 8.44 (s, 1 H), 7.69 (s, 1 H), 7.48 (br d, 1 H), 6.99-
403.2
99.1%

7.33 (m, 2 H), 6.72-6.94 (m, 1.5 H), 6.51-6.71 (m, 1.5 H), 4.85
[M + H]⁺

(br s, 0.3 H), 4.36 (br d, 0.7 H), 3.80 (br s, 0.7 H), 3.37-3.48 (m,

0.3 H), 3.09 (br s, 1 H), 2.82 (br d, 1 H)

1204
(CD₃OD) δ 8.59-8.76 (m, 1 H), 7.91-8.05 (m, 1 H), 7.70 (s, 1 H),
498.2
100%

7.52-7.67 (m, 1.4 H), 6.91-7.05 (m, 1.6 H), 6.72-6.83 (m, 1 H),
[M + H]⁺

4.94-5.15 (m, 1 H), 3.83-3.95 (m, 3 H), 3.68-3.82 (m, 0.7 H),

3.39 (td, 0.3 H), 2.79-3.25 (m, 2 H), 2.59-2.72 (m, 3 H)

1205
(CD₃OD) δ 8.57-8.79 (m, 1 H), 7.94-8.07 (m, 1 H), 7.70 (s, 1 H),
498.2
100%

7.52-7.67 (m, 1.3 H), 6.90-7.06 (m, 1.7 H), 6.73-6.83 (m, 1 H),
[M + H]⁺

5.12 (br dd, 1 H), 3.86-3.95 (m, 3 H), 3.69-3.83 (m, 0.7 H), 3.39

(td, 0.3 H), 2.78-3.25 (m, 2 H), 2.63-2.71 (m, 3 H)

1206
(CD₃OD) δ 7.93-8.15 (m, 2 H), 7.69 (s, 1 H), 7.53 (s, 0.3 H),
460.2
98.2%

6.94 (s, 0.7 H), 6.73-6.85 (m, 1 H), 6.66 (s, 0.6 H), 6.53-6.63 (m,
[M + H]⁺

1.4 H), 5.06 (dd, 1 H), 3.83-4.01 (m, 6 H), 3.70-3.79 (m, 0.7 H),

3.39 (td, 0.3 H), 2.77-3.24 (m, 2 H), 2.62-2.71 (m, 3 H)

1207
(CD₃OD) δ 7.95-8.16 (m, 2 H), 7.69 (s, 1 H), 7.53 (br s, 0.3 H),
460.2
97.2%

6.93 (s, 0.7 H), 6.72-6.85 (m, 1 H), 6.66 (s, 0.7 H), 6.52-6.63 (m,
[M + H]⁺

1.3 H), 5.06 (br dd, 1 H), 3.85-4.01 (m, 6 H), 3.70-3.82 (m, 0.7

H), 3.35-3.44 (m, 0.3 H), 2.79-3.23 (m, 2 H), 2.61-2.73 (m, 3 H)

1208
(CD₃OD) δ 7.98 (br s, 1 H), 7.65-7.72 (m, 1 H), 7.49-7.64 (m,
464.2
98.9%

1.5 H), 7.11-7.21 (m, 1 H), 6.94-7.06 (m, 1.5 H), 6.78 (s, 0.5H),
[M + H]⁺

6.64 (s, 0.5 H), 5.11 (dd, 0.6 H), 4.95 (br d, 0.4 H), 3.93 (br d,

0.5 H), 3.88 (s, 3 H), 3.38 (td, 0.5 H), 3.12-3.23 (m, 0.6 H), 2.93-

3.04 (m, 0.4 H), 2.85 (br dd, 1 H), 2.62-2.70 (m, 3 H)

1209
(CD₃OD) δ 7.95-8.03 (m, 1 H), 7.67-7.72 (m, 1 H), 7.50-7.65
464.2
94.5%

(m, 1.5 H), 7.11-7.21 (m, 1 H), 6.94-7.08 (m, 1.5 H), 6.79 (d, 0.5
[M + H]⁺

H), 6.64 (s, 0.5 H), 5.11 (dd, 0.6 H), 4.94-4.96 (m, 0.4 H), 3.92

(br d, 0.5 H), 3.89 (s, 3 H), 3.38 (td, 0.5 H), 3.11-3.24 (m, 0.6

H), 2.93-3.05 (m, 0.4 H), 2.85 (br dd, 1 H), 2.62-2.71 (m, 3 H)

1210
(CD₃OD) δ 7.55-7.76 (m, 2 H), 7.17 (dd, 1 H), 6.97-7.06 (m, 1
441.2
98.9%

H), 6.49-6.94 (m, 2 H), 4.96-4.97 (m, 0.5 H), 4.36 (br s, 0.5 H),
[M + H]⁺

3.85 (br s, 0.5 H), 3.38-3.44 (m, 0.5 H), 2.71-3.18 (m, 2 H), 2.36

(s, 3 H), 1.62 (br s, 6 H)

1211
(CD₃OD) δ 7.56-7.69 (m, 2 H), 7.14-7.26 (m, 1 H), 7.02 (d, 1
441.2
97.8%

H), 6.42-6.98 (m, 2 H), 4.98-5.00 (m, 0.5 H), 4.35 (br s, 0.5 H),
[M + H]⁺

3.85 (br s, 0.5 H), 3.38-3.48 (m, 0.5 H), 2.68-3.19 (m, 2 H), 2.36

(s, 3 H), 1.62 (br s, 6 H)

1212
(CD₃OD) δ 7.57-7.69 (m, 2 H), 7.17 (dd, 1 H), 7.02 (dd, 1 H),
427.1
98.6%

6.50-6.94 (m, 2 H), 4.98-5.01 (m, 1.5 H), 4.36 (br s, 0.5 H), 3.84
[M + H]⁺

(br s, 0.5 H), 3.37-3.43 (m, 0.5 H), 2.72-3.10 (m, 2 H), 2.36 (s, 3

H), 1.56 (br s, 3 H)

1213
(CD₃OD) δ 7.52-7.73 (m, 2 H), 7.09-7.24 (m, 1 H), 7.02 (d, 1
427.1
99.5%

H), 6.47-6.90 (m, 2 H), 4.99-5.05 (m, 1.5 H), 4.37 (br s, 0.5 H),
[M + H]⁺

3.84 (br s, 0.5 H), 3.38-3.47 (m, 0.5 H), 2.74-3.14 (m, 2 H), 2.36

(s, 3 H), 1.56 (br s, 3 H)

1214
(CD₃OD) δ 8.30-8.54 (m, 1 H), 7.91-8.07 (m, 1 H), 7.71 (s, 1 H),
464.1
100%

7.56 (s, 0.3 H), 7.19-7.36 (m, 1 H), 6.95 (s, 0.6 H), 6.69-6.89 (m,
[M + H]⁺

2 H), 5.10 (br dd, 1 H), 3.88 (s, 3 H), 3.72-3.80 (m, 0.6 H), 3.37-

3.43 (m, 0.4 H), 2.78-3.24 (m, 2 H), 2.61-2.73 (m, 3 H)

1215
(CD₃OD) δ 8.31-8.50 (m, 1 H), 7.82-8.07 (m, 1 H), 7.70 (s, 1 H),
464.2
99.4%

7.55 (s, 0.3 H), 7.30 (br t, 1 H), 6.95 (s, 0.7 H), 6.67-6.88 (m, 2
[M + H]⁺

H), 5.10 (br dd, 1 H), 3.89 (s, 3 H), 3.72-3.80 (m, 0.5 H), 3.39-

3.44 (m, 0.5 H), 2.82-3.23 (m, 2 H), 2.57-2.73 (m, 3 H)

1216
(CD₃OD) δ 8.30 (br d, 1 H), 7.68 (s, 1 H), 7.28 (s, 0.4 H), 7.15
459.2
99.7%

(s, 0.6 H), 6.96-7.03 (m, 1 H), 6.73-6.90 (m, 2 H), 6.52-6.64 (m,
[M + H]⁺

1 H), 4.29 (br d, 1 H), 3.75 (br t, 0.6 H), 3.36-3.47 (m, 0.4 H),

2.77-3.14 (m, 2 H), 2.44 (br s, 3 H), 1.72-1.91 (m, 6 H)

1217
(CD₃OD) δ 8.29 (br d, 1 H), 7.68 (br s, 1 H), 7.28 (s, 0.4 H),
459.2
98.6%

7.15 (s, 0.6 H), 6.96-7.03 (m, 1 H), 6.71-6.89 (m, 2 H), 6.52-6.65
[M + H]⁺

(m, 1 H), 4.29 (br d, 1 H), 3.75 (br t, 0.6 H), 3.37-3.50 (m, 0.4

H), 2.74-3.15 (m, 2 H), 2.44 (br s, 3 H), 1.68-1.93 (m, 6 H)

1218
(CD₃OD) δ 8.69 (d, 1 H), 7.61-7.71 (m, 2 H), 7.27 (s, 0.5 H),
513.2
98.8%

7.14 (s, 0.5 H), 6.96-7.02 (m, 1 H), 6.76-6.90 (m, 1.5 H), 6.57
[M + H]⁺

(br d, 0.5 H), 4.28-4.37 (m, 0.8 H), 3.69-3.80 (m, 1 H), 3.41-3.51

(m, 0.2 H), 2.79-3.15 (m, 2 H), 1.69-1.91 (m, 6 H)

1219
(CD₃OD) δ 8.69 (d, 1 H), 7.60-7.75 (m, 2 H), 7.27 (s, 0.5 H),
513.2
98.5%

7.14 (s, 0.5 H), 6.96-7.02 (m, 1 H), 6.76-6.89 (m, 1.5 H), 6.57
[M + H]⁺

(br s, 0.5 H), 4.25-4.40 (m, 1 H), 3.67-3.83 (m, 0.8 H), 3.40-3.51

(m, 0.2 H), 2.77-3.15 (m, 2 H), 1.67-1.93 (m, 6 H)

1220
(CD₃OD) δ 8.32 (d, 1 H), 7.69 (s, 1 H), 6.99-7.33 (m, 2 H), 6.43-
455.2
99.8%

6.90 (m, 3 H), 4.35-4.46 (m, 1 H), 3.45-3.79 (m, 1 H), 2.81-3.13
[M + H]⁺

(m, 2 H), 2.46 (s, 3 H), 1.28-1.43 (m, 4H)

1221
(CD₃OD) δ 8.32 (d, 1 H), 7.69 (s, 1 H), 6.99-7.28 (m, 2 H), 6.55-
455.2
98.5%

6.89 (m, 3 H), 4.34-4.47 (m, 1 H), 3.65-3.81 (m, 1 H), 2.80-3.11
[M + H]⁺

(m, 2 H), 2.46 (s, 3 H), 1.26-1.42 (m, 4 H)

1222
(CD₃OD) δ 8.71 (d, 1 H), 7.62-7.74 (m, 2 H), 6.98-7.28 (m, 2
509.1
99.4%

H), 6.54-6.90 (m, 2 H), 4.44 (br d, 1 H), 3.74 (br s, 1 H), 2.81-
[M + H]⁺

3.17 (m, 2 H), 1.21-1.46 (m, 4 H)

1223
(CD₃OD) δ 8.71 (br d, 1 H), 7.60-7.76 (m, 2 H), 6.96-7.30 (m, 2
509.2
99.6%

H), 6.53-6.92 (m, 2 H), 4.35-4.57 (m, 1 H), 3.76 (br d, 1 H),
[M + H]⁺

2.81-3.16 (m, 2 H), 1.22-1.46 (m, 4H)

1224
(CD₃OD) δ 8.41 (s, 1 H), 8.07-8.19 (m, 1 H), 7.71 (s, 1 H), 7.60
434.2
100%

(s, 0.3 H), 7.42-7.53 (m, 1 H), 7.19-7.33 (m, 1 H), 6.98 (s, 0.7
[M + H]⁺

H), 6.80 (d, 0.7 H), 6.58-6.73 (m, 1.3 H), 5.12 (dd, 1 H), 4.02(s,

3 H), 3.73-3.91 (m, 0.7 H), 3.43 (td, 0.3 H), 3.13-3.25 (m, 0.7

H), 2.95-3.07 (m, 0.3 H), 2.80-2.90 (m, 1 H)

1225
(CD₃OD) δ 8.42 (s, 1 H), 8.09-8.18 (m, 1 H), 7.77 (s, 1 H), 7.61
434.2
97.8%

(s, 0.3 H), 7.41-7.54 (m, 1 H), 7.20-7.36 (m, 1 H), 6.99 (s, 0.7
[M + H]⁺

H), 6.70-6.87 (m, 1 H), 6.62-6.70 (m, 1 H), 5.13 (br dd, 1 H),

4.02 (s, 3 H), 3.75-3.91 (m, 0.7 H), 3.43 (td, 0.3 H), 3.13-3.26

(m, 0.7 H), 2.94-3.07 (m, 0.3 H), 2.87 (br dd, 1 H)

1226
(CD₃OD) δ 8.33 (d, 1 H), 7.68 (s, 1 H), 7.27 (s, 0.5 H), 7.14(s,
463.2
99.1%

0.5 H), 6.93-7.01 (m, 1 H), 6.68-6.85 (m, 2.5 H), 6.56 (br s, 0.5
[M + H]⁺

H), 4.31 (br d, 1 H), 3.75 (br t, 0.6 H), 3.40 (br s, 0.4 H), 2.74-

3.15 (m, 2 H), 1.68-1.90 (m, 6 H)

1227
(CD₃OD) δ 8.30-8.36 (m, 1 H), 7.70 (br s, 1 H), 7.27 (s, 0.5 H),
463.1
99.6%

7.14 (s, 0.5 H), 6.91-7.02 (m, 1 H), 6.68-6.87 (m, 2.5 H), 6.57
[M + H]⁺

(br s, 0.5 H), 4.31 (br dd, 1 H), 3.75 (br t, 0.6 H), 3.34-3.46 (m,

0.4 H), 2.74-3.16 (m, 2 H), 1.69-1.92 (m, 6 H)

1228
(CD₃OD) δ 8.45 (br d, 1 H), 7.69 (s, 1 H), 7.01-7.33 (m, 2 H),
479.1
99.6%

6.70-6.89 (m, 2.5 H), 6.56 (br s, 0.5 H), 4.32 (br d, 1 H), 3.70-
[M + H]⁺

3.80 (m, 0.6 H), 3.38-3.50 (m, 0.4 H), 2.75-3.16 (m, 2 H), 1.72-

1.91 (m, 6 H)

1229
(CD₃OD) δ 8.38-8.44 (m, 1 H), 7.68 (br s, 1 H), 6.99-7.30 (m, 2
479.1
98.9%

H), 6.70-6.88 (m, 2.5 H), 6.55 (br s, 0.5 H), 4.26-4.37 (m, 1 H),
[M + H]⁺

3.74 (br t, 0.6 H), 3.41 (br s, 0.4 H), 2.75-3.15 (m, 2 H), 1.69-

1.89 (m, 6 H)

1230
(CD₃OD) δ 7.68 (s, 1 H), 7.47 (br s, 1 H), 6.97-7.31 (m, 2 H),
459.2
99.1%

6.37-6.95 (m, 3 H), 4.65-4.75 (m, 0.4 H), 4.22-4.41 (m, 0.6 H),
[M + H]⁺

3.45-3.97 (m, 1 H), 2.80-3.12 (m, 2 H), 2.65 (br d, 3 H), 1.65-

2.03 (m, 6 H)

1231
(CD₃OD) δ 7.56 (s, 1 H), 7.35 (br d, 1 H), 6.85-7.20 (m, 2 H),
459.2
96.3%

6.21-6.83 (m, 3 H), 4.54-4.64 (m, 0.4 H), 4.19 (br d, 0.6 H),
[M + H]⁺

3.36-3.83 (m, 1 H), 2.67-3.01 (m, 2 H), 2.40-2.66 (m, 3 H), 1.48-

2.07 (m, 6 H)

1232
(CD₃OD) δ 7.70 (s, 1 H), 7.61 (br s, 1 H), 7.10-7.44 (m, 2 H),
479.2
99.8%

7.00-7.09 (m, 1 H), 6.61-6.93 (m, 2 H), 4.71-4.84 (m, 0.5 H),
[M + H]⁺

4.23-4.45 (m, 0.5 H), 3.37-4.01 (m, 1 H), 2.73-3.21 (m, 2 H),

1.70-1.97 (m, 6 H)

1233
(CD₃OD) δ 7.69 (s, 1 H), 7.62 (br s, 1 H), 7.07-7.43 (m, 2 H),
479.1
99.4%

7.02-7.07 (m, 1 H), 6.57-6.96 (m, 2 H), 4.75-4.88 (m, 0.5 H),
[M + H]⁺

4.25-4.44 (m, 0.5 H), 3.38-3.99 (m, 1 H), 2.72-3.21 (m, 2 H),

1.72-1.96 (m, 6 H)

1234
(CD₃OD) δ 8.36 (d, 1 H), 7.70 (s, 1 H), 7.07-7.28 (m, 1 H), 6.96-
459.2
99.1%

7.01 (m, 1 H), 6.56-6.89 (m, 3 H), 4.29-4.55 (m, 1 H), 3.54-3.87
[M + H]⁺

(m, 1 H), 2.80-3.14 (m, 2 H), 1.26-1.43 (m, 4H)

1235
(CD₃OD) δ 8.36 (d, 1 H), 7.70 (s, 1 H), 7.09-7.32 (m, 1 H), 6.96-
459.1
93.9%

7.01 (m, 1 H), 6.58-6.90 (m, 3 H), 4.33-4.55 (m, 1 H), 3.51-3.84
[M + H]⁺

(m, 1 H), 2.82-3.16 (m, 2 H), 1.26-1.43 (m, 4H)

1236
(CD₃OD) δ 7.55-7.74 (m, 2 H), 7.00-7.28 (m, 3 H), 6.52-6.93
475.1
99.6%

(m, 2 H), 5.02-5.17 (m, 0.2 H), 4.28-4.55 (m, 0.8 H), 3.52-4.00
[M + H]⁺

(m, 1 H), 2.79-3.16 (m, 2 H), 1.26-1.46 (m, 4H)

1237
(CD₃OD) δ 7.57-7.73 (m, 2 H), 6.99-7.29 (m, 3 H), 6.65-6.95
475.1
98.0%

(m, 2 H), 4.99-5.12 (m, 0.2 H), 4.36-4.55 (m, 0.8 H), 3.51-4.01
[M + H]⁺

(m, 1 H), 2.80-3.10 (m, 2 H), 1.26-1.43 (m, 4H)

1238
(CD₃OD) δ 7.69 (s, 1 H), 7.48 (br d, 1 H), 6.96-7.33 (m, 2 H),
461.2
95.1%

6.71-6.93 (m, 1.7 H), 6.66 (t, 1.3 H), 4.79-4.84 (m, 0.4 H), 4.38
[M + H]⁺

(br d, 0.6 H), 3.81 (br s, 0.6 H), 3.45 (br s, 0.4 H), 2.95-3.23 (m,

1 H), 2.86 (br s, 1 H), 1.52-1.71 (m, 6 H)

1239
(CD₃OD) δ 7.73 (br s, 1 H), 7.49 (br d, 1 H), 6.97-7.34 (m, 2 H),
461.2
97.3%

6.72-6.93 (m, 1.7 H), 6.58-6.71 (m, 1.3 H), 4.74-4.82 (m, 0.5 H),
[M + H]⁺

4.39 (br d, 0.5 H), 3.80 (br s, 0.5 H), 3.37-3.49 (m, 0.5 H), 2.93-

3.22 (m, 1 H), 2.85 (br d, 1 H), 1.59-1.71 (m, 6 H)

1240
(CD₃OD) δ 8.43 (s, 1 H), 7.68 (s, 1 H), 7.21 (br d, 3 H), 6.90 (br
429.2
99.6%

s, 0.7 H), 6.40-6.71 (m, 1.3 H), 6.23-6.38 (m, 1 H), 4.42 (q, 2.8
[M + H]⁺

H), 3.82 (br s, 1.2 H), 3.07 (br s, 1 H), 2.82 (br d, 1 H), 1.57 (t, 3 H)

1241
(CD₃OD) δ 8.43 (s, 1 H), 7.68 (s, 1 H), 7.21 (br d, 3 H), 6.90 (br
429.1
98.3%

s, 0.6 H), 6.61 (br s, 1.4 H), 6.26-6.37 (m, 1 H), 4.42 (q, 2.7 H),
[M + H]⁺

3.82 (br s, 1.3 H), 3.07 (br s, 1 H), 2.81 (br d, 1 H), 1.57 (t, 3 H)

1242
(CD₃OD) δ 7.59-7.85 (m, 1 H), 6.89-7.55 (m, 3 H), 6.23-6.72
440.2
99.7%

(m, 2 H), 4.33-4.51 (m, 2 H), 3.38-3.89 (m, 2 H), 2.78-3.25 (m, 2
[M + H]⁺

H), 1.79-2.03 (m, 6 H), 1.46-1.65 (m, 3 H)

1243
(CD₃OD) δ 7.57 (s, 1 H), 6.78-7.47 (m, 3 H), 6.05-6.57 (m, 2 H),
440.2
98.5%

4.22-4.37 (m, 2 H), 3.24-3.77 (m, 2 H), 2.67-3.10 (m, 2 H), 1.62-
[M + H]⁺

1.94 (m, 6 H), 1.33-1.56 (m, 3 H)

1244
(CD₃OD) δ 7.68 (s, 1 H), 7.21 (br d, 3 H), 6.80-7.12 (m, 0.8 H),
487.2
99.9%

6.45-6.66 (m, 1.2 H), 6.25-6.39 (m, 1 H), 4.82 (br s, 0.3 H),
[M + H]⁺

4.26-4.49 (m, 2.7 H), 3.83 (br s, 0.6 H), 3.37-3.48 (m, 0.4 H),

2.94-3.20 (m, 1 H), 2.83 (br d, 1 H), 1.55-1.70 (m, 9 H)

1245
(CD₃OD) δ 7.69 (s, 1 H), 7.11-7.41 (m, 3 H), 6.81-7.10 (m, 0.8
487.2
99.8%

H), 6.48-6.67 (m, 1.2 H), 6.23-6.40 (m, 1 H), 4.76-4.81 (m, 0.3
[M + H]⁺

H), 4.32-4.47 (m, 2.7 H), 3.83 (br s, 0.6 H), 3.38-3.48 (m, 0.4

H), 2.93-3.21 (m, 1 H), 2.84 (br d, 1 H), 1.54-1.71 (m, 9 H)

1246
(CD₃OD) δ 7.63-7.81 (m, 1 H), 7.42-7.55 (m, 1.4 H), 7.20-7.34
394.1
100%

(m, 1 H), 6.93 (s, 0.6 H), 6.78 (d, 0.6 H), 6.59-6.73 (m, 1.4 H),
[M + H]

5.03 (br dd, 1 H), 3.71-3.87 (m, 0.6 H), 3.37-3.45 (m, 0.4 H),

3.08-3.23 (m, 0.7 H), 2.93-3.04 (m, 0.3 H), 2.83 (dd, 1 H), 2.27-

2.41 (m, 1 H), 1.20-1.32 (m, 4H)

1247
(CD₃OD) δ 7.70 (d, 1 H), 7.42-7.55 (m, 1.3 H), 7.21-7.33 (m, 1
394.2
97.1%

H), 6.93 (s, 0.7 H), 6.78 (d, 0.7 H), 6.60-6.70 (m, 1.3 H), 5.03
[M + H]⁺

(br dd, 1 H), 3.67-3.86 (m, 0.7 H), 3.37-3.44 (m, 0.3 H), 2.93-

3.21 (m, 1 H), 2.75-2.89 (m, 1 H), 2.28-2.42 (m, 1 H), 1.23-1.32

(m, 4 H)

1248
(CD₃OD) δ 7.59-7.80 (m, 1 H), 7.40-7.53 (m, 1.3 H), 7.18-7.34
410.2
100%

(m, 1 H), 6.95 (s, 0.7 H), 6.79 (d, 0.7 H), 6.59-6.72 (m, 1.3 H),
[M + H]⁺

5.01 (br dd, 1 H), 3.70-3.92 (m, 0.7 H), 3.37-3.44 (m, 0.3 H),

3.08-3.22 (m, 0.7 H), 2.92-3.05 (m, 0.3 H), 2.86 (br s, 1 H),

1.45-1.53 (m, 9 H)

1249
(CD₃OD) δ 7.64-7.81 (m, 1 H), 7.41-7.55 (m, 1.3 H), 7.20-7.32
410.2
100%

(m, 1 H), 6.95 (s, 0.7 H), 6.79 (d, 0.7 H), 6.66 (q, 1.3 H), 5.01
[M + H]⁺

(br dd, 1 H), 3.71-3.92 (m, 0.6 H), 3.36-3.43 (m, 0.4 H), 3.10-

3.23 (m, 0.7 H), 2.94-3.08 (m, 0.3 H), 2.84 (br dd, 1 H), 1.42-

1.58 (m, 9 H)

1250
(CD₃OD) δ 8.46 (d, 1 H), 7.53-7.74 (m, 2 H), 7.21 (ddd, 1 H),
409.2
99.8%

6.41-6.95 (m, 3 H), 4.05-4.55 (m, 1 H), 3.45-3.87 (m, 1 H), 2.77-
[M + H]⁺

3.18 (m, 2 H), 2.40 (s, 3 H), 1.66-1.90 (m, 6 H)

1251
(CD₃OD) δ 8.43-8.50 (m, 1 H), 7.55-7.76 (m, 2 H), 7.21 (ddd, 1
409.2
99.7%

H), 6.40-6.96 (m, 3 H), 4.04-4.51 (m, 1 H), 3.47-3.88 (m, 1 H),
[M + H]⁺

2.74-3.16 (m, 2 H), 2.40 (s, 3 H), 1.59-1.91 (m, 6 H)

1252
(CD₃OD) δ 7.67 (s, 1 H), 7.47 (br d, 1 H), 7.12 (dd, 1 H), 6.72
423.2
99.8%

(d, 3 H), 4.14-4.52 (m, 1 H), 3.44-4.04 (m, 1 H), 2.78-3.12 (m, 2
[M + H]⁺

H), 2.67 (s, 3 H), 2.38 (s, 3 H), 1.67-1.90 (m, 6 H)

1253
(CD₃OD) δ 7.67 (s, 1 H), 7.48 (br d, 1 H), 7.12 (dd, 1 H), 6.72
423.2
99.7%

(d, 3 H), 4.10-4.52 (m, 1 H), 3.45-4.06 (m, 1 H), 2.78-3.14 (m, 2
[M + H]⁺

H), 2.67 (s, 3 H), 2.38 (s, 3 H), 1.67-1.91 (m, 6H)

1254
(CD₃OD) δ 8.43 (d, 1 H), 7.53-7.70 (m, 2 H), 6.99-7.30 (m, 2
445.2
97.0%

H), 6.83-6.87 (m, 2 H), 6.53-6.62 (m, 1 H), 4.81 (br d, 0.4 H),
[M + H]

4.29 (br d, 0.6 H), 3.74 (br t, 0.6 H), 3.37-3.50 (m, 0.4 H), 2.71-

3.15 (m, 2 H), 1.69-1.93 (m, 6 H)

1255
(CD₃OD) δ 8.44 (d, 1 H), 7.56-7.70 (m, 2 H), 7.00-7.30 (m, 2
445.2
98.4%

H), 6.85 (br t, 2 H), 6.54-6.63 (m, 1 H), 4.77-4.83 (m, 0.4 H),
[M + H]⁺

4.29 (br dd, 0.6 H), 3.74 (br t, 0.6 H), 3.37-3.47 (m, 0.4 H), 2.76-

3.15 (m, 2 H), 1.69-1.90 (m, 6 H)

1256
(CD₃OD) δ 7.74 (br s, 1 H), 7.58 (s, 1 H), 7.12-7.34 (m, 2 H),
485.2
99.3%

6.45-7.11 (m, 3 H), 4.01-4.41 (m, 0.7 H), 3.26-3.98 (m, 1.3 H),
[M + H]

2.80-3.07 (m, 1 H), 2.63-2.79 (m, 1 H), 1.45-1.98 (m, 6 H)

1257
(CD₃OD) δ 7.86 (br s, 1 H), 7.69 (s, 1 H), 7.33-7.40 (m, 1 H),
485.2
99.3%

7.25-7.32 (m, 1 H), 6.62-7.24 (m, 3 H), 4.07-4.58 (m, 0.7 H),
[M + H]'

3.34-4.07 (m, 1.3 H), 2.92-3.20 (m, 1 H), 2.83 (br dd, 1 H), 1.65-

2.04 (m, 6 H)

1258
(CD₃OD) δ 9.42 (d, 1 H), 9.11 (d, 1 H), 8.27-8.42 (m, 2 H),
432.1
100%

6.91-7.86 (m, 3 H), 6.75-6.90 (m, 2 H), 4.93-5.07 (m, 1 H), 3.43-
[M + H]⁺

3.89 (m, 1 H), 2.97-3.26 (m, 1 H), 2.88 (br dd, 1 H)

1259
(CD₃OD) δ 9.30 (d, 1 H), 9.00 (d, 1 H), 8.00-8.35 (m, 3 H),
432.2
94.5%

6.82-7.56 (m, 2 H), 6.68-6.85 (m, 2 H), 4.82-5.04 (m, 1 H), 3.31-
[M + H]⁺

3.76 (m, 1 H), 2.89-3.18 (m, 1 H), 2.74-2.88 (m, 1 H)

1260
(CD₃OD) δ 8.30 (d, 1 H), 7.66 (s, 1 H), 6.98 (d, 1 H), 6.39-6.91
423.2
100%

(m, 3 H), 4.74 (br s, 0.5 H), 4.27 (br d, 0.5 H), 3.73 (br s, 0.5 H),
[M + H]⁺

3.36-3.50 (m, 0.5 H), 2.70-3.17 (m, 2 H), 2.35-2.48 (m, 6 H),

1.64-1.90 (m, 6 H)

1261
(CD₃OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.97 (d, 1 H), 6.40-6.91
423.2
99.6%

(m, 3 H), 4.75 (br s, 0.5 H), 4.27 (br d, 0.5 H), 3.74 (br s, 0.5 H),
[M + H]⁺

3.36-3.56 (m, 0.5 H), 2.69-3.18 (m, 2 H), 2.34-2.50 (m, 6 H),

1.63-1.91 (m, 6 H)

1262
(CD₃OD) δ 8.69 (d, 1 H), 7.57-7.75 (m, 2 H), 6.98 (t, 1 H), 6.40-
477.2
100%

6.93 (m, 2 H), 4.71-4.81 (m, 0.5 H), 4.31 (br d, 0.5 H), 3.72 (br
[M + H]⁺

s, 0.5 H), 3.38-3.55 (m, 0.5 H), 2.73-3.16 (m, 2 H), 2.39 (s, 3 H),

1.61-1.93 (m, 6 H)

1263
(CD₃OD) δ 8.69 (d, 1 H), 7.52-7.82 (m, 2 H), 6.98 (t, 1 H), 6.32-
477.2
100%

6.93 (m, 2 H), 4.78 (br s, 0.5 H), 4.31 (br d, 0.5 H), 3.72 (br s,
[M + H]⁺

0.5 H), 3.46 (br d, 0.5 H), 2.72-3.22 (m, 2 H), 2.39 (s, 3 H),

1.62-1.91 (m, 6 H)

1264
(CD₃OD) δ 7.74 (br d, 1 H), 7.56 (s, 1 H), 7.21-7.26 (m, 1 H),
477.2
100%

7.11-7.19 (m, 1 H), 6.45-6.87 (m, 2 H), 4.50 (br s, 0.5 H), 4.05-
[M + H]⁺

4.31 (m, 0.5 H), 3.72-3.89 (m, 0.5 H), 3.23-3.39 (m, 0.5 H),

2.64-2.98 (m, 2 H), 2.25 (s, 3 H), 1.55-1.79 (m, 6 H)

1265
(CD₃OD) δ 7.87 (br d, 1 H), 7.68 (s, 1 H), 7.36 (br d, 1 H), 7.24-
477.2
98.4%

7.32 (m, 1 H), 6.55-6.97 (m, 2 H), 4.62 (br s, 0.5 H), 4.17-4.44
[M + H]⁺

(m, 0.5 H), 3.79-4.04 (m, 0.5 H), 3.37-3.56 (m, 0.5 H), 2.78-3.10

(m, 2 H), 2.37 (s, 3 H), 1.66-1.90 (m, 6 H)

1266
(CD₃OD) δ 7.67 (s, 1 H), 7.62 (br d, 1 H), 7.17-7.22 (m, 1 H),
443.1
100%

7.05 (d, 1 H), 6.80 (br d, 2 H), 4.62 (s, 0.5 H), 4.23-4.41 (m, 0.5
[M + H]⁺

H), 3.76-4.00 (m, 0.5 H), 3.39-3.55 (m, 0.5 H), 2.79-3.13 (m, 2

H), 2.40 (s, 3 H), 1.71-1.90 (m, 6 H)

1267
(CD₃OD) δ 7.55 (s, 1 H), 7.49 (br d, 1 H), 7.06 (dd, 1 H), 6.92
443.1
99.8%

(d, 1 H), 6.40-6.80 (m, 2 H), 4.50 (s, 0.5 H), 4.16-4.31 (m, 0.5
[M + H]⁺

H), 3.68-3.86 (m, 0.5 H), 3.24-3.41 (m, 0.5 H), 2.67-3.00 (m, 2

H), 2.27 (s, 3 H), 1.59-1.77 (m, 6 H)

1268
(CD₃OD) δ 7.87 (br d, 1 H), 7.69 (br s, 1 H), 7.33-7.40 (m, 1 H),
509.2
98.1%

7.24-7.33 (m, 1 H), 6.94-7.23 (m, 1 H), 6.74 - 6.98 (m, 2 H),
[M + H]⁺

4.40 (br s, 1 H), 3.90 (br s, 1 H), 2.68-3.24 (m, 2 H), 1.19-1.46

(m, 4 H)

1269
(CD₃OD) δ 7.87 (br d, 1 H), 7.69 (br s, 1 H), 7.32-7.42 (m, 1 H),
509.2
95.2%

7.25-7.32 (m, 1 H), 7.08 (br s, 1 H), 6.72-6.96 (m, 2 H), 4.40 (br
[M + H]⁺

s, 1 H), 3.90 (br s, 1 H), 2.61-3.20 (m, 2 H), 1.33 (br d, 4 H)

1270
(CD₃OD) δ 8.15-8.87 (m, 3 H), 7.96 (d, 1 H), 7.59-7.71 (m, 2
452.2
100%

H), 7.44 (ddd, 1 H), 6.49-7.14 (m, 4 H), 4.60 (br s, 1 H), 3.33-
[M + H]⁺

3.89 (m, 1 H), 3.01-3.13 (m, 1 H), 2.78 (br dd, 1 H)

1271
(CD₃OD) δ 8.23-9.01 (m, 3 H), 7.97 (d, 1 H), 7.60-7.71 (m, 2
452.2
98.8%

H), 7.40-7.48 (m, 1 H), 6.47-7.14 (m, 4 H), 4.62 (br s, 1 H),
[M + H]⁺

3.35-3.96 (m, 1 H), 3.04-3.14 (m, 1 H), 2.74-2.83 (m, 1 H)

1272
(CD₃OD) δ 6.58-7.25 (m, 3 H), 6.36-6.44 (m, 1 H), 6.09 (s, 1 H),
418.1
97.4%

5.85 (ddd, 1 H), 5.70 (d, 1 H), 4.78-5.58 (m, 4 H), 3.06 (br s, 1
[M + H]⁺

H), 1.79-2.37 (m, 1 H), 1.44-1.55 (m, 1 H), 1.19 (br dd, 1 H)

1273
(CD₃OD) δ 8.21-8.83 (m, 3 H), 7.97 (d, 1 H), 7.67 (s, 1 H), 7.43
418.1
98.4%

(dd, 1 H), 7.29 (d, 1 H), 6.43-7.13 (m, 4 H), 4.61 (br s, 1 H),
[M + H]⁺

3.35-3.95 (m, 1 H), 3.01-3.13 (m, 1 H), 2.77 (br dd, 1 H)

1274
(CD₃OD) δ 8.33 (br d, 1 H), 7.67 (s, 1 H), 6.41-7.05 (m, 4H),
427.2
100%

4.77 (br s, 0.5 H), 4.30 (br s, 0.5 H), 3.73 (br s, 0.5 H), 3.39 (br
[M + H]⁺

s, 0.5 H), 2.71-3.15 (m, 2 H), 2.38 (s, 3 H), 1.64-1.92 (m, 6 H)

1275
(CD₃OD) δ 8.34 (d, 1 H), 7.67 (s, 1 H), 6.40-7.07 (m, 4 H), 4.77
427.2
98.1%

(br s, 0.5 H), 4.29 (br d, 0.5 H), 3.72 (br s, 0.5 H), 3.48 (br s, 0.5
[M + H]⁺

H), 2.74-3.17 (m, 2 H), 2.38 (s, 3 H), 1.65-1.87 (m, 6 H)

1276
(CD₃OD) δ 8.44 (d, 1 H), 7.67 (s, 1 H), 7.29 (d, 1 H), 6.39-6.97
443.2
100%

(m, 3 H), 4.77 (br s, 0.5 H), 4.29 (br d, 0.5 H), 3.72 (br s, 0.5 H),
[M + H]⁺

3.37-3.52 (m, 0.5 H), 2.76-3.16 (m, 2 H), 2.39 (s, 3 H), 1.68-1.91

(m, 6 H)

1277
(CD₃OD) δ 8.44 (br d, 1 H), 7.67 (br s, 1 H), 7.29 (d, 1 H), 6.40-
443.2
98.5%

7.02 (m, 3 H), 4.76 (br s, 0.5 H), 4.29 (br s, 0.5 H), 3.72 (br s,
[M + H]⁺

0.5 H), 3.40 (br s, 0.5 H), 2.70-3.15 (m, 2 H), 2.39 (s, 3 H), 1.63-

1.90 (m, 6 H)

1278
(CD₃OD) δ 7.68 (s, 1 H), 7.47 (br d, 1 H), 7.24 (ddd, 1 H), 6.42-
427.1
100%

7.00 (m, 3 H), 4.91-5.12 (m, 0.5 H), 4.32 (dt, 0.5 H), 3.38-3.94
[M + H]⁺

(m, 1 H), 2.72-3.15 (m, 2 H), 2.40 (s, 3 H), 1.67-1.91 (m, 6 H)

1279
(CD₃OD) δ 7.68 (s, 1 H), 7.47 (br d, 1 H), 7.24 (ddd, 1 H), 6.52-
427.1
99.9%

6.89 (m, 3 H), 4.93-5.07 (m, 0.5 H), 4.25-4.38 (m, 0.5 H), 3.46-
[M + H]⁺

3.96 (m, 1 H), 2.80-3.15 (m, 2 H), 2.40 (s, 3 H), 1.70-1.89 (m, 6 H)

1280
(CD₃OD) δ 7.70 (s, 1 H), 7.48 (br d, 1 H), 6.96-7.27 (m, 2 H),
455.2
98.1%

6.67-6.91 (m, 2 H), 6.46-6.64 (m, 1 H), 4.42 (br s, 1 H), 3.87 (br
[M + H]⁺

s, 1 H), 2.77-3.15 (m, 2 H), 2.67 (br s, 3 H), 1.26-1.41 (m, 4H)

1281
(CD₃OD) δ 7.68 (s, 1 H), 7.48 (br d, 1 H), 6.96-7.27 (m, 2 H),
455.2
100%

6.65-6.91 (m, 2 H), 6.43-6.63 (m, 1 H), 4.40 (br s, 1 H), 3.88 (br
[M + H]⁺

s, 1 H), 2.82 (br d, 2 H), 2.67 (br s, 3 H), 1.27-1.44 (m, 4H)

1282
(CD₃OD) δ 8.52-8.62 (m, 1 H), 7.69 (s, 1 H), 7.38-7.51 (m, 1.3
400.2
100%

H), 7.08-7.14 (m, 0.2 H), 6.70-7.01 (m, 3.5 H), 4.97 (br dd, 1 H),
[M + H]⁺

3.65-3.83 (m, 0.5 H), 3.35-3.41 (m, 0.5 H), 2.79-3.18 (m, 2 H),

2.59-2.69 (m, 3 H)

1283
(CD₃OD) δ 8.52-8.63 (m, 1 H), 7.69 (s, 1 H), 7.37-7.52 (m, 1.3
400.2
100%

H), 7.07-7.14 (m, 0.2 H), 6.70-7.02 (m, 3.5 H), 4.97 (br dd, 1 H),
[M + H]⁺

3.67-3.78 (m, 0.5 H), 3.35-3.42 (m, 0.5 H), 2.78-3.18 (m, 2 H),

2.61-2.69 (m, 3 H)

1284
(CD₃OD) δ 8.46 (br d, 1 H), 7.54-7.73 (m, 2 H), 7.43-7.49 (m,
390.2
100%

0.3 H), 7.14-7.25 (m, 1 H), 6.85-6.94 (m, 1.7 H), 6.51-6.67 (m, 1
[M + H]⁺

H), 4.97 (br s, 1 H), 3.38-3.82 (m, 1 H), 2.81-3.20 (m, 2 H), 1.61

(s, 3 H), 1.39-1.46 (m, 2 H), 1.11 (d, 2 H)

1285
(CD₃OD) δ 8.40-8.52 (m, 1 H), 7.54-7.76 (m, 2 H), 7.46 (s, 0.3
390.2
94.1%

H), 7.14-7.26 (m, 1 H), 6.83-6.97 (m, 1.7 H), 6.53-6.66 (m, 1 H),
[M + H]⁺

5.00 (br d, 1 H), 3.40-3.79 (m, 1 H), 2.80-3.19 (m, 2 H), 1.61 (s,

3 H), 1.39-1.46 (m, 2 H), 1.11 (d, 2 H)

1286
(CD₃OD) δ 8.24-8.88 (m, 3 H), 7.97 (d, 1 H), 7.66 (s, 1 H), 7.44
398.2
100%

(dd, 1 H), 6.32-7.19 (m, 5 H), 4.61-4.74 (m, 1 H), 3.39-3.95 (m,
[M + H]⁺

1 H), 3.02-3.12 (m, 1 H), 2.77 (br dd, 1 H), 2.44 (s, 3 H)

1287
(CD₃OD) δ 8.20-9.02 (m, 3 H), 7.97 (d, 1 H), 7.66 (s, 1 H), 7.39-
398.2
98.9%

7.48 (m, 1 H), 6.38-7.12 (m, 5 H), 4.60-4.78 (m, 1 H), 3.36-3.94
[M + H]⁺

(m, 1 H), 3.01-3.12 (m, 1 H), 2.77 (br dd, 1 H), 2.44 (s, 3 H)

1288
(CD₃OD) δ 8.21-8.92 (m, 3 H), 7.97 (d, 1 H), 7.66 (s, 1 H), 7.41-
402.2
100%

7.46 (m, 1 H), 6.47-7.11 (m, 5 H), 4.62 (br s, 1 H), 3.33-3.92 (m,
[M + H]⁺

1 H), 3.02-3.14 (m, 1 H), 2.77 (br dd, 1 H)

1289
(CD₃OD) δ 8.20-8.90 (m, 3 H), 7.96 (d, 1 H), 7.66 (s, 1 H), 7.43
402.2
100%

(dd, 1 H), 6.48-7.12 (m, 5 H), 4.62 (br s, 1 H), 3.34-3.93 (m, 1
[M + H]⁺

H), 3.01-3.14 (m, 1 H), 2.77 (br dd, 1 H)

1290
(CD₃OD) δ 8.69 (d, 1 H), 8.44 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1
385.1
99.3%

H), 7.69 (s, 1 H), 7.51-7.61 (m, 2 H), 7.12-7.23 (m, 1 H), 6.84 (t,
[M + H]⁺

1 H), 6.64 (s, 1 H), 6.53 (s, 1 H), 4.44 (dd, 1 H), 3.69-3.85 (m, 1

H), 3.02-3.17 (m, 1 H), 2.84 (dd, 1 H)

1291
(CD₃OD) δ 8.69 (d, 1 H), 8.44 (d, 1 H), 8.13 (d, 1 H), 7.96-8.05
385.1
96.9%

(m, 1 H), 7.69 (s, 1 H), 7.52-7.63 (m, 2 H), 7.18 (dd, 1 H), 6.85
[M + H]⁺

(t, 1 H), 6.64 (s, 1 H), 6.54 (s, 1 H), 4.44 (dd, 1 H), 3.75-3.87 (m,

1 H), 3.04-3.17 (m, 1 H), 2.85 (dd, 1 H)

1292
(CD₃OD) δ 9.31 (s, 1 H), 8.80 (d, 1 H), 8.33-8.61 (m, 2 H), 7.64-
447.1
100%

7.77 (m, 2 H), 7.56 (s, 0.3 H), 7.23-7.37 (m, 1 H), 6.97 (s, 0.7
[M + H]⁺

H), 6.68-6.92 (m, 2 H), 5.10 (br dd, 1 H), 3.73-3.86 (m, 0.7 H),

3.43 (td, 0.3 H), 2.79-3.26 (m, 2 H)

1293
(CD₃OD) δ 9.31 (s, 1 H), 8.80 (d, 1 H), 8.32-8.60 (m, 2 H), 7.64-
447.1
98.5%

7.76 (m, 2 H), 7.56 (s, 0.3 H), 7.25-7.35 (m, 1 H), 6.97(s, 0.7
[M + H]⁺

H), 6.68-6.90 (m, 2 H), 5.10 (dd, 1 H), 3.66-3.89 (m, 0.7 H),

3.43 (td, 0.3 H), 2.82-3.25 (m, 2 H)

1294
(CD₃OD) δ 8.67 (d, 1 H), 8.40-8.52 (m, 1 H), 7.94 (d, 1 H),
465.1
99.9%

7.69-7.83 (m, 2 H), 7.47 (s, 0.4 H), 7.26-7.38 (m, 1 H), 6.99 (s,
[M + H]⁺

0.6 H), 6.77-6.92 (m, 2 H), 4.95-5.03 (m, 1 H), 3.76-3.86 (m, 0.5

H), 3.42-3.51 (m, 0.5 H), 3.02-3.24 (m, 1 H), 2.88 (br d, 1 H)

1295
(CD₃OD) δ 8.67 (d, 1 H), 8.36-8.53 (m, 1 H), 7.95 (t, 1 H), 7.71-
465.1
99.5%

7.80 (m, 2 H), 7.47 (s, 0.3 H), 7.21-7.36 (m, 1 H), 6.99 (s, 0.7
[M + H]⁺

H), 6.77-6.92 (m, 2 H), 4.98 (br d, 1 H), 3.71-3.93 (m, 0.5 H),

3.40-3.55 (m, 0.5 H), 2.99-3.29 (m, 1 H), 2.81-2.96 (m, 1 H)

1296
(CD₃OD) δ 7.69 (d, 1 H), 7.56-7.65 (m, 1 H), 7.44 (s, 0.4H),
424.2
100%

7.14-7.23 (m, 1 H), 7.05 (d, 1 H), 6.94 (s, 0.6 H), 6.61-6.81 (m, 1
[M + H]⁺

H), 4.92-5.07 (m, 1 H), 3.80-3.92 (m, 0.6 H), 3.35-3.42 (m, 0.4

H), 2.81-3.19 (m, 2 H), 1.60 (s, 3 H), 1.38-1.46 (m, 2 H), 1.10

(d, 2 H)

1297
(CD₃OD) δ 7.58 (d, 1 H), 7.44-7.53 (m, 1 H), 7.32 (s, 0.4 H),
424.1
92.3%

7.03-7.11 (m, 1 H), 6.90-6.96 (m, 1 H), 6.83 (s, 0.6 H), 6.50-6.69
[M + H]⁺

(m, 1 H), 4.90 (br dd, 1 H), 3.75 (ddd, 0.6 H), 3.28 (br d, 0.4 H),

2.74 (br d, 2 H), 1.48 (s, 3 H), 1.29 (br d, 2 H), 0.98 (d, 2 H)

1298
(CD₃OD) δ 8.80-9.04 (m, 1 H), 8.39-8.60 (m, 2 H), 8.29 (d, 1
477.2
90.8%

H), 7.82 (s, 0.3 H), 7.64 (dd, 1 H), 7.26-7.43 (m, 1 H), 7.20 (s,
[M + H]⁺

0.7 H), 7.06 (s, 0.3 H), 6.89-6.97 (m, 1.7 H), 5.25 (br dd, 1 H),

4.01 (s, 3 H), 3.65-3.84 (m, 1 H), 3.38-3.55 (m, 1 H), 2.94-3.19

(m, 1 H)

1299
(CD₃OD) δ 8.87-9.06 (m, 1 H), 8.41-8.65 (m, 2 H), 8.28 (br d, 1
477.1
94.0%

H), 7.82 (s, 0.3 H), 7.63 (dd, 1 H), 7.38 (d, 1 H), 7.20 (s, 0.7 H),
[M + H]⁺

7.06 (s, 0.3 H), 6.86-6.97 (m, 1.7 H), 5.25 (br dd, 1 H), 4.01 (s, 3

H), 3.75 (br t, 1 H), 3.38-3.54 (m, 1 H), 2.93-3.18 (m, 1 H)

1300
(CD₃OD) δ 9.48 (d, 1 H), 8.81-8.90 (m, 2 H), 8.63-8.76 (m, 1
482.2
100%

H), 7.73-7.84 (m, 1 H), 7.59-7.73 (m, 1 H), 6.80-7.57 (m, 3 H),
[M + H]⁺

4.94-5.13 (m, 1 H), 3.40-3.91 (m, 1 H), 2.81-3.28 (m, 2 H)

1301
(CD₃OD) δ 9.48 (s, 1 H), 8.81-9.04 (m, 2 H), 8.63-8.81 (m, 1 H),
482.1
99.9%

7.73-7.91 (m, 1 H), 7.59-7.72 (m, 1 H), 6.79-7.59 (m, 3 H), 5.07
[M + H]⁺

(br dd, 1 H), 3.41-3.96 (m, 1 H), 2.82-3.30 (m, 2 H)

1302
(CD₃OD) δ 9.31 (br s, 1 H), 8.46-8.83 (m, 3 H), 7.71 (s, 3.5 H),
481.1
100%

6.91-7.04 (m, 1.5 H), 6.66-6.87 (m, 1 H), 5.12 (dd, 0.7 H), 4.95
[M + H]⁺

(br dd, 0.3 H), 3.70-3.86 (m, 0.7 H), 3.37-3.50 (m, 0.3 H), 2.78-

3.26 (m, 2 H)

1303
(CD₃OD) δ 9.31 (d, 1 H), 8.48-8.87 (m, 3 H), 7.54-7.74 (m, 3.5
481.1
99.3%

H), 6.92-7.06 (m, 1.5 H), 6.73-6.85 (m, 1 H), 5.12 (dd, 0.7 H),
[M + H]⁺

4.95 (br dd, 0.3 H), 3.75-3.84 (m, 0.7 H), 3.43 (td, 0.3 H), 2.82-

3.26 (m, 2 H)

1304
(CD₃OD) δ 8.61-8.72 (m, 2 H), 8.42-8.49 (m, 1 H), 7.71 (s, 1 H),
495.1
100%

7.46-7.66 (m, 2 H), 6.94-7.03 (m, 2 H), 6.77-6.83 (m, 1 H), 5.12
[M + H]⁺

(dd, 0.6 H), 4.95 (br dd, 0.4 H), 3.80 (td, 0.7 H), 3.42 (td, 0.3 H),

3.17-3.26 (m, 1 H), 2.81-3.05 (m, 4 H)

1305
(CD₃OD) δ 8.61-8.72 (m, 2 H), 8.41-8.49 (m, 1 H), 7.71 (s, 1 H),
495.1
99.6%

7.45-7.66 (m, 2 H), 6.94-7.02 (m, 2 H), 6.78-6.83 (m, 1 H), 5.12
[M + H]⁺

(br dd, 0.6 H), 4.92-4.97 (m, 0.4 H), 3.75-3.85 (m, 0.7 H), 3.42

(td, 0.3 H), 3.15-3.27 (m, 1 H), 2.82-3.06 (m, 4 H)

1306
(CD₃OD) δ 9.31 (s, 1 H), 8.75-8.90 (m, 1 H), 8.44-8.63 (m, 1 H),
447.2
100%

7.50-7.73 (m, 3.5 H), 7.11-7.25 (m, 1 H), 6.98-7.06 (m, 1.5 H),
[M + H]⁺

6.80 (s, 0.6 H), 6.65 (s, 0.4 H), 5.12 (dd, 0.6 H), 4.95 (br dd, 0.4

H), 3.87-4.00 (m, 0.6 H), 3.40 (td, 0.4 H), 2.97-3.25 (m, 1 H),

2.87 (dd, 1 H)

1307
(CD₃OD) δ 9.31 (br s, 1 H), 8.74-8.85 (m, 1 H), 8.55 (br d, 1 H),
447.1
95.4%

7.47-7.73 (m, 3.5 H), 7.11-7.22 (m, 1 H), 6.95-7.07 (m, 1.5 H),
[M + H]⁺

6.80 (s, 0.6 H), 6.64 (s, 0.4 H), 5.11 (br dd, 0.6 H), 4.95 (br dd,

0.4 H), 3.87-3.98 (m, 0.6 H), 3.40 (td, 0.4 H), 2.96-3.26 (m, 1

H), 2.87 (br dd, 1 H)

1308
(CD₃OD) δ 9.31 (br s, 1 H), 8.80 (br d, 1 H), 8.55 (br d, 1 H),
427.2
100%

7.85 (d, 1 H), 7.67 (br d, 1 H), 7.39-7.53 (m, 1.4 H), 7.06-7.18
[M + H]⁺

(m, 1 H), 7.03 (s, 0.6 H), 6.61-6.75 (m, 1.6 H), 6.50 (s, 0.4H),

5.10 (br dd, 0.6 H), 4.95 (br d, 0.4 H), 3.87-3.99 (m, 0.6 H),

3.37-3.46 (m, 0.4 H), 2.83-3.26 (m, 2 H), 2.49-2.68 (m, 3 H)

1309
(CD₃OD) δ 9.31 (s, 1 H), 8.72-8.94 (m, 1 H), 8.54 (br d, 1 H),
427.2
96.9%

7.62-7.81 (m, 2 H), 7.37-7.55 (m, 1.4 H), 7.05-7.17 (m, 1 H),
[M + H]⁺

7.00 (s, 0.6 H), 6.59-6.76 (m, 1.6 H), 6.48 (s, 0.4 H), 5.08 (br dd,

0.5 H), 4.95 (br d, 0.5 H), 3.89-3.98 (m, 0.5 H), 3.41 (td, 0.5 H),

2.83-3.25 (m, 2 H), 2.48-2.70 (m, 3 H)

1310
(CD₃OD) δ 9.05 (d, 2 H), 8.21-8.40 (m, 1 H), 7.69-7.75 (m, 2
428.1
100%

H), 6.76-7.05 (m, 3 H), 6.61-6.69 (m, 1 H), 4.98 (br d, 1 H),
[M + H]⁺

3.79-3.86 (m, 0.5 H), 3.46-3.50 (m, 0.5 H), 2.85-3.21 (m, 2 H),

2.44-2.49 (m, 3 H)

1311
(CD₃OD) δ 9.00-9.10 (m, 2 H), 8.21-8.37 (m, 1 H), 7.67-7.75
428.1
98.6%

(m, 2 H), 7.48 (s, 0.3 H), 6.76-7.03 (m, 2.7 H), 6.60-6.71 (m, 1
[M + H]⁺

H), 4.97-5.01 (m, 1 H), 3.79-3.87 (m, 0.5 H), 3.46 (br d, 0.5 H),

2.84-3.26 (m, 2 H), 2.42-2.50 (m, 3 H)

1312
(CD₃OD) δ 9.03-9.07 (m, 2 H), 8.28-8.41 (m, 1 H), 7.66-7.75
432.2
100%

(m, 2 H), 7.38-7.55 (m, 0.3 H), 6.73-7.07 (m, 3.7 H), 4.95-5.04
[M + H]

(m, 1 H), 3.81-3.86 (m, 0.6 H), 3.42-3.51 (m, 0.4 H), 2.83-3.24

(m, 2 H)

1313
(CD₃OD) δ 9.05 (d, 2 H), 8.27-8.41 (m, 1 H), 7.67-7.77 (m, 2
432.2
99.6%

H), 7.47 (br s, 0.3 H), 6.78-7.03 (m, 3.7 H), 4.96-5.05 (m, 1 H),
[M + H]⁺

3.79-3.87 (m, 0.6 H), 3.42-3.50 (m, 0.4 H), 2.85-3.27 (m, 2 H)

1314
(CD₃OD) δ 8.77 (d, 1 H), 8.50-8.64 (m, 1 H), 8.31 (d, 1 H),
463.2
100%

8.02-8.16 (m, 1 H), 7.61-7.76 (m, 2 H), 7.52 (s, 0.2 H), 7.37-7.47
[M + H]⁺

(m, 1 H), 6.75-7.17 (m, 3.8 H), 4.93-5.07 (m, 1 H), 3.72-3.86 (m,

0.5 H), 3.42 (td, 0.5 H), 2.80-3.27 (m, 2 H)

1315
(CD₃OD) δ 8.77 (d, 1 H), 8.49-8.64 (m, 1 H), 8.31 (d, 1 H), 8.08
463.2
99.1%

(t, 1 H), 7.62-7.75 (m, 2 H), 7.52 (s, 0.2 H), 7.37-7.48 (m, 1 H),
[M + H]⁺

6.77-7.15 (m, 3.8 H), 4.93-5.06 (m, 1 H), 3.71-3.85 (m, 0.5 H),

3.42 (td, 0.5 H), 2.81-3.26 (m, 2 H)

1316
(CD₃OD) δ 8.50-8.63 (m, 1 H), 8.36-8.45 (m, 1 H), 8.04-8.15
466.2
100%

(m, 1 H), 7.70 (s, 1 H), 7.58 (s, 0.2 H), 7.37-7.49 (m, 1 H), 6.67-
[M + H]⁺

7.18 (m, 3.8 H), 5.09 (dd, 0.5 H), 4.93 (br d, 0.5 H), 4.00 (s, 3

H), 3.69-3.83 (m, 0.5 H), 3.35-3.45 (m, 0.5 H), 2.74-3.24 (m, 2 H)

1317
(CD₃OD) δ 8.51-8.62 (m, 1 H), 8.33-8.43 (m, 1 H), 8.02-8.17
466.2
100%

(m, 1 H), 7.70 (s, 1 H), 7.58 (s, 0.2 H), 7.34-7.47 (m, 1 H), 6.70-
[M + H]⁺

7.17 (m, 3.8 H), 5.09 (dd, 0.5 H), 4.93 (br d, 0.5 H), 4.00 (s, 3

H), 3.69-3.82 (m, 0.5 H), 3.39 (td, 0.5 H), 2.79-3.23 (m, 2 H)

1318
(CD₃OD) δ 7.68 (d, 1 H), 7.35-7.52 (m, 1.5 H), 7.08-7.16 (m, 1
404.2
100%

H), 6.95 (s, 0.5 H), 6.43-6.76 (m, 2 H), 4.93-5.03 (m, 1 H), 3.83-
[M + H]⁺

3.92 (m, 0.6 H), 3.36-3.42 (m, 0.4 H), 2.82-3.17 (m, 2 H), 2.61-

2.69 (m, 3 H), 1.61 (s, 3 H), 1.38-1.44 (m, 2 H), 1.08-1.13 (m, 2 H)

1319
(CD₃OD) δ 7.71 (d, 1 H), 7.36 (dd, 1.5 H), 7.07-7.17 (m, 1 H),
404.2
99.6%

6.96 (s, 0.5 H), 6.42-6.78 (m, 2 H), 4.99 (br dd, 1 H), 3.77-3.94
[M + H]⁺

(m, 0.6 H), 3.40 (br d, 0.4 H), 2.81-3.14 (m, 2 H), 2.61-2.69 (m,

3 H), 1.61 (s, 3 H), 1.38-1.46 (m, 2 H), 1.08-1.14 (m, 2H)

1320
(CD₃OD) δ 8.19-8.75 (m, 1 H), 7.71 (s, 1 H), 7.24-7.54 (m, 1.4
424.2
100%

H), 6.83-6.96 (m, 1.6 H), 6.68-6.77 (m, 1 H), 5.01 (dd, 0.8 H),
[M + H]⁺

4.87 (br s, 0.2 H), 3.35-3.80 (m, 1 H), 2.90-3.23 (m, 1 H), 2.83

(br d, 1 H), 1.54-1.68 (m, 3 H), 1.36-1.48 (m, 2H), 1.06-1.16

(m, 2 H)

1321
(CD₃OD) δ 8.22-8.66 (m, 1 H), 7.71 (s, 1 H), 7.17-7.55 (m, 1.5
424.2
100%

H), 6.81-6.98 (m, 1.5 H), 6.67-6.79 (m, 1 H), 5.01 (br dd, 0.8 H),
[M + H]⁺

4.87 (br s, 0.2 H), 3.36-3.80 (m, 1 H), 2.91-3.23 (m, 1 H), 2.83

(br d, 1 H), 1.51-1.66 (m, 3 H), 1.36-1.49 (m, 2 H), 1.04-1.17

(m, 2 H)

1322
(CD₃OD) δ 8.09-8.55 (m, 1 H), 7.70 (s, 1 H), 7.37-7.52 (m, 0.3
404.2
100%

H), 6.86-7.06 (m, 1.7 H), 6.76-6.84 (m, 1 H), 6.51-6.67 (m, 1 H),
[M + H]⁺

4.98 (dd, 0.8 H), 4.85 (br d, 0.2 H), 3.36-3.84 (m, 1 H), 2.90-

3.24 (m, 1 H), 2.73-2.89 (m, 1 H), 2.44-2.50 (m, 3 H), 1.61 (s, 3

H), 1.35-1.49 (m, 2 H), 1.04-1.18 (m, 2 H)

1323
(CD₃OD) δ 8.13-8.50 (m, 1 H), 7.70 (s, 1 H), 7.36-7.53 (m, 0.3
404.2
100%

H), 6.86-7.10 (m, 1.7 H), 6.74-6.86 (m, 1 H), 6.50-6.68 (m, 1 H),
[M + H]⁺

4.99 (br dd, 1 H), 3.40-3.80 (m, 1 H), 3.15 (br s, 1 H), 2.76-2.90

(m, 1 H), 2.44-2.50 (m, 3 H), 1.61 (s, 3 H), 1.37-1.49 (m, 2 H),

1.03-1.22 (m, 2 H)

1324
(CD₃OD) δ 8.44-8.80 (m, 1 H), 7.59-7.77 (m, 2 H), 7.42-7.48
458.2
100%

(m, 0.3 H), 6.83-7.12 (m, 1.7 H), 6.73-6.82 (m, 1 H), 5.03 (br dd,
[M + H]⁺

0.8 H), 4.88 (br s, 0.2 H), 3.37-3.80 (m, 1 H), 2.92-3.24 (m, 1

H), 2.83 (br d, 1 H), 1.57-1.65 (m, 3 H), 1.36-1.48 (m, 2 H),

1.03-1.21 (m, 2 H)

1325
(CD₃OD) δ 8.71 (br d, 1 H), 7.60-7.75 (m, 2 H), 7.45 (br d, 0.3
458.2
100%

H), 6.84-7.10 (m, 1.7 H), 6.69-6.83 (m, 1 H), 5.03 (dd, 0.8 H),
[M + H]⁺

4.86-4.89 (m, 0.2 H), 3.40-3.80 (m, 1 H), 3.15 (br d, 1 H), 2.83

(br d, 1 H), 1.57-1.65 (m, 3 H), 1.38-1.49 (m, 2 H), 1.07-1.15

(m, 2 H)

1326
(CD₃OD) δ 8.11-8.93 (m, 3 H), 7.96 (d, 1 H), 7.65 (s, 1 H), 7.43
414.2

100% /

(dd, 1 H), 6.29-7.25 (m, 5 H), 4.31-4.86 (m, 1 H), 3.95 (s, 3 H),
[M + H]⁺

3.34-3.87 (m, 1 H), 2.98-3.14 (m, 1 H), 2.76 (br dd, 1 H)

1327
(CD₃OD) δ 8.05-8.87 (m, 3 H), 7.97 (d, 1 H), 7.65 (s, 1 H), 7.39-
414.2
100%

7.48 (m, 1 H), 6.23-7.15 (m, 5 H), 4.60 (br s, 1 H), 3.95 (s, 3H),
[M + H]⁺

3.38-3.80 (m, 1 H), 3.00-3.12 (m, 1 H), 2.76 (br d, 1 H)

1328
(CD₃OD) δ 8.61-8.66 (m, 1 H), 8.44 (dd, 1 H), 8.27-8.36 (m, 1
445.2
100%

H), 7.70 (br s, 1 H), 7.44-7.57 (m, 1 H), 6.90-7.03 (m, 2 H),
[M + H]⁺

6.73-6.86 (m, 2 H), 5.10 (br dd, 0.6 H), 4.94 (br d, 0.4 H), 3.74-

3.84 (m, 0.6 H), 3.38-3.47 (m, 0.4 H), 2.84-3.25 (m, 5 H)

1329
(CD₃OD) δ 8.61-8.66 (m, 1 H), 8.44 (dd, 1 H), 8.27-8.36 (m, 1
445.2
99.7%

H), 7.70 (br s, 1 H), 7.44-7.57 (m, 1 H), 6.90-7.03 (m, 2 H),
[M + H]⁺

6.73-6.86 (m, 2 H), 5.10 (br dd, 0.6 H), 4.94 (br d, 0.4 H), 3.74-

3.84 (m, 0.6 H), 3.38-3.47 (m, 0.4 H), 2.84-3.25 (m, 5 H)

1330
(CD₃OD) δ 8.64 (d, 1 H), 8.43-8.48 (m, 1 H), 8.24-8.33 (m, 1
441.2
100%

H), 7.69 (s, 1 H), 7.46-7.54 (m, 1 H), 6.95-7.03 (m, 2 H), 6.73-
[M + H]⁺

6.81 (m, 1 H), 6.57-6.66 (m, 1 H), 5.07 (dd, 0.6 H), 4.90-4.94

(m, 0.4 H), 3.76-3.86 (m, 0.6 H), 3.40-3.49 (m, 0.4 H), 2.82-3.26

(m, 5 H), 2.41-2.47 (m, 3 H)

1331
(CD₃OD) δ 8.64 (br d, 1 H), 8.43-8.48 (m, 1 H), 8.24-8.32 (m, 1
441.2
99.2%

H), 7.70 (s, 1 H), 7.46-7.53 (m, 1 H), 6.95-7.02 (m, 2 H), 6.74-
[M + H]⁺

6.82 (m, 1 H), 6.58-6.66 (m, 1 H), 5.08 (br dd, 0.7 H), 4.90-4.95

(m, 0.3 H), 3.77-3.86 (m, 0.6 H), 3.44 (td, 0.4 H), 2.80-3.26 (m,

5 H), 2.40-2.47 (m, 3 H)

1332
(CD₃OD) δ 9.36 (d, 1 H), 8.66-8.84 (m, 2 H), 8.24-8.43 (m, 1
448.1
100%

H), 7.63 (br s, 1 H), 6.84-7.43 (m, 2 H), 6.62-6.82 (m, 2 H), 4.93
[M + H]⁺

(br dd, 1 H), 3.30-3.79 (m, 1 H), 2.66-3.17 (m, 2 H)

1333
(CD₃OD) δ 9.36 (d, 1 H), 8.65-8.84 (m, 2 H), 8.21-8.42 (m, 1
448.1
98.9%

H), 7.64 (br s, 1 H), 6.84-7.45 (m, 2 H), 6.60-6.83 (m, 2 H),
[M + H]⁺

4.87-5.03 (m, 1 H), 3.31-3.77 (m, 1 H), 2.66-3.13 (m, 2 H)

1334
(CD₃OD) δ 8.63-8.67 (m, 1 H), 8.45-8.50 (m, 1 H), 7.47-7.72
461.1
100%

(m, 3 H), 7.14-7.22 (m, 1 H), 6.96-7.08 (m, 2 H), 6.81 (s, 0.6H),
[M + H]⁺

6.66 (s, 0.4 H), 5.12 (dd, 0.5 H), 4.96 (br dd, 0.5 H), 3.88-3.99

(m, 0.6 H), 3.41 (td, 0.4 H), 2.83-3.26 (m, 5 H)

1335
(CD₃OD) δ 8.63-8.67 (m, 1 H), 8.47 (br d, 1 H), 7.48-7.73 (m, 3
461.2
99.6%

H), 7.13-7.22 (m, 1 H), 6.95-7.08 (m, 2 H), 6.81 (s, 0.6 H), 6.66
[M + H]⁺

(s, 0.4 H), 5.12 (br dd, 0.5 H), 4.93-4.99 (m, 0.5 H), 3.89-3.98

(m, 0.6 H), 3.36-3.45 (m, 0.4 H), 2.83-3.27 (m, 5 H)

1336
(CD₃OD) δ 9.03 (t, 2 H), 7.62-7.77 (m, 2 H), 7.37-7.54 (m, 1.5
428.2
100%

H), 6.99-7.15 (m, 1.5 H), 6.39-6.76 (m, 2 H), 4.95 (br d, 1 H),
[M + H]⁺

3.79-4.08 (m, 0.8 H), 3.36-3.42 (m, 0.2 H), 2.94-3.26 (m, 1 H),

2.78-2.92 (m, 1 H), 2.42-2.70 (m, 3 H)

1337
(CD₃OD) δ 9.03 (t, 2 H), 7.64-7.77 (m, 2 H), 7.36-7.55 (m, 1.5
428.2
96.5%

H), 6.99-7.15 (m, 1.5 H), 6.42-6.74 (m, 2 H), 4.95 (br d, 1 H),
[M + H]⁺

3.80-4.01 (m, 0.8 H), 3.37-3.43 (m, 0.2 H), 2.96-3.26 (m, 1 H),

2.82-2.92 (m, 1 H), 2.43-2.70 (m, 3 H)

1338
(CD₃OD) δ 9.36 (dd, 1 H), 8.65-8.85 (m, 2 H), 7.60 (d, 1 H),
428.1
100%

6.83-7.45 (m, 3 H), 6.29-6.70 (m, 2 H), 4.89 (td, 1 H), 3.74-3.92
[M + H]⁺

(m, 0.5 H), 3.24-3.38 (m, 0.5 H), 2.84-3.16 (m, 1 H), 2.69-2.82

(m, 1 H), 2.32-2.66 (m, 3 H)

1339
(CD₃OD) δ 9.36 (dd, 1 H), 8.68-8.81 (m, 2 H), 7.59 (d, 1 H),
428.1
98.4%

6.83-7.43 (m, 3 H), 6.32-6.66 (m, 2 H), 4.84-4.95 (m, 1 H), 3.77-
[M + H]⁺

3.93 (m, 0.5 H), 3.24-3.37 (m, 0.5 H), 2.83-3.18 (m, 1 H), 2.70-

2.83 (m, 1 H), 2.34-2.64 (m, 3 H)

1340
(CD₃OD) δ 9.31 (s, 1 H), 8.74-8.89 (m, 1 H), 8.34-8.63 (m, 1 H),
481.1
100%

7.78-7.92 (m, 1 H), 7.65-7.76 (m, 2 H), 7.56 (br s, 0.5 H), 7.19-
[M + H]⁺

7.42 (m, 2 H), 6.80-7.05 (m, 1 H), 6.65 (s, 0.5 H), 4.93-5.16 (m,

1 H), 3.57-4.07 (m, 1 H), 2.96-3.25 (m, 1 H), 2.84-2.92 (m, 1 H)

1341
(CD₃OD) δ 9.30 (s, 1 H), 8.73-8.95 (m, 1 H), 8.44-8.66 (m, 1 H),
481.1
97.5%

7.78-7.94 (m, 1 H), 7.62-7.77 (m, 2 H), 7.56 (br s, 0.5 H), 7.18-
[M + H]⁺

7.39 (m, 2 H), 6.83-7.05 (m, 1 H), 6.65 (s, 0.5H), 4.92-5.16 (m,

1 H), 3.98 (br t, 1 H), 2.96-3.24 (m, 1 H), 2.87 (br d, 1 H)

1342
(CD₃OD) δ 8.64 (td, 1 H), 8.42-8.49 (m, 1 H), 7.79-7.89 (m, 1
495.2
100%

H), 7.67-7.75 (m, 1 H), 7.45-7.60 (m, 1.5 H), 7.21-7.39 (m, 2 H),
[M + H]⁺

6.84-7.00 (m, 1 H), 6.66 (s, 0.5 H), 5.12 (dd, 0.5 H), 4.96 (br dd,

0.5 H), 3.94-4.03 (m, 0.5 H), 3.34 (br d, 0.5 H), 2.85-3.29 (m, 5 H)

1343
(CD₃OD) δ 8.64 (br t, 1 H), 8.46 (br t, 1 H), 7.80-7.90 (m, 1 H),
495.2
99.8%

7.66-7.77 (m, 1 H), 7.46-7.60 (m, 1.5 H), 7.21-7.38 (m, 2 H),
[M + H]⁺

6.86-7.01 (m, 1 H), 6.67 (s, 0.5 H), 5.12 (br dd, 0.4 H), 4.96 (br

dd, 0.6 H), 3.93-4.03 (m, 0.5 H), 3.32-3.36 (m, 0.5 H), 2.85-3.29

(m, 5 H)

1344
(CD₃OD) δ 8.46 (dd, 1 H), 8.27 (d, 1 H), 7.81-7.94 (m, 1 H),
511.1
96.1%

7.68-7.76 (m, 1 H), 7.63 (ddd, 1.5 H), 7.35-7.40 (m, 0.5 H),
[M + H]⁺

7.23-7.33 (m, 1.5 H), 7.00 (br s, 0.5 H), 6.89 (s, 0.5 H), 6.69 (s,

0.5 H), 4.97-5.10 (m, 1 H), 4.01 (d, 3.5 H), 3.39 (br d, 0.5 H),

3.14-3.27 (m, 0.5 H), 2.96-3.07 (m, 0.5 H), 2.82-2.94 (m, 1 H)

1345
(CD₃OD) δ 8.45 (dd, 1 H), 8.26 (d, 1 H), 7.81-7.93 (m, 1 H),
511.1
92.3%

7.68-7.76 (m, 1 H), 7.58-7.66 (m, 1.5 H), 7.35-7.40 (m, 0.5 H),
[M + H]⁺

7.22-7.34 (m, 1.5 H), 7.00 (s, 0.5 H), 6.67-6.90 (m, 1 H), 4.96-

5.10 (m, 1 H), 4.01 (d, 3.5 H), 3.37-3.45 (m, 0.5 H), 3.12-3.26

(m, 0.5 H), 2.95-3.10 (m, 0.5 H), 2.82-2.95 (m, 1 H)

1346
(CD₃OD) δ 9.30 (s, 1 H), 8.80 (d, 1 H), 8.32-8.61 (m, 2 H), 7.54-
413.2
100%

7.74 (m, 3.3 H), 7.13-7.27 (m, 1 H), 6.80-7.03 (m, 1.7 H), 6.54-
[M + H]⁺

6.71 (m, 1 H), 4.91-5.11 (m, 1 H), 3.37-3.85 (m, 1 H), 2.82-3.25

(m, 2 H)

1347
(CD₃OD) δ 9.30 (s, 1 H), 8.80 (dd, 1 H), 8.34-8.62 (m, 2 H),
413.1
100%

7.54-7.72 (m, 3.3 H), 7.12-7.27 (m, 1 H), 6.78-7.03 (m, 1.7 H),
[M + H]⁺

6.49-6.69 (m, 1 H), 5.06 (br dd, 0.5 H), 4.93 (br d, 0.5 H), 3.72-

3.87 (m, 0.7 H), 3.43 (td, 0.3 H), 2.81-3.24 (m, 2 H)

1348

¹H NMR(METHANOL-d₄) δ 8.51-8.62 (m, 1 H), 7.94-8.03 (m,
480.2
100%

1 H), 7.70 (s, 1 H), 7.58 (s, 0.2 H), 7.37-7.50 (m, 1 H), 6.71-7.16
[M + H]⁺

(m, 3.8 H), 5.10 (br dd, 0.5 H), 4.93 (br d, 0.5 H), 3.88 (s, 3 H),

3.70-3.83 (m, 0.5 H), 3.37-3.42 (m, 0.5 H), 2.78-3.25 (m, 2 H),

2.61-2.71 (m, 3 H)

1349
(CD₃OD) δ 8.46-8.65 (m, 1 H), 7.92-8.07 (m, 1 H), 7.70 (s, 1 H),
480.2
100%

7.58 (s, 0.2 H), 7.33-7.50 (m, 1 H), 6.66-7.15 (m, 3.8 H), 5.10
[M + H]⁺

(br dd, 0.5 H), 4.93 (br d, 0.5 H), 3.88 (s, 3 H), 3.68-3.81 (m, 0.5

H), 3.37-3.45 (m, 0.5 H), 2.78-3.26 (m, 2 H), 2.60-2.76 (m, 3 H)

1350
(CD₃OD) δ 8.47-8.64 (m, 1 H), 7.70 (s, 1 H), 7.39-7.49 (m,
446.2
96.2%

1.3H), 6.67-7.15 (m, 3.7 H), 4.92-5.00 (m, 1 H), 3.68-3.82 (m,
[M + H]⁺

0.5 H), 3.34-3.43 (m, 0.5 H), 2.77-3.21 (m, 2 H), 1.79-1.97 (m, 6 H)

1351
(CD₃OD) δ 8.49-8.64 (m, 1 H), 7.70 (s, 1 H), 7.38-7.48 (m, 1.3
446.2
91.3%

H), 6.67-7.15 (m, 3.7 H), 4.92-5.01 (m, 1 H), 3.67-3.83 (m, 0.5
[M + H]⁺

H), 3.35-3.43 (m, 0.5 H), 2.80-3.20 (m, 2 H), 1.81-1.95 (m, 6H)

1352
(CD₃OD) δ 8.43-8.63 (m, 1 H), 7.64-7.85 (m, 2 H), 7.36-7.59
466.2
100%

(m, 1.3 H), 6.71-7.15 (m, 4.7 H), 4.92-5.09 (m, 1 H), 4.02 (s, 3
[M + H]⁺

H), 3.67-3.86 (m, 0.5 H), 3.39 (td, 0.5 H), 2.76-3.26 (m, 2 H)

1353
(CD₃OD) δ 8.59 (br s, 1 H), 7.80 (br s, 2 H), 7.38-7.56 (m, 1 H),
466.2
100%

6.74-7.14 (m, 5 H), 5.03 (br d, 1 H), 4.02 (d, 3 H), 3.77 (br t, 0.5
[M + H]⁺

H), 3.39 (br s, 0.5 H), 2.79-3.25 (m, 2 H)

1354
(CD₃OD) δ 7.86 (dd, 1 H), 7.64-7.76 (m, 1 H), 7.52 (br s, 0.5 H),
458.1
100%

7.25-7.41 (m, 2 H), 6.83-7.01 (m, 1 H), 6.66 (s, 0.5 H), 4.99-5.04
[M + H]⁺

(m, 1 H), 3.59-4.01 (m, 1 H), 2.80-3.19 (m, 2 H), 1.61 (s, 3 H),

1.38-1.46 (m, 2 H), 1.06-1.16 (m, 2 H)

1355
(CD₃OD) δ 7.74 (dd, 1 H), 7.52-7.63 (m, 1 H), 7.41 (br s, 0.5 H),
458.2
98.8%

7.11-7.27 (m, 2 H), 6.70-6.85 (m, 1 H), 6.53 (s, 0.5 H), 4.81-4.94
[M + H]⁺

(m, 1 H), 3.24-3.88 (m, 1 H), 2.68-3.05 (m, 2 H), 1.48 (s, 3 H),

1.26-1.33 (m, 2 H), 0.95-1.03 (m, 2 H)

1356
(CD₃OD) δ 8.61-8.66 (m, 1 H), 8.37-8.47 (m, 2 H), 7.71 (s, 1 H),
461.1
100%

7.45-7.54 (m, 1.4 H), 7.25-7.32 (m, 1 H), 6.96 (s, 0.6 H), 6.72-
[M + H]⁺

6.87 (m, 2 H), 5.10 (dd, 0.6 H), 4.94 (br d, 0.4 H), 3.74-3.84 (m,

0.6 H), 3.43 (td, 0.3 H), 3.14-3.26 (m, 0.7 H), 2.92-3.06 (m, 3

H), 2.80-2.90 (m, 1 H)

1357
(CD₃OD) δ 8.64 (br d, 1 H), 8.37-8.47 (m, 2 H), 7.70 (br s, 1 H),
461.1
99.7%

7.45-7.55 (m, 1 H), 7.26-7.32 (m, 1 H), 6.96 (br s, 1 H), 6.72-
[M + H]⁺

6.87 (m, 2 H), 5.10 (br dd, 0.6 H), 4.93 (br dd, 0.4 H), 3.75-3.84

(m, 0.6 H), 3.43 (td, 0.4 H), 2.80-3.26 (m, 5 H)

1358
(CD₃OD) δ 8.60-8.65 (m, 1 H), 8.38-8.45 (m, 1 H), 7.70 (d, 1
441.2
100%

H), 7.39-7.51 (m, 2 H), 6.95-7.14 (m, 2 H), 6.60-6.72 (m, 1.6 H),
[M + H]⁺

6.48 (s, 0.4 H), 5.08 (dd, 0.6 H), 4.94 (br s, 0.4 H), 3.88-3.98 (m,

0.6 H), 3.41 (td, 0.4 H), 3.13-3.24 (m, 0.5 H), 2.81-3.04 (m, 4.5

H), 2.65 (s, 1.8 H), 2.47 (s, 1.2H)

1359
(CD₃OD) δ 8.63 (br d, 1 H), 8.43 (br s, 1 H), 7.73 (br s, 1 H),
441.2
99.4%

7.39-7.52 (m, 2 H), 6.96-7.16 (m, 2 H), 6.60-6.75 (m, 1.6 H),
[M + H]⁺

6.49 (s, 0.4 H), 5.09 (br dd, 1 H), 3.88-3.98 (m, 0.6 H), 3.41 (br

t, 0.4 H), 3.14-3.25 (m, 0.6 H), 2.81-3.05 (m, 4.4 H), 2.66 (br s,

1.8 H), 2.48 (br s, 1.2 H)

1360
(CD₃OD) δ 9.35 (s, 1 H), 8.69-8.83 (m, 2 H), 7.69-7.83 (m, 1 H),
482.1
100%

7.54-7.66 (m, 1 H), 7.23-7.50 (m, 1 H), 6.84-7.23 (m, 2 H), 6.54-
[M + H]⁺

6.81 (m, 1 H), 4.86-4.99 (m, 1 H), 3.82-3.95 (m, 0.5 H), 3.25-

3.33 (m, 0.5 H), 2.85-3.16 (m, 1 H), 2.71-2.82 (m, 1 H)

1361
(CD₃OD) δ 9.35 (s, 1 H), 8.65-8.83 (m, 2 H), 7.67-7.86 (m, 1 H),
482.1
98.6%

7.53-7.67 (m, 1 H), 7.24-7.51 (m, 1 H), 6.84-7.23 (m, 2 H), 6.49-
[M + H]⁺

6.84 (m, 1 H), 4.89-5.00 (m, 1 H), 3.82-3.95 (m, 0.5 H), 3.24-

3.32 (m, 0.5 H), 2.86-3.15 (m, 1 H), 2.70-2.84 (m, 1 H)

1362
(CD₃OD) δ 9.30-9.42 (m, 1 H), 8.74 (br d, 2 H), 8.24-8.41 (m, 1
414.2
100%

H), 7.60 (br s, 1 H), 6.83-7.54 (m, 3 H), 6.67-6.83 (m, 1 H),
[M + H]⁺

6.46-6.61 (m, 1 H), 4.90 (br dd, 1 H), 3.62-3.76 (m, 0.5 H), 3.33

(td, 0.5 H), 2.84-3.17 (m, 1 H), 2.76 (br d, 1 H)

1363
(CD₃OD) δ 9.33-9.44 (m, 1 H), 8.71-8.80 (m, 2 H), 8.26-8.39
414.2
100%

(m, 1 H), 7.60-7.73 (m, 1 H), 6.85-7.54 (m, 3 H), 6.68-6.82 (m, 1
[M + H]⁺

H), 6.47-6.62 (m, 1 H), 4.91 (br dd, 1 H), 3.62-3.76 (m, 0.5 H),

3.26-3.39 (m, 0.5 H), 2.86-3.16 (m, 1 H), 2.69-2.83 (m, 1 H)

1364
(CD₃OD) δ 8.63 (br d, 1 H), 8.37-8.48 (m, 2 H), 7.70 (br s, 1 H),
427.1
100%

7.45-7.61 (m, 2.4 H), 7.13-7.23 (m, 1 H), 6.96 (s, 0.6 H), 6.80-
[M + H]⁺

6.88 (m, 1 H), 6.57-6.65 (m, 1 H), 5.07 (br dd, 1 H), 3.75-3.84

(m, 0.7 H), 3.42 (td, 0.3 H), 3.15-3.24 (m, 0.6 H), 2.82-3.04 (m,

4.4 H)

1365
(CD₃OD) δ 8.64 (dd, 1 H), 8.38-8.48 (m, 2 H), 7.70 (br s, 1 H),
427.1
99.7%

7.47-7.62 (m, 2.4 H), 7.15-7.23 (m, 1 H), 6.97 (s, 0.6 H), 6.81-
[M + H]⁺

6.89 (m, 1 H), 6.59-6.66 (m, 1 H), 5.07 (dd, 0.6 H), 4.93 (br d,

0.4 H), 3.75-3.85 (m, 0.7 H), 3.43 (td, 0.3 H), 3.15-3.25 (m, 0.7

H), 2.83-3.06 (m, 4.3 H)

1366
(CD₃OD) δ 7.88 (s, 1 H), 7.54-7.67 (m, 2 H), 7.24-7.49 (m, 1 H),
480.2
100%

6.83-7.20 (m, 3 H), 6.48-6.69 (m, 1 H), 4.81-5.03 (m, 1 H), 3.78
[M + H]⁺

(d, 3.6 H), 3.24-3.30 (m, 0.4 H), 2.69-3.09 (m, 2 H), 2.56 (d, 3 H)

1367
(CD₃OD) δ 7.87 (s, 1 H), 7.54-7.67 (m, 2 H), 7.24-7.48 (m, 1 H),
480.1
99.2%

6.84-7.20 (m, 3 H), 6.51-6.68 (m, 1 H), 4.81-5.04 (m, 1 H), 3.78
[M + H]⁺

(d, 3.6 H), 3.25-3.31 (m, 0.4 H), 2.70-3.12 (m, 2 H), 2.56 (d, 3 H)

1368
(CD₃OD) δ 8.43-8.57 (m, 1 H), 7.69 (s, 1 H), 7.29 (d, 1 H), 6.73-
432.1
100%

7.03 (m, 4 H), 6.28-6.64 (m, 1 H), 4.05-4.12 (m, 1 H), 3.95 (s, 3
[M + H]⁺

H), 3.66-3.77 (m, 0.6 H), 3.20-3.28 (m, 0.3 H), 2.94-3.03 (m, 1

H), 2.72-2.82 (m, 1 H)

1369
(CD₃OD) δ 8.42-8.55 (m, 1 H), 7.69 (s, 1 H), 7.29 (d, 1 H), 6.73-
432.1
100%

7.05 (m, 4 H), 6.32-6.64 (m, 1 H), 4.04-4.14 (m, 1 H), 3.95 (s, 3
[M + H]⁺

H), 3.72 (br t, 0.6 H), 3.25 (br t, 0.4 H), 2.93-3.04 (m, 1 H),

2.71-2.83 (m, 1 H)

1370
(CD₃OD) δ 8.68-8.83 (m, 1 H), 7.60-7.71 (m, 2 H), 6.74-7.06
466.1
99.8%

(m, 4 H), 6.31-6.65 (m, 1 H), 4.06-4.13 (m, 1 H), 3.96 (s, 3 H),
[M + H]⁺

3.67-3.76 (m, 0.6 H), 3.19-3.25 (m, 0.4 H), 2.93-3.05 (m, 1 H),

2.70-2.84 (m, 1 H)

1371
(CD₃OD) δ 8.67-8.82 (m, 1 H), 7.58-7.73 (m, 2 H), 6.72-7.05
466.2
99.4%

(m, 4 H), 6.31-6.65 (m, 1 H), 4.09 (br d, 1 H), 3.96 (s, 3 H),
[M + H]⁺

3.66-3.78 (m, 0.6 H), 3.25 (br d, 0.4 H), 2.99 (br t, 1 H), 2.72-

2.85 (m, 1 H)

1372
(CD₃OD) δ 8.55-8.71 (m, 1 H), 7.69 (s, 1 H), 7.43 (br d, 1 H),
448.2
99.7%

6.72-7.14 (m, 5 H), 6.32-6.66 (m, 1 H), 4.04-4.14 (m, 1 H), 3.95
[M + H]⁺

(s, 3 H), 3.65-3.78 (m, 0.6 H), 3.17-3.27 (m, 0.4 H), 2.92-3.05

(m, 1 H), 2.70-2.83 (m, 1H)

1373
(CD₃OD) δ 8.57-8.71 (m, 1 H), 7.69 (s, 1 H), 7.43 (br d, 1 H),
448.2
99.0%

6.73-7.14 (m, 5 H), 6.31-6.63 (m, 1 H), 4.04-4.14 (m, 1 H), 3.95
[M + H]⁺

(s, 3 H), 3.65-3.78 (m, 0.6 H), 3.20-3.27 (m, 0.4 H), 2.93-3.05

(m, 1 H), 2.77 (br t, 1 H)

1374
(CD₃OD) δ 8.91 (br s, 1 H), 8.47-8.66 (m, 1 H), 8.34 (s, 1 H),
502.2
100%

7.56-7.82 (m, 2 H), 7.37-7.52 (m, 1 H), 6.72-7.14 (m, 4 H), 5.08
[M + H]⁺

(br dd, 1 H), 3.77 (br t, 0.5 H), 3.36-3.47 (m, 0.5 H), 2.76-3.25

(m, 2 H)

1375
(CD₃OD) δ 8.88-8.96 (m, 1 H), 8.51-8.63 (m, 1 H), 8.35 (s, 1 H),
502.2
100%

7.55-7.84 (m, 2 H), 7.38-7.52 (m, 1 H), 6.74-7.16 (m, 4 H), 5.10
[M + H]⁺

(br dd, 1 H), 3.71-3.88 (m, 0.5 H), 3.42 (td, 0.5 H), 2.79-3.26 (m,

2 H)

1376
(CD₃OD) δ 8.48-8.61 (m, 1 H), 8.33 (d, 1 H), 7.82 (s, 0.3 H),
502.2
100%

7.64-7.76 (m, 1.5 H), 7.53 (d, 0.5 H), 7.38-7.47 (m, 1 H), 7.21
[M + H]⁺

(d, 1 H), 6.75-7.13 (m, 3.7 H), 4.94-5.10 (m, 1 H), 3.73-3.83 (m,

0.5 H), 3.35-3.46 (m, 0.5 H), 2.80-3.26 (m, 2 H)

1377
(CD₃OD) δ 8.49-8.61 (m, 1 H), 8.33 (d, 1 H), 7.82 (s, 0.3 H),
502.2
99.3%

7.69 (br d, 1.5 H), 7.53 (d, 0.5 H), 7.37-7.47 (m, 1 H), 7.21 (d, 1
[M + H]⁺

H), 6.73-7.15 (m, 3.7 H), 4.92-5.11 (m, 1 H), 3.71-3.86 (m, 0.5

H), 3.35-3.50 (m, 0.5 H), 2.79-3.26 (m, 2 H)

1378
(CD₃OD) δ 8.29-8.39 (m, 1 H), 7.70 (s, 1 H), 7.45 (s, 0.3 H),
408.2
100%

6.65-7.02 (m, 3.7 H), 5.01 (dd, 1 H), 3.74 (ddd, 0.7 H), 3.37-3.46
[M + H]⁺

(m, 0.3 H), 2.80-3.18 (m, 2 H), 1.58-1.63 (m, 3 H), 1.39-1.47 (m,

2 H), 1.08-1.14 (m, 2 H)

1379
(CD₃OD) δ 8.30-8.39 (m, 1 H), 7.70 (s, 1 H), 7.45 (s, 0.3 H),
408.1
99.6%

6.68-7.02 (m, 3.7 H), 5.01 (dd, 1 H), 3.64-3.81 (m, 0.7 H), 3.36-
[M + H]⁺

3.44 (m, 0.3 H), 2.79-3.18 (m, 2 H), 1.61 (s, 3 H), 1.39-1.47 (m,

2 H), 1.05-1.16 (m, 2 H)

1380
(CD₃OD) δ 9.03 (d, 2 H), 8.71 (d, 1 H), 7.44-7.74 (m, 3.5 H),
482.1
100%

6.81-7.01 (m, 2.5 H), 4.92-5.04 (m, 1 H), 3.80 (ddd, 0.7 H), 3.44
[M + H]⁺

(td, 0.3 H), 3.17-3.27 (m, 0.7 H), 3.00-3.07 (m, 0.3 H), 2.78-2.94

(m, 1 H)

1381
(CD₃OD) δ 9.03 (d, 2 H), 8.71 (d, 1 H), 7.43-7.79 (m, 3.5 H),
482.2
93.5%

6.81-7.01 (m, 2.5 H), 4.92-5.06 (m, 1 H), 3.74-3.85 (m, 0.7 H),
[M + H]⁺

3.41-3.49 (m, 0.3 H), 2.98-3.28 (m, 1 H), 2.86 (br d, 1 H)

1382
(CD₃OD) δ 8.37-8.52 (m, 1 H), 8.07-8.16 (m, 1 H), 7.95 (t, 1 H),
427.2
100%

7.78-7.88 (m, 1 H), 6.98-7.68 (m, 4 H), 6.82-6.92 (m, 1 H), 6.60-
[M + H]⁺

6.74 (m, 1 H), 4.93-5.10 (m, 1 H), 3.75-3.87 (m, 0.5 H), 3.36-

3.52 (m, 0.5 H), 2.98-3.29 (m, 1 H), 2.80-2.92 (m, 1 H), 2.66 (s,

3 H)

1383
(CD₃OD) δ 8.38-8.53 (m, 1 H), 8.04-8.16 (m, 1 H), 7.95 (t, 1 H),
427.2
100%

7.72 (s, 1 H), 6.95-7.67 (m, 4 H), 6.80-6.96 (m, 1 H), 6.55-6.74
[M + H]⁺

(m, 1 H), 5.02 (dd, 1 H), 3.74-3.92 (m, 0.5 H), 3.38-3.52 (m, 0.5

H), 2.93-3.29 (m, 1 H), 2.76-2.92 (m, 1 H), 2.66 (s, 3 H)

1384
(CD₃OD) δ 7.75-7.98 (m, 1 H), 7.62 (br s, 1 H), 6.97-7.39 (m, 3
432.1
99.9%

H), 6.60-6.97 (m, 2 H), 6.33-6.53 (m, 1 H), 4.75 (s, 0.5 H), 4.08
[M + H]⁺

(br s, 0.5 H), 4.02 (s, 3 H), 3.70-3.87 (m, 0.5 H), 3.15 (s, 0.5H),

2.95-3.08 (m, 1 H), 2.81 (br d, 1 H)

1385
(CD₃OD) δ 7.70 (s, 1 H), 7.61 (br s, 1 H), 6.95-7.37 (m, 3 H),
432.1
99.6%

6.61-6.95 (m, 2 H), 6.33-6.51 (m, 1 H), 4.85 (br d, 0.5 H), 4.06-
[M + H]⁺

4.12 (m, 0.5 H), 4.02 (br d, 3 H), 3.79 (br s, 0.5 H), 3.28 (br s,

0.5 H), 3.00 (br d, 1 H), 2.68-2.87 (m, 1 H)

1386
(CD₃OD) δ 7.87 (br d, 1 H), 7.71 (br d, 1 H), 6.95-7.53 (m, 3 H),
466.1
99.6%

6.59-6.95 (m, 2 H), 6.29-6.59 (m, 1 H), 4.82 (br d, 0.5 H), 4.07
[M + H]⁺

(br d, 0.5 H), 3.97 (br d, 3 H), 3.78 (br t, 0.5 H), 3.18-3.30 (m,

0.5 H), 3.01 (br d, 1 H), 2.67-2.88 (m, 1 H)

1387
(CD₃OD) δ 7.88 (br d, 1 H), 7.70 (br s, 1 H), 6.95-7.54 (m, 3 H),
466.1
98.2%

6.59-6.95 (m, 2 H), 6.27-6.58 (m, 1 H), 4.83 (br d, 0.5 H), 4.07
[M + H]⁺

(br d, 0.5 H), 3.97 (br d, 3 H), 3.70-3.86 (m, 0.5 H), 3.29 (br s,

0.5 H), 3.01 (br d, 1 H), 2.66-2.87 (m, 1 H)

1388
(CD₃OD) δ 7.68 (br d, 1 H), 6.97-7.57 (m, 3 H), 6.58-6.97 (m, 3
412.2
96.9%

H), 6.28-6.44 (m, 1 H), 4.76-4.86 (m, 0.5 H), 4.06 (br d, 0.5 H),
[M + H]⁺

3.97 (br d, 3 H), 3.81 (br t, 0.5 H), 3.37 (br s, 0.5 H), 3.00 (br d,

1 H), 2.82 (br s, 1 H), 2.63-2.77 (m, 3 H)

1389
(CD₃OD) δ 7.68 (br d, 1 H), 6.96-7.56 (m, 3 H), 6.58-6.96 (m, 3
412.2
99.6%

H), 6.26-6.43 (m, 1 H), 4.82 (br d, 0.5 H), 4.06 (br d, 0.5 H),
[M + H]⁺

3.97 (br d, 3 H), 3.74-3.88 (m, 0.5 H), 3.35-3.42 (m, 0.5 H), 3.00

(br d, 1 H), 2.82 (br s, 1 H), 2.63-2.79 (m, 3 H)

1390
(CD₃OD) δ 7.66-7.80 (m, 2 H), 7.38-7.60 (m, 1 H), 7.14-7.34
426.1
100%

(m, 2.5 H), 6.93 (s, 0.5 H), 6.60-6.79 (m, 1 H), 5.01 (dd, 1 H),
[M + H]⁺

3.81-3.93 (m, 0.6 H), 3.35-3.39 (m, 0.4 H), 2.80-3.17 (m, 2 H),

2.28-2.38 (m, 1 H), 1.26-1.32 (m, 2 H), 1.20-1.25 (m, 2 H)

1391
(CD₃OD) δ 7.66-7.80 (m, 2 H), 7.52 (s, 1 H), 7.13-7.37 (m, 2.5
426.2
92.9%

H), 6.93 (s, 0.5 H), 6.61-6.78 (m, 1 H), 5.01 (dd, 1 H), 3.79-3.92
[M + H]⁺

(m, 0.6 H), 3.35-3.40 (m, 0.4 H), 2.81-3.18 (m, 2 H), 2.28-2.38

(m, 1 H), 1.26-1.32 (m, 2 H), 1.23 (br dd, 2 H)

1392
(CD₃OD) δ 8.84-9.11 (m, 2 H), 7.47-7.73 (m, 3 H), 6.94-7.36
448.1
100%

(m, 3 H), 6.59-6.88 (m, 1 H), 4.99 (ddd, 1 H), 3.88-3.99 (m, 0.5
[M + H]⁺

H), 3.34-3.46 (m, 0.5 H), 2.82-3.27 (m, 2 H)

1393
(CD₃OD) δ 9.03 (dd, 2 H), 7.52-7.76 (m, 3 H), 7.45-7.50 (m, 0.3
448.1
99.4%

H), 6.96-7.21 (m, 2.7 H), 6.58-6.86 (m, 1 H), 4.94-5.05 (m, 1 H),
[M + H]⁺

3.87-3.99 (m, 0.5 H), 3.34-3.44 (m, 0.5 H), 2.83-3.25 (m, 2 H)

1394
(CD₃OD) δ 8.51-8.68 (m, 2 H), 8.41-8.50 (m, 1 H), 7.70-7.77
477.2
100%

(m, 1 H), 7.39-7.59 (m, 2.3 H), 6.77-7.16 (m, 3.7 H), 4.93-5.18
[M + H]⁺

(m, 1 H), 3.72-3.86 (m, 0.5 H), 3.42 (td, 0.5 H), 3.18-3.26 (m,

0.5 H), 2.83-3.06 (m, 4.5 H)

1395
(CD₃OD) δ 8.51-8.70 (m, 2 H), 8.37-8.50 (m, 1 H), 7.74 (br s, 1
477.2
99.5%

H), 7.37-7.59 (m, 2.5 H), 6.75-7.16 (m, 3.5 H), 4.93-5.17 (m, 1
[M + H]⁺

H), 3.72-3.88 (m, 0.5 H), 3.37-3.51 (m, 0.5 H), 3.18-3.26 (m, 0.5

H), 2.82-3.06 (m, 4.5 H)

1396
(CD₃OD) δ 8.07-8.17 (m, 1 H), 7.95 (t, 1 H), 7.72 (d, 1 H), 7.58-
461.1
100%

7.69 (m, 1 H), 7.03-7.58 (m, 3 H), 6.96-7.03 (m, 1 H), 6.62-6.87
[M + H]⁺

(m, 1 H), 4.93-5.12 (m, 1 H), 3.88-4.01 (m, 0.5 H), 3.41 (td, 0.5

H), 2.95-3.28 (m, 1 H), 2.79-2.94 (m, 1 H), 2.66 (s, 3 H)

1397
(CD₃OD) δ 8.08-8.19 (m, 1 H), 7.95 (td, 1 H), 7.72 (d, 1 H),
461.1
98.3%

7.57-7.68 (m, 1 H), 7.04-7.57 (m, 3 H), 6.95-7.04 (m, 1 H), 6.60-
[M + H]⁺

6.88 (m, 1 H), 4.95-5.09 (m, 1 H), 3.88-4.01 (m, 0.5 H), 3.38-

3.47 (m, 0.5 H), 2.96-3.30 (m, 1 H), 2.82-2.96 (m, 1 H), 2.66 (d,

3 H)

1398
(CD₃OD) δ 8.11 (dd, 1 H), 7.95 (td, 1 H), 7.71 (d, 1 H), 6.97-
441.2
100%

7.61 (m, 4 H), 6.65-6.77 (m, 1 H), 6.43-6.65 (m, 1 H), 4.94-5.09
[M + H]⁺

(m, 1 H), 3.89-4.02 (m, 0.5 H), 3.36-3.44 (m, 0.5 H), 2.96-3.28

(m, 1 H), 2.80-2.96 (m, 1 H), 2.45-2.74 (m, 6 H)

1399
(CD₃OD) δ 8.11 (dd, 1 H), 7.95 (td, 1 H), 7.71 (d, 1 H), 6.98-
441.2
99.6%

7.58 (m, 4 H), 6.66-6.77 (m, 1 H), 6.44-6.66 (m, 1 H), 5.00 (td, 1
[M + H]⁺

H), 3.88-4.02 (m, 0.5 H), 3.36-3.44 (m, 0.5 H), 2.94-3.26 (m, 1

H), 2.81-2.94 (m, 1 H), 2.45-2.76 (m, 6 H)

1400
(CD₃OD) δ 7.98 (d, 1 H), 7.68-7.88 (m, 2 H), 7.53-7.66 (m, 1
495.1
100%

H), 7.22-7.51 (m, 2 H), 6.83-7.22 (m, 2 H), 6.53-6.81 (m, 1 H),
[M + H]⁺

4.83-4.99 (m, 1 H), 3.82-3.94 (m, 0.5 H), 3.24-3.31 (m, 0.5 H),

2.84-3.16 (m, 1 H), 2.71-2.84 (m, 1 H), 2.54 (d, 3 H)

1401
(CD₃OD) δ 7.99 (d, 1 H), 7.67-7.88 (m, 2 H), 7.53-7.67 (m, 1
495.1
88.1%

H), 7.23-7.51 (m, 2 H), 6.82-7.23 (m, 2 H), 6.52-6.82 (m, 1 H),
[M + H]⁺

4.83-5.00 (m, 1 H), 3.87 (br t, 0.5 H), 3.24-3.32 (m, 0.5 H), 2.85-

3.16 (m, 1 H), 2.68-2.85 (m, 1 H), 2.54 (d, 3 H)

1402
(CD₃OD) δ 7.76 (br d, 1 H), 7.69 (br d, 1 H), 7.29-7.63 (m, 2 H),
448.2
99.9%

6.94-7.29 (m, 2 H), 6.61-6.94 (m, 2 H), 6.25-6.52 (m, 1 H), 4.83
[M + H]⁺

(br s, 1 H), 4.07 (br d, 0.5 H), 3.96 (br d, 3 H), 3.69-3.86 (m, 0.5

H), 3.00 (br d, 1 H), 2.64-2.90 (m, 1 H)

1403
(CD₃OD) δ 7.76 (br d, 1 H), 7.70 (br d, 1 H), 7.29-7.59 (m, 2 H),
448.2
98.2%

6.94-7.29 (m, 2 H), 6.61-6.94 (m, 2 H), 6.27-6.53 (m, 1 H), 4.83
[M + H]⁺

(br s, 1 H), 4.07 (br d, 0.5 H), 3.96 (br d, 3 H), 3.78 (br t, 0.5 H),

3.00 (br d, 1 H), 2.69-2.87 (m, 1 H)

1404
(CD₃OD) δ 8.35 (d, 1 H), 7.43-7.88 (m, 3.5 H), 7.19-7.36 (m, 2
470.1
100%

H), 6.99 (s, 0.5 H), 6.72-6.88 (m, 1 H), 6.60-6.71 (m, 1 H), 5.08
[M + H]⁺

(br dd, 0.7 H), 4.96-4.98 (m, 0.3 H), 3.78-3.93 (m, 0.5 H), 3.40-

3.53 (m, 0.5 H), 2.96-3.24 (m, 1 H), 2.87 (br d, 1 H)

1405
(CD₃OD) δ 8.36 (d, 1 H), 7.96-8.16 (m, 1 H), 7.43-7.89 (m, 2.5
470.1
100%

H), 7.19-7.36 (m, 2 H), 7.06 (s, 0.5 H), 6.79-6.93 (m, 1 H), 6.58-
[M + H]⁺

6.75 (m, 1 H), 5.13 (br dd, 0.7 H), 4.95-4.97 (m, 0.3 H), 3.75-

3.90 (m, 0.7 H), 3.41-3.54 (m, 0.3 H), 3.24 (br d, 0.8 H), 3.04 (br

d, 0.2 H), 2.84-2.97 (m, 1 H)

1406
(CD₃OD) δ 8.40 (s, 1 H), 8.11 (s, 1 H), 7.66-7.80 (m, 2 H), 7.36-
466.2
100%

7.60 (m, 1 H), 6.97-7.34 (m, 3 H), 6.61-6.81 (m, 1 H), 4.95-5.15
[M + H]⁺

(m, 1 H), 4.02 (d, 3 H), 3.82-3.97 (m, 0.6 H), 3.36-3.43 (m, 0.4

H), 2.83-3.24 (m, 2 H)

1407
(CD₃OD) δ 8.41 (s, 1 H), 8.11 (s, 1 H), 7.67-7.82 (m, 2 H), 7.36-
466.2
99.2%

7.61 (m, 1 H), 6.95-7.33 (m, 3 H), 6.61-6.83 (m, 1 H), 4.93-5.15
[M + H]⁺

(m, 1 H), 4.02 (d, 3 H), 3.82-3.95 (m, 0.6 H), 3.36-3.44 (m, 0.4

H), 2.82-3.24 (m, 2 H)

1408
(CD₃OD) δ 8.45-8.65 (m, 1 H), 7.69 (s, 1 H), 7.43 (br t, 1.3 H),
442.1
100

6.65-7.17 (m, 3.7 H), 4.98 (br dd, 1 H), 3.63-3.83 (m, 0.5 H),
[M + H]⁺

3.34-3.44 (m, 0.5 H), 2.73-3.22 (m, 2 H), 1.45-1.51 (m, 9 H)

1409
(CD₃OD) δ 8.43-8.68 (m, 1 H), 7.69 (s, 1 H), 7.43 (br t, 1.3 H),
442.2
99.1%

6.70-7.14 (m, 3.7 H), 4.98 (br dd, 1 H), 3.63-3.81 (m, 0.5 H),
[M + H]⁺

3.34-3.43 (m, 0.5 H), 2.73-3.22 (m, 2 H), 1.43-1.58 (m, 9 H)

1410
(DMSO-d₆) δ 9.02-9.18 (m, 2 H), 8.56-8.81 (m, 1 H), 8.23 (s,
448.1
100%

0.3 H), 7.74-7.85 (m, 1 H), 7.63 (s, 1 H), 7.36-7.49 (m, 1 H),
[M + H]⁺

6.68-6.94 (m, 2.7 H), 4.70-4.92 (m, 1 H), 3.60-3.81 (m, 0.6 H),

2.98-3.09 (m, 1 H), 2.62-2.92 (m, 1.4 H)

1411
(DMSO-d₆) δ 8.99-9.17 (m, 2 H), 8.61-8.72 (m, 0.8 H), 8.23 (s,
448.1
97.3%

0.2 H), 7.36-7.87 (m, 3 H), 7.19 (br d, 0.3 H), 6.67-6.95 (m, 2.7
[M + H]⁺

H), 4.85 (br dd, 1 H), 3.66-3.75 (m, 0.5 H), 2.97-3.10 (m, 1 H),

2.73-2.94 (m, 1.5 H)

1412
(CD₃OD) δ 9.02 (d, 2 H), 8.49-8.62 (m, 1 H), 7.65-7.77 (m, 2
464.1
100%

H), 7.38-7.51 (m, 1.3 H), 7.08-7.15 (m, 0.2 H), 6.80-7.02 (m, 3.5
[M + H]⁺

H), 4.94-5.03 (m, 1 H), 3.79 (ddd, 0.5 H), 3.37-3.49 (m, 0.5 H),

2.83-3.25 (m, 2 H)

1413
(CD₃OD) δ 9.03 (d, 2 H), 8.51-8.62 (m, 1 H), 7.64-7.75 (m, 2
464.2
95.7%

H), 7.39-7.49 (m, 1.3 H), 7.09-7.15 (m, 0.2 H), 6.81-7.00 (m, 3.5
[M + H]⁺

H), 4.92-5.04 (m, 1 H), 3.73-3.87 (m, 0.5 H), 3.43 (td, 0.5 H),

2.83-3.26 (m, 2 H)

1414
(CD₃OD) δ 9.46 (s, 1 H), 8.80-8.89 (m, 2 H), 8.50-8.64 (m, 1 H),
464.2
100%

7.71 (s, 1 H), 7.39-7.52 (m, 1.4 H), 7.09-7.14 (m, 0.2 H), 6.80-
[M + H]⁺

7.00 (m, 3.4 H), 4.94-5.10 (m, 1 H), 3.72-3.89 (m, 0.5 H), 3.43

(td, 0.5 H), 2.83-3.24 (m, 2 H)

1415
(CD₃OD) δ 9.41-9.53 (m, 1 H), 8.80-8.90 (m, 2 H), 8.50-8.66
464.2
94.7%

(m, 1 H), 7.74 (br s, 1 H), 7.40-7.52 (m, 1.4H), 7.09-7.14 (m,
[M + H]*

0.2 H), 6.81-7.00 (m, 3.4 H), 5.03 (br dd, 1 H), 3.70-3.87 (m, 0.5

H), 3.37-3.50 (m, 0.5 H), 2.85-3.24 (m, 2 H)

1416
(CD₃OD) δ 9.27 (s, 1 H), 8.37-8.92 (m, 3 H), 7.88-8.11 (m, 4 H),
461.2
100%

7.55-7.68 (m, 2 H), 7.12-7.43 (m, 2 H), 6.39-6.99 (m, 3 H), 4.49-
[M + H]⁺

4.75 (m, 1 H), 3.38-3.86 (m, 1 H), 3.01-3.14 (m, 1 H), 2.77 (br

dd, 1 H)

1417
(CD₃OD) δ 9.20-9.35 (m, 1 H), 8.24-8.97 (m, 3 H), 7.86-8.13
461.2
100%

(m, 4 H), 7.54-7.72 (m, 2 H), 7.33-7.44 (m, 1 H), 7.13-7.26 (m, 1
[M + H]⁺

H), 6.35-7.03 (m, 3 H), 4.43-4.79 (m, 1 H), 3.38-3.97 (m, 1 H),

3.02-3.16 (m, 1 H), 2.78 (br d, 1 H)

1418
(CD₃OD) δ 7.67-7.80 (m, 2 H), 7.44 (d, 1 H), 6.94-7.32 (m, 3
442.2
100%

H), 6.60-6.80 (m, 1 H), 4.93-5.03 (m, 1 H), 3.81-3.93 (m, 0.6 H),
[M + H]⁺

3.36-3.42 (m, 0.4 H), 2.82-3.19 (m, 2 H), 1.49 (d, 9 H)

1419
(CD₃OD) δ 7.55-7.69 (m, 2 H), 7.29-7.47 (m, 1 H), 6.82-7.21
442.2
99.1%

(m, 3 H), 6.48-6.69 (m, 1 H), 4.82-4.91 (m, 1 H), 3.69-3.83 (m,
[M + H]⁺

0.6 H), 3.24-3.28 (m, 0.4 H), 2.70-3.07 (m, 2 H), 1.37 (d, 9 H)

1420
(CD₃OD) δ 8.61-8.71 (m, 1 H), 8.15-8.26 (m, 1 H), 7.98 (tt, 1
463.1
100%

H), 7.53-7.67 (m, 3 H), 7.25-7.48 (m, 1 H), 6.87-7.21 (m, 3 H),
[M + H]⁺

6.50-6.70 (m, 1 H), 4.83-4.95 (m, 1 H), 3.77-3.87 (m, 0.6 H),

3.24-3.30 (m, 0.4 H), 2.73-3.15 (m, 2 H)

1421
(CD₃OD) δ 8.61-8.75 (m, 1 H), 8.12-8.29 (m, 1 H), 7.98 (tt, 1
463.1
100%

H), 7.53-7.69 (m, 3 H), 7.26-7.49 (m, 1 H), 6.87-7.21 (m, 3 H),
[M + H]⁺

6.48-6.72 (m, 1 H), 4.81-4.93 (m, 1 H), 3.76-3.87 (m, 0.6 H),

3.24-3.30 (m, 0.4 H), 2.72-3.14 (m, 2 H)

1422
(CD₃OD) δ 9.32 (s, 1 H), 8.80 (br d, 1 H), 8.50-8.65 (m, 2 H),
463.2
100%

7.64-7.77 (m, 2 H), 7.42-7.58 (m, 1.2 H), 6.91-7.17 (m, 2.6 H),
[M + H]⁺

6.77-6.87 (m, 1.2 H), 5.10 (br d, 1 H), 3.79 (br t, 0.5 H), 3.42 (br

s, 0.5 H), 2.78-3.23 (m, 2 H)

1423
(CD₃OD) δ 9.31 (br s, 1 H), 8.80 (br d, 1 H), 8.47-8.66 (m, 2 H),
463.2
97.7%

7.64-7.76 (m, 2 H), 7.44 (br d, 1.2 H), 6.90-7.16 (m, 3.6 H),
[M + H]⁺

6.76-6.87 (m, 1.2 H), 5.10 (br d, 1 H), 3.72-3.89 (m, 0.5 H), 3.43

(br s, 0.5 H), 2.81-3.24 (m, 2 H)

1424
(CD₃OD) δ 8.52-8.64 (m, 1 H), 8.45 (d, 1 H), 8.26 (d, 1 H), 7.73
493.1
100%

(br s, 1 H), 7.62 (dd, 1 H), 7.40-7.57 (m, 1.3 H), 6.78-7.16 (m,
[M + H]⁺

3.7 H), 4.95-5.10 (m, 1 H), 4.00 (s, 3 H), 3.72-3.87 (m, 0.5 H),

3.43 (td, 0.5 H), 2.75-3.28 (m, 2 H)

1425
(CD₃OD) δ 8.51-8.65 (m, 1 H), 8.44 (d, 1 H), 8.25 (d, 1 H), 7.73
493.2
94.4%

(br s, 1 H), 7.52-7.64 (m, 1.3 H), 7.38-7.49 (m, 1 H), 6.78-7.16
[M + H]⁺

(m, 3.7 H), 4.95-5.10 (m, 1 H), 4.00 (s, 3 H), 3.74-3.86 (m, 0.5

H), 3.39-3.48 (m, 0.5 H), 2.81-3.27 (m, 2 H)

1426
(CD₃OD) δ 8.40-8.63 (m, 2 H), 7.87 (t, 1 H), 7.58-7.75 (m, 2 H),
481.1
100%

7.29-7.48 (m, 1.3 H), 6.68-7.14 (m, 3.7 H), 4.94 (br dd, 1 H),
[M + H]⁺

3.68-3.81 (m, 0.5 H), 3.36-3.43 (m, 0.5 H), 2.77-3.22 (m, 2 H)

1427
(CD₃OD) δ 8.45-8.70 (m, 2 H), 7.93 (t, 1 H), 7.65-7.79 (m, 2 H),
481.2
99.5%

7.36-7.51 (m, 1.3 H), 6.77-7.16 (m, 3.7 H), 4.94-5.04 (m, 1 H),
[M + H]⁺

3.69-3.86 (m, 0.5 H), 3.42 (td, 0.5 H), 2.81-3.27 (m, 2 H)

1428
(CD₃OD) δ 8.23-8.38 (m, 1 H), 8.11 (br d, 1 H), 7.95 (br t, 1 H),
441.1
100%

7.72 (s, 1 H), 7.54 (br d, 1.3 H), 6.94-7.08 (m, 1.7 H), 6.73-6.86
[M + H]'

(m, 1 H), 6.54-6.72 (m, 1 H), 5.02 (br dd, 1 H), 3.82 (br t, 0.6

H), 3.39-3.51 (m, 0.4 H), 2.96-3.28 (m, 1 H), 2.87 (br d, 1 H),

2.66 (s, 3 H), 2.36-2.56 (m, 3 H)

1429
(CD₃OD) δ 8.24-8.37 (m, 1 H), 8.11 (br d, 1 H), 7.95 (t, 1 H),
441.2
99.3%

7.73 (s, 1 H), 7.54 (d, 1.3 H), 6.95-7.05 (m, 1.7 H), 6.72-6.85 (m,
[M + H]⁺

1 H), 6.57-6.70 (m, 1 H), 4.93-5.06 (m, 1 H), 3.78-3.87 (m, 0.6

H), 3.45 (td, 0.4H), 2.99-3.27 (m, 1 H), 2.81-2.94 (m, 1 H), 2.66

(s, 3 H), 2.40-2.52 (m, 3 H)

1430
(CD₃OD) δ 8.38-8.51 (m, 1 H), 8.11 (d, 1 H), 7.95 (t, 1 H), 7.75
461.1
100%

(br s, 1 H), 7.54 (d, 1.3 H), 7.26-7.36 (m, 1 H), 7.00(s, 0.7H),
[M + H]⁺

6.82-6.92 (m, 1 H), 6.71-6.82 (m, 1 H), 4.92-5.11 (m, 1 H), 3.75-

3.87 (m, 0.6 H), 3.40-3.51 (m, 0.4 H), 2.98-3.28 (m, 1 H), 2.79-

2.94 (m, 1 H), 2.66 (s, 3 H)

1431
(CD₃OD) δ 8.27-8.42 (m, 1 H), 7.99 (d, 1 H), 7.83 (t, 1 H), 7.66
461.2
98.7%

(br s, 1 H), 7.42 (d, 1.3 H), 7.13-7.27 (m, 1 H), 6.88 (s, 0.7 H),
[M + H]⁺

6.70-6.81 (m, 1 H), 6.60-6.70 (m, 1 H), 4.82-4.98 (m, 1 H), 3.62-

3.76 (m, 0.6 H), 3.27-3.40 (m, 0.4 H), 2.84-3.16 (m, 1 H), 2.68-

2.84 (m, 1 H), 2.54 (s, 3 H)

1432
(CD₃OD) δ 8.51-8.65 (m, 1 H), 8.00 (d, 1 H), 7.77-7.89 (m, 1
495.1
100%

H), 7.62 (s, 1 H), 7.47-7.58 (m, 1 H), 7.36-7.47 (m, 1.3 H), 6.80-
[M + H]⁺

6.95 (m, 1.7 H), 6.62-6.76 (m, 1 H), 4.83-4.99 (m, 1 H), 3.63-

3.75 (m, 0.6 H), 3.26-3.40 (m, 0.4 H), 2.86-3.16 (m, 1 H), 2.70-

2.82 (m, 1 H), 2.50-2.58 (m, 3 H)

1433
(CD₃OD) δ 8.52-8.66 (m, 1 H), 7.99 (d, 1 H), 7.77-7.90 (m, 1
495.1
96.5%

H), 7.60-7.70 (m, 1 H), 7.49-7.57 (m, 1 H), 7.38-7.46 (m, 1.3 H),
[M + H]⁺

6.81-6.96 (m, 1.7 H), 6.64-6.77 (m, 1 H), 4.82-4.99 (m, 1 H),

3.62-3.75 (m, 0.6 H), 3.27-3.40 (m, 0.4 H), 2.85-3.17 (m, 1 H),

2.69-2.82 (m, 1 H), 2.43-2.60 (m, 3 H)

1434
(CD₃OD) δ 8.98 (s, 1 H), 8.23-8.78 (m, 2 H), 7.83-8.04 (m, 2 H),
464.2
100%

7.56-7.70 (m, 3 H), 7.16-7.22 (m, 1 H), 6.35-6.95 (m, 4 H), 4.46-
[M + H]⁺

4.73 (m, 1 H), 3.95 (s, 3 H), 3.46-3.77 (m, 1 H), 3.01-3.15 (m, 1

H), 2.70-2.80 (m, 1 H)

1435
(CD₃OD) δ 8.97 (s, 1 H), 8.27-8.77 (m, 2 H), 7.85-8.02 (m, 2 H),
464.2
99.8%

7.55-7.70 (m, 3 H), 7.15-7.22 (m, 1 H), 6.39-7.02 (m, 4 H), 4.47-
[M + H]⁺

4.71 (m, 1 H), 3.95 (s, 3 H), 3.36-3.80 (m, 1 H), 3.00-3.14 (m, 1

H), 2.71-2.81 (m, 1 H)

1436
(CD₃OD) δ 7.66-7.81 (m, 2 H), 7.37-7.60 (m, 1 H), 6.95-7.32
446.1
99.9%

(m, 3 H), 6.60-6.81 (m, 1 H), 4.94-5.02 (m, 1 H), 3.82-3.96 (m,
[M + H]⁺

0.6 H), 3.35-3.40 (m, 0.4 H), 2.82-3.20 (m, 2 H), 1.86-1.97 (m, 6 H)

1437
(CD₃OD) δ 7.56-7.69 (m, 2 H), 7.26-7.49 (m, 1 H), 6.83-7.20
446.1
99.4%

(m, 3 H), 6.48-6.68 (m, 1 H), 4.82-4.90 (m, 1 H), 3.72-3.84 (m,
[M + H]⁺

0.6 H), 3.23-3.27 (m, 0.4 H), 2.70-3.08 (m, 2 H), 1.75-1.83 (m, 6 H)

1438
(CD₃OD) δ 7.83 (dd, 1 H), 7.69-7.80 (m, 2 H), 7.38-7.61 (m, 1
466.1
98.9%

H), 6.98-7.34 (m, 4 H), 6.61-6.80 (m, 1 H), 4.95-5.09 (m, 1 H),
[M + H]⁺

4.05 (d, 3 H), 3.91 (ddd, 0.6 H), 3.36-3.41 (m, 0.4 H), 2.83-3.24

(m, 2 H)

1439
(CD₃OD) δ 7.71 (dd, 1 H), 7.56-7.68 (m, 2 H), 7.26-7.48 (m, 1
466.1
100%

H), 6.84-7.22 (m, 4 H), 6.48-6.70 (m, 1 H), 4.83-4.96 (m, 1 H),
[M + H]⁺

3.93 (d, 3 H), 3.79 (ddd, 0.6 H), 3.23-3.30 (m, 0.4 H), 2.71-3.13

(m, 2 H)

1440
(CD₃OD) δ 8.93 (d, 1 H), 8.36 (s, 1 H), 7.66-7.82 (m, 3 H), 7.45-
502.1
100%

7.58 (m, 1 H), 7.16-7.34 (m, 2.5 H), 6.98 (s, 0.5 H), 6.61-6.83
[M + H]⁺

(m, 1 H), 4.96-5.14 (m, 1 H), 3.86-3.98 (m, 0.6 H), 3.36-3.43 (m,

0.4 H), 2.84-3.21 (m, 2 H)

1441
(CD₃OD) δ 8.93 (d, 1 H), 8.36 (s, 1 H), 7.66-7.83 (m, 3 H), 7.44-
502.1
99.6%

7.58 (m, 1 H), 7.16-7.34 (m, 2.5 H), 6.98 (s, 0.5 H), 6.63-6.80
[M + H]⁺

(m, 1 H), 4.95-5.13 (m, 1 H), 3.86-3.99 (m, 0.6 H), 3.37-3.43 (m,

0.4 H), 2.84-3.22 (m, 2 H)

1442
(CD₃OD) δ 8.21 (dd, 1 H), 7.53-7.73 (m, 3 H), 7.29-7.45 (m, 1
502.2
100%

H), 6.98-7.20 (m, 3.5 H), 6.85 (s, 0.5 H), 6.45-6.67 (m, 1 H),
[M + H]⁺

4.83-4.98 (m, 1 H), 3.74-3.85 (m, 0.6 H), 3.22-3.28 (m, 0.4 H),

2.71-3.11 (m, 2 H)

1443
(CD₃OD) δ 8.23 (dd, 1 H), 7.54-7.73 (m, 3 H), 7.30-7.47 (m, 1
502.1
99.9%

H), 7.02-7.20 (m, 3.5 H), 6.86 (s, 0.5 H), 6.49-6.69 (m, 1 H),
[M + H]⁺

4.83-4.97 (m, 1 H), 3.73-3.86 (m, 0.6 H), 3.24-3.29 (m, 0.4 H),

2.72-3.12 (m, 2 H)

1444
(CD₃OD) δ 9.14 (d, 1 H), 8.47 (s, 1 H), 7.71 (br d, 1 H), 7.50-
504.1
100%

7.67 (m, 1.5 H), 7.13-7.27 (m, 1 H), 6.94-7.10 (m, 1.5 H), 6.59-
[M + H]⁺

6.86 (m, 1 H), 5.11 (br dd, 1 H), 3.83-4.02 (m, 0.5 H), 3.36-3.48

(m, 0.5 H), 2.80-3.25 (m, 2 H)

1445
(CD₃OD) δ 9.02 (d, 1 H), 8.36 (s, 1 H), 7.60 (br d, 1 H), 7.36-
504.1
99.6%

7.55 (m, 1.5 H), 7.01-7.13 (m, 1 H), 6.84-6.99 (m, 1.5 H), 6.48-
[M + H]⁺

6.79 (m, 1 H), 4.99 (br dd, 1 H), 3.74-3.86 (m, 0.5 H), 3.25-3.36

(m, 0.5 H), 2.66-3.15 (m, 2 H)

1446
(CD₃OD) δ 9.15 (d, 1 H), 8.48 (s, 1 H), 7.72 (d, 1 H), 7.40-7.54
484.1
100%

(m, 1.5 H), 7.13 (ddd, 1 H), 7.00 (s, 0.5 H), 6.72 (dd, 1 H), 6.45-
[M + H]⁺

6.65 (m, 1 H), 5.07 (dd, 1 H), 3.87-4.01 (m, 0.5 H), 3.36-3.47

(m, 0.5 H), 2.82-3.25 (m, 2 H), 2.51-2.73 (m, 3 H)

1447
(CD₃OD) δ 9.15 (d, 1 H), 8.48 (s, 1 H), 7.71 (d, 1 H), 7.40-7.56
484.1
99.7%

(m, 1.5 H), 7.07-7.21 (m, 1 H), 7.00 (s, 0.5 H), 6.66-6.78 (m, 1
[M + H]⁺

H), 6.43-6.65 (m, 1 H), 5.07 (br dd, 1 H), 3.84-4.04 (m, 0.5 H),

3.39-3.47 (m, 0.5 H), 2.80-3.26 (m, 2 H), 2.50-2.74 (m, 3 H)

1448
(CD₃OD) δ 8.38-8.50 (m, 1 H), 7.70 (s, 1 H), 7.56-7.64 (m, 1 H),
378.2
100%

7.41-7.52 (m, 0.3 H), 7.13-7.28 (m, 1 H), 6.92-6.99 (m, 0.7 H),
[M + H]⁺

6.79-6.91 (m, 1 H), 6.46-6.71 (m, 1 H), 4.93-5.04 (m, 1 H), 3.65-

3.84 (m, 0.7 H), 3.34-3.43 (m, 1 H), 3.28-3.31 (m, 0.3 H), 2.92-

3.22 (m, 1 H), 2.83 (br dd, 1 H), 1.45 (d, 6 H)

1449
(CD₃OD) δ 8.33-8.52 (m, 1 H), 7.71 (s, 1 H), 7.55-7.64 (m, 1 H),
378.2
100%

7.45-7.49 (m, 0.3 H), 7.14-7.25 (m, 1 H), 6.92-6.97 (m, 0.7 H),
[M + H]⁺

6.83-6.90 (m, 1 H), 6.53-6.65 (m, 1 H), 4.91 - 5.02 (m, 1 H),

3.75 (ddd, 0.7 H), 3.34-3.44 (m, 1 H), 3.29-3.31 (m, 0.3 H) ,

2.90-3.24 (m, 1 H), 2.83 (br dd, 1 H), 1.45 (d, 6 H)

1450
(CD₃OD) δ 8.24-8.37 (m, 1 H), 7.68-7.75 (m, 1 H), 7.46 (s, 0.3
392.2
100%

H), 6.97-7.03 (m, 1 H), 6.95 (s, 0.7H), 6.76-6.82 (m, 1 H), 6.53-
[M + H]⁺

6.66 (m, 1 H), 4.97 (br dd, 1 H), 3.70-3.80 (m, 1 H), 3.34-3.44

(m, 1 H), 2.93-3.21 (m, 1 H), 2.83 (br dd, 1 H), 2.38-2.49 (m, 3

H), 1.45 (d, 6 H)

1451
(CD₃OD) δ 8.23-8.37 (m, 1 H), 7.70 (s, 1 H), 7.40-7.50 (m, 0.3
392.2
99.3%

H), 6.97-7.03 (m, 1 H), 6.95 (s, 0.7 H), 6.75-6.83 (m, 1 H), 6.52-
[M + H]⁺

6.67 (m, 1 H), 4.97 (br dd, 1 H), 3.68-3.82 (m, 0.7 H), 3.34-3.44

(m, 1 H), 3.29-3.32 (m, 0.3 H), 2.93-3.21 (m, 1 H), 2.77-2.88 (m,

1 H), 2.37-2.50 (m, 3 H), 1.45 (d, 6 H)

1452
(CD₃OD) δ 8.27-8.43 (m, 1 H), 7.71 (s, 1 H), 7.37 (br d, 0.3 H),
396.2
100%

6.90-7.04 (m, 1.7 H), 6.80-6.89 (m, 1 H), 6.68-6.79 (m, 1 H),
[M + H]⁺

5.00 (dd, 1 H), 3.69-3.80 (m, 0.7 H), 3.34-3.44 (m, 1 H), 3.30 (br

d, 0.3 H), 2.94-3.22 (m, 1 H), 2.84 (br dd, 1 H), 1.45 (d, 6H)

1453
(CD₃OD) δ 8.26-8.43 (m, 1 H), 7.71 (s, 1 H), 7.36-7.54 (m, 0.3
396.1
99.5%

H), 6.59-7.09 (m, 3.7 H), 4.92-5.04 (m, 1 H), 3.68-3.81 (m, 0.7
[M + H]⁺

H), 3.34-3.45 (m, 1 H), 3.25-3.30 (m, 0.3 H), 2.92-3.23 (m, 1 H),

2.84 (br dd, 1 H), 1.45 (d, 6 H)

1454
(CD₃OD) δ 8.45 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.85 (t, 1
382.1
100%

H), 6.65 (s, 1 H), 6.27 (s, 1 H), 4.21 (dd, 1 H), 3.62-3.77 (m, 1
[M + H]⁺

H), 2.95-3.08 (m, 1 H), 2.79 (br dd, 1 H), 2.04-2.13 (m, 1 H),

1.04-1.15 (m, 4 H)

1455
(CD₃OD) δ 8.45 (d, 1 H), 7.68 (s, 1 H), 7.31 (d, 1 H), 6.86 (t, 1
382.1
99.5%

H), 6.65 (s, 1 H), 6.27 (br s, 1 H), 4.21 (dd, 1 H), 3.61-3.74 (m, 1
[M + H]⁺

H), 2.97-3.11 (m, 1 H), 2.80 (br dd, 1 H), 1.98-2.16 (m, 1 H),

1.03-1.14 (m, 4 H)

1456
(DMSO-d₆) δ 12.02-12.24 (m, 1 H), 8.00 (d, 1 H), 7.47-7.71 (m,
434.2
92.8%

2 H), 7.17-7.42 (m, 1.4 H), 6.94-7.02 (m, 1 H), 6.66-6.93 (m, 2.6
[M + H]⁺

H), 4.77-4.96 (m, 1 H), 4.00 (s, 3 H), 3.60-3.86 (m, 0.8 H), 3.37

(br s, 0.2 H), 2.85-3.10 (m, 1 H), 2.69-2.84 (m, 1 H)

1457
(DMSO-d₆) δ 12.09 (br s, 1 H), 8.00 (d, 1 H), 7.48-7.70 (m, 2
434.2
97.8%

H), 7.19-7.42 (m, 1.4 H), 6.94-7.01 (m, 1 H), 6.70-6.94 (m, 2.6
[M + H]⁺

H), 4.72-4.96 (m, 1 H), 4.00 (s, 3 H), 3.64-3.84 (m, 0.7 H), 3.35-

3.40 (m, 0.3 H), 2.84-3.11 (m, 1 H), 2.70-2.84 (m, 1 H)

1458
(DMSO-d₆) δ 11.87-12.43 (m, 1 H), 8.70 (br d, 1 H), 8.10 (br t, 1
449.2
100%

H), 7.83 (dt, 1 H), 7.49-7.67 (m, 2 H), 7.29 (br d, 1 H), 7.15 (br
[M + H]⁺

s, 0.3 H), 6.69-6.96 (m, 2.7 H), 4.83 (br dd, 1 H), 3.76 (br s, 0.7

H), 3.36-3.46 (m, 0.3 H), 2.69-3.13 (m, 2 H)

1459
(DMSO-d₆) δ 11.96-12.28 (m, 1 H), 8.70 (br d, 1 H), 8.11 (br t, 1
449.1
100%

H), 7.83 (dt, 1 H), 7.47-7.69 (m, 2 H), 7.21-7.39 (m, 1 H), 7.14
[M + H]⁺

(s, 0.3 H), 6.69-6.99 (m, 2.7 H), 4.83 (br dd, 1 H), 3.62-3.86 (m,

0.7 H), 3.36-3.44 (m, 0.3 H), 2.71-3.13 (m, 2 H)

1460
(DMSO-d₆) δ 12.11 (br s, 1 H), 9.32-9.65 (m, 1 H), 8.83-9.01
432.1
100%

(m, 2 H), 7.50-7.72 (m, 2 H), 7.21-7.39 (m, 1 H), 7.12 (s, 0.3 H),
[M + H]⁺

6.68-7.00 (m, 2.7 H), 4.83 (br dd, 1 H), 3.64-3.87 (m, 0.7 H),

3.40 (br t, 0.3 H), 2.72-3.13 (m, 2 H)

1461
(DMSO-d₆) δ 12.05-12.26 (m, 1 H), 9.18-9.73 (m, 1 H), 8.94 (br
432.1
100%

d, 2 H), 7.49-7.70 (m, 2 H), 7.22-7.39 (m, 1 H), 7.12 (s, 0.3H),
[M + H]⁺

6.71-6.97 (m, 2.7 H), 4.83 (br d, 1 H), 3.78 (br t, 0.7 H), 3.40 (br

s, 0.3 H), 2.71-3.15 (m, 2 H)

1462
(CD₃OD) δ 7.92-8.21 (m, 1 H), 7.71 (d, 1 H), 7.59 (s, 0.3 H),
448.1
100%

7.37-7.53 (m, 1 H), 7.16-7.33 (m, 1 H), 6.98 (s, 0.7 H), 6.55-6.87
[M + H]⁺

(m, 2 H), 5.13 (br dd, 1 H), 3.91 (s, 3 H), 3.41-3.85 (m, 1 H),

2.95-3.26 (m, 1 H), 2.79-2.93 (m, 1 H), 2.64-2.74 (m, 3 H)

1463
(CD₃OD) δ 7.91-8.13 (m, 1 H), 7.71 (d, 1 H), 7.59 (s, 0.4H),
448.1
96.8%

7.42-7.54 (m, 1 H), 7.15-7.37 (m, 1 H), 6.98 (s, 0.6 H), 6.50-6.89
[M + H]⁺

(m, 2 H), 5.07-5.17 (m, 1 H), 3.91 (s, 3 H), 3.45-3.85 (m, 1 H),

2.98-3.23 (m, 1 H), 2.80-2.92 (m, 1 H), 2.66-2.74 (m, 3 H)

1464
(CD₃OD) δ 8.41-8.63 (m, 1 H), 8.05 (d, 1 H), 7.65-7.96 (m, 2
477.2
100%

H), 7.34-7.60 (m, 2.3 H), 6.73-7.15 (m, 3.7 H), 5.03 (br dd, 1 H),
[M + H]⁺

3.71-3.86 (m, 0.5 H), 3.35-3.46 (m, 0.5 H), 2.79-3.24 (m, 2 H),

2.62 (s, 3 H)

1465
(CD₃OD) δ 8.49-8.63 (m, 1 H), 8.09 (d, 1 H), 7.80-7.99 (m, 2
477.1
98.5%

H), 7.38-7.60 (m, 2.3 H), 6.74-7.17 (m, 3.7 H), 4.95-5.11 (m, 1
[M + H]⁺

H), 3.78 (ddd, 0.5 H), 3.41 (td, 0.5 H), 2.80-3.27 (m, 2 H), 2.64

(s, 3 H)

1466
(CD₃OD) δ 8.49-8.63 (m, 1 H), 8.18-8.35 (m, 1 H), 7.39-7.73
480.2
100%

(m, 2.3 H), 6.75-7.13 (m, 3.7 H), 5.09 (dd, 1 H), 3.91 (s, 3 H),
[M + H]⁺

3.70-3.81 (m, 0.5 H), 3.39 (td, 0.5 H), 2.79-3.24 (m, 2 H), 2.47-

2.60 (m, 3 H)

1467
(CD₃OD) δ 8.49-8.63 (m, 1 H), 8.20-8.32 (m, 1 H), 7.35-7.75
480.2
99.8%

(m, 2.3 H), 6.76-7.14 (m, 3.7 H), 5.09 (br dd, 1 H), 3.91 (s, 3 H),
[M + H]⁺

3.70-3.81 (m, 0.5 H), 3.39 (td, 0.5 H), 2.80-3.24 (m, 2 H), 2.43-

2.61 (m, 3 H)

1468
(CD₃OD) δ 9.32 (s, 1 H), 8.82 (dd, 1 H), 8.56 (ddt, 1 H), 7.65-
463.2
100%

7.81 (m, 3 H), 6.99-7.61 (m, 4 H), 6.62-6.84 (m, 1 H), 4.96-5.16
[M + H]⁺

(m, 1 H), 3.88-4.00 (m, 0.6 H), 3.36-3.44 (m, 0.4 H), 2.84-3.26

(m, 2 H)

1469
(CD₃OD) δ 9.32 (s, 1 H), 8.76-8.86 (m, 1 H), 8.56 (ddt, 1 H),
463.1
99.6%

7.65-7.80 (m, 3 H), 6.99-7.59 (m, 4 H), 6.62-6.83 (m, 1 H), 4.95-
[M + H]⁺

5.14 (m, 1 H), 3.89-3.99 (m, 0.6 H), 3.36-3.44 (m, 0.4 H), 2.85-

3.27 (m, 2 H)

1470
(CD₃OD) δ 8.27-8.44 (m, 1 H), 8.10-8.18 (m, 1 H), 7.96 (t, 1 H),
445.2
99.3%

7.75 (br s, 1 H), 7.54 (d, 1.3 H), 6.90-7.08 (m, 1.7 H), 6.74-6.89
[M + H]⁺

(m, 2 H), 5.05 (br dd, 1 H), 3.75-3.87 (m, 0.5 H), 3.39-3.53 (m,

0.5 H), 2.82-3.29 (m, 2 H), 2.67 (s, 3 H)

1471
(CD₃OD) δ 8.17-8.29 (m, 1 H), 7.97-8.03 (m, 1 H), 7.84 (t, 1 H),
445.1
88.9%

7.67 (br d, 1 H), 7.42 (d, 1.3 H), 6.81-6.92 (m, 1.7 H), 6.66-6.79
[M + H]⁺

(m, 2 H), 4.94 (br dd, 1 H), 3.64-3.74 (m, 0.5 H), 3.26-3.39 (m,

0.5 H), 2.70-3.17 (m, 2 H), 2.54 (s, 3 H)

1472
(CD₃OD) δ 9.02 (s, 1 H), 8.35 (s, 1 H), 8.11-8.26 (m, 1 H), 7.34-
484.1
100%

7.84 (m, 1.3 H), 6.88 (br t, 1.7 H), 6.68 (br s, 1 H), 6.40-6.59 (m,
[M + H]⁺

1 H), 4.94 (br dd, 1 H), 3.68 (br t, 0.7 H), 3.31 (br t, 0.3 H), 2.67-

3.16 (m, 2 H), 2.26-2.41 (m, 3 H)

1473
(CD₃OD) δ 9.02 (s, 1 H), 8.35 (s, 1 H), 8.11-8.23 (m, 1 H), 7.43-
484.1
99.6%

7.64 (m, 1.3 H), 6.82-6.91 (m, 1.7 H), 6.61-6.71 (m, 1 H), 6.42-
[M + H]⁺

6.57 (m, 1 H), 4.94 (br dd, 1 H), 3.60-3.75 (m, 0.7 H), 3.25-3.35

(m, 0.3 H), 2.67-3.14 (m, 2 H), 2.26-2.39 (m, 3 H)

1474
(CD₃OD) δ 8.52 (d, 1 H), 7.71 (s, 1 H), 7.41-7.59 (m, 1.4 H),
488.1
100%

7.18-7.32 (m, 2 H), 6.99 (s, 0.6 H), 6.72-6.87 (m, 1 H), 6.61-6.71
[M + H]⁺

(m, 1 H), 5.08 (br dd, 1 H), 3.79-3.94 (m, 0.6 H), 3.40-3.51 (m,

0.4 H), 3.14-3.24 (m, 0.7 H), 3.03 (br t, 0.3 H), 2.87 (br d, 1 H)

1475
(CD₃OD) δ 8.52 (d, 1 H), 7.72 (br s, 1 H), 7.42-7.59 (m, 1.3 H),
488.1
100%

7.19-7.34 (m, 2 H), 6.99 (s, 0.7 H), 6.72-6.88 (m, 1 H), 6.56-6.71
[M + H]⁺

(m, 1 H), 5.08 (br dd, 0.6 H), 4.97 (br d, 0.4 H), 3.80-3.91 (m,

0.6 H), 3.40-3.54 (m, 0.4 H), 3.13-3.28 (m, 0.8 H), 2.98-3.09 (m,

0.2 H), 2.87 (br d, 1 H)

1476
(CD₃OD) δ 8.35-8.54 (m, 2 H), 7.49-7.75 (m, 1 H), 7.25-7.34
504.1
100%

(m, 2 H), 6.70-7.00 (m, 3 H), 4.94-5.09 (m, 1 H), 3.73-3.84 (m,
[M + H]⁺

0.6 H), 3.41 (br dd, 0.4 H), 3.15-3.26 (m, 0.7 H), 3.00 (br d, 0.3

H), 2.80-2.90 (m, 1 H)

1477
(CD₃OD) δ 8.37-8.53 (m, 2 H), 7.49-7.73 (m, 1 H), 7.25-7.32
504.1
88.6%

(m, 2 H), 6.71-6.98 (m, 3 H), 4.92-5.09 (m, 1 H), 3.72-3.84 (m,
[M + H]⁺

0.7 H), 3.41 (td, 0.3 H), 3.14-3.25 (m, 0.7 H), 2.95-3.07 (m, 0.3

H), 2.81-2.89 (m, 1 H)

1478
(CD₃OD) δ 8.49 (d, 1 H), 8.23-8.33 (m, 1 H), 7.50-7.75 (m, 1
484.2
100%

H), 7.26 (d, 1 H), 6.94-7.01 (m, 2 H), 6.73-6.81 (m, 1 H), 6.58-
[M + H]⁺

6.67 (m, 1 H), 4.91-5.06 (m, 1 H), 3.74-3.84 (m, 0.7 H), 3.43 (td,

0.3 H), 3.14-3.25 (m, 0.7 H), 2.96-3.06 (m, 0.3 H), 2.78-2.89 (m,

1 H), 2.39-2.48 (m, 3 H)

1479
(CD₃OD) δ 8.50 (d, 1 H), 8.22-8.33 (m, 1 H), 7.53-7.90 (m, 1
484.1
87.8%

H), 7.26 (d, 1 H), 6.94-7.03 (m, 2 H), 6.74-6.82 (m, 1 H), 6.59-
[M + H]⁺

6.68 (m, 1 H), 4.91-5.09 (m, 1 H), 3.72-3.84 (m, 0.7 H), 3.43 (td,

0.3 H), 3.16-3.26 (m, 0.7 H), 2.97-3.08 (m, 0.3 H), 2.87 (br dd, 1

H), 2.38-2.48 (m, 3 H)

1480
(CD₃OD) δ 8.48-8.63 (m, 2 H), 7.70 (s, 1.3 H), 7.44 (br d, 1 H),
520.2
100%

7.08-7.30 (m, 1.2 H), 6.73-7.01 (m, 3.5 H), 4.93-5.09 (m, 1 H),
[M + H]⁺

3.71-3.87 (m, 0.7 H), 3.36-3.44 (m, 0.3 H), 3.15-3.26 (m, 0.7 H),

2.97-3.06 (m, 0.3 H), 2.79-2.90 (m, 1 H)

1481
(CD₃OD) δ 8.47-8.64 (m, 2 H), 7.53-7.73 (m, 1.3 H), 7.44 (br d,
520.2
89.6%

1 H), 7.09-7.29 (m, 1.2 H), 6.74-7.01 (m, 3.5 H), 4.93-5.10 (m, 1
[M + H]⁺

H), 3.73-3.83 (m, 0.7 H), 3.40 (td, 0.3 H), 3.16-3.25 (m, 0.7 H),

3.01 (br s, 0.3 H), 2.81-2.90 (m, 1 H)

1482
(CD₃OD) δ 8.49 (d, 1 H), 8.26-8.38 (m, 1 H), 7.46-7.73 (m, 1.3
488.2
87.1%

H), 7.27 (d, 1 H), 6.72-7.01 (m, 3.7 H), 4.92-5.08 (m, 1 H), 3.79
[M + H]⁺

(ddd, 0.7 H), 3.43 (td, 0.3 H), 3.12-3.24 (m, 0.7 H), 2.95-3.06

(m, 0.3 H), 2.79-2.90 (m, 1 H)

1483
(CD₃OD) δ 8.49 (d, 1 H), 8.27-8.37 (m, 1 H), 7.49-7.71 (m, 1.3
488.2
90.0%

H), 7.26 (d, 1 H), 6.73-7.00 (m, 3.7 H), 4.92-5.08 (m, 1 H), 3.79
[M + H]⁺

(ddd, 0.7 H), 3.43 (td, 0.3 H), 3.12-3.24 (m, 0.7 H), 2.95-3.07

(m, 0.3 H), 2.78-2.90 (m, 1 H)

1484
(CD₃OD) δ 8.37-8.53 (m, 1 H), 7.71 (s, 1 H), 7.45 (s, 0.3 H),
412.1
100%

7.28-7.35 (m, 1 H), 6.94 (s, 0.7 H), 6.81-6.90 (m, 1 H), 6.64-6.79
[M + H]⁺

(m, 1 H), 5.00 (br dd, 1 H), 3.67-3.81 (m, 0.7 H), 3.34-3.45 (m,

1.3 H), 2.93-3.21 (m, 1 H), 2.84 (br dd, 1 H), 1.46 (d, 6 H)

1485
(CD₃OD) δ 8.39-8.50 (m, 1 H), 7.71 (s, 1 H), 7.45 (s, 0.3 H),
412.1
96.2%

7.27-7.36 (m, 1 H), 6.94 (s, 0.7 H), 6.83-6.91 (m, 1 H), 6.64-6.79
[M + H]⁺

(m, 1 H), 5.00 (br dd, 1 H), 3.64-3.85 (m, 0.7 H), 3.34-3.45 (m,

1.3 H), 2.92-3.22 (m, 1 H), 2.84 (br dd, 1 H), 1.46 (d, 6 H)

1486
(CD₃OD) δ 8.62-8.75 (m, 1 H), 7.60-7.76 (m, 2 H), 7.41 (s, 0.3
446.2
100%

H), 6.89-7.07 (m, 1.7 H), 6.70-6.84 (m, 1 H), 4.95-5.07 (m, 1 H),
[M + H]⁺

3.69-3.79 (m, 1 H), 3.35-3.45 (m, 1 H), 2.91-3.25 (m, 1 H), 2.84

(br d, 1 H), 1.38-1.51 (m, 6 H)

1487
(CD₃OD) δ 8.62-8.78 (m, 1 H), 7.60 (s, 2 H), 7.40-7.51 (m, 0.3
446.2
99.8%

H), 6.90-7.06 (m, 1.7 H), 6.69-6.85 (m, 1 H), 4.93-5.06 (m, 1 H),
[M + H]⁺

3.84 (br d, 1 H), 3.35-3.46 (m, 1 H), 2.91-3.24 (m, 1 H), 2.84 (br

dd, 1 H), 1.36-1.51 (m, 6 H)

1488
(CD₃OD) δ 7.70 (d, 1 H), 7.54-7.66 (m, 1 H), 7.38-7.51 (m, 0.4
412.1
100%

H), 7.14-7.24 (m, 1 H), 7.01-7.09 (m, 1 H), 6.96 (br s, 0.6 H),
[M + H]⁺

6.79 (s, 0.6 H), 6.65 (s, 0.4 H), 4.92-5.05 (m, 1 H), 3.80-3.97 (m,

0.6 H), 3.34-3.44 (m, 1.4 H), 2.91-3.23 (m, 1 H), 2.74-2.90 (m, 1

H), 1.45 (d, 6 H)

1489
(CD₃OD) δ 7.80 (d, 1 H), 7.56-7.68 (m, 1 H), 7.49 (s, 0.4 H),
412.1
99.7%

7.14-7.24 (m, 1 H), 7.02-7.09 (m, 1 H), 6.98 (s, 0.6 H), 6.80 (s,
[M + H]⁺

0.6 H), 6.67 (s, 0.4 H), 4.93-5.06 (m, 1 H), 3.78-3.94 (m, 0.7 H),

3.34-3.44 (m, 1.3 H), 2.91-3.24 (m, 1 H), 2.86 (dd, 1 H), 1.45 (d,

6 H)

1490
(CD₃OD) δ 7.69 (d, 1 H), 7.37-7.52 (m, 1.4 H), 7.08-7.18 (m, 1
392.2
100%

H), 6.97 (br s, 0.6 H), 6.68-6.77 (m, 1 H), 6.41-6.63 (m, 1 H),
[M + H]⁺

4.92-5.01 (m, 1 H), 3.82-3.95 (m, 0.7 H), 3.34-3.42 (m, 1.3 H),

2.92-3.21 (m, 1 H), 2.84 (br d, 1 H), 2.55-2.73 (m, 3 H), 1.45 (d,

6 H)

1491
(CD₃OD) δ 7.70 (d, 1 H), 7.37-7.54 (m, 1.4 H), 7.07-7.19 (m, 1
392.2
99.2%

H), 6.97 (s, 0.6 H), 6.68-6.78 (m, 1 H), 6.41-6.65 (m, 1 H), 4.92-
[M + H]⁺

5.01 (m, 1 H), 3.81-3.96 (m, 0.7 H), 3.34-3.43 (m, 1.3 H), 2.91-

3.20 (m, 1 H), 2.78-2.90 (m, 1 H), 2.56-2.72 (m, 3 H), 1.45 (d, 6 H)

1492
(CD₃OD) δ 7.65-7.80 (m, 2 H), 7.58 (s, 0.2 H), 7.40-7.50 (m, 1
428.2
100%

H), 7.25-7.32 (m, 1.3 H), 7.14-7.24 (m, 1 H), 6.95 (s, 0.5 H),
[M + H]⁺

6.58-6.81 (m, 1 H), 4.92-5.03 (m, 1 H), 3.79-3.95 (m, 0.6 H),

3.34-3.40 (m, 1.4 H), 2.92-3.21 (m, 1 H), 2.84 (br d, 1 H), 1.45

(d, 6 H)

1493
(CD₃OD) δ 7.64-7.81 (m, 2 H), 7.58 (s, 0.2 H), 7.39-7.48 (m, 1.3
428.2
94.2%

H), 7.24-7.35 (m, 1 H), 7.12-7.23 (m, 1 H), 6.95 (s, 0.5 H), 6.54-
[M + H]⁺

6.80 (m, 1 H), 4.92-5.05 (m, 1 H), 3.77-3.96 (m, 0.6 H), 3.34-

3.41 (m, 1.4 H), 2.91-3.22 (m, 1 H), 2.75-2.89 (m, 1 H), 1.45(d,

6 H)

1494
(DMSO-d₆) δ 11.64-12.72 (m, 1 H), 8.50-9.07 (m, 1 H), 8.17-
445.1
100%

8.49 (m, 1 H), 7.61-7.74 (m, 1 H), 7.45-7.61 (m, 2 H), 7.21-7.36
[M + H]⁺

(m, 1 H), 6.52-7.19 (m, 3 H), 4.74-4.96 (m, 1 H), 3.69-3.83 (m, 1

H), 2.97-3.10 (m, 2 H), 2.82-2.90 (m, 3 H), 2.75-2.80 (m, 1 H)

1495
(DMSO-d₆) δ 11.80-12.36 (m, 1 H), 8.70 (br s, 1 H), 8.14-8.47
445.1
98.2%

(m, 1 H), 7.41-7.73 (m, 3 H), 7.19-7.37 (m, 1 H), 7.10(s, 1H),
[M + H]⁺

6.64-6.95 (m, 3 H), 4.67-4.95 (m, 1 H), 3.58-3.94 (m, 1 H), 2.98-

3.14 (m, 1 H), 2.82-2.90 (m, 3 H), 2.69-2.80 (m, 1 H)

1496
(CD₃OD) δ 8.03-8.27 (m, 1 H), 7.95 (t, 1 H), 7.71 (s, 1 H), 7.32-
445.1
100%

7.63 (m, 2.3 H), 7.20-7.31 (m, 1 H), 7.00 (s, 0.7 H), 6.71-6.87
[M + H]⁺

(m, 1 H), 6.56-6.71 (m, 1 H), 5.01-5.13 (m, 1 H), 3.79-3.93 (m,

0.7 H), 3.48 (br dd, 0.3 H), 2.98-3.25 (m, 1 H), 2.88 (br dd, 1 H),

2.66 (s, 3 H)

1497
(CD₃OD) δ 8.06-8.31 (m, 1 H), 7.96 (t, 1 H), 7.71 (s, 1 H), 7.35-
445.2
91.5%

7.64 (m, 2.4 H), 7.18-7.34 (m, 1 H), 7.00 (s, 0.6 H), 6.50-6.91
[M + H]⁺

(m, 2 H), 4.97-5.09 (m, 1 H), 3.43-3.91 (m, 1 H), 2.97-3.25 (m, 1

H), 2.88 (br dd, 1 H), 2.66 (s, 3 H)

1498
(CD₃OD) δ 9.04 (dd, 2 H), 7.68-7.77 (m, 3 H), 6.97-7.45 (m, 4
464.2
100%

H), 6.60-6.80 (m, 1 H), 4.96-5.04 (m, 1 H), 3.88-3.99 (m, 0.6 H),
[M + H]⁺

3.34-3.39 (m, 0.4 H), 2.84-3.23 (m, 2 H)

1499
(CD₃OD) δ 9.05 (dd, 2 H), 7.68-7.80 (m, 3 H), 6.98-7.47 (m, 4
464.2
99.7%

H), 6.59-6.82 (m, 1 H), 4.96-5.04 (m, 1 H), 3.87-4.00 (m, 0.6 H),
[M + H]⁺

3.35-3.40 (m, 0.4 H), 2.84-3.27 (m, 2 H)

1500
(CD₃OD) δ 8.64-8.69 (m, 1 H), 8.47 (d, 1 H), 7.68-7.81 (m, 2
477.1
100%

H), 7.35-7.61 (m, 2 H), 6.96-7.32 (m, 3 H), 6.64-6.83 (m, 1 H),
[M + H]

4.96-5.16 (m, 1 H), 3.89-4.01 (m, 0.5 H), 3.36-3.45 (m, 0.5 H),

2.86-3.27 (m, 5 H)

1501
(CD₃OD) δ 8.63-8.68 (m, 1 H), 8.47 (br d, 1 H), 7.68-7.81 (m, 2
477.2
99.4%

H), 7.35-7.61 (m, 2 H), 6.97-7.33 (m, 3 H), 6.62-6.85 (m, 1 H),
[M + H]⁺

4.98-5.17 (m, 1 H), 3.88-4.00 (m, 0.5 H), 3.37-3.46 (m, 0.5 H),

2.85-3.26 (m, 5 H)

1502
(CD₃OD) δ 9.03 (s, 1 H), 8.36 (s, 1 H), 7.58-7.79 (m, 2 H), 7.24-
520.1
100%

7.51 (m, 1 H), 6.83-7.24 (m, 3 H), 6.49-6.73 (m, 1 H), 4.84-5.05
[M + H]⁺

(m, 1 H), 3.72-3.87 (m, 0.5 H), 3.25-3.32 (m, 0.5 H), 2.84-3.14

(m, 1 H), 2.72-2.84 (m, 1 H)

1503
(CD₃OD) δ 9.03 (s, 1 H), 8.36 (s, 1 H), 7.55-7.74 (m, 2 H), 7.31-
520.1
97.1%

7.50 (m, 1 H), 6.83-7.28 (m, 3 H), 6.49-6.71 (m, 1 H), 4.85-4.98
[M + H]⁺

(m, 1 H), 3.75-3.85 (m, 0.5 H), 3.24-3.31 (m, 0.5 H), 2.85-3.13

(m, 1 H), 2.69-2.85 (m, 1 H)

1504
(CD₃OD) δ 8.98-9.09 (m, 1 H), 8.25-8.42 (m, 2 H), 7.60 (s, 1 H),
504.1
100%

7.45 (s, 0.3 H), 7.14-7.26 (m, 1 H), 6.85 (s, 0.7 H), 6.70-6.81 (m,
[M + H]⁺

1 H), 6.59-6.69 (m, 1 H), 4.83-5.03 (m, 1 H), 3.67 (ddd, 0.7 H),

3.30 (td, 0.3 H), 2.83-3.14 (m, 1 H), 2.66-2.81 (m, 1 H)

1505
(CD₃OD) δ 9.09-9.19 (m, 1 H), 8.37-8.51 (m, 2 H), 7.72 (s, 1 H),
504.1
99.5%

7.57 (br s, 0.3 H), 7.26-7.37 (m, 1 H), 6.97 (br s, 0.7 H), 6.81-
[M + H]⁺

6.91 (m, 1 H), 6.71-6.80 (m, 1 H), 4.94-5.13 (m, 1 H), 3.73-3.85

(m, 0.7 H), 3.42 (td, 0.3 H), 2.94-3.28 (m, 1 H), 2.77-2.94 (m, 1 H)

1506
(CD₃OD) δ 8.52 (d, 1 H), 8.38-8.50 (m, 1 H), 7.71 (s, 1 H), 7.48-
470.1
100%

7.67 (m, 1.3 H), 7.14-7.33 (m, 2 H), 6.93-7.05 (m, 0.7 H), 6.78-
[M + H]⁺

6.92 (m, 1 H), 6.57-6.70 (m, 1 H), 4.94-5.09 (m, 1 H), 3.66-3.91

(m, 0.7 H), 3.42-3.54 (m, 0.3 H), 2.94-3.27 (m, 1 H), 2.74-2.91

(m, 1 H)

1507
(CD₃OD) δ 8.52 (d, 1 H), 8.39-8.49 (m, 1 H), 7.71 (s, 1 H), 7.53-
470.2
98.9%

7.65 (m, 1.3 H), 7.29 (d, 1 H), 7.16-7.25 (m, 1 H), 6.99 (s, 0.7
[M + H]⁺

H), 6.82-6.91 (m, 1 H), 6.59-6.68 (m, 1 H), 4.94-5.08 (m, 1 H),

3.74-3.86 (m, 0.7 H), 3.39-3.47 (m, 0.3 H), 2.97-3.26 (m, 1 H),

2.78-2.91 (m, 1 H)

1508
(CD₃OD) δ 8.40-8.59 (m, 1 H), 7.72 (d, 1 H), 7.54-7.66 (m, 1
504.1
100%

H), 7.44-7.53 (m, 0.4 H), 7.29 (t, 1 H), 7.12-7.24 (m, 1 H), 6.95-
[M + H]⁺

7.09 (m, 1.6 H), 6.54-6.87 (m, 1 H), 4.93-5.13 (m, 1 H), 3.80-

4.06 (m, 0.5 H), 3.34-3.48 (m, 0.5 H), 2.96-3.28 (m, 1 H), 2.88

(br d, 1 H)

1509
(CD₃OD) δ 8.52 (t, 1 H), 7.72 (d, 1 H), 7.55-7.67 (m, 1 H), 7.49
504.1
99.5%

(s, 0.4 H), 7.29 (br s, 1 H), 7.12-7.23 (m, 1 H), 6.95-7.09 (m, 1.6
[M + H]⁺

H), 6.60-6.85 (m, 1 H), 4.93-5.13 (m, 1 H), 3.84-4.00 (m, 0.5 H),

3.35-3.45 (m, 0.5 H), 2.95-3.27 (m, 1 H), 2.82-2.93 (m, 1 H)

1510
(CD₃OD) δ 8.43-8.61 (m, 1 H), 7.65-7.79 (m, 1 H), 7.36-7.56
484.2
100%

(m, 1.5 H), 7.29 (t, 1 H), 7.07-7.20 (m, 1 H), 7.01(s, 0.5H),
[M + H]⁺

6.66-6.78 (m, 1 H), 6.40-6.66 (m, 1 H), 4.95-5.12 (m, 1 H), 4.03

(br d, 0.5 H), 3.36-3.45 (m, 0.5 H), 3.09 (s, 1 H), 2.79-2.93 (m, 1

H), 2.42-2.74 (m, 3 H)

1511
(CD₃OD) δ 8.39-8.61 (m, 1 H), 7.71 (d, 1 H), 7.38 (s, 1.5 H),
484.2
97.6%

7.29 (t, 1 H), 6.93-7.19 (m, 1.5 H), 6.66-6.78 (m, 1 H), 6.37-6.65
[M + H]⁺

(m, 1 H), 4.97-5.11 (m, 1 H), 3.78-4.16 (m, 0.5 H), 3.37-3.43 (m,

0.5 H), 2.95-3.27 (m, 1 H), 2.80-2.93 (m, 1 H), 2.45-2.73 (m, 3 H)

1512
(CD₃OD) δ 8.62-8.72 (m, 1 H), 8.50 (d, 1 H), 7.51-7.74 (m, 2
538.2
99.0%

H), 7.27 (d, 1 H), 6.93-7.03 (m, 2 H), 6.76-6.83 (m, 1 H), 4.93-
[M + H]⁺

5.09 (m, 1 H), 3.74-3.83 (m, 0.7 H), 3.37-3.46 (m, 0.3 H), 3.20

(br t, 0.7 H), 2.96-3.06 (m, 0.3 H), 2.85 (br d, 1 H)

1513
(CD₃OD) δ 8.63-8.72 (m, 1 H), 8.50 (d, 1 H), 7.52-7.73 (m, 2
538.2
91.3%

H), 7.27 (d, 1 H), 6.93-7.04 (m, 2 H), 6.75-6.84 (m, 1 H), 4.93-
[M + H]⁺

5.11 (m, 1 H), 3.73-3.84 (m, 0.7 H), 3.41 (td, 0.3 H), 3.14-3.27

(m, 0.7 H), 2.95-3.06 (m, 0.3 H), 2.80-2.90 (m, 1 H)

1514
(CD₃OD) δ 8.37-8.54 (m, 1 H), 7.45-7.86 (m, 2 H), 7.13-7.31
390.2
99.3%

(m, 1 H), 6.48-7.00 (m, 3 H), 4.99 (br dd, 1 H), 3.68-4.01 (m, 1.6
[M + H]⁺

H), 3.39 (td, 0.4 H), 2.72-3.27 (m, 2 H), 2.42-2.61 (m, 4 H),

1.96-2.34 (m, 2 H)

1515
(CD₃OD) δ 8.34-8.53 (m, 1 H), 7.40-7.73 (m, 2 H), 7.09-7.26
390.2
96.0%

(m, 1 H), 6.48-7.02 (m, 3 H), 4.96 (br dd, 1 H), 3.67-3.99 (m, 1.6
[M + H]⁺

H), 3.34-3.46 (m, 0.4 H), 2.73-3.22 (m, 2 H), 2.37-2.64 (m, 4 H),

1.90-2.29 (m, 2 H)

1516
(CD₃OD) δ 8.32-8.53 (m, 1 H), 7.69 (s, 1 H), 7.19-7.50 (m, 1 H),
424.1
100%

6.60-7.01 (m, 3 H), 4.99 (dd, 1 H), 3.69-3.98 (m, 1.6 H), 3.34-
[M + H]⁺

3.44 (m, 0.4 H), 2.72-3.20 (m, 2 H), 2.39-2.62 (m, 4 H), 1.87-

2.31 (m, 2 H)

1517
(CD₃OD) δ 8.30-8.60 (m, 1 H), 7.69 (s, 1 H), 7.23-7.51 (m, 1 H),
424.1
100%

6.62-6.97 (m, 3 H), 4.99 (br dd, 1 H), 3.65-3.98 (m, 1.6 H), 3.36
[M + H]⁺

(br dd, 0.4 H), 2.77-3.21 (m, 2 H), 2.39-2.63 (m, 4 H), 1.93-2.33

(m, 2 H)

1518
(CD₃OD) δ 8.57-8.79 (m, 1 H), 7.39-7.78 (m, 2 H), 6.65-7.11
458.2
100%

(m, 3 H), 4.92-5.10 (m, 1 H), 3.60-3.95 (m, 2 H), 2.75-3.25 (m, 2
[M + H]⁺

H), 2.43-2.61 (m, 4 H), 1.93-2.33 (m, 2 H)

1519
(CD₃OD) δ 8.55-8.78 (m, 1 H), 7.42-7.74 (m, 2 H), 6.56-7.17
458.1
100%

(m, 3 H), 4.92-5.09 (m, 1 H), 3.65-3.94 (m, 1.6 H), 3.38 (td, 0.4
[M + H]⁺

H), 2.74-3.25 (m, 2 H), 2.37-2.62 (m, 4 H), 1.92-2.32 (m, 2 H)

1520
(CD₃OD) δ 8.49-8.67 (m, 1 H), 7.69 (s, 1 H), 7.38-7.53 (m, 1 H),
440.2
100%

6.66-7.16 (m, 4 H), 4.99 (br dd, 1 H), 3.64-3.99 (m, 1.6 H), 3.34-
[M + H]⁺

3.43 (m, 0.4 H), 2.75-3.22 (m, 2 H), 2.32-2.61 (m, 4 H), 1.94-

2.29 (m, 2 H)

1521
(CD₃OD) δ 8.48-8.67 (m, 1 H), 7.69 (s, 1 H), 7.35-7.55 (m, 1 H),
440.2
97.0%

6.64-7.15 (m, 4 H), 4.99 (br dd, 1 H), 3.65-4.01 (m, 1.6 H), 3.37
[M + H]⁺

(br dd, 0.4 H), 2.71-3.25 (m, 2 H), 2.38-2.61 (m, 4 H), 1.92-2.28

(m, 2 H)

1522
(DMSO-d₆) δ 12.13 (br s, 1 H), 9.04-9.71 (m, 1 H), 8.73-9.01
431.1
100%

(m, 1 H), 8.33-8.59 (m, 1 H), 7.44-7.80 (m, 3 H), 7.22-7.41 (m, 1
[M + H]⁺

H), 7.06-7.19 (m, 0.3 H), 6.54-6.99 (m, 2.7 H), 4.82 (br dd, 1 H),

3.40-3.88 (m, 1 H), 2.73-3.16 (m, 2 H)

1523
(DMSO-d₆) δ 12.10 (br s, 1 H), 9.05-9.83 (m, 1 H), 8.86 (br d, 1
431.1
97.4%

H), 8.22-8.68 (m, 1 H), 7.46-7.81 (m, 3 H), 7.19-7.43 (m, 1 H),
[M + H]⁺

7.10 (s, 0.3 H), 6.60-7.00 (m, 2.7 H), 4.82 (br dd, 1 H), 3.41-3.82

(m, 1 H), 2.77-3.11 (m, 2 H)

1524
(DMSO-d₆) δ 12.11 (br s, 1 H), 8.52 (d, 1 H), 8.11-8.34 (m, 1
461.1
99.4%

H), 7.48-7.76 (m, 3 H), 7.25-7.38 (m, 1 H), 7.21 (br d, 0.3 H),
[M + H]⁺

6.31-7.10 (m, 2.7 H), 4.87 (br dd, 1 H), 3.96 (s, 3 H), 3.38-3.82

(m, 1 H), 2.72-3.12 (m, 2 H)

1525
(DMSO-d₆) δ 12.11 (br s, 1 H), 8.52 (d, 1 H), 8.15-8.30 (m, 1
461.1
98.2%

H), 7.49-7.75 (m, 3 H), 7.25-7.35 (m, 1 H), 7.23 (br s, 0.4 H),
[M + H]⁺

6.45-7.02 (m, 2.6 H), 4.68-4.99 (m, 1 H), 3.95 (s, 3 H), 3.38-3.81

(m, 1 H), 2.71-3.13 (m, 2 H)

1526
(CD₃OD) δ 7.62-7.72 (m, 2 H), 7.40-7.55 (m, 1 H), 7.20-7.29
434.2
100%

(m, 1 H), 6.94-7.10 (m, 2 H), 6.60-6.81 (m, 2 H), 4.95-5.12 (m, 1
[M + H]⁺

H), 4.27-4.37 (m, 3 H), 3.77-3.90 (m, 0.7 H), 3.40-3.50 (m, 0.3

H), 2.95-3.22 (m, 1 H), 2.80-2.91 (m, 1 H)

1527
(CD₃OD) δ 7.60-7.76 (m, 2 H), 7.39-7.57 (m, 1 H), 7.19-7.29
434.2
99.4%

(m, 1 H), 6.92-7.11 (m, 2 H), 6.59-6.81 (m, 2 H), 5.09 (br dd, 1
[M + H]⁺

H), 4.27-4.36 (m, 3 H), 3.83 (br s, 0.5 H), 3.37-3.51 (m, 0.5 H),

2.94-3.22 (m, 1 H), 2.77-2.92 (m, 1 H)

1528
(CD₃OD) δ 7.67-7.73 (m, 1 H), 7.41-7.52 (m, 2 H), 7.18-7.28
448.1
98.6%

(m, 1 H), 6.96 (s, 1 H), 6.59-6.81 (m, 2 H), 5.10 (br dd, 0.5 H),
[M + H]⁺

4.94 (br d, 0.5 H), 4.20-4.26 (m, 3 H), 3.84 (ddd, 0.5 H), 3.41

(td, 0.5 H), 3.15-3.25 (m, 1 H), 2.80-3.06 (m, 1 H), 2.32-2.41 (m,

3 H)

1529
(CD₃OD) δ 7.70 (br d, 1 H), 7.42-7.52 (m, 2 H), 7.24 (ddd, 1 H),
448.2
98.3%

6.96 (s, 1 H), 6.60-6.80 (m, 2 H), 5.10 (dd, 0.7 H), 4.92-4.97 (m,
[M + H]⁺

0.3 H), 4.21-4.24 (m, 3 H), 3.81-3.89 (m, 0.6 H), 3.41 (td, 0.4

H), 3.16-3.25 (m, 1 H), 2.82-3.05 (m, 1 H), 2.32-2.40 (m, 3 H)

1530
(CD₃OD) δ 8.52-8.63 (m, 1 H), 7.72 (s, 1 H), 7.39-7.58 (m, 1.3
480.1
100%

H), 6.75-7.18 (m, 4.7 H), 4.92-5.09 (m, 1 H), 3.92 (s, 3 H), 3.78
[M + H]⁺

(ddd, 0.5 H), 3.36-3.46 (m, 0.5 H), 2.79-3.27 (m, 2 H), 2.40 (s, 3 H)

1531
(CD₃OD) δ 8.50-8.64 (m, 1 H), 7.72 (s, 1 H), 7.35-7.59 (m, 1.3
480.1
99.6%

H), 6.74-7.17 (m, 4.7 H), 4.92-5.13 (m, 1 H), 3.92 (s, 3 H), 3.72-
[M + H]⁺

3.85 (m, 0.5 H), 3.36-3.45 (m, 0.5 H), 2.80-3.27 (m, 2 H), 2.41

(s, 3 H)

1532
(CD₃OD) δ 8.52-8.68 (m, 1 H), 7.40-7.79 (m, 3.3 H), 6.76-7.17
466.1
92.4%

(m, 4.7 H), 5.09 (br dd, 1 H), 4.23-4.39 (m, 3 H), 3.74-3.86 (m,
[M + H]⁺

0.5 H), 3.38-3.50 (m, 0.5 H), 2.79-3.26 (m, 2 H)

1533
(CD₃OD) δ 8.37-8.56 (m, 1 H), 7.28-7.65 (m, 3.3 H), 6.64-7.05
466.1
98.1%

(m, 4.7 H), 4.82-5.04 (m, 1 H), 4.15-4.27 (m, 3 H), 3.58-3.77 (m,
[M + H]⁺

0.5 H), 3.25-3.38 (m, 0.5 H), 2.69-3.16 (m, 2 H)

1534
(CD₃OD) δ 9.48 (dd, 1 H), 8.82-8.90 (m, 2 H), 7.68-7.81 (m, 2
464.1
100%

H), 7.39-7.61 (m, 1 H), 6.99-7.33 (m, 3 H), 6.62-6.84 (m, 1 H),
[M + H]⁺

4.96-5.07 (m, 1 H), 3.89-3.99 (m, 0.6 H), 3.36-3.41 (m, 0.4 H),

2.86-3.26 (m, 2 H)

1535
(CD₃OD) δ 9.48 (dd, 1 H), 8.81-8.90 (m, 2 H), 7.69-7.82 (m, 2
464.1
99.1%

H), 7.38-7.61 (m, 1 H), 6.99-7.34 (m, 3 H), 6.61-6.83 (m, 1 H),
[M + H]⁺

4.96-5.08 (m, 1 H), 3.89-4.00 (m, 0.6 H), 3.36-3.42 (m, 0.4 H),

2.85-3.26 (m, 2 H)

1536
(CD₃OD) δ 7.68-7.79 (m, 2 H), 7.39-7.60 (m, 1 H), 6.97-7.31
480.1
100%

(m, 3 H), 6.60-6.79 (m, 2 H), 4.95-5.08 (m, 1 H), 3.91 (d, 3.6 H),
[M + H]⁺

3.35-3.41 (m, 0.4 H), 2.84-3.20 (m, 2 H), 2.40 (d, 3 H)

1537
(CD₃OD) δ 7.68-7.79 (m, 2 H), 7.38-7.60 (m, 1 H), 6.96-7.32
480.2
99.0%

(m, 3 H), 6.60-6.79 (m, 2 H), 4.94-5.11 (m, 1 H), 3.91 (d, 3.6 H),
[M + H]⁺

3.34-3.40 (m, 0.4 H), 2.82-3.23 (m, 2 H), 2.40 (d, 3 H)

1538
(CD₃OD) δ 8.99-9.06 (m, 1 H), 8.53-8.64 (m, 1 H), 8.37 (s, 1 H),
538.2
100%

7.63 (br s, 1 H), 7.43-7.57 (m, 1.3 H), 6.82-6.95 (m, 1.7 H),
[M + H]⁺

6.64-6.75 (m, 1 H), 4.83-5.04 (m, 1 H), 3.63-3.73 (m, 0.7 H),

3.31 (td, 0.3 H), 2.84-3.15 (m, 1 H), 2.76 (br d, 1 H)

1539
(CD₃OD) δ 8.98-9.07 (m, 1 H), 8.54-8.63 (m, 1 H), 8.33-8.40
538.2
98.8%

(m, 1 H), 7.60 (br s, 1 H), 7.43-7.56 (m, 1.3 H), 6.82-6.94 (m,
[M + H]⁺

1.7 H), 6.66-6.75 (m, 1 H), 4.82-5.04 (m, 1 H), 3.61-3.74 (m, 0.7

H), 3.31 (td, 0.3 H), 2.83-3.15 (m, 1 H), 2.77 (br s, 1 H)

1540
(CD₃OD) δ 9.15 (s, 1 H), 8.48 (s, 1 H), 8.28-8.39 (m, 1 H), 7.55-
488.2
99.9%

7.74 (m, 1.3 H), 6.93-7.03 (m, 1.7 H), 6.80-6.89 (m, 1 H), 6.72-
[M + H]⁺

6.79 (m, 1 H), 4.94-5.13 (m, 1 H), 3.80 (ddd, 0.7 H), 3.43 (td,

0.3 H), 2.95-3.25 (m, 1 H), 2.82-2.91 (m, 1 H)

1541
(CD₃OD) δ 9.03 (s, 1 H), 8.36 (s, 1 H), 8.16-8.27 (m, 1 H), 7.40-
488.1
99.3%

7.66 (m, 1.3 H), 6.81-6.92 (m, 1.7 H), 6.68-6.79 (m, 1 H), 6.60-
[M + H]⁺

6.68 (m, 1 H), 4.82-5.01 (m, 1 H), 3.63-3.73 (m, 0.7 H), 3.31 (td,

0.3 H), 2.84-3.14 (m, 1 H), 2.74 (br d, 1 H)

1542
(CD₃OD) δ 8.52 (dd, 1 H), 7.79-7.93 (m, 1 H), 7.65-7.77 (m, 1
538.1
100%

H), 7.50-7.60 (m, 0.5 H), 7.20-7.41 (m, 3 H), 6.99 (s, 0.5 H),
[M + H]⁺

6.63-6.91 (m, 1 H), 4.93-5.12 (m, 1 H), 3.88-4.07 (m, 0.5 H),

3.34-3.41 (m, 0.5 H), 2.96-3.26 (m, 1 H), 2.81-2.93 (m, 1 H)

1543
(CD₃OD) δ 8.46 (s, 1 H), 7.80-7.93 (m, 1 H), 7.65-7.78 (m, 1 H),
538.1
99.9%

7.56 (s, 0.5 H), 7.21-7.41 (m, 3 H), 7.03 (s, 0.5 H), 6.63-6.92 (m,
[M + H]⁺

1 H), 4.93-5.12 (m, 1 H), 4.05 (br d, 0.5 H), 3.37 (br d, 0.5 H),

2.96-3.25 (m, 1 H), 2.82-2.94 (m, 1 H)

1544
(CD₃OD) δ 8.44-8.56 (m, 1 H), 7.68-7.81 (m, 2 H), 7.59 (s, 0.1
520.1
100%

H), 7.14-7.50 (m, 4.3 H), 7.11 (s, 0.1 H), 6.93-7.01 (m, 0.5 H),
[M + H]⁺

6.56-6.83 (m, 1 H), 4.93-5.10 (m, 1 H), 3.83-4.01 (m, 0.5 H),

3.35-3.41 (m, 0.5 H), 2.95-3.27 (m, 1 H), 2.80-2.93 (m, 1 H)

1545
(CD₃OD) δ 8.52 (t, 1 H), 7.64-7.82 (m, 2 H), 7.59 (s, 0.2 H),
520.2
99.7%

7.36-7.47 (m, 0.8 H), 7.07-7.34 (m, 3.5 H), 6.99 (s, 0.5 H), 6.59-
[M + H]⁺

6.82 (m, 1 H), 4.94-5.10 (m, 1 H), 3.83-3.98 (m, 0.6 H), 3.37 (br

s, 0.4 H), 2.95-3.26 (m, 1 H), 2.80-2.93 (m, 1 H)

1546
(CD₃OD) δ 8.27-8.97 (m, 3 H), 7.94 (d, 1 H), 7.60-7.71 (m, 2
509.2
100%

H), 7.46 (br d, 1 H), 6.39-7.18 (m, 3 H), 4.61 (br s, 1 H), 3.55 (s,
[M + H]⁺

3 H), 3.01-3.16 (m, 1 H), 2.78 (br d, 1 H), 2.30 (s, 6 H)

1547
(CD₃OD) δ 8.14-9.03 (m, 3 H), 7.94 (d, 1 H), 7.60-7.70 (m, 2
509.2
99.0%

H), 7.46 (d, 1 H), 6.28-7.19 (m, 3 H), 4.61 (br s, 1 H), 3.55(s, 3
[M + H]⁺

H), 3.02-3.14 (m, 1 H), 2.78 (br d, 1 H), 2.30 (s, 6 H)

1548
(CD₃OD) δ 8.12-9.00 (m, 3 H), 7.97 (d, 1 H), 7.56-7.83 (m, 2
496.2
100%

H), 7.45 (d, 1 H), 6.45-7.19 (m, 3 H), 4.59-4.79 (m, 1 H), 4.54
[M + H]⁺

(s, 2 H), 3.52-4.12 (s, 1 H)3.32-3.48 (m, 3 H)2.98-3.22 (m, 1

H), 2.68-2.89 (m, 1 H)

1549
(CD₃OD) δ 8.69-8.94 (m, 3 H), 7.97 (d, 1 H), 7.58-7.78 (m, 2
496.2
99.4%

H), 7.45 (d, 1 H), 6.39-7.14 (m, 3 H), 4.59-4.80 (m, 1 H), 4.55
[M + H]⁺

(s, 2 H), 3.40-4.05 (m, 4 H), 3.01-3.20 (m, 1 H), 2.70-2.90 (m, 1 H)

1550
(DMSO-d₆) δ 12.06 (br s, 1 H), 9.50 (s, 1 H), 9.04 (br s, 1 H),
529.1
98.2%

8.41-8.78 (m, 2 H), 8.14-8.26 (m, 2 H), 7.88-8.07 (m, 2 H), 7.74
[M + H]⁺

(br d, 1 H), 7.60 (s, 1 H), 7.38-7.45 (m, 1 H), 6.30-7.15 (m, 3 H),

4.48 (br s, 1 H), 3.73 (br s, 1 H), 3.00 (br s, 1 H), 2.65-2.75 (m, 1 H)

1551
(DMSO-d₆) δ 12.05 (br s, 1 H), 9.50 (s, 1 H), 9.03 (br s, 1 H),
529.1
91.5%

8.39-8.79 (m, 2 H), 8.12-8.26 (m, 2 H), 7.89-8.07 (m, 2 H), 7.74
[M + H]⁺

(br d, 1 H), 7.60 (s, 1 H), 7.34-7.47 (m, 1 H), 6.26-7.21 (m, 3 H),

4.50 (br s, 1 H), 3.75 (s, 1 H), 3.00 (br s, 1 H), 2.71 (br d, 1 H)

1552
(DMSO-d₆) δ 12.05 (br s, 1 H), 8.93-9.18 (m, 2 H), 8.25-8.53
532.3
100%

(m, 2 H), 7.88-8.07 (m, 2 H), 7.67-7.80 (m, 2 H), 7.59 (s, 1 H),
[M + H]⁺

6.32-7.10 (m, 3 H), 4.51 (br s, 1 H), 3.88 (s, 3 H), 3.70 (s, 1 H),

2.99 (br s, 1 H), 2.66-2.73 (m, 1 H)

1553
(DMSO-d₆) δ 12.05 (br s, 1 H), 8.88-9.19 (m, 2 H), 8.29 (s, 2 H),
532.2
99.8%

7.90-8.07 (m, 2 H), 7.67-7.80 (m, 2 H), 7.59 (s, 1 H), 6.21-7.14
[M + H]⁺

(m, 3 H), 4.51 (br s, 1 H), 3.88 (s, 3 H), 3.70 (br s, 1 H), 2.99 (br

s, 1 H), 2.70 (br d, 1 H)

1554
(CD₃OD) δ 7.67-7.74 (m, 1 H), 7.41-7.53 (m, 1.3 H), 7.16-7.31
396.2
100%

(m, 1 H), 6.95 (s, 0.7 H), 6.79 (d, 0.7 H), 6.59-6.69 (m, 1.3 H),
[M + H]⁺

5.01 (br dd, 1 H), 3.73-3.84 (m, 0.7 H), 3.34-3.44 (m, 1.3 H),

2.91-3.22 (m, 1 H), 2.77-2.89 (m, 1 H), 1.45 (d, 6 H)

1555
(CD₃OD) δ 7.67-7.73 (m, 1 H), 7.41-7.52 (m, 1.3 H), 7.19-7.31
396.2
99.5%

(m, 1 H), 6.95 (s, 0.7 H), 6.76-6.82 (m, 0.7 H), 6.59-6.69 (m, 1.3
[M + H]⁺

H), 4.95-5.06 (m, 1 H), 3.73-3.85 (m, 0.7 H), 3.34-3.44 (m, 1.3

H), 2.94-3.22 (m, 1 H), 2.78-2.90 (m, 1 H), 1.46 (d, 6 H)

1556
(CD₃OD) δ 8.13-8.40 (m, 1 H), 7.35-7.78 (m, 1 H), 6.44-7.12
404.2
100%

(m, 4 H), 4.97 (br dd, 1 H), 3.69-3.93 (m, 1.6 H), 3.39 (td, 0.4
[M + H]⁺

H), 2.72-3.21 (m, 2 H), 2.31-2.61 (m, 7 H), 1.97-2.28 (m, 2 H)

1557
(CD₃OD) δ 8.14-8.40 (m, 1 H), 7.42-7.85 (m, 1 H), 6.35-7.18
404.2
95.9%

(m, 4 H), 4.96 (br dd, 1 H), 3.68-3.92 (m, 1.6 H), 3.38 (td, 0.4
[M + H]⁺

H), 2.77-3.21 (m, 2 H), 2.32-2.69 (m, 7 H), 1.89-2.31 (m, 2 H)

1558
(CD₃OD) δ 8.21-8.43 (m, 1 H), 7.69 (s, 1 H), 6.59-7.11 (m, 4 H),
408.2
100%

4.99 (br dd, 1 H), 3.66-3.92 (m, 1.6 H), 3.34-3.42 (m, 0.4 H),
[M + H]⁺

2.77-3.21 (m, 2 H), 2.40-2.60 (m, 4 H), 1.95-2.27 (m, 2 H)

1559
(CD₃OD) δ 8.24-8.43 (m, 1 H), 7.38-7.83 (m, 1 H), 6.60-7.07
408.2
98.5%

(m, 4 H), 5.00 (br dd, 1 H), 3.71-3.94 (m, 1.6 H), 3.34-3.43 (m,
[M + H]⁺

0.4 H), 2.76-3.22 (m, 2 H), 2.39-2.60 (m, 4 H), 2.00-2.25 (m, 2 H)

1560
(CD₃OD) δ 7.42-7.71 (m, 2 H), 6.56-7.27 (m, 4 H), 5.00 (br dd,
424.2
100%

1 H), 3.76-3.97 (m, 1.6 H), 3.34-3.41 (m, 0.4 H), 2.78-3.21 (m, 2
[M + H]⁺

H), 2.40-2.60 (m, 4 H), 1.95-2.28 (m, 2 H)

1561
(CD₃OD) δ 7.41-7.72 (m, 2 H), 6.59-7.23 (m, 4 H), 5.00 (br dd,
424.1
98.7%

1 H), 3.76-3.94 (m, 1.6 H), 3.34-3.43 (m, 0.4 H), 2.77-3.20 (m, 2
[M + H]⁺

H), 2.40-2.57 (m, 4 H), 1.95-2.27 (m, 2 H)

1562
(CD₃OD) δ 7.68 (d, 1 H), 7.35-7.51 (m, 1.4 H), 7.11 (dt, 1 H),
404.2
100%

6.95 (s, 0.6 H), 6.39-6.75 (m, 2 H), 4.96 (br dd, 1 H), 3.79-3.99
[M + H]⁺

(m, 1.6 H), 3.34-3.43 (m, 0.4 H), 2.75-3.20 (m, 2 H), 2.38-2.71

(m, 7 H), 1.94-2.32 (m, 2 H)

1563
(CD₃OD) δ 7.69 (d, 1 H), 7.36-7.51 (m, 1.4 H), 7.10 (dt, 1 H),
404.2
94.5%

6.95 (s, 0.6 H), 6.31-6.80 (m, 2 H), 4.96 (br dd, 1 H), 3.77-3.98
[M + H]⁺

(m, 1.5 H), 3.32-3.41 (m, 0.5 H), 2.76-3.20 (m, 2 H), 2.39-2.73

(m, 7 H), 1.94-2.29 (m, 2 H)

1564
(CD₃OD) δ 7.66-7.80 (m, 1 H), 7.41-7.61 (m, 1.3 H), 7.18-7.32
448.1
100%

(m, 1 H), 6.98 (s, 0.7 H), 6.70-6.86 (m, 2 H), 6.61-6.70 (m, 1 H),
[M + H]⁺

5.06 (br dd, 0.8 H), 3.92 (s, 3 H), 3.41-3.88 (m, 1.2 H), 3.20 (br

d, 1 H), 2.86 (br dd, 1 H), 2.41 (s, 3 H)

1565
(CD₃OD) δ 7.71 (s, 1 H), 7.41-7.60 (m, 1.4 H), 7.20-7.31 (m, 1
448.1
99.6%

H), 6.98 (s, 0.6 H), 6.70-6.84 (m, 2 H), 6.60-6.70 (m, 1 H), 5.06
[M + H]⁺

(br dd, 1 H), 3.92 (s, 3 H), 3.42-3.88 (m, 1 H), 2.94-3.27 (m, 1

H), 2.86 (br dd, 1 H), 2.41 (s, 3 H)

1566
(CD₃OD) δ 8.30 (br s, 1 H), 7.64-7.82 (m, 1 H), 7.58 (br s, 0.3
448.2
100%

H), 7.37-7.54 (m, 1 H), 7.13-7.34 (m, 1 H), 6.97 (s, 0.7 H), 6.70-
[M + H]⁺

6.85 (m, 1 H), 6.60-6.70 (m, 1 H), 4.97-5.17 (m, 1 H), 3.94 (s, 3

H), 3.39-3.86 (m, 1 H), 2.96-3.25 (m, 1 H), 2.78-2.93 (m, 1 H),

2.47-2.61 (m, 3 H)

1567
(CD₃OD) δ 8.30 (s, 1 H), 7.71 (s, 1 H), 7.58 (s, 0.3 H), 7.42-7.54
448.2
100%

(m, 1 H), 7.19-7.33 (m, 1 H), 6.97 (s, 0.7 H), 6.70-6.85 (m, 1H),
[M + H]⁺

6.61-6.70 (m, 1 H), 5.02-5.18 (m, 1 H), 3.94 (s, 3 H), 3.42-3.88

(m, 1 H), 2.94-3.26 (m, 1 H), 2.79-2.93 (m, 1 H), 2.49-2.62 (m, 3 H)

1568
(CD₃OD) δ 8.53-8.64 (m, 1 H), 7.72 (s, 1 H), 7.41-7.56 (m, 2 H),
480.2
100%

6.73-7.15 (m, 4 H), 4.95-5.17 (m, 1 H), 4.16-4.27 (m, 3 H), 3.75-
[M + H]⁺

3.88 (m, 0.5 H), 3.42 (td, 0.5 H), 2.85-3.26 (m, 2 H), 2.29-2.44

(m, 3 H)

1569
(CD₃OD) δ 8.54-8.64 (m, 1 H), 7.77 (br d, 1 H), 7.43-7.55 (m, 2
480.1
97.3%

H), 6.78-7.17 (m, 4 H), 4.95-5.16 (m, 1 H), 4.20-4.27 (m, 3 H),
[M + H]⁺

3.74-3.89 (m, 0.5 H), 3.39-3.49 (m, 0.5 H), 2.85-3.25 (m, 2 H),

2.33-2.46 (m, 3 H)

1570
(CD₃OD) δ 9.11-9.18 (m, 1 H), 8.46-8.62 (m, 2 H), 7.72 (s, 1 H),
520.1
99.3%

7.40-7.62 (m, 1.4 H), 6.91-7.16 (m, 2.6 H), 6.75-6.88 (m, 1 H),
[M + H]⁺

4.95-5.13 (m, 1 H), 3.74-3.84 (m, 0.7 H), 3.39-3.47 (m, 0.3 H),

2.95-3.26 (m, 1 H), 2.80-2.92 (m, 1 H)

1571
(CD₃OD) δ 8.97-9.07 (m, 1 H), 8.32-8.52 (m, 2 H), 7.60 (s, 1 H),
520.1
99.5%

7.28-7.49 (m, 1.4 H), 6.76-7.06 (m, 2.6 H), 6.62-6.74 (m, 1 H),
[M + H]⁺

4.82-5.03 (m, 1 H), 3.62-3.72 (m, 0.7 H), 3.26-3.35 (m, 0.3 H),

2.83-3.14 (m, 1 H), 2.67-2.81 (m, 1 H)

1572
(CD₃OD) δ 7.08-7.90 (m, 6 H), 6.53-6.99 (m, 1 H), 4.96-5.06
440.1
97.5%

(m, 1 H), 3.76-3.97 (m, 1.6 H), 3.34 (br s, 0.4 H), 2.77-3.16 (m,
[M + H]⁺

2 H), 2.36-2.63 (m, 4 H), 1.92-2.28 (m, 2 H)

1573
(CD₃OD) δ 7.08-7.81 (m, 5 H), 6.52-6.99 (m, 2 H), 4.91-5.03
440.1
98.2%

(m, 1 H), 3.75-3.95 (m, 1.6 H), 3.32-3.39 (m, 0.4 H), 2.74-3.19
[M + H]⁺

(m, 2 H), 2.42-2.57 (m, 4 H), 1.94-2.26 (m, 2 H)

1574
(CD₃OD) δ 7.61-7.75 (m, 1 H), 7.37-7.52 (m, 1 H), 7.17-7.30
408.1
100%

(m, 1 H), 6.45-7.13 (m, 3 H), 5.00 (dd, 1 H), 3.73-3.94 (m, 1.6
[M + H]⁺

H), 3.33-3.43 (m, 0.4 H), 2.74-3.21 (m, 2 H), 2.37-2.61 (m, 4 H),

1.94-2.29 (m, 2 H)

1575
(CD₃OD) δ 7.62-7.74 (m, 1 H), 7.20-7.52 (m, 2 H), 6.58-6.98
408.2
99.7%

(m, 3 H), 4.91-5.05 (m, 1 H), 3.65-3.98 (m, 1.7 H), 3.35-3.43 (m,
[M + H]⁺

0.3 H), 2.75-3.22 (m, 2 H), 2.41-2.57 (m, 4 H), 1.95-2.28 (m, 2 H)

1576
(CD₃OD) δ 8.43 (d, 1 H), 7.66 (s, 1 H), 7.57 (d, 1 H), 7.39 (d, 1
357.1
100%

H), 7.31 (d, 1 H), 7.14-7.22 (m, 2 H), 7.03-7.11 (m, 1 H), 6.83 (t,
[M + H]⁺

1 H), 6.60 (d, 2 H), 4.54 (dd, 1 H), 3.72 (td, 1 H), 2.98-3.11 (m,

1 H), 2.81 (dd, 1 H)

1577
(CD₃OD) δ 8.43 (br d, 1 H), 7.66 (s, 1 H), 7.57 (br d, 1 H), 7.39
357.2
99.5%

(d, 1 H), 7.31 (d, 1 H), 7.13-7.23 (m, 2 H), 7.07 (t, 1 H), 6.83 (br
[M + H]⁺

t, 1 H), 6.50-6.66 (m, 2 H), 4.54 (dd, 1 H), 3.61-3.81 (m, 1 H),

2.94-3.12 (m, 1 H), 2.81 (br dd, 1 H)

1578
(CD₃OD) δ 8.45 (dd, 1 H), 8.26 (dd, 1 H), 7.68-7.81 (m, 2 H),
493.1
100%

7.38-7.64 (m, 2 H), 6.99-7.34 (m, 3 H), 6.61-6.83 (m, 1 H), 4.97-
[M + H]⁺

5.07 (m, 1 H), 4.00 (d, 3.6 H), 3.37-3.42 (m, 0.4 H), 2.84-3.25

(m, 2 H)

1579
(CD₃OD) δ 8.34 (dd, 1 H), 8.15 (dd, 1 H), 7.57-7.68 (m, 2 H),
493.1
99.7%

7.27-7.52 (m, 2 H), 6.86-7.20 (m, 3 H), 6.48-6.70 (m, 1 H), 4.83-
[M + H]⁺

4.94 (m, 1 H), 3.78-3.90 (m, 3.6 H), 3.24-3.29 (m, 0.4 H), 2.73-

3.10 (m, 2 H)

1580
(CD₃OD) δ 8.51-8.59 (m, 1 H), 7.79-7.91 (m, 1 H), 7.57-7.70
481.1
99.1%

(m, 3 H), 6.86-7.48 (m, 4 H), 6.46-6.72 (m, 1 H), 4.83-4.93 (m, 1
[M + H]⁺

H), 3.76-3.87 (m, 0.5 H), 3.22-3.31 (m, 0.5 H), 2.73-3.15 (m, 2 H)

1581
(CD₃OD) δ 8.61-8.72 (m, 1 H), 7.91-8.00 (m, 1 H), 7.68-7.82
481.1
97.5%

(m, 3 H), 6.99-7.60 (m, 4 H), 6.56-6.86 (m, 1 H), 4.95-5.02 (m, 1
[M + H]⁺

H), 3.85-4.02 (m, 0.5 H), 3.36-3.45 (m, 0.5 H), 2.83-3.27 (m, 2 H)

1582
(CD₃OD) δ 8.28 (s, 1 H), 7.68-7.81 (m, 2 H), 7.35-7.60 (m, 1 H),
480.2
98.6%

6.95-7.33 (m, 3 H), 6.57-6.81 (m, 1 H), 4.94-5.14 (m, 1 H), 3.93
[M + H]⁺

(d, 3.5 H), 3.34-3.44 (m, 0.5 H), 2.82-3.25 (m, 2 H), 2.51-2.58

(m, 3 H)

1583
(CD₃OD) δ 8.15 (s, 1 H), 7.54-7.68 (m, 2 H), 7.23-7.48 (m, 1 H),
480.2
98.5%

6.84-7.19 (m, 3 H), 6.51-6.68 (m, 1 H), 4.82-5.04 (m, 1 H), 3.80
[M + H]⁺

(d, 3.5 H), 3.22-3.31 (m, 0.5 H), 2.72-3.07 (m, 2 H), 2.41 (d, 3 H)

1584
(CD₃OD) δ 7.67-7.80 (m, 2 H), 7.35-7.59 (m, 2 H), 6.97-7.32
480.1
100%

(m, 3 H), 6.65-6.81 (m, 1 H), 4.96-5.13 (m, 1 H), 4.23 (d, 3 H),
[M + H]⁺

3.94 (ddd, 0.6 H), 3.37-3.44 (m, 0.4 H), 2.84-3.23 (m, 2 H), 2.37

(d, 3 H)

1585
(CD₃OD) δ 7.56-7.68 (m, 2 H), 7.23-7.47 (m, 2 H), 6.85-7.20
480.1
96.4%

(m, 3 H), 6.54-6.69 (m, 1 H), 4.84-5.01 (m, 1 H), 4.09-4.16 (m, 3
[M + H]⁺

H), 3.82 (ddd, 0.6 H), 3.25-3.33 (m, 0.4 H), 2.72-3.13 (m, 2 H),

2.25 (d, 3 H)

1586
(CD₃OD) δ 8.39-8.46 (m, 1 H), 7.69 (s, 1 H), 7.37-7.49 (m, 0.3
460.1
100%

H), 7.26-7.32 (m, 1 H), 6.92 (br s, 0.7 H), 6.81-6.89 (m, 1 H),
[M + H]⁺

6.68-6.75 (m, 1 H), 4.99 (br dd, 1 H), 3.67-3.82 (m, 1.7 H), 3.35-

3.44 (m, 0.3 H), 2.94-3.20 (m, 5 H), 2.82 (br d, 1 H)

1587
(CD₃OD) δ 8.39-8.46 (m, 1 H), 7.69 (s, 1 H), 7.44 (s, 0.3 H),
460.1
99.0%

7.26-7.32 (m, 1 H), 6.92 (s, 0.7 H), 6.82-6.88 (m, 1 H), 6.69-6.75
[M + H]⁺

(m, 1 H), 4.99 (dd, 1 H), 3.68-3.81 (m, 1.7 H), 3.38 (td, 0.3 H),

2.97-3.19 (m, 5 H), 2.77-2.87 (m, 1 H)

1588
(CD₃OD) δ 8.29 (d, 1 H), 7.65 (s, 1 H), 6.97 (d, 1 H), 6.77 (t, 1
362.2
100%

H), 6.50 (s, 1 H), 6.24 (br s, 1 H), 4.17 (dd, 1 H), 3.67 (ddd, 1
[M + H]⁺

H), 2.95-3.08 (m, 1 H), 2.77 (dd, 1 H), 2.42 (s, 3 H), 1.99-2.16

(m, 1 H), 1.04-1.13 (m, 4H)

1589
(CD₃OD) δ 8.28 (d, 1 H), 7.65 (s, 1 H), 6.96 (br d, 1 H), 6.76 (t,
362.2
99.8%

1 H), 6.50 (s, 1 H), 6.24 (s, 1 H), 4.17 (dd, 1 H), 3.67 (ddd, 1 H),
[M + H]⁺

2.95-3.06 (m, 1 H), 2.76 (dd, 1 H), 2.41 (s, 3 H), 2.01-2.12 (m, 1

H), 1.00-1.15 (m, 4 H)

1590
(CD₃OD) δ 8.68 (d, 1 H), 7.60-7.67 (m, 2 H), 6.98 (t, 1 H), 6.68
416.2
98.7%

(s, 1 H), 6.27 (s, 1 H), 4.20 (dd, 1 H), 3.68 (ddd, 1 H), 2.96-3.06
[M + H]⁺

(m, 1 H), 2.78 (dd, 1 H), 2.02-2.11 (m, 1 H), 1.00-1.16 (m, 4H)

1591
(CD₃OD) δ 8.68 (d, 1 H), 7.59-7.67 (m, 2 H), 6.98 (t, 1 H), 6.68
416.2
98.9%

(s, 1 H), 6.27 (br s, 1 H), 4.20 (dd, 1 H), 3.64-3.72 (m, 1 H),
[M + H]⁺

2.95-3.06 (m, 1 H), 2.78 (br dd, 1 H), 2.01-2.11 (m, 1 H), 1.00-

1.13 (m, 4 H)

1592
(CD₃OD) δ 8.29-8.53 (m, 3 H), 7.70-7.72 (m, 1 H), 7.64 (s, 1 H),
318.2
100%

7.61-7.72 (m, 1 H), 7.56 (d, 1 H), 7.07-7.28 (m, 2 H), 6.83 (td, 1
[M + H]⁺

H), 6.65 (t, 1 H), 6.54 (s, 1 H), 4.96-5.12 (m, 1 H), 3.40-3.56 (m,

1 H), 2.81-3.00 (m, 1 H), 2.70 (dd, 1 H)

1593
(CD₃OD) δ 8.32-8.53 (m, 3 H), 7.67 (s, 1 H), 7.56 (d, 1 H), 7.07-
318.1
99.4%

7.26 (m, 2 H), 6.83 (t, 1 H), 6.66 (t, 1 H), 6.54 (s, 1 H), 5.04 (br
[M + H]⁺

dd, 1 H), 3.39-3.55 (m, 1 H), 2.83-3.00 (m, 1 H), 2.70 (dd, 1 H)

1594
(CD₃OD) δ 7.92-8.04 (m, 1 H), 7.77-7.88 (m, 1 H), 7.55-7.69
477.2
100%

(m, 2 H), 7.25-7.50 (m, 2 H), 6.85-7.22 (m, 3 H), 6.47-6.71 (m, 1
[M + H]⁺

H), 4.85-4.96 (m, 1 H), 3.75-3.88 (m, 0.5 H), 3.24 (br d, 0.5 H),

2.71-3.13 (m, 2 H), 2.54 (br d, 3 H)

1595
(CD₃OD) δ 8.07-8.19 (m, 1 H), 7.95 (td, 1 H), 7.68-7.84 (m, 2
477.2
98.2%

H), 7.39-7.61 (m, 2 H), 6.98-7.34 (m, 3 H), 6.60-6.88 (m, 1 H),
[M + H]⁺

4.97-5.08 (m, 1 H), 3.86-3.99 (m, 0.5 H), 3.36-3.42 (m, 0.5 H),

2.85-3.24 (m, 2 H), 2.67 (d, 3 H)

1596
(CD₃OD) δ 9.01 (s, 1 H), 8.78 (br s, 2 H), 7.85-8.03 (m, 2 H),
532.2
100%

7.56-7.75 (m, 3 H), 6.42-7.17 (m, 4 H), 4.65 (br s, 1 H), 3.96 (s,
[M + H]⁺

3 H), 3.44-3.81 (m, 1 H), 3.03-3.16 (m, 1 H), 2.73-2.83 (m, 1 H)

1597
(CD₃OD) δ 9.01 (d, 1 H), 8.24-8.89 (m, 2 H), 7.86-8.04 (m, 2
532.2
98.4%

H), 7.56-7.74 (m, 3 H), 6.37-7.09 (m, 4 H), 4.66 (br s, 1 H), 3.96
[M + H]⁺

(s, 3 H), 3.46-3.83 (m, 1 H), 3.04-3.15 (m, 1 H), 2.79 (br d, 1 H)

1598
(CD₃OD) δ 8.23-8.37 (m, 1 H), 7.35-7.76 (m, 1.4 H), 6.90-7.07
440.1
100%

(m, 1.6 H), 6.73-6.86 (m, 1 H), 6.52-6.69 (m, 1 H), 4.98 (dd, 1
[M + H]⁺

H), 3.69-3.90 (m, 1.6 H), 3.36-3.47 (m, 0.4 H), 2.92-3.24 (m, 5

H), 2.84 (br dd, 1 H), 2.37-2.52 (m, 3 H)

1599
(CD₃OD) δ 8.22-8.38 (m, 1 H), 7.43-7.78 (m, 1.4 H), 6.91-7.06
440.1
99.3%

(m, 1.6 H), 6.74-6.87 (m, 1 H), 6.53-6.70 (m, 1 H), 4.98 (br dd, 1
[M + H]⁺

H), 3.69-3.87 (m, 1.6 H), 3.37-3.45 (m, 0.4 H), 2.92-3.27 (m, 5

H), 2.84 (br dd, 1 H), 2.37-2.54 (m, 3 H)

1600
(CD₃OD) δ 8.64-8.76 (m, 1 H), 7.71 (s, 1 H), 7.60-7.68 (m, 1 H),
494.1
100%

7.47 (br s, 0.4 H), 6.92-7.06 (m, 1.6 H), 6.73-6.86 (m, 1 H),
[M + H]⁺

4.94-5.10 (m, 1 H), 3.68-3.88 (m, 1.6 H), 3.36-3.46 (m, 0.4 H),

2.93-3.25 (m, 5 H), 2.76-2.91 (m, 1 H)

1601
(CD₃OD) δ 8.65-8.77 (m, 1 H), 7.72 (s, 1 H), 7.59-7.68 (m, 1 H),
494.1
99.5%

7.47 (s, 0.4 H), 6.92-7.07 (m, 1.6 H), 6.73-6.85 (m, 1 H), 4.93-
[M + H]⁺

5.10 (m, 1 H), 3.69-3.87 (m, 1.6 H), 3.37-3.47 (m, 0.4 H), 2.94-

3.25 (m, 5 H), 2.79-2.90 (m, 1 H)

1602
(CD₃OD) δ 8.51-8.70 (m, 1 H), 7.71 (s, 1 H), 7.45 (br d, 1.3 H),
476.2
100%

6.73-7.16 (m, 3.7 H), 4.92-5.05 (m, 1 H), 3.68-3.89 (m, 1.5 H),
[M + H]⁺

3.36-3.47 (m, 0.5 H), 2.70-3.23 (m, 6 H)

1603
(CD₃OD) δ 8.52-8.66 (m, 1 H), 7.71 (s, 1 H), 7.38-7.51 (m, 1.3
476.2
99.5%

H), 6.72-7.19 (m, 3.7 H), 4.92-5.05 (m, 1 H), 3.69-3.86 (m, 1.5
[M + H]⁺

H), 3.34-3.44 (m, 0.5 H), 2.82-3.22 (m, 6 H)

1604
(CD₃OD) δ 8.26-8.42 (m, 1 H), 7.71 (s, 1 H), 7.46 (s, 0.5 H),
444.2
100%

6.67-7.05 (m, 3.5 H), 5.01 (dd, 1 H), 3.68-3.88 (m, 1.5 H), 3.41
[M + H]⁺

(td, 0.5 H), 2.76-3.24 (m, 6 H)

1605
(CD₃OD) δ 8.16-8.30 (m, 1 H), 7.55-7.65 (m, 1 H), 7.34 (s, 0.5
444.1
92.0%

H), 6.57-6.91 (m, 3.5 H), 4.89 (br dd, 1 H), 3.53-3.75 (m, 1.5 H),
[M + H]⁺

3.29 (td, 0.5 H), 2.68-3.09 (m, 6 H)

1606
(CD₃OD) δ 8.56 (br d, 1 H), 7.65 (s, 1 H), 7.41 (br d, 1 H), 6.68-
398.2
93.1%

7.12 (m, 3 H), 6.26 (s, 1 H), 4.13-4.25 (m, 1 H), 3.56-3.75 (m, 1
[M + H]⁺

H), 3.00 (br d, 1 H), 2.78 (dd, 1 H), 1.97-2.13 (m, 1 H), 0.99-

1.12 (m, 4 H)

1607
(CD₃OD) δ 8.57 (d, 1 H), 7.66 (s, 1 H), 7.41 (br d, 1 H), 6.64-
398.2
98.1%

7.17 (m, 3 H), 6.27 (s, 1 H), 4.19 (dd, 1 H), 3.67 (ddd, 1 H),
[M + H]⁺

2.94-3.07 (m, 1 H), 2.78 (dd, 1 H), 2.02-2.15 (m, 1 H), 0.96-1.16

(m, 4 H)

1608
(CD₃OD) δ 7.60-7.82 (m, 3 H), 7.35-7.59 (m, 1 H), 6.97-7.33
466.1
100%

(m, 4 H), 6.62-6.85 (m, 1 H), 5.09 (br dd, 1 H), 4.33 (br d, 3 H),
[M + H]⁺

3.86-4.02 (m, 0.6 H), 3.37-3.43 (m, 0.4 H), 2.84-3.25 (m, 2 H)

1609
(CD₃OD) δ 7.49-7.70 (m, 3 H), 7.24-7.47 (m, 1 H), 6.85-7.21
466.2
95.3%

(m, 4 H), 6.49-6.70 (m, 1 H), 4.85-5.01 (m, 1 H), 4.21 (br d, 3
[M + H]⁺

H), 3.73-3.89 (m, 0.6 H), 3.25-3.33 (m, 0.4 H), 2.73-3.13 (m, 2 H)

1610
(CD₃OD) δ 8.68 (d, 2 H), 8.12 (d, 1 H), 8.00 (td, 1 H), 7.84 (s, 1
453.2
98.9%

H), 7.48-7.66 (m, 2 H), 6.76-7.03 (m, 2 H), 6.58 (s, 1 H), 4.48
[M + H]⁺

(dd, 1 H), 3.80 (ddd, 1 H), 3.00-3.21 (m, 1 H), 2.87 (dd, 1 H)

1611
(CD₃OD) δ 8.57-8.78 (m, 2 H), 8.12 (d, 1 H), 8.00 (td, 1 H), 7.69
453.2
99.7%

(s, 1 H), 7.49-7.64 (m, 2 H), 6.76-7.03 (m, 2 H), 6.55 (br s, 1 H),
[M + H]⁺

4.47 (dd, 1 H), 3.80 (ddd, 1 H), 2.67-3.21 (m, 2 H)

1612
(CD₃OD) δ 8.69 (d, 1 H), 8.33 (d, 1 H), 8.13 (d, 1 H), 8.01 (td, 1
403.2
100%

H), 7.70 (s, 1 H), 7.55 (dd, 1 H), 6.95 (dd, 1 H), 6.77-6.86 (m, 2
[M + H]⁺

H), 6.54 (s, 1 H), 4.47 (dd, 1 H), 3.75-3.86 (m, 1 H), 3.03-3.16

(m, 1 H), 2.86 (br dd, 1 H)

1613
(CD₃OD) δ 8.68 (d, 1 H), 8.32 (d, 1 H), 8.12 (d, 1 H), 7.99 (td, 1
403.2
99.6%

H), 7.71 (s, 1 H), 7.51-7.57 (m, 1 H), 6.94 (dd, 1 H), 6.75-6.84
[M + H]⁺

(m, 2 H), 6.53 (s, 1 H), 4.45 (dd, 1 H), 3.75-3.86 (m, 1 H), 3.03-

3.15 (m, 1 H), 2.84 (dd, 1 H)

1614
(CD₃OD) δ 8.12-9.01 (m, 2 H), 8.07 (d, 1 H), 7.86 (d, 1 H),
537.3
99.2%

7.57-7.72 (m, 2 H), 7.42 (dd, 1 H), 6.41-7.07 (m, 3 H), 4.65 (br
[M + H]⁺

s, 1 H), 3.79-3.95 (m, 4 H), 3.40-3.78 (m, 1 H), 3.02-3.17 (m, 5

H), 2.77 (br d, 1 H)

1615
(CD₃OD) δ 8.12-8.93 (m, 2 H), 8.09 (d, 1 H), 7.86 (d, 1 H),
537.2
99.7%

7.57-7.70 (m, 2 H), 7.44 (dd, 1 H), 6.43-7.08 (m, 3 H), 4.65 (br
[M + H]⁺

s, 1 H), 3.82-3.90 (m, 4 H), 3.38-3.80 (m, 1 H), 3.03-3.16 (m, 5

H), 2.78 (br d, 1 H)

1616
(CD₃OD) δ 8.42 (d, 2 H), 8.32 (d, 1 H), 7.65 (s, 1 H), 7.19 (s, 1
336.1
100%

H), 6.95 (dd, 1 H), 6.72-6.82 (m, 1 H), 6.62-6.70 (m, 2 H), 5.03-
[M + H]⁺

5.13 (m, 1 H), 3.42-3.55 (m, 1 H), 2.83-2.99 (m, 1 H), 2.71 (br

dd, 1 H)

1617
(CD₃OD) δ 8.41 (d, 2 H), 8.32 (d, 1 H), 7.64 (s, 1 H), 7.18 (s, 1
336.2
90.7%

H), 6.94 (dd, 1 H), 6.75-6.84 (m, 1 H), 6.60-6.73 (m, 2 H), 5.06
[M + H]⁺

(br dd, 1 H), 3.40-3.53 (m, 1 H), 2.82-2.97 (m, 1 H), 2.71 (br dd,

1 H)

1618
(CD₃OD) δ 8.41 (d, 2 H), 8.28 (br d, 1 H), 7.64 (s, 1 H), 7.20(s,
332.2
100%

1 H), 6.96 (d, 1 H), 6.75 (t, 1 H), 6.65 (t, 1 H), 6.53 (s, 1 H), 5.03
[M + H]⁺

(br dd, 1 H), 3.47 (ddd, 1 H), 2.83-3.04 (m, 1 H), 2.70 (br dd, 1

H), 2.43 (s, 3 H)

1619
(CD₃OD) δ 8.28 (d, 2 H), 8.16 (br d, 1 H), 7.52 (s, 1 H), 7.08(s,
332.1
97.3%

1 H), 6.83 (br d, 1 H), 6.62 (t, 1 H), 6.52 (t, 1 H), 6.41(s, 1H),
[M + H]⁺

4.91 (br dd, 1 H), 3.29-3.40 (m, 1 H), 2.72-2.86 (m, 1 H), 2.57

(br dd, 1 H), 2.30 (s, 3 H)

1620
(500 MHz, CD₃OD) δ 8.88 (s, 1 H), 8.05-8.80 (m, 2 H), 7.85-
478.2
100%

7.96 (m, 1 H), 7.77 (dd, 1 H), 7.51-7.64 (m, 2 H), 6.23-7.01 (m,
[M + H]

5 H), 4.52 (br s, 1 H), 3.81-3.89 (m, 3 H), 3.28-3.77 (m, 1 H),

2.91-3.04 (m, 1 H), 2.67 (br d, 1 H), 2.34 (s, 3 H)

1621
(500 MHZ, CD₃OD) δ 9.01 (s, 1 H), 8.27-8.94 (m, 2 H), 8.01 (d,
478.2
98.8%

1 H), 7.89 (dd, 1 H), 7.60-7.77 (m, 2 H), 6.39-7.09 (m, 5 H),
[M + H]⁺

4.64 (br s, 1 H), 3.94-4.09 (m, 3 H), 3.43-3.89 (m, 1 H), 3.02-

3.21 (m, 1 H), 2.79 (br d, 1 H), 2.38-2.61 (m, 3 H)

1622
(CD₃OD) δ 8.69 (d, 1 H), 8.43 (d, 1 H), 8.13 (d, 1 H), 8.00(t, 1
419.1
100%

H), 7.68 (s, 1 H), 7.54 (dd, 1 H), 7.28 (d, 1 H), 6.83 (t, 1H), 6.76
[M + H]⁺

(s, 1 H), 6.53 (br s, 1 H), 4.46 (dd, 1 H), 3.79 (td, 1 H), 2.99-3.17

(m, 1 H), 2.84 (br d, 1 H)

1623
(CD₃OD) δ 8.68 (d, 1 H), 8.43 (d, 1 H), 8.13 (d, 1 H), 8.00 (t, 1
419.1
99.0%

H), 7.68 (s, 1 H), 7.44-7.57 (m, 1 H), 7.28 (d, 1 H), 6.82 (t, 1 H),
[M + H]⁺

6.76 (s, 1 H), 6.53 (s, 1 H), 4.46 (dd, 1 H), 3.71-3.86 (m, 1 H),

3.02-3.17 (m, 1 H), 2.84 (dd, 1 H)

1624
(CD₃OD) δ 8.26-8.85 (m, 3 H), 7.97 (d, 1 H), 7.68 (s, 1 H), 7.43-
455.3
97.4%

7.52 (m, 1 H), 6.37-7.14 (m, 4 H), 4.63-4.87 (m, 1 H), 3.58 (s, 3
[M + H]⁺

H), 3.03-3.18 (m, 1 H), 2.70-2.85 (m, 1 H), 2.47 (s, 3 H), 2.32 (s,

6 H)

1625
(CD₃OD) δ 8.24-9.00 (m, 3 H), 7.97 (d, 1 H), 7.68 (s, 1 H), 7.48
455.3
99.0%

(dd, 1 H), 6.28-7.14 (m, 4 H), 4.64-4.88 (m, 1 H), 3.58 (s, 3 H),
[M + H]⁺

3.00-3.16 (m, 1 H), 2.69-2.86 (m, 1 H), 2.46 (s, 3 H), 2.32 (s, 6 H)

1626
(CD₃OD) δ 8.61-8.82 (m, 1 H), 8.12 (d, 1 H), 7.99 (td, 1 H), 7.72
435.1
100%

(dd, 1 H), 7.67 (s, 1 H), 7.54 (ddd, 1 H), 7.20-7.50 (m, 2 H), 7.16
[M + H]⁺

(d, 1 H), 6.73 (s, 1 H), 6.53 (s, 1 H), 4.45 (dd, 1 H), 3.85 (ddd, 1

H), 3.01-3.15 (m, 1 H), 2.85 (dd, 1 H)

1627
(CD₃OD) δ 8.69 (br s, 1 H), 8.13 (br d, 1 H), 8.01 (br t, 1 H),
435.2
99.0%

7.64-7.81 (m, 2 H), 7.55 (br s, 1 H), 7.21-7.50 (m, 2 H), 7.17 (br
[M + H]⁺

d, 1 H), 6.74 (s, 1 H), 6.54 (br d, 1 H), 4.46 (br dd, 1 H), 3.78-

3.97 (m, 1 H), 3.01-3.22 (m, 1 H), 2.76-2.95 (m, 1 H)

1628
Data provided above

1629
Data provided above

1630
(CD₃OD) δ 8.24-8.97 (m, 3 H), 8.08 (s, 1 H), 7.85-8.03 (m, 2 H),
478.2
100%

7.59-7.73 (m, 2 H), 6.41-7.11 (m, 4 H), 4.63 (br s, 1 H), 3.95 (s,
[M + H]⁺

3 H), 3.39-3.83 (m, 1 H), 3.00-3.16 (m, 1 H), 2.77 (br d, 1 H),

2.44 (s, 3 H)

1631
(CD₃OD) δ 8.29-8.96 (m, 3 H), 8.11 (s, 1 H), 7.88-8.04 (m, 2 H),
478.2
98.7%

7.63-7.77 (m, 2 H), 6.45-7.12 (m, 4 H), 4.69-4.86 (m, 1 H), 3.97
[M + H]⁺

(s, 3 H), 3.05-3.16 (m, 1 H), 2.80 (br d, 1 H), 2.46 (s, 3 H)

1632
(CD₃OD) δ 9.03 (s, 1 H), 8.02 (d, 1 H), 7.90 (dd, 2 H), 7.63-7.76
532.2
100%

(m, 2 H), 7.24-7.51 (m, 2 H), 6.76 (d, 2 H), 4.56-4.75 (m, 2 H),
[M + H]⁺

3.98 (s, 3 H), 2.98-3.18 (m, 1 H), 2.78 (dd, 1 H)

1633
(CD₃OD) δ 9.03 (s, 1 H), 8.03 (d, 1 H), 7.91 (dd, 2 H), 7.63-7.82
532.2
100%

(m, 2 H), 7.28-7.50 (m, 2 H), 6.77 (d, 2 H), 4.56-4.73 (m, 2 H),
[M + H]⁺

3.98 (s, 3 H), 3.01-3.19 (m, 1 H), 2.80 (dd, 1 H)

1634
(CD₃OD) δ 8.22-9.20 (m, 3 H), 8.01 (d, 1 H), 7.71 (s, 1 H), 7.50
475.2
98.0%

(dd, 1 H), 7.33 (d, 1 H), 6.89 (br t, 3 H), 4.62-4.72 (m, 1 H), 3.92
[M + H]⁺

(s, 2 H), 3.37-3.60 (m, 1 H), 3.00-3.18 (m, 1 H), 2.80 (br dd, 1

H), 2.56 (s, 6 H)

1635
(CD₃OD) δ 8.23-9.22 (m, 3 H), 8.01 (d, 1 H), 7.71 (s, 1 H), 7.50
475.2
100%

(dd, 1 H), 7.33 (d, 1 H), 6.89 (s, 3 H), 4.60-4.73 (m, 1 H), 3.94
[M + H]⁺

(s, 2 H), 3.36-3.58 (m, 1 H), 3.02-3.18 (m, 1 H), 2.72-2.88 (m, 1

H), 2.58 (s, 6 H)

1636
(CD₃OD) δ 8.68 (d, 1 H), 8.28 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1
399.2
99.6%

H), 7.68 (s, 1 H), 7.54 (ddd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1H),
[M + H]⁺

6.64 (s, 1 H), 6.52 (s, 1 H), 4.43 (dd, 1 H), 3.71-3.86 (m, 1 H),

3.01-3.15 (m, 1 H), 2.83 (br dd, 1 H), 2.42 (s, 3 H)

1637
(CD₃OD) δ 8.69 (d, 1 H), 8.29 (br d, 1 H), 8.13 (d, 1 H), 8.00
399.2
99.6%

(td, 1 H), 7.68 (s, 1 H), 7.40-7.59 (m, 1 H), 6.97 (br d, 1 H), 6.77
[M + H]⁺

(t, 1 H), 6.64 (s, 1 H), 6.52 (br s, 1 H), 4.44 (dd, 1 H), 3.69-3.86

(m, 1 H), 3.01-3.18 (m, 1 H), 2.84 (br dd, 1 H), 2.43 (s, 3 H)

1638
(CD₃OD) δ 8.68 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1 H), 7.67 (s, 1
419.1
100%

H), 7.52-7.62 (m, 2 H), 7.16 (dd, 1 H), 6.98-7.05 (m, 1 H), 6.76
[M + H]⁺

(s, 1 H), 6.54 (s, 1 H), 4.45 (dd, 1 H), 3.87 (td, 1 H), 3.04-3.15

(m, 1 H), 2.85 (dd, 1 H)

1639
(CD₃OD) δ 8.68 (d, 1 H), 8.13 (d, 1 H), 8.00 (td, 1 H), 7.67 (s, 1
419.1
95.0%

H), 7.59 (d, 1 H), 7.54 (dd, 1 H), 7.16 (dd, 1 H), 7.01(d, 1H),
[M + H]⁺

6.76 (s, 1 H), 6.54 (s, 1 H), 4.45 (dd, 1 H), 3.82-3.92 (m, 1 H),

3.03-3.15 (m, 1 H), 2.85 (dd, 1 H)

1640
(CD₃OD) δ 8.68 (br d, 1 H), 8.12 (d, 1 H), 7.99 (td, 1 H), 7.74
399.2
98.5%

(br s, 1 H), 7.54 (ddd, 1 H), 7.45 (d, 1 H), 7.09 (dd, 1 H), 6.87 (s,
[M + H]⁺

1 H), 6.36-6.64 (m, 2 H), 4.43 (dd, 1 H), 3.74-3.99 (m, 1 H),

2.98-3.22 (m, 1 H), 2.85 (br d, 1 H), 2.56-2.67 (m, 3 H)

1641
(CD₃OD) δ 8.67 (d, 1 H), 8.11 (d, 1 H), 7.99 (td, 1 H), 7.66(s, 1
399.2
96.8%

H), 7.50-7.58 (m, 1 H), 7.44 (d, 1 H), 7.08 (dd, 1 H), 6.68 (d, 1
[M + H]⁺

H), 6.45-6.61 (m, 2 H), 4.42 (dd, 1 H), 3.85 (td, 1 H), 2.98-3.15

(m, 1 H), 2.83 (br dd, 1 H), 2.60 (s, 3 H)

1642
(CD₃OD) δ 8.29 (d, 1 H), 7.68 (s, 1 H), 7.39 (d, 1 H), 7.31 (d, 1
371.2
99.7%

H), 7.18 (td, 1 H), 7.03-7.12 (m, 1 H), 6.96 (d, 1 H), 6.76 (t, 1
[M + H]⁺

H), 6.60 (d, 2 H), 4.54 (dd, 1 H), 3.73 (ddd, 1 H), 2.98-3.13 (m,

1 H), 2.82 (dd, 1 H), 2.42 (s, 3 H)

1643
(CD₃OD) δ 8.28 (d, 1 H), 7.67 (s, 1 H), 7.38 (d, 1 H), 7.31 (d, 1
371.2
98.0%

H), 7.18 (td, 1 H), 7.04-7.11 (m, 1 H), 6.96 (d, 1 H), 6.75 (t, 1
[M + H]⁺

H), 6.55-6.65 (m, 2 H), 4.54 (dd, 1 H), 3.73 (ddd, 1 H), 2.98-

3.13 (m, 1 H), 2.82 (dd, 1 H), 2.42 (s, 3 H)

1644
(CD₃OD) δ 9.24 (s, 1 H), 8.75-8.96 (m, 1 H), 8.25-8.45 (s, 1 H),
479.2
99.3%

7.99-8.10 (m, 2 H), 7.84-7.97 (m, 2 H), 7.72 (s, 1 H), 7.31-7.45
[M + H]⁺

(m, 1 H), 6.49-7.09 (m, 4 H), 4.67-4.88 (m, 1 H), 3.37-3.96 (m, 1

H), 3.02-3.19 (m, 1 H), 2.78 (br dd, 1 H)

1645
(CD₃OD) δ 9.18 (s, 1 H), 8.24-8.59 (m, 4 H), 7.80-8.04 (m, 4 H),
479.2
99.1%

7.25-7.37 (m, 1 H), 6.61-6.96 (m, 4 H), 4.58 (br s, 1 H), 3.30-
[M + H]⁺

3.68 (m, 1 H), 2.98-3.16 (m, 1 H), 2.78 (br dd, 1 H)

1646
(CD₃OD) δ 9.01 (s, 1 H), 8.16-8.90 (m, 2 H), 8.02 (d, 1 H), 7.90
482.2
94.3%

(dd, 1 H), 7.60-7.74 (m, 2 H), 6.49-7.07 (m, 5 H), 4.62 (br s, 1
[M + H]⁺

H), 3.97 (s, 3 H), 3.41-3.86 (m, 1 H), 3.00-3.22 (m, 1 H), 2.80

(br dd, 1 H)

1647
(CD₃OD) δ 9.02 (s, 1 H), 8.44 (br s, 2 H), 8.02 (dd, 1 H), 7.91
482.2
98.6%

(dd, 1 H), 7.59-7.78 (m, 2 H), 6.49-7.15 (m, 5 H), 4.62 (s, 1 H),
[M + H]⁺

3.98 (s, 3 H), 3.42-3.90 (m, 1 H), 3.02-3.21 (m, 1 H), 2.69-2.89

(m, 1 H)

1648
(CD₃OD) δ 9.27 (s, 1 H), 8.22-9.01 (m, 3 H), 7.89-8.11 (m, 4 H),
475.2
96.4%

7.67 (s, 1 H), 7.29-7.45 (m, 1 H), 6.35-7.11 (m, 4 H), 4.64-4.79
[M + H]⁺

(m, 1 H), 3.40-3.84 (m, 1 H), 3.02-3.18 (m, 1 H), 2.70-2.86 (m, 1

H), 2.44 (s, 3 H)

1649
(CD₃OD) δ 9.30 (s, 1 H), 8.23-9.07 (m, 3 H), 7.91-8.12 (m, 4 H),
475.2
97.5%

7.70 (s, 1 H), 7.35-7.45 (m, 1 H), 6.45-7.06 (m, 4 H), 4.66-4.81
[M + H]⁺

(m, 1 H), 3.39-4.00 (m, 1 H), 3.05-3.16 (m, 1 H), 2.80 (br d, 2

H), 2.37-2.52 (m, 3 H)

1650
(CD₃OD) δ 8.43-8.76 (m, 3 H), 7.98 (d, 1 H), , 7.68-7.69 (m, 1
462.1
96.2%

H), 7.40-7.40 (m, 1 H), 7.33 (d, 1 H), 6.57-7.02 (m, 3 H), 4.94-
[M + H]⁺

5.07 (m, 1 H), 4.55 (s, 2 H), 3.40-3.78 (m, 4 H), 3.04-3.18 (m, 1

H), 2.80 (br dd, 1 H)

1651
(CD₃OD) δ 8.37-8.83 (m, 3 H), 7.91-8.02 (m, 1 H), 7.66-7.79
462.1
98.9%

(m, 1 H), 7.41-7.49 (m, 1 H), 7.32 (d, 1 H), 6.56-6.99 (m, 3 H),
[M + H]⁺

4.93-4.60-4.75 (m, 1 H), 4.54 (s, 2 H), 3.38-3.87 (m, 4 H), 3.03-

3.16 (m, 1 H), 2.80 (br dd, 1 H)

1652
(CD₃OD) δ 8.51 (d, 1 H), 8.02 - 8.42 (d, 1 H), 7.72 (s, 1 H), 7.52
500.1
99.7%

(s, 0.3 H), 7.29 (d, 1 H), 6.97 (s, 0.7 H), 6.52-6.86 (m, 3
[M + H]⁺

H), 5.02-5.10 (m, 1 H), 3.91-4.01 (m, 3 H), 3.74-3.84 (m, 0.7 H),

3.38-3.46 (m, 0.3 H), 3.14-3.25 (m, 0.7 H), 3.02 (ddd, 0.3 H),

2.77-2.91 (m, 1 H)

1653
(CD₃OD) δ 8.50 (d, 1 H), 7.92 - 8.22 (d, 1 H), 7.72 (s, 1 H), 7.50
500.1
99.4%

(s, 0.3 H), 7.30 (d, 1 H), 6.97 (s, 0.7 H), 6.48-6.76(m, 3
[M + H]⁺

H), 4.92-5.15 (m, 1 H), 3.94-4.06 (m, 3 H), 3.71-3.80 (m, 0.7 H),

3.35-3.43 (m, 0.3 H), 3.10-3.24 (m, 0.7 H), 3.03 (ddd, 0.3 H),

2.77-2.91 (m, 1 H)

1654
(CD₃OD) δ 8.36 (br d, 1 H), 7.71 (br s, 1 H), 7.46 (br s, 0.3 H),
442.1
97.4%

7.18-7.28 (m, 0.2 H), 7.02-7.07 (m, 0.5 H), 6.95-7.02 (m, 1 H),
[M + H]⁺

6.81-6.95 (m, 2 H), 6.63-6.79 (m, 1 H), 5.01 (br dd, 0.4 H), 4.85-

4.87 (m, 0.6 H), 3.64-3.81 (m, 0.7 H), 3.37-3.42 (m, 0.3 H),

2.92-3.22 (m, 1 H), 2.85 (br s, 1 H), 2.27-2.38 (m, 1 H), 1.20-

1.32 (m, 4 H)

1655
(CD₃OD) δ 8.28-8.51 (m, 1 H), 7.70 (s, 1 H), 7.46 (br s, 0.3 H),
442.2
95.2%

7.18-7.26 (m, 0.2 H), 7.02-7.09 (m, 0.5 H), 6.95-7.02 (m, 1 H),
[M + H]⁺

6.81-6.95 (m, 2 H), 6.65-6.77 (m, 1 H), 5.01 (br dd, 0.5 H), 4.84-

4.87 (m, 0.5 H), 3.66-3.82 (m, 0.7 H), 3.38-3.44 (m, 0.3 H),

2.91-3.23 (m, 1 H), 2.83 (br d, 1 H), 2.28-2.42 (m, 1 H), 1.19-

1.32 (m, 4 H)

1656
(CD₃OD) δ 8.63-8.69 (m, 1 H), 8.28-8.42 (m, 1 H), 7.89-8.00
497.1
100%

(m, 1 H), 7.68-7.81 (m, 2 H), 7.20-7.50 (m, 0.7 H), 6.92-7.07 (m,
[M + H]⁺

2 H), 6.74-6.90 (m, 2.3 H), 4.94-5.03 (m, 1 H), 3.81 (ddd, 0.7

H), 3.45 (td, 0.3 H), 2.98-3.29 (m, 1 H), 2.87 (br dd, 1 H)

1657
(CD₃OD) δ 8.50-8.59 (m, 1 H), 8.16-8.30 (m, 1 H), 7.83 (t, 1 H),
497.1
99.4%

7.57-7.70 (m, 2 H), 7.05-7.40 (m, 0.7 H), 6.82-6.97 (m, 2 H),
[M + H]⁺

6.60-6.81 (m, 2.3 H), 4.84-4.92 (m, 1 H), 3.63-3.75 (m, 0.7 H),

3.33 (td, 0.3 H), 2.85-3.17 (m, 1 H), 2.76 (br dd, 1 H)

1658
(CD₃OD) δ 8.30-8.40 (m, 1 H), 7.97-8.05 (m, 1 H), 7.71 (s, 1 H),
496.2
98.9%

7.57 (s, 0.3 H), 7.19-7.25 (m, 0.2 H), 6.70-7.07 (m, 4.5 H), 4.94-
[M + H]⁺

5.17 (m, 1 H), 3.90 (s, 3 H), 3.72-3.83 (m, 0.7 H), 3.35-3.46 (m,

0.3 H), 2.96-3.26 (m, 1 H), 2.80-2.91 (m, 1 H), 2.63-2.73 (m, 3 H)

1659
(CD₃OD) δ 8.28-8.41 (m, 1 H), 7.96-8.06 (m, 1 H), 7.71 (s, 1 H),
496.2
99.4%

7.57 (s, 0.3 H), 7.17-7.27 (m, 0.2 H), 6.68-7.09 (m, 4.5 H), 4.94-
[M + H]⁺

5.16 (m, 1 H), 3.90 (s, 3 H), 3.71-3.83 (m, 0.7 H), 3.36-3.47 (m,

0.3 H), 2.95-3.26 (m, 1 H), 2.78-2.92 (m, 1 H), 2.62-2.75 (m, 3 H)

1660
(CD₃OD) δ 8.89-9.00 (m, 1 H), 8.29-8.43 (m, 2 H), 7.49-7.87
518.1
100%

(m, 2.3 H), 7.18-7.30 (m, 0.2 H), 6.66-7.09 (m, 4.5 H), 4.95-5.15
[M + H]⁺

(m, 1 H), 3.73-3.86 (m, 0.7 H), 3.42 (td, 0.3 H), 2.95-3.27 (m, 1

H), 2.87 (br dd, 1 H)

1661
(CD₃OD) δ 8.77-8.85 (m, 1 H), 8.17-8.28 (m, 2 H), 7.37-7.73
518.2
100%

(m, 2.3 H), 7.07-7.14 (m, 0.2 H), 6.55-6.96 (m, 4.5 H), 4.81-5.03
[M + H]⁺

(m, 1 H), 3.61-3.72 (m, 0.7 H), 3.30 (td, 0.3 H), 2.83-3.14 (m, 1

H), 2.74 (br d, 1 H)

1662
(CD₃OD) δ 8.21-8.52 (m, 2 H), 7.84 (s, 0.3 H), 7.66-7.76 (m, 1.5
518.1
100%

H), 7.48-7.59 (m, 0.5 H), 7.18-7.29 (m, 1.2 H), 6.94-7.08 (m, 2.2
[M + H]⁺

H), 6.81-6.91 (m, 1.3 H), 6.70-6.79 (m, 1 H), 5.06 (dd, 0.8 H),

4.96 (br s, 0.2 H), 3.74-3.87 (m, 0.7 H), 3.43 (td, 0.3 H), 2.95-

3.28 (m, 1 H), 2.87 (br d, 1 H)

1663
(CD₃OD) δ 8.27-8.48 (m, 2 H), 7.84 (s, 0.3 H), 7.71 (d, 1.4 H),
518.2
99.4%

7.49-7.63 (m, 0.6 H), 7.19-7.28 (m, 1.2 H), 6.93-7.08 (m, 2.1 H),
[M + H]⁺

6.80-6.91 (m, 1.3 H), 6.70-6.79 (m, 1 H), 5.06 (dd, 0.7 H), 4.96

(br s, 0.3 H), 3.74-3.88 (m, 0.7 H), 3.42 (br t, 0.3 H), 2.97-3.27

(m, 1 H), 2.87 (br d, 1 H)

1664
(CD₃OD) δ 8.30 (d, 3 H), 7.53 (s, 1 H), 7.01-7.20 (m, 2 H), 6.69
352.1
99.0%

(t, 1 H), 6.47-6.61 (m, 2 H), 4.95 (br dd, 1 H), 3.35 (td, 1 H),
[M + H]⁺

2.70-2.87 (m, 1 H), 2.59 (br dd, 1 H)

1665
(CD₃OD) δ 8.27-8.49 (m, 3 H), 7.64 (s, 1 H), 7.11-7.34 (m, 2 H),
352.1
98.5%

6.81 (t, 1 H), 6.58-6.71 (m, 2 H), 5.06 (br dd, 1 H), 3.37-3.53 (m,
[M + H]⁺

1 H), 2.81-2.99 (m, 1 H), 2.70 (br dd, 1 H)

1666
(CD₃OD) δ 8.79 (br d, 1 H), 8.22-8.66 (m, 2 H), 7.89 (d, 1 H),
466.2
98.8%

7.63-7.72 (m, 2 H), 7.35 (dd, 1 H), 6.62-7.06 (m, 3 H), 4.61-4.72
[M + H]⁺

(m, 1 H), 3.35-3.88 (m, 1 H), 3.05-3.14 (m, 1 H), 2.79 (br dd, 1

H), 2.41 (s, 3 H)

1667
(CD₃OD) δ 8.78 (br d, 1 H), 8.21-8.67 (m, 2 H), 7.89 (d, 1 H),
466.1
98.5%

7.63-7.72 (m, 2 H), 7.34 (dd, 1 H), 6.60-7.09 (m, 3 H), 4.61-4.72
[M + H]⁺

(m, 1 H), 3.36-3.85 (m, 1 H), 3.05-3.14 (m, 1 H), 2.79 (dd, 1 H),

2.40 (s, 3 H)

1668
(CD₃OD) δ 8.32-8.61 (m, 3 H), 7.89 (d, 1 H), 7.67 (s, 1 H), 7.32-
412.2
98.6%

7.35 (m, 1 H), 7.00 (d, 1 H), 6.49-6.83 (m, 3 H), 4.61-4.74 (m, 1
[M + H]⁺

H), 3.40-3.75 (m, 1 H), 3.03-3.12 (m, 1 H), 2.78 (br dd, 1 H),

2.45 (s, 3 H), 2.40 (s, 3 H)

1669
(CD₃OD) δ 8.33-8.68 (m, 3 H), 7.90 (d, 1 H), 7.67 (s, 1 H), 7.34
412.2
96.8%

(d, 1 H), 7.01 (d, 1 H), 6.43-6.89 (m, 3 H), 4.61-4.75 (m, 1 H),
[M + H]⁺

3.35-3.79 (m, 1 H), 3.03-3.12 (m, 1 H), 2.78 (br dd, 1 H), 2.46

(s, 3 H), 2.40 (s, 3 H)

1670
(CD₃OD) δ 8.20-8.65 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.33
416.2
98.5%

(d, 1 H), 6.61-7.01 (m, 4 H), 4.63 (br dd, 1 H), 3.44-3.80 (m, 1
[M + H]⁺

H), 3.04-3.15 (m, 1 H), 2.78 (br dd, 1 H), 2.40 (s, 3 H)

1671
(CD₃OD) δ 8.20-8.69 (m, 3 H), 7.89 (d, 1 H), 7.62-7.73 (m, 1
416.2
99.6%

H), 7.34 (dd, 1 H), 6.60-7.03 (m, 4 H), 4.56-4.72 (m, 1 H), 3.37-
[M + H]⁺

3.80 (m, 1 H), 3.04-3.15 (m, 1 H), 2.79 (br dd, 1 H), 2.40 (s, 3 H)

1672
(CD₃OD) δ 8.43 (br s, 3 H), 7.87 (br d, 1 H), 7.66 (s, 1 H), 7.16-
442.2
96.1%

7.39 (m, 1 H), 6.49-7.03 (m, 4 H), 4.62-4.69 (m, 1 H), 3.40-3.96
[M + H]⁺

(m, 1 H), 2.96-3.18 (m, 1 H), 2.77 (br d, 1 H), 1.89-2.14 (m, 1

H), 0.90-1.12 (m, 2 H), 0.61-0.83 (m, 2 H)

1673
(CD₃OD) δ 8.43 (s, 3 H), 7.87 (d, 1 H), 7.66 (s, 1 H), 7.21 (dd, 1
442.2
99.5%

H), 6.41-7.08 (m, 4 H), 4.62-4.70 (m, 1 H), 3.42-3.97 (m, 1 H),
[M + H]⁺

2.92-3.16 (m, 1 H), 2.77 (br d, 1 H), 1.83-2.18 (m, 1 H), 0.94-

1.10 (m, 2 H), 0.67-0.88 (m, 2 H)

1674
(DMSO-d₆) δ 12.04 (br s, 1 H), 9.01 (br s, 1 H), 8.17-8.66 (m, 2
482.1
100%

H), 7.52-7.87 (m, 3 H), 6.47-7.35 (m, 4 H), 4.33-4.66 (m, 1 H),
[M + H]⁺

3.84 (s, 3 H), 3.16-3.32 (m, 1 H), 2.61-3.08 (m, 2 H)

1675
(DMSO-d₆) δ 12.04 (br s, 1 H), 9.01 (br s, 1 H), 8.24-8.62 (m, 2
482.2
100%

H), 7.52-8.00 (m, 3 H), 6.34-7.35 (m, 4 H), 4.40-4.63 (m, 1 H),
[M + H]⁺

3.84 (s, 3 H), 3.31-3.33 (m, 1 H), 2.57-3.07 (m, 2 H)

1676
(DMSO-d₆) δ 11.93-12.14 (m, 1 H), 8.88 (br s, 1 H), 8.51 (d, 2
464.2
99.0%

H), 7.85 (d, 1 H), 7.39-7.61 (m, 2 H), 7.12-7.31 (m, 2 H), 6.97
[M + H]⁺

(br s, 1 H), 6.49-6.79 (m, 2 H), 4.38-4.63 (m, 1 H), 3.85 (s, 4 H),

2.65-3.06 (m, 2 H)

1677
(DMSO-d₆) δ 11.89-12.99 (m, 1 H), 8.88 (br s, 1 H), 8.27-8.56
464.2
99.0%

(m, 2 H), 7.62-7.91 (m, 2 H), 7.38-7.57 (m, 1 H), 7.09-7.34 (m, 2
[M + H]⁺

H), 6.98 (br t, 1 H), 6.70 (br s, 2 H), 4.30-4.67 (m, 1 H), 3.85(s,

4 H), 2.64-3.05 (m, 2 H)

1678
(CD₃OD) δ 8.28-8.94 (m, 2 H), 7.95 (t, 1 H), 7.62-7.86 (m, 2 H),
515.1
100%

7.35-7.60 (m, 0.4 H), 7.10-7.34 (m, 1 H), 6.71-7.09 (m, 2.6 H),
[M + H]⁺

5.01 (br dd, 1 H), 3.73-3.90 (m, 0.6 H), 3.42-3.49 (m, 0.4 H),

2.98-3.29 (m, 1 H), 2.88 (br d, 1 H)

1679
(CD₃OD) δ 8.18-8.76 (m, 2 H), 7.75-7.93 (m, 1 H), 7.50-7.74
515.1
96.1%

(m, 2 H), 7.34 (br s, 0.4 H), 7.01-7.22 (m, 1 H), 6.51-7.00 (m,
[M + H]⁺

2.6 H), 4.89 (br dd, 1 H), 3.59-3.81 (m, 0.6 H), 3.30-3.36 (m, 0.4

H), 2.86-3.17 (m, 1 H), 2.67-2.83 (m, 1 H)

1680
(CD₃OD) δ 9.48 (d, 1 H), 8.70-9.09 (m, 2 H), 8.35-8.63 (m, 1
498.1
100%

H), 7.73 (s, 1 H), 7.51 (s, 0.4 H), 7.14-7.34 (m, 1 H), 6.76-7.02
[M + H]⁺

(m, 2.6 H), 5.06 (br dd, 1 H), 3.72-3.92 (m, 0.6 H), 3.42-3.50 (m,

0.4 H), 2.98-3.30 (m, 1 H), 2.77-2.95 (m, 1 H)

1681
(CD₃OD) δ 9.09-9.84 (m, 1 H), 8.72-9.06 (m, 2 H), 8.29-8.67
498.1
99.6%

(m, 1 H), 7.72 (s, 1 H), 7.51 (br s, 0.4 H), 7.11-7.37 (m, 1 H),
[M + H]⁺

6.58-7.09 (m, 2.6 H), 5.06 (br dd, 1 H), 3.77-3.87 (m, 0.6 H),

3.45 (br dd, 0.4 H), 3.22 (br d, 1 H), 2.88 (br d, 1 H)

1682
(CD₃OD) δ 8.35-8.54 (m, 2 H), 8.06-8.15 (m, 1 H), 7.73 (s, 1 H),
500.1
100%

7.59 (s, 0.3 H), 7.12-7.28 (m, 1 H), 6.73-7.03 (m, 2.7 H), 5.12
[M + H]⁺

(br dd, 1 H), 4.02 (s, 3 H), 3.44-3.83 (m, 1 H), 2.83-3.25 (m, 2 H)

1683
(CD₃OD) δ 8.27-8.40 (m, 2 H), 7.96-8.02 (m, 1 H), 7.62 (s, 1 H),
500.2
99.7%

7.47 (s, 0.3 H), 7.05-7.13 (m, 1 H), 6.62-6.86 (m, 2.7 H), 5.00
[M + H]⁺

(br dd, 1 H), 3.90 (s, 3 H), 3.32-3.72 (m, 1 H), 2.70-3.12 (m, 2 H)

1684
(CD₃OD) δ 8.43-8.53 (m, 1 H), 7.96-8.03 (m, 1 H), 7.71-7.79
514.2
99.8%

(m, 1 H), 7.59 (s, 0.3 H), 7.17-7.25 (m, 1 H), 6.76-6.99 (m, 2.7
[M + H]⁺

H), 5.13 (br dd, 1 H), 3.90 (s, 3 H), 3.43-3.81 (m, 1 H), 2.84-

3.24 (m, 2 H), 2.63-2.71 (m, 3 H)

1685
(CD₃OD) δ 8.32-8.40 (m, 1 H), 7.85-7.93 (m, 1 H), 7.61 (s, 1 H),
514.2
99.2%

7.46 (s, 0.3 H), 7.06-7.13 (m, 1 H), 6.63-6.86 (m, 2.7 H), 5.01
[M + H]⁺

(br dd, 1 H), 3.75-3.83 (m, 3 H), 3.32-3.68 (m, 1 H), 2.74-3.13

(m, 2 H), 2.52-2.61 (m, 3 H)

1686
(CD₃OD) δ 8.28-8.41 (m, 1 H), 7.71 (br s, 1 H), 7.01-7.48 (m, 1
458.2
100%

H), 6.81-7.01 (m, 3 H), 6.61-6.78 (m, 1 H), 4.93-5.03 (m, 1 H),
[M + H]⁺

3.69-3.79 (m, 0.6 H), 3.36-3.45 (m, 0.4 H), 2.93-3.22 (m, 1 H),

2.84 (br dd, 1 H), 1.43-1.58 (m, 9 H)

1687
(CD₃OD) δ 8.28-8.41 (m, 1 H), 7.71 (s, 1 H), 7.01-7.46 (m, 1 H),
458.2
99.5%

6.80-7.01 (m, 3 H), 6.64-6.78 (m, 1 H), 4.92-5.03 (m, 1 H), 3.74
[M + H]⁺

(ddd, 0.6 H), 3.40 (td, 0.4 H), 2.93-3.23 (m, 1 H), 2.84 (dd, 1 H),

1.41-1.58 (m, 9 H)

1688
(CD₃OD) δ 8.76-8.81 (m, 1 H), 8.28-8.41 (m, 2 H), 8.10 (td, 1
479.1
98.7%

H), 7.64-7.74 (m, 2 H), 7.04-7.54 (m, 1 H), 6.72-7.04 (m, 4 H),
[M + H]⁺

4.94-5.07 (m, 1 H), 3.81 (ddd, 0.7 H), 3.45 (td, 0.3 H), 2.96-3.29

(m, 1 H), 2.87 (br d, 1 H)

1689
(CD₃OD) δ 8.63-8.71 (m, 1 H), 8.16-8.29 (m, 2 H), 7.98 (td, 1
479.1
98.4%

H), 7.51-7.65 (m, 2 H), 6.92-7.43 (m, 1 H), 6.61-6.92 (m, 4 H),
[M + H]⁺

4.81-4.95 (m, 1 H), 3.69 (ddd, 0.7 H), 3.33 (td, 0.3 H), 2.86-3.16

(m, 1 H), 2.66-2.80 (m, 1 H)

1690
(DMSO-d₆) δ 12.00 (br s, 1 H), 8.68 (s, 2 H), 7.91 (d, 1 H), 7.34-
455.2
100%

7.65 (m, 3 H), 6.24-7.25 (m, 4 H), 4.33-4.68 (m, 1 H), 3.38-4.08
[M + H]⁺

(m, 3 H), 2.84-3.05 (m, 1 H), 2.69 (br s, 4 H), 2.17 (s, 6 H)

1691
(DMSO-d₆) δ 12.00 (br s, 1 H), 8.68 (s, 2 H), 7.91 (br d, 1 H),
455.2
100%

7.31-7.61 (m, 3 H), 6.43-7.23 (m, 4 H), 4.31-4.65 (m, 1 H), 3.44
[M + H]⁺

(s, 3 H), 2.94 (br s, 1 H), 2.69 (br s, 4 H), 2.17 (s, 6H)

1692
(CD₃OD) δ 8.54 (br d, 1 H), 8.29 (d, 2 H), 7.41-7.60 (m, 2 H),
386.1
100%

7.08 (s, 1 H), 6.74-6.92 (m, 1 H), 6.38-6.66 (m, 2 H), 4.96 (br
[M + H]⁺

dd, 1 H), 3.27-3.48 (m, 1 H), 2.70-2.88 (m, 1 H), 2.59 (br dd, 1 H)

1693
(CD₃OD) δ 8.54 (br d, 1 H), 8.29 (d, 2 H), 7.40-7.58 (m, 2 H),
386.1
97.0%

7.09 (s, 1 H), 6.82 (br t, 1 H), 6.44-6.62 (m, 2 H), 4.96 (br dd, 1
[M + H]⁺

H), 3.25-3.44 (m, 1 H), 2.70-2.91 (m, 1 H), 2.59 (br dd, 1 H)

1694
(CD₃OD) δ 8.42 (s, 1 H), 8.37 (br d, 1 H), 7.86 (d, 1 H), 7.65(s,
438.2
100%

1 H), 7.19 (d, 1 H), 6.99 (br d, 1 H), 6.79 (br t, 1 H), 6.53 (br s, 1
[M + H]⁺

H), 4.60 (br s, 1 H), 3.37-3.91 (m, 1 H), 2.98-3.11 (m, 1 H),

2.70-2.89 (m, 1 H), 2.44 (s, 3 H), 1.93-2.06 (m, 1 H), 0.95-1.06

(m, 2 H), 0.70-0.82 (m, 2 H)

1695
(CD₃OD) δ 8.42 (s, 1 H), 8.37 (br s, 1 H), 7.87 (d, 1 H), 7.65 (s,
438.2
98.7%

1 H), 7.20 (dd, 1 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.53 (br s, 1 H),
[M + H]⁺

4.60 (s, 1 H), 3.48 (s, 1 H), 2.97-3.13 (m, 1 H), 2.63-2.85 (m, 1

H), 2.44 (s, 3 H), 1.89-2.12 (m, 1 H), 0.97-1.14 (m, 2 H), 0.73-

0.86 (m, 2 H)

1696
(DMSO-d₆) δ 12.02 (br s, 1 H), 8.19-8.77 (m, 3 H), 7.85 (dd, 1
432.2
100%

H), 7.56 (d, 1 H), 7.04-7.33 (m, 2 H), 6.50-6.95 (m, 3 H), 4.26-
[M + H]⁺

4.74 (m, 1 H), 3.84 (d, 4 H), 2.61-3.08 (m, 2 H)

1697
(DMSO-d₆) δ 11.94-12.13 (m, 1 H), 8.20-8.75 (m, 3 H), 7.85 (d,
432.2
100%

1 H), 7.57 (s, 1 H), 7.06-7.31 (m, 2 H), 6.47-6.91 (m, 3 H), 4.29-
[M + H]⁺

4.72 (m, 1 H), 3.84 (s, 3 H), 3.25-3.33 (m, 1 H), 2.62-3.05 (m, 2 H)

1698
(DMSO-d₆) δ 12.02 (br s, 1 H), 8.74 (br d, 1 H), 8.51 (s, 2 H),
448.1
97.5%

7.85 (d, 1 H), 7.18-7.65 (m, 3 H), 6.30-7.02 (m, 3 H), 4.36-4.68
[M + H]⁺

(m, 1 H), 3.85 (s, 3 H), 3.30 (br s, 1 H), 2.59-3.06 (m, 2 H)

1699
(DMSO-d₆) δ 12.02 (br s, 1 H), 8.73 (br s, 1 H), 8.51 (s, 2 H),
448.1
93.6%

7.85 (d, 1 H), 7.18-7.65 (m, 3 H), 6.40-6.95 (m, 3 H), 4.30-4.67
[M + H]⁺

(m, 1 H), 3.85 (s, 3 H), 3.29-3.32 (m, 1 H), 2.57-3.07 (m, 2 H)

1700
(CD₃OD) δ 8.34-8.55 (m, 2 H), 8.15 (dd, 1 H), 7.79 (d, 1 H),
318.2
100%

7.63 (s, 1 H), 7.56 (d, 1 H), 7.12-7.20 (m, 1 H), 6.75-6.91 (m, 2
[M + H]⁺

H), 6.52 (s, 1 H), 4.69 (dd, 1 H), 3.62 (ddd, 1 H), 2.90-3.06 (m, 1

H), 2.75 (dd, 1 H)

1701
(CD₃OD) δ 8.25-8.53 (m, 2 H), 8.04 (dd, 1 H), 7.67 (d, 1 H),
318.2
100%

7.51 (s, 1 H), 7.38-7.47 (m, 1 H), 7.06 (s, 1 H), 6.70(s, 2H),
[M + H]⁺

6.40 (s, 1 H), 4.57 (dd, 1 H), 3.50 (ddd, 1 H), 2.78-2.93 (m, 1 H),

2.63 (dd, 1 H)

1702
(CD₃OD) δ 8.39-8.84 (m, 1 H), 7.67-7.93 (m, 2 H), 7.53 (s, 0.4
500.1
100%

H), 7.14-7.37 (m, 1 H), 6.56-7.14 (m, 3.6 H), 5.06 (br dd, 1 H),
[M + H]⁺

4.04 (s, 3 H), 3.79 (ddd, 0.6 H), 3.39-3.46 (m, 0.4 H), 3.21 (br t,

1 H), 2.75-2.94 (m, 1 H)

1703
(CD₃OD) δ 8.15-9.00 (m, 1 H), 7.68-7.98 (m, 2 H), 7.53 (br s,
500.1
99.7%

0.4 H), 7.11-7.31 (m, 1 H), 6.59-7.09 (m, 3.6 H), 5.06 (br dd, 1
[M + H]⁺

H), 4.05 (s, 3 H), 3.79 (br dd, 0.6 H), 3.42 (br s, 0.4 H), 3.21 (br

s, 1 H), 2.86 (br d, 1 H)

1704
(CD₃OD) δ 8.22-8.82 (m, 2 H), 7.38-8.13 (m, 2.4 H), 7.11-7.37
536.1
100%

(m, 2 H), 6.65-7.09 (m, 2.6 H), 5.07 (dd, 1 H), 3.76-3.84 (m, 0.6
[M + H]⁺

H), 3.39-3.47 (m, 0.4 H), 3.22 (br s, 1 H), 2.78-2.94 (m, 1 H)

1705
(CD₃OD) δ 8.18-8.80 (m, 2 H), 7.41-8.03 (m, 2.4 H), 7.11-7.36
536.1
100%

(m, 2 H), 6.65-7.07 (m, 2.6 H), 5.07 (br dd, 1 H), 3.76-3.85 (m,
[M + H]⁺

0.6 H), 3.43 (td, 0.4 H), 2.96-3.29 (m, 1 H), 2.87 (br d, 1 H)

1706
(CD₃OD) δ 8.38-8.57 (m, 2 H), 7.72 (s, 1 H), 7.41-7.59 (m, 0.3
554.2
100%

H), 7.12-7.33 (m, 2 H), 6.85-7.02 (m, 1.7 H), 6.73-6.83 (m, 1 H),
[M + H]⁺

4.94-5.13 (m, 1 H), 3.73-3.88 (m, 0.6 H), 3.44 (td, 0.4 H), 2.96-

3.25 (m, 1 H), 2.79-2.92 (m, 1 H)

1707
(CD₃OD) δ 8.42-8.56 (m, 2 H), 7.72 (s, 1 H), 7.53 (s, 0.3 H),
554.2
100%

7.16-7.34 (m, 2 H), 6.86-7.03 (m, 1.7 H), 6.73-6.85 (m, 1 H),
[M + H]⁺

4.95-5.12 (m, 1 H), 3.75-3.86 (m, 0.6 H), 3.44 (td, 0.4 H), 2.97-

3.27 (m, 1 H), 2.79-2.93 (m, 1 H)

1708
(CD₃OD) δ 8.51 (d, 1 H), 8.25-8.42 (m, 1 H), 7.72 (s, 1 H), 7.40-
536.1
100%

7.59 (m, 0.3 H), 7.29 (d, 1 H), 7.17-7.25 (m, 0.2 H), 6.93-7.09
[M + H]⁺

(m, 2.2 H), 6.80-6.91 (m, 1.3 H), 6.70-6.80 (m, 1 H), 4.95-5.12

(m, 1 H), 3.74-3.87 (m, 0.6 H), 3.43 (td, 0.4 H), 2.95-3.27 (m, 1

H), 2.87 (br d, 1 H)

1709
(CD₃OD) δ 8.39 (d, 1 H), 8.16-8.30 (m, 1 H), 7.60 (s, 1 H), 7.30-
536.1
99.6%

7.44 (m, 0.3 H), 7.17 (d, 1 H), 7.06-7.13 (m, 0.2 H), 6.80-6.97
[M + H]⁺

(m, 2.2 H), 6.68-6.79 (m, 1.3 H), 6.57-6.68 (m, 1 H), 4.94 (br dd,

1 H), 3.63-3.73 (m, 0.6 H), 3.31 (td, 0.4 H), 2.85-3.15 (m, 1 H),

2.75 (br d, 1 H)

1710
(CD₃OD) δ 8.30 (d, 1 H), 7.68 (s, 1 H), 6.92-7.19 (m, 1.7 H),
372.1
100%

6.67-6.91 (m, 1.3 H), 6.58 (s, 1 H), 6.39 (s, 1 H), 4.32 (dd, 1 H),
[M + H]⁺

3.62-3.89 (m, 1 H), 2.98-3.16 (m, 1 H), 2.83 (br dd, 1 H), 2.44

(s, 3 H)

1711
(CD₃OD) δ 8.31 (d, 1 H), 7.68 (s, 1 H), 6.94-7.22 (m, 1.7 H),
372.2
99.7%

6.70-6.92 (m, 1.3 H), 6.58 (s, 1 H), 6.39 (br s, 1 H), 4.32 (dd, 1
[M + H]⁺

H), 3.78 (ddd, 1 H), 2.98-3.18 (m, 1 H), 2.84 (br dd, 1 H), 2.45

(s, 3 H)

1712
(CD₃OD) δ 8.29-8.96 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.45
448.2
100%

(br d, 1 H), 7.33 (d, 1 H), 6.63-7.16 (m, 4 H), 4.58-4.74 (m, 1 H),
[M + H]⁺

3.39-3.82 (m, 1 H), 2.75-3.11 (m, 2 H), 2.40 (s, 3 H)

1713
(CD₃OD) δ 8.25-8.92 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.45
448.1
99.5%

(br d, 1 H), 7.34 (dd, 1 H), 6.60-7.15 (m, 4 H), 4.59-4.74 (m, 1
[M + H]⁺

H), 3.35-3.79 (m, 1 H), 2.76-3.15 (m, 2 H), 2.40 (s, 3 H)

1714
(CD₃OD) δ 8.28-8.72 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.28-
432.1
100%

7.35 (m, 2 H), 6.47-6.93 (m, 3 H), 4.62 (br s, 1 H), 3.38-3.84 (m,
[M + H]⁺

1 H), 2.76-3.13 (m, 2 H), 2.39 (s, 3 H)

1715
(CD₃OD) δ 8.24-8.77 (m, 3 H), 7.89 (d, 1 H), 7.68 (s, 1 H), 7.28-
432.1
99.7%

7.36 (m, 2 H), 6.50-6.94 (m, 3 H), 4.58-4.72 (m, 1 H), 3.37 (br s,
[M + H]⁺

1 H), 2.75-3.12 (m, 2 H), 2.39 (s, 3 H)

1716
(CD₃OD) δ 8.77 (br d, 1 H), 8.43 (s, 2 H), 7.86 (d, 1 H), 7.57-
492.2
98.0%

7.73 (m, 2 H), 7.21 (d, 1 H), 7.00 (br t, 1 H), 6.49-6.90 (m, 2 H),
[M + H]⁺

4.57-4.68 (m, 1.6 H), 3.40-3.72 (m, 0.4 H), 2.98-3.15 (m, 1 H),

2.77 (br dd, 1 H), 1.91-2.12 (m, 1 H), 0.96-1.10 (m, 2 H), 0.67-

0.85 (m, 2 H)

1717
(CD₃OD) δ 8.77 (br d, 1 H), 8.42 (s, 2 H), 7.86 (d, 1 H), 7.52-
492.2
98.1%

7.73 (m, 2 H), 7.21 (dd, 1 H), 7.00 (t, 1 H), 6.47-6.92 (m, 2 H),
[M + H]⁺

4.59 (s, 1.5 H), 3.40-3.69 (m, 0.5 H), 2.97-3.17 (m, 1 H), 2.77

(br dd, 1 H), 1.92-2.09 (m, 1 H), 0.96-1.09 (m, 2 H), 0.71-0.83

(m, 2 H)

1718
(DMSO-d₆) δ 11.99 (br s, 1 H), 8.51 (d, 2 H), 7.86 (d, 1 H),
428.2
99.9%

7.45-7.62 (m, 2 H), 7.08-7.29 (m, 2 H), 6.24-6.94 (m, 3 H), 4.35-
[M + H]⁺

4.71 (m, 1 H), 3.42-4.33 (m, 4 H), 2.86-3.01 (m, 1 H), 2.56-2.78

(m, 4 H)

1719
(DMSO-d₆) δ 11.99 (br s, 1 H), 8.51 (d, 2 H), 7.87 (d, 1 H), 7.55
428.2
99.8%

(br s, 2 H), 7.10-7.32 (m, 2 H), 6.33-6.92 (m, 3 H), 4.51 (br d, 1
[M + H]⁺

H), 3.53-4.28 (m, 4 H), 2.85-3.00 (m, 1 H), 2.69 (br s, 4 H)

1720
(DMSO-d₆) δ 12.02 (br s, 1 H), 8.08-8.84 (m, 2 H), 7.86 (br d, 1
432.2
99.7%

H), 7.46-7.66 (m, 2 H), 7.24 (br d, 2 H), 6.34-7.02 (m, 3 H),
[M + H]⁺

4.28-4.74 (m, 1 H), 3.54-4.26 (m, 4 H), 2.89-3.05 (m, 1 H), 2.69

(br d, 1 H)

1721
(DMSO-d₆) δ 11.84-12.18 (m, 1 H), 8.15-8.69 (m, 2 H), 7.86 (d,
432.1
98.5%

1 H), 7.44-7.65 (m, 2 H), 7.15-7.38 (m, 2 H), 6.27-6.95 (m, 3 H),
[M + H]⁺

4.49 (br d, 1 H), 3.85 (s, 4 H), 2.86-3.05 (m, 1 H), 2.63-2.76 (m,

1 H)

1722
(CD₃OD) δ 8.32-8.38 (m, 1 H), 8.02-8.13 (m, 1 H), 7.84 (s, 0.3
482.1
99.6%

H), 7.71 (d, 1.5 H), 7.53 (d, 0.5 H), 7.21-7.27 (m, 1 H), 6.97(s,
[M + H]⁺

0.7 H), 6.75-6.84 (m, 1 H), 6.56-6.71 (m, 2 H), 4.97-5.08 (m, 1

H), 3.94-4.01 (m, 3 H), 3.74-3.84 (m, 0.5 H), 3.39-3.53 (m, 0.5

H), 3.13-3.26 (m, 0.8 H), 2.95-3.08 (m, 0.2 H), 2.81-2.91 (m, 1 H)

1723
(CD₃OD) δ 8.19-8.27 (m, 1 H), 7.89-8.03 (m, 1 H), 7.72 (s, 0.3
482.2
98.7%

H), 7.54-7.63 (m, 1.5 H), 7.37-7.45 (m, 0.5 H), 7.08-7.14 (m, 1
[M + H]⁺

H), 6.85 (s, 0.7 H), 6.63-6.72 (m, 1 H), 6.43-6.59 (m, 2 H), 4.84-

4.94 (m, 1 H), 3.81-3.89 (m, 3 H), 3.61-3.73 (m, 0.6 H), 3.27-

3.36 (m, 0.4 H), 3.02-3.15 (m, 0.7 H), 2.84-2.96 (m, 0.3 H),

2.69-2.81 (m, 1 H)

1724
(CD₃OD) δ 8.32-8.65 (m, 1 H), 7.70 (s, 1 H), 7.46 (br s, 0.3 H),
460.2
100%

7.22 (br d, 1 H), 6.86-6.97 (m, 1.7 H), 6.69-6.79 (m, 1 H), 4.94-
[M + H]⁺

5.07 (m, 1 H), 3.74 (ddd, 0.6 H), 3.36-3.47 (m, 0.4 H), 2.83 (br

d, 2 H), 2.29-2.38 (m, 1 H), 1.20-1.33 (m, 4H)

1725
(CD₃OD) δ 8.38-8.56 (m, 1 H), 7.70 (s, 1 H), 7.47 (s, 0.3 H),
460.2
100%

7.16-7.27 (m, 1 H), 6.83-6.99 (m, 1.7 H), 6.66-6.79 (m, 1 H),
[M + H]⁺

5.02 (br dd, 1 H), 3.74 (ddd, 0.6 H), 3.35-3.45 (m, 0.4 H), 2.80-

3.21 (m, 2 H), 2.26-2.39 (m, 1 H), 1.19-1.33 (m, 4 H)

1726
(CD₃OD) δ 8.39-8.57 (m, 1 H), 7.71 (s, 1 H), 7.41 (s, 0.3 H),
480.1
100%

7.17-7.25 (m, 1 H), 6.88-6.98 (m, 1.7 H), 6.70-6.82 (m, 1 H),
[M + H]⁺

4.99 (br dd, 1 H), 3.77 (ddd, 0.6 H), 3.40 (br d, 0.4 H), 2.85 (br

dd, 2 H), 1.83-1.97 (m, 6 H)

1727
(CD₃OD) δ 8.39-8.56 (m, 1 H), 7.71 (s, 1 H), 7.41 (s, 0.3 H),
480.2
99.4%

7.17-7.25 (m, 1 H), 6.88-6.98 (m, 1.7 H), 6.70-6.80 (m, 1 H),
[M + H]⁺

4.94-5.03 (m, 1 H), 3.77 (ddd, 0.6 H), 3.40 (td, 0.4 H), 2.81-3.21

(m, 2 H), 1.78-2.01 (m, 6 H)

1728
(CD₃OD) δ 8.17-8.54 (m, 1 H), 7.72 (br s, 1 H), 7.42 (br s, 0.3
462.1
100%

H), 7.18-7.25 (m, 0.2 H), 6.91-7.10 (m, 2 H), 6.80-6.90 (m, 1.3
[M + H]⁺

H), 6.56-6.79 (m, 1.2 H), 4.98 (br dd, 1 H), 3.68-3.83 (m, 0.7 H),

3.37-3.46 (m, 0.3 H), 3.09-3.23 (m, 0.8 H), 2.99 (br d, 0.2 H),

2.85 (br d, 1 H), 1.75-2.00 (m, 6 H)

1729
(CD₃OD) δ 8.27-8.41 (m, 1 H), 7.71 (s, 1 H), 7.42 (s, 0.3 H),
462.2
100%

7.18-7.26 (m, 0.2 H), 6.92-7.09 (m, 2.2 H), 6.82-6.90 (m, 1.3 H),
[M + H]⁺

6.64-6.79 (m, 1 H), 4.98 (br dd, 1 H), 3.64-3.88 (m, 0.7 H), 3.38-

3.44 (m, 0.3 H), 3.13-3.23 (m, 0.7 H), 2.94-3.06 (m, 0.3 H), 2.85

(dd, 1 H), 1.78-2.00 (m, 6 H)

1730
(CD₃OD) δ 8.62 (br d, 3 H), 7.96 (d, 1 H), 7.67 (br s, 1 H), 7.31-
434.1
99.5%

7.51 (m, 2 H), 6.49-7.20 (m, 5 H), 4.94-5.29 (m, 1 H), 3.33-3.92
[M + H]⁺

(m, 1 H), 2.97-3.14 (m, 1 H), 2.78 (br d, 1 H)

1731
(CD₃OD) δ 8.62 (br d, 3 H), 7.96 (d, 1 H), 7.66 (s, 1 H), 7.36-
434.1
99.8%

7.51 (m, 2 H), 6.63-7.16 (m, 5 H), 4.93-5.21 (m, 1 H), 3.57 (br s,
[M + H]⁺

1 H), 3.00-3.16 (m, 1 H), 2.77 (br dd, 1 H)

1732
(CD₃OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (br d, 1 H), 7.12 (d,
408.1
97.2%

0.5 H), 6.90-7.05 (m, 2 H), 6.85 (d, 0.5 H), 6.76 (s, 1 H), 6.41
[M + H]⁺

(br s, 1 H), 4.34 (dd, 1 H), 3.77 (ddd, 1 H), 2.99-3.17 (m, 1 H),

2.84 (br dd, 1 H)

1733
(CD₃OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (d, 1 H), 7.12 (d,
408.1
97.1%

0.5 H), 6.90-7.04 (m, 2 H), 6.85 (d, 0.5 H), 6.76 (s, 1 H), 6.41 (s,
[M + H]⁺

1 H), 4.35 (dd, 1 H), 3.77 (ddd, 1 H), 2.98-3.19 (m, 1 H), 2.84

(dd, 1 H)

1734
(CD₃OD) δ 8.70 (d, 1 H), 7.54-7.84 (m, 2 H), 6.93-7.21 (m, 1.7
426.1
98.6%

H), 6.69-6.90 (m, 1.3 H), 6.42 (s, 1 H), 4.36 (dd, 1 H), 3.78 (ddd,
[M + H]⁺

1 H), 3.07 (br d, 1 H), 2.85 (dd, 1 H)

1735
(CD₃OD) δ 8.58 (d, 1 H), 7.32-7.74 (m, 2 H), 6.81-7.05 (m, 1.7
426.1
97.4%

H), 6.56-6.78 (m, 1.3 H), 6.30 (s, 1 H), 4.24 (dd, 1 H), 3.66 (ddd,
[M + H]⁺

1 H), 2.96 (br s, 1 H), 2.73 (dd, 1 H)

1736
(CD₃OD) δ 8.35 (d, 1 H), 7.69 (s, 1 H), 7.12 (s, 0.3 H), 6.78-7.03
376.1
98.9%

(m, 2.7 H), 6.72 (s, 1 H), 6.39 (s, 1 H), 4.34 (dd, 1 H), 3.78 (ddd,
[M + H]⁺

1 H), 2.98-3.18 (m, 1 H), 2.84 (dd, 1 H)

1737
(CD₃OD) δ 8.35 (d, 1 H), 7.70 (s, 1 H), 7.12 (s, 0.3 H), 6.76-7.06
376.1
100%

(m, 2.7 H), 6.72 (s, 1 H), 6.40 (s, 1 H), 4.34 (dd, 1 H), 3.78 (ddd,
[M + H]⁺

1 H), 2.99-3.21 (m, 1 H), 2.84 (dd, 1 H)

1738
(CD₃OD) δ 8.45 (d, 1 H), 7.69 (s, 1 H), 7.31 (d, 1 H), 7.12 (s, 0.3
392.1
98.2%

H), 6.99 (s, 0.5 H), 6.81-6.91 (m, 1.2 H), 6.71 (s, 1 H), 6.39 (br
[M + H]⁺

s, 1 H), 4.34 (dd, 1 H), 3.78 (ddd, 1 H), 2.98-3.15 (m, 1 H), 2.84

(br dd, 1 H)

1739
(CD₃OD) δ 8.45 (d, 1 H), 7.70 (s, 1 H), 7.30 (d, 1 H), 7.12 (s, 0.3
392.1
99.6%

H), 6.99 (s, 0.5 H), 6.78-6.91 (m, 1.2 H), 6.71 (s, 1 H), 6.39 (s, 1
[M + H]⁺

H), 4.34 (dd, 1 H), 3.78 (ddd, 1 H), 2.96-3.19 (m, 1 H), 2.84 (dd,

1 H)

1740
(CD₃OD) δ 7.66 (s, 1 H), 7.45 (d, 1 H), 6.82-7.15 (m, 2 H), 6.70
372.1
98.9%

(d, 1 H), 6.50 (s, 1 H), 6.38 (s, 1 H), 4.31 (dd, 1 H), 3.78 (ddd, 1
[M + H]⁺

H), 2.98-3.12 (m, 1 H), 2.82 (dd, 1 H), 2.62 (s, 3 H)

1741
(CD₃OD) δ 7.66 (s, 1 H), 7.44 (br d, 1 H), 6.82-7.16 (m, 2 H),
372.2
98.5%

6.68 (br d, 1 H), 6.50 (s, 1 H), 6.38 (s, 1 H), 4.30 (dd, 1 H), 3.72-
[M + H]⁺

3.84 (m, 1 H), 3.03 (br d, 1 H), 2.81 (br dd, 1 H), 2.61 (s, 3 H)

1742
(CD₃OD) δ 8.30-8.76 (m, 3 H), 7.86 (d, 1 H), 7.66 (s, 1 H), 7.43
474.2
92.4%

(br d, 1 H), 6.51-7.24 (m, 5 H), 4.62 (br d, 1 H), 3.39-3.70 (m, 1
[M + H]⁺

H), 3.01-3.11 (m, 1 H), 2.77 (br dd, 1 H), 1.92-2.07 (m, 1 H),

0.97-1.07 (m, 2 H), 0.69-0.83 (m, 2 H)

1743
(CD₃OD) δ 8.30-8.76 (m, 3 H), 7.86 (d, 1 H), 7.66 (s, 1 H), 7.43
474.2
93.8%

(br d, 1 H), 6.48-7.24 (m, 5 H), 4.62 (br s, 1 H), 3.39-3.75 (m, 1
[M + H]⁺

H), 2.98-3.14 (m, 1 H), 2.77 (br dd, 1 H), 1.93-2.08 (m, 1 H),

0.94-1.08 (m, 2 H), 0.70-0.82 (m, 2 H)

1744
(CD₃OD) δ 8.62-9.24 (m, 1 H), 8.40 (s, 1 H), 7.88 (d, 1 H), 7.55-
458.2
100%

7.68 (m, 2 H), 7.13-7.24 (m, 2 H), 7.05 (d, 1 H), 6.45-6.94 (m, 2
[M + H]⁺

H), 4.63 (br s, 1 H), 3.35-3.64 (m, 1 H), 2.98-3.11 (m, 1 H), 2.75

(dd, 1 H), 1.94-2.06 (m, 1 H), 0.97-1.07 (m, 2 H), 0.71-0.80 (m,

2 H)

1745
(CD₃OD) δ 8.52-9.28 (m, 1 H), 8.41 (s, 1 H), 7.88 (d, 1 H), 7.56-
458.2
99.0%

7.68 (m, 2 H), 6.98-7.25 (m, 3 H), 6.49-6.92 (m, 2 H), 4.61-4.72
[M + H]⁺

(m, 1 H), 3.36-3.68 (m, 1 H), 2.96-3.12 (m, 1 H), 2.75 (dd, 1 H),

1.94-2.06 (m, 1 H), 0.96-1.08 (m, 2 H), 0.73-0.83 (m, 2 H)

1746
(CD₃OD) δ 8.77 (br d, 1 H), 8.35 (br s, 1 H), 7.92 (d, 1 H), 7.84
495.2
100%

(d, 1 H), 7.57-7.71 (m, 2 H), 7.38 (dd, 1 H), 7.00 (t, 1 H), 6.59-
[M + H]⁺

6.92 (m, 2 H), 4.64 (br s, 1 H), 3.42-3.78 (m, 1 H), 3.02-3.16 (m,

1 H), 2.95 (s, 6 H), 2.71-2.83 (m, 1 H)

1747
(CD₃OD) δ 8.78 (br s, 1 H), 8.37 (br s, 1 H), 7.92 (d, 1 H), 7.84
495.2
99.8%

(d, 1 H), 7.55-7.72 (m, 2 H), 7.39 (dd, 1 H), 7.00 (br t, 1 H),
[M + H]⁺

6.56-6.92 (m, 2 H), 4.65 (br s, 1 H), 3.56 (br s, 1 H), 3.03-3.18

(m, 1 H), 2.95 (s, 6 H), 2.77 (br d, 1 H)

1748
(CD₃OD) δ 9.00 (s, 2 H), 8.15 (br d, 1 H), 7.99 (d, 1 H), 7.88(d,
494.3
98.4%

1 H), 7.61-7.69 (m, 2 H), 6.65-7.16 (m, 3 H), 6.58 (d, 2 H), 4.59
[M + H]⁺

(br d, 1 H), 3.96 (s, 7 H), 3.07 (br d, 1 H), 2.72-2.83 (m, 1 H)

1749
(CD₃OD) δ 8.95 (br d, 2 H), 8.13 (br s, 1 H), 7.96 (br d, 1 H),
494.2
99.2%

7.73-7.90 (m, 1 H), 7.57-7.72 (m, 2 H), 6.61-7.20 (m, 3 H), 6.54
[M + H]⁺

(br d, 2 H), 4.59 (br s, 1 H), 3.41-3.98 (m, 7 H), 2.92-3.18 (m, 1

H), 2.76 (br d, 1 H)

1750
(CD₃OD) δ 8.37 (br d, 2 H), 7.92 (d, 1 H), 7.85 (d, 1 H), 7.65(s,
441.2
100%

1 H), 7.38 (dd, 1 H), 6.99 (d, 1 H), 6.38-6.91 (m, 3 H), 4.63-4.71
[M + H]⁺

(m, 1 H), 3.58 (br s, 1 H), 3.00-3.16 (m, 1 H), 2.95 (s, 6 H), 2.76

(br d, 1 H), 2.44 (s, 3 H)

1751
(CD₃OD) δ 8.37 (br d, 2 H), 7.91 (d, 1 H), 7.84 (d, 1 H), 7.65(s,
441.2
100%

1 H), 7.38 (dd, 1 H), 6.99 (d, 1 H), 6.43-6.91 (m, 3 H), 4.61-4.70
[M + H]⁺

(m, 1 H), 3.56 (br s, 1 H), 3.00-3.14 (m, 1 H), 2.95 (s, 6 H), 2.76

(br d, 1 H), 2.44 (s, 3 H)

1752
(CD₃OD) δ 8.64 (s, 2 H), 8.40 (d, 1 H), 7.44-7.72 (m, 2 H), 7.07-
386.1
100%

7.30 (m, 2 H), 6.80 (td, 1 H), 6.54 (s, 1 H), 5.15 (dd, 1 H), 3.42-
[M + H]⁺

3.60 (m, 1 H), 2.58-3.02 (m, 2 H)

1753
(CD₃OD) δ 8.63 (s, 2 H), 8.39 (dd, 1 H), 7.63 (s, 1 H), 7.53 (d, 1
386.2
99.5%

H), 7.23 (s, 1 H), 7.14 (ddd, 1 H), 6.80 (td, 1 H), 6.45-6.61 (m, 1
[M + H]⁺

H), 5.14 (dd, 1 H), 3.50 (td, 1 H), 2.71-2.99 (m, 2 H)

1754
(CD₃OD) δ 8.65 (s, 2 H), 8.26 (d, 1 H), 7.65 (s, 1 H), 7.24 (s, 1
400.2
100%

H), 6.95 (d, 1 H), 6.74 (t, 1 H), 6.54 (s, 1 H), 5.16 (dd, 1 H), 3.52
[M + H]⁺

(td, 1 H), 2.68-2.98 (m, 2 H), 2.41 (s, 3 H)

1755
(CD₃OD) δ 8.65 (s, 2 H), 8.26 (d, 1 H), 7.64 (s, 1 H), 7.24 (s, 1
400.2
99.5%

H), 6.95 (d, 1 H), 6.74 (t, 1 H), 6.54 (s, 1 H), 5.15(dd, 1 H), 3.52
[M + H]⁺

(td, 1 H), 2.67-3.00 (m, 2 H), 2.41 (s, 3 H)

1756
Data provided above

1757
Data provided above

1758
(CD₃OD) δ 8.30-8.40 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H),
476.2
99.8%

7.05-7.13 (m, 1 H), 6.76-6.85 (m, 1.7 H), 6.56-6.68 (m, 1 H),
[M + H]⁺

4.89 (br dd, 1 H), 3.63 (ddd, 0.6 H), 3.28 (td, 0.4 H), 2.69-3.08

(m, 2 H), 1.32-1.42 (m, 9 H)

1759
(CD₃OD) δ 8.30-8.40 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H),
476.1
99.4%

7.05-7.12 (m, 1 H), 6.75-6.84 (m, 1.7 H), 6.57-6.69 (m, 1 H),
[M + H]⁺

4.88 (br dd, 1 H), 3.58-3.67 (m, 0.6 H), 3.28 (td, 0.4 H), 2.70-

3.08 (m, 2 H), 1.33-1.41 (m, 9 H)

1760
(CD₃OD) δ 8.78 (d, 1 H), 8.42-8.53 (m, 1 H), 8.32 (d, 1 H), 8.09
497.1
100%

(t, 1 H), 7.65-7.76 (m, 2 H), 7.51 (s, 0.3 H), 7.17-7.25 (m, 1H),
[M + H]⁺

6.86-7.00 (m, 1.7 H), 6.75-6.82 (m, 1 H), 4.94-5.09 (m, 1 H),

3.77-3.85 (m, 0.6 H), 3.45 (td, 0.4 H), 2.84-3.24 (m, 2 H)

1761
(CD₃OD) δ 8.78 (d, 1 H), 8.42-8.56 (m, 1 H), 8.32 (d, 1 H), 8.09
497.1
99.5%

(td, 1 H), 7.63-7.76 (m, 2 H), 7.51 (s, 0.3 H), 7.15-7.26 (m, 1 H),
[M + H]⁺

6.86-7.01 (m, 1.7 H), 6.77-6.84 (m, 1 H), 4.94-5.09 (m, 1 H),

3.77-3.85 (m, 0.6 H), 3.40-3.49 (m, 0.4 H), 2.85-3.27 (m, 2 H)

1762
(CD₃OD) δ 8.56 (br d, 1 H), 8.41 (d, 2 H), 7.64 (s, 1 H), 7.40 (br
368.1
100%

d, 1 H), 7.21 (s, 1 H), 6.81-7.13 (m, 2 H), 6.71 (s, 1 H), 6.66 (t, 1
[M + H]⁺

H), 5.06 (dd, 1 H), 3.40-3.51 (m, 1 H), 2.84-2.97 (m, 1 H), 2.70

(br dd, 1 H)

1763
(CD₃OD) δ 8.56 (d, 1 H), 8.41 (d, 2 H), 7.64 (s, 1 H), 7.40 (br d,
368.2
98.2%

1 H), 7.21 (s, 1 H), 6.81-7.12 (m, 2 H), 6.71 (s, 1 H), 6.66 (t, 1
[M + H]⁺

H), 5.06 (dd, 1 H), 3.40-3.52 (m, 1 H), 2.84-2.99 (m, 1 H), 2.70

(dd, 1 H)

1764
(CD₃OD) δ 8.39 (d, 2 H), 7.82 (d, 1 H), 7.61 (s, 1 H), 7.09-7.34
386.1
99.3%

(m, 3 H), 6.75 (s, 1 H), 6.64 (t, 1 H), 5.08 (dd, 1 H), 3.61 (td, 1
[M + H]⁺

H), 2.83-2.97 (m, 1 H), 2.71 (dd, 1 H)

1765
(CD₃OD) δ 8.39 (d, 2 H), 7.82 (d, 1 H), 7.61 (s, 1 H), 7.08-7.38
386.1
98.4%

(m, 3 H), 6.75 (s, 1 H), 6.64 (t, 1 H), 5.08 (br dd, 1 H), 3.54-3.68
[M + H]⁺

(m, 1 H), 2.83-2.97 (m, 1 H), 2.71 (br dd, 1 H)

1766
(CD₃OD) δ 8.60 (d, 1 H), 7.70 (s, 1 H), 7.45 (br d, 1 H), 6.83-
426.1
99.8%

7.15 (m, 2 H), 6.76 (s, 1 H), 6.43 (s, 1 H), 4.36 (dd, 1 H), 3.73-
[M + H]⁺

3.84 (m, 1 H), 3.02-3.16 (m, 1 H), 2.85 (dd, 1 H)

1767
(CD₃OD) δ 8.60 (br d, 1 H), 7.70 (s, 1 H), 7.45 (br d, 1 H), 6.83-
426.1
99.6%

7.15 (m, 2 H), 6.76 (s, 1 H), 6.43 (br s, 1 H), 4.36 (dd, 1 H), 3.79
[M + H]⁺

(td, 1 H), 3.02-3.15 (m, 1 H), 2.85 (br dd, 1 H)

1768
(CD₃OD) δ 8.22-8.77 (m, 3 H), 7.86 (d, 1 H), 7.66 (s, 1 H), 7.29
458.2
98.1%

(d, 1 H), 7.20 (dd, 1 H), 6.54-7.03 (m, 3 H), 4.60 (br s, 1 H),
[M + H]⁺

3.61 (q, 1 H), 3.00-3.17 (m, 1 H), 2.66-2.83 (m, 1 H), 1.97-2.06

(m, 1 H), 0.98-1.07 (m, 2 H), 0.73-0.81 (m, 2 H)

1769
(CD₃OD) δ 8.25-8.68 (m, 3 H), 7.86 (d, 1 H), 7.67 (s, 1 H), 7.29
458.1
97.8%

(d, 1 H), 7.19 (br d, 1 H), 6.40-6.97 (m, 3 H), 4.61 (br s, 1H),
[M + H]⁺

3.44-3.80 (m, 1 H), 3.01-3.18 (m, 1 H), 2.77 (br d, 1 H), 1.95-

2.05 (m, 1 H), 0.97-1.07 (m, 2 H), 0.71-0.80 (m, 2 H)

1770
(CD₃OD) δ 8.03-8.83 (m, 2 H), 7.80-7.95 (m, 2 H), 7.66 (s, 1 H),
477.2
99.4%

7.33-7.49 (m, 2 H), 6.59-7.17 (m, 4 H), 4.64 (br s, 1 H), 3.40-
[M + H]⁺

3.81 (m, 1 H), 3.01-3.17 (m, 1 H), 2.95 (s, 6 H), 2.77 (br d, 1 H)

1771
(CD₃OD) δ 8.00-8.80 (m, 2 H), 7.77-7.97 (m, 2 H), 7.66 (s, 1 H),
477.2
99.4%

7.31-7.47 (m, 2 H), 6.55-7.18 (m, 4 H), 4.64 (br s, 1 H), 3.43-
[M + H]⁺

3.92 (m, 1 H), 3.01-3.13 (m, 1 H), 2.95 (s, 6 H), 2.77 (br d, 1 H)

1772
(CD₃OD) δ 8.41 (br d, 2 H), 7.92 (d, 1 H), 7.85 (d, 1 H), 7.66(s,
445.2
100%

1 H), 7.38 (dd, 1 H), 6.97 (dd, 1 H), 6.55-6.91 (m, 3 H), 4.63 (br
[M + H]⁺

s, 1 H), 3.45-3.80 (m, 1 H), 3.02-3.16 (m, 1 H), 2.95 (s, 6H),

2.77 (br dd, 1 H)

1773
(CD₃OD) δ 8.41 (br d, 2 H), 7.91 (d, 1 H), 7.84 (d, 1 H), 7.65(s,
445.2
99.8%

1 H), 7.37 (dd, 1 H), 6.96 (dd, 1 H), 6.56-6.89 (m, 3 H), 4.63 (br
[M + H]⁺

s, 1 H), 3.43-3.78 (m, 1 H), 3.02-3.13 (m, 1 H), 2.94 (s, 6 H),

2.76 (br dd, 1 H)

1774
(CD₃OD) δ 8.57-8.74 (m, 3 H), 7.55-7.71 (m, 2 H), 7.24 (s, 1 H),
454.1
99.4%

6.95 (t, 1 H), 6.71 (s, 1 H), 5.20 (dd, 1 H), 3.45-3.63 (m, 1 H),
[M + H]⁺

2.67-3.00 (m, 2 H)

1775
(CD₃OD) δ 8.56-8.75 (m, 3 H), 7.54-7.69 (m, 2 H), 7.24 (s, 1 H),
454.1
98.1%

6.95 (t, 1 H), 6.71 (s, 1 H), 5.20 (dd, 1 H), 3.44-3.58 (m, 1 H),
[M + H]⁺

2.69-2.98 (m, 2 H)

1776
(CD₃OD) δ 8.49-8.69 (m, 3 H), 7.65 (s, 1 H), 7.39 (br d, 1 H),
436.1
100%

7.25 (s, 1 H), 7.09 (s, 0.2 H), 6.78-7.00 (m, 1.8 H), 6.72 (s, 1 H),
[M + H]⁺

5.18 (dd, 1 H), 3.51 (td, 1 H), 2.69-2.96 (m, 2 H)

1777
(CD₃OD) δ 8.47-8.71 (m, 3 H), 7.65 (s, 1 H), 7.39 (br d, 1 H),
436.1
100%

7.25 (s, 1 H), 7.09 (s, 0.2 H), 6.78-6.99 (m, 1.8 H), 6.72 (s, 1 H),
[M + H]⁺

5.18 (dd, 1 H), 3.51 (td, 1 H), 2.68-2.98 (m, 2 H)

1778
(CD₃OD) δ 8.67 (s, 2 H), 8.32 (d, 1 H), 7.66 (s, 1 H), 7.24 (s, 1
404.1
99.5%

H), 6.94 (dd, 1 H), 6.81 (td, 1 H), 6.70 (s, 1 H), 5.20 (dd, 1 H),
[M + H]⁺

3.48-3.63 (m, 1 H), 2.69-3.03 (m, 2 H)

1779
(CD₃OD) δ 8.64 (s, 2 H), 8.28 (d, 1 H), 7.65 (s, 1 H), 7.22 (s, 1
404.2
99.3%

H), 6.91 (dd, 1 H), 6.73-6.82 (m, 1 H), 6.67 (s, 1 H), 5.17 (dd, 1
[M + H]⁺

H), 3.51 (td, 1 H), 2.67-2.98 (m, 2 H)

1780
(CD₃OD) δ 8.65 (s, 2 H), 8.40 (d, 1 H), 7.65 (s, 1 H), 7.17-7.34
420.1
99.0%

(m, 2 H), 6.80 (t, 1 H), 6.66 (s, 1 H), 5.18 (dd, 1 H), 3.51 (td, 1
[M + H]⁺

H), 2.72-2.97 (m, 2 H)

1781
(CD₃OD) δ 8.66 (s, 2 H), 8.40 (br d, 1 H), 7.65 (s, 1 H), 7.13-
420.1
99.4%

7.33 (m, 2 H), 6.81 (t, 1 H), 6.66 (s, 1 H), 5.19 (dd, 1 H), 3.42-
[M + H]⁺

3.59 (m, 1 H), 2.66-2.98 (m, 2 H)

1782
(CD₃OD) δ 8.91-8.95 (m, 1 H), 8.44-8.53 (m, 1 H), 8.34-8.39
536.1
100%

(m, 1 H), 7.78-7.82 (m, 1.2 H), 7.51-7.67 (m, 1 H), 7.16-7.26 (m,
[M + H]⁺

1 H), 6.88-6.99 (m, 1.8 H), 6.76-6.83 (m, 1 H), 5.12 (dd, 1 H),

3.75-3.83 (m, 0.6 H), 3.40-3.48 (m, 0.4 H), 2.84-3.22 (m, 2 H)

1783
(CD₃OD) δ 8.89-8.96 (m, 1 H), 8.43-8.52 (m, 1 H), 8.36 (s, 1
536.2
100%

H), 7.72-7.82 (m, 1.2 H), 7.51-7.67 (m, 1 H), 7.17-7.28 (m, 1 H),
[M + H]⁺

6.87-7.00 (m, 1.8 H), 6.74-6.83 (m, 1 H), 4.97-5.16 (m, 1 H),

3.75-3.83 (m, 0.6 H), 3.43 (td, 0.4 H), 2.85-3.22 (m, 2 H)

1784
(CD₃OD) δ 8.38-8.98 (m, 3 H), 7.91 (d, 1 H), 7.63-7.72 (m, 2
510.2
99.5%

H), 7.42 (dd, 1 H), 7.02 (br t, 1 H), 6.58-6.92 (m, 2 H), 4.89-4.96
[M + H]⁺

(m, 1 H), 3.69 (t, 2 H), 3.35-3.51 (m, 4 H), 3.04-3.19 (m, 1 H),

2.95 (t, 2 H), 2.73-2.84 (m, 1 H)

1785
(CD₃OD) δ 8.28-8.95 (m, 3 H), 7.91 (d, 1 H), 7.63-7.73 (m, 2
510.2
100%

H), 7.43 (dd, 1 H), 6.58-7.10 (m, 3 H), 4.90-5.03 (m, 1 H), 3.69
[M + H]⁺

(t, 2 H), 3.37 (s, 4 H), 3.04-3.16 (m, 1 H), 2.95 (t, 2 H), 2.80 (br

dd, 1 H)

1786
(CD₃OD) δ 8.05-8.86 (m, 2 H), 7.76 (d, 1 H), 7.54 (s, 1 H), 7.33
416.2
99.5%

(d, 1 H), 7.18 (dd, 1 H), 7.11 (ddd, 1 H), 6.42-6.87 (m, 3 H),
[M + H]⁺

4.49-4.58 (m, 1 H), 3.24 (br s, 1 H), 2.89-3.01 (m, 1 H), 2.65 (br

dd, 1 H), 2.26 (s, 3 H)

1787
(CD₃OD) δ 8.22-8.92 (m, 2 H), 7.90 (d, 1 H), 7.66 (s, 1 H), 7.47
416.2
99.5%

(dd, 1 H), 7.33 (dd, 1 H), 7.25 (ddd, 1 H), 6.55-6.96 (m, 3 H),
[M + H]⁺

4.62 (br s, 1 H), 3.35-3.77 (m, 1 H), 3.03-3.12 (m, 1 H), 2.78

(dd, 1 H), 2.40 (s, 3 H)

1788
(CD₃OD) δ 8.42 (s, 2 H), 8.14 (br d, 1 H), 7.86 (d, 1 H), 7.64 (s,
454.2
97.5%

1 H), 7.20 (dd, 1 H), 6.39-6.93 (m, 4 H), 4.60-4.70 (m, 1 H),
[M + H]⁺

3.95 (s, 3 H), 3.37-3.74 (m, 1 H), 2.98-3.11 (m, 1 H), 2.75 (br

dd, 1 H), 1.94-2.07 (m, 1 H), 0.94-1.08 (m, 2 H), 0.71-0.85 (m, 2 H)

1789
(CD₃OD) δ 8.42 (s, 2 H), 8.14 (br d, 1 H), 7.86 (d, 1 H), 7.64 (s,
454.2
97.8%

1 H), 7.20 (d, 1 H), 6.37-7.01 (m, 4 H), 4.59-4.71 (m, 1 H), 3.95
[M + H]⁺

(s, 3 H), 3.49 (br s, 1 H), 3.00-3.10 (m, 1 H), 2.70-2.81 (m, 1 H),

1.95-2.08 (m, 1 H), 0.94-1.08 (m, 2 H), 0.72-0.83 (m, 2 H)

1790
(CD₃OD) δ 8.42 (s, 2 H), 7.87 (d, 1 H), 7.64 (s, 1 H), 7.46 (d, 1
442.2
99.7%

H), 7.14-7.30 (m, 2 H), 6.38-7.05 (m, 3 H), 4.59-4.71 (m, 1 H),
[M + H]⁺

3.45-3.98 (m, 1 H), 2.96-3.15 (m, 1 H), 2.76 (br d, 1 H), 1.96-

2.09 (m, 1 H), 0.95-1.07 (m, 2 H), 0.72-0.84 (m, 2 H)

1791
(CD₃OD) δ 8.42 (s, 2 H), 7.87 (d, 1 H), 7.65 (s, 1 H), 7.45 (d, 1
442.2
99.7%

H), 7.13-7.31 (m, 2 H), 6.44-7.01 (m, 3 H), 4.60-4.70 (m, 1 H),
[M + H]⁺

3.47-3.92 (m, 1 H), 2.96-3.11 (m, 1 H), 2.76 (br dd, 1 H), 1.91-

2.08 (m, 1 H), 0.97-1.11 (m, 2 H), 0.68-0.84 (m, 2 H)

1792
(CD₃OD) δ 8.51 (br d, 2 H), 7.77-7.94 (m, 2 H), 7.67 (s, 1 H),
461.2
100%

7.37 (dd, 1 H), 7.29 (d, 1 H), 6.36-6.96 (m, 3 H), 4.63 (br s, 1
[M + H]⁺

H), 3.38-3.72 (m, 1 H), 3.00-3.14 (m, 1 H), 2.94 (s, 6 H), 2.71-

2.82 (m, 1 H)

1793
(CD₃OD) δ 8.51 (br d, 2 H), 7.80-7.95 (m, 2 H), 7.66 (s, 1 H),
461.2
99.4%

7.37 (dd, 1 H), 7.29 (d, 1 H), 6.49-6.98 (m, 3 H), 4.65 (br s, 1
[M + H]⁺

H), 3.43-3.83 (m, 1 H), 3.01-3.15 (m, 1 H), 2.94 (s, 6 H), 2.77

(br dd, 1 H)

1794
(CD₃OD) δ 8.49-9.39 (m, 1 H), 7.80-7.94 (m, 2 H), 7.63 (s, 1 H),
441.2
99.9%

7.47 (d, 1 H), 7.36 (dd, 1 H), 7.13 (dd, 1 H), 6.34-6.91 (m, 3 H),
[M + H]⁺

4.62-4.71 (m, 1 H), 3.49 (br s, 1 H), 3.00-3.10 (m, 1 H), 2.94 (s,

6 H), 2.69-2.78 (m, 4 H)

1795
(CD₃OD) δ 8.23-9.44 (m, 1 H), 7.78-7.95 (m, 2 H), 7.64 (s, 1 H),
441.3
99.7%

7.47 (d, 1 H), 7.37 (dd, 1 H), 7.13 (dd, 1 H), 6.33-6.97 (m, 3 H),
[M + H]⁺

4.63-4.73 (m, 1 H), 3.39-3.86 (m, 1 H), 2.99-3.14 (m, 1 H), 2.95

(s, 6 H), 2.70-2.78 (m, 4 H)

1796
(CD₃OD) δ 8.24-8.53 (m, 3 H), 7.79 (d, 1 H), 7.56 (s, 1 H), 7.30
460.2
100%

(dd, 1 H), 6.87 (dd, 1 H), 6.40-6.82 (m, 3 H), 4.82 (br s, 1 H),
[M + H]⁺

3.57 (t, 2 H), 3.24 (s, 4 H), 2.91-3.04 (m, 1 H), 2.83 (t, 2 H), 2.67

(br dd, 1 H)

1797
(CD₃OD) δ 8.25-8.55 (m, 3 H), 7.80 (d, 1 H), 7.56 (s, 1 H), 7.30
460.2
99.2%

(dd, 1 H), 6.87 (dd, 1 H), 6.49-6.80 (m, 3 H), 4.81 (br s, 1 H),
[M + H]⁺

3.57 (t, 2 H), 3.22-3.33 (m, 4 H), 2.88-3.05 (m, 1 H), 2.83 (t, 2

H), 2.67 (br dd, 1 H)

1798
(CD₃OD) δ 8.17 (d, 1 H), 7.55 (s, 1 H), 6.86 (d, 1 H), 6.66 (t, 1
378.2
99.8%

H), 6.42 (s, 1 H), 6.17 (s, 1 H), 4.10 (dd, 1 H), 3.60 (ddd, 1 H),
[M + H]⁺

2.83-3.00 (m, 1 H), 2.69 (dd, 1 H), 2.31 (s, 3 H), 1.28(s, 9H)

1799
(CD₃OD) δ 8.17 (br d, 1 H), 7.55 (s, 1 H), 6.86 (br d, 1 H), 6.66
378.2
99.7%

(t, 1 H), 6.42 (s, 1 H), 6.17 (s, 1 H), 4.10 (br dd, 1 H), 3.51-3.70
[M + H]⁺

(m, 1 H), 2.84-2.99 (m, 1 H), 2.69 (br dd, 1 H), 2.31 (s, 3 H),

1.28 (s, 9 H)

1800
(CD₃OD) δ 8.63 (s, 2 H), 7.51-7.65 (m, 2 H), 7.24 (s, 1 H), 7.13
420.1
99.5%

(dd, 1 H), 6.98 (dd, 1 H), 6.69 (s, 1 H), 5.19 (dd, 1 H), 3.62 (td, 1
[M + H]⁺

H), 2.71-2.97 (m, 2 H)

1801
(CD₃OD) δ 8.64 (s, 2 H), 7.50-7.67 (m, 2 H), 7.24 (s, 1 H), 7.14
420.1
99.8%

(dd, 1 H), 6.98 (dd, 1 H), 6.69 (s, 1 H), 5.19 (dd, 1 H), 3.55-3.71
[M + H]⁺

(m, 1 H), 2.72-2.95 (m, 2 H)

1802
(CD₃OD) δ 8.63 (s, 2 H), 7.61 (s, 1 H), 7.42 (d, 1 H), 7.24 (s, 1
400.2
99.6%

H), 7.07 (dd, 1 H), 6.66 (d, 1 H), 6.51 (s, 1 H), 5.17 (dd, 1 H),
[M + H]⁺

3.63 (td, 1 H), 2.70-2.95 (m, 2 H), 2.64 (s, 3 H)

1803
(CD₃OD) δ 8.64 (s, 2 H), 7.61 (s, 1 H), 7.43 (d, 1 H), 7.24 (s, 1
400.2
99.2%

H), 7.08 (dd, 1 H), 6.67 (d, 1 H), 6.51 (s, 1 H), 5.17 (dd, 1 H),
[M + H]⁺

3.63 (td, 1 H), 2.71-2.94 (m, 2 H), 2.64 (s, 3 H)

1804
(CD₃OD) δ 8.46 (d, 1 H), 8.31 (d, 1 H), 8.16 (dd, 1 H), 7.80 (d, 1
332.2
100%

H), 7.64 (s, 1 H), 6.98 (d, 1 H), 6.82 (br s, 1 H), 6.77 (t, 1 H),
[M + H]⁺

6.53 (s, 1 H), 4.70 (br dd, 1 H), 3.57-3.72 (m, 1 H), 2.91-3.06

(m, 1 H), 2.76 (dd, 1 H), 2.43 (s, 3 H)

1805
(CD₃OD) δ 8.46 (d, 1 H), 8.31 (d, 1 H), 8.13-8.22 (m, 1 H), 7.80
332.2
97.6%

(d, 1 H), 7.64 (s, 1 H), 6.98 (d, 1 H), 6.82 (s, 1 H), 6.77(t, 1 H),
[M + H]⁺

6.53 (s, 1 H), 4.70 (br dd, 1 H), 3.63 (ddd, 1 H), 2.88-3.06 (m, 1

H), 2.76 (dd, 1 H), 2.43 (s, 3 H)

1806
(CD₃OD) δ 8.46 (d, 1 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.21 (ddd,
376.1
99.6%

1 H), 6.88 (td, 1 H), 6.59 (s, 1 H), 6.40 (s, 1 H), 4.34 (dd, 1 H),
[M + H]⁺

3.79 (ddd, 1 H), 3.02-3.14 (m, 1 H), 2.84 (dd, 1 H)

1807
(CD₃OD) δ 8.46 (d, 1 H), 7.69 (s, 1 H), 7.60 (d, 1 H), 7.15-7.27
376.1
99.9%

(m, 1 H), 6.81-6.93 (m, 1 H), 6.59 (s, 1 H), 6.40 (s, 1 H), 4.34
[M + H]⁺

(dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.14 (m, 1 H), 2.84 (dd, 1 H)

1808
(CD₃OD) δ 8.31 (d, 1 H), 7.70 (s, 1 H), 7.00 (d, 1 H), 6.80 (t, 1
390.2
100%

H), 6.59 (s, 1 H), 6.41 (s, 1 H), 4.34 (dd, 1 H), 3.79 (ddd, 1 H),
[M + H]⁺

3.00-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.45 (s, 3 H)

1809
(CD₃OD) δ 8.31 (d, 1 H), 7.70 (s, 1 H), 7.00 (d, 1 H), 6.80(t, 1
390.1
100%

H), 6.59 (s, 1 H), 6.41 (s, 1 H), 4.34 (dd, 1 H), 3.79 (ddd, 1 H),
[M + H]⁺

3.00-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.45 (s, 3 H)

1810
(CD₃OD) δ 8.63 (s, 2 H), 7.80 (d, 1 H), 7.62 (s, 1 H), 7.18-7.30
454.2
98.9%

(m, 3 H), 6.77 (s, 1 H), 5.21 (dd, 1 H), 3.65 (td, 1 H), 2.83-2.96
[M + H]⁺

(m, 1 H), 2.70-2.81 (m, 1 H)

1811
(CD₃OD) δ 8.53 (s, 2 H), 7.70 (d, 1 H), 7.52 (s, 1 H), 7.06-7.23
454.1
99.7%

(m, 3 H), 6.67 (s, 1 H), 5.11 (dd, 1 H), 3.48-3.63 (m, 1 H), 2.57-
[M + H]⁺

2.89 (m, 2 H)

1812
(CD₃OD) δ 8.54 (s, 2 H), 7.47-7.66 (m, 2 H), 7.26-7.44 (m, 1 H),
436.1
99.8%

7.02-7.16 (m, 3 H), 6.56 (s, 1 H), 5.10 (dd, 1 H), 3.52 (td, 1 H),
[M + H]⁺

2.58-2.87 (m, 2 H)

1813
(CD₃OD) δ 8.53 (s, 2 H), 7.49-7.63 (m, 2 H), 7.26-7.44 (m, 1 H),
436.1
99.8%

6.97-7.15 (m, 3 H), 6.56 (s, 1 H), 5.10 (dd, 1 H), 3.43-3.59 (m, 1
[M + H]⁺

H), 2.59-2.86 (m, 2 H)

1814
(CD₃OD) δ 8.45 (d, 1 H), 8.13 (br d, 1 H), 7.49-7.71 (m, 3 H),
317.2
100%

7.12-7.24 (m, 1 H), 7.05 (d, 1 H), 6.83 (t, 1 H), 6.77 (br s, 1 H),
[M + H]⁺

6.66 (dd, 1 H), 6.50 (s, 1 H), 4.56 (br dd, 1 H), 3.51-3.63 (m, 1

H), 2.87-3.06 (m, 1 H), 2.68 (br d, 1 H)

1815
(CD₃OD) δ 8.45 (br d, 1 H), 8.13 (br d, 1 H), 7.47-7.69 (m, 3 H),
317.2
100%

7.12-7.25 (m, 1 H), 7.05 (d, 1 H), 6.71-6.89 (m, 2 H), 6.66 (dd, 1
[M + H]⁺

H), 6.50 (s, 1 H), 4.56 (br dd, 1 H), 3.51-3.64 (m, 1 H), 2.89-

3.04 (m, 1 H), 2.68 (br d, 1 H)

1816
(CD₃OD) δ 8.58 (br d, 1 H), 8.47 (d, 1 H), 8.16 (dd, 1 H), 7.80
368.1
100%

(d, 1 H), 7.67 (br s, 1 H), 7.42 (br d, 1 H), 6.79-7.15 (m, 3 H),
[M + H]⁺

6.70 (s, 1 H), 4.71 (dd, 1 H), 3.61 (ddd, 1 H), 2.91-3.04 (m, 1 H),

2.77 (br d, 1 H)

1817
(CD₃OD) δ 8.59 (d, 1 H), 8.47 (d, 1 H), 8.17 (dd, 1 H), 7.80-7.86
368.1
98.2%

(m, 2 H), 7.42 (br d, 1 H), 6.79-7.16 (m, 3 H), 6.71 (s, 1 H), 4.71
[M + H]⁺

(dd, 1 H), 3.61 (ddd, 1 H), 2.93-3.05 (m, 1 H), 2.78 (br dd, 1 H)

1818
(CD₃OD) δ 8.69 (d, 1 H), 8.47 (d, 1 H), 8.17 (dd, 1 H), 7.81 (d, 1
386.2
100%

H), 7.57-7.72 (m, 2 H), 6.97 (t, 1 H), 6.86 (br s, 1 H), 6.69 (s, 1
[M + H]⁺

H), 4.72 (br dd, 1 H), 3.61 (ddd, 1 H), 2.92-3.06 (m, 1 H), 2.77

(br dd, 1 H)

1819
(CD₃OD) δ 8.69 (d, 1 H), 8.47 (d, 1 H), 8.17 (dd, 1 H), 7.81 (d, 1
386.2
99.6%

H), 7.57-7.72 (m, 2 H), 6.97 (t, 1 H), 6.86 (br s, 1 H), 6.69 (s, 1
[M + H]⁺

H), 4.72 (br dd, 1 H), 3.61 (ddd, 1 H), 2.92-3.05 (m, 1 H), 2.77

(br dd, 1 H)

1820
(CD₃OD) δ 8.71 (d, 1 H), 7.71 (s, 1 H), 7.64 (d, 1 H), 7.01(t, 1
444.1
95.6%

H), 6.77 (s, 1 H), 6.43 (s, 1 H), 4.38 (dd, 1 H), 3.80 (td, 1 H),
[M + H]⁺

3.03-3.15 (m, 1 H), 2.86 (dd, 1 H)

1821
(CD₃OD) δ 8.71 (d, 1 H), 7.70 (s, 1 H), 7.64 (d, 1 H), 7.00(t, 1
444.1
93.2%

H), 6.77 (s, 1 H), 6.43 (br s, 1 H), 4.38 (dd, 1 H), 3.72-3.86 (m, 1
[M + H]⁺

H), 3.02-3.16 (m, 1 H), 2.86 (br dd, 1 H)

1822
(CD₃OD) δ 8.24 (d, 1 H), 7.58 (s, 1 H), 6.86 (dd, 1 H), 6.73 (td,
394.1
99.7%

1 H), 6.61 (s, 1 H), 6.29 (s, 1 H), 4.24 (dd, 1 H), 3.68 (ddd, 1 H),
[M + H]⁺

2.91-3.03 (m, 1 H), 2.73 (dd, 1 H)

1823
(CD₃OD) δ 8.23 (d, 1 H), 7.58 (s, 1 H), 6.86 (dd, 1 H), 6.73 (td,
394.1
99.8%

1 H), 6.61 (s, 1 H), 6.29 (s, 1 H), 4.24 (dd, 1 H), 3.68 (ddd, 1 H),
[M + H]⁺

2.90-3.03 (m, 1 H), 2.73 (dd, 1 H)

1824
(CD₃OD) δ 8.57 (d, 1 H), 7.67 (s, 1 H), 7.43 (br d, 1 H), 6.67-
414.2
98.4%

7.18 (m, 3 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.72 (ddd, 1 H),
[M + H]⁺

2.95-3.14 (m, 1 H), 2.83 (dd, 1 H), 1.41 (s, 9 H)

1825
(CD₃OD) δ 8.57 (d, 1 H), 7.67 (s, 1 H), 7.43 (br d, 1 H), 6.62-
414.2
99.8%

7.19 (m, 3 H), 6.31 (br s, 1 H), 4.24 (dd, 1 H), 3.72 (ddd, 1 H),
[M + H]⁺

2.97-3.11 (m, 1 H), 2.83 (br dd, 1 H), 1.41 (s, 9 H)

1826
(CD₃OD) δ 8.27 (d, 1 H), 8.06 (s, 2 H), 7.61 (s, 1 H), 7.05(s, 1
347.2
97.1%

H), 6.95 (d, 1 H), 6.74 (t, 1 H), 6.49 (s, 1 H), 4.81 (br dd, 1 H),
[M + H]⁺

3.43 (ddd, 1 H), 2.84-2.95 (m, 1 H), 2.59-2.68 (m, 1 H), 2.42 (s,

3 H)

1827
(CD₃OD) δ 8.16 (d, 1 H), 7.91-7.99 (m, 2 H), 7.50 (s, 1 H), 6.93
347.2
93.3%

(s, 1 H), 6.80-6.86 (m, 1 H), 6.62 (t, 1 H), 6.37 (s, 1 H), 4.65-
[M + H]⁺

4.70 (m, 1 H), 3.27-3.36 (m, 1 H), 2.72-2.83 (m, 1 H), 2.52 (dd,

1 H), 2.30 (s, 3 H)

1828
(CD₃OD) δ 8.59 (d, 1 H), 8.40 (s, 1 H), 7.81 (s, 1 H), 7.69 (s, 1
402.1
100%

H), 7.42 (d, 1 H), 6.81-7.14 (m, 2 H), 6.75 (d, 2 H), 4.72 (br dd,
[M + H]⁺

1 H), 3.61 (ddd, 1 H), 2.91-3.05 (m, 1 H), 2.79 (dd, 1 H)

1829
(CD₃OD) δ 8.59 (d, 1 H), 8.41 (s, 1 H), 7.81 (s, 1 H), 7.69 (s, 1
402.1
99.9%

H), 7.43 (d, 1 H), 6.81-7.15 (m, 2 H), 6.75 (d, 2 H), 4.73(dd, 1
[M + H]⁺

H), 3.61 (ddd, 1 H), 2.92-3.04 (m, 1 H), 2.79 (dd, 1 H)

1830
(CD₃OD) δ 8.41 (d, 1 H), 7.66 (s, 1 H), 7.26 (d, 1 H), 6.82 (t, 1
396.1
99.7%

H), 6.65 (s, 1 H), 6.30 (s, 1 H), 4.23 (dd, 1 H), 3.60-3.76 (m, 2
[M + H]⁺

H), 2.95-3.09 (m, 1 H), 2.79 (br dd, 1 H), 2.33-2.48 (m, 4 H),

1.95-2.17 (m, 2 H)

1831
(CD₃OD) δ 8.36-8.51 (m, 1 H), 7.68 (s, 1 H), 7.28 (d, 1 H), 6.84
396.1
98.9%

(t, 1 H), 6.67 (s, 1 H), 6.31 (s, 1 H), 4.25 (dd, 1 H), 3.60-3.76 (m,
[M + H]⁺

2 H), 2.98-3.09 (m, 1 H), 2.77-2.86 (m, 1 H), 2.33-2.49 (m, 4 H),

1.97-2.20 (m, 2 H)

1832
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.86 (t, 1
398.2
100%

H), 6.67 (s, 1 H), 6.30 (br s, 1 H), 4.24 (dd, 1 H), 3.71 (ddd, 1
[M + H]⁺

H), 2.97-3.11 (m, 1 H), 2.82 (br dd, 1 H), 1.41 (s, 9 H)

1833
(CD₃OD) δ 8.44 (d, 1 H), 7.68 (s, 1 H), 7.30 (d, 1 H), 6.85(t, 1
398.2
100%

H), 6.67 (s, 1 H), 6.30 (br s, 1 H), 4.24 (dd, 1 H), 3.71 (ddd, 1
[M + H]⁺

H), 2.96-3.10 (m, 1 H), 2.76-2.90 (m, 1 H), 1.41 (s, 9H)

1834
(CD₃OD) δ 8.66 (d, 1 H), 8.06 (s, 2 H), 7.63 (s, 1 H), 7.59 (d, 1
401.1
89.0%

H), 7.05 (s, 1 H), 6.94 (t, 1 H), 6.66 (s, 1 H), 4.84 (br d, 1 H),
[M + H]⁺

3.42 (ddd, 1 H), 2.86-2.96 (m, 1 H), 2.61-2.69 (m, 1 H)

1835
(CD₃OD) δ 8.54 (d, 1 H), 7.94 (s, 2 H), 7.52 (s, 1 H), 7.43-7.50
401.2
97.7%

(m, 1 H), 6.94 (s, 1 H), 6.82 (t, 1 H), 6.54 (s, 1 H), 4.72 (br d, 1
[M + H]⁺

H), 3.30 (ddd, 1 H), 2.73-2.84 (m, 1 H), 2.53 (dd, 1 H)

1836
(CD₃OD) δ 8.31 (d, 1 H), 8.06 (s, 2 H), 7.62 (s, 1 H), 7.03 (s, 1
351.1
98.8%

H), 6.92 (dd, 1 H), 6.78 (td, 1 H), 6.62 (s, 1 H), 4.78-4.84 (m, 1
[M + H]⁺

H), 3.42 (ddd, 1 H), 2.83-2.97 (m, 1 H), 2.65 (dd, 1 H)

1837
(CD₃OD) δ 8.19 (d, 1 H), 7.94 (s, 2 H), 7.50 (s, 1 H), 6.91(s, 1
351.2
90.6%

H), 6.80 (dd, 1 H), 6.67 (td, 1 H), 6.50 (s, 1 H), 4.70 (br d, 1 H),
[M + H]⁺

3.30 (ddd, 1 H), 2.70-2.88 (m, 1 H), 2.53 (dd, 1 H)

1838
(CD₃OD) δ 8.18-8.32 (m, 1 H), 7.68 (s, 1 H), 7.45 (br s, 0.3 H),
416.2
96.5%

6.93 (s, 0.7 H), 6.58-6.84 (m, 3 H), 4.97 (br dd, 1 H), 3.65-3.78
[M + H]⁺

(m, 0.7 H), 3.34-3.42 (m, 0.3 H), 3.06-3.18 (m, 0.7 H), 2.91-3.03

(m, 0.3 H), 2.81 (br dd, 1 H), 2.26-2.36 (m, 1 H), 2.01-2.14 (m, 1

H), 1.19-1.30 (m, 4 H), 0.97-1.08 (m, 2 H), 0.72-0.83 (m, 2 H)

1839
(CD₃OD) δ 8.20-8.35 (m, 1 H), 7.68 (s, 1 H), 7.45 (br s, 0.3 H),
416.2
91.5%

6.93 (s, 0.7 H), 6.65-6.84 (m, 3 H), 4.97 (br dd, 1 H), 3.66-3.77
[M + H]⁺

(m, 0.6 H), 3.33-3.44 (m, 0.4 H), 3.06-3.18 (m, 0.6 H), 2.91-3.03

(m, 0.4 H), 2.76-2.87 (m, 1 H), 2.24-2.44 (m, 1 H), 2.09 (td, 1

H), 1.20-1.30 (m, 4 H), 0.94-1.09 (m, 2 H), 0.69-0.86 (m, 2 H)

1840
(CD₃OD) δ 8.19-8.32 (m, 1 H), 7.69 (s, 1 H), 6.93-7.48 (m, 1 H),
432.2
100%

6.66-6.85 (m, 3 H), 4.93-5.00 (m, 1 H), 3.75 (ddd, 0.7 H), 3.40
[M + H]⁺

(td, 0.3 H), 3.09-3.21 (m, 0.7 H), 2.92-3.02 (m, 0.3 H), 2.83 (br

dd, 1 H), 2.00-2.17 (m, 1 H), 1.42-1.53 (m, 9 H), 0.96-1.07 (m, 2

H), 0.71-0.82 (m, 2 H)

1841
(CD₃OD) δ 8.18-8.33 (m, 1 H), 7.69 (s, 1 H), 7.41 (br s, 0.3 H),
432.2
95.1%

6.95 (s, 0.7 H), 6.63-6.84 (m, 3 H), 4.96 (dd, 1 H), 3.75 (ddd, 0.7
[M + H]⁺

H), 3.35-3.45 (m, 0.3 H), 3.09-3.20 (m, 0.7 H), 2.92-3.03 (m, 0.3

H), 2.83 (br dd, 1 H), 2.01-2.15 (m, 1 H), 1.43-1.53 (m, 9 H),

0.98-1.07 (m, 2 H), 0.73-0.81 (m, 2 H)

1842
Data provided above

1843
Data provided above

1844
(CD₃OD) δ 8.31 (d, 1 H), 7.52-7.79 (m, 2 H), 7.23 (t, 2 H), 7.00
434.1
99.7%

(d, 1 H), 6.79 (t, 1 H), 6.62 (s, 1 H), 6.42(s, 1 H), 4.36(dd, 1H),
[M + H]⁺

3.81 (ddd, 1 H), 3.02-3.17 (m, 1 H), 2.86 (br dd, 1 H), 2.45 (s, 3 H)

1845
(CD₃OD) δ 8.31 (d, 1 H), 7.54-7.78 (m, 2 H), 7.22 (t, 2 H), 6.99
434.2
99.7%

(d, 1 H), 6.79 (t, 1 H), 6.61 (s, 1 H), 6.42 (s, 1 H), 4.36 (dd, 1H),
[M + H]⁺

3.80 (ddd, 1 H), 3.00-3.18 (m, 1 H), 2.85 (dd, 1 H), 2.45 (s, 3 H)

1846
(CD₃OD) δ 8.70 (br d, 1 H), 7.48-7.85 (m, 3 H), 7.22 (t, 2 H),
488.1
97.8%

6.99 (t, 1 H), 6.79 (s, 1 H), 6.43 (br s, 1 H), 4.40 (dd, 1 H), 3.65-
[M + H]⁺

3.95 (m, 1 H), 2.99-3.19 (m, 1 H), 2.87 (br dd, 1 H)

1847
(CD₃OD) δ 8.70 (d, 1 H), 7.47-7.87 (m, 3 H), 7.22 (t, 2 H), 6.99
488.1
99.4%

(t, 1 H), 6.79 (s, 1 H), 6.44 (s, 1 H), 4.40 (dd, 1 H), 3.67-3.99 (m,
[M + H]⁺

1 H), 3.00-3.20 (m, 1 H), 2.87 (br dd, 1 H)

1848
(CD₃OD) δ 8.46 (br d, 1 H), 7.77 (br s, 1 H), 7.32 (d, 1 H), 6.87
410.1
99.8%

(t, 1 H), 6.72 (s, 1 H), 6.42 (s, 1 H), 4.36 (dd, 1 H), 3.69-3.86 (m,
[M + H]⁺

1 H), 3.01-3.16 (m, 1 H), 2.86 (br d, 1 H)

1849
(CD₃OD) δ 8.34 (d, 1 H), 7.65 (s, 1 H), 7.20 (d, 1 H), 6.75 (t, 1
410.1
99.6%

H), 6.60 (s, 1 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.67 (ddd, 1 H),
[M + H]⁺

2.90-3.02 (m, 1 H), 2.74 (dd, 1 H)

1850
(CD₃OD) δ 7.60 (s, 1 H), 7.36 (d, 1 H), 7.02 (dd, 1 H), 6.62(d, 1
390.1
99.4%

H), 6.41 (s, 1 H), 6.29 (s, 1 H), 4.23 (dd, 1 H), 3.69 (ddd, 1 H),
[M + H]⁺

2.90-3.02 (m, 1 H), 2.74 (dd, 1 H), 2.52 (s, 3 H)

1851
(CD₃OD) δ 7.73 (s, 1 H), 7.48 (d, 1 H), 7.13 (dd, 1 H), 6.73 (d, 1
390.1
93.6%

H), 6.53 (s, 1 H), 6.41 (s, 1 H), 4.35 (dd, 1 H), 3.80 (ddd, 1 H),
[M + H]⁺

3.02-3.14 (m, 1 H), 2.85 (dd, 1 H), 2.63 (s, 3 H)

1852
(CD₃OD) δ 8.43 (d, 1 H), 7.94 (s, 2 H), 7.51 (s, 1 H), 7.28 (br d,
383.2
100%

1 H), 6.83-6.99 (m, 1.8 H), 6.77 (t, 1 H), 6.70 (s, 0.2 H), 6.55(s,
[M + H]⁺

1 H), 4.70 (br d, 1 H), 3.25-3.34 (m, 1 H), 2.72-2.84 (m, 1 H),

2.53 (dd, 1 H)

1853
(CD₃OD) δ 8.43 (d, 1 H), 7.94 (s, 2 H), 7.51 (s, 1 H), 7.27 (br d,
383.2
99.3%

1 H), 6.92-6.99 (m, 1.2 H), 6.84 (s, 0.6 H), 6.77 (t, 1 H), 6.70 (s,
[M + H]⁺

0.2 H), 6.55 (s, 1 H), 4.70 (br d, 1 H), 3.26-3.34 (m, 1 H), 2.73-

2.83 (m, 1 H), 2.52 (dd, 1 H)

1854
(CD₃OD) δ 8.63 (br d, 1 H), 8.17-8.32 (m, 1 H), 7.92 (br t, 1 H),
471.2
98.6%

7.68-7.80 (m, 2 H), 7.47 (br s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.82
[M + H]⁺

(m, 3 H), 4.93-4.99 (m, 1 H), 3.77-3.87 (m, 0.7 H), 3.45 (td, 0.3

H), 3.17-3.26 (m, 0.7 H), 2.98-3.07 (m, 0.3 H), 2.85 (br d, 1 H),

2.02-2.15 (m, 1 H), 0.95-1.07 (m, 2 H), 0.70-0.81 (m, 2 H)

1855
(CD₃OD) δ 8.62 (d, 1 H), 8.19-8.31 (m, 1 H), 7.91 (t, 1 H), 7.69-
471.2
97.9%

7.77 (m, 2 H), 7.47 (s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.82 (m, 3
[M + H]⁺

H), 4.93-4.99 (m, 1 H), 3.77-3.86 (m, 0.7 H), 3.45 (td, 0.3 H),

3.17-3.26 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.86 (br dd, 1 H),

2.01-2.14 (m, 1 H), 0.96-1.07 (m, 2 H), 0.72-0.81 (m, 2 H)

1856
(CD₃OD) δ 9.44 (s, 1 H), 8.79-8.86 (m, 2 H), 8.19-8.30 (m, 1 H),
454.2
99.9%

7.70 (s, 1 H), 7.50 (br s, 0.3 H), 6.98 (s, 0.7 H), 6.67-6.85 (m, 3
[M + H]⁺

H), 5.01- 4.89 (br dd, 1 H), 3.77-3.86 (m, 0.6 H), 3.45 (td, 0.4

H), 3.14-3.27 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.80-2.91 (m, 1

H), 2.00-2.15 (m, 1 H), 0.96-1.08 (m, 2 H), 0.71-0.82 (m, 2 H)

1857
(CD₃OD) δ 9.45 (s, 1 H), 8.83 (br d, 2 H), 8.17-8.34 (m, 1 H),
454.2
99.3%

7.70 (s, 1 H), 7.50 (s, 0.3 H), 6.99 (s, 0.7 H), 6.72-6.82 (m, 3 H),
[M + H]⁺

4.93-5.05 (m, 1 H), 3.78-3.86 (m, 0.7 H), 3.45 (td, 0.3 H), 3.15-

3.26 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.86 (br dd, 1 H), 1.99-

2.15 (m, 1 H), 0.97-1.08 (m, 2 H), 0.72-0.82 (m, 2 H)

1858
(CD₃OD) δ 8.13-8.23 (m, 1 H), 7.58 (s, 1 H), 7.35 (s, 0.3 H),
392.2
100%

6.91-6.97 (m, 1 H), 6.82 (s, 0.7 H), 6.65-6.76 (m, 1 H), 6.49-6.61
[M + H]⁺

(m, 1 H), 4.82-4.87 (m, 1 H), 3.60-3.69 (m, 0.6 H), 3.24-3.34 (m,

0.4 H), 2.83-3.13 (m, 2 H), 2.71 (br dd, 1 H), 2.48-2.55 (m, 3 H),

1.18-1.26 (m, 6 H)

1859
(CD₃OD) δ 8.14-8.23 (m, 1 H), 7.58 (s, 1 H), 7.35 (s, 0.3 H),
392.2
99.7%

6.91-6.98 (m, 1 H), 6.82 (s, 0.7 H), 6.68-6.76 (m, 1 H), 6.48-6.61
[M + H]⁺

(m, 1 H), 4.81-4.88 (m, 1 H), 3.60-3.70 (m, 0.6 H), 3.24-3.34 (m,

0.4 H), 2.81-3.14 (m, 2 H), 2.65-2.77 (m, 1 H), 2.48-2.58 (m, 3

H), 1.18-1.26 (m, 6 H)

1860
(CD₃OD) δ 8.46 (d, 1 H), 8.03 (dd, 2 H), 7.69 (s, 1 H), 7.60 (d, 1
402.2
100%

H), 7.30 (t, 2 H), 7.16-7.24 (m, 1 H), 6.86 (t, 1 H), 6.60(s, 1H),
[M + H]⁺

6.45 (s, 1 H), 4.37 (dd, 1 H), 3.73-3.83 (m, 1 H), 3.02-3.21 (m, 1

H), 2.85 (dd, 1 H)

1861
(CD₃OD) δ 8.46 (br d, 1 H), 7.97-8.09 (m, 2 H), 7.67-7.73 (m, 1
402.2
95.2%

H), 7.60 (br d, 1 H), 7.27-7.34 (m, 2 H), 7.16-7.24 (m, 1 H),
[M + H]⁺

6.83-6.92 (m, 1 H), 6.60 (s, 1 H), 6.45 (s, 1 H), 4.32-4.45 (m, 1

H), 3.73-3.86 (m, 1 H), 3.04-3.18 (m, 1 H), 2.78-2.92 (m, 1 H)

1862
(CD₃OD) δ 8.58 (br d, 1 H), 7.50-7.82 (m, 2 H), 7.42 (br d, 1 H),
470.1
99.7%

7.20 (t, 2 H), 6.83-7.14 (m, 2 H), 6.79 (s, 1 H), 6.44 (br s, 1 H),
[M + H]⁺

4.38 (br dd, 1 H), 3.70-3.90 (m, 1 H), 3.01-3.17 (m, 1 H), 2.86

(br d, 1 H)

1863
(CD₃OD) δ 8.59 (d, 1 H), 7.55-7.79 (m, 2 H), 7.44 (br d, 1 H),
470.2
99.5%

7.22 (t, 2 H), 6.84-7.15 (m, 2 H), 6.79 (s, 1 H), 6.44 (s, 1 H),
[M + H]⁺

4.38 (dd, 1 H), 3.80 (ddd, 1 H), 3.01-3.20 (m, 1 H), 2.86 (dd, 1 H)

1864
(CD₃OD) δ 8.35 (d, 1 H), 7.52-7.80 (m, 2 H), 7.22 (t, 2 H), 6.97
438.1
99.4%

(dd, 1 H), 6.84 (td, 1 H), 6.74 (s, 1 H), 6.42 (br s, 1 H), 4.38 (dd,
[M + H]⁺

1 H), 3.81 (ddd, 1 H), 3.01-3.18 (m, 1 H), 2.86 (dd, 1 H)

1865
(CD₃OD) δ 8.23 (d, 1 H), 7.36-7.70 (m, 2 H), 7.10 (t, 2 H), 6.85
438.2
99.3%

(dd, 1 H), 6.72 (td, 1 H), 6.62 (s, 1 H), 6.30 (br s, 1 H), 4.26 (dd,
[M + H]⁺

1 H), 3.69 (ddd, 1 H), 2.88-3.06 (m, 1 H), 2.74 (br dd, 1 H)

1866
(CD₃OD) δ 8.35 (br s, 1 H), 7.30-7.91 (m, 3 H), 6.94-7.19 (m, 1
391.2
100%

H), 6.27-6.87 (m, 3 H), 4.56-4.75 (m, 1 H), 4.26-4.43 (m, 0.5 H),
[M + H]⁺

3.64 (br s, 0.5 H), 2.53-3.10 (m, 2 H), 1.31 (br s, 9 H)

1867
(CD₃OD) δ 8.31 (br s, 1 H), 7.33-7.96 (m, 3 H), 7.04 (br t, 1 H),
391.2
99.5%

6.21-6.89 (m, 3 H), 4.70-4.81 (m, 1 H), 4.14-4.47 (m, 0.5 H),
[M + H]⁺

3.63 (br s, 0.5 H), 2.47-3.08 (m, 2 H), 1.29 (br s, 9 H)

1868
(CD₃OD) δ 8.32-8.56 (m, 2 H), 8.11 (s, 1 H), 7.79 (br s, 1 H),
494.1
100%

7.58 (s, 0.3 H), 7.41-7.51 (m, 1 H), 6.96 (s, 0.7 H), 6.60-6.86 (m,
[M + H]⁺

2 H), 5.10 (br dd, 1 H), 4.00 (s, 3 H), 3.68-3.81 (m, 0.7 H), 3.37-

3.45 (m, 0.3 H), 3.12-3.23 (m, 0.7 H), 2.94-3.05 (m, 0.3 H), 2.85

(br d, 1 H)

1869
(CD₃OD) δ 8.29-8.57 (m, 2 H), 8.11 (s, 1 H), 7.83 (br d, 1 H),
494.1
99.4%

7.59 (s, 0.3 H), 7.43-7.50 (m, 1 H), 6.97 (s, 0.7 H), 6.65-6.85 (m,
[M + H]⁺

2 H), 5.11 (br dd, 1 H), 4.01 (s, 3 H), 3.68-3.84 (m, 0.7 H), 3.41

(br d, 0.3 H), 2.95-3.24 (m, 1 H), 2.86 (br d, 1 H)

1870
(CD₃OD) δ 8.69 (d, 1 H), 8.14 (br d, 1 H), 7.71 (s, 1 H), 7.54-
385.1
98.2%

7.66 (m, 2 H), 7.06 (d, 1 H), 6.96 (t, 1 H), 6.86 (s, 1 H), 6.60-
[M + H]⁺

6.74 (m, 2 H), 4.57 (br dd, 1 H), 3.46-3.62 (m, 1 H), 2.90-3.03

(m, 1 H), 2.70 (br dd, 1 H)

1871
(CD₃OD) δ 8.69 (d, 1 H), 8.09-8.23 (m, 1 H), 7.77 (s, 1 H), 7.55-
385.2
95.9%

7.69 (m, 2 H), 7.06 (d, 1 H), 6.96 (t, 1 H), 6.89 (s, 1 H), 6.62-
[M + H]⁺

6.75 (m, 2 H), 4.57 (br dd, 1 H), 3.49-3.61 (m, 1 H), 2.91-3.05

(m, 1 H), 2.70 (br dd, 1 H)

1872
(CD₃OD) δ 8.41 (d, 1 H), 8.06 (s, 2 H), 7.63 (s, 1 H), 7.26(d, 1
367.1
99.7%

H), 7.03 (s, 1 H), 6.80 (t, 1 H), 6.61 (s, 1 H), 4.83 (br d, 1 H),
[M + H]⁺

3.39-3.46 (m, 1 H), 2.84-2.95 (m, 1 H), 2.65 (br dd, 1 H)

1873
(CD₃OD) δ 8.41 (d, 1 H), 8.06 (s, 2 H), 7.62 (s, 1 H), 7.26(d, 1
367.1
98.5%

H), 7.03 (s, 1 H), 6.80 (t, 1 H), 6.61 (s, 1 H), 4.83 (br d, 1 H),
[M + H]⁺

3.39-3.46 (m, 1 H), 2.85-2.95 (m, 1 H), 2.65 (dd, 1 H)

1874
(CD₃OD) δ 8.16-8.43 (m, 1 H), 7.68 (s, 1 H), 7.44 (s, 0.5 H),
404.2
100%

6.76-7.09 (m, 2.5 H), 6.41-6.71 (m, 1 H), 4.97 (br dd, 1 H), 3.66-
[M + H]⁺

3.78 (m, 0.5 H), 3.38 (td, 0.5 H), 2.89-3.21 (m, 1 H), 2.71-2.88

(m, 3 H), 2.19-2.40 (m, 1 H), 1.13-1.34 (m, 7 H)

1875
(CD₃OD) δ 8.19-8.36 (m, 1 H), 7.68 (s, 1 H), 7.44 (br s, 0.5 H),
404.2
94.8%

6.75-7.05 (m, 2.5 H), 6.50-6.68 (m, 1 H), 4.97 (br dd, 1 H), 3.65-
[M + H]⁺

3.84 (m, 0.5 H), 3.32-3.44 (m, 0.5 H), 2.90-3.22 (m, 1 H), 2.69-

2.87 (m, 3 H), 2.18-2.39 (m, 1 H), 1.13-1.42 (m, 7 H)

1876
(CD₃OD) δ 8.39 (s, 1 H), 8.20-8.30 (m, 1 H), 8.07-8.12 (m, 1 H),
556.2
100%

7.69 (s, 1 H), 7.57 (s, 0.3 H), 6.97 (s, 0.7 H), 6.70-6.83 (m, 3 H),
[M + H]⁺

5.07 (br dd, 1 H), 4.00 (s, 3 H), 3.74-3.82 (m, 0.7 H), 3.42 (td,

0.3 H), 3.13-3.23 (m, 0.7 H), 2.95-3.03 (m, 0.3 H), 2.80-2.87 (m,

1 H), 2.01-2.15 (m, 1 H), 0.97-1.07 (m, 2 H), 0.73-0.81 (m, 2 H)

1877
(CD₃OD) δ 8.38 (s, 1 H), 8.20-8.29 (m, 1 H), 8.06-8.12 (m, 1 H),
556.1
95.1%

7.69 (s, 1 H), 7.58 (s, 0.3 H), 6.96 (s, 0.7 H), 6.69-6.83 (m, 3 H),
[M + H]⁺

5.07 (dd, 1 H), 4.00 (s, 3 H), 3.74-3.82 (m, 0.7 H), 3.42 (td, 0.3

H), 3.12-3.22 (m, 0.7 H), 2.93-3.04 (m, 0.3 H), 2.77-2.89 (m, 1

H), 2.01-2.15 (m, 1 H), 0.96-1.07 (m, 2 H), 0.72-0.81 (m, 2 H)

1878
(CD₃OD) δ 8.91 (s, 1 H), 8.34 (s, 1 H), 8.21-8.30 (m, 1 H), 7.92-
492.2
98.9%

8.00 (m, 1 H), 7.61-7.81 (m, 1 H), 7.50 (s, 0.2 H), 7.02 (s, 0.8
[M + H]⁺

H), 6.74-6.84 (m, 3 H), 5.10 (br dd, 1 H), 3.74-3.83 (m, 0.7 H),

3.39-3.48 (m, 0.3 H), 3.17-3.24 (m, 0.7 H), 2.97-3.05 (m, 0.3 H),

2.83-2.92 (m, 1 H), 2.01-2.15 (m, 1 H), 0.98-1.06 (m, 2 H), 0.74-

0.81 (m, 2 H)

1879
(CD₃OD) δ 8.92 (s, 1 H), 8.35 (s, 1 H), 8.21-8.30 (m, 1 H), 7.89-
492.2
98.2%

7.99 (m, 1 H), 7.61-7.82 (m, 1 H), 7.50 (s, 0.2H), 7.02 (s, 0.8
[M + H]⁺

H), 6.75-6.84 (m, 3 H), 5.10 (br dd, 1 H), 3.72-3.85 (m, 0.7 H),

3.39-3.47 (m, 0.3 H), 3.17-3.24 (m, 0.7 H), 3.00 (br dd, 0.3 H),

2.82-2.92 (m, 1 H), 2.03-2.15 (m, 1 H), 0.98-1.07 (m, 2 H), 0.74-

0.81 (m, 2 H)

1880
(CD₃OD) δ 8.49 (d, 1 H), 8.19-8.33 (m, 1 H), 7.70 (s, 1 H), 7.52
510.2
100%

(s, 0.3 H), 7.26 (d, 1 H), 6.98 (s, 0.7 H), 6.70-6.83 (m, 3 H),
[M + H]⁺

4.92-5.05 (m, 1 H), 3.73-3.87 (m, 0.7 H), 3.43 (td, 0.3 H), 3.15-

3.24 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.85 (br dd, 1 H), 2.01-

2.15 (m, 1 H), 0.96-1.07 (m, 2 H), 0.71-0.82 (m, 2 H)

1881
(CD₃OD) δ 8.49 (d, 1 H), 8.16-8.32 (m, 1 H), 7.70 (s, 1 H), 7.52
510.2
99.5%

(s, 0.3 H), 7.26 (br s, 1 H), 6.98 (s, 0.7 H), 6.67-6.85 (m, 3 H),
[M + H]⁺

4.92-5.06 (m, 1 H), 3.70-3.89 (m, 0.7 H), 3.43 (td, 0.3 H), 3.14-

3.25 (m, 0.7 H), 2.96-3.06 (m, 0.3 H), 2.85 (br dd, 1 H), 2.00-

2.15 (m, 1 H), 0.95-1.10 (m, 2 H), 0.74-0.79 (dt, 2 H)

1882
(CD₃OD) δ 8.08-8.25 (m, 1 H), 7.58 (s, 1 H), 7.34 (s, 0.3 H),
418.2
100%

6.91-6.98 (m, 1 H), 6.69-6.83 (m, 1.7 H), 6.46-6.60 (m, 1 H),
[M + H]⁺

4.87 (br dd, 1 H), 3.58-3.67 (m, 0.7 H), 3.26-3.34 (m, 0.3 H),

2.81-3.09 (m, 2 H), 2.71 (br dd, 1 H), 2.17-2.26 (m, 1 H), 1.08-

1.26 (m, 10 H)

1883
(CD₃OD) δ 8.08-8.25 (m, 1 H), 7.58 (s, 1 H), 7.34 (s, 0.3 H),
418.2
99.4%

6.91-6.98 (m, 1 H), 6.69-6.83 (m, 1.7 H), 6.46-6.60 (m, 1 H),
[M + H]⁺

4.87 (br dd, 1 H), 3.58-3.67 (m, 0.6 H), 3.26-3.34 (m, 0.4 H),

2.81-3.09 (m, 2 H), 2.71 (br dd, 1 H), 2.17-2.26 (m, 1 H), 1.08-

1.26 (m, 10 H)

1884
(CD₃OD) δ 8.07-8.23 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H),
438.2
100%

6.88-6.99 (m, 1 H), 6.84 (s, 0.7 H), 6.68-6.76 (m, 1 H), 6.48-6.62
[M + H]⁺

(m, 1 H), 4.83-4.88 (m, 1 H), 3.66 (ddd, 0.6 H), 3.30 (td, 0.4 H),

2.83-3.12 (m, 2 H), 2.73 (br dd, 1 H), 1.73-1.84 (m, 6 H), 1.18-

1.26 (m, 6 H)

1885
(CD₃OD) δ 8.12-8.23 (m, 1 H), 7.59 (s, 1 H), 7.29 (s, 0.3 H),
438.2
99.1%

6.91-6.99 (m, 1 H), 6.84 (s, 0.7 H), 6.68-6.76 (m, 1 H), 6.46-6.63
[M + H]⁺

(m, 1 H), 4.82-4.88 (m, 1 H), 3.62-3.71 (m, 0.6 H), 3.26-3.35 (m,

0.4 H), 2.83-3.13 (m, 2 H), 2.73 (br dd, 1 H), 1.73-1.86 (m, 6 H),

1.19-1.26 (m, 6 H)

1886
(CD₃OD) δ 8.37-8.44 (m, 1 H), 8.24-8.35 (m, 1 H), 8.06-8.16
458.2
98.8%

(m, 1 H), 7.71 (s, 1 H), 7.57 (br s, 0.3 H), 7.02-7.11 (m, 1 H),
[M + H]⁺

6.80-6.99 (m, 1.7 H), 6.62-6.74 (m, 1 H), 4.99-5.13 (m, 1 H),

4.02 (s, 3 H), 3.75-3.85 (m, 0.7 H), 3.38-3.50 (m, 0.3 H), 2.99-

3.25 (m, 2 H), 2.81-2.92 (m, 1 H), 1.31-1.37 (m, 6 H)

1887
(CD₃OD) δ 8.40 (s, 1 H), 8.23-8.35 (m, 1 H), 8.07-8.13 (m, 1 H),
458.2
95.4%

7.71 (s, 1 H), 7.57 (s, 0.3 H), 7.02-7.10 (m, 1 H), 6.81-6.99 (m,
[M + H]⁺

1.7 H), 6.62-6.74 (m, 1 H), 5.01-5.13 (m, 1 H), 4.01 (s, 3H),

3.75-3.86 (m, 0.7 H), 3.38-3.50 (m, 0.3 H), 2.97-3.24 (m, 2 H),

2.81-2.90 (m, 1 H), 1.29-1.37 (m, 6 H)

1888
(CD₃OD) δ 8.34-8.60 (m, 1 H), 7.62-7.91 (m, 2 H), 7.33-7.60
494.1
98.5%

(m, 1.3 H), 6.89-7.17 (m, 1.7 H), 6.50-6.88 (m, 2 H), 5.03 (br dd,
[M + H]⁺

1 H), 4.03 (s, 3 H), 3.71-3.81 (m, 0.6 H), 3.36-3.44 (m, 0.4 H),

3.12-3.24 (m, 0.5 H), 2.94-3.05 (m, 0.5 H), 2.84 (br d, 1 H)

1889
(CD₃OD) δ 8.34-8.56 (m, 1 H), 7.63-7.89 (m, 2 H), 7.26-7.61
494.1
98.0%

(m, 1.3 H), 6.87-7.12 (m, 1.6 H), 6.59-6.84 (m, 2 H), 5.04 (br dd,
[M + H]⁺

1 H), 4.03 (s, 3 H), 3.72-3.81 (m, 0.5 H), 3.34-3.44 (m, 0.5 H),

3.10-3.25 (m, 0.7 H), 2.93-3.07 (m, 0.3 H), 2.78-2.89 (m, 1 H)

1890
(CD₃OD) δ 8.32 (d, 1 H), 7.97-8.09 (m, 2 H), 7.69 (s, 1 H), 7.24-
416.2
99.4%

7.35 (m, 2 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.59 (s, 1 H), 6.45(s,
[M + H]⁺

1 H), 4.37 (dd, 1 H), 3.79 (ddd, 1 H), 3.03-3.17 (m, 1 H), 2.85

(dd, 1 H), 2.45 (s, 3 H)

1891
(CD₃OD) δ 8.20 (d, 1 H), 7.85-8.00 (m, 2 H), 7.57 (s, 1 H), 7.12-
416.2
98.3%

7.25 (m, 2 H), 6.87 (d, 1 H), 6.67 (t, 1 H), 6.47 (s, 1 H), 6.33(s,
[M + H]⁺

1 H), 4.25 (dd, 1 H), 3.60-3.74 (m, 1 H), 2.90-3.04 (m, 1 H),

2.66-2.79 (m, 1 H), 2.33 (s, 3 H)

1892
(CD₃OD) δ 8.71 (d, 1 H), 7.97-8.09 (m, 2 H), 7.70 (s, 1 H), 7.63
470.1
99.9%

(d, 1 H), 7.25-7.35 (m, 2 H), 6.99 (t, 1 H), 6.78 (s, 1 H), 6.48(s,
[M + H]⁺

1 H), 4.41 (dd, 1 H), 3.71-3.87 (m, 1 H), 3.03-3.19 (m, 1 H),

2.87 (dd, 1 H)

1893
(CD₃OD) δ 8.70 (d, 1 H), 7.98-8.08 (m, 2 H), 7.71 (s, 1 H), 7.63
470.1
98.5%

(d, 1 H), 7.23-7.34 (m, 2 H), 6.99 (t, 1 H), 6.78 (s, 1 H), 6.48(s,
[M + H]⁺

1 H), 4.41 (dd, 1 H), 3.79 (ddd, 1 H), 3.05-3.18 (m, 1 H), 2.87

(dd, 1 H)

1894
(CD₃OD) δ 8.75 (d, 1 H), 8.17-8.35 (m, 2 H), 8.06 (td, 1 H),
441.2
99.0%

7.58-7.75 (m, 2 H), 7.48 (s, 0.5 H), 6.92-7.05 (m, 1.5 H), 6.55-
[M + H]⁺

6.86 (m, 2 H), 4.99 (br dd, 1 H), 3.81 (ddd, 0.5 H), 3.44 (td, 0.5

H), 2.91-3.25 (m, 1 H), 2.72-2.88 (m, 3 H), 1.22-1.35 (m, 3 H)

1895
(CD₃OD) δ 8.76 (d, 1 H), 8.19-8.35 (m, 2 H), 8.06 (td, 1 H),
441.2
99.7%

7.58-7.76 (m, 2 H), 7.48 (s, 0.5 H), 6.92-7.07 (m, 1.5 H), 6.73-
[M + H]⁺

6.85 (m, 1 H), 6.59-6.70 (m, 1 H), 5.00 (br dd, 1 H), 3.81 (ddd,

0.5 H), 3.44 (td, 0.5 H), 2.93-3.25 (m, 1 H), 2.71-2.89 (m, 3 H),

1.23-1.33 (m, 3 H)

1896
(CD₃OD) δ 8.77 (d, 1 H), 8.19-8.33 (m, 2 H), 8.08 (td, 1 H),
453.2
100%

7.62-7.72 (m, 2 H), 7.50 (s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.84 (m,
[M + H]⁺

3 H), 4.92-5.04 (m, 1 H), 3.82 (ddd, 0.7 H), 3.45 (td, 0.3 H),

3.16-3.25 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.86 (br dd, 1 H),

2.02-2.15 (m, 1 H), 0.97-1.08 (m, 2 H), 0.72-0.82 (m, 2 H)

1897
(CD₃OD) δ 8.76 (d, 1 H), 8.19-8.32 (m, 2 H), 8.07 (td, 1 H),
453.2
99.7%

7.62-7.74 (m, 2 H), 7.50 (s, 0.3 H), 6.99 (s, 0.7 H), 6.71-6.82 (m,
[M + H]⁺

3 H), 4.92-5.04 (m, 1 H), 3.77-3.86 (m, 0.7 H), 3.44 (td, 0.3 H),

3.16-3.25 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.81-2.90 (m, 1 H),

2.02-2.15 (m, 1 H), 0.97-1.07 (m, 2 H), 0.73-0.82 (m, 2 H)

1898
(CD₃OD) δ 8.19-8.38 (m, 1 H), 7.97-8.06 (m, 1 H), 7.71 (s, 1 H),
470.2
95.8%

7.57 (s, 0.3), 6.99 (s, 0.7), 6.73-6.85 (m, 3 H), 5.07-5.12 (m, 1
[M + H]⁺

H), 3.88-3.94 (m, 3 H), 3.76-3.85 (m, 0.7H), 3.46-3.51 (m,

0.3H), 3.14-3.26 (m, 1 H), 2.81-2.92 (m, 1 H), 2.62-2.76 (m, 3

H), 2.01-2.21 (m, 1 H), 0.99-1.10 (m, 2 H), 0.75-0.86 (m, 2 H)

1899
(CD₃OD) δ 8.08-8.24 (m, 1 H), 7.84-7.94 (m, 1 H), 7.60 (br s, 1
470.2
95.0%

H), 7.45 (br s, 0.3 H), 6.87 (br s, 0.7 H), 6.57-6.76 (m, 3 H),
[M + H]⁺

4.82-5.07 (m, 1 H), 3.75-3.84 (m, 3 H), 3.60-3.74 (m, 0.7 H),

3.27-3.40 (m, 0.3 H), 3.02-3.14 (m, 0.7 H), 2.83-2.97 (m, 0.3 H),

2.68-2.81 (m, 1 H), 2.50-2.62 (m, 3 H), 1.91-2.07 (m, 1 H), 0.85-

1.01 (m, 2 H), 0.62-0.72 (m, 2 H)

1900
(CD₃OD) δ 8.21-8.33 (m, 1 H), 7.83 (d, 1 H), 7.72 (s, 1 H), 7.54
456.2
98.4%

(s, 0.3 H), 6.95-7.05 (m, 1.7 H), 6.70-6.85 (m, 3 H), 4.99-5.08
[M + H]⁺

(m, 1 H), 4.05 (s, 3 H), 3.75-3.87 (m, 0.7 H), 3.44 (td, 0.3H),

3.14-3.26 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.81-2.91 (m, 1 H),

2.02-2.18 (m, 1 H), 0.98-1.11 (m, 2 H), 0.74-0.85 (m, 2 H)

1901
(CD₃OD) δ 8.21-8.35 (m, 1 H), 7.83 (d, 1 H), 7.72 (s, 1 H), 7.55
456.2
99.4%

(br s, 0.3 H), 6.97-7.03 (m, 1.7 H), 6.71-6.86 (m, 3 H), 5.04-5.09
[M + H]⁺

(m, 1 H), 4.05 (s, 3 H), 3.75-3.88 (m, 0.7 H), 3.45-3.51 (m, 0.3

H), 3.15-3.26 (m, 0.7 H), 2.97-3.07 (m, 0.3 H), 2.87 (br dd, 1 H),

2.02-2.19 (m, 1 H), 0.98-1.10 (m, 2 H), 0.71-0.86 (m, 2 H)

1902
(CD₃OD) δ 8.22-8.40 (m, 1 H), 7.71 (s, 1 H), 7.34-7.48 (m, 0.3
434.2
100%

H), 7.03-7.11 (m, 1 H), 6.80-7.00 (m, 1.7 H), 6.59-6.75 (m, 1 H),
[M + H]⁺

4.95-5.01 (m, 1 H), 3.70-3.82 (m, 0.6 H), 3.38-3.47 (m, 0.4 H),

2.92-3.25 (m, 2 H), 2.84 (br d, 1 H), 1.44-1.54 (m, 9 H), 1.30-

1.40 (m, 6 H)

1903
(CD₃OD) δ 8.24-8.36 (m, 1 H), 7.71 (s, 1 H), 7.41 (s, 0.3 H),
434.2
99.4%

7.04-7.11 (m, 1 H), 6.80-6.99 (m, 1.7 H), 6.58-6.74 (m, 1 H),
[M + H]⁺

4.98 (br dd, 1 H), 3.72-3.82 (m, 0.6 H), 3.42 (td, 0.4 H), 2.97-

3.26 (m, 2 H), 2.84 (br d, 1 H), 1.45-1.53 (m, 9 H), 1.31-1.38 (m,

6 H)

1904
(DMSO-d₆) δ 7.97 (br s, 1 H), 7.41-7.55 (m, 2 H), 7.24-7.33 (m,
455.2
99.7%

1 H), 6.83-6.95 (m, 2 H), 6.67 (br s, 0.3 H), 6.14-6.32 (m, 1.7
[M + H]⁺

H), 5.86-6.07 (m, 2 H), 4.15-4.25 (m, 1 H), 2.96-3.06 (m, 0.6 H),

2.60-2.72 (m, 0.4 H), 2.03-2.43 (m, 3 H), 0.49-0.57 (m, 6 H)

1905
(DMSO-d₆) δ 7.97 (br d, 1 H), 7.42-7.55 (m, 2 H), 7.28 (td, 1 H),
455.2
98.6%

6.81-6.94 (m, 2 H), 6.68 (br s, 0.3 H), 6.16-6.29 (m, 1.7 H),
[M + H]⁺

5.87-6.06 (m, 2 H), 4.22 (br s, 1 H), 2.99-3.08 (m, 0.6 H), 2.62-

2.72 (m, 0.4 H), 2.03-2.42 (m, 3 H), 0.47-0.57 (m, 6 H)

1906
(CD₃OD) δ 8.65 (d, 1 H), 8.21-8.38 (m, 1 H), 7.94 (t, 1 H), 7.68-
473.2
100%

7.79 (m, 2 H), 7.45 (br s, 0.3 H), 6.97-7.10 (m, 1.7 H), 6.68-6.88
[M + H]⁺

(m, 2 H), 4.93-5.02 (m, 1 H), 3.76-3.87 (m, 0.6 H), 3.43-3.52 (m,

0.4 H), 3.01-3.28 (m, 2 H), 2.87 (br d, 1 H), 1.31-1.38 (m, 6 H)

1907
(CD₃OD) δ 8.65 (d, 1 H), 8.23-8.36 (m, 1 H), 7.94 (t, 1 H), 7.68-
473.2
99.7%

7.79 (m, 2 H), 7.45 (br s, 0.3 H), 6.97-7.11 (m, 1.7 H), 6.68-6.89
[M + H]⁺

(m, 2 H), 4.93-5.01 (m, 1 H), 3.79-3.89 (m, 0.6 H), 3.43-3.52 (m,

0.4 H), 3.00-3.27 (m, 2 H), 2.82-2.92 (m, 1 H), 1.31-1.37 (m, 6 H)

1908
(CD₃OD) δ 8.36-8.57 (m, 1 H), 7.69 (s, 1 H), 7.35-7.56 (m, 1.3
454.1
99.3%

H), 6.90 (s, 0.7 H), 6.74-6.82 (m, 1 H), 6.59-6.71 (m, 1 H), 4.99
[M + H]⁺

(br dd, 1 H), 3.66-3.76 (m, 0.6 H), 3.34-3.40 (m, 0.4 H), 3.07-

3.18 (m, 0.7 H), 2.91-3.01 (m, 0.3 H), 2.76-2.86 (m, 1 H), 2.24-

2.38 (m, 1 H), 1.19-1.31 (m, 4H)

1909
(CD₃OD) δ 8.38-8.53 (m, 1 H), 7.69 (s, 1 H), 7.34-7.59 (m, 1.3
454.1
93.7%

H), 6.90 (s, 0.7 H), 6.75-6.82 (m, 1 H), 6.60-6.72 (m, 1 H), 4.99
[M + H]⁺

(br dd, 1 H), 3.67-3.75 (m, 0.6 H), 3.35-3.40 (m, 0.4 H), 3.08-

3.17 (m, 0.7 H), 2.92-3.01 (m, 0.3 H), 2.81 (br d, 1 H), 2.26-2.39

(m, 1 H), 1.19-1.29 (m, 4H)

1910
(CD₃OD) δ 8.78 (br d, 1 H), 8.40-8.52 (m, 1 H), 8.31 (d, 1 H),
491.1
99.9%

8.08 (t, 1 H), 7.62-7.76 (m, 2 H), 7.39-7.55 (m, 1.4 H), 6.97 (s,
[M + H]⁺

0.6 H), 6.67-6.84 (m, 2 H), 4.94-5.07 (m, 1 H), 3.74-3.83 (m, 0.7

H), 3.38-3.46 (m, 0.3 H), 3.16-3.25 (m, 0.7 H), 2.96-3.06 (m, 0.3

H), 2.81-2.89 (m, 1 H)

1911
(CD₃OD) δ 8.77 (dd, 1 H), 8.39-8.52 (m, 1 H), 8.25-8.35 (m, 1
491.1
98.6%

H), 8.08 (td, 1 H), 7.60-7.74 (m, 2 H), 7.40-7.53 (m, 1.3 H), 6.97
[M + H]⁺

(s, 0.7 H), 6.66-6.86 (m, 2 H), 5.02 (br dd, 1 H), 3.74-3.83 (m,

0.5 H), 3.42 (td, 0.5 H), 3.16-3.25 (m, 0.7 H), 2.97-3.06 (m, 0.3

H), 2.80-2.92 (m, 1 H)

1912
(CD₃OD) δ 8.47 (d, 1 H), 7.86-7.97 (m, 2 H), 7.58 (s, 1 H), 7.31
452.2
99.3%

(br d, 1 H), 7.13-7.22 (m, 2 H), 7.00 (s, 0.2, 6.78-6.88 (m, 1.5,
[M + H]⁺

6.73 (s, 0.3, 6.66 (s, 1 H), 6.35 (s, 1 H), 4.27 (dd, 1 H), 3.67

(ddd, 1 H), 2.91-3.07 (m, 1 H), 2.74 (dd, 1 H)

1913
(CD₃OD) δ 8.60 (br d, 1 H), 7.97-8.10 (m, 2 H), 7.70 (s, 1 H),
452.2
98.8%

7.44 (br d, 1 H), 7.25-7.34 (m, 2 H), 7.12 (s, 0.2, 6.90-7.01 (m,
[M + H]⁺

1.5, 6.85 (s, 0.3) 6.78 (s, 1 H), 6.47 (s, 1 H), 4.39 (br dd, 1 H),

3.74-3.83 (m, 1 H), 3.06-3.16 (m, 1 H), 2.86 (br dd, 1 H)

1914
(CD₃OD) δ 8.36-8.49 (m, 2 H), 7.76 (dd, 1 H), 7.64 (s, 1 H),
385.2
100%

7.56 (d, 1 H), 7.10-7.24 (m, 2 H), 6.91 (s, 1 H), 6.83 (td, 1 H),
[M + H]⁺

6.53 (s, 1 H), 4.71 (br dd, 1 H), 3.61 (ddd, 1 H), 2.89-3.02 (m, 1

H), 2.73 (dd, 1 H)

1915
(CD₃OD) δ 8.26-8.36 (m, 2 H), 7.64 (dd, 1 H), 7.52 (s, 1 H),
385.1
99.2%

7.44 (d, 1 H), 6.97-7.10 (m, 2 H), 6.79 (s, 1 H), 6.71 (td, 1 H),
[M + H]⁺

6.41 (s, 1 H), 4.59 (br dd, 1 H), 3.40-3.55 (m, 1 H), 2.75-2.91

(m, 1 H), 2.61 (dd, 1 H)

1916
(CD₃OD) δ 8.46 (br d, 1 H), 8.30 (s, 1 H), 7.65 (dd, 1 H), 7.53
435.1
100%

(s, 1 H), 7.29 (br d, 1 H), 6.68-7.08 (m, 4 H), 6.58 (s, 1 H), 4.61
[M + H]⁺

(br dd, 1 H), 3.42-3.54 (m, 1 H), 2.77-2.91 (m, 1 H), 2.62 (br dd,

1 H)

1917
(CD₃OD) δ 8.58 (br d, 1 H), 8.42 (s, 1 H), 7.72-7.85 (m, 1 H),
435.1
100%

7.66 (s, 1 H), 7.42 (br d, 1 H), 6.79-7.22 (m, 4 H), 6.70 (s, 1 H),
[M + H]⁺

4.73 (br dd, 1 H), 3.53-3.65 (m, 1 H), 2.91-3.04 (m, 1 H), 2.69-

2.82 (m, 1 H)

1918
(CD₃OD) δ 8.18-8.44 (m, 1 H), 7.52-7.98 (m, 2 H), 6.98 (br d, 1
389.2
98.5%

H), 6.43-6.89 (m, 3 H), 4.40-4.57 (m, 0.5 H), 3.57-3.84 (m, 0.5
[M + H]⁺

H), 2.90-3.18 (m, 1 H), 2.61-2.88 (m, 1 H), 2.43 (s, 3 H), 2.08-

2.31 (m, 1 H), 0.93-1.36 (m, 5 H)

1919
(CD₃OD) δ 8.24-8.44 (m, 1 H), 7.53-7.95 (m, 2 H), 7.00 (br d, 1
389.2
97.4%

H), 6.41-6.93 (m, 3 H), 4.39-4.55 (m, 0.5 H), 3.64-3.85 (m, 0.5
[M + H]⁺

H), 2.93-3.11 (m, 1 H), 2.82 (br d, 1 H), 2.45 (s, 3 H), 2.19 (br d,

1 H), 0.95-1.39 (m, 5 H)

1920
(CD₃OD) δ 8.19 (br s, 1 H), 7.35-7.98 (m, 2 H), 6.13-7.14 (m, 4
405.2
99.7%

H), 4.42-4.67 (m, 1 H), 3.23-3.81 (m, 1 H), 2.57-3.08 (m, 2 H),
[M + H]⁺

2.32 (s, 3 H), 1.32 (br s, 9 H)

1921
(CD₃OD) δ 8.31 (br d, 1 H), 7.39-8.06 (m, 2 H), 6.28-7.19 (m, 4
405.2
99.6%

H), 4.53-4.70 (m, 1 H), 3.35-3.96 (m, 1 H), 2.65-3.17 (m, 2 H),
[M + H]⁺

2.45 (br s, 3 H), 1.42 (br s, 9 H)

1922
(CD₃OD) δ 8.23-8.33 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.5 H),
424.2
99.1%

6.88-7.04 (m, 1.5 H), 6.81 (q, 1 H), 6.52-6.69 (m, 1 H), 4.92-
[M + H]⁺

4.99 (m, 1 H), 3.76 (ddd, 0.5 H), 3.36-3.44 (m, 0.5 H), 2.77-3.21

(m, 4 H), 1.83-1.93 (m, 6 H), 1.27-1.35 (m, 3 H)

1923
(CD₃OD) δ 8.17-8.38 (m, 1 H), 7.69 (s, 1 H), 7.40 (s, 0.5 H),
424.2
98.6%

6.89-7.09 (m, 1.5 H), 6.75-6.87 (m, 1 H), 6.50-6.69 (m, 1 H),
[M + H]⁺

4.96 (br d, 1 H), 3.76 (ddd, 0.5 H), 3.39 (br dd, 0.5 H), 2.74-3.20

(m, 4 H), 1.77-1.98 (m, 6 H), 1.27-1.34 (m, 3 H)

1924
(CD₃OD) δ 8.21-8.42 (m, 2 H), 7.98-8.14 (m, 1 H), 7.48-7.76
444.2
96.6%

(m, 1.5 H), 6.90-7.08 (m, 1.5 H), 6.76-6.86 (m, 1 H), 6.55-6.68
[M + H]⁺

(m, 1 H), 5.06 (br dd, 1 H), 4.00 (s, 3 H), 3.72-3.83 (m, 0.5H),

3.41 (td, 0.5 H), 2.75-3.22 (m, 4 H), 1.23-1.36 (m, 3 H)

1925
(CD₃OD) δ 8.21-8.44 (m, 2 H), 8.02-8.16 (m, 1 H), 7.69 (s, 1.5
444.2
95.6%

H), 6.91-7.10 (m, 1.5 H), 6.73-6.87 (m, 1 H), 6.46-6.72 (m, 1 H),
[M + H]⁺

5.07 (br dd, 1 H), 4.00 (s, 3 H), 3.71-3.83 (m, 0.5 H), 3.38-3.45

(m, 0.5 H), 2.79-3.21 (m, 4 H), 1.24-1.36 (m, 3H)

1926
(500 MHZ, CD₃OD) δ 8.18-8.35 (m, 1 H), 7.77-7.87 (m, 1 H),
444.2
99.2%

7.71 (s, 1 H), 7.53 (s, 0.5 H), 6.94-7.07 (m, 2.5 H), 6.75-6.87 (m,
[M + H]⁺

1 H), 6.56-6.73 (m, 1 H), 5.03 (br dd, 1 H), 4.03 (s, 3 H), 3.71-

3.86 (m, 0.5 H), 3.43 (td, 0.5 H), 2.91-3.26 (m, 1 H), 2.72-2.88

(m, 3 H), 1.15-1.42 (m, 3 H)

1927
(CD₃OD) δ 8.02-8.26 (m, 1 H), 7.68 (d, 1 H), 7.59 (s, 1 H), 7.40
444.2
99.3%

(s, 0.5 H), 6.77-6.98 (m, 2.5 H), 6.61-6.74 (m, 1 H), 6.46-6.57
[M + H]⁺

(m, 1 H), 4.91 (br dd, 1 H), 3.90 (s, 3 H), 3.60-3.76 (m, 0.5 H),

3.31 (td, 0.5 H), 2.82-3.13 (m, 1 H), 2.60-2.78 (m, 3 H), 1.04-

1.26 (m, 3 H)

1928
(CD₃OD) δ 9.08-9.19 (m, 1 H), 8.48 (s, 1 H), 8.21-8.33 (m, 1 H),
510.2
99.6%

7.72 (s, 1 H), 7.50-7.62 (m, 0.3 H), 6.92-7.08 (m, 0.7 H), 6.72-
[M + H]⁺

6.85 (m, 3 H), 4.94-5.12 (m, 1 H), 3.77-3.88 (m, 0.7 H), 3.41-

3.51 (m, 0.3 H), 3.14-3.24 (m, 0.7 H), 2.96-3.08 (m, 0.3 H),

2.80-2.92 (m, 1 H), 1.99-2.21 (m, 1 H), 0.96-1.12 (m, 2 H), 0.72-

0.87 (m, 2 H)

1929
(CD₃OD) δ 9.09-9.16 (m, 1 H), 8.48 (s, 1 H), 8.22-8.32 (m, 1 H),
510.2
99.1%

7.72 (s, 1 H), 7.58 (s, 0.3 H), 6.99 (s, 0.7 H), 6.72-6.86 (m, 3 H),
[M + H]⁺

5.07 (dd, 1 H), 3.77-3.87 (m, 0.7 H), 3.41-3.49 (m, 0.3 H), 3.15-

3.23 (m, 0.7 H), 2.97-3.06 (m, 0.3 H), 2.82-2.91 (m, 1 H), 2.03-

2.17 (m, 1 H), 1.00-1.09 (m, 2 H), 0.75-0.84 (m, 2H)

1930
(CD₃OD) δ 8.08-8.29 (m, 2 H), 7.72 (s, 0.3 H), 7.59 (d, 1.5 H),
492.2
99.3%

7.42 (s, 0.5 H), 7.11 (d, 1 H), 6.88 (s, 0.7 H), 6.59-6.75 (m, 3 H),
[M + H]⁺

4.92 (dd, 1 H), 3.63-3.77 (m, 0.7 H), 3.33 (td, 0.3 H), 3.03-3.14

(m, 0.7 H), 2.85-2.96 (m, 0.3 H), 2.75 (br dd, 1 H), 1.90-2.05 (m,

1 H), 0.85-0.98 (m, 2 H), 0.61-0.71 (m, 2 H)

1931
(CD₃OD) δ 8.09-8.25 (m, 2 H), 7.72 (s, 0.3 H), 7.55-7.62 (m, 1.5
492.2
99.1%

H), 7.42 (s, 0.5 H), 7.11 (d, 1 H), 6.88 (s, 0.7 H), 6.60-6.73 (m, 3
[M + H]⁺

H), 4.92 (dd, 1 H), 3.64-3.75 (m, 0.7 H), 3.29-3.38 (m, 0.3 H),

3.04-3.13 (m, 0.7 H), 2.85-2.96 (m, 0.3 H), 2.70-2.80 (m, 1 H),

1.88-2.08 (m, 1 H), 0.87-0.98 (m, 2 H), 0.63-0.72 (m, 2 H)

1932
(CD₃OD) δ 8.18-8.28 (m, 1 H), 7.69 (s, 1 H), 7.52 (s, 0.3 H),
470.2
99.8%

6.96 (s, 0.7 H), 6.69-6.80 (m, 4 H), 5.00 (br dd, 1 H), 3.88 (s, 3
[M + H]⁺

H), 3.74-3.82 (m, 0.7 H), 3.41 (td, 0.3 H), 3.12-3.23 (m, 0.7 H),

2.95-3.03 (m, 0.3 H), 2.79-2.87 (m, 1 H), 2.37 (s, 3 H), 2.00-2.13

(m, 1 H), 0.95-1.05 (m, 2 H), 0.70-0.80 (m, 2 H)

1933
(CD₃OD) δ 8.18-8.29 (m, 1 H), 7.69 (s, 1 H), 7.52 (s, 0.3 H),
470.2
99.6%

6.97 (s, 0.7 H), 6.68-6.81 (m, 4 H), 5.00 (br dd, 1 H), 3.88 (s, 3
[M + H]⁺

H), 3.75-3.83 (m, 0.7 H), 3.41 (td, 0.3 H), 3.11-3.23 (m, 0.7 H),

2.94-3.04 (m, 0.3 H), 2.78-2.88 (m, 1 H), 2.37 (s, 3 H), 1.99-2.14

(m, 1 H), 0.94-1.07 (m, 2 H), 0.68-0.83 (m, 2 H)

1934
(CD₃OD) δ 9.31-9.40 (m, 1 H), 8.73 (br d, 2 H), 8.12-8.22 (m, 1
456.2
100%

H), 7.60 (s, 1 H), 7.36 (s, 0.3 H), 6.85-6.98 (m, 1.7 H), 6.58-6.76
[M + H]⁺

(m, 2 H), 4.84-4.94 (m, 1 H), 3.65-3.79 (m, 0.7 H), 3.32-3.42 (m,

0.3 H), 2.87-3.13 (m, 2 H), 2.76 (br dd, 1 H), 1.19-1.25 (m, 6 H)

1935
(CD₃OD) δ 9.29-9.41 (m, 1 H), 8.71-8.77 (m, 2 H), 8.12-8.23
456.2
99.7%

(m, 1 H), 7.60 (s, 1 H), 7.37 (s, 0.3 H), 6.86-6.98(m, 1.7 H),
[M + H]⁺

6.58-6.76 (m, 2 H), 4.91 (br dd, 1 H), 3.67-3.78 (m, 0.7 H), 3.31-

3.42 (m, 0.3 H), 2.88-3.13 (m, 2 H), 2.70-2.81 (m, 1 H), 1.20-

1.26 (m, 6 H)

1936
(CD₃OD) δ 8.77-8.84 (m, 1 H), 8.10-8.25 (m, 2 H), 7.39-7.69
494.2
100%

(m, 2.5 H), 6.85-6.97 (m, 1.5 H), 6.51-6.75 (m, 2 H), 4.96 (br dd,
[M + H]⁺

1 H), 3.65-3.76 (m, 0.7 H), 3.33 (td, 0.3 H), 2.86-3.13 (m, 2 H),

2.69-2.79 (m, 1 H), 1.18-1.25 (m, 6 H)

1937
(CD₃OD) δ 8.90-8.95 (m, 1 H), 8.24-8.38 (m, 2 H), 7.50-7.84
494.2
99.8%

(m, 2.5 H), 6.97-7.09 (m, 1.5 H), 6.65-6.88 (m, 2 H), 5.08 (br dd,
[M + H]⁺

1 H), 3.76-3.87 (m, 0.7 H), 3.45 (td, 0.3 H), 2.98-3.25 (m, 2 H),

2.82-2.92 (m, 1 H), 1.31-1.37 (m, 6 H)

1938
(CD₃OD) δ 8.31-8.54 (m, 1 H), 7.70 (s, 1 H), 7.29-7.50 (m, 1.4
474.1
96.1%

H), 6.93 (br s, 0.6 H), 6.58-6.84 (m, 2 H), 4.97 (br dd, 1 H),
[M + H]⁺

3.69-3.78 (m, 0.6 H), 3.35-3.41 (m, 0.4 H), 2.94-3.20 (m, 1 H),

2.78-2.88 (m, 1 H), 1.85-1.93 (m, 6 H)

1939
(CD₃OD) δ 8.31-8.62 (m, 1 H), 7.70 (s, 1 H), 7.29-7.56 (m, 1.3
474.1
91.2%

H), 6.93 (br s, 0.7 H), 6.52-6.85 (m, 2 H), 4.97 (br dd, 1 H),
[M + H]⁺

3.35-3.79 (m, 1 H), 2.93-3.20 (m, 1 H), 2.83 (br d, 1 H), 1.78-

1.97 (m, 6 H)

1940
(CD₃OD) δ 8.42 (s, 1 H), 8.31 (d, 1 H), 7.77 (dd, 1 H), 7.64 (s, 1
399.2
99.9%

H), 7.14 (d, 1 H), 6.86-7.01 (m, 2 H), 6.76 (t, 1 H), 6.53(s, 1H),
[M + H]⁺

4.72 (br dd, 1 H), 3.55-3.68 (m, 1 H), 2.88-3.02 (m, 1 H), 2.74

(dd, 1 H), 2.43 (s, 3 H)

1941
(CD₃OD) δ 8.42 (s, 1 H), 8.31 (d, 1 H), 7.77 (dd, 1 H), 7.64 (s, 1
399.2
98.8%

H), 7.14 (d, 1 H), 6.87-7.01 (m, 2 H), 6.76 (t, 1 H), 6.53 (s, 1H),
[M + H]⁺

4.72 (br dd, 1 H), 3.55-3.68 (m, 1 H), 2.89-3.03 (m, 1 H), 2.74

(dd, 1 H), 2.43 (s, 3 H)

1942
(CD₃OD) δ 8.41 (s, 1 H), 8.32 (d, 1 H), 7.76 (dd, 1 H), 7.70 (s, 1
403.1
99.1%

H), 7.13 (d, 1 H), 6.88-6.99 (m, 2 H), 6.80 (td, 1 H), 6.65 (s, 1
[M + H]⁺

H), 4.71 (br dd, 1 H), 3.59 (ddd, 1 H), 2.85-3.02 (m, 1 H), 2.73

(dd, 1 H)

1943
(CD₃OD) δ 8.40 (s, 1 H), 8.32 (d, 1 H), 7.76 (dd, 1 H), 7.63 (s, 1
403.2
97.4%

H), 7.13 (d, 1 H), 6.86-6.97 (m, 2 H), 6.79 (td, 1 H), 6.65 (s, 1
[M + H]⁺

H), 4.72 (br dd, 1 H), 3.59 (ddd, 1 H), 2.85-3.01 (m, 1 H), 2.73

(dd, 1 H)

1944
(CD₃OD) δ 8.29 (d, 1 H), 8.14 (s, 1 H), 7.67 (s, 1 H), 6.31-7.05
389.2
94.8%

(m, 4 H), 4.36 (br s, 1 H), 3.71 (br s, 1 H), 2.96-3.14 (m, 1 H),
[M + H]⁺

2.78 (br dd, 1 H), 2.44 (s, 3 H), 2.19-2.38 (m, 1 H), 0.83-1.07

(m, 4 H)

1945
(CD₃OD) δ 8.31 (d, 1 H), 8.15 (s, 1 H), 7.68 (s, 1 H), 6.55-7.05
389.2
98.3%

(m, 4 H), 4.39 (br s, 1 H), 3.52-3.85 (m, 1 H), 3.06 (br s, 1 H),
[M + H]⁺

2.80 (br dd, 1 H), 2.46 (s, 3 H), 2.24-2.41 (m, 1 H), 0.92-1.03

(m, 4 H)

1946
(CD₃OD) δ 9.09-9.17 (m, 1 H), 8.48 (s, 1 H), 8.23-8.37 (m, 1 H),
512.2
99.4%

7.71 (s, 1 H), 7.56 (s, 0.3 H), 7.03-7.11 (m, 1 H), 6.81-6.99 (m,
[M + H]⁺

1.7 H), 6.64-6.74 (m, 1 H), 4.99-5.13 (m, 1 H), 3.77-3.87 (m, 0.7

H), 3.41-3.52 (m, 0.3 H), 2.98-3.25 (m, 2 H), 2.83-2.92 (m, 1 H),

1.32-1.38 (m, 6 H)

1947
(CD₃OD) δ 9.07-9.17 (m, 1 H), 8.48 (s, 1 H), 8.24-8.35 (m, 1 H),
512.2
99.4%

7.72 (s, 1 H), 7.56 (s, 0.3 H), 7.03-7.11 (m, 1 H), 6.81-6.99 (m,
[M + H]⁺

1.7 H), 6.63-6.74 (m, 1 H), 5.07 (br dd, 1 H), 3.76-3.87 (m, 0.7

H), 3.45 (td, 0.3 H), 3.20 (td, 2 H), 2.80-2.92 (m, 1 H), 1.31-1.38

(m, 6 H)

1948
(CD₃OD) δ 8.11-8.22 (m, 1 H), 7.83-7.89 (m, 1 H), 7.59 (s, 1 H),
472.2
98.0%

7.44 (s, 0.3 H), 6.90-6.96 (m, 1 H), 6.67-6.87 (m, 1.7 H), 6.53-
[M + H]⁺

6.61 (m, 1 H), 4.84-5.04 (m, 1 H), 3.77 (s, 3 H), 3.64-3.73 (m,

0.7 H), 3.32 (td, 0.3 H), 2.84-3.13 (m, 2 H), 2.68-2.79 (m, 1 H),

2.51-2.59 (m, 3 H), 1.18-1.25 (m, 6 H)

1949
(CD₃OD) δ 8.11-8.22 (m, 1 H), 7.83-7.90 (m, 1 H), 7.59 (s, 1 H),
472.2
94.1%

7.43 (s, 0.3 H), 6.90-6.98 (m, 1 H), 6.66-6.86 (m, 1.7 H), 6.52-
[M + H]⁺

6.61 (m, 1 H), 4.98 (br dd, 1 H), 3.77 (s, 3 H), 3.63-3.72 (m, 0.7

H), 3.26-3.37 (m, 0.3 H), 2.84-3.14 (m, 2 H), 2.67-2.78 (m, 1 H),

2.52-2.59 (m, 3 H), 1.18-1.25 (m, 6 H)

1950
(CD₃OD) δ 8.23-8.36 (m, 1 H), 7.82 (d, 1 H), 7.71 (s, 1 H), 7.48-
458.2
99.7%

7.56 (m, 0.3 H), 7.03-7.09 (m, 1 H), 6.79-7.01 (m, 2.7 H), 6.64-
[M + H]⁺

6.74 (m, 1 H), 5.04 (br dd, 1 H), 4.04 (s, 3 H), 3.81 (ddd, 0.7 H),

3.45 (td, 0.3 H), 2.98-3.25 (m, 2 H), 2.82-2.91 (m, 1 H), 1.28-

1.38 (m, 6 H)

1951
(CD₃OD) δ 8.24-8.36 (m, 1 H), 7.83 (d, 1 H), 7.71 (s, 1 H), 7.52
458.2
99.7%

(s, 0.3 H), 7.03-7.10 (m, 1 H), 6.80-7.02 (m, 2.7 H), 6.64-6.75
[M + H]⁺

(m, 1 H), 4.97-5.10 (m, 1 H), 4.04 (s, 3 H), 3.74-3.89 (m, 0.7 H),

3.41-3.51 (m, 0.3 H), 2.98-3.27 (m, 2 H), 2.81-2.91 (m, 1 H),

1.30-1.38 (m, 6 H)

1952
(CD₃OD) δ 8.36 (d, 1 H), 7.97-8.09 (m, 2 H), 7.70 (s, 1 H), 7.30
420.1
99.1%

(t, 2 H), 6.93-7.01 (m, 1 H), 6.80-6.87 (m, 1 H), 6.73 (s, 1H),
[M + H]⁺

6.46 (br s, 1 H), 4.39 (dd, 1 H), 3.73-3.86 (m, 1 H), 3.03-3.19

(m, 1 H), 2.86 (br dd, 1 H)

1953
(CD₃OD) δ 8.31-8.41 (m, 1 H), 7.98-8.09 (m, 2 H), 7.67-7.75
420.1
99.4%

(m, 1 H), 7.24-7.37 (m, 2 H), 6.92-7.03 (m, 1 H), 6.80-6.88 (m, 1
[M + H]⁺

H), 6.73 (s, 1 H), 6.38-6.53 (m, 1 H), 4.34-4.45 (m, 1 H), 3.72-

3.87 (m, 1 H), 3.04-3.18 (m, 1 H), 2.81-2.94 (m, 1 H)

1954
(CD₃OD) δ 8.34 (d, 1 H), 7.57-7.75 (m, 2 H), 6.94 (dd, 1 H),
353.1
99.8%

6.78-6.90 (m, 2 H), 6.62-6.76 (m, 2 H), 6.21 (dd, 1 H), 4.52-4.59
[M + H]⁺

(m, 1 H), 3.56 (ddd, 1 H), 2.89-3.02 (m, 1 H), 2.62-2.77 (m, 1 H)

1955
(CD₃OD) δ 8.34 (d, 1 H), 7.59-7.72 (m, 2 H), 6.94 (dd, 1 H),
353.1
99.6%

6.77-6.89 (m, 2 H), 6.60-6.76 (m, 2 H), 6.21 (dd, 1 H), 4.58 (br
[M + H]⁺

s, 1 H), 3.49-3.64 (m, 1 H), 2.84-3.03 (m, 1 H), 2.70 (br dd, 1 H)

1956
(CD₃OD) δ 8.22-8.50 (m, 1 H), 7.54-8.13 (m, 2 H), 7.48 (d, 1
395.2
99.1%

H), 7.02-7.34 (m, 1 H), 6.76 (br d, 1.6 H), 6.33-6.65 (m, 1.4 H),
[M + H]⁺

4.60-4.71 (m, 0.5 H), 4.34 (br s, 0.5 H), 3.66 (br s, 0.5 H), 3.27-

3.37 (m, 0.5 H), 2.80-3.07 (m, 1 H), 2.73 (br d, 1 H), 1.58-2.02

(m, 6 H)

1957
(CD₃OD) δ 8.35 (br s, 1 H), 7.91 (br s, 0.4 H), 7.54-7.73 (m, 1.6
395.2
99.3%

H), 7.49 (d, 1 H), 7.02-7.20 (m, 1 H), 6.76 (br s, 1.6 H), 6.31-
[M + H]⁺

6.63 (m, 1.4 H), 4.57-4.70 (m, 0.5 H), 4.19-4.42 (m, 0.5 H), 3.66

(br s, 0.6 H), 3.27-3.34 (m, 0.4 H), 2.99 (br s, 1 H), 2.73 (br d, 1

H), 1.72 (br d, 6 H)

1958
(CD₃OD) δ 8.20 (br s, 1 H), 7.90 (br s, 0.5 H), 7.48-7.72 (m, 1.5
409.2
99.6%

H), 6.89 (br d, 1 H), 6.61-6.83 (m, 1.6 H), 6.32-6.59 (m, 1.4 H),
[M + H]⁺

4.58-4.71 (m, 0.5 H), 4.35 (br s, 0.5 H), 3.66 (br s, 0.5 H), 3.25-

3.36 (m, 0.5 H), 2.82-3.11 (m, 1 H), 2.72 (br s, 1 H), 2.34 (s, 3

H), 1.57-1.87 (m, 6 H)

1959
(CD₃OD) δ 8.06-8.33 (m, 1 H), 7.91 (br s, 0.5 H), 7.50-7.72 (m,
409.2
99.4%

1.5 H), 6.89 (br d, 1 H), 6.63-6.83 (m, 1.5 H), 6.34-6.61 (m, 1.5
[M + H]⁺

H), 4.56-4.69 (m, 0.5 H), 4.25-4.42 (m, 0.5 H), 3.52-3.73 (m, 0.5

H), 3.27 (br d, 0.5 H), 2.80-3.08 (m, 1 H), 2.73 (br d, 1 H), 2.34

(s, 3 H), 1.55-1.83 (m, 6 H)

1960
(CD₃OD) δ 8.28 (br s, 2 H), 7.73-8.16 (m, 2 H), 7.70 (s, 1 H),
429.2
98.3%

7.00 (br d, 1 H), 6.70-6.96 (m, 2 H), 6.63 (br s, 1 H), 4.62 (br s,
[M + H]⁺

1 H), 3.98 (s, 3 H), 3.80 (br s, 0.5 H), 3.37-3.54 (m, 0.5 H), 2.78-

3.22 (m, 2 H), 2.45 (s, 3 H)

1961
(CD₃OD) δ 8.04-8.35 (m, 2 H), 7.64-8.02 (m, 2 H), 7.59 (s, 1 H),
429.2
89.5%

6.89 (br d, 1 H), 6.56-6.83 (m, 2 H), 6.51 (br s, 1 H), 4.49 (br s,
[M + H]⁺

1 H), 3.86 (s, 3 H), 3.68 (br s, 0.5 H), 3.25-3.43 (m, 0.5 H), 2.58-

3.12 (m, 2 H), 2.34 (s, 3 H)

1962
(CD₃OD) δ 8.23 (br s, 1 H), 7.67-8.02 (m, 2 H), 7.64 (s, 1 H),
443.2
100%

6.89 (br d, 1 H), 6.57-6.84 (m, 2 H), 6.50 (br s, 1 H), 4.60-4.69
[M + H]⁺

(m, 1 H), 3.74 (br s, 3 H), 3.24-3.68 (m, 1 H), 2.63-3.12 (m, 2

H), 2.52 (br d, 3 H), 2.34 (s, 3 H)

1963
(CD₃OD) δ 8.23 (br s, 1 H), 7.82 (br s, 2 H), 7.65 (br s, 1 H),
443.2
99.0%

6.89 (br d, 1 H), 6.58-6.84 (m, 2 H), 6.51 (br s, 1 H), 4.56-4.68
[M + H]⁺

(m, 1 H), 3.74 (br s, 3 H), 3.25-3.69 (m, 1 H), 2.69-3.08 (m, 2

H), 2.39-2.63 (m, 3 H), 2.34 (s, 3 H)

1964
(CD₃OD) δ 8.68-8.76 (m, 1 H), 8.33 (br s, 1 H), 8.23 (br d, 1.5
426.2
100%

H), 7.87-8.10 (m, 1.5 H), 7.71 (br s, 1 H), 7.52-7.63 (m, 1 H),
[M + H]⁺

7.01 (br d, 1 H), 6.57-6.97 (m, 3 H), 4.70-4.82 (m, 1 H), 3.41-

3.95 (m, 1 H), 2.96-3.28 (m, 1 H), 2.86 (br s, 1 H), 2.47 (s, 3 H)

1965
(CD₃OD) δ 8.73 (d, 1 H), 8.33 (br s, 1 H), 8.24 (br s, 1.5 H),
426.2
99.9%

7.87-8.10 (m, 1.5 H), 7.70 (br s, 1 H), 7.59 (dd, 1 H), 7.01 (br d,
[M + H]⁺

1 H), 6.55-6.97 (m, 3 H), 4.63-4.80 (m, 1 H), 3.43-3.91 (m, 1 H),

2.95-3.28 (m, 1 H), 2.86 (br s, 1 H), 2.47 (s, 3 H)

1966
(CD₃OD) δ 8.69 (br d, 1 H), 8.29-8.54 (m, 2 H), 8.02 (td, 1 H),
429.1
100%

7.66-7.83 (m, 1.3 H), 7.48-7.66 (m, 2 H), 7.08-7.32 (m, 1 H),
[M + H]⁺

6.75-7.06 (m, 1.7 H), 6.50-6.72 (m, 1 H), 5.13 (dd, 1 H), 3.66-

3.88 (m, 0.6 H), 3.45 (td, 0.4 H), 2.95-3.28 (m, 1 H), 2.83 (dd, 1 H)

1967
(CD₃OD) δ 8.70 (br d, 1 H), 8.25-8.53 (m, 2 H), 8.02 (td, 1 H),
429.1
99.8%

7.47-7.87 (m, 3.3 H), 7.11-7.32 (m, 1 H), 6.77-7.04 (m, 1.7 H),
[M + H]⁺

6.51-6.72 (m, 1 H), 5.13 (dd, 1 H), 3.65-3.89 (m, 0.7 H), 3.45

(td, 0.3 H), 2.97-3.27 (m, 1 H), 2.84 (dd, 1 H)

1968
(CD₃OD) δ 8.70 (br d, 1 H), 8.25-8.45 (m, 2 H), 7.92-8.11 (m, 1
447.1
100%

H), 7.65-7.82 (m, 1.4 H), 7.57 (dd, 1 H), 6.90-7.04 (m, 1.6 H),
[M + H]⁺

6.70-6.90 (m, 2 H), 5.17 (dd, 1 H), 3.77 (ddd, 0.6 H), 3.44 (td,

0.4 H), 2.96-3.27 (m, 1 H), 2.84 (dd, 1 H)

1969
(CD₃OD) δ 8.58 (br d, 1 H), 8.08-8.35 (m, 2 H), 7.79-8.00 (m, 1
447.1
99.8%

H), 7.64 (br s, 1.4 H), 7.45 (dd, 1 H), 6.44-7.08 (m, 3.6 H), 5.06
[M + H]⁺

(br dd, 1 H), 3.57-3.76 (m, 0.6 H), 3.32 (td, 0.4 H), 2.85-3.16 (m,

1 H), 2.73 (br dd, 1 H)

1970
(CD₃OD) δ 8.46-9.12 (m, 1 H), 8.19-8.43 (m, 2 H), 8.01 (td, 1
443.1
100%

H), 7.64-7.87 (m, 1.3 H), 7.56 (dd, 1 H), 6.98 (q, 1.7 H), 6.71-
[M + H]⁺

6.84 (m, 1 H), 6.52-6.69 (m, 1 H), 5.13 (dd, 1 H), 3.69-3.85 (m,

0.7 H), 3.40-3.51 (m, 0.3 H), 2.96-3.27 (m, 1 H), 2.84 (dd, 1 H),

2.29-2.56 (m, 3 H)

1971
(CD₃OD) δ 8.51-9.00 (m, 1 H), 8.19-8.48 (m, 2 H), 7.92-8.15
443.2
100%

(m, 1 H), 7.47-7.86 (m, 2.3 H), 6.92-7.11 (m, 1.7 H), 6.71-6.89
[M + H]⁺

(m, 1 H), 6.51-6.69 (m, 1 H), 5.13 (br dd, 1 H), 3.71-3.85 (m, 0.7

H), 3.41-3.50 (m, 0.3 H), 2.96-3.27 (m, 1 H), 2.84 (br dd, 1 H),

2.39-2.53 (m, 3 H)

1972
(CD₃OD) δ 9.46-9.54 (m, 2 H), 9.41 (s, 1 H), 8.26-8.36 (m, 1 H),
428.2
99.9%

7.72-7.79 (m, 1 H), 7.56 (s, 0.3 H), 6.98-7.05 (m, 1.7 H), 6.77-
[M + H]⁺

6.85 (m, 1 H), 6.59-6.69 (m, 1 H), 5.11 (br d, 1 H), 3.80-3.87 (m,

0.7 H), 3.50 (br d, 0.3 H), 3.16-3.24 (m, 0.7 H), 3.00-3.05 (m,

0.3 H), 2.84-2.92 (m, 1 H), 2.43-2.49 (m, 3 H)

1973
(CD₃OD) δ 9.46-9.52 (m, 2 H), 9.40 (s, 1 H), 8.26-8.35 (m, 1 H),
428.1
98.8%

7.72 (s, 1 H), 7.55 (br s, 0.3 H), 7.01 (br t, 1.7 H), 6.77-6.84 (m,
[M + H]⁺

1 H), 6.60-6.68 (m, 1 H), 5.09 (br d, 1 H), 3.83 (ddd, 0.7 H),

3.46-3.52 (m, 0.3 H), 3.15-3.27 (m, 0.7 H), 2.98-3.08 (m, 0.3 H),

2.83-2.93 (m, 1 H), 2.42-2.49 (m, 3 H)

1974
(CD₃OD) δ 9.47-9.53 (m, 2 H), 9.40 (s, 1 H), 8.31-8.39 (m, 1 H),
432.2
99.7%

7.72 (s, 1 H), 7.51-7.60 (m, 0.3 H), 6.95-7.02 (m, 1.7 H), 6.81-
[M + H]⁺

6.90 (m, 1 H), 6.75-6.80 (m, 1 H), 5.11 (m, 1 H), 3.75-3.90 (m,

0.7 H), 3.39-3.51 (m, 0.3 H), 3.16-3.26 (m, 0.7 H), 2.99-3.05 (m,

0.3 H), 2.83-2.94 (m, 1 H)

1975
(CD₃OD) δ 9.44-9.55 (m, 2 H), 9.40 (s, 1 H), 8.30-8.40 (m, 1 H),
432.1
98.9%

7.72 (s, 1 H), 7.56 (s, 0.3 H), 6.94-7.04 (m, 1.7 H), 6.82-6.90 (m,
[M + H]⁺

1 H), 6.76-6.81 (m, 1 H), 5.11 (br d, 1 H), 3.78-3.87 (m, 0.7 H),

3.46 (br d, 0.3 H), 3.17-3.27 (m, 0.7 H), 2.97-3.05 (m, 0.3 H),

2.90 (br s, 1 H)

1976
(CD₃OD) δ 8.34 (d, 1 H), 8.07-8.18 (m, 1 H), 7.63 (s, 1 H), 7.54-
335.1
99.7%

7.61 (m, 1 H), 7.05 (d, 1 H), 6.94 (dd, 1 H), 6.76-6.85(m, 2H),
[M + H]⁺

6.67 (dd, 1 H), 6.63 (s, 1 H), 4.57 (dd, 1 H), 3.52-3.64 (m, 1 H),

2.88-3.05 (m, 1 H), 2.69 (dd, 1 H)

1977
(CD₃OD) δ 8.34 (d, 1 H), 8.10-8.17 (m, 1 H), 7.62 (s, 1 H), 7.55-
335.2
98.6%

7.61 (m, 1 H), 7.05 (d, 1 H), 6.94 (dd, 1 H), 6.76-6.86 (m, 2 H),
[M + H]⁺

6.67 (dd, 1 H), 6.63 (s, 1 H), 4.52-4.60 (m, 1 H), 3.51-3.63 (m, 1

H), 2.88-3.03 (m, 1 H), 2.69 (dd, 1 H)

1978
(CD₃OD) δ 8.58 (br d, 1 H), 8.13 (dd, 1 H), 7.54-7.66 (m, 2 H),
367.2
98.9%

7.41 (br d, 1 H), 6.74-7.13 (m, 4 H), 6.62-6.72 (m, 2 H), 4.56 (br
[M + H]⁺

d, 1 H), 3.49-3.61 (m, 1 H), 2.90-3.03 (m, 1 H), 2.69 (br dd, 1 H)

1979
(CD₃OD) δ 8.58 (br d, 1 H), 8.13 (dd, 1 H), 7.54-7.67 (m, 2 H),
367.1
96.6%

7.41 (br d, 1 H), 6.75-7.12 (m, 4 H), 6.63-6.71 (m, 2 H), 4.55 (br
[M + H]⁺

s, 1 H), 3.56 (ddd, 1 H), 2.89-3.03 (m, 1 H), 2.69 (br dd, 1 H)

1980
(CD₃OD) δ 9.04 (br d, 2 H), 8.22-8.38 (m, 1 H), 7.66-7.79 (m, 2
456.2
99.6%

H), 7.46 (br s, 0.3 H), 6.95-7.13 (m, 1.7 H), 6.69-6.89 (m, 2 H),
[M + H]⁺

5.00-5.02 (m, 1 H), 3.76-3.90 (m, 0.6 H), 3.44-3.51 (m, 0.4 H),

2.97-3.27 (m, 2 H), 2.88 (br d, 1 H), 1.30-1.42 (m, 6 H)

1981
(CD₃OD) δ 9.02-9.08 (m, 2 H), 8.23-8.36 (m, 1 H), 7.68-7.75
456.2
99.0%

(m, 2 H), 7.41-7.49 (m, 0.3 H), 6.97-7.11 (m, 1.7 H), 6.69-6.88
[M + H]⁺

(m, 2 H), 4.99-5.03 (m, 1 H), 3.79-3.88 (m, 0.6 H), 3.43-3.53 (m,

0.4 H), 2.99-3.27 (m, 2 H), 2.88 (br d, 1 H), 1.31-1.38 (m, 6 H)

1982
(CD₃OD) δ 8.22-8.39 (m, 2 H), 7.49-7.86 (m, 2.3 H), 7.23 (d, 1
494.2
100%

H), 6.95-7.11 (m, 1.7 H), 6.64-6.89 (m, 2 H), 5.04 (br dd, 1 H),
[M + H]⁺

3.77-3.88 (m, 0.6 H), 3.42-3.52 (m, 0.4 H), 3.21 (tt, 2 H), 2.83-

2.93 (m, 1 H), 1.30-1.39 (m, 6 H)

1983
(CD₃OD) δ 8.22-8.37 (m, 2 H), 7.47-7.86 (m, 2.3 H), 7.24 (d, 1
494.2
100%

H), 6.96-7.11 (m, 1.7 H), 6.63-6.90 (m, 2 H), 5.04 (br dd, 1 H),
[M + H]⁺

3.77-3.89 (m, 0.6 H), 3.41-3.52 (m, 0.4 H), 2.99-3.27 (m, 2 H),

2.83-2.92 (m, 1 H), 1.31-1.38 (m, 6 H)

1984
(CD₃OD) δ 8.52 (d, 1 H), 8.21-8.37 (m, 2 H), 7.63 (s, 0.3 H),
512.2
100%

7.29 (d, 1 H), 7.10 (br t, 1.7 H), 6.78-6.91 (m, 2 H), 5.13 (br dd,
[M + H]⁺

1 H), 3.77-3.86 (m, 0.6 H), 3.42-3.53 (m, 0.4 H), 3.03-3.29 (m, 2

H), 2.95 (br d, 1 H), 1.32-1.38 (m, 6 H)

1985
(CD₃OD) δ 8.40 (d, 1 H), 8.12-8.26 (m, 1 H), 7.60 (br s, 1 H),
512.2
99.7%

7.40 (br s, 0.3 H), 7.17 (d, 1 H), 6.84-7.00 (m, 1.7 H), 6.54-6.77
[M + H]⁺

(m, 2 H), 4.90-4.95 (m, 1 H), 3.65-3.75 (m, 0.6 H), 3.29-3.39 (m,

0.4 H), 2.90-3.14 (m, 2 H), 2.70-2.81 (m, 1 H), 1.20-1.26 (m, 6 H)

1986
(CD₃OD) δ 8.34 (d, 1 H), 8.14 (s, 1 H), 7.67 (s, 1 H), 6.42-7.07
393.2
99.2%

(m, 4 H), 4.18-4.57 (m, 1 H), 3.70 (br s, 1 H), 2.93-3.18 (m, 1
[M + H]⁺

H), 2.79 (br dd, 1 H), 2.20-2.45 (m, 1 H), 0.83-1.13 (m, 4H)

1987
(CD₃OD) δ 8.34 (d, 1 H), 8.14 (s, 1 H), 7.67 (s, 1 H), 6.46-7.05
393.2
98.0%

(m, 4 H), 4.38 (br s, 1 H), 3.54-3.84 (m, 1 H), 3.01-3.15 (m, 1
[M + H]⁺

H), 2.72-2.86 (m, 1 H), 2.35 (br s, 1 H), 0.91-1.00 (m, 4 H)

1988
(CD₃OD) δ 8.23-8.32 (m, 1 H), 8.08-8.12 (m, 1 H), 7.65-7.73
349.2
100%

(m, 1.3 H), 7.37-7.43 (m, 1 H), 6.81-7.14 (m, 1.7 H), 6.71-6.80
[M + H]⁺

(m, 1 H), 6.49-6.64 (m, 1 H), 5.04 (dd, 1 H), 3.69 (ddd, 0.7 H),

3.33-3.40 (m, 0.3 H), 3.07-3.18 (m, 0.7 H), 2.90-3.00 (m, 0.3 H),

2.78 (dd, 1 H), 2.36-2.47 (m, 3 H)

1989
(CD₃OD) δ 8.25-8.31 (m, 1 H), 8.09-8.12 (m, 1 H), 7.68 (s, 1 H),
349.1
99.4%

7.38-7.44 (m, 1 H), 6.93-7.00 (m, 2 H), 6.73-6.81 (m, 1 H), 6.47-
[M + H]⁺

6.63 (m, 1 H), 4.94-5.08 (m, 1 H), 3.69 (ddd, 0.7 H), 3.35-3.41

(m, 0.3 H), 3.08-3.18 (m, 0.7 H), 2.90-2.98 (m, 0.3 H), 2.78 (dd,

1 H), 2.38-2.47 (m, 3 H)

1990
(CD₃OD) δ 8.39-8.52 (m, 1 H), 7.65-7.80 (m, 1.3 H), 7.53-7.64
392.1
100%

(m, 1 H), 7.14-7.27 (m, 1 H), 6.79-6.99 (m, 1.7 H), 6.51-6.67 (m,
[M + H]⁺

1 H), 5.14 (br dd, 0.5 H), 4.79-4.87 (m, 0.5 H), 3.62-3.78 (m, 0.5

H), 3.36-3.48 (m, 0.5 H), 2.91-3.22 (m, 1 H), 2.80 (br d, 1 H),

2.48-2.63 (m, 1 H), 1.12-1.43 (m, 4 H)

1991
(CD₃OD) δ 8.37-8.50 (m, 1 H), 7.65-7.78 (m, 1.3 H), 7.53-7.64
392.1
96.4%

(m, 1 H), 7.12-7.27 (m, 1 H), 6.79-6.98 (m, 1.7 H), 6.51-6.68 (m,
[M + H]⁺

1 H), 5.14 (dd, 0.5 H), 4.79-4.86 (m, 0.5 H), 3.64-3.78 (m, 0.5

H), 3.36-3.47 (m, 0.5 H), 2.92-3.21 (m, 1 H), 2.80 (br dd, 1 H),

2.49-2.63 (m, 1 H), 1.16-1.40 (m, 4 H)

1992
(CD₃OD) δ 8.28-8.40 (m, 1 H), 7.66-7.78 (m, 1.3 H), 6.89-7.03
410.1
99.6%

(m, 1.7 H), 6.79-6.89 (m, 1 H), 6.69-6.77 (m, 1 H), 5.17 (dd, 0.5
[M + H]⁺

H), 4.85 (br d, 0.5 H), 3.66-3.78 (m, 0.5 H), 3.36-3.46 (m, 0.5

H), 2.92-3.21 (m, 1 H), 2.81 (dd, 1 H), 2.51-2.62 (m, 1 H), 1.17-

1.40 (m, 4 H)

1993
(CD₃OD) δ 8.26-8.42 (m, 1 H), 7.66-7.77 (m, 1.3 H), 6.89-7.04
410.1
88.5%

(m, 1.7 H), 6.78-6.89 (m, 1 H), 6.67-6.77 (m, 1 H), 5.17 (dd, 0.5
[M + H]⁺

H), 4.85 (br d, 0.5 H), 3.71 (ddd, 0.5 H), 3.36-3.49 (m, 0.5 H),

2.92-3.20 (m, 1 H), 2.81 (dd, 1 H), 2.49-2.63 (m, 1 H), 1.17-1.41

(m, 4 H)

1994
(CD₃OD) δ 8.20-8.43 (m, 1 H), 7.63-7.84 (m, 2 H), 6.65-7.03
450.1
99.2%

(m, 5 H), 5.22 (dd, 1 H), 3.99 (s, 3 H), 3.65-3.79 (m, 0.6 H), 3.42
[M + H]⁺

(td, 0.4 H), 2.92-3.24 (m, 1 H), 2.82 (br dd, 1 H)

1995
(CD₃OD) δ 8.17-8.41 (m, 1 H), 7.51-7.84 (m, 2 H), 6.60-7.02
450.1
99.1%

(m, 5 H), 5.22 (dd, 1 H), 3.98 (s, 3 H), 3.65-3.78 (m, 0.6 H),
[M + H]⁺

3.37-3.50 (m, 0.4 H), 2.94-3.25 (m, 1 H), 2.73-2.89 (m, 1 H)

1996
(CD₃OD) δ 8.24-8.37 (m, 1 H), 7.64-7.78 (m, 1.3 H), 6.90-7.05
406.2
100%

(m, 1.7 H), 6.74-6.84 (m, 1 H), 6.51-6.65 (m, 1 H), 5.14 (dd, 0.5
[M + H]⁺

H), 4.80-4.87 (m, 0.5 H), 3.72 (ddd, 0.5 H), 3.42 (td, 0.5 H),

2.93-3.21 (m, 1 H), 2.80 (dd, 1 H), 2.52-2.63 (m, 1 H), 2.40-2.50

(m, 3 H), 1.16-1.41 (m, 4H)

1997
(CD₃OD) δ 8.25-8.37 (m, 1 H), 7.65-7.77 (m, 1.3 H), 6.89-7.05
406.2
99.6%

(m, 1.7 H), 6.73-6.84 (m, 1 H), 6.54-6.66 (m, 1 H), 5.14 (dd, 0.5
[M + H]⁺

H), 4.79-4.86 (m, 0.5 H), 3.65-3.78 (m, 0.5 H), 3.37-3.48 (m, 0.5

H), 2.93-3.22 (m, 1 H), 2.80 (dd, 1 H), 2.51-2.63 (m, 1 H), 2.39-

2.50 (m, 3 H), 1.16-1.42 (m, 4 H)

1998
(CD₃OD) δ 8.18-8.39 (m, 1 H), 7.59-7.82 (m, 2.5 H), 6.85-7.02
446.2
99.1%

(m, 2.5 H), 6.69-6.81 (m, 1 H), 6.50-6.66 (m, 1 H), 5.18 (dd, 1
[M + H]⁺

H), 3.98 (s, 3 H), 3.65-3.84 (m, 0.7 H), 3.43 (td, 0.3 H), 2.92-

3.24 (m, 1 H), 2.81 (br dd, 1 H), 2.34-2.48 (m, 3 H)

1999
(CD₃OD) δ 8.15-8.36 (m, 1 H), 7.54-7.80 (m, 2.5 H), 6.86-7.04
446.2
98.8%

(m, 2.5 H), 6.70-6.82 (m, 1 H), 6.45-6.67 (m, 1 H), 5.18 (dd, 1
[M + H]⁺

H), 3.98 (s, 3 H), 3.67-3.80 (m, 0.6 H), 3.43 (td, 0.4 H), 2.94-

3.24 (m, 1 H), 2.81 (br dd, 1 H), 2.32-2.50 (m, 3 H)

2000
(CD₃OD) δ 8.37-8.51 (m, 1 H), 8.01-8.27 (m, 2.5 H), 7.68 (d, 1
401.1
100%

H), 7.46-7.64 (m, 3 H), 7.06-7.31 (m, 1 H), 6.98 (s, 0.5 H), 6.74-
[M + H]⁺

6.91 (m, 1 H), 6.47-6.71 (m, 1 H), 5.49 (dd, 0.5 H), 4.90-4.95

(m, 0.5 H), 3.64-3.81 (m, 0.7 H), 3.36-3.56 (m, 0.3 H), 3.10 (s, 1

H), 2.82 (br d, 1 H)

2001
(CD₃OD) δ 8.38-8.50 (m, 1 H), 8.05-8.27 (m, 2.5 H), 7.69 (s, 1
401.1
99.4%

H), 7.49-7.66 (m, 3 H), 7.08-7.27 (m, 1 H), 6.99 (s, 0.5 H), 6.73-
[M + H]⁺

6.92 (m, 1 H), 6.44-6.71 (m, 1 H), 5.35-5.59 (m, 0.5 H), 4.93 (s,

0.5 H), 3.64-3.85 (m, 0.5 H), 3.32-3.51 (m, 0.5 H), 2.98-3.20 (m,

1 H), 2.72-2.87 (m, 1 H)

2002
(CD₃OD) δ 8.18-8.46 (m, 1.4 H), 7.94-8.16 (m, 2 H), 7.69 (s, 1
419.1
100%

H), 7.58 (dq, 2 H), 6.89-7.08 (m, 1.6 H), 6.62-6.88 (m, 2 H),
[M + H]⁺

5.53 (br dd, 0.5 H), 4.93-5.05 (m, 0.5 H), 3.73 (td, 0.6 H), 3.38-

3.52 (m, 0.4 H), 2.95-3.25 (m, 1 H), 2.82 (br d, 1 H)

2003
(CD₃OD) δ 8.20-8.44 (m, 1.5 H), 8.00-8.19 (m, 2 H), 7.69 (s, 1
419.1
99.6%

H), 7.46-7.63 (m, 2 H), 6.88-7.09 (m, 1.5 H), 6.58-6.87 (m, 2 H),
[M + H]⁺

5.53 (br dd, 0.5 H), 4.94-4.99 (m, 0.5 H), 3.66-3.76 (m, 0.6 H),

3.40-3.49 (m, 0.4 H), 2.94-3.25 (m, 1 H), 2.77-2.88 (m, 1 H)

2004
(CD₃OD) δ 8.28-8.55 (m, 1 H), 7.42-7.92 (m, 3.4 H), 7.14-7.26
416.2
98.4%

(m, 1 H), 7.05-7.10 (m, 1 H), 6.96 (br s, 0.6 H), 6.81-6.89 (m, 1
[M + H]⁺

H), 6.47-6.76 (m, 1 H), 5.04 (br dd, 1 H), 4.22-4.41 (m, 3 H),

3.39-3.86 (m, 1 H), 2.95-3.26 (m, 1 H), 2.75-2.93 (m, 1 H)

2005
(CD₃OD) δ 8.33-8.55 (m, 1 H), 7.48-7.78 (m, 3.3 H), 7.14-7.24
416.2
97.6%

(m, 1 H), 7.05-7.10 (m, 1 H), 6.96 (s, 0.7 H), 6.78-6.89 (m, 1 H),
[M + H]⁺

6.55-6.68 (m, 1 H), 5.04 (dd, 1 H), 4.23-4.37 (m, 3 H), 3.74-3.85

(m, 0.6 H), 3.37-3.45 (m, 0.4 H), 2.94-3.24 (m, 1 H), 2.78-2.90

(m, 1 H)

2006
(CD₃OD) δ 8.22-8.37 (m, 1 H), 7.64-7.75 (m, 1 H), 7.51 (s, 0.3
472.2
100%

H), 6.95-7.22 (m, 1.7 H), 6.63-6.92 (m, 3 H), 5.02 (br dd, 1 H),
[M + H]⁺

3.88-3.96 (m, 3 H), 3.75-3.86 (m, 0.6 H), 3.40-3.48 (m, 0.4 H),

2.98-3.27 (m, 2 H), 2.86 (br d, 1 H), 2.41 (s, 3 H), 1.30-1.39 (m,

6 H)

2007
(CD₃OD) δ 8.24-8.36 (m, 1 H), 7.63-7.74 (m, 1 H), 7.51 (s, 0.3
472.2
100%

H), 6.96-7.22 (m, 1.7 H), 6.60-6.92 (m, 3 H), 4.99-5.07 (m, 1 H),
[M + H]⁺

3.88-3.96 (m, 3 H), 3.75-3.85 (m, 0.6 H), 3.40-3.49 (m, 0.4 H),

2.97-3.27 (m, 2 H), 2.86 (br d, 1 H), 2.41 (s, 3 H), 1.31-1.39 (m,

6 H)

2008
(CD₃OD) δ 8.46 (d, 1 H), 7.99-8.06 (m, 2 H), 7.70 (s, 1 H), 7.26-
436.1
99.1%

7.34 (m, 3 H), 6.85 (t, 1 H), 6.72 (s, 1 H), 6.42-6.49 (m, 1 H),
[M + H]⁺

4.39 (dd, 1 H), 3.79 (ddd, 1 H), 3.05-3.16 (m, 1 H), 2.81-2.92

(m, 1 H)

2009
(CD₃OD) δ 8.45 (d, 1 H), 7.96-8.12 (m, 2 H), 7.70 (s, 1 H), 7.16-
436.1
99.3%

7.40 (m, 3 H), 6.85 (t, 1 H), 6.72 (s, 1 H), 6.45 (br s, 1 H), 4.39
[M + H]⁺

(dd, 1 H), 3.71-3.84 (m, 1 H), 3.04-3.16 (m, 1 H), 2.80-2.91 (m,

1 H)

2010
(CD₃OD) δ 7.97-8.14 (m, 2 H), 7.68 (s, 1 H), 7.47 (d, 1 H), 7.30
416.2
100%

(t, 2 H), 7.12 (dd, 1 H), 6.71 (d, 1 H), 6.53 (s, 1 H), 6.46 (s, 1 H),
[M + H]⁺

4.36 (dd, 1 H), 3.82 (td, 1 H), 3.04-3.15 (m, 1 H), 2.81-2.91 (m,

1 H), 2.63 (s, 3 H)

2011
(CD₃OD) δ 7.99-8.08 (m, 2 H), 7.68 (s, 1 H), 7.47 (d, 1 H), 7.25-
416.2
99.6%

7.34 (m, 2 H), 7.12 (dd, 1 H), 6.71 (d, 1 H), 6.53 (s, 1 H), 6.46
[M + H]⁺

(s, 1 H), 4.36 (dd, 1 H), 3.76-3.88 (m, 1 H), 3.03-3.17 (m, 1 H),

2.86 (dd, 1 H), 2.63 (s, 3 H)

2012
(CD₃OD) δ 8.69 (d, 1 H), 8.43 (s, 1 H), 7.78 (dd, 1 H), 7.57-7.70
453.1
100%

(m, 2 H), 7.16 (d, 1 H), 6.91-7.01 (m, 2 H), 6.70 (s, 1 H), 4.74
[M + H]⁺

(br dd, 1 H), 3.53-3.67 (m, 1 H), 2.89-3.03 (m, 1 H), 2.75 (dd, 1 H)

2013
(CD₃OD) δ 8.57 (d, 1 H), 8.31 (s, 1 H), 7.66 (dd, 1 H), 7.44-7.57
453.2
79.7%

(m, 2 H), 7.04 (d, 1 H), 6.85 (br t, 2 H), 6.58 (s, 1 H), 4.62 (br
[M + H]⁺

dd, 1 H), 3.43-3.54 (m, 1 H), 2.76-2.91 (m, 1 H), 2.63 (dd, 1 H)

2014
(CD₃OD) δ 8.69 (d, 1 H), 8.13 (s, 1 H), 7.53-7.75 (m, 2 H), 6.45-
443.2
99.9%

7.12 (m, 3 H), 4.39 (br s, 1 H), 3.37-3.87 (m, 1 H), 3.05 (br s, 1
[M + H]⁺

H), 2.71-2.86 (m, 1 H), 2.36 (br s, 1 H), 0.89-1.03 (m, 4 H)

2015
(CD₃OD) δ 8.68 (d, 1 H), 8.13 (s, 1 H), 7.55-7.74 (m, 2 H), 6.51-
443.2
98.8%

7.06 (m, 3 H), 4.41 (br s, 1 H), 3.39-3.85 (m, 1 H), 3.05 (br s, 1
[M + H]⁺

H), 2.79 (br dd, 1 H), 2.36 (br s, 1 H), 0.74-1.15 (m, 4 H)

2016
(CD₃OD) δ 8.31-8.53 (m, 1 H), 7.54-7.89 (m, 3 H), 7.09-7.29
432.1
100%

(m, 1 H), 6.75-7.02 (m, 3 H), 6.48-6.69 (m, 1 H), 5.18 (br d, 1
[M + H]⁺

H), 3.98 (s, 3 H), 3.72 (br t, 0.5 H), 3.40 (br d, 0.5 H), 2.72-3.25

(m, 2 H)

2017
(CD₃OD) δ 8.29-8.53 (m, 1 H), 7.50-7.83 (m, 3 H), 7.09-7.26
432.1
98.0%

(m, 1 H), 6.77-6.97 (m, 3 H), 6.50-6.67 (m, 1 H), 5.18 (br dd, 1
[M + H]⁺

H), 3.98 (s, 3 H), 3.59-3.83 (m, 0.5 H), 3.42 (td, 0.5 H), 2.93-

3.23 (m, 1 H), 2.81 (br dd, 1 H)

2018
(CD₃OD) δ 8.28-8.41 (m, 2 H), 8.08 (s, 1 H), 7.84 (s, 0.3 H),
450.2
100%

7.65-7.76 (m, 1 H), 6.91-7.03 (m, 1.7 H), 6.72-6.90 (m, 2 H),
[M + H]⁺

5.29 (dd, 0.6 H), 4.93-4.99 (m, 0.4 H), 4.00 (s, 3 H), 3.68-3.80

(m, 0.6 H), 3.45 (td, 0.4 H), 2.95-3.23 (m, 1 H), 2.77-2.90 (m, 1 H)

2019
(CD₃OD) δ 8.28-8.40 (m, 2 H), 8.08 (s, 1 H), 7.84 (s, 0.3 H),
450.1
99.8%

7.71 (s, 1 H), 6.89-7.03 (m, 1.7 H), 6.69-6.88 (m, 2 H), 5.29 (dd,
[M + H]⁺

0.6 H), 4.93-4.98 (m, 0.4 H), 4.00 (d, 3 H), 3.68-3.81 (m, 0.6 H),

3.45 (td, 0.4 H), 2.96-3.24 (m, 1 H), 2.84 (br d, 1 H)

2020
(CD₃OD) δ 8.19-8.44 (m, 1 H), 7.83-7.97 (m, 1 H), 7.63-7.82
399.2
100%

(m, 2 H), 7.43-7.62 (m, 2.2 H), 6.93-7.13 (m, 1.8 H), 6.72-6.89
[M + H]⁺

(m, 1 H), 6.42-6.71 (m, 1 H), 5.00 (br d, 1 H), 3.70-3.90 (m, 0.5

H), 3.39-3.49 (m, 0.5 H), 2.96-3.29 (m, 1 H), 2.78-2.91 (m, 1 H),

2.37-2.55 (m, 3 H)

2021
(CD₃OD) δ 8.20-8.39 (m, 1 H), 7.82-7.96 (m, 1 H), 7.62-7.79
399.2
98.2%

(m, 2 H), 7.40-7.61 (m, 2.2 H), 6.91-7.11 (m, 1.8 H), 6.71-6.85
[M + H]⁺

(m, 1 H), 6.41-6.70 (m, 1 H), 4.98-5.03 (m, 1 H), 3.67-3.87 (m,

0.5 H), 3.36-3.47 (m, 0.5 H), 2.97-3.26 (m, 1 H), 2.73-2.90 (m, 1

H), 2.31-2.55 (m, 3 H)

2022
(DMSO-d₆) δ 12.00-12.33 (m, 1 H), 8.59-9.05 (m, 1 H), 7.93-
451.2
100%

8.32 (m, 2.5 H), 7.44-7.77 (m, 4 H), 7.05-7.35 (m, 1 H), 6.85-
[M + H]⁺

7.04 (m, 1 H), 6.57-6.81 (m, 1.5 H), 5.40-5.56 (m, 0.6 H), 4.76-

4.91 (m, 0.4 H), 3.62-3.78 (m, 0.6 H), 3.24-3.30 (m, 0.4 H),

2.73-3.11 (m, 2 H)

2023
(DMSO-d₆) δ 11.96-12.33 (m, 1 H), 8.65-8.97 (m, 1 H), 7.94-
451.1
99.8%

8.37 (m, 2.5 H), 7.44-7.71 (m, 4 H), 7.09-7.44 (m, 1 H), 6.87-
[M + H]⁺

7.04 (m, 1 H), 6.64-6.84 (m, 1.5 H), 5.33-5.63 (m, 0.6 H), 4.84

(br dd, 0.4 H), 3.51-3.78 (m, 0.5 H), 3.22-3.31 (m, 0.5 H), 2.72-

3.12 (m, 2 H)

2024
(CD₃OD) δ 8.21-8.40 (m, 1 H), 7.64 (d, 1 H), 6.92-7.01 (m, 1
322.1
99.6%

H), 6.88 (s, 0.6 H), 6.71-6.81 (m, 1 H), 6.48-6.67 (m, 1.4 H),
[M + H]⁺

4.76 (br dd, 0.3 H), 4.51 (br dd, 0.7 H), 3.62-3.71 (m, 0.5 H),

3.22 (td, 0.5 H), 2.90-3.00 (m, 0.5 H), 2.65-2.85 (m, 1.5 H),

2.06-2.44 (m, 4 H), 0.78-1.13 (m, 4 H)

2025
(CD₃OD) δ 8.23-8.37 (m, 1 H), 7.64 (d, 1 H), 6.92-7.00 (m, 1
322.2
99.6%

H), 6.88 (s, 0.6 H), 6.70-6.79 (m, 1 H), 6.47-6.64 (m, 1.4 H),
[M + H]⁺

4.76 (br dd, 0.3 H), 4.51 (br dd, 0.7 H), 3.66 (ddd, 0.5 H), 3.22

(td, 0.5 H), 2.89-3.01 (m, 0.5 H), 2.64-2.85 (m, 1.5 H), 2.03-2.44

(m, 4 H), 0.76-1.13 (m, 4 H)

2026
(CD₃OD) δ 8.28 (br d, 1 H), 7.61-7.69 (m, 1 H), 6.88-7.06 (m,
358.2
100%

1.8 H), 6.71-6.80 (m, 1 H), 6.47-6.58 (m, 1.2 H), 4.84 (br d, 0.3
[M + H]⁺

H), 4.33 (br dd, 0.7 H), 3.70 (ddd, 0.7 H), 3.35-3.43 (m, 0.3 H),

3.09 (td, 0.8 H), 2.69-2.96 (m, 2.2 H), 2.42 (s, 3 H), 1.99-2.12

(m, 1 H), 1.81 (br dd, 1 H)

2027
(CD₃OD) δ 8.23-8.40 (m, 1 H), 7.66 (d, 1 H), 6.96 (br dd, 1 H),
358.2
100%

6.68-6.88 (m, 1.5 H), 6.32-6.60 (m, 1.5 H), 4.75 (br dd, 0.5 H),
[M + H]⁺

4.31 (br dd, 0.5 H), 3.65-3.81 (m, 0.5 H), 3.48 (td, 0.5 H), 2.95-

3.25 (m, 1.5 H), 2.67-2.87 (m, 1.5 H), 2.41 (s, 3 H), 2.06-2.21

(m, 1 H), 1.70-1.95 (m, 1 H)

2028
(CD₃OD) δ 8.25-8.32 (m, 1 H), 7.59-7.71 (m, 1 H), 6.91-7.02
358.2
100%

(m, 2 H), 6.76 (t, 1 H), 6.47-6.57 (m, 1 H), 4.83 (br d, 0.2 H),
[M + H]⁺

4.33 (dd, 0.8 H), 3.70 (ddd, 0.8 H), 3.34-3.42 (m, 0.2 H), 3.09

(ddd, 0.8 H), 2.69-2.94 (m, 2.2 H), 2.42 (s, 3 H), 2.05 (dtd, 1 H),

1.76-1.88 (m, 1 H)

2029
(CD₃OD) δ 8.24-8.43 (m, 1 H), 7.66 (d, 1 H), 6.97 (br dd, 1 H),
358.2
98.5%

6.68-6.87 (m, 1.5 H), 6.35-6.55 (m, 1.5 H), 4.75 (br dd, 1 H),
[M + H]

4.31 (dd, 0.5 H), 3.66-3.77 (m, 0.5 H), 3.43-3.53 (m, 0.5 H),

3.20 (td, 0.5 H), 2.95-3.14 (m, 1 H), 2.71-2.85 (m, 1 H), 2.41 (s,

3 H), 2.04-2.18 (m, 1 H), 1.74-1.91 (m, 1H)

2030
(CD₃OD) δ 8.32 (d, 1 H), 7.66 (s, 1 H), 6.90-7.01 (m, 1.7 H),
362.2
100%

6.81 (td, 1 H), 6.50-6.69 (m, 1.3 H), 4.85 (br d, 0.4 H), 4.36 (dd,
[M + H]⁺

0.6 H), 3.69 (ddd, 0.8 H), 3.36-3.41 (m, 0.2 H), 3.04-3.15 (m,

0.8 H), 2.69-2.96 (m, 2.2 H), 1.99-2.11 (m, 1 H), 1.73-1.91 (m, 1 H)

2031
(CD₃OD) δ 8.28-8.44 (m, 1 H), 7.67 (d, 1 H), 6.89-7.00 (m, 1
362.1
90.8%

H), 6.39-6.89 (m, 3 H), 4.76 (br dd, 0.7 H), 4.34 (br dd, 0.3 H),
[M + H]⁺

3.66-3.77 (m, 0.5 H), 3.41-3.51 (m, 0.5 H), 3.09-3.22 (m, 1 H),

2.95-3.08 (m, 0.5 H), 2.69-2.88 (m, 1.5 H), 2.06-2.19 (m, 1 H),

1.76-1.96 (m, 1 H)

2032
(CD₃OD) δ 8.72 (d, 1 H), 7.85-8.47 (m, 4 H), 7.68 (s, 1 H), 7.49-
430.1
100%

7.61 (m, 1 H), 6.65-7.04 (m, 4 H), 4.61-4.76 (m, 1 H), 3.41-3.90
[M + H]⁺

(m, 1 H), 2.94-3.24 (m, 1 H), 2.70-2.93 (m, 1 H)

2033
(CD₃OD) δ 8.71 (dt, 1 H), 7.85-8.50 (m, 4 H), 7.68 (br s, 1 H),
430.1
99.6%

7.57 (dd, 1 H), 6.67-7.02 (m, 4 H), 4.61-4.74 (m, 1 H), 3.38-3.90
[M + H]⁺

(m, 1 H), 2.95-3.25 (m, 1 H), 2.85 (br d, 1 H)

2034
(CD₃OD) δ 8.50-8.80 (m, 2 H), 7.81-8.36 (m, 3 H), 7.69 (br s, 1
462.2
100%

H), 7.53-7.61 (m, 1 H), 7.44 (br d, 1 H), 6.52-7.28 (m, 4 H),
[M + H]⁺

4.62-4.79 (m, 1 H), 3.40-3.88 (m, 1 H), 2.68-3.27 (m, 2 H)

2035
(CD₃OD) δ 8.42-8.80 (m, 2 H), 7.87-8.32 (m, 3 H), 7.68 (br s, 1
462.1
99.7%

H), 7.57 (br dd, 1 H), 7.44 (br d, 1 H), 6.69-7.15 (m, 4 H), 4.62-
[M + H]⁺

4.78 (m, 1 H), 3.42-3.90 (m, 1 H), 2.74-3.25 (m, 2 H)

2036
(CD₃OD) δ 8.50-8.86 (m, 2 H), 7.83-8.32 (m, 3 H), 7.46-7.77
480.1
99.9%

(m, 3 H), 6.64-7.16 (m, 3 H), 4.62-4.79 (m, 1 H), 3.43-3.91 (m, 1
[M + H]⁺

H), 2.70-3.25 (m, 2 H)

2037
(CD₃OD) δ 8.57-8.85 (m, 2 H), 7.88-8.30 (m, 3 H), 7.50-7.72
480.2
99.8%

(m, 3 H), 6.69-7.10 (m, 3 H), 4.62-4.79 (m, 1 H), 3.42-3.88 (m, 1
[M + H]⁺

H), 2.78-3.25 (m, 2 H)

2038
(CD₃OD) δ 8.58 (d, 1 H), 8.13 (s, 1 H), 7.68 (s, 1 H), 7.42 (br d,
425.2
99.0%

1 H), 6.65-7.14 (m, 4 H), 4.38 (br s, 1 H), 3.69 (br s, 1 H), 2.94-
[M + H]⁺

3.15 (m, 1 H), 2.79 (br dd, 1 H), 2.36 (br s, 1 H), 0.90-0.99 (m, 4 H)

2039
(CD₃OD) δ 8.58 (d, 1 H), 8.13 (s, 1 H), 7.67 (s, 1 H), 7.42 (br d,
425.2
100%

1 H), 6.64-7.15 (m, 4 H), 4.37 (br s, 1 H), 3.70 (br s, 1 H), 2.96-
[M + H]⁺

3.19 (m, 1 H), 2.79 (br dd, 1 H), 2.09-2.46 (m, 1 H), 0.90-1.00

(m, 4 H)

2040
(CD₃OD) δ 8.43 (d, 1 H), 8.13 (s, 1 H), 7.68 (s, 1 H), 7.29 (d, 1
409.1
99.5%

H), 6.42-6.94 (m, 3 H), 4.39 (br s, 1 H), 3.38-3.93 (m, 1 H),
[M + H]⁺

2.95-3.16 (m, 1 H), 2.72-2.87 (m, 1 H), 2.36 (br s, 1 H), 0.89-

1.03 (m, 4 H)

2041
(CD₃OD) δ 8.43 (d, 1 H), 8.13 (s, 1 H), 7.67 (s, 1 H), 7.29 (d, 1
409.2
99.1%

H), 6.35-7.00 (m, 3 H), 4.39 (br s, 1 H), 3.36-3.80 (m, 1 H), 3.05
[M + H]⁺

(br s, 1 H), 2.79 (br dd, 1 H), 2.21-2.47 (m, 1 H), 0.92-1.04 (m, 4 H)

2042
(CD₃OD) δ 8.03 (s, 1 H), 7.40-7.60 (m, 2 H), 6.43-7.08 (m, 4 H),
409.2
99.6%

4.28 (br s, 1 H), 3.76 (br s, 1 H), 2.89 (br d, 1 H), 2.68 (br dd, 1
[M + H]⁺

H), 2.25 (br s, 1 H), 0.85 (br d, 4 H)

2043
(CD₃OD) δ 8.03 (s, 1 H), 7.37-7.60 (m, 2 H), 6.47-7.13 (m, 4 H),
409.2
99.8%

4.29 (br s, 1 H), 3.27-3.87 (m, 1 H), 2.82-2.99 (m, 1 H), 2.68
[M + H]⁺

(dd, 1 H), 2.25 (br s, 1 H), 0.86 (br d, 4 H)

2044
(CD₃OD) δ 8.30-8.38 (m, 1 H), 8.24 (s, 1 H), 7.96 (s, 1 H), 7.72
432.1
100%

(s, 0.4 H), 7.55-7.60 (m, 1 H), 7.44-7.51 (m, 1 H), 7.04-7.14 (m,
[M + H]⁺

1 H), 6.83 (s, 0.6 H), 6.75 (br dd, 1 H), 6.43-6.55 (m, 1 H), 5.13

(dd, 0.6 H), 4.80-4.85 (m, 0.4 H), 3.88 (s, 3 H), 3.57-3.68 (m, 0.6

H), 3.32 (td, 0.4 H), 2.84-3.12 (m, 1 H), 2.71 (br d, 1 H)

2045
(CD₃OD) δ 8.28-8.39 (m, 1 H), 8.25 (s, 1 H), 7.96 (s, 1 H), 7.68-
432.1
100%

7.75 (m, 0.4 H), 7.54-7.61 (m, 1 H), 7.41-7.52 (m, 1 H), 7.02-
[M + H]⁺

7.14 (m, 1 H), 6.83 (s, 0.6 H), 6.69-6.79 (m, 1 H), 6.42-6.57 (m,

1 H), 5.13 (dd, 0.6 H), 4.80-4.86 (m, 0.4 H), 3.88 (s, 3 H), 3.57-

3.68 (m, 0.6 H), 3.26-3.41 (m, 0.4 H), 2.84-3.11 (m, 1 H), 2.71

(br d, 1 H)

2046
(CD₃OD) δ 8.12-8.27 (m, 2 H), 7.96 (s, 1 H), 7.72 (s, 0.4 H),
446.2
100%

7.52-7.61 (m, 1 H), 6.79-6.93 (m, 1.6 H), 6.59-6.72 (m, 1 H),
[M + H]⁺

6.44-6.54 (m, 1 H), 5.07-5.35 (m, 0.6 H), 4.80-4.86 (m, 0.4 H),

3.88 (s, 3 H), 3.58-3.68 (m, 0.6 H), 3.33 (td, 0.4 H), 2.84-3.13

(m, 1 H), 2.71 (br d, 1 H), 2.28-2.37 (m, 3 H)

2047
(CD₃OD) δ 8.11-8.28 (m, 2 H), 7.96 (s, 1 H), 7.72 (s, 0.4 H),
446.2
99.2%

7.52-7.62 (m, 1 H), 6.78-6.92 (m, 1.6 H), 6.60-6.73 (m, 1 H),
[M + H]⁺

6.44-6.55 (m, 1 H), 5.08-5.35 (m, 0.6 H), 4.80-4.87 (m, 0.4 H),

3.88 (s, 3 H), 3.57-3.68 (m, 0.6 H), 3.28-3.38 (m, 0.4 H), 2.83-

3.12 (m, 1 H), 2.62-2.77 (m, 1 H), 2.28-2.36 (m, 3 H)

2048
(CD₃OD) δ 8.25-8.47 (m, 1 H), 7.76 (d, 1 H), 7.56-7.69 (m, 2.4
385.1
98.2%

H), 7.42-7.53 (m, 2 H), 7.36-7.42 (m, 1 H), 7.00-7.16 (m, 1 H),
[M + H]⁺

6.89 (s, 0.6 H), 6.67-6.82 (m, 1 H), 6.40-6.58 (m, 1 H), 4.85-4.92

(m, 1 H), 3.58-3.75 (m, 0.5 H), 3.23-3.37 (m, 0.5 H), 2.85-3.17

(m, 1 H), 2.73 (br dd, 1 H)

2049
(CD₃OD) δ 8.20-8.44 (m, 1 H), 7.76 (d, 1 H), 7.55-7.69 (m, 2.3
385.2
97.7%

H), 7.42-7.52 (m, 2 H), 7.35-7.42 (m, 1 H), 7.03-7.17 (m, 1 H),
[M + H]⁺

6.90 (s, 0.7 H), 6.67-6.83 (m, 1 H), 6.39-6.60 (m, 1 H), 4.88 (br

dd, 1 H), 3.59-3.74 (m, 0.6 H), 3.25-3.35 (m, 0.4 H), 2.87-3.16

(m, 1 H), 2.74 (br dd, 1 H)

2050
(CD₃OD) δ 8.25-8.42 (m, 1 H), 7.84-7.91 (m, 1 H), 7.65-7.83
403.1
100%

(m, 2.4 H), 7.45-7.62 (m, 2 H), 6.92-7.04 (m, 1.6 H), 6.81-6.91
[M + H]⁺

(m, 1 H), 6.67-6.81 (m, 1 H), 4.98-5.06 (m, 1 H), 3.70-3.89 (m,

0.7 H), 3.41 (td, 0.3 H), 2.98-3.28 (m, 1 H), 2.85 (br dd, 1 H)

2051
(CD₃OD) δ 8.27-8.45 (m, 1 H), 7.86-7.95 (m, 1 H), 7.71-7.84
403.2
99.2%

(m, 2.3 H), 7.47-7.66 (m, 2 H), 6.93-7.08 (m, 1.7 H), 6.83-6.91
[M + H]⁺

(m, 1 H), 6.70-6.82 (m, 1 H), 4.99-5.09 (m, 1 H), 3.73-3.87 (m,

0.6 H), 3.38-3.48 (m, 0.4 H), 3.00-3.31 (m, 1 H), 2.88 (dd, 1 H)

2052
(DMSO-d₆) δ 11.98-12.19 (m, 1 H), 8.66-8.95 (m, 1 H), 7.81-
435.2
99.2%

8.06 (m, 2 H), 7.61-7.71 (m, 1 H), 7.56-7.61 (m, 1 H), 7.47-7.55
[M + H]⁺

(m, 2 H), 7.08-7.45 (m, 1 H), 6.88-7.05 (m, 1 H), 6.58-6.83 (m, 2

H), 4.84 (br dd, 1 H), 3.55-3.80 (m, 0.6 H), 3.15-3.30 (m, 0.4 H),

2.85-3.11 (m, 1 H), 2.65-2.83 (m, 1 H)

2053
(DMSO-d₆) δ 11.86-12.54 (m, 1 H), 8.57-9.00 (m, 1 H), 7.84-
435.2
98.8%

7.99 (m, 2 H), 7.63-7.70 (m, 1 H), 7.55-7.62 (m, 1 H), 7.46-7.54
[M + H]⁺

(m, 2.3 H), 7.46 (br s, 1 H), 6.89-7.03 (m, 1 H), 6.62-6.86 (m,

1.7 H), 4.84 (br dd, 1 H), 3.64-3.75 (m, 0.5 H), 3.20-3.27 (m, 0.5

H), 2.84-3.12 (m, 1 H), 2.77 (br d, 1 H)

2054
(DMSO-d₆) δ 11.83-12.41 (m, 1 H), 8.74-9.12 (m, 1 H), 7.83-
453.1
99.4%

8.06 (m, 2 H), 7.69-7.82 (m, 1 H), 7.62-7.68 (m, 1 H), 7.46-7.61
[M + H]⁺

(m, 2.5 H), 6.93-7.09 (m, 1 H), 6.57-6.85 (m, 1.5 H), 4.86 (br dd,

1 H), 3.59-3.83 (m, 0.6 H), 3.16-3.28 (m, 0.4 H), 2.85-3.11 (m, 1

H), 2.71-2.83 (m, 1 H)

2055
(DMSO-d₆) δ 11.98-12.28 (m, 1 H), 8.81-9.08 (m, 1 H), 7.81-
453.2
99.0%

8.03 (m, 2 H), 7.69-7.79 (m, 1 H), 7.62-7.69 (m, 1 H), 7.45-7.61
[M + H]⁺

(m, 2.5 H), 6.95-7.10 (m, 1 H), 6.58-6.85 (m, 1.5 H), 4.86 (br dd,

1 H), 3.63-3.79 (m, 0.6 H), 3.20-3.30 (m, 0.4 H), 2.84-3.11 (m, 1

H), 2.72-2.83 (m, 1 H)

2056
(CD₃OD) δ 8.28 (d, 1 H), 7.70 (s, 1 H), 6.69-6.86 (m, 3 H), 6.42
416.2
99.5%

(s, 1 H), 4.35 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.00-3.16 (m, 1 H),
[M + H]⁺

2.85 (dd, 1 H), 2.00-2.17 (m, 1 H), 0.93-1.09 (m, 2 H), 0.67-0.84

(m, 2 H)

2057
(CD₃OD) δ 8.29 (d, 1 H), 7.70 (s, 1 H), 6.72-6.89 (m, 3 H), 6.41
416.2
99.8%

(s, 1 H), 4.35 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.01-3.16 (m, 1 H),
[M + H]⁺

2.85 (dd, 1 H), 2.02-2.16 (m, 1 H), 0.96-1.09 (m, 2 H), 0.71-0.85

(m, 2 H)

2058
(CD₃OD) δ 8.28 (d, 1 H), 7.67 (s, 1 H), 6.65-6.87 (m, 3 H), 6.27
388.2
99.8%

(s, 1 H), 4.19 (dd, 1 H), 3.62-3.79 (m, 1 H), 2.93-3.10 (m, 1 H),
[M + H]⁺

2.80 (dd, 1 H), 2.00-2.18 (m, 2 H), 1.01-1.14 (m, 6 H), 0.75-0.82

(m, 2 H)

2059
(CD₃OD) δ 8.28 (d, 1 H), 7.67 (s, 1 H), 6.64-6.86 (m, 3 H), 6.27
388.2
99.7%

(s, 1 H), 4.19 (dd, 1 H), 3.62-3.75 (m, 1 H), 2.94-3.10 (m, 1 H),
[M + H]⁺

2.80 (dd, 1 H), 2.03-2.15 (m, 2 H), 0.98-1.14 (m, 6 H), 0.71-0.82

(m, 2 H)

2060
(CD₃OD) δ 8.16-8.34 (m, 1 H), 7.70 (s, 1 H), 7.42 (s, 0.3 H),
436.2
99.9%

6.95 (s, 0.7 H), , 6.60-6.85 (m, 3 H), 4.97 (br d, 1 H), 3.76 (ddd,
[M + H]⁺

0.7 H), 3.40 (td, 0.3 H), 3.08-3.23 (m, 0.7 H), 2.94-3.04 (m, 0.3

H), 2.84 (br dd, 1 H), 2.02-2.15 (m, 1 H), 1.80-1.97 (m, 6 H),

0.92-1.11 (m, 2 H), 0.71-0.83 (m, 2 H)

2061
(CD₃OD) δ 8.15-8.35 (m, 1 H), 7.70 (s, 1 H), 7.42 (s, 0.3 H),
436.2
99.1%

6.95 (s, 0.7 H), 6.66-6.87 (m, 3 H), 4.95-5.01 (m, 1 H), 3.70-3.84
[M + H]⁺

(m, 0.7 H), 3.35-3.44 (m, 0.3 H), 3.10-3.22 (m, 0.7 H), 2.93-3.05

(m, 0.3 H), 2.78-2.89 (m, 1 H), 2.03-2.15 (m, 1 H), 1.80-1.97 (m,

6 H), 0.96-1.09 (m, 2 H), 0.73-0.83 (m, 2 H)

2062
(CD₃OD) δ 8.44 (d, 1 H), 7.54-7.79 (m, 2 H), 7.15-7.38 (m, 3
454.1
100%

H), 6.69-6.93 (m, 2 H), 6.42 (s, 1 H), 4.38 (dd, 1 H), 3.80 (ddd, 1
[M + H]⁺

H), 3.00-3.20 (m, 1 H), 2.86 (dd, 1 H)

2063
(CD₃OD) δ 8.32 (d, 1 H), 7.42-7.68 (m, 2 H), 7.00-7.24 (m, 3
454.1
96.6%

H), 6.53-6.82 (m, 2 H), 6.30 (s, 1 H), 4.26 (dd, 1 H), 3.68 (ddd, 1
[M + H]⁺

H), 2.90-3.06 (m, 1 H), 2.73 (dd, 1 H)

2064
(CD₃OD) δ 8.37 (br s, 1 H), 8.01 (br s, 0.5 H), 7.64-7.84 (m, 1.5
413.2
100%

H), 6.99 (br t, 1 H), 6.87 (br s, 1.6 H), 6.57-6.81 (m, 1.4H),
[M + H]⁺

4.73-4.83 (m, 0.4 H), 4.49 (br s, 0.6 H), 3.78 (br s, 0.6 H), 3.36-

3.46 (m, 0.4 H), 3.12 (br s, 1 H), 2.84 (br s, 1 H), 1.73-1.95 (m, 6 H)

2065
(CD₃OD) δ 8.36 (br s, 1 H), 8.01 (br s, 0.4 H), 7.62-7.88 (m, 1.6
413.2
100%

H), 6.93-7.05 (m, 1 H), 6.86 (br s, 1.5 H), 6.52-6.80 (m, 1.5 H),
[M + H]⁺

4.69-4.81 (m, 0.4 H), 4.46 (br s, 0.6 H), 3.78 (br s, 0.6 H), 3.37

(br s, 0.4 H), 2.94-3.19 (m, 1 H), 2.83 (br s, 1 H), 1.84 (br d, 6 H)

2066
(CD₃OD) δ 8.38 (br s, 1 H), 7.74-8.15 (m, 2 H), 7.70 (s, 1 H),
447.2
100%

6.94-7.07 (m, 1 H), 6.59-6.93 (m, 3 H), 4.66-4.87 (m, 1 H), 3.86
[M + H]⁺

(br s, 3 H), 3.50 (s, 1 H), 2.78-3.23 (m, 2 H), 2.44-2.77 (m, 3 H)

2067
(CD₃OD) δ 8.39 (br s, 1 H), 7.75-8.16 (m, 2 H), 7.70 (s, 1 H),
447.2
100%

6.99 (br t, 1 H), 6.57-6.94 (m, 3 H), 4.65-4.84 (m, 1 H), 3.86 (br
[M + H]⁺

s, 3 H), 3.50 (s, 1 H), 2.79-3.26 (m, 2 H), 2.66 (br s, 3 H)

2068
(CD₃OD) δ 8.62 (br s, 1 H), 7.76-8.15 (m, 2 H), 7.70 (s, 1 H),
479.2
99.7%

7.46 (br d, 1 H), 6.63-7.18 (m, 4 H), 4.65-4.84 (m, 1 H), 3.86 (br
[M + H]⁺

s, 3 H), 3.38-3.82 (m, 1 H), 2.78-3.24 (m, 2 H), 2.42-2.76 (m, 3 H)

2069
(CD₃OD) δ 8.62 (br s, 1 H), 7.75-8.13 (m, 2 H), 7.70 (s, 1 H),
479.2
98.9%

7.45 (br d, 1 H), 6.67-7.18 (m, 4 H), 4.82 (br s, 1 H), 3.86 (br s,
[M + H]⁺

3 H), 3.37-3.82 (m, 1 H), 2.79-3.25 (m, 2 H), 2.43-2.78 (m, 3 H)

2070
(CD₃OD) δ 8.16 (s, 1 H), 7.43-7.68 (m, 2 H), 6.47-7.17 (m, 4 H),
389.2
100%

4.38 (br s, 1 H), 3.58-3.99 (m, 1 H), 2.78-3.11 (m, 2 H), 2.66 (s,
[M + H]⁺

3 H), 2.32 (br s, 1 H), 0.97 (br d, 4 H)

2071
(CD₃OD) δ 8.16 (s, 1 H), 7.39-7.76 (m, 2 H), 6.22-7.18 (m, 4 H),
389.2
95.0%

4.39 (br s, 1 H), 3.53-4.00 (m, 1 H), 2.76-3.14 (m, 2 H), 2.66 (s,
[M + H]⁺

3 H), 2.32 (br s, 1 H), 0.97 (br d, 4 H)

2072
(CD₃OD) δ 8.24 (br d, 1 H), 7.66-8.14 (m, 2 H), 7.57 (s, 1 H),
473.2
99.0%

6.50-6.90 (m, 4 H), 4.37-4.63 (m, 1 H), 3.83 (s, 3 H), 3.51-3.73
[M + H]⁺

(m, 0.7 H), 3.27-3.46 (m, 0.3 H), 2.86-3.11 (m, 1 H), 2.72 (br d,

1 H), 2.25-2.37 (m, 1 H), 0.80-0.95 (m, 4H)

2073
(CD₃OD) δ 8.23 (br s, 1 H), 7.65-8.14 (m, 2 H), 7.57 (s, 1 H),
473.2
98.8%

6.48-6.91 (m, 4 H), 4.37-4.64 (m, 1 H), 3.82 (br s, 3 H), 3.49-
[M + H]⁺

3.71 (m, 0.7 H), 3.26-3.42 (m, 0.3 H), 2.88-3.08 (m, 1 H), 2.71

(br d, 1 H), 2.31 (quin, 1 H), 0.78-0.95 (m, 4H)

2074
(CD₃OD) δ 8.33 (br d, 1 H), 7.78-8.25 (m, 2 H), 7.69 (s, 1 H),
469.2
99.5%

6.50-7.06 (m, 4 H), 4.48-4.76 (m, 1 H), 3.94 (br s, 3 H), 3.65-
[M + H]⁺

3.84 (m, 0.6 H), 3.41-3.59 (m, 0.4 H), 3.00-3.20 (m, 1 H), 2.73-

2.93 (m, 1 H), 2.38-2.54 (m, 4 H), 0.86-1.14 (m, 4H)

2075
(CD₃OD) δ 8.15-8.31 (m, 1 H), 7.68-8.13 (m, 2 H), 7.57 (s, 1 H),
469.2
99.5%

6.41-6.90 (m, 4 H), 4.42-4.70 (m, 1 H), 3.81 (br s, 3 H), 3.51-
[M + H]⁺

3.71 (m, 0.6 H), 3.25-3.38 (m, 0.4 H), 2.86-3.10 (m, 1 H), 2.60-

2.81 (m, 1 H), 2.26-2.38 (m, 4 H), 0.80-0.94 (m, 4H)

2076
(CD₃OD) δ 8.47-8.63 (m, 1 H), 8.10 (s, 1 H), 7.65-7.77 (m, 1 H),
385.1
100%

7.34-7.49 (m, 2 H), 6.67-7.15 (m, 4 H), 5.07 (dd, 1 H), 3.68
[M + H]⁺

(ddd, 0.7 H), 3.33-3.38 (m, 0.3 H), 3.06-3.19 (m, 0.7 H), 2.89-

3.01 (m, 0.3 H), 2.79 (dd, 1 H)

2077
(CD₃OD) δ 8.50-8.60 (m, 1 H), 8.10 (s, 1 H), 7.64-7.78 (m, 1 H),
385.1
98.1%

7.33-7.49 (m, 2 H), 6.68-7.16 (m, 4 H), 5.08 (dd, 1 H), 3.68
[M + H]⁺

(ddd, 0.7 H), 3.33-3.38 (m, 0.3 H), 3.07-3.19 (m, 0.7 H), 2.91-

3.01 (m, 0.3 H), 2.79 (dd, 1 H)

2078
(CD₃OD) δ 8.61-8.73 (m, 1 H), 8.11 (s, 1 H), 7.68-7.79 (m, 1 H),
403.1
99.9%

7.56-7.65 (m, 1 H), 7.34-7.46 (m, 1 H), 6.92-7.04 (m, 2 H), 6.64-
[M + H]⁺

6.82 (m, 1 H), 5.10 (dd, 1 H), 3.68 (ddd, 0.7 H), 3.33-3.38 (m,

0.3 H), 3.09-3.19 (m, 0.7 H), 2.91-3.01 (m, 0.3 H), 2.79 (dd, 1 H)

2079
(CD₃OD) δ 8.62-8.73 (m, 1 H), 8.11 (s, 1 H), 7.67-7.78 (m, 1 H),
403.1
98.8%

7.55-7.66 (m, 1 H), 7.35-7.46 (m, 1 H), 6.90-7.04 (m, 2 H), 6.64-
[M + H]⁺

6.80 (m, 1 H), 5.10 (dd, 1 H), 3.68 (ddd, 0.6 H), 3.33-3.38 (m,

0.4 H), 3.09-3.19 (m, 0.7 H), 2.92-3.01 (m, 0.3 H), 2.79 (dd, 1 H)

2080
(CD₃OD) δ 8.27-8.42 (m, 1 H), 7.60-7.68 (m, 1 H), 6.74-6.99
340.2
99.7%

(m, 2.7 H), 6.50-6.68 (m, 1 H), 6.11 (s, 0.3 H), 4.78 (br dd, 0.3
[M + H]⁺

H), 4.01 (br dd, 0.7 H), 3.85 (t, 0.3 H), 3.45-3.62 (m, 1.4 H),

3.12 (td, 0.3 H), 2.47-2.86 (m, 2 H), 1.80-2.42 (m, 6 H)

2081
(CD₃OD) δ 8.27-8.41 (m, 1 H), 7.61-7.67 (m, 1 H), 6.89-6.99
340.2
99.5%

(m, 1 H), 6.74-6.87 (m, 1.7 H), 6.51-6.65 (m, 1 H), 6.11 (s, 0.3
[M + H]⁺

H), 4.78 (br dd, 0.3 H), 4.02 (dd, 0.7 H), 3.86 (quin, 0.3 H),

3.47-3.60 (m, 1.4 H), 3.07-3.17 (m, 0.3 H), 2.47-2.86 (m, 2 H),

1.80-2.42 (m, 6 H)

2082
(CD₃OD) δ 8.18 (d, 1 H), 7.55 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1
364.2
99.3%

H), 6.49 (s, 1 H), 6.18 (s, 1 H), 4.10 (dd, 1 H), 3.59 (ddd, 1 H),
[M + H]⁺

2.86-3.12 (m, 2 H), 2.67 (dd, 1 H), 2.32 (s, 3 H), 1.22 (dd, 6 H)

2083
(CD₃OD) δ 8.18 (d, 1 H), 7.55 (s, 1 H), 6.93 (d, 1 H), 6.61-6.78
364.2
99.3%

(m, 1 H), 6.49 (s, 1 H), 6.18 (s, 1 H), 4.10 (dd, 1 H), 3.59 (ddd, 1
[M + H]⁺

H), 2.87-3.12 (m, 2 H), 2.67 (dd, 1 H), 2.32 (s, 3 H), 1.17-1.25

(m, 6 H)

2084
(CD₃OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 6.83-7.15 (m, 3 H), 6.66
400.2
99.9%

(s, 1 H), 6.39 (s, 1 H), 4.33 (dd, 1 H), 3.79 (ddd, 1 H), 3.03-3.25
[M + H]⁺

(m, 2 H), 2.84 (dd, 1 H), 1.35 (dd, 6 H)

2085
(CD₃OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 6.83-7.15 (m, 3 H), 6.62-
400.2
99.8%

6.70 (m, 1 H), 6.39 (s, 1 H), 4.33 (dd, 1 H), 3.73-3.86 (m, 1 H),
[M + H]⁺

3.02-3.24 (m, 2 H), 2.84 (dd, 1 H), 1.35 (dd, 6 H)

2086
(CD₃OD) δ 8.03 (dd, 2 H), 7.68 (s, 1 H), 7.59 (dd, 1 H), 7.28 (t,
436.1
100%

2 H), 7.17 (dd, 1 H), 7.03 (dd, 1 H), 6.71 (s, 1 H), 6.47 (s, 1 H),
[M + H]⁺

4.38 (dd, 1 H), 3.76-3.91 (m, 1 H), 3.02-3.17 (m, 1 H), 2.87 (dd,

1 H)

2087
(CD₃OD) δ 8.03 (dd, 2 H), 7.68 (s, 1 H), 7.60 (d, 1 H), 7.29 (t, 2
436.1
99.3%

H), 7.17 (dd, 1 H), 7.03 (d, 1 H), 6.71 (s, 1 H), 6.47 (s, 1H),
[M + H]⁺

4.38 (dd, 1 H), 3.77-3.91 (m, 1 H), 3.04-3.16 (m, 1 H), 2.79-2.94

(m, 1 H)

2088
(CD₃OD) δ 7.59-7.69 (m, 3 H), 7.15-7.26 (m, 3 H), 7.04 (dd, 1
454.1
100%

H), 6.74 (s, 1 H), 6.43 (s, 1 H), 4.38 (dd, 1 H), 3.87 (ddd, 1 H),
[M + H]⁺

3.01-3.19 (m, 1 H), 2.86 (dd, 1 H)

2089
(CD₃OD) δ 7.57-7.71 (m, 3 H), 7.14-7.26 (m, 3 H), 7.03 (dd, 1
454.1
98.4%

H), 6.73 (s, 1 H), 6.43 (s, 1 H), 4.38 (dd, 1 H), 3.87 (ddd, 1 H),
[M + H]⁺

3.01-3.18 (m, 1 H), 2.86 (dd, 1 H)

2090
(CD₃OD) δ 7.46-7.59 (m, 2 H), 7.35 (d, 1 H), 6.96-7.13 (m, 3
434.2
100%

H), 6.59 (d, 1 H), 6.25-6.47 (m, 2 H), 4.24 (dd, 1 H), 3.72 (ddd,
[M + H]⁺

1 H), 2.88-3.05 (m, 1 H), 2.73 (dd, 1 H), 2.51 (s, 3 H)

2091
(CD₃OD) δ 7.57-7.69 (m, 2 H), 7.47 (d, 1 H), 7.08-7.25 (m, 3
434.2
100%

H), 6.71 (d, 1 H), 6.38-6.56 (m, 2 H), 4.36 (dd, 1 H), 3.84 (ddd,
[M + H]⁺

1 H), 3.01-3.16 (m, 1 H), 2.85 (dd, 1 H), 2.63 (s, 3H)

2092
(CD₃OD) δ 7.75 (d, 1 H), 7.58-7.71 (m, 2 H), 7.50 (s, 0.3 H),
470.2
100%

7.36 (s, 0.5 H), 7.17-7.31 (m, 4.2 H), 6.70 (s, 1 H), 6.42 (br s, 1
[M + H]⁺

H), 4.38 (dd, 1 H), 3.78-3.91 (m, 1 H), 3.01-3.18 (m, 1 H), 2.86

(br dd, 1 H)

2093
(CD₃OD) δ 7.74 (d, 1 H), 7.58-7.71 (m, 2 H), 7.49 (s, 0.3 H),
470.2
100%

7.36 (s, 0.5 H), 7.16-7.31 (m, 4.2 H), 6.70 (s, 1 H), 6.42 (s, 1H),
[M + H]⁺

4.38 (dd, 1 H), 3.75-3.94 (m, 1 H), 3.01-3.18 (m, 1 H), 2.86 (dd,

1 H)

2094
(CD₃OD) δ 8.26-8.35 (m, 2 H), 7.65 (dd, 1 H), 7.53 (s, 1 H),
419.1
99.5%

7.15 (d, 1 H), 7.02 (d, 1 H), 6.80 (s, 1 H), 6.70 (t, 1 H), 6.53(s, 1
[M + H]⁺

H), 4.61 (br dd, 1 H), 3.40-3.56 (m, 1 H), 2.76-2.91 (m, 1 H),

2.62 (br dd, 1 H)

2095
(CD₃OD) δ 8.44 (br d, 2 H), 7.78 (dd, 1 H), 7.66 (s, 1 H), 7.28
419.1
98.6%

(d, 1 H), 7.15 (d, 1 H), 6.92 (s, 1 H), 6.82 (t, 1H), 6.65(s, 1H),
[M + H]⁺

4.73 (br dd, 1 H), 3.53-3.66 (m, 1 H), 2.89-3.03 (m, 1 H), 2.75

(br dd, 1 H)

2096
(CD₃OD) δ 8.39 (s, 1 H), 7.76 (dd, 1 H), 7.62 (s, 1 H), 7.44 (d, 1
399.2
97.4%

H), 7.20 (d, 1 H), 7.10 (dd, 1 H), 6.80 (s, 1 H), 6.69 (d, 1H),
[M + H]⁺

6.48 (s, 1 H), 4.83 (br dd, 1 H), 3.60-3.73 (m, 1 H), 2.88-3.01

(m, 1 H), 2.74 (dd, 1 H), 2.69 (s, 3 H)

2097
(CD₃OD) δ 8.28 (s, 1 H), 7.64 (dd, 1 H), 7.50 (s, 1 H), 7.33 (d, 1
399.2
96.1%

H), 7.09 (d, 1 H), 6.98 (dd, 1 H), 6.68 (s, 1 H), 6.58(d, 1H),
[M + H]⁺

6.36 (s, 1 H), 4.72 (br dd, 1 H), 3.50-3.62 (m, 1 H), 2.77-2.89

(m, 1 H), 2.62 (dd, 1 H), 2.57 (s, 3 H)

2098
(CD₃OD) δ 8.20-8.54 (m, 1 H), 7.54-7.99 (m, 2 H), 6.91-7.05
393.2
99.4%

(m, 1 H), 6.46-6.89 (m, 3 H), 4.34-4.81 (m, 1 H), 3.42-3.93 (m, 1
[M + H]⁺

H), 2.69-3.21 (m, 2 H), 2.18 (br d, 1 H), 1.14 (br s, 4 H)

2099
(CD₃OD) δ 8.20-8.54 (m, 1 H), 7.67 (s, 2 H), 6.91-7.07 (m, 1 H),
393.2
98.4%

6.39-6.90 (m, 3 H), 4.42-4.79 (m, 1 H), 3.38-4.00 (m, 1 H), 2.61-
[M + H]⁺

3.15 (m, 2 H), 2.18 (br d, 1 H), 1.14 (br s, 4 H)

2100
(CD₃OD) δ 8.36 (br s, 1 H), 7.58-8.04 (m, 2 H), 6.55-7.10 (m, 4
409.2
100%

H), 4.58-4.84 (m, 1 H), 3.35-3.87 (m, 1 H), 2.68-3.21 (m, 2 H),
[M + H]⁺

1.26-1.55 (m, 9 H)

2101
(CD₃OD) δ 8.23 (br s, 1 H), 7.37-7.93 (m, 2 H), 6.38-7.02 (m, 4
409.2
99.6%

H), 4.46-4.74 (m, 1 H), 3.24-3.81 (m, 1 H), 2.53-3.10 (m, 2 H),
[M + H]⁺

1.08-1.49 (m, 9 H)

2102
(CD₃OD) δ 8.58 (br d, 1 H), 7.50-7.95 (m, 2 H), 7.43 (br d, 1 H),
425.2
100%

6.48-7.17 (m, 4 H), 4.38-4.83 (m, 1 H), 3.34-3.88 (m, 1 H), 2.69-
[M + H]⁺

3.12 (m, 2 H), 2.18 (br s, 1 H), 1.14 (br s, 4 H)

2103
(CD₃OD) δ 8.41-8.77 (m, 1 H), 7.55-7.99 (m, 2 H), 7.43 (br d, 1
425.2
99.2%

H), 6.39-7.20 (m, 4 H), 4.40-4.82 (m, 1 H), 3.43-3.88 (m, 1 H),
[M + H]⁺

2.67-3.12 (m, 2 H), 2.18 (br d, 1 H), 1.14 (br s, 4 H)

2104
(CD₃OD) δ 8.48-8.75 (m, 1 H), 7.34-8.01 (m, 3 H), 6.57-7.20
441.2
100%

(m, 4 H), 4.60-4.85 (m, 1 H), 3.34-3.86 (m, 1 H), 2.68-3.20 (m, 2
[M + H]

H), 1.25-1.60 (m, 9 H)

2105
(CD₃OD) δ 8.60 (br d, 1 H), 7.57-8.02 (m, 2 H), 7.45 (br d, 1 H),
441.2
99.5%

6.58-7.18 (m, 4 H), 4.62-4.84 (m, 1 H), 3.34-3.88 (m, 1 H), 2.68-
[M + H]⁺

3.25 (m, 2 H), 1.25-1.58 (m, 9 H)

2106
(CD₃OD) δ 8.42-8.92 (m, 1 H), 8.02 (br s, 0.4 H), 7.65-7.86 (m,
445.2
100%

1.6 H), 7.46 (br d, 1 H), 7.14 (s, 0.2 H), 6.55-7.05 (m, 3.8 H),
[M + H]⁺

4.73-4.83 (m, 0.3 H), 4.47 (br s, 0.7 H), 3.77 (br s, 0.6 H), 3.38-

3.47 (m, 0.4 H), 2.96-3.22 (m, 1 H), 2.85 (br s, 1 H), 1.70-1.95

(m, 6 H)

2107
(CD₃OD) δ 8.48-8.79 (m, 1 H), 8.01 (br s, 0.4 H), 7.70 (br s, 1.6
445.2
99.1%

H), 7.46 (br d, 1 H), 7.13 (s, 0.2 H), 6.58-7.07 (m, 3.8 H), 4.82
[M + H]⁺

(br s, 0.5 H), 4.47 (br s, 0.5 H), 3.77 (br s, 0.6 H), 3.38-3.47 (m,

0.4 H), 2.94-3.21 (m, 1 H), 2.86 (br d, 1 H), 1.69-1.99 (m, 6 H)

2108
(CD₃OD) δ 8.70 (br s, 1 H), 7.58-8.11 (m, 4 H), 6.71-7.04 (m, 4
483.1
100%

H), 4.67-4.83 (m, 1 H), 3.99 (s, 3 H), 3.39-3.86 (m, 1 H), 2.78-
[M + H]⁺

3.23 (m, 2 H)

2109
(CD₃OD) δ 8.70 (br s, 1 H), 7.59-8.08 (m, 4 H), 6.77-7.05 (m, 4
483.2
98.5%

H), 4.69-4.83 (m, 1 H), 3.99 (s, 3 H), 3.44-3.89 (m, 1 H), 2.81-
[M + H]⁺

3.24 (m, 2 H)

2110
(CD₃OD) δ 8.74 (br s, 1 H), 7.97 (br s, 2 H), 7.57-7.75 (m, 2 H),
497.2
99.8%

6.61-7.12 (m, 3 H), 4.64-4.85 (m, 1 H), 3.87 (br s, 3 H), 3.35-
[M + H]⁺

3.81 (m, 1 H), 2.79-3.23 (m, 2 H), 2.67 (br s, 3 H)

2111
(CD₃OD) δ 8.60 (br s, 1 H), 7.63-8.03 (m, 2 H), 7.44-7.62 (m, 2
497.2
99.5%

H), 6.51-6.95 (m, 3 H), 4.52-4.73 (m, 1 H), 3.69-3.82 (m, 3 H),
[M + H]⁺

3.26-3.66 (m, 1 H), 2.62-3.12 (m, 2 H), 2.31-2.61 (m, 3 H)

2112
(CD₃OD) δ 8.13 (s, 1 H), 7.62-7.76 (m, 2 H), 7.34-7.56 (m, 1 H),
425.2
100%

7.15-7.29 (m, 2 H), 6.47-6.95 (m, 2 H), 4.37 (br s, 1 H), 3.83 (br
[M + H]⁺

s, 1 H), 3.01 (br s, 1 H), 2.78 (dd, 1 H), 2.30 (br d, 1 H), 0.96 (br

d, 4 H)

2113
(CD₃OD) δ 8.14 (s, 1 H), 7.62-7.77 (m, 2 H), 7.34-7.56 (m, 1 H),
425.2
100%

7.13-7.31 (m, 2 H), 6.45-6.95 (m, 2 H), 4.39 (br s, 1 H), 3.56-
[M + H]⁺

3.98 (m, 1 H), 3.01 (br s, 1 H), 2.78 (dd, 1 H), 2.31 (br s, 1 H),

0.96 (br d, 4 H)

2114
(CD₃OD) δ 8.60 (br d, 1 H), 7.86-8.45 (m, 2 H), 7.74 (s, 1 H),
505.2
99.6%

7.43 (br d, 1 H), 7.14 (s, 0.3 H), 6.70-7.03 (m, 3.7 H), 4.45-4.86
[M + H]⁺

(m, 1 H), 3.86-4.07 (m, 3 H), 3.39-3.83 (m, 1 H), 2.99-3.22 (m, 1

H), 2.84 (br d, 1 H), 2.35-2.52 (m, 1 H), 0.88-1.10 (m, 4H)

2115
(CD₃OD) δ 8.59 (br d, 1 H), 7.88-8.43 (m, 2 H), 7.81 (br s, 1 H),
505.2
99.4%

7.42 (br d, 1 H), 7.13 (s, 0.3 H), 6.76-7.02 (m, 3.7 H), 4.41-4.81
[M + H]⁺

(m, 1 H), 3.93 (br s, 3 H), 3.39-3.81 (m, 1 H), 2.99-3.22 (m, 1

H), 2.72-2.93 (m, 1 H), 2.36-2.50 (m, 1 H), 0.91-1.07 (m, 4H)

2116
(CD₃OD) δ 8.72 (br d, 1 H), 7.78-8.30 (m, 2 H), 7.70 (s, 1 H),
523.2
99.3%

7.63 (br d, 1 H), 6.99 (t, 1 H), 6.70-6.94 (m, 2 H), 4.43-4.77 (m,
[M + H]⁺

1 H), 3.94 (br s, 3 H), 3.40-3.84 (m, 1 H), 2.99-3.23 (m, 1 H),

2.75-2.92 (m, 1 H), 2.38-2.50 (m, 1 H), 0.94-1.06 (m, 4H)

2117
(CD₃OD) δ 8.71 (br d, 1 H), 7.77-8.34 (m, 2 H), 7.70 (s, 1 H),
523.2
99.1%

7.63 (br d, 1 H), 6.98 (t, 1 H), 6.72-6.94 (m, 2 H), 4.44-4.79 (m,
[M + H]⁺

1 H), 3.87-4.00 (m, 3 H), 3.38-3.82 (m, 1 H), 2.97-3.23 (m, 1 H),

2.84 (br d, 1 H), 2.33-2.52 (m, 1 H), 0.91-1.08 (m, 4 H)

2118
(CD₃OD) δ 8.68 (d, 1 H), 8.35 (d, 1 H), 7.85-8.22 (m, 2 H),
470.2
100%

7.45-7.76 (m, 2 H), 6.59-7.28 (m, 4 H), 4.44-4.81 (m, 1 H), 3.45-
[M + H]⁺

3.89 (m, 1 H), 2.96-3.28 (m, 1 H), 2.83 (br d, 1 H), 2.33-2.57 (m,

1 H), 0.94-1.16 (m, 4 H)

2119
(CD₃OD) δ 8.68 (d, 1 H), 8.35 (d, 1 H), 7.83-8.25 (m, 2 H),
470.2
99.7%

7.44-7.75 (m, 2 H), 6.62-7.25 (m, 4 H), 4.30-4.60 (m, 1 H), 3.46-
[M + H]⁺

3.87 (m, 1 H), 2.94-3.28 (m, 1 H), 2.83 (br d, 1 H), 2.43 (br s, 1

H), 0.97-1.19 (m, 4 H)

2120
(CD₃OD) δ 8.67 (d, 1 H), 8.31 (d, 1 H), 7.83-8.21 (m, 2 H),
466.2
100%

7.44-7.72 (m, 2 H), 6.55-7.06 (m, 4 H), 4.39-4.59 (m, 1 H), 3.50-
[M + H]⁺

3.90 (m, 1 H), 2.94-3.26 (m, 1 H), 2.73-2.90 (m, 1 H), 2.46 (s, 4

H), 0.93-1.19 (m, 4 H)

2121
(CD₃OD) δ 8.67 (d, 1 H), 8.31 (d, 1 H), 7.84-8.19 (m, 2 H),
466.2
99.7%

7.38-7.73 (m, 2 H), 6.43-7.05 (m, 4 H), 4.42-4.58 (m, 1 H), 3.48-
[M + H]⁺

3.91 (m, 1 H), 2.95-3.26 (m, 1 H), 2.75-2.90 (m, 1 H), 2.46 (s, 4

H), 0.90-1.20 (m, 4H)

2122
(CD₃OD) δ 8.68 (d, 1 H), 8.59 (br d, 1 H), 7.81-8.22 (m, 2 H),
502.2
100%

7.68 (br s, 1 H), 7.48-7.59 (m, 1 H), 7.43 (br d, 1 H), 6.60-7.20
[M + H]⁺

(m, 4 H), 4.38-4.60 (m, 1 H), 3.49-3.88 (m, 1 H), 2.98-3.27 (m, 1

H), 2.83 (br d, 1 H), 2.36-2.52 (m, 1 H), 0.92-1.19 (m, 4H)

2123
(CD₃OD) δ 8.67 (d, 1 H), 8.59 (br d, 1 H), 7.85-8.24 (m, 2 H),
502.2
99.6%

7.68 (br s, 1 H), 7.48-7.58 (m, 1 H), 7.43 (br d, 1 H), 6.68-7.17
[M + H]⁺

(m, 4 H), 4.28-4.59 (m, 1 H), 3.46-3.90 (m, 1 H), 2.96-3.28 (m, 1

H), 2.83 (br d, 1 H), 2.43 (br d, 1 H), 0.94-1.18 (m, 4 H)

2124
(CD₃OD) δ 8.55-8.80 (m, 2 H), 7.83-8.27 (m, 2 H), 7.59-7.78
520.2
98.7%

(m, 2 H), 7.54 (br dd, 1 H), 6.98 (br t, 3 H), 4.59 (s, 1 H), 3.50-
[M + H]⁺

3.89 (m, 1 H), 3.01-3.25 (m, 1 H), 2.76-2.92 (m, 1 H), 2.35-2.54

(m, 1 H), 0.96-1.16 (m, 4H)

2125
(CD₃OD) δ 8.63-8.76 (m, 2 H), 7.81-8.28 (m, 2 H), 7.45-7.76
520.2
91.1%

(m, 3 H), 6.57-7.30 (m, 3 H), 4.42-4.68 (m, 1 H), 3.50-3.92 (m, 1
[M + H]⁺

H), 2.95-3.26 (m, 1 H), 2.83 (br dd, 1 H), 2.37-2.53 (m, 1 H),

0.98-1.16 (m, 4 H)

2126
(CD₃OD) δ 8.31 (s, 1 H), 8.13 (br s, 1 H), 7.58 (br s, 1.7 H),
331.2
97.8%

6.93-7.10 (m, 2.3 H), 6.40-6.87 (m, 4 H), 4.56 (br s, 1 H), 3.58
[M + H]⁺

(br s, 1 H), 2.65-3.09 (m, 2 H), 2.44 (br s, 3 H)

2127
(CD₃OD) δ 8.31 (d, 1 H), 8.13 (br d, 1 H), 7.62 (s, 1 H), 7.58 (t,
331.2
95.2%

1 H), 7.05 (d, 1 H), 6.97 (d, 1 H), 6.72-6.85 (m, 2 H), 6.63-6.70
[M + H]⁺

(m, 1 H), 6.50 (s, 1 H), 4.57 (br dd, 1 H), 3.53-3.66 (m, 1 H),

2.87-3.05 (m, 1 H), 2.60-2.75 (m, 1 H), 2.42 (s, 3 H)

2128
(CD₃OD) δ 8.03 (dd, 2 H), 7.85 (d, 1 H), 7.69 (s, 1 H), 7.23-7.36
470.2
99.7%

(m, 4 H), 6.74 (s, 1 H), 6.46 (br s, 1 H), 4.38 (dd, 1 H), 3.79 (td,
[M + H]⁺

1 H), 3.01-3.21 (m, 1 H), 2.87 (br dd, 1 H)

2129
(CD₃OD) δ 8.03 (dd, 2 H), 7.85 (d, 1 H), 7.69 (s, 1 H), 7.23-7.36
470.2
94.3%

(m, 4 H), 6.74 (s, 1 H), 6.46 (br s, 1 H), 4.38 (dd, 1 H), 3.79 (td,
[M + H]⁺

1 H), 3.01-3.21 (m, 1 H), 2.87 (br dd, 1 H)

2130
(CD₃OD) δ 8.02 (dd, 2 H), 7.74 (d, 1 H), 7.68 (s, 1 H), 7.49 (s,
452.2
99.5%

0.3 H), 7.36 (s, 0.5 H), 7.25-7.33 (m, 3 H), 7.16-7.23 (m, 1.2 H),
[M + H]⁺

6.70 (s, 1 H), 6.46 (s, 1 H), 4.39 (dd, 1 H), 3.77-3.89 (m, 1 H),

3.04-3.17 (m, 1 H), 2.81-2.92 (m, 1 H)

2131
(CD₃OD) δ 8.01 (br t, 2 H), 7.74 (br d, 1 H), 7.68 (s, 1 H), 7.49
452.1
98.6%

(s, 0.3 H), 7.35 (s, 0.5 H), 7.28 (q, 3 H), 7.13-7.23 (m, 1.2H),
[M + H]⁺

6.69 (s, 1 H), 6.45 (br s, 1 H), 4.38 (br dd, 1 H), 3.83 (br t, 1 H),

3.02-3.17 (m, 1 H), 2.86 (br d, 1 H)

2132
(CD₃OD) δ 7.86 (d, 1 H), 7.53-7.75 (m, 2 H), 7.11-7.41 (m, 4
488.2
100%

H), 6.77 (s, 1 H), 6.42 (br s, 1 H), 4.39 (dd, 1 H), 3.73-3.93 (m, 1
[M + H]⁺

H), 3.01-3.17 (m, 1 H), 2.86 (dd, 1 H)

2133
(CD₃OD) δ 7.86 (d, 1 H), 7.55-7.76 (m, 2 H), 7.11-7.44 (m, 4
488.2
97.1%

H), 6.77 (s, 1 H), 6.42 (br s, 1 H), 4.39 (dd, 1 H), 3.83 (td, 1 H),
[M + H]⁺

3.00-3.20 (m, 1 H), 2.86 (dd, 1 H)

2134
(CD₃OD) δ 8.43 (d, 1 H), 7.50-7.75 (m, 3 H), 7.01-7.27 (m, 1
335.1
98.8%

H), 6.76-6.94 (m, 2 H), 6.69 (s, 1 H), 6.50 (s, 1 H), 6.18 (dd, 1
[M + H]⁺

H), 4.55 (dd, 1 H), 3.54 (ddd, 1 H), 2.83-3.01 (m, 1 H), 2.67 (br

dd, 1 H)

2135
(CD₃OD) δ 8.43 (d, 1 H), 7.40-7.75 (m, 3 H), 7.06-7.27 (m, 1
335.2
98.9%

H), 6.75-6.91 (m, 2 H), 6.69 (s, 1 H), 6.50 (s, 1 H), 6.18 (dd, 1
[M + H]⁺

H), 4.55 (dd, 1 H), 3.54 (ddd, 1 H), 2.84-3.00 (m, 1 H), 2.67 (br

dd, 1 H)

2136
(CD₃OD) δ 8.40 (s, 1 H), 7.76 (dd, 1 H), 7.63 (s, 1 H), 7.56 (dd,
419.1
100%

1 H), 7.19 (d, 1 H), 7.15 (dd, 1 H), 7.00 (dd, 1 H), 6.85(s, 1H),
[M + H]⁺

6.65 (s, 1 H), 4.81 (br dd, 1 H), 3.68 (ddd, 1 H), 2.87-3.04 (m, 1

H), 2.75 (dd, 1 H)

2137
(CD₃OD) δ 8.28 (s, 1 H), 7.65 (dd, 1 H), 7.52 (s, 1 H), 7.46 (dd,
419.1
100%

1 H), 7.08 (d, 1 H), 7.04 (dd, 1 H), 6.90 (dd, 1 H), 6.73 (s, 1H),
[M + H]⁺

6.54 (s, 1 H), 4.69 (br dd, 1 H), 3.56 (ddd, 1 H), 2.76-2.91 (m, 1

H), 2.63 (dd, 1 H)

2138
(CD₃OD) δ 8.40 (s, 1 H), 7.76 (dd, 1 H), 7.67-7.73 (m, 1 H),
435.1
100%

7.64 (s, 1 H), 7.30-7.60 (m, 1 H), 7.25 (dd, 1 H), 7.13-7.21 (m, 2
[M + H]⁺

H), 6.82 (s, 1 H), 6.62 (s, 1 H), 4.83 (br dd, 1 H), 3.60-3.71 (m, 1

H), 2.89-3.02 (m, 1 H), 2.75 (dd, 1 H)

2139
(CD₃OD) δ 8.40 (s, 1 H), 7.76 (dd, 1 H), 7.71 (d, 1 H), 7.63 (s, 1
435.1
100%

H), 7.30-7.59 (m, 1 H), 7.22-7.28 (m, 1 H), 7.14-7.21 (m, 2H),
[M + H]⁺

6.81 (s, 1 H), 6.62 (s, 1 H), 4.84 (br dd, 1 H), 3.59-3.72 (m, 1 H),

2.89-3.02 (m, 1 H), 2.75 (dd, 1 H)

2140
(CD₃OD) δ 8.52-8.94 (m, 1 H), 7.47-8.03 (m, 3 H), 6.91-7.19
443.2
100%

(m, 1 H), 6.51-6.88 (m, 2 H), 4.65-4.80 (m, 0.5 H), 4.32-4.56 (m,
[M + H]⁺

0.5 H), 3.51-3.88 (m, 1 H), 2.69-3.10 (m, 2 H), 2.18 (br d, 1 H),

1.02-1.27 (m, 4 H)

2141
(CD₃OD) δ 8.57-8.90 (m, 1 H), 7.44-8.06 (m, 3 H), 6.99 (br s, 1
443.2
99.6%

H), 6.42-6.92 (m, 2 H), 4.64-4.82 (m, 0.5 H), 4.38-4.57 (m, 0.5
[M + H]⁺

H), 3.42-3.89 (m, 1 H), 2.69-3.19 (m, 2 H), 2.18 (br s, 1 H),

0.98-1.23 (m, 4 H)

2142
(CD₃OD) δ 8.47-8.79 (m, 1 H), 7.43-7.82 (m, 3 H), 6.89 (br t, 1
459.2
100%

H), 6.46-6.80 (m, 2 H), 4.53-4.74 (m, 1 H), 3.24-3.72 (m, 1 H),
[M + H]⁺

2.61-3.06 (m, 2 H), 1.17-1.38 (m, 9 H)

2143
(CD₃OD) δ 8.71 (br s, 1 H), 7.51-7.94 (m, 3 H), 6.52-7.18 (m, 3
459.2
99.5%

H), 4.66-4.88 (m, 1 H), 3.37-3.91 (m, 1 H), 2.69-3.23 (m, 2 H),
[M + H]⁺

1.26-1.58 (m, 9 H)

2144
(CD₃OD) δ 8.74 (br d, 1 H), 7.75-8.05 (m, 1 H), 7.60-7.73 (m, 2
463.2
100%

H), 7.01 (br s, 1 H), 6.60-6.94 (m, 2 H), 4.82 (br s, 0.3 H), 4.48
[M + H]⁺

(br s, 0.7 H), 3.78 (br s, 0.5 H), 3.36-3.48 (m, 0.5 H), 3.15 (br s,

1 H), 2.86 (br d, 1 H), 1.73-1.91 (m, 6 H)

2145
(CD₃OD) δ 8.72 (br s, 1 H), 7.75-8.09 (m, 1 H), 7.60-7.74 (m, 2
463.2
98.5%

H), 7.01 (br s, 1 H), 6.56-6.95 (m, 2 H), 4.75-4.84 (m, 0.5 H),
[M + H]⁺

4.48 (br s, 0.5 H), 3.78 (br s, 0.6 H), 3.36-3.47 (m, 0.4 H), 2.95-

3.23 (m, 1 H), 2.84 (br s, 1 H), 1.69-1.92 (m, 6 H)

2146
(CD₃OD) δ 8.29 (d, 1 H), 7.74 (s, 1 H), 7.05 (d, 1 H), 6.84 (t, 1
418.2
100%

H), 6.66 (s, 1 H), 6.40 (s, 1 H), 4.33 (dd, 1 H), 3.79 (ddd, 1 H),
[M + H]⁺

2.99-3.25 (m, 2 H), 2.84 (br dd, 1 H), 1.33 (dd, 6 H)

2147
(CD₃OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 7.07 (d, 1 H), 6.86 (t, 1
418.2
99.6%

H), 6.67 (s, 1 H), 6.40 (s, 1 H), 4.35 (dd, 1 H), 3.81 (ddd, 1 H),
[M + H]⁺

3.05-3.26 (m, 2 H), 2.85 (dd, 1 H), 1.35 (dd, 6 H)

2148
(CD₃OD) δ 8.42 (s, 1 H), 8.25-8.35 (m, 1 H), 7.73-7.82 (m, 1 H),
427.2
98.7%

7.65 (s, 1 H), 7.11-7.18 (m, 1 H), 7.04 (d, 1 H), 6.92 (s, 1 H),
[M + H]⁺

6.81 (t, 1 H), 6.60 (s, 1 H), 4.68-4.75 (m, 1 H), 3.56-3.70 (m, 1

H), 3.18 (dt, 1 H), 2.89-3.03 (m, 1 H), 2.74 (br dd, 1 H), 1.33

(dd, 6 H)

2149
(CD₃OD) δ 8.27-8.36 (m, 1 H), 8.13-8.23 (m, 1 H), 7.62-7.70
427.2
99.6%

(m, 1 H), 7.46-7.57 (m, 1 H), 7.03 (d, 1 H), 6.92(d, 1 H), 6.80
[M + H]⁺

(s, 1 H), 6.70 (t, 1 H), 6.48 (s, 1 H), 4.60 (br dd, 1 H), 3.45-3.57

(m, 1 H), 3.07 (dt, 1 H), 2.77-2.91 (m, 1 H), 2.56-2.69 (m, 1 H),

1.21 (dd, 6 H)

2150
(CD₃OD) δ 7.96 (d, 1 H), 7.56 (s, 1 H), 6.63-7.05 (m, 2 H), 6.39-
388.2
99.7%

6.54 (m, 2 H), 6.25 (s, 1 H), 4.19 (dd, 1 H), 3.84 (s, 3 H), 3.54-
[M + H]⁺

3.72 (m, 1 H), 2.84-3.04 (m, 1 H), 2.71 (dd, 1H)

2151
(CD₃OD) δ 8.07 (d, 1 H), 7.66 (s, 1 H), 7.10 (s, 0.2 H), 6.97(s,
388.2
99.1%

0.5 H), 6.73-6.87 (m, 1.3 H), 6.48-6.65 (m, 2 H), 6.35 (s, 1 H),
[M + H]⁺

4.30 (dd, 1 H), 3.94 (s, 3 H), 3.66-3.79 (m, 1 H), 2.97-3.13 (m, 1

H), 2.81 (dd, 1 H)

2152
(CD₃OD) δ 8.36 (d, 1 H), 7.69 (s, 1 H), 7.10-7.26 (m, 0.5 H),
424.1
99.7%

6.92-7.07 (m, 2 H), 6.80-6.90 (m, 1.5 H), 6.70 (s, 1 H), 6.39 (s, 1
[M + H]⁺

H), 4.34 (dd, 1 H), 3.77 (ddd, 1 H), 2.98-3.20 (m, 1 H), 2.84 (dd,

1 H)

2153
(CD₃OD) δ 8.36 (d, 1 H), 7.69 (s, 1 H), 7.08-7.27 (m, 0.5 H),
424.1
98.1%

6.93-7.07 (m, 2 H), 6.79-6.93 (m, 1.5 H), 6.70 (s, 1 H), 6.39 (s, 1
[M + H]⁺

H), 4.34 (dd, 1 H), 3.77 (ddd, 1 H), 2.98-3.16 (m, 1 H), 2.84 (dd,

1 H)

2154
(CD₃OD) δ 8.24 (br d, 1 H), 7.59 (br s, 1 H), 7.10 (s, 0.2 H),
442.1
99.6%

6.82-6.97 (m, 1.5 H), 6.68-6.81 (m, 1.3 H), 6.58 (s, 1 H), 6.29
[M + H]⁺

(br s, 1 H), 4.23 (dd, 1 H), 3.55-3.76 (m, 1 H), 2.86-3.06 (m, 1

H), 2.74 (br d, 1 H)

2155
(CD₃OD) δ 8.24 (d, 1 H), 7.58 (s, 1 H), 7.10 (s, 0.3 H), 6.80-6.96
442.1
99.1%

(m, 1.5 H), 6.70-6.78 (m, 1.2 H), 6.58 (s, 1 H), 6.29 (s, 1H),
[M + H]⁺

4.24 (dd, 1 H), 3.66 (ddd, 1 H), 2.88-3.05 (m, 1 H), 2.73 (dd, 1 H)

2156
(CD₃OD) δ 9.23 (s, 1 H), 8.67 (br d, 2 H), 8.24 (br d, 1 H), 7.68
400.2
99.4%

(s, 1 H), 6.92 (br d, 1 H), 6.67-6.78 (m, 1 H), 6.42-6.63 (m, 2 H),
[M + H]⁺

4.41 (br dd, 1 H), 3.70-3.87 (m, 1 H), 2.96-3.14 (m, 1 H), 2.77-

2.88 (m, 1 H), 2.38 (s, 3 H)

2157
(CD₃OD) δ 9.28 (d, 1 H), 8.66-8.77 (m, 2 H), 8.29 (d, 1 H), 7.68
400.2
99.4%

(s, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.63 (s, 1 H), 6.51(s, 1H),
[M + H]⁺

4.43 (dd, 1 H), 3.81 (ddd, 1 H), 3.03-3.15 (m, 1 H), 2.84 (dd, 1

H), 2.43 (s, 3 H)

2158
(CD₃OD) δ 9.24 (s, 1 H), 8.68 (br dd, 2 H), 8.30 (br d, 1 H), 7.68
404.2
99.9%

(s, 1 H), 6.91 (br dd, 1 H), 6.69-6.84 (m, 2 H), 6.49 (br s, 1 H),
[M + H]⁺

4.43 (br dd, 1 H), 3.73-3.86 (m, 1 H), 3.00-3.17 (m, 1 H), 2.84

(br dd, 1 H)

2159
(CD₃OD) δ 9.23 (s, 1 H), 8.62-8.71 (m, 2 H), 8.28 (d, 1 H), 7.68
404.2
99.0%

(s, 1 H), 6.90 (dd, 1 H), 6.69-6.82 (m, 2 H), 6.49 (s, 1 H), 4.42
[M + H]⁺

(br dd, 1 H), 3.73-3.86 (m, 1 H), 3.00-3.14 (m, 1 H), 2.83 (br dd,

1 H)

2160
(CD₃OD) δ 9.27 (s, 1 H), 8.70 (br dd, 2 H), 8.42 (br d, 1 H), 7.69
420.1
100%

(s, 1 H), 7.27 (br d, 1 H), 6.82 (t, 1 H), 6.75 (s, 1 H), 6.51(s, 1
[M + H]⁺

H), 4.45 (br dd, 1 H), 3.75-3.86 (m, 1 H), 3.03-3.15 (m, 1 H),

2.85 (br dd, 1 H)

2161
(CD₃OD) δ 9.26 (s, 1 H), 8.65-8.77 (m, 2 H), 8.40 (d, 1 H), 7.69
420.1
98.8%

(s, 1 H), 7.25 (d, 1 H), 6.80 (t, 1 H), 6.74 (s, 1 H), 6.50 (s, 1 H),
[M + H]⁺

4.44 (dd, 1 H), 3.69-3.89 (m, 1 H), 3.00-3.20 (m, 1 H), 2.84 (br

dd, 1 H)

2162
(CD₃OD) δ 9.27 (d, 1 H), 8.94 (d, 1 H), 8.67 (d, 1 H), 8.09 (dd, 1
454.2
99.5%

H), 7.69 (s, 1 H), 7.61 (d, 1 H), 6.96 (t, 1 H), 6.82 (s, 1H), 6.55
[M + H]⁺

(s, 1 H), 4.49 (dd, 1 H), 3.82 (ddd, 1 H), 3.04-3.18 (m, 1 H), 2.86

(dd, 1 H)

2163
(CD₃OD) δ 9.27 (d, 1 H), 8.94 (d, 1 H), 8.68 (d, 1 H), 8.10 (dd, 1
454.2
96.9%

H), 7.69 (s, 1 H), 7.61 (d, 1 H), 6.97 (t, 1 H), 6.82 (s, 1H), 6.55
[M + H]⁺

(br s, 1 H), 4.49 (dd, 1 H), 3.72-3.92 (m, 1 H), 3.01-3.19 (m, 1

H), 2.86 (br dd, 1 H)

2164
(CD₃OD) δ 8.07 (d, 1 H), 7.67 (s, 1 H), 6.79 (t, 1 H), 6.53-6.64
406.1
100%

(m, 2 H), 6.36 (s, 1 H), 4.31 (dd, 1 H), 3.94 (s, 3 H), 3.75 (td, 1
[M + H]⁺

H), 2.99-3.14 (m, 1 H), 2.82 (br dd, 1 H)

2165
(CD₃OD) δ 8.07 (d, 1 H), 7.67 (s, 1 H), 6.79 (t, 1 H), 6.50-6.65
406.1
99.6%

(m, 2 H), 6.36 (br s, 1 H), 4.31 (dd, 1 H), 3.95 (s, 3 H), 3.69-3.83
[M + H]⁺

(m, 1 H), 2.99-3.12 (m, 1 H), 2.76-2.87 (m, 1 H)

2166
(CD₃OD) δ 8.16 (d, 1 H), 7.57 (s, 1 H), 6.59-7.03 (m, 4 H), 6.28
398.2
90.7%

(s, 1 H), 4.21 (dd, 1 H), 3.67 (ddd, 1 H), 2.83-3.03 (m, 1 H), 2.72
[M + H]⁺

(dd, 1 H), 1.78-2.10 (m, 1 H), 0.88-0.96 (m, 2 H), 0.62-0.71 (m,

2 H)

2167
(CD₃OD) δ 8.17 (d, 1 H), 7.58 (s, 1 H), 6.56-7.04 (m, 4 H), 6.28
398.2
100%

(s, 1 H), 4.21 (dd, 1 H), 3.67 (td, 1 H), 2.85-3.06 (m, 1 H), 2.72
[M + H]⁺

(dd, 1 H), 1.87-2.06 (m, 1 H), 0.86-1.01 (m, 2 H), 0.63-0.73 (m,

2 H)

2168
(CD₃OD) δ 8.31 (br d, 1 H), 7.66 (s, 1 H), 7.06 (d, 1 H), 6.84 (t,
390.2
98.6%

1 H), 6.59 (s, 1 H), 6.14-6.33 (m, 1 H), 4.19 (dd, 1 H), 3.70 (td, 1
[M + H]⁺

H), 3.20 (dt, 1 H), 2.95-3.10 (m, 1 H), 2.73-2.87 (m, 1 H), 2.02-

2.15 (m, 1 H), 1.34 (dd, 6 H), 1.04-1.15 (m, 4H)

2169
(CD₃OD) δ 8.19 (d, 1 H), 7.54 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1
390.2
97.5%

H), 6.47 (s, 1 H), 6.14 (br s, 1 H), 4.07 (dd, 1 H), 3.58 (td, 1 H),
[M + H]⁺

3.08 (dt, 1 H), 2.85-2.96 (m, 1 H), 2.67 (br dd, 1 H), 1.92-2.05

(m, 1 H), 1.22 (dd, 6 H), 0.92-1.03 (m, 4H)

2170
(CD₃OD) δ 8.30 (s, 1 H), 8.16 (d, 1 H), 7.65 (dd, 1 H), 7.54 (s, 1
425.2
80.9%

H), 7.03 (d, 1 H), 6.81 (s, 1 H), 6.59-6.70 (m, 2 H), 6.57 (s, 1H),
[M + H]⁺

4.60 (br dd, 1 H), 3.44-3.58 (m, 1 H), 2.78-2.91 (m, 1 H), 2.62

(dd, 1 H), 1.89-2.02 (m, 1 H), 0.86-0.96 (m, 2 H), 0.59-0.69 (m,

2 H)

2171
(CD₃OD) δ 8.30 (s, 1 H), 8.16 (d, 1 H), 7.65 (dd, 1 H), 7.54 (s, 1
425.2
96.3%

H), 7.03 (d, 1 H), 6.82 (s, 1 H), 6.60-6.70 (m, 2 H), 6.57 (s, 1 H),
[M + H]⁺

4.60 (br dd, 1 H), 3.44-3.57 (m, 1 H), 2.79-2.90 (m, 1 H), 2.62

(dd, 1 H), 1.91-2.01 (m, 1 H), 0.85-0.96 (m, 2 H), 0.61-0.69 (m,

2 H)

2172
(CD₃OD) δ 8.40 (d, 2 H), 8.25 (d, 1 H), 7.64 (s, 1 H), 7.22 (s, 1
358.2
100%

H), 6.70-6.81 (m, 2 H), 6.69 (s, 1 H), 6.64 (t, 1 H), 5.03 (dd, 1
[M + H]⁺

H), 3.48 (ddd, 1 H), 2.85-2.98 (m, 1 H), 2.70 (dd, 1 H), 2.01-

2.13 (m, 1 H), 0.97-1.07 (m, 2 H), 0.71-0.81 (m, 2 H)

2173
(CD₃OD) δ 8.41 (d, 2 H), 8.25 (d, 1 H), 7.64 (s, 1 H), 7.22 (s, 1
358.2
100%

H), 6.71-6.80 (m, 2 H), 6.69 (s, 1 H), 6.65 (t, 1 H), 5.04 (dd, 1
[M + H]⁺

H), 3.48 (ddd, 1 H), 2.84-3.00 (m, 1 H), 2.70 (dd, 1 H), 2.00-

2.13 (m, 1 H), 0.97-1.07 (m, 2 H), 0.70-0.81 (m, 2 H)

2174
(CD₃OD) δ 8.56 (s, 2 H), 8.14 (d, 1 H), 7.55 (s, 1 H), 7.16 (s, 1
426.2
100%

H), 6.52-6.74 (m, 3 H), 5.06 (dd, 1 H), 3.42 (td, 1 H), 2.74-2.87
[M + H]⁺

(m, 1 H), 2.60-2.69 (m, 1 H), 1.89-2.06 (m, 1 H), 0.84-0.95 (m, 2

H), 0.59-0.71 (m, 2 H)

2175
(CD₃OD) δ 8.56 (s, 2 H), 8.14 (d, 1 H), 7.55 (s, 1 H), 7.16 (s, 1
426.2
99.7%

H), 6.54-6.73 (m, 3 H), 5.07 (dd, 1 H), 3.42 (td, 1 H), 2.72-2.90
[M + H]⁺

(m, 1 H), 2.57-2.71 (m, 1 H), 1.86-2.06 (m, 1 H), 0.85-0.97 (m, 2

H), 0.59-0.73 (m, 2 H)

2176
(CD₃OD) δ 9.28 (d, 1 H), 8.67-8.75 (m, 2 H), 8.28 (d, 1 H), 7.68
428.2
100%

(s, 1 H), 7.03 (d, 1 H), 6.81 (t, 1 H), 6.72 (s, 1 H), 6.51 (s, 1 H),
[M + H]⁺

4.43 (dd, 1 H), 3.82 (td, 1 H), 3.04-3.23 (m, 2 H), 2.85 (dd, 1 H),

1.29-1.35 (m, 6 H)

2177
(CD₃OD) δ 9.29 (d, 1 H), 8.68-8.75 (m, 2 H), 8.29 (d, 1 H), 7.68
428.2
99.0%

(s, 1 H), 7.04 (d, 1 H), 6.82 (t, 1 H), 6.72 (s, 1 H), 6.51 (s, 1H),
[M + H]⁺

4.44 (dd, 1 H), 3.77-3.88 (m, 1 H), 3.04-3.25 (m, 2 H), 2.85 (dd,

1 H), 1.29-1.35 (m, 6 H)

2178
(CD₃OD) δ 9.27 (d, 1 H), 8.94 (d, 1 H), 8.32 (br d, 1 H), 8.10
404.2
100%

(dd, 1 H), 7.69 (br s, 1 H), 6.95 (dd, 1 H), 6.73-6.86 (m, 2 H),
[M + H]⁺

6.52 (s, 1 H), 4.47 (dd, 1 H), 3.72-3.89 (m, 1 H), 2.98-3.17 (m, 1

H), 2.86 (br d, 1 H)

2179
(CD₃OD) δ 9.28 (d, 1 H), 8.95 (d, 1 H), 8.33 (br d, 1 H), 8.10
404.2
94.6%

(dd, 1 H), 7.69 (br s, 1 H), 6.95 (dd, 1 H), 6.73-6.87 (m, 2 H),
[M + H]⁺

6.53 (s, 1 H), 4.47 (br dd, 1 H), 3.69-3.91 (m, 1 H), 3.01-3.16

(m, 1 H), 2.78-2.93 (m, 1 H)

2180
(CD₃OD) δ 9.28 (d, 1 H), 8.95 (d, 1 H), 8.29 (d, 1 H), 8.11 (dd, 1
428.2
100%

H), 7.68 (s, 1 H), 7.04 (d, 1 H), 6.82 (t, 1 H), 6.72 (s, 1 H), 6.52
[M + H]⁺

(br s, 1 H), 4.46 (dd, 1 H), 3.83 (ddd, 1 H), 3.02-3.24 (m, 2 H),

2.86 (br dd, 1 H), 1.32 (dd, 6 H)

2181
(CD₃OD) δ 9.27 (s, 1 H), 8.94 (d, 1 H), 8.28 (d, 1 H), 8.10 (d, 1
428.2
97.8%

H), 7.68 (s, 1 H), 7.04 (d, 1 H), 6.82 (t, 1 H), 6.72 (s, 1 H), 6.52
[M + H]⁺

(br s, 1 H), 4.46 (dd, 1 H), 3.75-3.93 (m, 1 H), 3.00-3.23 (m, 2

H), 2.86 (br dd, 1 H), 1.28-1.34 (m, 6 H)

2182
(CD₃OD) δ 9.27 (s, 1 H), 8.94 (d, 1 H), 8.42 (d, 1 H), 8.10 (dd, 1
420.1
100%

H), 7.69 (s, 1 H), 7.27 (d, 1 H), 6.82 (t, 1 H), 6.76(s, 1H), 6.53
[M + H]⁺

(br s, 1 H), 4.47 (dd, 1 H), 3.81 (td, 1 H), 3.01-3.16 (m, 1 H),

2.86 (br dd, 1 H)

2183
(CD₃OD) δ 9.26 (s, 1 H), 8.94 (d, 1 H), 8.42 (d, 1 H), 8.09 (d, 1
420.1
96.9%

H), 7.69 (s, 1 H), 7.27 (d, 1 H), 6.82 (t, 1 H), 6.75 (s, 1H), 6.52
[M + H]⁺

(s, 1 H), 4.47 (dd, 1 H), 3.70-3.89 (m, 1 H), 3.00-3.16 (m, 1 H),

2.85 (br dd, 1 H)

2184
(CD₃OD) δ 8.68 (s, 2 H), 8.29 (d, 1 H), 7.66 (s, 1 H), 7.26 (s, 1
428.2
100%

H), 7.05 (d, 1 H), 6.82 (t, 1 H), 6.63 (s, 1 H), 5.18 (dd, 1 H),
[M + H]⁺

3.47-3.60 (m, 1 H), 3.19 (dt, 1 H), 2.86-2.99 (m, 1 H), 2.70-2.81

(m, 1 H), 1.34 (dd, 6 H)

2185
(CD₃OD) δ 8.66 (s, 2 H), 8.27 (d, 1 H), 7.67 (s, 1 H), 7.25 (s, 1
428.2
100%

H), 7.03 (d, 1 H), 6.80 (t, 1 H), 6.61 (s, 1 H), 5.17 (dd, 1H),
[M + H]⁺

3.46-3.59 (m, 1 H), 3.17 (dt, 1 H), 2.85-2.98 (m, 1 H), 2.69-2.79

(m, 1 H), 1.32 (dd, 6 H)

2186
(CD₃OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.74-6.85 (m, 2 H), 6.69
362.2
99.7%

(s, 1 H), 6.31 (s, 1 H), 4.22 (dd, 1 H), 3.64-3.78 (m, 1 H), 2.97-
[M + H]⁺

3.10 (m, 1 H), 2.79 (dd, 1 H), 2.45 (s, 3 H), 2.04-2.15 (m, 1 H),

1.00-1.07 (m, 2 H), 0.75-0.83 (m, 2 H)

2187
(CD₃OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.75-6.85 (m, 2 H), 6.69
362.2
91.9%

(s, 1 H), 6.31 (s, 1 H), 4.22 (dd, 1 H), 3.71 (ddd, 1 H), 2.95-3.12
[M + H]⁺

(m, 1 H), 2.79 (dd, 1 H), 2.45 (s, 3 H), 1.99-2.21 (m, 1 H), 0.99-

1.08 (m, 2 H), 0.73-0.82 (m, 2 H)

2188
(CD₃OD) δ 8.31 (d, 1 H), 7.67 (s, 1 H), 6.99 (d, 1 H), 6.79 (t, 1
376.2
99.8%

H), 6.52 (s, 1 H), 6.24 (s, 1 H), 4.18 (dd, 1 H), 3.64-3.76 (m, 1
[M + H]⁺

H), 2.96-3.08 (m, 1 H), 2.79 (dd, 1 H), 2.44 (s, 3 H), 1.50 (s, 3

H), 1.23-1.31 (m, 2 H), 0.91-0.97 (m, 2 H)

2189
(CD₃OD) δ 8.31 (d, 1 H), 7.67 (s, 1 H), 6.99 (d, 1 H), 6.79 (t, 1
376.2
99.8%

H), 6.52 (s, 1 H), 6.24 (s, 1 H), 4.18 (dd, 1 H), 3.62-3.76 (m, 1
[M + H]⁺

H), 2.94-3.09 (m, 1 H), 2.79 (dd, 1 H), 2.44 (s, 3 H), 1.50 (s, 3

H), 1.24-1.31 (m, 2 H), 0.90-0.99 (m, 2 H)

2190
(CD₃OD) δ 8.32 (d, 1 H), 7.51-7.58 (m, 1 H), 7.46 (d, 1 H),
372.1
100%

7.02-7.11 (m, 1 H), 6.70-6.78 (m, 1 H), 6.45 (s, 1 H), 6.25 (s, 1
[M + H]⁺

H), 4.18 (dd, 1 H), 3.64 (ddd, 1 H), 2.85-3.00 (m, 1 H), 2.70 (dd,

1 H), 1.92-2.06 (m, 3 H)

2191
(CD₃OD) δ 8.32 (d, 1 H), 7.56 (s, 1 H), 7.47 (d, 1 H), 6.99-7.13
372.1
99.9%

(m, 1 H), 6.74 (t, 1 H), 6.45 (s, 1 H), 6.25 (s, 1 H), 4.18(dd, 1
[M + H]⁺

H), 3.64 (ddd, 1 H), 2.87-3.00 (m, 1 H), 2.70 (dd, 1 H), 1.99 (t, 3 H)

2192
(CD₃OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 7.00 (d, 1 H), 6.80 (t, 1
386.2
100%

H), 6.59 (s, 1 H), 6.38 (s, 1 H), 4.31 (dd, 1 H), 3.73-3.84 (m, 1
[M + H]⁺

H), 3.00-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.45 (s, 3 H), 2.12 (t, 3 H)

2193
(CD₃OD) δ 8.31 (d, 1 H), 7.69 (s, 1 H), 7.00 (d, 1 H), 6.80(t, 1
386.2
100%

H), 6.59 (s, 1 H), 6.38 (br s, 1 H), 4.31 (dd, 1 H), 3.78 (ddd, 1
[M + H]⁺

H), 2.95-3.13 (m, 1 H), 2.83 (br dd, 1 H), 2.45 (s, 3 H), 2.12 (t, 3 H)

2194
(CD₃OD) δ 8.70 (d, 1 H), 7.70 (s, 1 H), 7.64 (d, 1 H), 6.96-7.03 (m, 1
440.2
99.9%

H), 6.71-6.80 (m, 1 H), 6.41 (s, 1 H), 4.35 (dd, 1 H), 3.71-3.85 (m, 1
[M + H]⁺

H), 3.02-3.13 (m, 1 H), 2.85 (dd, 1 H), 2.03-2.19 (m, 3 H)

2195
(CD₃OD) δ 8.69 (d, 1 H), 7.69 (s, 1 H), 7.63 (d, 1 H), 6.99 (t, 1 H),
440.2
99.4%

6.76 (s, 1 H), 6.40 (br s, 1 H), 4.34 (dd, 1 H), 3.70-3.84 (m, 1 H), 3.01-
[M + H]⁺

3.14 (m, 1 H), 2.85 (br dd, 1 H), 2.11 (t, 3 H)

2196
(CD₃OD) δ 8.35 (d, 1 H), 7.69 (s, 1 H), 6.97 (dd, 1 H), 6.80-6.87
390.2
99.4%

(m, 1 H), 6.69-6.74 (m, 1 H), 6.38 (s, 1 H), 4.27-4.38 (m, 1 H),
[M + H]⁺

3.71-3.85 (m, 1 H), 3.01-3.12 (m, 1 H), 2.84 (dd, 1 H), 2.12 (t, 3 H)

2197
(CD₃OD) δ 8.35 (d, 1 H), 7.69 (s, 1 H), 6.97 (dd, 1 H), 6.84 (td,
390.2
99.8%

1 H), 6.72 (s, 1 H), 6.38 (s, 1 H), 4.27-4.39 (m, 1 H), 3.78 (ddd,
[M + H]⁺

1 H), 3.01-3.14 (m, 1 H), 2.84 (dd, 1 H), 2.12 (t, 3 H)

2198
(CD₃OD) δ 9.29 (dd, 1 H), 8.25-8.52 (m, 2 H), 7.89 (dd, 1 H),
420.1
100%

7.70 (s, 1 H), 7.29 (d, 1 H), 6.73-6.95 (m, 2 H), 6.57 (br s, 1 H),
[M + H]⁺

4.50 (dd, 1 H), 3.74-3.95 (m, 1 H), 3.12 (br d, 1 H), 2.88 (br dd,

1 H)

2199
(CD₃OD) δ 9.19-9.41 (m, 1 H), 8.25-8.55 (m, 2 H), 7.89 (dd, 1
420.1
98.6%

H), 7.71 (s, 1 H), 7.29 (d, 1 H), 6.73-6.91 (m, 2 H), 6.57 (s, 1 H),
[M + H]⁺

4.50 (dd, 1 H), 3.68-4.01 (m, 1 H), 3.03-3.23 (m, 1 H), 2.87 (dd,

1 H)

2200
(CD₃OD) δ 8.65 (s, 2 H), 8.04 (d, 1 H), 7.63 (s, 1 H), 7.21 (s, 1
416.2
100%

H), 6.75 (t, 1 H), 6.48-6.63 (m, 2 H), 5.15 (dd, 1 H), 3.93 (s, 3
[M + H]⁺

H), 3.41-3.57 (m, 1 H), 2.84-2.95 (m, 1 H), 2.66-2.80 (m, 1 H)

2201
(CD₃OD) δ 8.65 (s, 2 H), 8.04 (d, 1 H), 7.64 (s, 1 H), 7.21 (s, 1
416.2
98.9%

H), 6.75 (t, 1 H), 6.45-6.61 (m, 2 H), 5.15 (dd, 1 H), 3.93(s, 3
[M + H]⁺

H), 3.41-3.57 (m, 1 H), 2.82-2.97 (m, 1 H), 2.69-2.78 (m, 1 H)

2202
(CD₃OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (br d, 1 H), 6.83-
422.2
96.6%

7.14 (m, 2 H), 6.76 (s, 1 H), 6.40 (s, 1 H), 4.33 (dd, 1H), 3.77
[M + H]⁺

(ddd, 1 H), 3.00-3.14 (m, 1 H), 2.84 (dd, 1 H), 2.12 (t, 3 H)

2203
(CD₃OD) δ 8.59 (d, 1 H), 7.69 (s, 1 H), 7.44 (br d, 1 H), 6.82-
422.2
99.9%

7.15 (m, 2 H), 6.76 (s, 1 H), 6.40 (s, 1 H), 4.33 (dd, 1 H), 3.77
[M + H]⁺

(ddd, 1 H), 2.99-3.13 (m, 1 H), 2.84 (br dd, 1 H), 2.12 (t, 3 H)

2204
(CD₃OD) δ 8.28 (d, 1 H), 7.69 (s, 1 H), 6.67-6.87 (m, 3 H), 6.39
412.2
99.7%

(br s, 1 H), 4.32 (dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.13 (m, 1 H),
[M + H]⁺

2.84 (br dd, 1 H), 2.02-2.18 (m, 4 H), 0.97-1.08 (m, 2 H), 0.71-

0.82 (m, 2 H)

2205
(CD₃OD) δ 8.28 (br d, 1 H), 7.69 (br s, 1 H), 6.73-6.84 (m, 3 H),
412.2
99.9%

6.39 (br s, 1 H), 4.32 (dd, 1 H), 3.72-3.88 (m, 1 H), 3.00-3.15
[M + H]

(m, 1 H), 2.77-2.92 (m, 1 H), 2.06-2.17 (m, 4 H), 1.00-1.08 (m, 2

H), 0.75-0.81 (m, 2 H)

2206
(CD₃OD) δ 8.54 (dd, 1 H), 8.22-8.42 (m, 2 H), 7.69 (s, 1 H),
413.2
99.6%

7.45 (dd, 1 H), 6.99 (d, 1 H), 6.78 (t, 1 H), 6.59 (s, 1 H), 6.46 (br
[M + H]⁺

s, 1 H), 4.39 (dd, 1 H), 3.71-3.92 (m, 1 H), 3.05-3.19 (m, 1 H),

2.88 (s, 4 H), 2.44 (s, 3 H)

2207
(CD₃OD) δ 8.47-8.62 (m, 1 H), 8.32 (t, 2 H), 7.76 (s, 1 H), 7.45
413.2
99.1%

(dd, 1 H), 6.99 (d, 1 H), 6.78 (t, 1 H), 6.60 (s, 1 H), 6.47 (s, 1 H),
[M + H]⁺

4.40 (dd, 1 H), 3.73-3.90 (m, 1 H), 3.02-3.20 (m, 1 H), 2.81-2.93

(m, 4 H), 2.44 (s, 3 H)

2208
(CD₃OD) δ 8.71 (br d, 1 H), 8.55 (d, 1 H), 8.33 (d, 1 H), 7.57-
467.2
100%

7.78 (m, 2 H), 7.45 (dd, 1 H), 6.99 (t, 1 H), 6.78 (s, 1 H), 6.49
[M + H]⁺

(br s, 1 H), 4.43 (dd, 1 H), 3.74-3.90 (m, 1 H), 3.05-3.19 (m, 1

H), 2.80-2.94 (m, 4 H)

2209
(CD₃OD) δ 8.71 (br d, 1 H), 8.55 (dd, 1 H), 8.33 (dd, 1 H), 7.56-
467.2
99.5%

7.80 (m, 2 H), 7.46 (dd, 1 H), 6.99 (br t, 1 H), 6.78 (s, 1 H), 6.49
[M + H]⁺

(br s, 1 H), 4.43 (dd, 1 H), 3.82 (br d, 1 H), 3.02-3.20 (m, 1 H),

2.89 (s, 4 H)

2210
(CD₃OD) δ 8.13-8.89 (m, 3 H), 7.71 (s, 1 H), 7.37-7.54 (m, 2 H),
449.2
99.9%

6.72-7.18 (m, 3 H), 6.48 (s, 1 H), 4.41 (dd, 1 H), 3.67-3.94 (m, 1
[M + H]⁺

H), 3.05-3.19 (m, 1 H), 2.74-3.01 (m, 4 H)

2211
(CD₃OD) δ 8.48-8.70 (m, 2 H), 8.33 (dd, 1 H), 7.70 (s, 1 H),
449.2
99.6%

7.36-7.60 (m, 2 H), 6.73-7.17 (m, 3 H), 6.48 (s, 1 H), 4.41 (dd, 1
[M + H]⁺

H), 3.81 (ddd, 1 H), 3.03-3.18 (m, 1 H), 2.77-2.97 (m, 4 H)

2212
(CD₃OD) δ 8.54 (dd, 1 H), 8.22-8.42 (m, 2 H), 7.69 (s, 1 H),
413.2
99.6%

7.45 (dd, 1 H), 6.99 (d, 1 H), 6.78 (t, 1 H), 6.59 (s, 1 H), 6.46 (br
[M + H]⁺

s, 1 H), 4.39 (dd, 1 H), 3.71-3.92 (m, 1 H), 3.05-3.19 (m, 1 H),

2.88 (s, 4 H), 2.44 (s, 3 H)

2213
(CD₃OD) δ 8.41 (dd, 1 H), 8.10-8.30 (m, 2 H), 7.58 (s, 1 H),
417.2
98.9%

7.32 (dd, 1 H), 6.53-6.90 (m, 3 H), 6.34 (s, 1 H), 4.28 (dd, 1 H),
[M + H]⁺

3.69 (ddd, 1 H), 2.90-3.07 (m, 1 H), 2.65-2.87 (m, 4 H)

2214
(CD₃OD) δ 8.25-8.34 (m, 1 H), 7.69 (br d, 1 H), 6.92-7.01 (m, 2
413.1
100%

H), 6.82-6.91 (m, 1 H), 6.77 (dt, 1 H), 6.34-6.72 (m, 1 H), 4.44
[M + H]⁺

(dd, 1 H), 4.10 (s, 3 H), 3.62-3.77 (m, 0.6 H), 3.10-3.28 (m, 1

H), 2.92-3.05 (m, 0.4 H), 2.68-2.87 (m, 1 H), 2.34-2.48 (m, 3 H)

2215
(CD₃OD) δ 8.23-8.38 (m, 1 H), 7.70 (br s, 1 H), 6.92-7.02 (m, 2
413.1
100%

H), 6.82-6.91 (m, 1 H), 6.77 (dt, 1 H), 6.35-6.72 (m, 1 H), 4.44
[M + H]⁺

(br dd, 1 H), 4.10 (s, 3 H), 3.58-3.77 (m, 0.6 H), 3.11-3.30 (m, 1

H), 2.93-3.03 (m, 0.4 H), 2.67-2.87 (m, 1 H), 2.35-2.49 (m, 3 H)

2216
(CD₃OD) δ 8.46 (br s, 1 H), 7.70 (s, 2 H), 7.32 (d, 1 H), 6.59-
427.1
100%

6.92 (m, 3 H), 4.42-4.80 (m, 1 H), 3.75 (br s, 1 H), 2.96-3.22 (m,
[M + H]⁺

1 H), 2.84 (br d, 1 H), 1.66 (br s, 6 H)

2217
(CD₃OD) δ 8.46 (br s, 1 H), 7.59-8.02 (m, 2 H), 7.31 (br s, 1 H),
427.1
99.4%

6.61-6.93 (m, 3 H), 4.35-4.65 (m, 1 H), 3.75 (br s, 1 H), 3.14 (br
[M + H]⁺

s, 1 H), 2.82 (br s, 1 H), 1.64 (br s, 6 H)

2218
(CD₃OD) δ 8.44-8.54 (m, 1 H), 7.70 (s, 1 H), 7.48 (s, 0.3 H),
434.1
100%

7.16-7.25 (m, 1 H), 6.87-6.98 (m, 1.7 H), 6.66-6.81 (m, 1 H),
[M + H]⁺

4.91-5.05 (m, 1 H), 3.75 (ddd, 0.6 H), 3.36-3.45 (m, 0.4H),

2.81-3.20 (m, 2 H), 2.62-2.69 (m, 3 H)

2219
(CD₃OD) δ 8.28-8.42 (m, 1 H), 7.58 (s, 1 H), 7.36 (s, 0.3 H),
434.1
99.8%

6.98-7.14 (m, 1 H), 6.72-6.88 (m, 1.7 H), 6.58-6.68 (m, 1 H),
[M + H]⁺

4.87 (br dd, 1 H), 3.63 (ddd, 0.6 H), 3.27 (td, 0.4 H), 2.67-3.09

(m, 2 H), 2.48-2.57 (m, 3 H)

2220
(CD₃OD) δ 7.73 (d, 1 H), 7.66 (s, 1 H), 7.32-7.50 (m, 0.7 H),
408.1
99.5%

7.23-7.30 (m, 1 H), 7.16-7.22 (m, 1.3 H), 6.78-7.12 (m, 1 H),
[M + H]⁺

6.66 (s, 1 H), 6.37 (br s, 1 H), 4.33 (dd, 1 H), 3.70-3.89 (m, 1 H),

2.99-3.10 (m, 1 H), 2.76-2.88 (m, 1 H)

2221
(CD₃OD) δ 7.72 (d, 1 H), 7.66 (s, 1 H), 7.31-7.50 (m, 0.8 H),
408.2
98.7%

7.23-7.30 (m, 1 H), 7.18 (t, 1.2 H), 6.81-7.12 (m, 1 H), 6.66 (s, 1
[M + H]⁺

H), 6.38 (s, 1 H), 4.33 (dd, 1 H), 3.79 (ddd, 1 H), 2.97-3.11 (m, 1

H), 2.82 (dd, 1 H)

2222
(CD₃OD) δ 8.27-8.39 (m, 1 H), 7.65 (s, 1 H), 6.88-7.02 (m, 1.8
362.1
97.2%

H), 6.81 (td, 1 H), 6.53-6.69 (m, 1.2 H), 4.85 (br s, 0.3 H), 4.36
[M + H]⁺

(dd, 0.7 H), 3.70 (ddd, 0.8 H), 3.36-3.41 (m, 0.2 H), 3.10 (ddd,

0.8 H), 2.69-2.95 (m, 2.2 H), 2.01-2.11 (m, 1 H), 1.75-1.88 (m, 1 H)

2223
(CD₃OD) δ 8.23-8.44 (m, 1 H), 7.67 (d, 1 H), 6.71-7.01 (m, 2.5
362.1
90.7%

H), 6.33-6.67 (m, 1.5 H), 4.76 (dd, 0.5 H), 4.33 (dd, 0.5 H), 3.70
[M + H]⁺

(ddd, 0.5 H), 3.39-3.52 (m, 0.5 H), 2.95-3.22 (m, 1.5 H), 2.66-

2.88 (m, 1.5 H), 2.05-2.19 (m, 1 H), 1.76-1.93 (m, 1 H)

2224
(CD₃OD) δ 8.34 (br s, 1 H), 7.95-8.23 (m, 2 H), 7.34-7.74 (m, 2
358.2
100%

H), 6.49-6.80 (m, 4 H), 4.54 (br s, 1 H), 3.41-3.62 (m, 1 H),
[M + H]⁺

2.78-2.94 (m, 1 H), 2.67 (br dd, 1 H), 1.86-2.04 (m, 1 H), 0.89

(br d, 2 H), 0.63 (br d, 2 H)

2225
(CD₃OD) δ 8.33 (br s, 1 H), 7.96-8.22 (m, 2 H), 7.35-7.76 (m, 2
358.2
98.3%

H), 6.50-6.80 (m, 4 H), 4.55 (br s, 1 H), 3.42-3.61 (m, 1 H),
[M + H]⁺

2.81-2.96 (m, 1 H), 2.56-2.79 (m, 1 H), 1.82-2.03 (m, 1 H), 0.88

(br d, 2 H), 0.63 (br d, 2 H)

2226
(CD₃OD) δ 8.15 (d, 1 H), 7.55 (s, 1 H), 6.61-6.72 (m, 2 H), 6.55
402.2
99.7%

(s, 1 H), 6.13 (s, 1 H), 4.06 (dd, 1 H), 3.59 (ddd, 1 H), 2.84-2.97
[M + H]⁺

(m, 1 H), 2.68 (dd, 1 H), 1.91-2.02 (m, 1 H), 1.38 (s, 3H), 1.12-

1.18 (m, 2 H), 0.87-0.95 (m, 2 H), 0.78-0.85 (m, 2 H), 0.61-0.70

(m, 2 H)

2227
(CD₃OD) δ 8.16 (d, 1 H), 7.55 (s, 1 H), 6.62-6.73 (m, 2 H), 6.56
402.2
99.6%

(s, 1 H), 6.13 (br s, 1 H), 4.07 (dd, 1 H), 3.59 (ddd, 1 H), 2.84-
[M + H]⁺

2.96 (m, 1 H), 2.68 (br dd, 1 H), 1.92-2.03 (m, 1 H), 1.38 (s, 3

H), 1.12-1.19 (m, 2 H), 0.89-0.95 (m, 2 H), 0.80-0.85 (m, 2 H),

0.62-0.70 (m, 2 H)

2228
(CD₃OD) δ 8.18 (d, 1 H), 7.54 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1
404.3
99.8%

H), 6.47 (s, 1 H), 6.12 (br s, 1 H), 4.06 (dd, 1 H), 3.59 (ddd, 1
[M + H]⁺

H), 3.02-3.13 (m, 1 H), 2.83-2.97 (m, 1 H), 2.68 (dd, 1 H), 1.38

(s, 3 H), 1.22 (dd, 6 H), 1.12-1.17 (m, 2 H), 0.78-0.86 (m, 2 H)

2229
(CD₃OD) δ 8.18 (d, 1 H), 7.54 (s, 1 H), 6.94 (d, 1 H), 6.72 (t, 1
404.3
99.3%

H), 6.47 (s, 1 H), 6.12 (s, 1 H), 4.06 (dd, 1 H), 3.53-3.67 (m, 1
[M + H]⁺

H), 3.01-3.14 (m, 1 H), 2.83-2.96 (m, 1 H), 2.68 (dd, 1 H), 1.38

(s, 3 H), 1.22 (dd, 6 H), 1.12-1.18 (m, 2 H), 0.77-0.86 (m, 2 H)

2230
(CD₃OD) δ 8.31 (d, 1 H), 7.62-7.73 (m, 1 H), 7.07 (d, 1 H),
414.2
100%

6.81-6.90 (m, 1 H), 6.66 (s, 1 H), 6.38 (s, 1 H), 4.32 (dd, 1 H),
[M + H]⁺

3.79 (ddd, 1 H), 3.20 (dt, 1 H), 3.01-3.12 (m, 1 H), 2.84 (dd, 1

H), 2.12 (t, 3 H), 1.32-1.37 (m, 6 H)

2231
(CD₃OD) δ 8.31 (d, 1 H), 7.68 (s, 1 H), 7.07 (d, 1 H), 6.85 (t, 1
414.2
99.4%

H), 6.66 (s, 1 H), 6.32-6.44 (m, 1 H), 4.32 (dd, 1 H), 3.79 (ddd, 1
[M + H]⁺

H), 3.20 (dt, 1 H), 3.01-3.12 (m, 1 H), 2.84 (br dd, 1 H), 2.12 (t,

3 H), 1.35 (dd, 6 H)

2232
(CD₃OD) δ 8.33 (d, 1 H), 7.58 (s, 1 H), 7.18 (d, 1 H), 6.74 (t, 1
406.1
100%

H), 6.59 (s, 1 H), 6.27 (s, 1 H), 4.21 (dd, 1 H), 3.65 (ddd, 1 H),
[M + H]⁺

2.89-3.01 (m, 1 H), 2.72 (dd, 1 H), 2.00 (t, 3 H)

2233
(CD₃OD) δ 8.33 (d, 1 H), 7.57 (s, 1 H), 7.19 (d, 1 H), 6.74 (t, 1
406.1
99.9%

H), 6.59 (s, 1 H), 6.26 (br s, 1 H), 4.21 (dd, 1 H), 3.65 (ddd, 1
[M + H]⁺

H), 2.89-3.00 (m, 1 H), 2.72 (br dd, 1 H), 2.00 (t, 3 H)

2234
(CD₃OD) δ 8.54 (dd, 1 H), 8.24-8.43 (m, 2 H), 7.72 (s, 1 H),
441.2
100%

7.45 (dd, 1 H), 7.06 (d, 1 H), 6.84 (t, 1 H), 6.68 (s, 1 H), 6.46(s,
[M + H]⁺

1 H), 4.40 (dd, 1 H), 3.74-3.92 (m, 1 H), 3.03-3.28 (m, 2 H),

2.78-2.95 (m, 4 H), 1.34 (dd, 6 H)

2235
(CD₃OD) δ 8.54 (dd, 1 H), 8.24-8.41 (m, 2 H), 7.70 (s, 1 H),
441.2
99.8%

7.45 (dd, 1 H), 7.05 (d, 1 H), 6.83 (t, 1 H), 6.68 (s, 1 H), 6.46 (s,
[M + H]⁺

1 H), 4.40 (dd, 1 H), 3.71-3.91 (m, 1 H), 3.01-3.28 (m, 2 H),

2.88 (s, 4 H), 1.33 (dd, 6 H)

2236
(CD₃OD) δ 8.26-8.61 (m, 3 H), 7.70 (s, 1 H), 7.45 (dd, 1 H),
433.1
100%

7.29 (d, 1 H), 6.66-6.90 (m, 2 H), 6.46 (s, 1 H), 4.41 (dd, 1H),
[M + H]⁺

3.81 (br dd, 1 H), 3.02-3.20 (m, 1 H), 2.76-3.00 (m, 4H)

2237
(CD₃OD) δ 8.11-8.50 (m, 3 H), 7.58 (s, 1 H), 7.11-7.41 (m, 2 H),
433.2
99.6%

6.54-6.79 (m, 2 H), 6.34 (s, 1 H), 4.29 (dd, 1 H), 3.54-3.81 (m, 1
[M + H]⁺

H), 2.99 (br s, 1 H), 2.61-2.85 (m, 4 H)

2238
(CD₃OD) δ 8.42 (d, 1 H), 7.60 (s, 1 H), 7.51 (d, 1 H), 7.06-7.23
316.1
100%

(m, 5 H), 6.74-6.84 (m, 2 H), 6.35 (s, 1 H), 6.00 (s, 1 H), 3.84-
[M + H]⁺

3.92 (m, 1 H), 3.53-3.68 (m, 1 H), 2.87-2.98 (m, 1 H), 2.67 (br

dd, 1 H)

2239
(CD₃OD) δ 8.42 (d, 1 H), 7.85 (s, 1 H), 7.52 (d, 1 H), 7.06-7.25
316.1
99.4%

(m, 5 H), 6.74-6.87 (m, 2 H), 6.37 (s, 1 H), 6.04 (s, 1 H), 3.78-
[M + H]⁺

3.97 (m, 1 H), 3.50-3.69 (m, 1 H), 2.94 (ddd, 1 H), 2.69 (br dd, 1 H)

2240
(CD₃OD) δ 9.33-9.50 (m, 1 H), 8.70-8.89 (m, 2 H), 7.93-8.51
427.2
100%

(m, 2 H), 7.64-7.88 (m, 1 H), 6.59-7.13 (m, 4 H), 4.64 (br s, 1
[M + H]⁺

H), 3.46-3.93 (m, 1 H), 2.97-3.22 (m, 1 H), 2.89 (br d, 1 H), 2.48

(s, 3 H)

2241
(CD₃OD) δ 9.42 (s, 1 H), 8.72-8.86 (m, 2 H), 7.92-8.49 (m, 2 H),
427.2
100%

7.70 (br s, 1 H), 6.64-7.07 (m, 4 H), 4.79 (br s, 0.5 H), 4.56-4.63
[M + H]⁺

(m, 0.5 H), 3.43-3.93 (m, 1 H), 2.96-3.29 (m, 1 H), 2.77-2.93 (m,

1 H), 2.48 (s, 3 H)

2242
(CD₃OD) δ 9.42 (s, 1 H), 8.73-8.82 (m, 2 H), 8.51-8.72 (m, 1 H),
463.1
100%

7.92-8.33 (m, 1 H), 7.71 (br s, 1 H), 7.46 (br d, 1 H), 6.69-7.20
[M + H]⁺

(m, 4 H), 4.60-4.83 (m, 1 H), 3.42-3.93 (m, 1 H), 2.99-3.25 (m, 1

H), 2.89 (br s, 1 H)

2243
(CD₃OD) δ 9.42 (s, 1 H), 8.72-8.85 (m, 2 H), 8.54-8.71 (m, 1 H),
463.2
96.3%

7.91-8.30 (m, 1 H), 7.71 (br s, 1 H), 7.46 (br d, 1 H), 6.72-7.19
[M + H]⁺

(m, 4 H), 4.65-4.80 (m, 1 H), 3.44-3.92 (m, 1 H), 3.04 (br s, 1

H), 2.86 (br s, 1 H)

2244
(CD₃OD) δ 9.42 (s, 1 H), 8.78 (s, 3 H), 7.91-8.27 (m, 1 H), 7.59-
481.2
99.6%

7.79 (m, 2 H), 6.71-7.18 (m, 3 H), 4.65-4.80 (m, 1 H), 3.42-3.92
[M + H]⁺

(m, 1 H), 2.97-3.22 (m, 1 H), 2.88 (br s, 1 H)

2245
(CD₃OD) δ 9.42 (s, 1 H), 8.78 (s, 3 H), 7.93-8.30 (m, 1 H), 7.57-
481.2
95.9%

7.80 (m, 2 H), 6.72-7.17 (m, 3 H), 4.82 (br s, 1 H), 3.43-3.93 (m,
[M + H]⁺

1 H), 2.98-3.28 (m, 1 H), 2.88 (br s, 1 H)

2246
(CD₃OD) δ 8.44 (s, 1 H), 8.08 (d, 1 H), 7.95 (s, 1 H), 7.79 (dd, 1
415.2
100%

H), 7.15 (d, 1 H), 7.00 (s, 1 H), 6.78(t, 1 H), 6.45-6.66 (m, 2 H),
[M + H]⁺

4.70 (br dd, 1 H), 3.95 (s, 3 H), 3.55-3.67 (m, 1 H), 2.89-3.05

(m, 1 H), 2.65-2.84 (m, 1 H)

2247
(CD₃OD) δ 8.43 (s, 1 H), 8.08 (d, 1 H), 7.69-7.91 (m, 2 H), 7.14
415.2
96.9%

(d, 1 H), 6.96 (s, 1 H), 6.77 (t, 1 H), 6.57 (t, 2 H), 4.70 (br dd, 1
[M + H]⁺

H), 3.95 (s, 3 H), 3.52-3.69 (m, 1 H), 2.89-3.05 (m, 1 H), 2.65-

2.83 (m, 1 H)

2248
(CD₃OD) δ 8.49 (d, 1 H), 7.68 (s, 1 H), 7.14-7.27 (m, 1 H), 6.91
406.1
100%

(t, 1 H), 6.70 (s, 1 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.70 (ddd, 1
[M + H]⁺

H), 2.99-3.11 (m, 1 H), 2.80 (dd, 1 H), 2.44 (s, 3H)

2249
(CD₃OD) δ 8.49 (d, 1 H), 7.68 (s, 1 H), 7.21 (br d, 1 H), 6.91 (t,
406.1
96.1%

1 H), 6.70 (s, 1 H), 6.31 (br s, 1 H), 4.24 (dd, 1 H), 3.64-3.78 (m,
[M + H]⁺

1 H), 2.97-3.11 (m, 1 H), 2.80 (br dd, 1 H), 2.44 (s, 3 H)

2250
(CD₃OD) δ 8.37 (d, 1 H), 7.58 (s, 1 H), 7.09 (d, 1 H), 6.72-7.01
442.1
99.6%

(m, 2 H), 6.62 (s, 1 H), 6.28 (s, 1 H), 4.23 (dd, 1 H), 3.66 (ddd, 1
[M + H]⁺

H), 2.85-3.03 (m, 1 H), 2.73 (dd, 1 H)

2251
(CD₃OD) δ 8.37 (d, 1 H), 7.57 (s, 1 H), 7.09 (br d, 1 H), 6.73-
442.1
98.9%

7.00 (m, 2 H), 6.62 (s, 1 H), 6.28 (br s, 1 H), 4.23 (dd, 1 H),
[M + H]⁺

3.60-3.73 (m, 1 H), 2.88-3.02 (m, 1 H), 2.73 (br dd, 1 H)

2252
(CD₃OD) δ 8.38 (d, 1 H), 7.61 (s, 1 H), 7.10 (d, 1 H), 6.80(t, 1
460.1
99.6%

H), 6.63 (s, 1 H), 6.30 (s, 1 H), 4.25 (dd, 1 H), 3.67 (ddd, 1 H),
[M + H]⁺

2.91-3.03 (m, 1 H), 2.74 (dd, 1 H)

2253
(CD₃OD) δ 8.50 (d, 1 H), 7.71 (s, 1 H), 7.22 (d, 1 H), 6.93 (t, 1
460.1
96.9%

H), 6.75 (s, 1 H), 6.42 (s, 1 H), 4.37 (dd, 1 H), 3.80 (td, 1 H),
[M + H]⁺

3.03-3.14 (m, 1 H), 2.86 (dd, 1 H)

2254
(CD₃OD) δ 8.07-8.59 (m, 3 H), 7.65 (s, 1 H), 6.95-7.28 (m, 2 H),
384.2
99.5%

6.77-6.95 (m, 2 H), 6.55-6.72 (m, 2 H), 5.06 (dd, 1 H), 3.38-3.57
[M + H]⁺

(m, 1 H), 2.82-2.99 (m, 1 H), 2.70 (br dd, 1 H)

2255
(CD₃OD) δ 8.22-8.50 (m, 3 H), 7.65 (s, 1 H), 6.96-7.28 (m, 2 H),
384.2
98.7%

6.76-6.96 (m, 2 H), 6.58-6.71 (m, 2 H), 5.06 (dd, 1 H), 3.46
[M + H]⁺

(ddd, 1 H), 2.82-2.98 (m, 1 H), 2.70 (br dd, 1 H)

2256
(CD₃OD) δ 8.68 (s, 2 H), 8.33 (d, 1 H), 7.67 (s, 1 H), 6.96-7.32
452.1
99.2%

(m, 2 H), 6.79-6.96 (m, 2 H), 6.68 (s, 1 H), 5.20 (dd, 1 H), 3.53
[M + H]⁺

(td, 1 H), 2.64-3.05 (m, 2 H)

2257
(CD₃OD) δ 8.68 (s, 2 H), 8.33 (d, 1 H), 7.67 (s, 1 H), 6.98-7.30
452.1
98.2%

(m, 2 H), 6.78-6.97 (m, 2 H), 6.68 (s, 1 H), 5.20 (dd, 1 H), 3.40-
[M + H]⁺

3.64 (m, 1 H), 2.51-3.02 (m, 2 H)

2258
(CD₃OD) δ 8.33 (d, 1 H), 7.56 (s, 1 H), 7.18 (d, 1 H), 6.73 (t, 1
396.2
100%

H), 6.52 (s, 1 H), 6.12 (s, 1 H), 4.08 (dd, 1 H), 3.57 (ddd, 1 H),
[M + H]⁺

2.84-2.97 (m, 1 H), 2.68 (dd, 1 H), 1.38 (s, 3 H), 1.11-1.18 (m, 2

H), 0.78-0.86 (m, 2 H)

2259
(CD₃OD) δ 8.33 (d, 1 H), 7.55 (s, 1 H), 7.18 (d, 1 H), 6.73 (t, 1
396.2
99.4%

H), 6.52 (s, 1 H), 6.12 (s, 1 H), 4.08 (dd, 1 H), 3.57 (ddd, 1 H),
[M + H]⁺

2.84-2.95 (m, 1 H), 2.68 (dd, 1 H), 1.38 (s, 3 H), 1.10-1.17 (m, 2

H), 0.79-0.85 (m, 2 H)

2260
(CD₃OD) δ 9.16 (d, 1 H), 8.69 (dd, 1 H), 8.40 (br d, 1 H), 8.31
427.2
99.0%

(br d, 1 H), 7.70 (s, 1 H), 7.61 (dd, 1 H), 7.06 (br d, 1 H), 6.84 (t,
[M + H]⁺

1 H), 6.69 (s, 1 H), 6.42-6.53 (m, 1 H), 4.41 (dd, 1 H), 3.76-3.90

(m, 1 H), 3.04-3.25 (m, 2 H), 2.87 (br dd, 1 H), 1.33 (t, 6 H)

2261
(CD₃OD) δ 9.16 (d, 1 H), 8.64-8.74 (m, 1 H), 8.40 (br d, 1 H),
427.2
97.3%

8.31 (d, 1 H), 7.72 (s, 1 H), 7.61 (dd, 1 H), 7.06 (d, 1 H), 6.84(t,
[M + H]⁺

1 H), 6.69 (s, 1 H), 6.49 (s, 1 H), 4.42 (dd, 1 H), 3.74-3.91 (m, 1

H), 3.01-3.25 (m, 2 H), 2.87 (br dd, 1 H), 1.33 (t, 6 H)

2262
(CD₃OD) δ 9.15 (s, 1 H), 8.69 (br d, 1 H), 8.45 (br d, 1 H), 8.39
419.1
100%

(br dd, 1 H), 7.71 (s, 1 H), 7.56-7.64 (m, 1 H), 7.29 (dd, 1 H),
[M + H]⁺

6.79-6.88 (m, 1 H), 6.73 (s, 1 H), 6.49 (s, 1 H), 4.43 (dd, 1 H),

3.81 (ddd, 1 H), 3.05-3.18 (m, 1 H), 2.87 (dd, 1 H)

2263
(CD₃OD) δ 9.15 (d, 1 H), 8.69 (dd, 1 H), 8.45 (d, 1 H), 8.39 (dt,
419.1
99.7%

1 H), 7.70 (s, 1 H), 7.61 (dd, 1 H), 7.30 (d, 1 H), 6.85(t, 1H),
[M + H]⁺

6.73 (s, 1 H), 6.49 (s, 1 H), 4.43 (dd, 1 H), 3.74-3.86 (m, 1 H),

3.05-3.18 (m, 1 H), 2.87 (dd, 1 H)

2264
(CD₃OD) δ 8.48-8.57 (m, 1 H), 8.28 (s, 2 H), 7.73 (s, 1 H), 7.43-
417.2
100%

7.56 (m, 1 H), 7.00 (d, 1 H), 6.79 (t, 1 H), 6.62 (s, 1 H), 6.47(s,
[M + H]⁺

1 H), 4.40 (dd, 1 H), 3.66-3.95 (m, 1 H), 3.01-3.20 (m, 1 H),

2.79-2.95 (m, 1 H), 2.45 (s, 3 H)

2265
(CD₃OD) δ 8.45-8.61 (m, 1 H), 8.24-8.41 (m, 2 H), 7.75 (br s, 1
417.2
99.3%

H), 7.44-7.56 (m, 1 H), 6.99 (d, 1 H), 6.79 (t, 1 H), 6.62 (s, 1H),
[M + H]⁺

6.47 (s, 1 H), 4.40 (dd, 1 H), 3.70-3.90 (m, 1 H), 3.04-3.22 (m, 1

H), 2.87 (br dd, 1 H), 2.44 (s, 3 H)

2266
(CD₃OD) δ 8.51 (br d, 1 H), 8.41 (d, 1 H), 7.82 (br d, 1 H), 7.67
399.2
99.7%

(s, 1 H), 7.55 (d, 1 H), 7.42 (dd, 1 H), 7.15 (t, 1 H), 6.76-6.87
[M + H]⁺

(m, 1 H), 6.62 (s, 1 H), 6.54 (s, 1 H), 4.44 (dd, 1 H), 3.77 (ddd, 1

H), 3.01-3.15 (m, 1 H), 2.82 (dd, 1 H), 2.68 (s, 3 H)

2267
(CD₃OD) δ 8.52 (br d, 1 H), 8.42 (br d, 1 H), 7.83 (br d, 1 H),
399.2
99.0%

7.67 (s, 1 H), 7.56 (br d, 1 H), 7.43 (dd, 1 H), 7.16 (br t, 1 H),
[M + H]⁺

6.78-6.88 (m, 1 H), 6.63 (s, 1 H), 6.54 (s, 1 H), 4.44 (dd, 1 H),

3.78 (ddd, 1 H), 3.02-3.15 (m, 1 H), 2.78-2.85 (m, 1 H), 2.68 (s,

3 H)

2268
(CD₃OD) δ 8.54 (d, 1 H), 8.29 (d, 1 H), 7.86 (d, 1 H), 7.67 (s, 1
413.2
99.9%

H), 7.45 (dd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.53-6.67 (m, 2
[M + H]⁺

H), 4.45 (dd, 1 H), 3.79 (ddd, 1 H), 3.04-3.15 (m, 1 H), 2.83 (br

dd, 1 H), 2.70 (s, 3 H), 2.43 (s, 3 H)

2269
(CD₃OD) δ 8.53 (d, 1 H), 8.29 (d, 1 H), 7.85 (d, 1 H), 7.67 (s, 1
413.2
98.8%

H), 7.45 (dd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.65(s, 1H), 6.55
[M + H]⁺

(br s, 1 H), 4.45 (dd, 1 H), 3.74-3.84 (m, 1 H), 3.02-3.16 (m, 1

H), 2.83 (br dd, 1 H), 2.70 (s, 3 H), 2.43 (s, 3 H)

2270
(CD₃OD) δ 8.44-8.47 (m, 1 H), 8.41 (d, 2 H), 7.65 (s, 1 H), 7.13-
402.2
99.6%

7.22 (m, 2 H), 6.86 (t, 1 H), 6.61-6.70 (m, 2 H), 5.07 (dd, 1 H),
[M + H]⁺

3.39-3.51 (m, 1 H), 2.85-2.96 (m, 1 H), 2.71 (dd, 1 H)

2271
(CD₃OD) δ 8.46 (d, 1 H), 8.41 (d, 2 H), 7.65 (s, 1 H), 7.15-7.21
402.1
98.9%

(m, 2 H), 6.87 (t, 1 H), 6.64-6.69 (m, 2 H), 5.07 (dd, 1 H), 3.41-
[M + H]⁺

3.51 (m, 1 H), 2.85-2.97 (m, 1 H), 2.71 (dd, 1 H)

2272
(CD₃OD) δ 8.28-8.49 (m, 2 H), 7.77 (dd, 1 H), 7.65 (s, 1 H),
415.2
99.1%

6.98-7.23 (m, 2 H), 6.73-6.98 (m, 3 H), 6.64 (s, 1 H), 4.73 (br
[M + H]⁺

dd, 1 H), 3.52-3.72 (m, 1 H), 2.88-3.04 (m, 1 H), 2.74 (br dd, 1 H)

2273
(CD₃OD) δ 8.22-8.53 (m, 2 H), 7.77 (dd, 1 H), 7.65 (s, 1 H),
415.2
92.9%

7.00-7.25 (m, 2 H), 6.79-6.97 (m, 3 H), 6.64 (s, 1 H), 4.73 (br
[M + H]⁺

dd, 1 H), 3.61 (ddd, 1 H), 2.87-3.03 (m, 1 H), 2.74 (dd, 1 H)

2274
(CD₃OD) δ 8.49-8.57 (m, 1 H), 8.37 (d, 1 H), 7.68 (s, 1 H), 7.45-
417.2
100%

7.54 (m, 2 H), 7.12 (dd, 1 H), 6.72 (d, 1 H), 6.43-6.59 (m, 2 H),
[M + H]⁺

4.40 (dd, 1 H), 3.78-3.94 (m, 1 H), 3.05-3.16 (m, 1 H), 2.87 (br

dd, 1 H), 2.64 (s, 3 H)

2275
(CD₃OD) δ 8.52 (ddd, 1 H), 8.37 (d, 1 H), 7.68 (s, 1 H), 7.42-
417.2
98.4%

7.54 (m, 2 H), 7.12 (dd, 1 H), 6.72 (d, 1 H), 6.43-6.59 (m, 2 H),
[M + H]⁺

4.40 (dd, 1 H), 3.87 (ddd, 1 H), 3.03-3.19 (m, 1 H), 2.86 (br dd,

1 H), 2.64 (s, 3 H)

2276
(CD₃OD) δ 8.68 (d, 1 H), 8.51-8.55 (m, 1 H), 7.85 (d, 1 H), 7.69
467.2
100%

(s, 1 H), 7.60 (d, 1 H), 7.45 (dd, 1 H), 6.96 (t, 1 H), 6.84 (s, 1H),
[M + H]⁺

6.58 (s, 1 H), 4.49 (dd, 1 H), 3.80 (ddd, 1 H), 3.04-3.16 (m, 1 H),

2.84 (dd, 1 H), 2.70 (s, 3 H)

2277
(CD₃OD) δ 8.68 (d, 1 H), 8.53 (d, 1 H), 7.85 (d, 1 H), 7.68 (s, 1
467.2
98.7%

H), 7.61 (d, 1 H), 7.45 (dd, 1 H), 6.96 (t, 1 H), 6.84(s, 1H), 6.58
[M + H]⁺

(s, 1 H), 4.49 (dd, 1 H), 3.74-3.85 (m, 1 H), 3.05-3.16 (m, 1 H),

2.84 (br dd, 1 H), 2.70 (s, 3 H)

2278
(CD₃OD) δ 8.51-8.62 (m, 2 H), 7.86 (d, 1 H), 7.68 (s, 1 H), 7.39-
449.2
98.6%

7.49 (m, 2 H), 6.81-7.12 (m, 3 H), 6.58 (br s, 1 H), 4.47 (dd, 1
[M + H]⁺

H), 3.78 (ddd, 1 H), 3.04-3.15 (m, 1 H), 2.84 (br dd, 1 H), 2.70

(s, 3 H)

2279
(CD₃OD) δ 8.50-8.63 (m, 2 H), 7.86 (d, 1 H), 7.68 (s, 1 H), 7.39-
449.2
96.9%

7.49 (m, 2 H), 6.79-7.15 (m, 3 H), 6.58 (s, 1 H), 4.47 (dd, 1 H),
[M + H]⁺

3.78 (ddd, 1 H), 3.05-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.70 (s, 3 H)

2280
(CD₃OD) δ 8.54 (dd, 1 H), 8.34 (d, 1 H), 7.86 (d, 1 H), 7.70 (s, 1
471.2
98.2%

H), 7.46 (dd, 1 H), 6.95 (dd, 1 H), 6.76-6.88 (m, 2 H), 6.56 (s, 1
[M + H]⁺

H), 4.48 (dd, 1 H), 3.75-3.85 (m, 1 H), 3.05-3.15 (m, 1 H), 2.84

(br dd, 1 H), 2.71 (s, 3 H)

2281
(CD₃OD) δ 8.53 (d, 1 H), 8.33 (d, 1 H), 7.86 (d, 1 H), 7.70 (s, 1
417.2
99.6%

H), 7.45 (dd, 1 H), 6.95 (dd, 1 H), 6.76-6.85 (m, 2 H), 6.56 (s, 1
[M + H]⁺

H), 4.47 (dd, 1 H), 3.75-3.85 (m, 1 H), 3.05-3.16 (m, 1 H), 2.84

(dd, 1 H), 2.70 (s, 3 H)

2282
(CD₃OD) δ 8.53 (d, 1 H), 8.26 (d, 1 H), 7.85 (d, 1 H), 7.68(s, 1
439.2
100%

H), 7.44 (dd, 1 H), 6.71-6.84 (m, 3 H), 6.56 (s, 1 H), 4.46 (dd, 1
[M + H]⁺

H), 3.73-3.87 (m, 1 H), 3.03-3.18 (m, 1 H), 2.83 (dd, 1 H), 2.70

(s, 3 H), 2.03-2.13 (m, 1 H), 0.96-1.05 (m, 2 H), 0.71-0.80 (m, 2 H)

2283
(CD₃OD) δ 8.54 (d, 1 H), 8.26 (d, 1 H), 7.85 (d, 1 H), 7.76 (s, 1
439.2
92.5%

H), 7.45 (dd, 1 H), 6.72-6.85 (m, 3 H), 6.58 (s, 1 H), 4.46 (dd, 1
[M + H]⁺

H), 3.80 (ddd, 1 H), 3.00-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.70 (s, 3

H), 2.04-2.14 (m, 1 H), 0.97-1.06 (m, 2 H), 0.72-0.80 (m, 2 H)

2284
(CD₃OD) δ 8.53 (br d, 1 H), 8.23-8.31 (m, 1 H), 7.64-7.88 (m, 2
441.2
100%

H), 7.36-7.49 (m, 1 H), 6.98-7.07 (m, 1 H), 6.72-6.84 (m, 2 H),
[M + H]⁺

6.55 (s, 1 H), 4.45 (br dd, 1 H), 3.80 (td, 1 H), 3.04-3.22 (m, 2

H), 2.83 (br dd, 1 H), 2.63-2.72 (m, 3 H), 1.23-1.36 (m, 6 H)

2285
(CD₃OD) δ 8.53 (d, 1 H), 8.28 (d, 1 H), 7.84 (d, 1 H), 7.67 (s, 1
441.2
98.4%

H), 7.44 (dd, 1 H), 7.02 (d, 1 H), 6.73-6.83 (m, 2 H), 6.55(s, 1
[M + H]⁺

H), 4.45 (dd, 1 H), 3.80 (ddd, 1 H), 3.04-3.22 (m, 2 H), 2.83 (dd,

1 H), 2.69 (s, 3 H), 1.31 (t, 6 H)

2286

¹H (METHANOL-d₄) δ 8.52 (d, 1 H), 8.42 (d, 1 H), 7.84 (br d, 1
433.1
100%

H), 7.68 (s, 1 H), 7.43 (dd, 1 H), 7.26 (d, 1 H), 6.74-6.85 (m, 2
[M + H]⁺

H), 6.55 (s, 1 H), 4.47 (dd, 1 H), 3.79 (ddd, 1 H), 3.04-3.14 (m, 1

H), 2.83 (dd, 1 H), 2.69 (s, 3 H)

2287
(CD₃OD) δ 8.51 (br d, 1 H), 8.40 (d, 1 H), 7.82 (br d, 1 H), 7.68
433.1
99.1%

(s, 1 H), 7.42 (dd, 1 H), 7.24 (d, 1 H), 6.74-6.83 (m, 2 H), 6.55
[M + H]⁺

(s, 1 H), 4.47 (br dd, 1 H), 3.73-3.84 (m, 1 H), 3.01-3.15 (m, 1

H), 2.63-2.73 (m, 1 H), 2.68 (s, 3 H)

2288
(CD₃OD) δ 8.54-8.60 (m, 1 H), 8.31-8.37 (m, 1 H), 7.86 (ddd, 1
421.1
100%

H), 7.68-7.71 (m, 1 H), 7.63 (dt, 1 H), 6.96 (dd, 1 H), 6.80-6.86
[M + H]⁺

(m, 1 H), 6.78-6.80 (m, 1 H), 6.54 (s, 1 H), 4.47 (dd, 1 H), 3.78-

3.86 (m, 1 H), 3.06-3.16 (m, 1 H), 2.86 (br dd, 1 H)

2289
(CD₃OD) δ 8.57 (d, 1 H), 8.30-8.39 (m, 1 H), 7.80-7.92 (m, 1
421.1
99.0%

H), 7.72 (s, 1 H), 7.64 (dt, 1 H), 6.96 (dd, 1 H), 6.81-6.86 (m, 1
[M + H]⁺

H), 6.78-6.80 (m, 1 H), 6.54 (s, 1 H), 4.47 (dd, 1 H), 3.77-3.88

(m, 1 H), 3.06-3.17 (m, 1 H), 2.86 (dd, 1 H)

2290
(CD₃OD) δ 8.10-8.24 (m, 1 H), 7.60 (s, 1 H), 7.40 (s, 0.3 H),
430.2
100%

6.81-6.96 (m, 1.7 H), 6.61-6.71 (m, 2 H), 6.42-6.58 (m, 1 H),
[M + H]⁺

4.89 (br dd, 1 H), 3.62-3.73 (m, 0.7 H), 3.31 (td, 0.3 H), 2.84-

3.14 (m, 1 H), 2.73 (br dd, 1 H), 2.25-2.38 (m, 6 H)

2291
(CD₃OD) δ 8.10-8.24 (m, 1 H), 7.61 (s, 1 H), 7.41 (s, 0.3 H),
430.2
98.8%

6.82-6.92 (m, 1.7 H), 6.60-6.72 (m, 2 H), 6.44-6.57 (m, 1 H),
[M + H]⁺

4.89 (br dd, 1 H), 3.62-3.72 (m, 0.7 H), 3.31 (td, 0.3 H), 2.84-

3.15 (m, 1 H), 2.69-2.78 (m, 1 H), 2.26-2.37 (m, 6 H)

2292
(CD₃OD) δ 8.11-8.25 (m, 1 H), 7.64 (d, 1 H), 7.57 (s, 1 H), 7.33-
430.2
100%

7.43 (m, 0.3 H), 6.83-6.93 (m, 1.7 H), 6.62-6.72 (m, 1 H), 6.47-
[M + H]⁺

6.58 (m, 1 H), 4.82-4.95 (m, 1H), 3.60-3.79 (m, 0.7 H), 3.27-

3.39 (m, 0.3 H), 3.04-3.15 (m, 0.7 H), 2.86-2.96 (m, 0.3 H),

2.68-2.80 (m, 1 H), 2.28-2.37 (m, 6 H)

2293
(CD₃OD) δ 8.12-8.24 (m, 1 H), 7.59 (d, 2 H), 7.38 (s, 0.3 H),
430.2
96.9%

6.83-6.93 (m, 1.7 H), 6.62-6.72 (m, 1 H), 6.45 (s, 1 H), 4.82-4.94
[M + H]⁺

(m, 1 H), 3.62-3.75 (m, 0.7 H), 3.27-3.39 (m, 0.3 H), 3.03-3.14

(m, 0.7 H), 2.84-2.97 (m, 0.3 H), 2.68-2.77 (m, 1 H), 2.27-2.40

(m, 6 H)

2294
(CD₃OD) δ 8.13-8.27 (m, 1 H), 7.60 (s, 1 H), 7.41 (s, 0.3 H),
434.1
99.2%

6.79-6.93 (m, 1.7 H), 6.59-6.78 (m, 3 H), 4.83-4.97 (m, 1 H),
[M + H]⁺

3.61-3.73 (m, 0.7 H), 3.29 (td, 0.3 H), 2.82-3.13 (m, 1 H), 2.74

(br dd, 1 H), 2.29 (s, 3 H)

2295
(CD₃OD) δ 8.15-8.28 (m, 1 H), 7.63 (s, 1 H), 7.42 (s, 0.3 H),
434.2
96.8%

6.79-6.90 (m, 1.7 H), 6.59-6.77 (m, 3 H), 4.92 (br dd, 1 H), 3.60-
[M + H]⁺

3.72 (m, 0.7 H), 3.29 (td, 0.3 H), 2.83-3.15 (m, 1 H), 2.68-2.79

(m, 1 H), 2.29 (s, 3 H)

2296
(CD₃OD) δ 8.15-8.30 (m, 1 H), 7.54-7.65 (m, 2 H), 7.36 (s, 0.3
434.2
100%

H), 6.80-6.92 (m, 1.7 H), 6.61-6.78 (m, 2 H), 4.83-4.96 (m, 1 H),
[M + H]⁺

3.61-3.75 (m, 0.7 H), 3.30 (td, 0.3 H), 3.02-3.15 (m, 0.7 H),

2.86-2.95 (m, 0.3 H), 2.69 (d, 1 H), 2.28-2.34 (m, 3 H)

2297
(CD₃OD) δ 8.17-8.28 (m, 1 H), 7.53-7.67 (m, 2 H), 7.40 (s, 0.3
434.2
98.2%

H), 6.80-6.91 (m, 1.7 H), 6.61-6.77 (m, 2 H), 4.84-4.96 (m, 1 H),
[M + H]⁺

3.68 (ddd, 0.7 H), 3.30 (td, 0.3 H), 3.02-3.14 (m, 0.7 H), 2.84-

2.96 (m, 0.3 H), 2.68-2.80 (m, 1 H), 2.26-2.37 (m, 3 H)

2298
(CD₃OD) δ 8.39 (d, 2 H), 8.04 (d, 1 H), 7.61 (s, 1 H), 7.15 (s, 1
348.1
99.8%

H), 6.73 (t, 1 H), 6.63 (t, 1 H), 6.46-6.57 (m, 2 H), 5.01 (dd, 1
[M + H]⁺

H), 3.93 (s, 3 H), 3.36-3.49 (m, 1 H), 2.78-2.95 (m, 1 H), 2.68

(dd, 1 H)

2299
(CD₃OD) δ 8.40 (d, 2 H), 8.05 (d, 1 H), 7.63 (s, 1 H), 7.17 (s, 1
348.1
98.7%

H), 6.75 (t, 1 H), 6.64 (t, 1 H), 6.51-6.58 (m, 2 H), 5.03 (dd, 1
[M + H]⁺

H), 3.94 (s, 3 H), 3.37-3.49 (m, 1 H), 2.83-2.95 (m, 1 H), 2.69

(dd, 1 H)

2300
(CD₃OD) δ 8.43 (d, 1 H), 7.65 (s, 1 H), 7.57 (d, 1 H), 7.12-7.22
350.2
99.9%

(m, 1 H), 6.85 (td, 1 H), 6.52 (s, 1 H), 6.27 (s, 1 H), 4.20 (dd, 1
[M + H]⁺

H), 3.68 (ddd, 1 H), 2.94-3.15 (m, 2 H), 2.78 (dd, 1 H), 1.35 (d,

6 H)

2301
(CD₃OD) δ 8.43 (d, 1 H), 7.65 (s, 1 H), 7.57 (d, 1 H), 7.14-7.25
350.2
99.6%

(m, 1 H), 6.85 (td, 1 H), 6.52 (s, 1 H), 6.27 (s, 1 H), 4.20(dd, 1
[M + H]⁺

H), 3.68 (ddd, 1 H), 2.95-3.19 (m, 2 H), 2.78 (dd, 1 H), 1.35 (d,

6 H)

2302
(CD₃OD) δ 8.28 (d, 1 H), 7.66 (s, 1 H), 6.97 (d, 1 H), 6.77 (t, 1
364.2
98.6%

H), 6.52 (s, 1 H), 6.28 (s, 1 H), 4.20 (dd, 1 H), 3.69 (ddd, 1 H),
[M + H]⁺

2.94-3.19 (m, 2 H), 2.78 (dd, 1 H), 2.42 (s, 3 H), 1.35 (dd, 6 H)

2303
(CD₃OD) δ 8.28 (d, 1 H), 7.65 (s, 1 H), 6.98 (d, 1 H), 6.77 (t, 1
364.2
99.6%

H), 6.52 (s, 1 H), 6.27 (br s, 1 H), 4.20 (dd, 1 H), 3.69 (ddd, 1
[M + H]⁺

H), 2.95-3.18 (m, 2 H), 2.79 (br dd, 1 H), 2.43 (s, 3 H), 1.35 (dd,

6 H)

2304
(CD₃OD) δ 8.70 (d, 1 H), 7.70 (s, 1 H), 7.64 (d, 1 H), 7.00(t, 1
418.2
99.9%

H), 6.73 (s, 1 H), 6.33 (s, 1 H), 4.26 (dd, 1 H), 3.72 (ddd, 1 H),
[M + H]⁺

2.98-3.19 (m, 2 H), 2.82 (dd, 1 H), 1.37 (d, 6 H)

2305
(CD₃OD) δ 8.67 (d, 1 H), 7.66 (s, 1 H), 7.62 (d, 1 H), 6.98 (t, 1
418.2
98.9%

H), 6.71 (s, 1 H), 6.31 (s, 1 H), 4.24 (dd, 1 H), 3.64-3.77 (m, 1
[M + H]⁺

H), 2.95-3.17 (m, 2 H), 2.80 (dd, 1 H), 1.35 (d, 6 H)

2306
(CD₃OD) δ 8.51 (br d, 1 H), 7.83 (br d, 1 H), 7.67 (s, 1 H), 7.57
433.2
100%

(br d, 1 H), 7.42 (dd, 1 H), 7.14 (dd, 1 H), 6.99 (br d, 1 H), 6.76
[M + H]⁺

(s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.79-3.95 (m, 1 H), 3.03-

3.17 (m, 1 H), 2.83 (dd, 1 H), 2.68 (s, 3 H)

2307
(CD₃OD) δ 8.51 (br d, 1 H), 7.83 (br d, 1 H), 7.66 (s, 1 H), 7.57
433.2
99.4%

(dd, 1 H), 7.42 (td, 1 H), 7.10-7.17 (m, 1 H), 6.99 (dd, 1 H), 6.76
[M + H]⁺

(s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H), 3.79-3.92 (m, 1 H), 3.02-

3.14 (m, 1 H), 2.83 (dd, 1 H), 2.68 (s, 3 H)

2308
(CD₃OD) δ 8.47-8.54 (m, 1 H), 7.77-7.88 (m, 1 H), 7.66 (s, 1 H),
413.2
100%

7.37-7.49 (m, 2 H), 7.01-7.14 (m, 1 H), 6.52-6.71 (m, 3 H), 4.45
[M + H]⁺

(br dd, 1 H), 3.79-3.93 (m, 1 H), 2.99-3.16 (m, 1 H), 2.83 (br dd,

1 H), 2.56-2.72 (m, 6 H)

2309
(CD₃OD) δ 8.52 (d, 1 H), 7.84 (br d, 1 H), 7.66 (s, 1 H), 7.39-
413.2
99.4%

7.48 (m, 2 H), 7.09 (dd, 1 H), 6.68 (br d, 1 H), 6.53-6.61 (m, 2
[M + H]⁺

H), 4.45 (dd, 1 H), 3.85 (ddd, 1 H), 3.03-3.15 (m, 1 H), 2.83 (dd,

1 H), 2.58-2.71 (m, 6 H)

2310
(CD₃OD) δ 8.27 (d, 1 H), 7.58 (s, 1 H), 7.15-7.23 (m, 2 H), 7.09
330.2
99.5%

(d, 2 H), 6.93 (d, 1 H), 6.69-6.80 (m, 2 H), 6.34 (s, 1 H), 5.99(s,
[M + H]⁺

1 H), 3.88 (br dd, 1 H), 3.60-3.70 (m, 1 H), 2.87-2.98 (m, 1 H),

2.66 (br dd, 1 H), 2.38 (s, 3 H)

2311
(CD₃OD) δ 8.28 (d, 1 H), 7.60 (s, 1 H), 7.17-7.24 (m, 2 H), 7.09
330.2
99.1%

(d, 2 H), 6.94 (d, 1 H), 6.75 (dt, 2 H), 6.35 (s, 1 H), 6.00(s, 1H),
[M + H]⁺

3.89 (br dd, 1 H), 3.60-3.71 (m, 1 H), 2.86-2.99 (m, 1 H), 2.67

(br dd, 1 H), 2.39 (s, 3 H)

2312
(CD₃OD) δ 8.31 (d, 1 H), 7.60 (s, 1 H), 7.17-7.24 (m, 2 H), 7.09
334.2
100%

(d, 2 H), 6.91 (dd, 1 H), 6.74-6.81 (m, 2 H), 6.47 (s, 1 H), 6.02
[M + H]⁺

(s, 1 H), 3.89 (br dd, 1 H), 3.59-3.69 (m, 1 H), 2.93 (tt, 1 H),

2.68 (br dd, 1 H)

2313
(CD₃OD) δ 8.31 (d, 1 H), 7.61 (s, 1 H), 7.17-7.24 (m, 2 H), 7.09
334.2
99.7%

(d, 2 H), 6.91 (dd, 1 H), 6.74-6.82 (m, 2 H), 6.47 (s, 1 H), 6.02
[M + H]⁺

(s, 1 H), 3.89 (br dd, 1 H), 3.59-3.68 (m, 1 H), 2.93 (ddd, 1 H),

2.68 (br dd, 1 H)

2314
(CD₃OD) δ 8.37 (d, 1 H), 7.55 (s, 1 H), 7.09 (br d, 1 H), 6.79 (t,
432.2
100%

1 H), 6.56 (s, 1 H), 6.15 (br s, 1 H), 4.09 (dd, 1 H), 3.51-3.63 (m,
[M + H]⁺

1 H), 2.85-2.96 (m, 1 H), 2.68 (br dd, 1 H), 1.92-2.02 (m, 1 H),

0.89-1.07 (m, 4 H)

2315
(CD₃OD) δ 8.37 (d, 1 H), 7.56 (s, 1 H), 7.09 (d, 1 H), 6.79 (t, 1
432.2
97.1%

H), 6.56 (s, 1 H), 6.15 (s, 1 H), 4.06-4.13 (m, 1 H), 3.57 (ddd, 1
[M + H]⁺

H), 2.85-2.97 (m, 1 H), 2.63-2.73 (m, 1 H), 1.93-1.99 (m, 1 H),

0.91-1.03 (m, 4 H)

2316
(CD₃OD) δ 8.56 (s, 2 H), 8.30-8.38 (m, 1 H), 7.56 (s, 1 H), 7.13
470.1
99.9%

(s, 1 H), 7.03-7.09 (m, 1 H), 6.76 (t, 1 H), 6.59 (s, 1 H), 5.09 (dd,
[M + H]⁺

1 H), 3.35-3.48 (m, 1 H), 2.74-2.87 (m, 1 H), 2.65 (dd, 1 H)

2317
(CD₃OD) δ 8.56 (s, 2 H), 8.34 (d, 1 H), 7.55 (s, 1 H), 7.13 (s, 1
470.1
96.0%

H), 7.06 (br d, 1 H), 6.76 (t, 1 H), 6.59 (s, 1 H), 5.09 (dd, 1H),
[M + H]⁺

3.42 (td, 1 H), 2.76-2.86 (m, 1 H), 2.62-2.68 (m, 1 H)

2318
(CD₃OD) δ 8.34 (s, 1 H), 8.23 (br d, 1 H), 7.97-8.12 (m, 1 H),
384.1
99.8%

7.69 (d, 1 H), 7.57 (br s, 1 H), 6.78-7.14 (m, 2 H), 6.68-6.75 (m,
[M + H]⁺

2 H), 6.52 (s, 1 H), 4.59 (br dd, 1 H), 3.42-3.56 (m, 1 H), 2.78-

2.92 (m, 1 H), 2.67 (br s, 1 H)

2319
(CD₃OD) δ 8.34 (d, 1 H), 8.23 (d, 1 H), 8.05 (dd, 1 H), 7.68 (d, 1
384.1
96.2%

H), 7.53 (s, 1 H), 6.79-7.18 (m, 2 H), 6.66-6.76 (m, 2 H), 6.51 (s,
[M + H]⁺

1 H), 4.59 (br dd, 1 H), 3.49 (br dd, 1 H), 2.86 (br s, 1 H), 2.67

(br d, 1 H)

2320
(CD₃OD) δ 8.57 (br d, 1 H), 7.66 (s, 1 H), 7.42 (br d, 1 H), 6.80-
400.2
99.9%

7.14 (m, 2 H), 6.70 (s, 1 H), 6.30 (br s, 1 H), 4.22 (dd, 1 H),
[M + H]⁺

3.61-3.78 (m, 1 H), 2.91-3.18 (m, 2 H), 2.80 (br dd, 1 H), 1.35

(d, 6 H)

2321
(CD₃OD) δ 8.57 (d, 1 H), 7.66 (s, 1 H), 7.42 (br d, 1 H), 6.80-
400.2
99.0%

7.14 (m, 2 H), 6.70 (s, 1 H), 6.30 (s, 1 H), 4.22 (dd, 1 H), 3.69
[M + H]⁺

(ddd, 1 H), 2.97-3.18 (m, 2 H), 2.80 (dd, 1 H), 1.35 (dd, 6 H)

2322
(CD₃OD) δ 8.32 (d, 1 H), 7.66 (s, 1 H), 6.73-7.04 (m, 2 H), 6.66
368.2
99.9%

(s, 1 H), 6.29 (s, 1 H), 4.22 (dd, 1 H), 3.61-3.79 (m, 1 H), 2.94-
[M + H]⁺

3.17 (m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)

2323
(CD₃OD) δ 8.32 (d, 1 H), 7.66 (s, 1 H), 6.77-7.01 (m, 2 H), 6.66
368.2
99.3%

(s, 1 H), 6.29 (s, 1 H), 4.22 (dd, 1 H), 3.70 (td, 1 H), 2.94-3.18
[M + H]⁺

(m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)

2324
(CD₃OD) δ 8.43 (d, 1 H), 7.66 (s, 1 H), 7.29 (d, 1 H), 6.84 (t, 1
384.2
100%

H), 6.65 (s, 1 H), 6.28 (br s, 1 H), 4.22 (dd, 1 H), 3.56-3.80 (m, 1
[M + H]⁺

H), 2.93-3.17 (m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)

2325
(CD₃OD) δ 8.43 (d, 1 H), 7.66 (s, 1 H), 7.29 (d, 1 H), 6.84 (t, 1
384.2
99.2%

H), 6.65 (s, 1 H), 6.28 (br s, 1 H), 4.22 (dd, 1 H), 3.69 (ddd, 1
[M + H]⁺

H), 2.92-3.20 (m, 2 H), 2.79 (br dd, 1 H), 1.35 (d, 6 H)

2326
(CD₃OD) δ 7.68 (s, 1 H), 7.58-7.65 (m, 1 H), 7.20 (dd, 1 H),
406.1
100%

7.06 (d, 1 H), 6.71 (s, 1 H), 6.40 (br s, 1 H), 4.29-4.40 (m, 1 H),
[M + H]⁺

3.76-3.90 (m, 1 H), 2.99-3.15 (m, 1 H), 2.85 (dd, 1 H), 2.12 (t, 3 H)

2327
(CD₃OD) δ 7.56 (s, 1 H), 7.49 (dd, 1 H), 7.07 (dd, 1 H), 6.93
406.1
99.4%

(dd, 1 H), 6.58 (s, 1 H), 6.28 (s, 1 H), 4.20 (br d, 1 H), 3.70 (br s,
[M + H]⁺

1 H), 2.88-3.01 (m, 1 H), 2.73 (dd, 1 H), 2.00 (t, 3 H)

2328
(CD₃OD) δ 7.68 (s, 1 H), 7.48 (d, 1 H), 7.13 (dd, 1 H), 6.73 (d, 1
386.2
100%

H), 6.51 (s, 1 H), 6.38 (br s, 1 H), 4.22-4.40 (m, 1 H), 3.71-3.87
[M + H]⁺

(m, 1 H), 2.96-3.13 (m, 1 H), 2.84 (dd, 1 H), 2.65 (s, 3 H), 2.12

(t, 3 H)

2329
(CD₃OD) δ 7.56 (s, 1 H), 7.35 (d, 1 H), 7.01 (dd, 1 H), 6.61 (d, 1
386.2
97.7%

H), 6.39 (s, 1 H), 6.26 (s, 1 H), 4.19 (dd, 1 H), 3.67 (td, 1 H),
[M + H]⁺

2.88-3.02 (m, 1 H), 2.72 (dd, 1 H), 2.52 (s, 3 H), 2.00 (t, 3 H)

2330
(CD₃OD) δ 8.41 (dd, 1 H), 8.25 (dd, 1 H), 7.41-7.61 (m, 2 H),
433.1
100%

7.32 (dd, 1 H), 7.05 (dd, 1 H), 6.91 (dd, 1 H), 6.57 (s, 1 H), 6.36
[M + H]⁺

(s, 1 H), 4.28 (dd, 1 H), 3.62-3.81 (m, 1 H), 2.91-3.08 (m, 1 H),

2.68-2.85 (m, 4 H)

2331
(CD₃OD) δ 8.41 (dd, 1 H), 8.25 (dd, 1 H), 7.43-7.66 (m, 2 H),
433.1
98.2%

7.32 (dd, 1 H), 7.05 (dd, 1 H), 6.91 (dd, 1 H), 6.57 (s, 1 H), 6.36
[M + H]⁺

(s, 1 H), 4.28 (dd, 1 H), 3.63-3.80 (m, 1 H), 2.88-3.07 (m, 1 H),

2.68-2.84 (m, 4 H)

2332
(CD₃OD) δ 8.42 (dd, 1 H), 8.23 (dd, 1 H), 7.56 (s, 1 H), 7.24-
413.2
99.9%

7.40 (m, 2 H), 6.99 (dd, 1 H), 6.58 (d, 1 H), 6.30-6.45 (m, 2 H),
[M + H]⁺

4.26 (dd, 1 H), 3.64-3.83 (m, 1 H), 2.88-3.07 (m, 1 H), 2.68-2.83

(m, 4 H), 2.50 (s, 3 H)

2333
(CD₃OD) δ 8.40 (dd, 1 H), 8.21 (dd, 1 H), 7.57 (s, 1 H), 7.23-
413.2
99.2%

7.41 (m, 2 H), 6.97 (dd, 1 H), 6.57 (d, 1 H), 6.26-6.46 (m, 2H),
[M + H]⁺

4.26 (dd, 1 H), 3.62-3.82 (m, 1 H), 2.89-3.04 (m, 1 H), 2.68-2.82

(m, 4 H), 2.49 (s, 3 H)

2334
(CD₃OD) δ 8.37-8.46 (m, 1 H), 8.23-8.27 (m, 1 H), 8.19 (d, 1
445.2
100%

H), 7.58 (s, 1 H), 7.34-7.44 (m, 1 H), 6.94 (d, 1 H), 6.72 (t, 1 H),
[M + H]⁺

6.58 (s, 1 H), 6.35 (s, 1 H), 4.28 (dd, 1 H), 3.64-3.77 (m, 1 H),

2.93-3.14 (m, 2 H), 2.75 (dd, 1 H), 1.22 (dd, 6 H)

2335
(CD₃OD) δ 8.36-8.44 (m, 1 H), 8.24 (br d, 1 H), 8.18 (d, 1 H),
445.2
98.9%

7.58 (s, 1 H), 7.38 (br t, 1 H), 6.93 (br d, 1 H), 6.67-6.76 (m, 1
[M + H]⁺

H), 6.58 (s, 1 H), 6.34 (s, 1 H), 4.28 (dd, 1 H), 3.63-3.78 (m, 1

H), 2.92-3.15 (m, 2 H), 2.75 (dd, 1 H), 1.21 (t, 6H)

2336
(CD₃OD) δ 8.52 (d, 1 H), 7.81-7.88 (m, 2 H), 7.69 (s, 1 H), 7.44
467.1
100%

(dd, 1 H), 7.20-7.35 (m, 2 H), 6.80 (s, 1 H), 6.57 (s, 1 H), 4.46
[M + H]⁺

(dd, 1 H), 3.83 (td, 1 H), 3.04-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.69

(s, 3 H)

2337
(CD₃OD) δ 8.53 (d, 1 H), 7.82-7.91 (m, 3 H), 7.46 (dd, 1 H),
467.2
99.2%

7.23-7.35 (m, 2 H), 6.83 (s, 1 H), 6.61 (s, 1 H), 4.48 (dd, 1 H),
[M + H]⁺

3.77-3.87 (m, 1 H), 3.06-3.17 (m, 1 H), 2.84-2.90 (m, 1 H), 2.71

(s, 3 H)

2338
(CD₃OD) δ 8.43 (d, 1 H), 8.30 (d, 1 H), 7.66-7.76 (m, 1 H), 7.57
403.2
100%

(s, 1 H), 7.41-7.52 (m, 2 H), 7.05 (dd, 1 H), 6.71 (td, 1 H), 6.51
[M + H]⁺

(s, 1 H), 6.40 (s, 1 H), 4.31 (dd, 1 H), 3.62-3.74 (m, 1 H), 2.91-

3.05 (m, 1 H), 2.72 (dd, 1 H)

2339
(CD₃OD) δ 8.43 (d, 1 H), 8.31 (d, 1 H), 7.72 (t, 1 H), 7.57 (s, 1
403.2
94.1%

H), 7.42-7.53 (m, 2 H), 7.01-7.11 (m, 1 H), 6.71 (t, 1 H), 6.52 (s,
[M + H]⁺

1 H), 6.40 (s, 1 H), 4.32 (dd, 1 H), 3.62-3.74 (m, 1 H), 2.91-3.05

(m, 1 H), 2.72 (dd, 1 H)

2340
(CD₃OD) δ 8.44 (d, 1 H), 8.17 (d, 1 H), 7.65-7.81 (m, 1 H),
417.2
99.9%

7.54-7.60 (m, 1 H), 7.50 (dt, 1 H), 6.82-6.88 (m, 1 H), 6.64 (t, 1
[M + H]⁺

H), 6.53 (s, 1 H), 6.41 (s, 1 H), 4.32 (dd, 1 H), 3.64-3.78 (m, 1

H), 2.92-3.05 (m, 1 H), 2.73 (dd, 1 H), 2.31 (s, 3 H)

2341
(CD₃OD) δ 8.44 (d, 1 H), 8.17 (d, 1 H), 7.72 (t, 1 H), 7.57 (s, 1
417.1
99.3%

H), 7.50 (dt, 1 H), 6.85 (d, 1 H), 6.64 (t, 1 H), 6.53(s, 1H), 6.41
[M + H]⁺

(s, 1 H), 4.33 (dd, 1 H), 3.70 (td, 1 H), 2.93-3.05 (m, 1 H), 2.73

(dd, 1 H), 2.31 (s, 3 H)

2342
(CD₃OD) δ 8.44 (d, 1 H), 7.80-7.95 (m, 2 H), 7.68 (s, 1 H), 7.58
399.1
100%

(d, 1 H), 7.40 (d, 1 H), 7.18 (dd, 1 H), 6.84 (td, 1 H), 6.62(s, 1
[M + H]⁺

H), 6.53 (s, 1 H), 4.44 (dd, 1 H), 3.64-3.84 (m, 1 H), 3.00-3.18

(m, 1 H), 2.83 (br dd, 1 H), 2.62 (s, 3 H)

2343
(CD₃OD) δ 8.43 (d, 1 H), 7.79-7.97 (m, 2 H), 7.67 (s, 1 H), 7.57
399.1
98.3%

(d, 1 H), 7.39 (d, 1 H), 7.12-7.22 (m, 1 H), 6.83(td, 1H), 6.62
[M + H]⁺

(s, 1 H), 6.53 (s, 1 H), 4.43 (dd, 1 H), 3.77 (ddd, 1 H), 3.03-3.17

(m, 1 H), 2.75-2.88 (m, 1 H), 2.61 (s, 3H)

2344
(CD₃OD) δ 8.29 (d, 1 H), 7.79-7.98 (m, 2 H), 7.68 (s, 1 H), 7.40
413.2
99.5%

(d, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.63 (s, 1 H), 6.53(s, 1H),
[M + H]⁺

4.44 (dd, 1 H), 3.69-3.85 (m, 1 H), 3.00-3.18 (m, 1 H), 2.75-2.88

(m, 1 H), 2.62 (s, 3 H), 2.43 (s, 3 H)

2345
(CD₃OD) δ 8.27 (d, 1 H), 7.77-7.93 (m, 2 H), 7.68 (s, 1 H), 7.37
413.2
99.6%

(d, 1 H), 6.94 (d, 1 H), 6.73 (t, 1 H), 6.62 (s, 1H), 6.52(s, 1 H),
[M + H]⁺

4.43 (dd, 1 H), 3.67-3.84 (m, 1 H), 3.02-3.15 (m, 1 H), 2.82 (br

dd, 1 H), 2.60 (s, 3 H), 2.40 (s, 3 H)

2346
(CD₃OD) δ 8.57 (d, 1 H), 7.80-7.97 (m, 2 H), 7.72 (s, 1 H), 7.29-
449.1
99.6%

7.49 (m, 2 H), 6.76-7.15 (m, 3 H), 6.56 (s, 1 H), 4.46(dd, 1 H),
[M + H]⁺

3.68-3.89 (m, 1 H), 3.02-3.19 (m, 1 H), 2.76-2.91 (m, 1 H), 2.62

(s, 3 H)

2347
(CD₃OD) δ 8.57 (br d, 1 H), 7.79-7.96 (m, 2 H), 7.69 (s, 1 H),
449.1
99.5%

7.35-7.51 (m, 2 H), 6.75-7.16 (m, 3 H), 6.56 (br s, 1 H), 4.46
[M + H]⁺

(dd, 1 H), 3.66-3.90 (m, 1 H), 3.00-3.20 (m, 1 H), 2.74-2.92 (m,

1 H), 2.62 (s, 3 H)

2348
(CD₃OD) δ 8.48 (d, 1 H), 8.43 (s, 1 H), 7.74-7.81 (m, 1 H), 7.65
469.1
98.0%

(s, 1 H), 7.12-7.22 (m, 2 H), 6.85-6.97 (m, 2 H), 6.67 (s, 1 H),
[M + H]⁺

4.74 (br dd, 1 H), 3.61 (ddd, 1 H), 2.91-3.01 (m, 1 H), 2.71-2.80

(m, 1 H)

2349
(CD₃OD) δ 8.36 (d, 1 H), 8.28-8.33 (m, 1 H), 7.66 (dd, 1 H),
469.1
98.5%

7.56 (s, 1 H), 7.00-7.10 (m, 2 H), 6.73-6.85 (m, 2 H), 6.55(s, 1
[M + H]⁺

H), 4.62 (br dd, 1 H), 3.42-3.55 (m, 1 H), 2.78-2.91 (m, 1 H),

2.63 (dd, 1 H)

2350
(CD₃OD) δ 8.40 (ddd, 1 H), 8.33 (d, 1 H), 8.25 (d, 1 H), 7.59 (s,
437.1
100%

1 H), 7.34-7.45 (m, 1 H), 7.18 (d, 1 H), 6.73 (t, 1 H), 6.62 (s, 1
[M + H]⁺

H), 6.35 (s, 1 H), 4.30 (dd, 1 H), 3.61-3.76 (m, 1 H), 2.92-3.07

(m, 1 H), 2.75 (dd, 1 H)

2351
(CD₃OD) δ 8.37-8.44 (m, 1 H), 8.34 (d, 1 H), 8.25 (br d, 1 H),
437.1
100%

7.59 (s, 1 H), 7.31-7.44 (m, 1 H), 7.19 (d, 1 H), 6.73 (t, 1 H),
[M + H]⁺

6.62 (s, 1 H), 6.35 (s, 1 H), 4.30 (dd, 1 H), 3.59-3.76 (m, 1 H),

2.91-3.07 (m, 1 H), 2.75 (br dd, 1 H)

2352
(CD₃OD) δ 8.52 (br d, 1 H), 7.84 (br d, 1 H), 7.67-7.75 (m, 2 H),
449.2
100%

7.13-7.51 (m, 4 H), 6.73 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H),
[M + H]⁺

3.78-3.90 (m, 1 H), 3.03-3.16 (m, 1 H), 2.84 (dd, 1 H), 2.68 (s, 3 H)

2353
(CD₃OD) δ 8.52 (d, 1 H), 7.84 (br d, 1 H), 7.65-7.75 (m, 2 H),
449.1
99.8%

7.13-7.49 (m, 4 H), 6.73 (s, 1 H), 6.56 (s, 1 H), 4.47 (dd, 1 H),
[M + H]⁺

3.79-3.90 (m, 1 H), 3.02-3.15 (m, 1 H), 2.84 (dd, 1 H), 2.68 (s, 3 H)

2354
(CD₃OD) δ 8.45 (d, 1 H), 8.17 (d, 1 H), 7.73 (t, 1 H), 7.58(s, 1
445.2
99.7%

H), 7.51 (dt, 1 H), 6.92 (d, 1 H), 6.70 (t, 1 H), 6.63 (s, 1H), 6.41
[M + H]⁺

(s, 1 H), 4.33 (dd, 1 H), 3.64-3.78 (m, 1 H), 2.94-3.11 (m, 2 H),

2.74 (dd, 1 H), 1.21 (t, 6 H)

2355
(CD₃OD) δ 8.44 (br d, 1 H), 8.17 (d, 1 H), 7.73 (t, 1 H), 7.58(s,
445.2
98.6%

1 H), 7.50 (dt, 1 H), 6.92 (d, 1 H), 6.67-6.74 (m, 1 H), 6.63 (s, 1
[M + H]⁺

H), 6.41 (s, 1 H), 4.33 (br dd, 1 H), 3.65-3.77 (m, 1 H), 2.94-

3.10 (m, 2 H), 2.74 (br dd, 1 H), 1.20 (t, 6 H)

2356
(CD₃OD) δ 8.68 (d, 1 H), 7.77-7.99 (m, 2 H), 7.69 (s, 1 H), 7.60
467.2
100%

(d, 1 H), 7.40 (d, 1 H), 6.96 (t, 1 H), 6.82 (s, 1 H), 6.56(s, 1H),
[M + H]⁺

4.47 (dd, 1 H), 3.66-3.91 (m, 1 H), 3.02-3.17 (m, 1 H), 2.85 (dd,

1 H), 2.62 (s, 3 H)

2357
(CD₃OD) δ 8.68 (d, 1 H), 7.78-7.97 (m, 2 H), 7.69 (s, 1 H), 7.60
467.1
97.8%

(d, 1 H), 7.40 (d, 1 H), 6.96 (t, 1 H), 6.82 (s, 1 H), 6.56(s, 1H),
[M + H]⁺

4.47 (dd, 1 H), 3.79 (td, 1 H), 3.05-3.20 (m, 1 H), 2.77-2.92 (m,

1 H), 2.61 (s, 3 H)

2358
(CD₃OD) δ 8.25 (d, 1 H), 7.78-7.98 (m, 2 H), 7.68 (s, 1 H), 7.38
439.2
100%

(d, 1 H), 6.68-6.87 (m, 3 H), 6.41-6.63 (m, 1 H), 4.44 (dd, 1 H),
[M + H]⁺

3.79 (td, 1 H), 2.99-3.20 (m, 1 H), 2.76-2.93 (m, 1 H), 2.61 (s, 3

H), 2.00-2.16 (m, 1 H), 0.72-1.04 (m, 4H)

2359
(CD₃OD) δ 8.26 (d, 1 H), 7.80-8.04 (m, 2 H), 7.68 (s, 1 H), 7.39
439.2
99.7%

(d, 1 H), 6.67-6.97 (m, 3 H), 6.39-6.64 (m, 1 H), 4.44 (dd, 1 H),
[M + H]⁺

3.66-3.91 (m, 1 H), 3.03-3.21 (m, 1 H), 2.76-2.97 (m, 1 H), 2.61

(s, 3 H), 1.97-2.28 (m, 1 H), 0.70-1.07 (m, 4 H)

2360
(CD₃OD) δ 8.29 (d, 1 H), 8.11 (q, 1 H), 8.00 (dd, 1 H), 7.68 (s, 1
417.2
100%

H), 7.21 (dd, 1 H), 6.97 (d, 1 H), 6.76 (t, 1 H), 6.63 (s, 1H), 6.50
[M + H]⁺

(s, 1 H), 4.42 (dd, 1 H), 3.79 (ddd, 1 H), 3.00-3.16 (m, 1 H), 2.84

(dd, 1 H), 2.43 (s, 3 H)

2361
(CD₃OD) δ 8.29 (d, 1 H), 8.11 (q, 1 H), 8.00 (dd, 1 H), 7.68 (s, 1
417.2
99.8%

H), 7.21 (dd, 1 H), 6.97 (d, 1 H), 6.77 (t, 1 H), 6.63 (s, 1 H), 6.50
[M + H]⁺

(s, 1 H), 4.42 (dd, 1 H), 3.79 (ddd, 1 H), 2.96-3.16 (m, 1 H), 2.84

(dd, 1 H), 2.43 (s, 3 H)

2362
(CD₃OD) δ 8.69 (d, 1 H), 8.11 (q, 1 H), 8.00 (dd, 1 H), 7.69 (s, 1
471.2
99.9%

H), 7.61 (d, 1 H), 7.22 (dd, 1 H), 6.97 (t, 1 H), 6.82 (s, 1 H), 6.53
[M + H]⁺

(br s, 1 H), 4.46 (dd, 1 H), 3.80 (ddd, 1 H), 3.00-3.19 (m, 1 H),

2.85 (br dd, 1 H)

2363
(CD₃OD) δ 8.68 (br d, 1 H), 8.07-8.16 (m, 1 H), 8.00 (br d, 1 H),
471.2
97.4%

7.69 (s, 1 H), 7.61 (br d, 1 H), 7.22 (br d, 1 H), 6.97 (br t, 1 H),
[M + H]⁺

6.82 (s, 1 H), 6.53 (br s, 1 H), 4.46 (dd, 1 H), 3.73-3.87 (m, 1 H),

3.00-3.16 (m, 1 H), 2.85 (br dd, 1 H)

2364
(CD₃OD) δ 8.71 (d, 1 H), 8.35-8.51 (m, 2 H), 7.90 (td, 1 H), 7.71
431.0
100%

(s, 1 H), 7.51-7.66 (m, 1.3 H), 7.15-7.27 (m, 1 H), 6.99 (s, 0.7
[M + H]⁺

H), 6.82-6.92 (m, 1 H), 6.58-6.70 (m, 1 H), 5.02 (br dd, 1 H),

3.75-3.87 (m, 0.7 H), 3.44 (td, 0.3 H), 3.15-3.26 (m, 0.7 H),

2.97-3.07 (m, 0.3 H), 2.86 (br dd, 1 H)

2365
(CD₃OD) δ 8.71 (d, 1 H), 8.35-8.50 (m, 2 H), 7.90 (td, 1 H),
431.0
100%

7.74-7.77 (m, 1 H), 7.52-7.66 (m, 1.3 H), 7.15-7.26 (m, 1 H),
[M + H]⁺

6.99 (s, 0.7 H), 6.81-6.92 (m, 1 H), 6.60-6.70 (m, 1 H), 5.03 (dd,

1 H), 3.74-3.86 (m, 0.7 H), 3.44 (td, 0.3 H), 3.16-3.28 (m, 0.7

H), 2.98-3.08 (m, 0.3 H), 2.82-2.90 (m, 1 H)

2366
(CD₃OD) δ 8.45 (br s, 1.4 H), 8.02 (br s, 0.6 H), 7.65 (s, 1 H),
384.1
100%

7.58 (br d, 1 H), 7.15-7.25 (m, 1 H), 6.91-7.13 (m, 1.3 H), 6.73-
[M + H]⁺

6.90 (m, 1.3 H), 6.61 (br s, 0.7 H), 6.07-6.47 (m, 0.7 H), 4.67-

4.84 (m, 0.6 H), 4.06 (br s, 0.4 H), 3.66 (br s, 0.5 H), 3.14-3.30

(m, 0.5 H), 2.93 (br s, 1 H), 2.70 (br d, 1 H)

2367
(CD₃OD) δ 8.46 (br s, 1.4 H), 8.03 (br s, 0.6 H), 7.65 (s, 1 H),
384.1
99.8%

7.58 (br d, 1 H), 7.16-7.23 (m, 1 H), 6.92-7.12 (m, 1.3 H), 6.77-
[M + H]⁺

6.91 (m, 1.4 H), 6.61 (br s, 0.6 H), 6.17-6.44 (m, 0.7 H), 4.64-

4.85 (m, 0.6 H), 4.06 (br s, 0.4 H), 3.66 (br s, 0.4 H), 3.16-3.31

(m, 0.6 H), 2.96 (br d, 1 H), 2.70 (br d, 1 H)

2368
(CD₃OD) δ 8.36-8.64 (m, 1 H), 7.77-8.34 (m, 1 H), 7.47-7.74
466.0
100%

(m, 2 H), 7.02-7.42 (m, 2 H), 6.76-6.99 (m, 1.5 H), 6.09-6.70 (m,
[M + H]⁺

1.5 H), 5.11 (q, 2 H), 4.06 (br d, 1 H), 3.70 (br s, 1 H), 2.90-3.04

(m, 1 H), 2.73 (dd, 1 H)

2369
(CD₃OD) δ 8.37-8.62 (m, 1 H), 7.79-8.35 (m, 1 H), 7.49-7.76
466.0
100%

(m, 2 H), 7.01-7.43 (m, 2 H), 6.80-6.99 (m, 1.4 H), 6.13-6.70 (m,
[M + H]⁺

1.6 H), 5.11 (q, 2 H), 4.05 (br s, 1 H), 3.70 (br s, 1 H), 2.90-3.04

(m, 1 H), 2.73 (br dd, 1 H)

2370
(CD₃OD) δ 8.26-8.62 (m, 1 H), 7.47-7.74 (m, 2.3 H), 7.09-7.43
399.0
99.2%

(m, 1.7 H), 6.79-6.99 (m, 1.6 H), 5.98-6.71 (m, 2.4 H), 4.13 (br
[M + H]⁺

dd, 1 H), 3.56-3.79 (m, 0.6 H), 2.86-3.28 (m, 1.4 H), 2.74 (br d,

1 H)

2371
(CD₃OD) δ 8.34-8.60 (m, 1 H), 7.50-7.75 (m, 2.2 H), 7.13-7.49
399.0
99.4%

(m, 1.8 H), 6.77-7.03 (m, 1.5 H), 5.99-6.69 (m, 2.5 H), 4.13 (br
[M + H]⁺

dd, 1 H), 3.57-3.76 (m, 0.6 H), 2.87-3.29 (m, 1.4 H), 2.74 (br d,

1 H)

2372
(CD₃OD) δ 8.35-8.53 (m, 1 H), 7.48-7.75 (m, 2 H), 7.08-7.28
417.2
100%

(m, 1 H), 6.73-7.03 (m, 2 H), 6.28-6.70 (m, 1 H), 4.44 (dd, 1 H),
[M + H]⁺

4.00-4.23 (m, 3 H), 3.68 (ddd, 1 H), 2.91-3.29 (m, 1 H), 2.67-

2.87 (m, 1 H)

2373
(CD₃OD) δ 8.37-8.51 (m, 1 H), 7.46-7.75 (m, 2 H), 7.10-7.26
417.2
100%

(m, 1 H), 6.75-7.00 (m, 2 H), 6.31-6.70 (m, 1 H), 4.44 (dd, 1 H),
[M + H]⁺

4.04-4.24 (m, 3 H), 3.68 (ddd, 1 H), 2.89-3.29 (m, 1 H), 2.71-

2.87 (m, 1 H)

2374
(CD₃OD) δ 8.34 (d, 1 H), 7.56 (s, 1 H), 7.49 (br d, 1 H), 7.04-
413.20
100%

7.17 (m, 1 H), 6.75 (td, 1.6 H), 6.25-6.56 (m, 1.4 H), 4.80-4.85
[M + H]⁺

(m, 1 H), 4.02-4.21 (m, 1 H), 3.56-3.76 (m, 1 H), 2.61-3.10 (m, 2

H), 1.46 (br d, 3 H)

2375
(CD₃OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.61 (br d, 1 H), 7.15-
413.20
96.6%

7.28 (m, 1 H), 6.87 (td, 1.6 H), 6.35-6.71 (m, 1.4 H), 4.92-4.96
[M + H]⁺

(m, 1 H), 4.21 (br d, 1 H), 3.64-3.86 (m, 1 H), 2.72-3.20 (m, 2

H), 1.59 (br d, 3 H)

2376
(CD₃OD) δ 8.46 (d, 1 H), 7.68 (s, 1 H), 7.61 (br d, 1 H), 7.15-
413.10
100%

7.28 (m, 1 H), 6.87 (td, 1.6 H), 6.30-6.69 (m, 1.4 H), 4.93-4.96
[M + H]⁺

(m, 1 H), 4.22 (br d, 1 H), 3.78 (br s, 1 H), 2.77-3.20 (m, 2 H),

1.48-1.65 (m, 3 H)

2377
(CD₃OD) δ 8.34 (d, 1 H), 7.56 (s, 1 H), 7.49 (br d, 1 H), 7.05-
413.0
97.3%

7.13 (m, 1 H), 6.75 (td, 1.6 H), 6.25-6.55 (m, 1.4 H), 4.80-4.85
[M + H]⁺

(m, 1 H), 3.99-4.19 (m, 1 H), 3.66 (br s, 1 H), 2.59-3.09 (m, 2

H), 1.47 (br d, 3 H)

2378
(CD₃OD) δ 8.37-8.44 (m, 1 H), 7.68 (s, 1 H), 7.19-7.45 (m, 1 H),
428.1
100%

6.78-6.97 (m, 2 H), 6.61-6.75 (m, 1 H), 4.93 (br d, 1 H), 3.63-
[M + H]⁺

3.80 (m, 0.7 H), 3.35-3.44 (m, 0.3 H), 2.91-3.20 (m, 1 H), 2.81

(br d, 1 H), 1.67 (s, 6 H)

2379
(CD₃OD) δ 8.37-8.44 (m, 1 H), 7.68 (s, 1 H), 7.22-7.42 (m, 1 H),
428.1
100%

6.78-6.94 (m, 2 H), 6.60-6.73 (m, 1 H), 4.93 (br d, 1 H), 3.61-
[M + H]⁺

3.78 (m, 0.6 H), 3.32-3.42 (m, 0.4 H), 2.91-3.19 (m, 1 H), 2.80

(dd, 1 H), 1.67 (s, 6 H)

2380
(CD₃OD) δ 8.39 (s, 1 H), 8.17-8.28 (m, 1 H), 8.10 (s, 1 H), 7.68
430.2
100%

(s, 1 H), 7.42-7.61 (m, 1 H), 7.02-7.12 (m, 1 H), 6.93 (br s, 1 H),
[M + H]⁺

6.44-6.60 (m, 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.67-3.84

(m, 1 H), 2.91-3.22 (m, 1 H), 2.82 (br d, 1 H), 2.23-2.36 (m, 3 H)

2381
(CD₃OD) δ 8.39 (s, 1 H), 8.15-8.28 (m, 1 H), 8.10 (s, 1 H), 7.68
430.2
99.8%

(s, 1 H), 7.42-7.58 (m, 1 H), 7.01-7.11 (m, 1 H), 6.93 (s, 1H),
[M + H]⁺

6.44-6.61 (m, 1 H), 5.05 (br dd, 1 H), 4.00 (s, 3 H), 3.70-3.83

(m, 0.7 H), 3.39-3.44 (m, 0.3 H), 2.92-3.22 (m, 1 H), 2.70-2.88

(m, 1 H), 2.21-2.34 (m, 3 H)

2382
(CD₃OD) δ 8.35 (br s, 1 H), 7.93 (br s, 1 H), 7.67 (s, 2 H), 6.91-
411.2
100%

7.04 (m, 1 H), 6.60-6.90 (m, 3 H), 4.41-4.83 (m, 1 H), 3.36-3.87
[M + H]⁺

(m, 1 H), 2.68-3.19 (m, 2 H), 1.64 (br s, 6 H)

2383
(CD₃OD) δ 8.35 (br s, 1 H), 7.93 (br s, 1 H), 7.68 (s, 2 H), 6.92-
411.2
99.1%

7.08 (m, 1 H), 6.57-6.91 (m, 3 H), 4.42-4.83 (m, 1 H), 3.36-3.90
[M + H]⁺

(m, 1 H), 2.73-3.24 (m, 2 H), 1.64 (br s, 6 H)

2384
(CD₃OD) δ 8.79 (br d, 1 H), 8.24-8.38 (m, 2 H), 8.10 (t, 1 H),
427.2
97.4%

7.64-7.73 (m, 2 H), 7.51 (s, 0.3 H), 7.32-7.39 (m, 1 H), 6.96 (s,
[M + H]⁺

0.7 H), 6.67-6.77 (m, 1 H), 6.44-6.53 (m, 1 H), 5.00 (br dd, 1 H),

3.75-3.86 (m, 0.7 H), 3.43 (br dd, 0.3 H), 2.97-3.26 (m, 1 H),

2.80-2.90 (m, 1 H), 2.34-2.42 (m, 3 H)

2385
(CD₃OD) δ 8.79 (br d, 1 H), 8.24-8.38 (m, 2 H), 8.10 (t, 1 H),
427.2
99.6%

7.64-7.74 (m, 2 H), 7.51 (s, 0.3 H), 7.32-7.41 (m, 1 H), 6.96 (s,
[M + H]⁺

0.7 H), 6.67-6.76 (m, 1 H), 6.44-6.55 (m, 1 H), 5.00 (br dd, 1 H),

3.75-3.86 (m, 0.7 H), 3.39-3.46 (m, 0.3 H), 2.98-3.27 (m, 1 H),

2.81-2.91 (m, 1 H), 2.33-2.41 (m, 3 H)

2386
(CD₃OD) δ 8.34-8.71 (m, 1 H), 7.66-7.80 (m, 1 H), 7.55-7.66
374.2
99.9%

(m, 1 H), 7.50 (d, 1 H), 7.17-7.27 (m, 1 H), 7.01 (s, 0.6 H), 6.83-
[M + H]⁺

6.93 (m, 1 H), 6.62-6.80 (m, 1 H), 6.27-6.58 (m, 1 H), 6.14 (br s,

0.4 H), 3.92 (br dd, 1 H), 3.57-3.82 (m, 1.6 H), 3.36-3.47 (m, 0.4

H), 2.87-3.10 (m, 1 H), 2.67-2.86 (m, 1 H), 1.10 (br s, 1 H),

0.64-0.98 (m, 3 H)

2387
(CD₃OD) δ 8.40-8.62 (m, 1 H), 7.66-7.74 (m, 1 H), 7.54-7.66
374.2
100%

(m, 1 H), 7.50 (d, 1 H), 7.21 (t, 1 H), 7.01(s, 0.6H), 6.83-6.94
[M + H]⁺

(m, 1 H), 6.60-6.80 (m, 1 H), 6.29-6.60 (m, 1 H), 6.14 (s, 0.4 H),

3.85-4.00 (m, 1 H), 3.57-3.80 (m, 1.6 H), 3.35-3.46 (m, 0.4 H),

2.87-3.10 (m, 1 H), 2.69-2.85 (m, 1 H), 1.10 (br d, 1 H), 0.63-

0.97 (m, 3 H)

2388
(CD₃OD) δ 8.31-8.40 (m, 1 H), 7.79-7.91 (m, 3 H), 7.53-7.78
429.2
91.1%

(m, 2 H), 7.06-7.19 (m, 1 H), 6.83-7.05 (m, 3 H), 6.44-6.81 (m,
[M + H]⁺

1.6 H), 5.88 (s, 0.4 H), 3.38-3.84 (m, 2 H), 2.57-3.16 (m, 2 H)

2389
(CD₃OD) δ 8.31-8.40 (m, 1 H), 7.79-7.92 (m, 3 H), 7.54-7.78
429.2
94.3%

(m, 2 H), 7.07-7.19 (m, 1 H), 6.84-7.05 (m, 3 H), 6.44-6.80 (m,
[M + H]⁺

1.6 H), 5.88 (s, 0.4 H), 3.40-3.83 (m, 2 H), 2.58-3.15 (m, 2 H)

2390
(CD₃OD) δ 8.31-8.51 (m, 1 H), 7.70 (s, 1 H), 6.69-7.19 (m, 3 H),
380.2
100%

6.32-6.61 (m, 2 H), 4.15 (br d, 1 H), 3.85 (s, 3 H), 3.63-3.78 (m,
[M + H]⁺

1 H), 2.69-3.10 (m, 2 H), 2.28 (br s, 3 H)

2391
(CD₃OD) δ 8.28-8.57 (m, 1 H), 7.70 (s, 1 H), 6.70-7.06 (m, 3 H),
380.2
99.7%

6.29-6.63 (m, 2 H), 4.15 (br d, 1 H), 3.61-3.91 (m, 4 H), 2.67-
[M + H]⁺

3.10 (m, 2 H), 2.16-2.32 (m, 3 H)

2392
(CD₃OD) δ 7.94-8.01 (m, 1 H), 7.58 (d, 1 H), 6.16-6.86 (m, 4
393.2
100%

H), 4.74-4.76 (m, 0.4 H), 4.22 (dd, 0.6 H), 3.79-3.89 (m, 6 H),
[M + H]⁺

3.55 (ddd, 0.5 H), 2.80-3.18 (m, 1.5 H), 2.57-2.76 (m, 1 H), 2.25

(s, 3 H)

2393
(CD₃OD) δ 8.04-8.14 (m, 1 H), 7.70 (d, 1 H), 6.27-6.98 (m, 4
393.2
99.0%

H), 4.86-4.88 (m, 0.4 H), 4.34 (dd, 0.6 H), 3.90-4.00 (m, 6 H),
[M + H]⁺

3.61-3.74 (m, 0.5 H), 2.92-3.29 (m, 1.5 H), 2.70-2.89 (m, 1 H),

2.37 (s, 3 H)

2394
(CD₃OD) δ 7.98 (d, 1 H), 7.83 (dd, 1 H), 7.69 (d, 1 H), 7.46 (dd,
430.2
100%

1.5 H), 7.11 (ddd, 1 H), 6.98 (s, 0.5 H), 6.70 (dd, 1 H), 6.42-6.64
[M + H]⁺

(m, 1 H), 4.91-5.11 (m, 1 H), 4.10 (s, 3 H), 3.85-3.98 (m, 0.6 H),

3.35-3.43 (m, 0.4 H), 2.78-3.24 (m, 2 H), 2.49-2.71 (m, 3 H)

2395
(CD₃OD) δ 7.98 (d, 1 H), 7.83 (d, 1 H), 7.69 (d, 1 H), 7.46(dd,
430.2
93.5%

1.4 H), 7.11 (ddd, 1 H), 6.98 (s, 0.6 H), 6.70 (dd, 1 H), 6.41-6.65
[M + H]⁺

(m, 1 H), 4.92-5.11 (m, 1 H), 4.10 (s, 3 H), 3.85-3.99 (m, 0.5 H),

3.34-3.45 (m, 0.5 H), 2.79-3.23 (m, 2 H), 2.43-2.71 (m, 3 H)

2396
(CD₃OD) δ 7.69 (d, 1 H), 7.51-7.63 (m, 1 H), 7.11-7.20 (m, 1
433.1
100%

H), 6.90-7.05 (m, 2 H), 6.78-6.87 (m, 1 H), 6.45-6.73 (m, 1 H),
[M + H]⁺

4.36 (dd, 1 H), 4.12 (d, 3 H), 3.69-3.81 (m, 0.5 H), 3.08-3.25 (m,

1 H), 2.92-3.03 (m, 0.5 H), 2.71-2.88 (m, 1 H)

2397
(CD₃OD) δ 7.69 (d, 1 H), 7.50-7.62 (m, 1 H), 7.11-7.19 (m, 1
433.1
96.7%

H), 6.90-7.04 (m, 2 H), 6.77-6.87 (m, 1 H), 6.43-6.73 (m, 1 H),
[M + H]⁺

4.36 (br dd, 1 H), 4.12 (d, 3 H), 3.71-3.81 (m, 0.5 H), 3.09-3.24

(m, 1 H), 2.91-3.03 (m, 0.5 H), 2.71-2.87 (m, 1H)

2398
(CD₃OD) δ 8.30-8.38 (m, 1 H), 7.61-7.74 (m, 1 H), 6.89-7.00
435.1
100%

(m, 2 H), 6.79-6.87 (m, 1 H), 6.76 (s, 0.6 H), 6.54 (s, 0.4 H),
[M + H]⁺

4.48 (dd, 1 H), 4.06-4.23 (m, 3 H), 3.68 (ddd, 0.6 H), 3.11-3.29

(m, 1 H), 2.92-3.04 (m, 0.4 H), 2.72-2.88 (m, 1 H)

2399
(CD₃OD) δ 8.26-8.40 (m, 1 H), 7.70 (d, 1 H), 6.89-7.03 (m, 2
435.1
100%

H), 6.79-6.88 (m, 1 H), 6.76 (s, 0.6 H), 6.54 (s, 0.4 H), 4.48 (dd,
[M + H]⁺

1 H), 4.12-4.17 (m, 3 H), 3.68 (ddd, 0.6 H), 3.11-3.28 (m, 1 H),

2.93-3.04 (m, 0.4 H), 2.72-2.88 (m, 1 H)

2400
(CD₃OD) δ 8.35-8.62 (m, 2 H), 7.69 (s, 1 H), 7.00-7.47 (m, 2 H),
403.1
97.1%

6.47-6.90 (m, 3 H), 4.34 (br d, 1 H), 3.73 (br s, 1 H), 2.94-3.25
[M + H]⁺

(m, 1 H), 2.81 (br d, 1 H)

2401
(CD₃OD) δ 8.39-8.57 (m, 2 H), 7.69 (s, 1 H), 6.97-7.40 (m, 2 H),
403.1
97.0%

6.44-6.88 (m, 3 H), 4.34 (br d, 1 H), 3.73 (br t, 1 H), 2.92-3.25
[M + H]⁺

(m, 1 H), 2.81 (br d, 1 H)

2402
(CDCl₃) δ 8.04-8.19 (m, 1 H), 7.56 (d, 1 H), 7.33 (dd, 1 H),
413.2
100%

6.88-7.01 (m, 2 H), 6.55-6.86 (m, 1 H), 6.29-6.54 (m, 1 H), 4.69-
[M + H]⁺

4.98 (m, 1 H), 3.23-3.85 (m, 1 H), 2.91-3.22 (m, 1 H), 2.74 (br d,

1 H), 2.28 (s, 3 H)

2403
(CDCl₃) δ 8.03-8.22 (m, 1 H), 7.58 (d, 1 H), 7.28-7.38 (m, 1 H),
413.2
99.2%

6.85-7.03 (m, 2 H), 6.22-6.85 (m, 2 H), 4.63-5.07 (m, 1 H), 4.09-
[M + H]⁺

4.20 (m, 3 H), 3.26-3.83 (m, 1 H), 2.89-3.25 (m, 1 H), 2.69-2.86

(m, 1 H), 2.29 (s, 3 H)

2404
(CD₃OD) δ 8.51 (br s, 1 H), 7.56-7.75 (m, 2 H), 7.44 (s, 0.3 H),
394.1
100%

7.12-7.30 (m, 1 H), 6.88 (s, 0.7 H), 6.52-6.72 (m, 1 H), 4.97 (br
[M + H]⁺

dd, 1 H), 3.34-3.78 (m, 1 H), 2.70-3.20 (m, 2 H), 2.30 (br d, 1

H), 1.18-1.30 (m, 4 H)

2405
(CD₃OD) δ 8.51 (br s, 1 H), 7.56-7.72 (m, 2 H), 7.44 (s, 0.3 H),
394.2
100%

7.22 (br t, 1 H), 6.88 (s, 0.7 H), 6.53-6.75 (m, 1 H), 4.97 (br dd,
[M + H]⁺

1 H), 3.34-3.79 (m, 1 H), 2.74-3.19 (m, 2 H), 2.20-2.41 (m, 1 H),

1.18-1.30 (m, 4 H)

2406
(CD₃OD) δ 8.63 (d, 1 H), 8.05 (br s, 1 H), 7.69 (s, 1 H), 6.96-
511.1
99.2%

7.31 (m, 2 H), 6.56-6.93 (m, 2 H), 4.76-4.81 (m, 0.3 H), 4.36 (br
[M + H]⁺

d, 0.7 H), 3.60-3.88 (m, 0.7 H), 3.39 (br s, 0.3 H), 2.72-3.25 (m,

2 H), 1.48-1.75 (m, 6 H)

2407
(CD₃OD) δ 8.63 (d, 1 H), 8.05 (br s, 1 H), 7.68 (s, 1 H), 6.95-
511.2
99.4%

7.30 (m, 2 H), 6.54-6.94 (m, 2 H), 4.84 (br s, 0.3 H), 4.36 (br d,
[M + H]⁺

0.7 H), 3.73 (br t, 0.7 H), 3.39 (br s, 0.3 H), 2.70-3.23 (m, 2 H),

1.49-1.76 (m, 6 H)

2408
(CD₃OD) δ 7.86 (dd, 1 H), 7.53-7.77 (m, 1.5 H), 7.23-7.42 (m, 2
460.2
100%

H), 6.81-7.04 (m, 1 H), 6.67 (s, 0.5 H), 4.96-5.02 (m, 1 H), 3.82-
[M + H]⁺

4.00 (m, 0.5 H), 2.93-3.32 (m, 1.5 H), 2.85 (dd, 1 H), 1.49 (d, 9 H)

2409
(CD₃OD) δ 7.75 (dd, 1 H), 7.36-7.65 (m, 1.5 H), 7.09-7.31 (m, 2
460.2
99.6%

H), 6.71-6.91 (m, 1 H), 6.55 (s, 0.5 H), 4.85-4.92 (m, 1 H), 3.71-
[M + H]⁺

3.88 (m, 0.5 H), 2.82-3.20 (m, 1.5 H), 2.73 (dd, 1 H), 1.37 (d, 9 H)

2410
(CD₃OD) δ 8.64 (br s, 1 H), 7.86-8.18 (m, 1 H), 7.69 (br s, 1 H),
467.2
100%

6.51-7.21 (m, 4 H), 4.47 (br d, 0.4 H), 4.11 (br d, 3 H), 3.67 (br
[M + H]⁺

s, 0.6 H), 2.64-3.25 (m, 3 H)

2411
(CD₃OD) δ 8.60-8.68 (m, 1 H), 7.89-8.21 (m, 1 H), 7.70 (d, 1
467.2
100%

H), 6.63-7.13 (m, 4 H), 4.47 (dd, 0.4 H), 4.04-4.18 (m, 3 H),
[M + H]⁺

3.67 (ddd, 0.6 H), 2.68-3.28 (m, 3 H)

2412
(CD₃OD) δ 7.71 (d, 1 H), 7.54-7.66 (m, 1 H), 7.14-7.23 (m, 1
451.1
100%

H), 7.05 (d, 1 H), 6.96 (br s, 1 H), 6.46-6.86 (m, 1 H), 4.96 (br d,
[M + H]⁺

0.5 H), 4.41 (dd, 0.5 H), 4.18 (d, 3 H), 3.73-3.85 (m, 0.5 H),

2.76-3.26 (m, 2.5 H)

2413
(CD₃OD) δ 7.57-7.63 (m, 1 H), 7.42-7.53 (m, 1 H), 7.02-7.11
451.1
98.4%

(m, 1 H), 6.94 (d, 1 H), 6.84 (br s, 1 H), 6.36-6.71 (m, 1 H), 4.84
[M + H]⁺

(br d, 0.5 H), 4.29 (br dd, 0.5 H), 4.06 (d, 3 H), 3.62-3.72 (m, 0.5

H), 2.64-3.12 (m, 2.5 H)

2414
(CD₃OD) δ 8.85-8.98 (m, 1 H), 8.77 (d, 1 H), 8.30 (d, 1 H), 8.08
481.2
100%

(t, 1 H), 7.63-7.83 (m, 3 H), 7.29-7.53 (m, 1.4 H), 6.79-6.99 (m,
[M + H]⁺

1.6 H), 4.93-5.04 (m, 1 H), 3.38-3.86 (m, 1 H), 2.95-3.26 (m, 1

H), 2.85 (br d, 1 H)

2415
(CD₃OD) δ 8.84-8.99 (m, 1 H), 8.77 (d, 1 H), 8.30 (d, 1 H), 8.08
481.1
99.8%

(t, 1 H), 7.63-7.82 (m, 3 H), 7.31-7.52 (m, 1.4 H), 6.78-6.98 (m,
[M + H]⁺

1.6 H), 4.95-5.06 (m, 1 H), 3.42-3.85 (m, 1 H), 2.93-3.26 (m, 1

H), 2.85 (br d, 1 H)

2416
(CD₃OD) δ 8.87-8.95 (m, 1 H), 8.35-8.43 (m, 1 H), 8.05-8.13
484.2
100%

(m, 1 H), 7.67-7.81 (m, 2 H), 7.58 (s, 0.3 H), 7.31-7.38 (m, 1 H),
[M + H]⁺

6.95 (s, 0.7 H), 6.76-6.84 (m, 1 H), 5.10 (dd, 1 H), 4.00 (s, 3 H),

3.37-3.81 (m, 1 H), 2.95-3.21 (m, 1 H), 2.78-2.87 (m, 1 H)

2417
(CD₃OD) δ 8.85-8.99 (m, 1 H), 8.38 (s, 1 H), 8.04-8.14 (m, 1 H),
484.2
98.9%

7.63-7.82 (m, 2 H), 7.58 (s, 0.3 H), 7.29-7.39 (m, 1 H), 6.94 (s,
[M + H]⁺

0.7 H), 6.74-6.85 (m, 1 H), 5.10 (br dd, 1 H), 4.00 (s, 3 H), 3.37-

3.84 (m, 1 H), 2.93-3.22 (m, 1 H), 2.75-2.91 (m, 1 H)

2418
(CD₃OD) δ 7.64-8.07 (m, 2 H), 7.20-7.47 (m, 2 H), 6.41-7.09
457.2
95.3%

(m, 2 H), 4.20 (dd, 1 H), 3.90 (d, 3 H), 3.62-3.78 (m, 0.5 H),
[M + H]⁺

3.22 (td, 4.5 Hz, 0.5 H), 2.90-3.15 (m, 1 H), 2.65-2.89 (m, 1 H),

1.92-2.10 (m, 1 H), 0.77-1.11 (m, 4 H)

2419
(CD₃OD) δ 7.59-7.99 (m, 2 H), 7.15-7.54 (m, 2 H), 6.44-7.04
457.2
81.0%

(m, 2 H), 4.03-4.29 (m, 1 H), 3.89 (d, 3 H), 3.67-3.76 (m, 0.5 H),
[M + H]⁺

3.22 (td, 4.6 Hz, 0.5 H), 2.89-3.13 (m, 1 H), 2.60-2.89 (m, 1 H),

1.91-2.13 (m, 1 H), 0.83-1.03 (m, 4 H)

2420
(CD₃OD) δ 8.86-8.96 (m, 1 H), 7.72-7.81 (m, 1 H), 7.69 (s, 1 H),
464.2
99.5%

7.29-7.45 (m, 1.3 H), 6.68-7.02 (m, 1.7 H), 4.93-5.01 (m, 1 H),
[M + H]⁺

3.35-3.80 (m, 1 H), 2.94-3.20 (m, 1 H), 2.82 (br dd, 1 H), 1.84-

1.93 (m, 6 H)

2421
(CD₃OD) δ 8.86-8.96 (m, 1 H), 7.72-7.81 (m, 1 H), 7.69 (s, 1 H),
464.2
98.2%

7.31-7.44 (m, 1.3 H), 6.64-7.04 (m, 1.7 H), 4.97 (br dd, 1 H),
[M + H]⁺

3.35-3.81 (m, 1 H), 2.93-3.20 (m, 1 H), 2.82 (br dd, 1 H), 1.78-

1.97 (m, 6 H)

2422
(CD₃OD) δ 7.86 (br d, 1 H), 7.66 (s, 1 H), 7.31-7.37 (m, 1 H),
461.2
99.2%

7.22-7.30 (m, 1 H), 6.84 (br s, 2 H), 4.78 (br s, 1 H), 4.36 (br s, 1
[M + H]⁺

H), 3.87 (br s, 0.5 H), 3.34-3.52 (m, 0.5 H), 3.05 (br s, 1 H), 2.79

(dd, 3.6 Hz, 1 H), 2.34 (s, 3 H), 1.56 (br s, 3 H)

2423
(CD₃OD) δ 7.85 (br d, 1 H), 7.65 (s, 1 H), 7.31-7.40 (m, 1 H),
461.2
99.7%

7.22-7.30 (m, 1 H), 6.83 (br s, 2 H), 4.68-4.77 (m, 1 H), 4.35 (br
[M + H]⁺

s, 1 H), 3.87 (br s, 0.5 H), 3.48 (br s, 0.5 H), 2.91-3.15 (m, 1 H),

2.68-2.87 (m, 1 H), 2.34 (s, 3 H), 1.56 (br s, 3 H)

2424
(CD₃OD) δ 8.63 (d, 2 H), 8.00 (d, 1 H), 7.56-7.67 (m, 2 H),
418.1
96.8%

7.40-7.45 (m, 1 H), 7.19 (t, 1 H), 7.02-7.09 (m, 2 H), 6.63 (br s,
[M + H]⁺

2 H), 4.63 (br s, 1 H), 3.48 (br s, 1 H), 3.00-3.10 (m, 1 H), 2.75

(dd, 1 H)

2425
(CD₃OD) δ 8.63 (d, 2 H), 8.00 (d, 1 H), 7.55-7.67 (m, 2 H),
418.2
98.7%

7.39-7.47 (m, 1 H), 7.18 (t, 1 H), 7.02-7.11 (m, 2 H), 6.64 (br s,
[M + H]⁺

2 H), 4.64 (br s, 1 H), 3.48 (br s, 1 H), 3.00-3.10 (m, 1 H), 2.75

(dd, 1 H)

2426
(CD₃OD) δ 9.02 (s, 1 H), 8.36 (s, 2 H), 7.35-7.74 (m, 2.3 H),
470.1
100%

7.02-7.18 (m, 1 H), 6.65-6.93 (m, 1.7 H), 6.41-6.58 (m, 1 H),
[M + H]⁺

4.94 (br dd, 1 H), 3.59-3.78 (m, 0.6 H), 3.25-3.40 (m, 0.4 H),

2.83-3.13 (m, 1 H), 2.77 (br s, 1 H)

2427
(CD₃OD) δ 9.14 (s, 1 H), 8.37-8.53 (m, 2 H), 7.54-7.77 (m, 2.3
470.1
99.1%

H), 7.15-7.30 (m, 1 H), 6.80-7.03 (m, 1.7 H), 6.53-6.71 (m, 1 H),
[M + H]⁺

4.92-5.13 (m, 1 H), 3.73-3.86 (m, 0.6 H), 3.38-3.52 (m, 0.4 H),

2.94-3.26 (m, 1 H), 2.86 (br d, 1 H)

2428
(CD₃OD) δ 9.13 (s, 1 H), 8.47 (s, 1 H), 7.80-7.98 (m, 1 H), 7.76
538.1
100%

(d, 1 H), 7.57 (s, 0.5 H), 7.22-7.44 (m, 2 H), 6.99 (s, 0.5 H),
[M + H]⁺

6.65-6.92 (m, 1 H), 4.96-5.17 (m, 1 H), 3.92-4.04 (m, 0.5 H),

3.36 (br d, 0.5 H), 2.86-3.26 (m, 2 H)

2429
(CD₃OD) δ 9.01 (s, 1 H), 8.34 (s, 1 H), 7.68-7.81 (m, 1 H), 7.62
538.1
99.4%

(br d, 1 H), 7.45 (s, 0.5 H), 7.07-7.29 (m, 2 H), 6.87 (s, 0.5H),
[M + H]⁺

6.51-6.78 (m, 1 H), 4.84-5.07 (m, 1 H), 3.79-3.91 (m, 0.5 H),

3.24 (br d, 0.5 H), 2.70-3.13 (m, 2 H)

2430
(CD₃OD) δ 7.20-7.90 (m, 4.5 H), 6.52-7.03 (m, 1.5 H), 4.92-
458.1
100%

5.05 (m, 1 H), 3.78-3.98 (m, 1.5 H), 2.80-3.28 (m, 2.5 H), 2.39-
[M + H]⁺

2.61 (m, 4 H), 1.98-2.29 (m, 2 H)

2431
(CD₃OD) δ 7.21-7.88 (m, 4.5 H), 6.56-7.03 (m, 1.5 H), 4.92-
458.2
94.4%

5.04 (m, 1 H), 3.72-3.99 (m, 1.5 H), 2.80-3.25 (m, 2.5 H), 2.40-
[M + H]⁺

2.57 (m, 4 H), 1.96-2.27 (m, 2 H)

2432
(CD₃OD) δ 8.33 (d, 1 H), 7.66 (s, 1 H), 6.95 (dd, 1 H), 6.82 (td,
366.2
98.2%

1 H), 6.64 (s, 1 H), 6.25 (s, 1 H), 4.19 (dd, 1 H), 3.67 (ddd, 1 H),
[M + H]⁺

2.96-3.08 (m, 1 H), 2.78 (br dd, 1 H), 1.99-2.11 (m, 1 H), 0.98-

1.16 (m, 4 H)

2433
(CD₃OD) δ 8.33 (d, 1 H), 7.67 (s, 1 H), 6.93-7.03 (m, 1 H), 6.82
366.2
98.8%

(td, 1 H), 6.64 (s, 1 H), 6.25 (s, 1 H), 4.19 (dd, 1 H), 3.67 (ddd, 1
[M + H]⁺

H), 2.90-3.08 (m, 1 H), 2.78 (dd, 1 H), 1.97-2.16 (m, 1 H), 0.89-

1.18 (m, 4 H)

2434
(CD₃OD) δ 8.25-8.90 (m, 3 H), 8.08 (s, 1 H), 7.87-8.01 (m, 2 H),
482.2
97.7%

7.57-7.78 (m, 2 H), 6.48-7.07 (m, 4 H), 4.93-5.08 (m, 1 H), 3.95
[M + H]⁺

(s, 3 H), 3.41-3.84 (m, 1 H), 2.72-3.15 (m, 2 H)

2435
(CD₃OD) δ 8.26-8.89 (m, 3 H), 7.80-8.13 (m, 3 H), 7.55-7.76
482.2
98.3%

(m, 2 H), 6.54-7.03 (m, 4 H), 4.92-5.07 (m, 1 H), 3.82-4.08 (m, 3
[M + H]⁺

H), 3.40-3.81 (m, 1 H), 2.72-3.13 (m, 2 H)

2436
(CD₃OD) δ 8.62 (s, 1.6 H), 8.17-8.52 (m, 1.4 H), 7.92 (s, 1 H),
444.2
100%

7.69 (s, 1 H), 7.44 (d, 1 H), 7.01 (br d, 1 H), 6.81 (br t, 1 H),
[M + H]⁺

6.45-6.65 (m, 1 H), 6.43-7.20 (m, 1 H), 4.63 (br s, 1 H), 4.54 (s,

2 H), 3.52-3.93 (m, 1 H), 3.44 (s, 3 H), 3.00-3.15 (m, 1 H), 2.72-

2.85 (m, 1 H), 2.46 (s, 3 H)

2437
(CD₃OD) δ 8.22-8.88 (m, 3 H), 7.97 (d, 1 H), 7.76 (br d, 1 H),
442.2
90.1%

7.44 (dd, 1 H), 6.35-7.08 (m, 4 H), 4.58-4.75 (m, 1 H), 4.49-4.57
[M + H]⁺

(m, 2 H), 3.50-3.89 (m, 1 H), 3.44 (s, 3 H), 3.00-3.17 (m, 1 H),

2.71-2.86 (m, 1 H), 2.46 (s, 3 H)

2438
(CD₃OD) δ 8.88 (s, 2 H), 8.11 (s, 1 H), 7.85-8.04 (m, 3 H), 7.59-
532.2
100%

7.77 (m, 2 H), 7.21-7.53 (m, 2 H), 6.30-7.08 (m, 2 H), 4.65-4.80
[M + H]⁺

(m, 1 H), 3.97 (s, 3 H), 3.37-3.51 (m, 1 H), 3.03-3.16 (m, 1 H),

2.78 (br dd, 1 H)

2439
(CD₃OD) δ 8.88 (s, 2 H), 8.12 (s, 1 H), 7.85-8.03 (m, 3 H), 7.61-
532.2
99.6%

7.75 (m, 2 H), 7.28-7.52 (m, 2 H), 6.39-7.11 (m, 2 H), 4.66-4.78
[M + H]⁺

(m, 1 H), 3.97 (s, 3 H), 3.36-3.52 (m, 1 H), 3.04-3.16 (m, 1 H),

2.78 (br dd, 1 H)

2440
(CD₃OD) δ 8.68 (d, 1 H), 8.13 (d, 1 H), 8.01 (td, 1 H), 7.84 (d, 1
453.1
100%

H), 7.69 (s, 1 H), 7.55 (ddd, 1 H), 7.17-7.37 (m, 2 H), 6.80 (s, 1
[M + H]⁺

H), 6.55 (s, 1 H), 4.45 (dd, 1 H), 3.74-3.94 (m, 1 H), 3.00-3.16

(m, 1 H), 2.86 (dd, 1 H)

2441
(CD₃OD) δ 8.67 (d, 1 H), 8.12 (d, 1 H), 8.00 (td, 1 H), 7.83 (d, 1
453.1
98.3%

H), 7.67 (s, 1 H), 7.54 (ddd, 1 H), 7.12-7.34 (m, 2 H), 6.78 (s, 1
[M + H]⁺

H), 6.53 (s, 1 H), 4.44 (dd, 1 H), 3.66-3.94 (m, 1 H), 2.96-3.22

(m, 1 H), 2.85 (dd, 1 H)

2442
(CD₃OD) δ 8.29 (d, 1 H), 7.67 (s, 1 H), 6.96 (d, 1 H), 6.77 (t, 1
336.2
100%

H), 6.54 (s, 1 H), 6.30 (s, 1 H), 4.21 (dd, 1 H), 3.59-3.85 (m, 1
[M + H]⁺

H), 2.95-3.14 (m, 1 H), 2.78 (dd, 1 H), 2.42 (d, 3 H), 2.40 (d, 3 H)

2443
(CD₃OD) δ 8.31 (br d, 1 H), 7.67 (s, 1 H), 7.00 (d, 1 H), 6.80(t,
336.2
99.7%

1 H), 6.54 (s, 1 H), 6.30 (s, 1 H), 4.22 (dd, 1 H), 3.70 (ddd, 1 H),
[M + H]⁺

2.96-3.12 (m, 1 H), 2.79 (br dd, 1 H), 2.75 (s, 3 H), 2.43 (s, 3H)

2444
(CD₃OD) δ 8.22-8.57 (m, 2 H), 8.12 (s, 0.8 H), 7.47-7.84 (m, 1
482.2
100%

H), 7.18-7.29 (m, 0.2 H), 6.91-7.15 (m, 2 H), 6.66-6.91 (m, 2 H),
[M + H]⁺

5.10 (br dd, 1 H), 4.02 (s, 3 H), 3.68-3.87 (m, 0.6 H), 3.36-3.48

(m, 0.4 H), 2.94-3.25 (m, 1 H), 2.77-2.92 (m, 1 H)

2445
(CD₃OD) δ 8.24-8.57 (m, 2 H), 8.12 (s, 0.8 H), 7.56-7.78 (m, 1
482.1
98.6%

H), 7.17-7.30 (m, 0.2 H), 6.91-7.14 (m, 2 H), 6.66-6.90 (m, 2 H),
[M + H]⁺

5.10 (dd, 1 H), 4.02 (s, 3 H), 3.67-3.89 (m, 0.6 H), 3.37-3.48 (m,

0.4 H), 2.95-3.27 (m, 1 H), 2.75-2.95 (m, 1 H)

2446
(CD₃OD) δ 8.90-8.96 (m, 1 H), 8.37 (s, 1 H), 8.03-8.11 (m, 1 H),
482.2
97.1%

7.82 (s, 0.2 H), 7.69 (d, 1.5 H), 7.51-7.57 (m, 0.5 H), 6.77-6.96
[M + H]⁺

(m, 1.8 H), 6.57-6.69 (m, 2 H), 5.06 (br dd, 1 H), 3.94-3.98 (m, 3

H), 3.78 (br s, 0.6 H), 3.37-3.50 (m, 0.4 H), 2.84-3.21 (m, 2 H)

2447
(CD₃OD) δ 8.94 (s, 1 H), 8.37 (s, 1 H), 8.00-8.14 (m, 1 H), 7.82
482.1
99.0%

(s, 0.2 H), 7.65-7.73 (m, 1.5 H), 7.54 (br d, 0.5 H), 6.76-6.99 (m,
[M + H]⁺

1.8 H), 6.57-6.72 (m, 2 H), 5.06 (br dd, 1 H), 3.93-3.99 (m, 3 H),

3.77 (br d, 0.6 H), 3.35-3.50 (m, 0.4 H), 2.85-3.16 (m, 2 H)

2448
(CD₃OD) δ 9.31-9.40 (m, 1 H), 8.68-8.79 (m, 2 H), 8.16-8.32
480.1
96.6%

(m, 1 H), 7.06-7.67 (m, 1.5 H), 6.61-6.96 (m, 4.5 H), 4.83-4.97
[M + H]⁺

(m, 1 H), 3.69 (ddd, 0.7 H), 3.34 (td, 0.3 H), 2.86-3.15 (m, 1 H),

2.69-2.81 (m, 1 H)

2449
(CD₃OD) δ 9.31-9.40 (m, 1 H), 8.68-8.79 (m, 2 H), 8.16-8.31
480.2
94.9%

(m, 1 H), 7.08-7.65 (m, 1.5 H), 6.61-6.96 (m, 4.5 H), 4.83-4.98
[M + H]⁺

(m, 1 H), 3.69 (ddd, 0.7 H), 3.34 (td, 0.3 H), 2.87-3.16 (m, 1 H),

2.75 (br d, 1 H)

2450
(DMSO-d₆) δ 11.99 (br s, 1 H), 8.21-8.74 (m, 3 H), 7.85 (d, 1
428.1
100%

H), 7.55 (s, 1 H), 7.24 (dd, 1 H), 6.33-7.07 (m, 4 H), 4.34-4.66
[M + H]⁺

(m, 1 H), 3.84 (s, 3 H), 3.25-3.31 (m, 1 H), 2.85-3.06 (m, 1 H),

2.67 (br s, 1 H), 2.40 (s, 3 H)

2451
(DMSO-d₆) δ 11.88-12.17 (m, 1 H), 8.20-8.87 (m, 3 H), 7.85 (d,
428.2
100%

1 H), 7.55 (s, 1 H), 7.17-7.33 (m, 1 H), 6.37-7.09 (m, 4 H), 4.34-
[M + H]⁺

4.69 (m, 1 H), 3.84 (s, 3 H), 3.33 (br s, 1 H), 2.86-3.05 (m, 1 H),

2.63-2.73 (m, 1 H), 2.34-2.44 (m, 3 H)

2452
(CD₃OD) δ 9.31 (s, 2 H), 8.67 (d, 1 H), 7.84-8.15 (m, 5 H), 7.65
529.2
100%

(s, 1 H), 7.25-7.51 (m, 3 H), 6.66 (br s, 2 H), 4.66 (br s, 1 H),
[M + H]⁺

3.36-3.64 (m, 1 H), 3.08 (br s, 1 H), 2.77 (dd, 1 H)

2453
(CD₃OD) δ 9.31 (s, 2 H), 8.67 (d, 1 H), 7.87-8.12 (m, 5 H), 7.65
529.2
100%

(s, 1 H), 7.15-7.52 (m, 3 H), 6.68 (br s, 2 H), 4.67 (br s, 1 H),
[M + H]⁺

3.48 (br s, 1 H), 2.98-3.20 (m, 1 H), 2.77 (dd, 1 H)

2454
(CD₃OD) δ 8.39 (d, 2 H), 7.48-7.70 (m, 2 H), 7.07-7.25 (m, 2
352.1
100%

H), 6.99 (d, 1 H), 6.56-6.72 (m, 2 H), 5.06 (br dd, 1 H), 3.50-
[M + H]⁺

3.65 (m, 1 H), 2.82-2.98 (m, 1 H), 2.70 (dd, 1 H)

2455
(CD₃OD) δ 8.27 (d, 2 H), 7.36-7.56 (m, 2 H), 6.95-7.16 (m, 2
352.1
99.2%

H), 6.86 (d, 1 H), 6.46-6.62 (m, 2 H), 4.93-4.98 (m, 1 H), 3.38-
[M + H]⁺

3.50 (m, 1 H), 2.70-2.86 (m, 1 H), 2.58 (dd, 1 H)

2456
(CD₃OD) δ 8.33 (d, 1 H), 7.56 (s, 1 H), 7.19 (d, 1 H), 6.74 (t, 1
356.1
100%

H), 6.55 (s, 1 H), 6.18 (s, 1 H), 4.12 (dd, 1 H), 3.58 (ddd, 1 H),
[M + H]⁺

2.84-3.00 (m, 1 H), 2.61-2.76 (m, 1 H), 2.33 (s, 3 H)

2457
(CD₃OD) δ 8.33 (d, 1 H), 7.56 (s, 1 H), 7.19 (d, 1 H), 6.74 (t, 1
356.1
93.9%

H), 6.55 (s, 1 H), 6.19 (s, 1 H), 4.12 (dd, 1 H), 3.58 (ddd, 1 H),
[M + H]⁺

2.86-2.98 (m, 1 H), 2.67 (br dd, 1 H), 2.33 (s, 3 H)

2458
(CD₃OD) δ 9.05-9.25 (m, 1 H), 8.48 (s, 1 H), 8.29-8.42 (m, 1 H),
536.1
100%

7.71 (s, 1 H), 7.56 (s, 0.3 H), 7.17-7.28 (m, 0.3 H), 6.94-7.08 (m,
[M + H]⁺

2.2 H), 6.81-6.91 (m, 1.2 H), 6.69-6.79 (m, 1 H), 5.08 (dd, 0.7

H), 4.95 (br d, 0.3 H), 3.72-3.88 (m, 0.7 H), 3.43 (td, 0.3 H),

3.12-3.26 (m, 0.7 H), 2.95-3.08 (m, 0.3 H), 2.78-2.92 (m, 1 H)

2459
(CD₃OD) δ 9.05-9.26 (m, 1 H), 8.48 (s, 1 H), 8.29-8.42 (m, 1 H),
536.2
99.9%

7.72 (s, 1 H), 7.56 (s, 0.3 H), 7.18-7.26 (m, 0.3 H), 6.94-7.08 (m,
[M + H]⁺

2.2 H), 6.81-6.92 (m, 1.2 H), 6.69-6.79 (m, 1 H), 5.08 (dd, 0.7

H), 4.95 (br d, 0.3 H), 3.71-3.86 (m, 0.7 H), 3.43 (td, 0.3 H),

3.13-3.26 (m, 0.7 H), 2.96-3.09 (m, 0.3 H), 2.79-2.92 (m, 1 H)

2460
(CD₃OD) δ 8.45 (d, 1 H), 7.43-7.85 (m, 2 H), 7.15-7.28 (m, 1
358.1
99.3%

H), 6.78-7.13 (m, 2 H), 6.58 (s, 1 H), 6.38 (s, 1 H), 4.32 (dd, 1
[M + H]⁺

H), 3.77 (ddd, 1 H), 2.97-3.18 (m, 1 H), 2.83 (br dd, 1 H)

2461
(CD₃OD) δ 8.44 (d, 1 H), 7.44-7.84 (m, 2 H), 7.20 (dd, 1 H),
358.2
99.4%

6.78-7.13 (m, 2 H), 6.57 (s, 1 H), 6.37 (s, 1 H), 4.31 (dd, 1 H),
[M + H]⁺

3.76 (ddd, 1 H), 2.95-3.16 (m, 1 H), 2.82 (br dd, 1 H)

2462
(CD₃OD) δ 8.07-9.10 (m, 2 H), 7.85 (d, 1 H), 7.75 (d, 1 H),
474.2
100%

7.40-7.66 (m, 2 H), 7.27-7.35 (m, 1 H), 7.16-7.23 (m, 2 H), 6.62
[M + H]⁺

(br s, 2 H), 4.61-4.73 (m, 1 H), 3.36-3.98 (m, 1 H), 2.98-3.10 (m,

1 H), 2.75 (dd, 1 H), 1.96-2.05 (m, 1 H), 0.98-1.06 (m, 2 H),

0.74-0.80 (m, 2 H)

2463
(CD₃OD) δ 8.41 (s, 2 H), 7.85 (d, 1 H), 7.74 (d, 1 H), 7.43-7.68
474.2
99.4%

(m, 2 H), 7.26-7.34 (m, 1 H), 7.16-7.24 (m, 2 H), 6.62 (br s, 2
[M + H]⁺

H), 4.60-4.72 (m, 1 H), 3.32-3.77 (m, 1 H), 2.99-3.10 (m, 1 H),

2.75 (dd, 1 H), 1.97-2.04 (m, 1 H), 0.99-1.05 (m, 2 H), 0.74-0.80

(m, 2 H)

2464
(DMSO-d₆) δ 12.02 (br s, 1 H), 8.50 (d, 2 H), 7.88 (d, 1 H), 7.69
448.1
99.8%

(br d, 1 H), 7.56 (s, 1 H), 7.07-7.33 (m, 3 H), 6.70 (br d, 2 H),
[M + H]⁺

4.33-4.72 (m, 1 H), 3.84 (s, 4 H), 2.93 (br d, 1 H), 2.56-2.75 (m,

1 H)

2465
(DMSO-d₆) δ 12.02 (br s, 1 H), 8.51 (s, 2 H), 7.88 (d, 1 H), 7.69
448.1
99.5%

(br d, 1 H), 7.56 (s, 1 H), 7.09-7.36 (m, 3 H), 6.33-6.93 (m, 2 H),
[M + H]⁺

4.50 (br d, 1 H), 3.84 (s, 4 H), 2.95 (br s, 1 H), 2.57-2.78 (m, 1 H)

2466
(CD₃OD) δ 8.59 (d, 1 H), 7.68 (s, 1 H), 7.35-7.50 (m, 1 H), 6.81-
372.2
99.6%

7.15 (m, 2 H), 6.71 (s, 1 H), 6.33 (s, 1 H), 4.24 (dd, 1 H), 3.69
[M + H]⁺

(ddd, 1 H), 2.98-3.11 (m, 1 H), 2.79 (dd, 1 H), 2.45 (s, 3 H)

2467
(CD₃OD) δ 8.47 (d, 1 H), 7.58 (s, 1 H), 7.32 (d, 1 H), 6.70-7.05
372.1
98.4%

(m, 2 H), 6.60 (s, 1 H), 6.21 (s, 1 H), 4.12 (dd, 1 H), 3.49-3.65
[M + H]⁺

(m, 1 H), 2.85-3.00 (m, 1 H), 2.62-2.74 (m, 1 H), 2.33 (s, 3 H)

2468
(CD₃OD) δ 9.05 (d, 2 H), 8.43-8.56 (m, 1 H), 7.69-7.75 (m, 2
498.1
100%

H), 7.47 (br s, 0.3 H), 7.18-7.26 (m, 1 H), 6.79-7.01 (m, 2.7 H),
[M + H]⁺

5.00 (td, 1 H), 3.78-3.85 (m, 0.6 H), 3.46 (td, 0.4 H), 2.86-3.26

(m, 2 H)

2469
(CD₃OD) δ 9.05 (d, 2 H), 8.42-8.53 (m, 1 H), 7.69-7.75 (m, 2
498.1
100%

H), 7.47 (s, 0.3 H), 7.18-7.26 (m, 1 H), 6.80-7.01 (m, 2.7 H),
[M + H]⁺

5.00 (td, 1 H), 3.82 (ddd, 0.6 H), 3.46 (td, 0.4 H), 2.85-3.26 (m,

2 H)

2470
(CD₃OD) δ 7.99-8.70 (m, 3 H), 7.76 (d, 1 H), 7.54 (s, 1 H), 7.20
428.2
100%

(d, 1 H), 6.34-6.87 (m, 4 H), 4.44-4.59 (m, 1 H), 3.84 (s, 3 H),
[M + H]⁺

3.27-3.59 (m, 1 H), 2.62-3.00 (m, 2 H), 2.27 (s, 3 H)

2471
(CD₃OD) δ 7.89-8.57 (m, 3 H), 7.74 (br d, 1 H), 7.54 (br s, 1 H),
428.2
100%

7.17 (br d, 1 H), 6.29-6.79 (m, 4 H), 4.45-4.60 (m, 1 H), 3.82 (s,
[M + H]⁺

3 H), 3.24-3.59 (m, 1 H), 2.60-3.01 (m, 2 H), 2.25 (br s, 3 H)

2472
(CD₃OD) δ 8.21-9.59 (m, 1 H), 7.79-7.95 (m, 3 H), 7.63 (s, 1 H),
495.2
99.7%

7.24-7.45 (m, 3 H), 6.67 (br s, 2 H), 4.64 (br d, 1 H), 3.48 (br s,
[M + H]⁺

1 H), 3.00-3.11 (m, 1 H), 2.95 (s, 6 H), 2.75 (dd, 1 H)

2473
(CD₃OD) δ 8.91 (br s, 1 H), 7.75-8.01 (m, 3 H), 7.64 (s, 1 H),
495.2
99.1%

7.21-7.46 (m, 3 H), 6.47-6.98 (m, 2 H), 4.64 (br d, 1 H), 3.38-
[M + H]

3.82 (m, 1 H), 2.99-3.11 (m, 1 H), 2.95 (s, 6 H), 2.75 (dd, 1H)

2474
(CD₃OD) δ 8.26-9.27 (m, 1 H), 7.80-7.96 (m, 2 H), 7.55-7.69
461.2
99.5%

(m, 2 H), 7.36 (dd, 1 H), 7.18 (dd, 1 H), 7.05 (d, 1 H), 6.50-6.96
[M + H]⁺

(m, 2 H), 4.64 (br s, 1 H), 3.42-3.97 (m, 1 H), 3.00-3.15 (m, 1

H), 2.94 (s, 6 H), 2.75 (dd, 1 H)

2475
(CD₃OD) δ 8.11-9.10 (m, 1 H), 7.77-7.94 (m, 2 H), 7.53-7.70
461.2
99.5%

(m, 2 H), 7.37 (dd, 1 H), 7.11-7.24 (m, 1 H), 7.06 (br d, 1 H),
[M + H]⁺

6.47-6.92 (m, 2 H), 4.64 (br s, 1 H), 3.48 (br s, 1 H), 2.99-3.17

(m, 1 H), 2.95 (s, 6 H), 2.75 (br dd, 1 H)

2476
(CD₃OD) δ 8.77 (br s, 1 H), 8.54 (s, 2 H), 7.91 (d, 1 H), 7.59-
523.2
97.7%

7.72 (m, 2 H), 7.39 (d, 1 H), 6.44-7.13 (m, 3 H), 4.59 (br s, 1 H),
[M + H]⁺

3.48 (br s, 1 H), 3.03-3.12 (m, 1 H), 2.85-2.91 (m, 2 H), 2.78 (br

d, 1 H), 2.63-2.70 (m, 2 H), 2.34 (s, 6 H)

2477
(CD₃OD) δ 8.78 (br s, 1 H), 8.54 (s, 2 H), 7.91 (d, 1 H), 7.56-
523.3
98.2%

7.73 (m, 2 H), 7.39 (d, 1 H), 6.41-7.16 (m, 3 H), 4.59 (br s, 1 H),
[M + H]⁺

3.38-3.76 (m, 1 H), 3.02-3.12 (m, 1 H), 2.84-2.90 (m, 2 H), 2.74-

2.81 (m, 1 H), 2.62-2.69 (m, 2 H), 2.33 (s, 6H)

2478
(CD₃OD) δ 8.27-8.76 (m, 3 H), 7.84 (s, 1 H), 7.67 (s, 1 H), 7.42
456.2
100%

(dd, 1 H), 6.99-7.06 (m, 1 H), 6.48-6.90 (m, 3 H), 4.96 (br s, 1
[M + H]⁺

H), 3.69 (t, 2 H), 3.34-3.42 (m, 4 H), 3.02-3.14 (m, 1 H), 2.95 (t,

2 H), 2.73-2.84 (m, 1 H), 2.42-2.50 (m, 3 H)

2479
(CD₃OD) δ 8.30 (s, 3 H), 7.85-7.95 (m, 1 H), 7.60-7.73 (m, 1 H),
456.2
91.8%

7.42 (dd, 1 H), 6.97-7.06 (m, 1 H), 6.46-6.91 (m, 3 H), 4.94-5.08
[M + H]⁺

(m, 1 H), 3.69 (t, 2 H), 3.37 (s, 4 H), 3.02-3.13 (m, 1 H), 2.89-

2.99 (m, 2 H), 2.70-2.83 (m, 1 H), 2.50 (s, 3 H)

2480
(CD₃OD) δ 8.30 (d, 1 H), 7.67 (s, 1 H), 6.98 (d, 1 H), 6.78 (t, 1
376.2
99.8%

H), 6.54 (s, 1 H), 6.31 (s, 1 H), 4.23 (dd, 1 H), 3.61-3.78 (m, 2
[M + H]⁺

H), 2.98-3.12 (m, 1 H), 2.80 (br dd, 1 H), 2.33-2.52 (m, 7 H),

1.98-2.22 (m, 2 H)

2481
(CD₃OD) δ 8.30 (br d, 1 H), 7.69 (s, 1 H), 6.98 (br d, 1 H), 6.78
376.2
99.8%

(t, 1 H), 6.54 (s, 1 H), 6.31 (s, 1 H), 4.23 (dd, 1 H), 3.61-3.77 (m,
[M + H]⁺

2 H), 2.97-3.10 (m, 1 H), 2.80 (br dd, 1 H), 2.38-2.46 (m, 7 H),

2.00-2.18 (m, 2 H)

2482
(CD₃OD) δ 8.57 (d, 1 H), 7.46-7.69 (m, 2 H), 6.88 (t, 1 H), 6.61
430.2
100%

(s, 1 H), 6.22 (s, 1 H), 4.15 (dd, 1 H), 3.51-3.67 (m, 2 H), 2.87-
[M + H]⁺

3.00 (m, 1 H), 2.70 (dd, 1 H), 2.23-2.35 (m, 4 H), 1.86-2.09 (m,

2 H)

2483
(CD₃OD) δ 8.57 (d, 1 H), 7.47-7.59 (m, 2 H), 6.83-6.92 (m, 1
430.1
100%

H), 6.61 (s, 1 H), 6.22 (s, 1 H), 4.15 (dd, 1 H), 3.50-3.63 (m, 2
[M + H]⁺

H), 2.87-2.96 (m, 1 H), 2.66-2.73 (m, 1 H), 2.25-2.35 (m, 4 H),

1.88-2.05 (m, 2 H)

2484
(CD₃OD) δ 8.46 (d, 1 H), 7.56 (s, 1 H), 7.32 (d, 1 H), 6.69-7.02
412.1
99.9%

(m, 2 H), 6.16-6.64 (m, 2 H), 4.13 (dd, 1 H), 3.45-3.66 (m, 2 H),
[M + H]⁺

2.85-2.98 (m, 1 H), 2.70 (dd, 1 H), 2.22-2.37 (m, 4 H), 1.85-2.08

(m, 2 H)

2485
(CD₃OD) δ 8.49 (br d, 1 H), 7.59 (s, 1 H), 7.35 (br d, 1 H), 6.74-
412.2
99.6%

7.04 (m, 2 H), 6.64 (s, 1 H), 6.24 (s, 1 H), 4.16 (dd, 1 H), 3.50-
[M + H]⁺

3.71 (m, 2 H), 2.89-3.01 (m, 1 H), 2.73 (br dd, 1 H), 2.24-2.40

(m, 4 H), 1.92-2.11 (m, 2 H)

2486
(CD₃OD) δ 7.67-7.79 (m, 2 H), 7.15-7.51 (m, 3 H), 6.69 (s, 1 H),
426.1
100%

6.41 (s, 1 H), 4.37 (dd, 1 H), 3.73-3.87 (m, 1 H), 3.01-3.14 (m, 1
[M + H]⁺

H), 2.86 (dd, 1 H)

2487
(CD₃OD) δ 7.64-7.80 (m, 2 H), 7.15-7.51 (m, 3 H), 6.69 (s, 1 H),
426.1
99.0%

6.41 (s, 1 H), 4.37 (dd, 1 H), 3.74-3.87 (m, 1 H), 3.02-3.14 (m, 1
[M + H]⁺

H), 2.86 (dd, 1 H)

2488
(CD₃OD) δ 8.58-8.75 (m, 1 H), 8.39 (s, 1 H), 8.10 (s, 1 H), 7.45-
494.1
100%

7.75 (m, 2.4 H), 7.17-7.37 (m, 1 H), 6.92 (s, 0.6 H), 6.55-6.75
[M + H]⁺

(m, 1 H), 5.09 (br d, 1 H), 4.00 (s, 3 H), 3.68-3.83 (m, 0.7 H),

3.34-3.44 (m, 0.3 H), 3.07-3.23 (m, 1 H), 2.71-2.91 (m, 1 H)

2489
(CD₃OD) δ 8.59-8.75 (m, 1 H), 8.40 (s, 1 H), 8.10 (s, 1 H), 7.70
494.1
99.4%

(s, 1 H), 7.47-7.62 (m, 1.4 H), 7.23-7.39 (m, 1 H), 6.93 (s, 0.6
[M + H]⁺

H), 6.57-6.75 (m, 1 H), 5.08 (dd, 1 H), 4.02 (s, 3 H), 3.71-3.86

(m, 0.7 H), 3.33-3.46 (m, 0.3 H), 2.93-3.24 (m, 1 H), 2.58-2.89

(m, 1 H)

2490
(CD₃OD) δ 7.86 (d, 1 H), 7.73 (s, 1 H), 7.25-7.40 (m, 2 H), 6.74
444.1
100%

(s, 1 H), 6.40 (s, 1 H), 4.37 (dd, 1 H), 3.73 (td, 1 H), 3.02-3.14
[M + H]⁺

(m, 1 H), 2.86 (dd, 1 H)

2491
(CD₃OD) δ 7.86 (d, 1 H), 7.71 (s, 1 H), 7.22-7.42 (m, 2 H), 6.73
444.1
98.2%

(s, 1 H), 6.40 (s, 1 H), 4.37 (dd, 1 H), 3.65-3.79 (m, 1 H), 3.00-
[M + H]⁺

3.13 (m, 1 H), 2.86 (dd, 1 H)

2492
(CD₃OD) δ 7.69 (s, 1 H), 7.62 (dd, 1 H), 7.20 (dd, 1 H), 7.06
410.1
95.7%

(dd, 1 H), 6.71 (s, 1 H), 6.42 (s, 1 H), 4.37 (dd, 1 H), 3.83 (ddd,
[M + H]⁺

1 H), 3.00-3.16 (m, 1 H), 2.86 (dd, 1 H)

2493
(CD₃OD) δ 7.57 (s, 1 H), 7.50 (dd, 1 H), 7.08 (dd, 1 H), 6.94
410.1
84.1%

(dd, 1 H), 6.59 (s, 1 H), 6.30 (s, 1 H), 4.25 (dd, 1 H), 3.71 (ddd,
[M + H]⁺

1 H), 2.89-3.04 (m, 1 H), 2.74 (dd, 1 H)

2494
(CD₃OD) δ 8.20-8.33 (m, 1 H), 7.70 (s, 1 H), 7.49 (br s, 0.3 H),
390.2
100%

6.96 (s, 0.7 H), 6.70-6.85 (m, 3 H), 4.93-5.01 (m, 1 H), 3.77
[M + H]⁺

(ddd, 0.7 H), 3.41 (td, 0.3 H), 2.93-3.21 (m, 1 H), 2.77-2.89 (m,

1 H), 2.60-2.70 (m, 3 H), 1.90-2.32 (m, 1 H), 0.96-1.10 (m, 2 H),

0.69-0.85 (m, 2 H)

2495
(CD₃OD) δ 8.21-8.33 (m, 1 H), 7.70 (s, 1 H), 7.45-7.53 (m, 0.3
390.2
100%

H), 6.96 (s, 0.7 H), 6.69-6.86 (m, 3 H), 4.98 (br d, 1 H), 3.77
[M + H]⁺

(ddd, 0.6 H), 3.39-3.46 (m, 0.4 H), 2.93-3.21 (m, 1 H), 2.79-2.90

(m, 1 H), 2.63-2.68 (m, 3 H), 2.04-2.17 (m, 1 H), 0.99-1.13 (m, 2

H), 0.75-0.87 (m, 2 H)

2496
(CD₃OD) δ 8.32-8.71 (m, 1 H), 7.49-8.01 (m, 3 H), 7.13-7.29
375.2
100%

(m, 1 H), 6.37-6.98 (m, 3 H), 4.68-4.79 (m, 0.5 H), 4.38-4.57
[M + H]⁺

(m, 0.5 H), 3.62-3.84 (m, 0.5 H), 2.93-3.14 (m, 1 H), 2.64-2.92

(m, 1 H), 2.20 (br d, 1 H), 0.92-1.40 (m, 4.5 H)

2497
(CD₃OD) δ 8.35-8.60 (m, 1 H), 7.49-8.04 (m, 3 H), 7.13-7.30
375.2
99.3%

(m, 1 H), 6.36-7.03 (m, 3 H), 4.70-4.80 (m, 0.5 H), 4.37-4.56 (m,
[M + H]⁺

0.5 H), 3.62-3.89 (m, 0.5 H), 2.93-3.15 (m, 1 H), 2.65-2.92 (m, 1

H), 2.21 (br d, 1 H), 0.94-1.39 (m, 4.5 H)

2498
(CD₃OD) δ 8.33 (br s, 1 H), 7.79-8.17 (m, 1 H), 7.74 (s, 1 H),
429.2
100%

7.67 (s, 1 H), 6.96-7.05 (m, 1 H), 6.83-6.96 (m, 2 H), 6.79 (br t,
[M + H]⁺

1 H), 6.65 (br s, 1 H), 4.80-4.82 (m, 1 H), 3.92-4.12 (m, 3 H),

3.71-3.86 (m, 0.5 H), 3.45-3.54 (m, 0.5 H), 3.01-3.21 (m, 1 H),

2.72-2.92 (m, 1 H), 2.45 (s, 3 H)

2499
(CD₃OD) δ 8.24-8.43 (m, 1 H), 7.79-8.16 (m, 1 H), 7.61-7.78
429.2
100%

(m, 2 H), 6.99 (br d, 1 H), 6.85-6.95 (m, 2 H), 6.73-6.82 (m, 1
[M + H]⁺

H), 6.51-6.68 (m, 1 H), 4.77 (br dd, 1 H), 4.00 (s, 3 H), 3.66-

3.88 (m, 0.6 H), 3.34-3.61 (m, 0.5 H), 2.97-3.20 (m, 0.5 H),

2.71-2.91 (m, 1 H), 2.45 (s, 3H)

2500
(500 MHz, CD₃OD) δ 8.15-8.36 (m, 1 H), 7.54-7.78 (m, 1.5 H),
380.2
100%

6.86-7.06 (m, 1.5 H), 6.70-6.85 (m, 1 H), 6.37-6.66 (m, 1 H),
[M + H]⁺

5.09 (dd, 1 H), 3.63-3.79 (m, 0.5 H), 3.34-3.47 (m, 0.5 H), 2.91-

3.20 (m, 1 H), 2.73-2.85 (m, 4 H), 2.35-2.49 (m, 3 H)

2501
(500 MHz, CD₃OD) δ 8.12-8.41 (m, 1 H), 7.68 (d, 1.5 H), 6.88-
380.1
99.4%

7.07 (m, 1.5 H), 6.69-6.81 (m, 1 H), 6.47-6.64 (m, 1 H), 5.09
[M + H]⁺

(dd, 1 H), 3.61-3.78 (m, 0.5 H), 3.32-3.47 (m, 0.5 H), 2.90-3.21

(m, 1 H), 2.73-2.87 (m, 4 H), 2.34-2.45 (m, 3 H)

2502
(CD₃OD) δ 8.18-8.40 (m, 1.4 H), 8.01-8.17 (m, 2 H), 7.69 (s, 1
415.1
100%

H), 7.44-7.64 (m, 2 H), 6.90-7.06 (m, 1.6 H), 6.70-6.84 (m, 1 H),
[M + H]⁺

6.48-6.67 (m, 1 H), 5.49 (dd, 0.5 H), 4.90 (br s, 0.5 H), 3.61-3.86

(m, 0.7 H), 3.44 (td, 0.3 H), 2.98-3.25 (m, 1 H), 2.74-2.88 (m, 1

H), 2.29-2.51 (m, 3 H)

2503
(CD₃OD) δ 8.21-8.40 (m, 1.4 H), 8.07-8.19 (m, 2 H), 7.71 (s, 1
415.2
99.6%

H), 7.51-7.66 (m, 2 H), 6.94-7.06 (m, 1.6 H), 6.72-6.85 (m, 1 H),
[M + H]⁺

6.49-6.69 (m, 1 H), 5.44-5.60 (m, 0.5 H), 4.93-4.98 (m, 0.5 H),

3.67-3.86 (m, 0.7 H), 3.41-3.55 (m, 0.3 H), 3.12 (s, 1 H), 2.76-

2.91 (m, 1 H), 2.35-2.53 (m, 3 H)

2504
(CD₃OD) δ 8.17-8.39 (m, 1 H), 7.71-8.05 (m, 1 H), 7.48-7.69
433.2
100%

(m, 2 H), 6.52-6.99 (m, 5 H), 4.82-4.97 (m, 1 H), 3.83-4.06 (m, 3
[M + H]⁺

H), 3.56-3.78 (m, 0.6 H), 3.34-3.49 (m, 0.4 H), 2.86-3.12 (m, 1

H), 2.59-2.82 (m, 1 H)

2505
(CD₃OD) δ 8.28-8.53 (m, 1 H), 7.84-8.15 (m, 1 H), 7.61-7.82
433.2
96.1%

(m, 2 H), 6.69-7.10 (m, 5 H), 4.95-5.05 (m, 1 H), 4.02 (s, 3 H),
[M + H]⁺

3.70-3.91 (m, 0.5 H), 3.45-3.59 (m, 0.5 H), 3.00-3.24 (m, 1 H),

2.73-2.94 (m, 1 H)

2506
(CD₃OD) δ 8.73 (br s, 1 H), 8.29 (br s, 1 H), 7.78-8.13 (m, 2 H),
483.2
100%

7.58-7.77 (m, 2 H), 6.63-7.12 (m, 3 H), 4.51-4.84 (m, 1 H), 3.99
[M + H]⁺

(s, 3 H), 3.37-3.88 (m, 1 H), 2.71-3.24 (m, 2 H)

2507
(CD₃OD) δ 8.73 (br s, 1 H), 8.29 (br s, 1 H), 7.77-8.12 (m, 2 H),
483.2
99.1%

7.58-7.77 (m, 2 H), 6.62-7.10 (m, 3 H), 4.63 (br s, 1 H), 3.98 (s,
[M + H]⁺

3 H), 3.80 (br s, 1 H), 2.78-3.26 (m, 2 H)

2508
(CD₃OD) δ 8.36 (d, 1 H), 7.67 (s, 1 H), 6.77-7.26 (m, 3 H), 6.64
414.2
100%

(s, 1 H), 6.26 (s, 1 H), 4.20 (dd, 1 H), 3.59-3.80 (m, 1 H), 2.95-
[M + H]⁺

3.10 (m, 1 H), 2.80 (br dd, 1 H), 2.00-2.18 (m, 1 H), 0.94-1.22

(m, 4 H)

2509
(CD₃OD) δ 8.24 (d, 1 H), 7.57 (s, 1 H), 6.64-7.16 (m, 3 H), 6.52
414.2
99.1%

(s, 1 H), 6.14 (s, 1 H), 4.08 (dd, 1 H), 3.47-3.67 (m, 1 H), 2.82-
[M + H]⁺

3.01 (m, 1 H), 2.68 (br dd, 1 H), 1.90-2.02 (m, 1 H), 0.86-1.08

(m, 4 H)

2510
(CD₃OD) δ 9.26 (s, 1 H), 8.60-8.77 (m, 3 H), 7.69 (s, 1 H), 7.59
454.1
98.7%

(br d, 1 H), 6.95 (br t, 1 H), 6.81 (s, 1 H), 6.53 (s, 1 H), 4.46(br
[M + H]⁺

dd, 1 H), 3.73-3.91 (m, 1 H), 3.03-3.18 (m, 1 H), 2.85 (br dd, 1 H)

2511
(CD₃OD) δ 9.27 (d, 1 H), 8.57-8.79 (m, 3 H), 7.69 (s, 1 H), 7.60
454.2
95.4%

(br d, 1 H), 6.96 (t, 1 H), 6.81 (s, 1 H), 6.54(s, 1 H), 4.46(dd, 1
[M + H]⁺

H), 3.71-3.88 (m, 1 H), 2.99-3.21 (m, 1 H), 2.86 (br dd, 1 H)

2512
(CD₃OD) δ 9.17 (dd, 1 H), 8.10-8.36 (m, 2 H), 7.77 (dd, 1 H),
428.2
100%

7.58 (s, 1 H), 6.93 (d, 1 H), 6.56-6.82 (m, 2 H), 6.44 (s, 1 H),
[M + H]⁺

4.37 (dd, 1 H), 3.63-3.86 (m, 1 H), 2.91-3.15 (m, 2 H), 2.75 (br

dd, 1 H), 1.21 (t, 6 H)

2513
(CD₃OD) δ 9.17 (dd, 1 H), 8.08-8.35 (m, 2 H), 7.77 (dd, 1 H),
428.2
99.3%

7.58 (s, 1 H), 6.92 (d, 1 H), 6.59-6.84 (m, 2 H), 6.44 (s, 1 H),
[M + H]⁺

4.37 (dd, 1 H), 3.63-3.85 (m, 1 H), 2.91-3.14 (m, 2 H), 2.75 (br

dd, 1 H), 1.21 (t, 6 H)

2514
(CD₃OD) δ 8.31-8.38 (m, 1 H), 7.67 (s, 1 H), 6.97 (dd, 1 H),
380.2
100%

6.84 (td, 1 H), 6.65 (s, 1 H), 6.25 (s, 1 H), 4.20 (dd, 1 H), 3.62-
[M + H]⁺

3.76 (m, 1 H), 2.95-3.09 (m, 1 H), 2.80 (br dd, 1 H), 1.50 (s, 3

H), 1.21-1.29 (m, 2 H), 0.91-0.96 (m, 2 H)

2515
(CD₃OD) δ 8.35 (d, 1 H), 7.67 (s, 1 H), 6.97 (dd, 1 H), 6.84 (td,
380.2
100%

1 H), 6.58-6.71 (m, 1 H), 6.25 (s, 1 H), 4.20 (dd, 1 H), 3.59-3.80
[M + H]⁺

(m, 1 H), 2.95-3.11 (m, 1 H), 2.80 (dd, 1 H), 1.50 (s, 3 H), 1.21-

1.34 (m, 2 H), 0.84-0.98 (m, 2 H)

2516
(CD₃OD) δ 9.42 (d, 1 H), 8.78 (s, 2 H), 8.32-8.65 (m, 1 H), 7.65-
431.2
100%

8.28 (m, 2 H), 6.67-7.17 (m, 4 H), 4.64 (br s, 1 H), 3.83 (br s, 0.5
[M + H]⁺

H), 3.45-3.63 (m, 0.5 H), 2.99-3.30 (m, 1 H), 2.76-2.96 (m, 1 H)

2517
(CD₃OD) δ 9.42 (s, 1 H), 8.78 (s, 2 H), 8.31-8.65 (m, 1 H), 7.61-
431.2
99.1%

8.28 (m, 2 H), 6.69-7.11 (m, 4 H), 4.82 (br s, 1 H), 3.82 (br s, 0.5
[M + H]⁺

H), 3.40-3.63 (m, 0.5 H), 2.98-3.30 (m, 1 H), 2.78-2.96 (m, 1 H)

2518
(CD₃OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 7.05 (d, 1 H), 6.83 (t, 1
440.2
99.6%

H), 6.60 (s, 1 H), 6.30 (s, 1 H), 4.23 (dd, 1 H), 3.71 (ddd, 1 H),
[M + H]⁺

3.49-3.62 (m, 1 H), 3.18 (dt, 1 H), 2.93-3.09 (m, 5 H), 2.80 (br

dd, 1 H), 1.32 (dd, 6 H)

2519
(CD₃OD) δ 8.29 (d, 1 H), 7.66 (s, 1 H), 7.05 (d, 1 H), 6.83 (t, 1
440.2
98.9%

H), 6.60 (s, 1 H), 6.29 (br s, 1 H), 4.23 (dd, 1 H), 3.71 (ddd, 1
[M + H]⁺

H), 3.49-3.62 (m, 1 H), 3.18 (dt, 1 H), 2.90-3.09 (m, 5 H), 2.79

(br dd, 1 H), 1.33 (dd, 6 H)

2520
(CD₃OD) δ 9.28 (d, 1 H), 8.68-8.75 (m, 2 H), 7.64-7.76 (m, 2
436.2
100%

H), 7.14-7.51 (m, 3 H), 6.74 (s, 1 H), 6.52 (br s, 1 H), 4.45 (dd, 1
[M + H]⁺

H), 3.80-3.95 (m, 1 H), 3.03-3.20 (m, 1 H), 2.86 (br dd, 1 H)

2521
(CD₃OD) δ 9.26 (d, 1 H), 8.67-8.74 (m, 2 H), 7.63-7.76 (m, 2
436.1
99.4%

H), 7.13-7.49 (m, 3 H), 6.73 (s, 1 H), 6.51 (s, 1 H), 4.45(dd, 1
[M + H]⁺

H), 3.77-3.96 (m, 1 H), 2.99-3.15 (m, 1 H), 2.85 (br dd, 1 H)

2522
(CD₃OD) δ 7.53-7.70 (m, 2 H), 7.02-7.40 (m, 3 H), 6.56 (s, 1 H),
422.2
100%

6.27 (s, 1 H), 4.13-4.29 (m, 1 H), 3.60-3.76 (m, 1 H), 2.86-3.00
[M + H]⁺

(m, 1 H), 2.73 (dd, 1 H), 2.00 (t, 3 H)

2523
(CD₃OD) δ 7.63 (d, 1 H), 7.57 (s, 1 H), 7.05-7.39 (m, 3 H), 6.55
422.2
96.4%

(s, 1 H), 6.26 (s, 1 H), 4.21 (dd, 1 H), 3.67 (td, 1 H), 2.89-3.02
[M + H]⁺

(m, 1 H), 2.73 (dd, 1 H), 2.00 (t, 3 H)

2524
(CD₃OD) δ 8.30-8.65 (m, 1 H), 8.03 (d, 0.3 H), 7.41-7.84 (m,
448.2
N/A

3.7 H), 7.17-7.32 (m, 2.5 H), 6.54-6.97 (m, 2.5 H), 4.36-4.78 (m,
[M + H]⁺

1 H), 3.38-3.86 (m, 1 H), 2.97-3.28 (m, 1 H), 2.76-2.91 (m, 1 H)

Cell Based Phenylalanine Flux Assay

Cells expressing R408W PAH were made by transducing A375 cells with lentivirus encoding human PAH with the R408W mutation in pLVX-Puro, then selecting with puromycin until stable cell lines were generated. A375 R408W cells were seeded into 96 well plates in DMEM+10% FBS at a density of 40,000 cells/well one hour prior to compound addition. Compounds were resuspended in DMSO, and 2-fold serial dilutions were performed to generate a 10-point dose curve. Compounds were added to plated cells in a total volume of 100 μl, and a final DMSO concentration of 0.50%. Each compound was tested in duplicate. Following compound addition, cells were placed in a 500 CO₂, 37° C. tissue culture incubator for 24 hrs. After the incubation period, 20 μM sepiapterin and 800 μM 13C9,15N-Phenylalanine were added. After 4 hours, cell media was removed. An aliquot of 10 μl of cell media was combined with 200 μl of extraction buffer (80% acetonitrile/20% H₂O) for each well. Determination of ¹³C-Tyrosine concentration was assessed by liquid chromatography mass spectrometry.

Specific compounds disclosed herein were tested in the foregoing assay and they were determined to have an AC₅₀according to the following scores: (A) less than or equal to 0.500 μM, (B) greater than 0.500 and less than 1.000 μM, (C) greater than or equal to 1.000 and less than 5.000 μM, (D) greater than or equal to 5.000 μM, (E) no fit, and (NT) not tested, as shown below. Where a compound was tested multiple times, the average value of the tests is reported.

Ex. #
AC₅₀

600
B

601
D

602
A

603
C

604
D

605
B

606
A

607
D

608
C

609
D

610
A

611
C

612
A

613
C

614
A

615
C

616
B

617
D

618
A

619
C

620
C

621
D

622
B

623
C

624
C

625
C

626
C

627
E

628
A

629
C

630
A

631
C

632
A

633
D

634
A

635
C

636
A

637
C

638
A

639
C

640
B

641
D

642
B

643
D

644
A

645
C

646
C

647
D

648
A

649
D

650
C

651
C

652
A

653
D

654
A

655
C

656
A

657
D

658
C

659
C

660
B

661
D

662
A

663
C

664
D

665
A

666
B

667
D

668
D

669
A

670
A

671
D

672
D

673
B

674
C

675
D

676
A

677
D

678
C

679
D

680
A

681
D

682
B

683
D

684
B

685
D

686
A

687
C

688
A

689
D

690
A

691
D

692
A

693
D

694
A

695
D

696
A

697
D

698
C

699
A

700
A

701
C

702
A

703
C

704
A

705
C

706
A

707
E

708
A

709
E

710
A

711
D

712
A

713
D

714
A

715
D

716
A

717
B

718
A

719
D

720
A

721
D

722
A

723
C

724
A

725
D

726
B

727
C

728
A

729
D

730
A

731
D

732
D

733
A

734
D

735
A

736
A

737
C

738
A

739
C

740
D

741
A

742
D

743
A

744
A

745
C

746
A

747
D

748
A

749
D

750
A

751
D

752
A

753
C

754
A

755
D

756
A

757
C

758
A

759
C

760
C

761
C

762
A

763
C

764
B

765
C

766
A

767
D

768
A

769
D

770
A

771
C

772
A

773
B

774
A

775
D

776
A

777
D

778
D

779
B

780
A

781
C

782
A

783
C

784
A

785
C

786
A

787
C

788
A

789
C

790
D

791
A

792
A

793
B

794
A

795
C

796
A

797
D

798
A

799
D

800
B

801
D

802
A

803
D

804
A

805
C

806
B

807
D

808
D

809
B

810
A

811
C

812
B

813
D

814
A

815
D

816
D

817
A

818
D

819
A

820
A

821
D

822
A

823
C

824
D

825
A

826
A

827
D

828
A

829
D

830
A

831
C

832
A

833
D

834
B

835
D

836
A

837
D

838
A

839
C

840
B

841
C

842
A

843
C

844
A

845
D

846
A

847
D

848
A

849
E

850
A

851
D

852
B

853
E

854
A

855
D

856
A

857
E

858
A

859
E

860
A

861
E

862
A

863
E

864
A

865
E

866
E

867
A

868
D

869
B

870
D

871
A

872
D

873
B

874
D

875
A

876
D

877
A

878
D

879
A

880
D

881
A

882
D

883
A

884
B

885
E

886
A

887
D

888
D

889
B

890
D

891
A

892
A

893
E

894
A

895
D

896
A

897
D

898
A

899
E

900
A

901
D

902
A

903
C

904
D

905
A

906
A

907
D

908
C

909
A

910
B

911
D

912
A

913
D

914
B

915
D

916
A

917
E

918
A

919
D

920
E

921
A

922
A

923
D

924
A

925
D

926
A

927
D

928
A

929
D

930
D

931
A

932
A

933
D

934
B

935
D

936
A

937
D

938
A

939
D

940
B

941
D

942
A

943
D

944
B

945
D

946
A

947
D

948
A

949
C

950
A

951
C

952
B

953
C

954
A

955
D

956
D

957
A

958
A

959
C

960
B

961
C

962
A

963
D

964
A

965
D

966
B

967
D

968
C

969
A

970
D

971
B

972
A

973
D

974
C

975
A

976
A

977
D

978
C

979
A

980
A

981
C

982
A

983
D

984
B

985
C

986
C

987
B

988
A

989
C

990
B

991
E

992
B

993
E

994
A

995
E

996
A

997
A

998
E

999
E

1000
B

1001
E

1002
E

1003
B

1004
E

1005
A

1006
E

1007
B

1008
E

1009
B

1010
B

1011
E

1012
B

1013
D

1014
A

1015
D

1016
A

1017
D

1018
A

1019
D

1020
A

1021
C

1022
A

1023
D

1024
A

1025
C

1026
C

1027
A

1028
A

1029
C

1030
A

1031
D

1032
B

1033
C

1034
B

1035
D

1036
B

1037
D

1038
A

1039
D

1040
B

1041
D

1042
A

1043
D

1044
A

1045
E

1046
D

1047
A

1048
E

1049
B

1050
A

1051
D

1052
A

1053
C

1054
A

1055
C

1056
A

1057
D

1058
B

1059
D

1060
A

1061
E

1062
A

1063
E

1064
B

1065
C

1066
A

1067
D

1068
A

1069
C

1070
A

1071
D

1072
B

1073
C

1074
B

1075
E

1076
A

1077
E

1078
A

1079
E

1080
E

1081
A

1082
A

1083
E

1084
A

1085
C

1086
A

1087
E

1088
B

1089
D

1090
B

1091
D

1092
B

1093
C

1094
A

1095
D

1096
D

1097
B

1098
D

1099
B

1100
B

1101
D

1102
B

1103
D

1104
A

1105
C

1106
A

1107
C

1108
D

1109
A

1110
B

1111
D

1112
A

1113
C

1114
B

1115
E

1116
A

1117
D

1118
A

1119
D

1120
A

1121
C

1122
C

1123
A

1124
B

1125
C

1126
A

1127
C

1128
B

1129
C

1130
B

1131
C

1132
A

1133
C

1134
A

1135
C

1136
C

1137
B

1138
A

1139
C

1140
B

1141
E

1142
A

1143
E

1144
B

1145
E

1146
A

1147
E

1148
B

1149
C

1150
A

1151
E

1152
A

1153
E

1154
A

1155
E

1156
A

1157
E

1158
B

1159
E

1160
C

1161
B

1162
A

1163
E

1164
A

1165
C

1166
B

1167
E

1168
B

1169
D

1170
D

1171
B

1172
A

1173
E

1174
B

1175
C

1176
A

1177
E

1178
A

1179
E

1180
B

1181
E

1182
C

1183
B

1184
B

1185
C

1186
B

1187
C

1188
B

1189
C

1190
B

1191
C

1192
A

1193
C

1194
C

1195
B

1196
A

1197
C

1198
B

1199
C

1200
B

1201
B

1202
A

1203
C

1204
A

1205
D

1206
B

1207
D

1208
A

1209
D

1210
B

1211
E

1212
B

1213
E

1214
A

1215
D

1216
E

1217
A

1218
E

1219
B

1220
A

1221
C

1222
A

1223
C

1224
B

1225
C

1226
A

1227
B

1228
E

1229
B

1230
A

1231
C

1232
A

1233
C

1234
A

1235
C

1236
A

1237
C

1238
A

1239
C

1240
A

1241
C

1242
C

1243
C

1244
C

1245
B

1246
B

1247
C

1248
C

1249
A

1250
A

1251
B

1252
A

1253
C

1254
C

1255
A

1256
A

1257
C

1258
B

1259
C

1260
A

1261
E

1262
A

1263
E

1264
E

1265
A

1266
A

1267
E

1268
A

1269
E

1270
A

1271
E

1272
A

1273
E

1274
A

1275
A

1276
A

1277
A

1278
A

1279
E

1280
A

1281
C

1282
E

1283
B

1284
A

1285
C

1286
A

1287
B

1288
B

1289
A

1290
C

1291
B

1292
A

1293
C

1294
C

1295
A

1296
A

1297
C

1298
C

1299
A

1300
A

1301
D

1302
A

1303
C

1304
A

1305
C

1306
A

1307
C

1308
A

1309
C

1310
C

1311
B

1312
C

1313
B

1314
A

1315
C

1316
A

1317
C

1318
C

1319
A

1320
C

1321
A

1322
C

1323
A

1324
C

1325
A

1326
A

1327
E

1328
A

1329
D

1330
A

1331
C

1332
A

1333
C

1334
A

1335
D

1336
C

1337
B

1338
D

1339
A

1340
B

1341
C

1342
B

1343
C

1344
C

1345
C

1346
B

1347
C

1348
A

1349
D

1350
A

1351
D

1352
A

1353
D

1354
B

1355
C

1356
A

1357
D

1358
A

1359
C

1360
D

1361
B

1362
B

1363
D

1364
A

1365
D

1366
A

1367
C

1368
A

1369
C

1370
A

1371
E

1372
A

1373
C

1374
A

1375
D

1376
D

1377
A

1378
A

1379
D

1380
C

1381
B

1382
A

1383
D

1384
A

1385
E

1386
B

1387
E

1388
A

1389
D

1390
B

1391
C

1392
C

1393
A

1394
A

1395
D

1396
A

1397
C

1398
A

1399
C

1400
A

1401
C

1402
B

1403
E

1404
C

1405
A

1406
A

1407
D

1408
C

1409
A

1410
C

1411
A

1412
E

1413
B

1414
A

1415
C

1416
A

1417
C

1418
C

1419
B

1420
D

1421
A

1422
A

1423
D

1424
A

1425
C

1426
A

1427
D

1428
D

1429
A

1430
D

1431
A

1432
C

1433
A

1434
B

1435
C

1436
B

1437
C

1438
B

1439
D

1440
B

1441
D

1442
A

1443
C

1444
A

1445
C

1446
B

1447
D

1448
B

1449
C

1450
A

1451
D

1452
A

1453
D

1454
D

1455
A

1456
A

1457
C

1458
C

1459
A

1460
E

1461
B

1462
A

1463
C

1464
C

1465
A

1466
A

1467
C

1468
A

1469
D

1470
A

1471
C

1472
B

1473
C

1474
A

1475
C

1476
A

1477
C

1478
A

1479
C

1480
A

1481
C

1482
A

1483
C

1484
A

1485
C

1486
A

1487
D

1488
A

1489
C

1490
B

1491
C

1492
B

1493
C

1494
A

1495
D

1496
A

1497
C

1498
E

1499
B

1500
A

1501
D

1502
B

1503
D

1504
A

1505
D

1506
A

1507
D

1508
A

1509
D

1510
B

1511
C

1512
A

1513
C

1514
A

1515
D

1516
E

1517
A

1518
E

1519
A

1520
A

1521
C

1522
A

1523
D

1524
D

1525
B

1526
B

1527
D

1528
A

1529
C

1530
D

1531
A

1532
A

1533
D

1534
C

1535
B

1536
D

1537
B

1538
B

1539
D

1540
B

1541
C

1542
B

1543
C

1544
A

1545
C

1546
B

1547
D

1548
B

1549
C

1550
A

1551
C

1552
A

1553
E

1554
D

1555
C

1556
A

1557
C

1558
C

1559
A

1560
D

1561
A

1562
B

1563
C

1564
D

1565
A

1566
B

1567
C

1568
A

1569
D

1570
A

1571
C

1572
C

1573
B

1574
C

1575
A

1576
E

1577
B

1578
B

1579
D

1580
A

1581
D

1582
B

1583
D

1584
B

1585
D

1586
C

1587
A

1588
D

1589
B

1590
E

1591
B

1592
B

1593
C

1594
A

1595
D

1596
A

1597
D

1598
B

1599
D

1600
B

1601
E

1602
B

1603
E

1604
B

1605
D

1606
E

1607
B

1608
B

1609
D

1610
B

1611
E

1612
D

1613
A

1614
B

1615
E

1616
A

1617
D

1618
A

1619
C

1620
D

1621
A

1622
C

1623
A

1624
B

1625
D

1626
B

1627
D

1628
B

1629
E

1630
B

1631
E

1632
B

1633
E

1634
B

1635
E

1636
E

1637
A

1638
E

1639
B

1640
B

1641
D

1642
D

1643
B

1644
A

1645
D

1646
B

1647
D

1648
B

1649
D

1650
B

1651
E

1652
B

1653
D

1654
B

1655
E

1656
D

1657
B

1658
B

1659
E

1660
B

1661
E

1662
B

1663
D

1664
A

1665
C

1666
B

1667
D

1668
B

1669
D

1670
B

1671
E

1672
A

1673
D

1674
B

1675
E

1676
B

1677
D

1678
D

1679
A

1680
B

1681
E

1682
A

1683
E

1684
A

1685
E

1686
E

1687
B

1688
E

1689
A

1690
B

1691
D

1692
A

1693
C

1694
A

1695
D

1696
B

1697
E

1698
A

1699
D

1700
C

1701
B

1702
A

1703
E

1704
A

1705
E

1706
A

1707
D

1708
B

1709
D

1710
D

1711
B

1712
B

1713
D

1714
A

1715
E

1716
A

1717
D

1718
B

1719
C

1720
B

1721
E

1722
D

1723
B

1724
A

1725
E

1726
B

1727
E

1728
B

1729
D

1730
A

1731
D

1732
E

1733
A

1734
E

1735
A

1736
E

1737
B

1738
E

1739
A

1740
D

1741
B

1742
A

1743
C

1744
C

1745
D

1746
A

1747
D

1748
B

1749
E

1750
B

1751
D

1752
A

1753
E

1754
A

1755
D

1756
D

1757
A

1758
E

1759
B

1760
A

1761
E

1762
A

1763
C

1764
C

1765
B

1766
E

1767
A

1768
A

1769
C

1770
B

1771
D

1772
B

1773
D

1774
A

1775
D

1776
A

1777
D

1778
A

1779
E

1780
A

1781
D

1782
B

1783
E

1784
B

1785
E

1786
B

1787
C

1788
B

1789
D

1790
B

1791
D

1792
A

1793
E

1794
B

1795
D

1796
B

1797
E

1798
D

1799
B

1800
A

1801
E

1802
B

1803
D

1804
C

1805
A

1806
E

1807
B

1808
E

1809
A

1810
B

1811
E

1812
B

1813
E

1814
A

1815
D

1816
D

1817
A

1818
D

1819
A

1820
D

1821
A

1822
D

1823
B

1824
E

1825
B

1826
E

1827
B

1828
C

1829
A

1830
D

1831
B

1832
E

1833
B

1834
E

1835
B

1836
E

1837
B

1838
A

1839
D

1840
A

1841
D

1842
D

1843
A

1844
D

1845
A

1846
E

1847
A

1848
D

1849
A

1850
B

1851
C

1852
B

1853
C

1854
D

1855
A

1856
E

1857
B

1858
A

1859
E

1860
E

1861
A

1862
D

1863
A

1864
E

1865
A

1866
A

1867
E

1868
A

1869
D

1870
A

1871
D

1872
D

1873
B

1874
D

1875
A

1876
B

1877
D

1878
B

1879
E

1880
A

1881
D

1882
A

1883
E

1884
A

1885
D

1886
A

1887
D

1888
D

1889
A

1890
E

1891
A

1892
E

1893
A

1894
D

1895
A

1896
D

1897
B

1898
A

1899
C

1900
A

1901
D

1902
A

1903
E

1904
D

1905
A

1906
A

1907
D

1908
A

1909
C

1910
D

1911
A

1912
D

1913
A

1914
A

1915
D

1916
A

1917
D

1918
B

1919
E

1920
A

1921
E

1922
A

1923
D

1924
A

1925
D

1926
D

1927
A

1928
B

1929
E

1930
A

1931
D

1932
D

1933
B

1934
A

1935
E

1936
A

1937
C

1938
A

1939
C

1940
D

1941
A

1942
E

1943
A

1944
A

1945
C

1946
A

1947
E

1948
A

1949
C

1950
D

1951
A

1952
D

1953
A

1954
C

1955
A

1956
E

1957
B

1958
E

1959
A

1960
B

1961
D

1962
B

1963
D

1964
B

1965
D

1966
A

1967
D

1968
A

1969
D

1970
A

1971
D

1972
B

1973
D

1974
B

1975
D

1976
D

1977
B

1978
D

1979
A

1980
E

1981
B

1982
D

1983
A

1984
A

1985
D

1986
A

1987
C

1988
E

1989
B

1990
E

1991
B

1992
D

1993
A

1994
D

1995
A

1996
C

1997
B

1998
A

1999
D

2000
C

2001
D

2002
B

2003
D

2004
B

2005
D

2006
E

2007
A

2008
E

2009
A

2010
A

2011
D

2012
E

2013
A

2014
A

2015
C

2016
A

2017
D

2018
A

2019
D

2020
A

2021
D

2022
B

2023
D

2024
A

2025
E

2026
E

2027
B

2028
A

2029
D

2030
A

2031
C

2032
A

2033
D

2034
B

2035
D

2036
A

2037
D

2038
C

2039
A

2040
A

2041
C

2042
B

2043
C

2044
D

2045
B

2046
D

2047
B

2048
B

2049
D

2050
A

2051
D

2052
B

2053
D

2054
B

2055
D

2056
D

2057
A

2058
E

2059
B

2060
D

2061
B

2062
D

2063
A

2064
A

2065
E

2066
B

2067
D

2068
B

2069
D

2070
A

2071
D

2072
D

2073
B

2074
A

2075
C

2076
B

2077
D

2078
B

2079
E

2080
A

2081
D

2082
E

2083
A

2084
D

2085
A

2086
A

2087
D

2088
D

2089
A

2090
D

2091
A

2092
D

2093
A

2094
E

2095
A

2096
D

2097
B

2098
A

2099
E

2100
A

2101
E

2102
A

2103
E

2104
A

2105
E

2106
A

2107
E

2108
E

2109
B

2110
A

2111
E

2112
B

2113
D

2114
B

2115
C

2116
A

2117
C

2118
A

2119
C

2120
A

2121
C

2122
A

2123
C

2124
A

2125
C

2126
D

2127
A

2128
E

2129
A

2130
D

2131
A

2132
C

2133
A

2134
C

2135
A

2136
A

2137
D

2138
A

2139
E

2140
A

2141
E

2142
A

2143
E

2144
A

2145
E

2146
E

2147
A

2148
A

2149
D

2150
D

2151
A

2152
E

2153
A

2154
D

2155
A

2156
E

2157
B

2158
E

2159
B

2160
D

2161
A

2162
B

2163
D

2164
A

2165
D

2166
D

2167
A

2168
C

2169
A

2170
A

2171
D

2172
A

2173
C

2174
A

2175
D

2176
D

2177
B

2178
B

2179
D

2180
B

2181
D

2182
B

2183
D

2184
E

2185
A

2186
E

2187
A

2188
D

2189
B

2190
E

2191
B

2192
E

2193
A

2194
E

2195
A

2196
E

2197
B

2198
B

2199
E

2200
A

2201
D

2202
D

2203
A

2204
E

2205
A

2206
B

2207
D

2208
B

2209
E

2210
C

2211
E

2212
A

2213
D

2214
A

2215
E

2216
B

2217
E

2218
C

2219
D

2220
D

2221
C

2222
E

2223
C

2224
C

2225
A

2226
D

2227
B

2228
D

2229
A

2230
D

2231
A

2232
D

2233
A

2234
B

2235
D

2236
A

2237
D

2238
C

2239
A

2240
B

2241
D

2242
B

2243
D

2244
B

2245
D

2246
D

2247
A

2248
E

2249
A

2250
E

2251
A

2252
E

2253
A

2254
A

2255
C

2256
A

2257
D

2258
D

2259
B

2260
D

2261
B

2262
B

2263
D

2264
B

2265
D

2266
D

2267
A

2268
D

2269
A

2270
A

2271
D

2272
A

2273
D

2274
B

2275
D

2276
A

2277
D

2278
D

2279
A

2280
A

2281
D

2282
D

2283
A

2284
D

2285
A

2286
D

2287
A

2288
E

2289
A

2290
E

2291
C

2292
A

2293
D

2294
D

2295
B

2296
A

2297
D

2298
C

2299
A

2300
E

2301
B

2302
E

2303
A

2304
E

2305
B

2306
D

2307
A

2308
D

2309
B

2310
C

2311
A

2312
C

2313
A

2314
A

2315
E

2316
A

2317
E

2318
D

2319
A

2320
E

2321
A

2322
D

2323
B

2324
D

2325
A

2326
E

2327
C

2328
D

2329
C

2330
B

2331
D

2332
B

2333
D

2334
D

2335
B

2336
B

2337
E

2338
B

2339
D

2340
D

2341
B

2342
C

2343
D

2344
D

2345
B

2346
D

2347
B

2348
B

2349
E

2350
B

2351
E

2352
B

2353
E

2354
D

2355
B

2356
E

2357
B

2358
D

2359
B

2360
D

2361
A

2362
E

2363
B

2364
D

2365
C

2366
C

2367
E

2368
C

2369
D

2370
C

2371
E

2372
C

2373
E

2374
E

2375
E

2376
C

2377
C

2378
C

2379
E

2380
C

2381
D

2382
C

2383
E

2384
C

2385
D

2386
C

2387
E

2388
C

2389
E

2390
C

2391
E

2392
E

2393
C

2394
D

2395
C

2396
C

2397
E

2398
C

2399
C

2400
A

2401
C

2402
E

2403
C

2404
C

2405
D

2406
A

2407
E

2408
E

2409
C

2410
B

2411
E

2412
C

2413
E

2414
C

2415
C

2416
C

2417
C

2418
E

2419
C

2420
C

2421
C

2422
C

2423
E

2424
C

2425
E

2426
C

2427
D

2428
C

2429
C

2430
C

2431
C

2432
E

2433
C

2434
C

2435
D

2436
C

2437
D

2438
C

2439
E

2440
C

2441
E

2442
E

2443
C

2444
E

2445
C

2446
C

2447
D

2448
C

2449
D

2450
C

2451
D

2452
C

2453
E

2454
C

2455
C

2456
C

2457
E

2458
C

2459
E

2460
E

2461
C

2462
C

2463
E

2464
C

2465
D

2466
E

2467
C

2468
E

2469
C

2470
C

2471
D

2472
C

2473
E

2474
C

2475
D

2476
C

2477
E

2478
C

2479
E

2480
D

2481
C

2482
C

2483
E

2484
E

2485
C

2486
E

2487
C

2488
C

2489
E

2490
E

2491
C

2492
E

2493
C

2494
C

2495
E

2496
C

2497
E

2498
E

2499
C

2500
E

2501
C

2502
C

2503
D

2504
D

2505
C

2506
C

2507
E

2508
E

2509
C

2510
C

2511
D

2512
C

2513
E

2514
E

2515
C

2516
C

2517
D

2518
E

2519
C

2520
E

2521
C

2522
E

2523
C

2524
B

Additionally, the following compounds were tested with an AC₅₀of C, D, or E:

Compound(s)
AC₅₀

4S and 4R enantiomers of 1-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
C, E

c]pyridin-5-yl]-3-(1,3-thiazol-2-yl)propan-1-one

4S and 4R enantiomers of 3-(5-methyl-1,3,4-thiadiazol-2-yl)-1-[4-{pyrazolo[1,5-a]pyridin-2-
D, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]propan-1-one

4S and 4R enantiomers of 5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
C, C

c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{4-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyridine

4S and 4R enantiomers of 2-{4-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyridine

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of dimethyl({3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)amine

4S and 4R enantiomers of 5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-
C, E

{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 1-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
C, D

c]pyridin-5-yl]-2-{pyrazolo[1,5-a]pyridin-3-yl}ethan-1-one

4S and 4R enantiomers of 5-cyclopropanecarbonyl-4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 1-[4-{pyrazolo[1,5-a]pyridin-2-yl}-3H,4H,5H,6H,7H-imidazo[4,5-
C, E

c]pyridin-5-yl]-2-(1,3,4-thiadiazol-2-yl)ethan-1-one

4S and 4R enantiomers of 1-methyl-4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}piperazine

4S and 4R enantiomers of 4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 2-{4-cyclopropyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H,8H-imidazo[4,5-c]azepine-5-carbonyl]-1,3-oxazol-2-yl}pyridine

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H,8H-
D, E

imidazo[4,5-c]azepine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 5-[(1R)-2,2-difluorocyclopropanecarbonyl]-4-{pyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 5-[(1S)-2,2-difluorocyclopropanecarbonyl]-4-{pyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 4-fluoro-1-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}piperidine

4S and 4R enantiomers of N,N-dimethyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-amine

4S and 4R enantiomers of 2-(3-fluoroazetidin-1-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of N-cyclopropyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-amine

4S and 4R enantiomers of 2-(methoxymethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-thiazole

4S and 4R enantiomers of 2-(methoxymethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4′S and 4′R enantiomers of 5′-(4-methyl-1,3-oxazole-5-carbonyl)-4′-{pyrazolo[1,5-a]pyridin-
C, E

2-yl}-1′,4′,5′,6′-tetrahydrospiro[cyclopropane-1,7′-imidazo[4,5-c]pyridine]

4S and 4R enantiomers of N-(2-methoxyethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
D, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-amine

4S and 4R enantiomers of dimethyl({5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}methyl)amine

4S and 4R enantiomers of 3-(difluoromethyl)-1-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 2-(methoxymethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 5-(difluoromethyl)-1-methyl-4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}-5-(trifluoromethyl)pyridine

4S and 4R enantiomers of 2-(1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]azetidin-1-yl}pyridine

4S and 4R enantiomers of 1-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of methyl3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]azetidine-1-carboxylate

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine

4S and 4R enantiomers of 2-[1-(2,2-difluoroethyl)-1H-pyrazol-4-yl]-5-[4-{pyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
D, E

c]pyridine-5-carbonyl]-1-(2,2,2-trifluoroethyl)azetidine

4S and 4R enantiomers of 2-{5-chloro-4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine

4S and 4R enantiomers of 2-(1H-pyrazol-3-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
C, E

c]pyridine-5-carbonyl]-1,3-oxazole-4-carboxamide

4S and 4R enantiomers of (1R)-1-{4-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 5-[4-{3-bromopyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole-4-carbonitrile

4S and 4R enantiomers of (1S)-1-{4-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 2-[4-{3-bromopyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 5-chloro-4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
D, E

c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
D, E

c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 1-methyl-3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 1-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-3-amine

4S and 4R enantiomers of 5-chloro-4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazole

4S and 4R enantiomers of (1S)-1-{5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-(difluoromethyl)-1,3-oxazol-2-

yl}ethan-1-ol

4S and 4R enantiomers of 4-ethyl-3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-4H-1,2,4-triazole

4S and 4R enantiomers of 2-{5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-4-(trifluoromethyl)-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,2-oxazol-3-yl}propan-2-ol

4S and 4R enantiomers of 2-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,2-oxazol-5-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,2,4-oxadiazol-3-yl}propan-2-ol

4S and 4R enantiomers of (1S)-1-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl]}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-methyl-1,3-oxazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 2-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,2,4-oxadiazol-5-yl}propan-2-ol

4S and 4R enantiomers of (1S)-1-[4-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-
C, E

2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl]ethan-1-ol

4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-4-(difluoromethyl)-1,3-oxazole

4S and 4R enantiomers of 5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-4-(trifluoromethyl)-1,3-oxazole

4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-[4-(difluoromethyl)-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-
D, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl]propan-2-ol

4S and 4R enantiomers of 5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-4-(trifluoromethyl)-1,3-oxazole

4S and 4R enantiomers of 1-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-4-(trifluoromethyl)-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{3-methylpyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{3-methylpyrazolo[1,5-
C, D

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{6-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-(difluoromethyl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-
E, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl]propan-2-ol

4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-yl)-5-[4-{4-methylpyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{5-methylpyrazolo[1,5-
C, D

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{5-methylpyrazolo[1,5-
C, D

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-1-(trifluoromethyl)-1H-pyrazole

4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-1-(trifluoromethyl)-1H-pyrazole

4S and 4R enantiomers of 2-[4-(difluoromethyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl]pyridine

4S and 4R enantiomers of 4-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 1-methyl-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
E, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-1-(propan-2-yl)-1H-pyrazole

4S and 4R enantiomers of 1-cyclopropyl-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
E, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-3-yl)-5-[4-
D, E

{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-

oxazole

4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-2-(1-methyl-1H-pyrazol-3-yl)-1,3-

oxazole

4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{4-
C, E

methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-

1,3-oxazole

4S and 4R enantiomers of 4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-dimethyl-1H-1,2,4-triazole

4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-pyrazol-4-yl)-5-[4-
C, E

{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-

oxazole

4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole

4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-1-(propan-2-yl)-1H-pyrazole

4S and 4R enantiomers of 3-tert-butyl-1-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 3-tert-butyl-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-pyrazole

4S and 4R enantiomers of 3-tert-butyl-1-methyl-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 1-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}-4-methylpiperazine

4S and 4R enantiomers of 1,3-dimethyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
E, E

imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-pyrazole

4S and 4R enantiomers of 3-tert-butyl-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-pyrazole

4S and 4R enantiomers of 4-(difluoromethyl)-2-(1-methyl-1H-imidazol-4-yl)-5-[4-
E, E

{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-

oxazole

4S and 4R enantiomers of 2-{3-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine

4S and 4R enantiomers of 2-{3-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazol-1-yl}pyridine

4S and 4R enantiomers of 1-methyl-4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}piperazine

4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-yl)-5-[4-[4-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-

carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-yl)-5-[4-{7-methylpyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[-4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(1-methyl-1H-imidazol-5-yl)-5-[4-[7-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-

carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 1-(difluoromethyl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-pyrazole

4S and 4R enantiomers of 2-methyl-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-
C, D

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 3-(difluoromethyl)-5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole

4S and 4R enantiomers of 3-cyclopropyl-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole

4S and 4R enantiomers of 3-(difluoromethyl)-1-methyl-5-[4-{7-methylpyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 1-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 1-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-3-(trifluoromethyl)-1H-1,2,4-triazole

4S and 4R enantiomers of 3-(difluoromethyl)-5-[4-{6-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole

4S and 4R enantiomers of 2-tert-butyl-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 4-(2,2-difluoroethyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 3-cyclopropyl-1-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-
C, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 1,3-dimethyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 2-{5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-[4-{6-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-tert-butyl-5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 4-(difluoromethyl)-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-
C, E

2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-{5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-{6-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-
C, C

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole-2-yl}pyridine

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-1-methyl-1H-1,2,4-triazole

4S and 4R enantiomers of 2-methyl-5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-
C, E

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole-2-yl}propan-2-ol

4S and 4R enantiomers of 2-tert-butyl-5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-{5-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-[5-
C, D

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-

carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-
C, E

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-3-cyclopropyl-1-methyl-1H-1,2,4-triazole

4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-dimethyl-1H-1,2,4-triazole

4S and 4R enantiomers of 3-(difluoromethyl)-1-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 1,3-dimethyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-[4-[5-
C, D

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-

carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-methyl-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-{5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of 5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-methyl-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-
C, E

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 5-[4-{5-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 5-[4-[6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-tert-butyl-5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol

4S and 4R enantiomers of 2-{4-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of (1S)-1-{4-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol

4S and 4R enantiomers of (1R)-1-{4-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-tert-butyl-5-[4-{3-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-methyl-5-[4-{6-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{6-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 5-[4-[5-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 5-[4-{6-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of (1R)-1-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-4-methyl-1,3-oxazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 2-{5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{4-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of (1R)-1-{4-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-
C, E

2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 2-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-(1,5-dimethyl-1H-pyrazol-4-yl)-5-[4-{3-methylpyrazolo[1,5-
C, C

a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of (1S)-1-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 1-methyl-3-(trifluoromethyl)-5-[4-[7-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-

carbonyl]-1H-1,2,4-triazole

4S and 4R enantiomers of (1R)-1-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}ethan-1-ol

4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-5-{pyrazolo[1,5-
C, E

a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 5-{pyrazolo[1,5-a]pyridine-3-carbonyl}-4-[7-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 1-methyl-4-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, C

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}-1H-pyrazole

4S and 4R enantiomers of 4-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine

4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(propan-2-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}propan-2-ol

4S and 4R enantiomers of 2-{5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-(propan-2-yl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-
C, C

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-4-yl)-1,3,4-

oxadiazole

4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-5-[1-(trifluoromethyl)-1H-pyrazol-4-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[7-(difluoromethyl)pyrazolo[1,5-
C, D

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-

oxadiazole

4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-

oxadiazole

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-
C, D

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-
C, E

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-
C, E

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-imidazol-5-yl)-1,3,4-

oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-
C, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-cyclopropyl-1,3,4-oxadiazole

4S and 4R enantiomers of N,N-dimethyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole-2-carboxamide

4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

3H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3-benzoxazole

4S and 4R enantiomers of ({3-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine

4S and 4R enantiomers of 2-{5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-N,N-dimethyl-1,3,4-oxadiazole-2-carboxamide

4S and 4R enantiomers of N,N-dimethyl-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole-2-carboxamide

4S and 4R enantiomers of dimethyl({3-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-

yl}methyl)amine

4S and 4R enantiomers of 5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-[7-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 2-[4-[4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-(1-methyl-1H-pyrazol-3-yl)-1,3,4-

oxadiazole

4S and 4R enantiomers of ({3-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-

yl}methyl)dimethylamine

4S and 4R enantiomers of ({3-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 4-{3-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine

4S and 4R enantiomers of 4-{3-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine

4S and 4R enantiomers of 3-fluoro-2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-5-[6-
C, E

(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-1H,4H,5H,6H,7H-imidazo[4,5-

c]pyridine

4S and 4R enantiomers of 4-{3-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine

4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrazine

4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-5-[6-
C, D

(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-1H,4H,5H,6H,7H-imidazo[4,5-

c]pyridine

4S and 4R enantiomers of 5-{6-methoxypyrazolo[1,5-a]pyridine-3-carbonyl}-4-[7-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of ({3-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine

4S and 4R enantiomers of ({3-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-

yl}methyl)dimethylamine

4S and 4R enantiomers of 4-{3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}morpholine

4S and 4R enantiomers of 4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 4-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{4-methylpyrazolo[1,5-
C, E

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-5-[6-
C, E

(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-1H,4H,5H,6H,7H-imidazo[4,5-

c]pyridine

4S and 4R enantiomers of 2-methyl-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3-benzoxazole

4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]pyrimidine

4S and 4R enantiomers of 2-[5-{6-methylpyrazolo[1,5-a]pyridine-3-carbonyl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]-7-(trifluoromethyl)pyrazolo[1,5-a]pyridine

4S and 4R enantiomers of 7-(difluoromethyl)-2-[5-{6-methylpyrazolo[1,5-a]pyridine-3-
C, E

carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]pyrazolo[1,5-a]pyridine

4S and 4R enantiomers of 5-{6-cyclopropylpyrazolo[1,5-a]pyridine-3-carbonyl}-4-[7-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-5-{6-
C, D

methoxypyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-[1-(trifluoromethyl)-1H-pyrazol-4-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-[4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-5-[6-
C, E

(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-1H,4H,5H,6H,7H-imidazo[4,5-

c]pyridine

4S and 4R enantiomers of 5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-{7-
C, E

methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-N,N-dimethyl-1,3,4-oxadiazole-2-carboxamide

4S and 4R enantiomers of N,N-dimethyl-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-
C, E

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole-2-carboxamide

4S and 4R enantiomers of 2-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]pyrimidine

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 5-{6-cyclopropylpyrazolo[1,5-a]pyridine-3-carbonyl}-4-{7-
C, D

methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-5-{6-
C, D

methoxypyrazolo[1,5-a]pyridine-3-carbonyl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 2-[4-[4-(trifluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-5-[1-(trifluoromethyl)-1H-pyrazol-4-

yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 7-(difluoromethyl)-2-[5-{pyrazolo[1,5-a]pyridine-3-carbonyl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]pyrazolo[1,5-a]pyridine

4S and 4R enantiomers of 5-[6-(methoxymethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-{4-
C, E

methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of ({3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}methyl)dimethylamine

4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3-benzoxazole

4S and 4R enantiomers of 4-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-[4-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-

1,3,4-oxadiazole

4S and 4R enantiomers of 2-methyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-methyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 4-{3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}-1-methyl-

1H-pyrazole

4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidine

4S and 4R enantiomers of 2-(difluoromethyl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-
C, E

2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclopropyl-5-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 7-methyl-2-[5-{6-methylpyrazolo[1,5-a]pyridine-3-carbonyl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]pyrazolo[1,5-a]pyridine

4S and 4R enantiomers of 3-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-6-amine

4S and 4R enantiomers of 5-[6-(2-methoxyethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-[7-
C, E

(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 4-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}morpholine

4S and 4R enantiomers of 2-(difluoromethyl)-5-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-(difluoromethyl)-1,3,4-oxadiazole

4S and 4R enantiomers of 7-chloro-2-[5-{6-methylpyrazolo[1,5-a]pyridine-3-carbonyl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-4-yl]pyrazolo[1,5-a]pyridine

4S and 4R enantiomers of 2-tert-butyl-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]pyrimidin-5-amine

4S and 4R enantiomers of 5-[6-(2-methoxyethyl)pyrazolo[1,5-a]pyridine-3-carbonyl]-4-
D, E

{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 3-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of (2-{3-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}ethyl)dimethylamine

4S and 4R enantiomers of dimethyl(2-{3-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-

yl}ethyl)amine

4S and 4R enantiomers of 2-cyclobutyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclobutyl-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-tert-butyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 6-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
D, E

c]pyridin-5-yl]pyridin-3-amine

4S and 4R enantiomers of 3-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-6-

amine

4S and 4R enantiomers of 2-cyclobutyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-tert-butyl-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
D, E

c]pyridin-5-yl]pyrimidin-5-amine

4S and 4R enantiomers of 2-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidin-5-amine

4S and 4R enantiomers of 2-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidin-5-amine

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-N,N-dimethylpyrazolo[1,5-a]pyridin-6-amine

4S and 4R enantiomers of 2-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
C, E

c]pyridine-5-carbonyl]-1,3-thiazole

4S and 4R enantiomers of 6-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyridin-3-amine

4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(1-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of dimethyl(2-{3-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-yl}ethyl)amine

4S and 4R enantiomers of dimethyl(2-{3-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]pyrazolo[1,5-a]pyridin-6-

yl}ethyl)amine

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-cyclobutyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-tert-butyl-5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclobutyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-cyclobutyl-5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-tert-butyl-5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-tert-butyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{7-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-(trifluoromethyl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-tert-butyl-5-[4-[7-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-5-(1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]pyrimidin-5-amine

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-(1-methyl-1H-pyrazol-3-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-(1,5-dimethyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-
C, D

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-methyl-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3,4-thiadiazole

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-methyl-1,3,4-thiadiazole

4S and 4R enantiomers of 2-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-
C, E

c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 2-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-carbonyl]-1,3-benzothiazole

4S and 4R enantiomers of 5-cyclopropanecarbonyl-4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 2-fluoro-6-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyridine

4S and 4R enantiomers of 2-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrimidine

4S and 4R enantiomers of 4-cyclopropyl-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-
C, D

yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 4-cyclopropyl-2-(1-methyl-1H-pyrazol-4-yl)-5-[4-{pyrazolo[1,5-
C, D

a]pyridin-2-yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazole

4S and 4R enantiomers of 5-cyclobutanecarbonyl-4-{pyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 5-cyclobutanecarbonyl-4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine

4S and 4R enantiomers of 5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-2-(1-methyl-1H-pyrazol-3-yl)-1,3-

oxazole

4S and 4R enantiomers of 5-(trifluoromethyl)-2-[4-[7-(trifluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyridine

4S and 4R enantiomers of 5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-2-(1-methyl-1H-pyrazol-4-yl)-1,3-oxazole

4S and 4R enantiomers of 5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridine-5-carbonyl]-2-(1-methyl-1H-pyrazol-4-yl)-1,3-

oxazole

4S and 4R enantiomers of 2-[4-[4-(difluoromethoxy)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine

4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine

4S and 4R enantiomers of 4-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 4-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-(1-methylcyclopropyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine

4S and 4R enantiomers of 4-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
E, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 4-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 3-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine

4S and 4R enantiomers of 3-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine

4S and 4R enantiomers of 3-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine

4S and 4R enantiomers of 3-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine

4S and 4R enantiomers of 3-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-[4-{4-methoxypyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-methyl-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(1-methylcyclopropyl)-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-
D, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-
D, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(2-fluoropropan-2-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-
C, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 3-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine

4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridazine

4S and 4R enantiomers of 4-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1-methyl-1H-pyrazole

4S and 4R enantiomers of 2-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-
E, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrimidine

4S and 4R enantiomers of 2-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(1-methylcyclopropyl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[4-(trifluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-[4-(difluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(3,3-difluorocyclobutyl)-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-
C, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrimidine

4S and 4R enantiomers of 2-{5-[4-{7-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine

4S and 4R enantiomers of 2-{5-[4-{7-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine

4S and 4R enantiomers of 3-{5-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 3-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-methyl-3-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridine-5-carbonyl]-1,3-oxazol-2-yl}pyrazine

4S and 4R enantiomers of 1-methyl-4-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridin-5-yl]-1H-pyrazole

4S and 4R enantiomers of 2-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-5-(3,3-difluorocyclobutyl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-{5-[4-[7-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyrazine

4S and 4R enantiomers of 3-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 3-{5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, C

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-2-methylpyridine

4S and 4R enantiomers of 1-methyl-4-[4-{4-methylpyrazolo[1,5-a]pyridin-2-yl}-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1H-pyrazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-
C, E

yl}-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-fluoro-3-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-(3-methyl-1H-pyrazol-4-yl)-5-[4-{4-methylpyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-carbonyl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-fluoropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridine-5-carbonyl]-5-(3-methyl-1H-pyrazol-4-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-fluoro-3-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 3-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-2-fluoropyridine

4S and 4R enantiomers of 2-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(2-fluoropropan-2-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(2-fluoropropan-2-yl)-5-[4-[4-(propan-2-yl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-[4-{4-chloropyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D, E

imidazo[4,5-c]pyridin-5-yl]-5-(2-fluoropropan-2-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 3-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-2-fluoropyridine

4S and 4R enantiomers of 2-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]pyrazine

4S and 4R enantiomers of 2-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-5-(propan-2-yl)-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(propan-2-yl)-5-[4-[4-(propan-2-yl)pyrazolo[1,5-a]pyridin-2-yl]-
D, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 2-(1,1-difluoroethyl)-5-[4-[7-(trifluoromethyl)pyrazolo[1,5-
C, E

a]pyridin-2-yl]-1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazole

4S and 4R enantiomers of 3-fluoro-2-{5-[4-[4-(trifluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 2-{5-[4-[4-(difluoromethyl)pyrazolo[1,5-a]pyridin-2-yl]-
C, E

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-3-fluoropyridine

4S and 4R enantiomers of 2-{5-[4-{4-cyclopropylpyrazolo[1,5-a]pyridin-2-yl}-
C, D

1H,4H,5H,6H,7H-imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}-3-fluoropyridine

4S and 4R enantiomers of 2-fluoro-6-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, E

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

4S and 4R enantiomers of 5-fluoro-2-{5-[4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
C, D

imidazo[4,5-c]pyridin-5-yl]-1,3,4-oxadiazol-2-yl}pyridine

2-[2-(3-fluoroazetidin-1-yl)ethyl]-5-(4-{pyrazolo[1,5-a]pyridin-2-yl}-1H,4H,5H,6H,7H-
D

imidazo[4,5-c]pyridine-5-carbonyl)-1,3,4-oxadiazole

Having now fully described the methods, compounds, and compositions of matter provided herein, it will be understood by those of skill in the art that the same can be performed within a wide and equivalent range of conditions, formulations, and other parameters without affecting the scope of the methods, compounds, and compositions provided herein or any embodiment thereof.

All patents, patent applications and publications cited herein are fully incorporated by reference herein in their entirety.

Number	Date	Country
2009000552	Dec 2008	WO
2017029202	Feb 2017	WO
2019105886	Jun 2019	WO
2020165318	Aug 2020	WO

	Number	Date	Country
Parent	18114635	Feb 2023	US
Child	18214831		US

Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

Field of Search

CPC

International Classifications

Disclaimer

Abstract

Description

Claims

RELATED APPLICATIONS

Foreign Referenced Citations (4)

Non-Patent Literature Citations (9)

Related Publications (1)

Provisional Applications (1)

Continuations (1)

Entry
Meanwell, N.A., “Synopsis of some recent tactical application of bioisosteres in drug design.” Journal of medicinal chemistry 54.8 (2011): 2529-2591.
Pey et al., Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest. Aug. 2008;118(8):2858-67.
Santos-Sierra et al., Novel pharmacological chaperones that correct phenylketonuria in mice. Hum Mol Genet. Apr. 15, 2012;21(8):1877-87.
STN, Imidazopyridine derivatives. Retrieved online at: www.stn.org. 3 pages, Jun. 13, 2021.
International Search Report and Written Opinion for Application No. PCT/US2023/013988, dated Jun. 9, 2023, 12 pages.
International Search Report and Written Opinion for Application No. PCT/US2023/013992, dated May 19, 2023, 14 pages.
International Search Report and Written Opinion for Application No. PCT/US2023/013989, dated May 24, 2023, 14 pages.
International Search Report and Written Opinion for Application No. PCT/US2023/013986, dated Jun. 20, 2023, 11 pages.
International Search Report and Written Opinion for Application No. PCT/US2023/013990, dated May 24, 2023, 14 pages.